<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults - Stoniute, A - 2023 | Cochrane Library</title> <meta content="Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults - Stoniute, A - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003781.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults - Stoniute, A - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003781.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003781.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults" name="citation_title"/> <meta content="Akvile Stoniute&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Newcastle University" name="citation_author_institution"/> <meta content="Priya Madhuvrata&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Sheffield Teaching Hospital NHS Foundation Trust" name="citation_author_institution"/> <meta content="priya.madhuvrata@nhs.net" name="citation_author_email"/> <meta content="Madeleine Still" name="citation_author"/> <meta content="Newcastle University" name="citation_author_institution"/> <meta content="Evelyn Barron-Millar" name="citation_author"/> <meta content="Newcastle University" name="citation_author_institution"/> <meta content="Ghulam Nabi" name="citation_author"/> <meta content="University of Dundee" name="citation_author_institution"/> <meta content="Muhammad Imran Omar" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD003781.pub3" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/05/09" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003781.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003781.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003781.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Cholinergic Antagonists [adverse effects]; *Drug-Related Side Effects and Adverse Reactions; Quality of Life; Systematic Reviews as Topic; Tolterodine Tartrate; *Urinary Bladder, Overactive [drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003781.pub3&amp;doi=10.1002/14651858.CD003781.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003781.pub3&amp;doi=10.1002/14651858.CD003781.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003781.pub3&amp;doi=10.1002/14651858.CD003781.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003781.pub3&amp;doi=10.1002/14651858.CD003781.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003781.pub3&amp;doi=10.1002/14651858.CD003781.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003781.pub3&amp;doi=10.1002/14651858.CD003781.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003781.pub3&amp;doi=10.1002/14651858.CD003781.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003781.pub3&amp;doi=10.1002/14651858.CD003781.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003781.pub3&amp;doi=10.1002/14651858.CD003781.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003781.pub3&amp;doi=10.1002/14651858.CD003781.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003781.pub3&amp;doi=10.1002/14651858.CD003781.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003781.pub3&amp;doi=10.1002/14651858.CD003781.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003781.pub3&amp;doi=10.1002/14651858.CD003781.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003781.pub3&amp;doi=10.1002/14651858.CD003781.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003781.pub3&amp;doi=10.1002/14651858.CD003781.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003781.pub3&amp;doi=10.1002/14651858.CD003781.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003781.pub3&amp;doi=10.1002/14651858.CD003781.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003781.pub3&amp;doi=10.1002/14651858.CD003781.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003781.pub3&amp;doi=10.1002/14651858.CD003781.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003781.pub3&amp;doi=10.1002/14651858.CD003781.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003781.pub3&amp;doi=10.1002/14651858.CD003781.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003781.pub3&amp;doi=10.1002/14651858.CD003781.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003781.pub3&amp;doi=10.1002/14651858.CD003781.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="k5rEBE5b";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003781\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003781\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003781\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003781\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","ru","ko","pt","th","ms","hr","fa","fr","hu"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003781.pub3",title:"Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults",firstPublishedDate:"May 9, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Incontinence Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=k5rEBE5b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003781.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003781.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003781.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003781.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003781.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003781.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;hu&quot;,&quot;title&quot;:&quot;Összefoglalás közérthető nyelven&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003781.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003781.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003781.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003781.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3972 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003781.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003781.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003781.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003781.pub3/full#CD003781-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003781.pub3/full#CD003781-sec-0101"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003781.pub3/full#CD003781-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003781.pub3/full#CD003781-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003781.pub3/full#CD003781-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003781.pub3/full#CD003781-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003781.pub3/full#CD003781-sec-0041"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003781.pub3/full#CD003781-sec-0095"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003781.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003781.pub3/appendices#CD003781-sec-0106"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003781.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003781.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/supinfo/CD003781-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/supinfo/CD003781-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003781.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003781.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003781.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003781.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003781.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003781.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="These authors should be considered joint first author"><a href="/cdsr/doi/10.1002/14651858.CD003781.pub3/information#CD003781-cr-0004">Akvile Stoniute</a><sup>a</sup></li> <li class="author custom-tooltip" title="These authors should be considered joint first author"><a href="/cdsr/doi/10.1002/14651858.CD003781.pub3/information#CD003781-cr-0005"><i class="icon corresponding-author fa fa-envelope"></i>Priya Madhuvrata</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003781.pub3/information#CD003781-cr-0006">Madeleine Still</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003781.pub3/information#CD003781-cr-0007">Evelyn Barron-Millar</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003781.pub3/information#CD003781-cr-0008">Ghulam Nabi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003781.pub3/information#CD003781-cr-0009">Muhammad Imran Omar</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/information/en#CD003781-sec-0117">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 09 May 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003781.pub3">https://doi.org/10.1002/14651858.CD003781.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003781-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003781-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD003781-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD003781-abs-0019">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003781-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003781-abs-0016">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD003781-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD003781-abs-0010">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003781-abs-0001" lang="en"> <section id="CD003781-sec-0001"> <h3 class="title" id="CD003781-sec-0001">Background</h3> <p>Around 16% of adults have symptoms of overactive bladder (OAB; urgency with frequency and/or urge incontinence), with prevalence increasing with age. Anticholinergic drugs are commonly used to treat this condition. </p> <p>This is an update of a Cochrane Review first published in 2002 and last updated in 2006. </p> </section> <section id="CD003781-sec-0002"> <h3 class="title" id="CD003781-sec-0002">Objectives</h3> <p>To assess the effects of anticholinergic drugs compared with placebo or no treatment for treating overactive bladder syndrome in adults. </p> </section> <section id="CD003781-sec-0003"> <h3 class="title" id="CD003781-sec-0003">Search methods</h3> <p>We searched the Cochrane Incontinence Specialised Register, which contains trials identified from the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, MEDLINE In‐Process, MEDLINE Epub Ahead of Print, ClinicalTrials.gov, WHO ICTRP and handsearching of journals and conference proceedings (searched 14 January 2020), and the reference lists of relevant articles. We updated this search on 3 May 2022, but these results have not yet been fully incorporated. </p> </section> <section id="CD003781-sec-0004"> <h3 class="title" id="CD003781-sec-0004">Selection criteria</h3> <p>We included randomised or quasi‐randomised trials in adults with overactive bladder syndrome that compared an anticholinergic drug alone with placebo treatment. </p> </section> <section id="CD003781-sec-0005"> <h3 class="title" id="CD003781-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed eligibility and extracted data from the included studies, including an assessment of the risk of bias. We assessed the certainty of the body of evidence using the GRADE approach. We processed data as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>. </p> </section> <section id="CD003781-sec-0006"> <h3 class="title" id="CD003781-sec-0006">Main results</h3> <p>We included 104 studies, 71 of which were new or updated for this version of the review. Although 12 studies did not report the number of participants, there were 47,106 people in the remainder of the included studies. The majority of the studies had insufficient information to allow judgement of risk of bias and we judged them to be unclear for all domains. Nine anticholinergic drugs were included in these studies: darifenacin; fesoterodine; imidafenacin; oxybutynin; propantheline; propiverine; solifenacin; tolterodine and trospium. No studies were found that compared anticholinergic drugs to no treatment. </p> <p>At the end of the treatment period, anticholinergics may slightly increase condition‐specific quality of life (mean difference (MD) 4.41 lower, 95% confidence interval (CI) 5.28 lower to 3.54 lower (scale range ‐100 to 0); 12 studies, 6804 participants; low‐certainty evidence). Anticholinergics are probably better than placebo in terms of patient perception of cure or improvement (risk ratio (RR) 1.38, 95% CI 1.15 to 1.66; 9 studies, 8457 participants; moderate‐certainty evidence), and the mean number of urgency episodes per 24‐hour period (MD 0.85 lower, 95% CI 1.03 lower to 0.67 lower; 23 studies, 16,875 participants; moderate‐certainty evidence). </p> <p>Compared to placebo, anticholinergics may result in an increase in dry mouth adverse events (RR 3.50, 95% CI 3.26 to 3.75; 66 studies, 38,368 participants; low‐certainty evidence), and may result in an increased risk of urinary retention (RR 3.52, 95% CI 2.04 to 6.08; 17 studies, 7862 participants; low‐certainty evidence). Taking anticholinergics may be more likely to lead to participants withdrawing from the studies due to adverse events (RR 1.37, 95% CI 1.21 to 1.56; 61 studies, 36,943 participants; low‐certainty evidence). However, taking anticholinergics probably reduces the mean number of micturitions per 24‐hour period compared to placebo (MD 0.85 lower, 95% CI 0.98 lower to 0.73 lower; 30 studies, 19,395 participants; moderate‐certainty evidence). </p> </section> <section id="CD003781-sec-0007"> <h3 class="title" id="CD003781-sec-0007">Authors' conclusions</h3> <p>The use of anticholinergic drugs by people with overactive bladder syndrome results in important but modest improvements in symptoms compared with placebo treatment. In addition, recent studies suggest that this is generally associated with only modest improvement in quality of life. Adverse effects were higher with all anticholinergics compared with placebo. Withdrawals due to adverse effects were also higher for all anticholinergics except tolterodine. It is not known whether any benefits of anticholinergics are sustained during long‐term treatment or after treatment stops. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003781-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003781-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD003781-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD003781-abs-0020">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003781-abs-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003781-abs-0017">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD003781-abs-0013">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/hu#CD003781-abs-0018">Magyar</a> </li> <li class="section-language"> <a class="" href="full/ko#CD003781-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD003781-abs-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD003781-abs-0009">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD003781-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD003781-abs-0011">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD003781-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003781-abs-0002" lang="en"> <h3>Effectiveness of anticholinergic drugs for treating people with overactive bladder syndrome </h3> <p><b>Review question</b> </p> <p>We wanted to see whether a group of drugs, called anticholinergics, made a difference to adults who had an overactive bladder (OAB) syndrome when compared to a placebo (fake) treatment. We collected and analysed all relevant studies to answer this question. </p> <p><b>Background</b> </p> <p>Overactive bladder syndrome is a common problem, especially as people get older. It means that you may suddenly feel the need to go to the toilet (called an 'urgency episode'), or suddenly leak a bit of urine. Overactive bladder is caused by your bladder muscle losing control unexpectedly. It is sometimes called 'irritable bladder', 'detrusor overactivity', 'urge incontinence' or 'urgency‐frequency syndrome'. </p> <p>Anticholinergic drugs are often given to people who have overactive bladder. They work by relaxing the muscles and can help some of the symptoms of overactive bladder, such as leakage or needing to go to the toilet at short notice. </p> <p><b>How up‐to‐date is this review?</b> </p> <p>We studied evidence that was available up until 14 January 2020.  We updated this search on 3 May 2022, but these results have not yet been fully incorporated into the review. </p> <p><b>Study characteristics</b> </p> <p>We included 104 studies in this review. Seventy‐one of these were new or had been updated since the last time this review was published in 2006. </p> <p>Twelve of these studies did not report how many people were included in their research. In total across the rest of the studies, 29,682 people were given an anticholinergic drug compared to 17,424 people who were given a placebo. The smallest study was made up of 18 people while the largest had 2334 participants. Most of the studies we included in the review lasted for 12 weeks. One study investigated symptoms only in men, while nine looked at symptoms in women. The rest of the studies included both men and women. </p> <p>We only included studies that used anticholinergic drugs taken by mouth, and only at dosages that doctors normally prescribe to patients. Across the studies, nine different anticholinergic drugs were included: darifenacin; fesoterodine; imidafenacin; oxybutynin; propantheline; propiverine; solifenacin; tolterodine and trospium. </p> <p><b>Study funding sources</b> </p> <p>Seventy studies included in this review were funded by the companies that make and sell the drugs. </p> <p><b>Key results</b> </p> <p>We found that people who take an anticholinergic drug for overactive bladder may feel a positive change in their quality of life. Also, our results show that more patients will probably perceive an improvement or cure of their symptoms of overactive bladder when compared to those who take the placebo treatment. </p> <p>Taking an anticholinergic drug probably results in a small reduction in the number of urgency episodes and the number of times people with overactive bladder go to the toilet in one day. </p> <p>Twenty‐two people in every 100 given an anticholinergic drug felt they had a dry mouth as a side effect of the drug, compared to 6 in 100 taking placebo. Taking anticholinergics may therefore increase the risk of having a dry mouth. Anticholinergics may also result in an increased risk of urinary retention: fewer than 2 in every 100 people felt they were unable to completely empty their bladder after taking an anticholinergic drug in comparison to fewer than 0.5 in every 100 people after taking placebo.  </p> <p><b>Authors’ conclusions</b> </p> <p>We found that anticholinergic drugs could result in small but important changes to a person’s quality of life and their overactive bladder symptoms, however it is unclear if these changes can be sustained over a long period of time.  </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003781-sec-0101" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003781-sec-0101"></div> <h3 class="title" id="CD003781-sec-0102">Implications for practice</h3> <section id="CD003781-sec-0102"> <p>The administration of anticholinergic drugs for overactive bladder syndrome results in differences compared to placebo medication. Those receiving anticholinergic therapy were more likely to perceive cure or improvement of symptoms, and a reduction in leakage and urgency episodes and voids (fewer than one per day). Evidence from more recently reported studies also indicates modestly improved quality of life. However, there was also a marked placebo response. When counselling those with overactive bladder syndrome, these benefits need to be balanced with the risk of side effects, such as dry mouth. Depending on the type of medication being offered, the risk of dry mouth may be increased by three times. </p> <p>The only long‐term follow‐up comes from open‐label studies, with anticholinergic therapy offered to all study participants regardless of their original allocation to active or placebo treatment. The short duration of most studies and the lack of long‐term follow‐up gives us little information about the long‐term effects and acceptability of anticholinergic therapy. </p> <p>Cost‐effectiveness was also not addressed by any of the studies identified for inclusion in this review. </p> <p>Although over 100 studies were identified for this review, most of the evidence assessed in our summary of findings table was of low to moderate certainty. The certainty in the evidence base could be increased by study authors reporting their methods in more detail. Finally, the six studies that are currently awaiting classification may alter the conclusions of this review once assessed. </p> </section> <h3 class="title" id="CD003781-sec-0103">Implications for research</h3> <section id="CD003781-sec-0103"> <p>Anticholinergics can help some people with overactive bladder syndrome with their quality of life, though it may be necessary to find the best one for each individual. To allow the results of trials to be considered together most usefully, any future research into overactive bladder syndrome should incorporate standardised, validated outcomes and quality of life measures that are relevant to those with overactive bladder syndrome. Furthermore, the patient perspective on outcomes and measures also needs to be considered so that trials are more relevant. Particular attention needs to be paid to the patient perception of change and satisfaction with outcome, quality of life and economic outcomes. The emphasis on reporting urodynamic measures needs to be redressed. Clearly reporting the methods of group allocation and the reasons for withdrawal from the studies would reduce the risk of bias and potentially identify issues with the study methodology. Outcome assessors should be blinded to group allocation and this should be more clearly reported in studies to further reduce the risk of bias. </p> <p>As anticholinergic drugs are not intended to be curative, sustained success is likely to depend on people continuing to take them. Trials are needed to assess the long‐term usefulness of these drugs. The most commonly prescribed anticholinergics have now been compared with placebo in a number of trials and have been found to be effective, albeit with adverse effects. In our view, placebo‐controlled trials should be confined to testing the short‐term efficacy and safety of any new anticholinergic therapies. Longer trial durations may provide new insights into the long‐term effectiveness of these therapies and provide data on the duration of adverse effects and the longevity of effects on patient quality of life. However, as most of the available anticholinergics are effective, new drugs might be better compared to existing first‐line treatments including both existing anticholinergics and bladder training.  </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003781-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003781-sec-0008"></div> <div class="table" id="CD003781-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Anticholinergics compared to placebo for overactive bladder syndrome in adults</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Anticholinergics compared to placebo for overactive bladder syndrome in adults</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> adults with overactive bladder syndrome<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> anticholinergics<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants (studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Without anticholinergics</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With anticholinergics</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change from baseline in condition‐specific quality of life</b><br/>Scale from: ‐100 to 0<br/>  </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 4.41 lower<br/>(5.28 lower to 3.54 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6804<br/>(12 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patient perception of cure or improvement</b><br/>  </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>424 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>161 more per 1000 (from 64 more to 280 more)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.38</p> <p>(1.15 to 1.66)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8457<br/>(9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean number of urgency episodes per 24 hours</b><br/>  </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of urgency episodes per 24 hours in placebo groups ranged from 1.8 to 10.61 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.85 lower<br/>(1.03 lower to 0.67 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16,875<br/>(23 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: dry mouth</b><br/>  </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>63 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>158 more per 1000 (from 143 more to 174 more)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.50</p> <p>(3.26 to 3.75)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38,368<br/>(66 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events:urinary retention</b><br/>  </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 more per 1000<br/>(from 4 more to 18 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.52</p> <p>(2.04 to 6.08)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7862<br/>(17 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to adverse events</b><br/>  </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 more per 1000<br/>(from 7 more to 19 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.37</p> <p>(1.21 to 1.56)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>3,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36,943<br/>(61 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean number of micturitions per 24 hours</b><br/>  </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of micturitions per 24 hours in placebo groups ranged from 8.6 to 11.69 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.85 lower<br/>(0.98 lower to 0.73 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19,395<br/>(30 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level for serious risk of bias: most of the domains were unclear. </p> <p><sup>2</sup>Downgraded one level for serious publication bias: strongly suspected as the plot does not resemble a symmetrical funnel, i.e. smaller studies without significant results were likely to remain unpublished. </p> <p><sup>3</sup>Downgraded two levels for very serious risk of bias: the majority of the domains were unclear or high risk. </p> <p><sup>4</sup>Downgraded one level for serious imprecision: low number of events reported. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003781-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003781-sec-0009"></div> <p>This is an update of a Cochrane Review first published in 2002 (<a href="./references#CD003781-bbs2-0368" title="Hay-SmithJ , HerbisonP , EllisG , MooreK . Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database of Systematic Reviews2002, Issue 3. Art. No: CD003781. [DOI: 10.1002/14651858.CD003781]">Hay‐Smith 2002</a>) and last updated in 2006 (<a href="./references#CD003781-bbs2-0369" title="NabiG , CodyJD , EllisG , HerbisonP , Hay-SmithJ . Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD003781. [DOI: 10.1002/14651858.CD003781.pub2] [CD003781]">Nabi 2006</a>).  </p> <p>For a glossary of plain language medical terms, please see <a href="./appendices#CD003781-sec-0107">Appendix 1</a>. </p> <section id="CD003781-sec-0010"> <h3 class="title" id="CD003781-sec-0010">Description of the condition</h3> <p>Overactive bladder (OAB) is one of several clinical syndromes under the wider umbrella term of lower urinary tract syndromes (LUTS, <a href="./references#CD003781-bbs2-0332" title="HardingCK , LapitanMC , ArlandisS , Bø K  ConstantiniE , GroenJ , et al. EAU guidelines on management of non-neurogenic female lower urinary tract symptoms (LUTS). Available at uroweb.org/wp-content/uploads/EAU-Guidelines-on-Non-Neurogenic-Female-LUTS-2021.pdf2021.">European Association of Urology 2021</a>). According to the International Continence Society (ICS), “overactive bladder syndrome (OAB) is defined as urinary urgency, usually with urinary frequency and nocturia, with or without urgency urinary incontinence" (<a href="./references#CD003781-bbs2-0340" title="Rahanama'iS , editor. ICS standardisation committee terminology discussions: overactive bladder. Last updated: 1 June 2018. Available at www.ics.org/committees/standardisation/terminologydiscussions/overactivebladder (accessed 14 July 2022).">ICS 2018</a>). To be called overactive bladder syndrome, the symptoms above should not be caused by metabolic problems such as diabetes mellitus, or problems with the urinary tract such as urinary tract infection. People with neurological causes of overactive bladder symptoms, such as Parkinson’s disease, are not excluded from the diagnosis. There remains some debate on whether the above definition is useful as overactive bladder is not necessarily the same disease process in every patient, but rather a collection of symptoms that could be bothersome caused by one of many possible disease processes (<a href="./references#CD003781-bbs2-0345" title="LeeUJ , ScottVC , RashidR , BehniwalA , WeinAJ , MaliskiSL , et al. Defining and managing overactive bladder: disagreement among the experts. Urology2013;81(2):257-62. [DOI: https://doi.org/10.1016/j.urology.2012.09.028]">Lee 2013</a>). Nonetheless, the term overactive bladder has been commonly used in the literature and we will continue to use this terminology within this systematic review. </p> <p>For the purposes of this Cochrane Review, urgency is defined as the sudden and compelling desire to pass urine, which is difficult to defer. Sometimes there is involuntary leakage of urine with the feeling of urgency, which is called urgency urinary incontinence (UUI). Frequency is the complaint of needing to void often during the day or at night. In clinical practice, a person who voids more than eight times in 24 hours is considered to have frequency. If a person wakes more than once at night to void, this is called nocturia. </p> <p>Frequency, urgency, UUI or a combination of these symptoms are a common problem amongst adults living in the community. These symptoms of overactive bladder can be bothersome and have marked effects on quality of life (<a href="./references#CD003781-bbs2-0341" title="JohnstonKM , WalkerDR , LakzadehP . Characterizing the health-related quality of life burden of overactive bladder using disease-specific patient-reported outcome measures: a systematic literature review. Advances in Therapy2019;36(3):548-62. [DOI: https://doi.org/10.1007/s12325-019-0880-8]">Johnston 2019</a>). A global systematic review of the prevalence of UUI identified ranges from 1.5% to 36.4% (<a href="./references#CD003781-bbs2-0350" title="MilsomI , CoyneKS , NicholsonS , KvaszM , ChenCI , WeinAJ . Global prevalence and economic burden of urgency urinary incontinence: a systematic review. European Urology2014;65(1):79-95. [DOI: https://doi.org/10.1016/j.eururo.2013.08.031]">Milsom 2014</a>). Al Edwan and colleagues, reporting on overactive bladder prevalence in North Africa and the Middle East, found that approximately 50% of women aged 40 years or over had symptoms suggestive of overactive bladder and over 90% of these had symptoms of urinary incontinence. They found that 74% of these women had never had treatment for their overactive bladder symptoms (<a href="./references#CD003781-bbs2-0327" title="Al EdwanG , AbdelazimMS , SalhabSE , Jamal, YM, SolimanMA . The prevalence of overactive bladder symptoms in women in Algeria, Egypt, Jordan and Lebanon: a cross-sectional population-based survey. Advances in Therapy2020;38(2):1155-67. [DOI: 10.1007/s12325-020-01588-4]">Al Edwan 2020</a>). </p> <p>While overactive bladder is often managed in the primary care setting several barriers, including embarrassment, poor communication and low patient adherence, contribute to the under treatment of patients with burdensome urinary symptoms (<a href="./references#CD003781-bbs2-0333" title="FilipettoFA , FuldaKG , HolthusenAE , McKeithenTM , McFaddenP . The patient perspective on overactive bladder: a mixed-methods needs assessment. BMC Family Practice2014;15:96. [DOI: https://doi.org/10.1186/1471-2296-15-96]">Filipetto 2014</a>). </p> </section> <section id="CD003781-sec-0011"> <h3 class="title" id="CD003781-sec-0011">Description of the intervention</h3> <p>Overactive bladder is a nonspecific storage symptom complex with poorly defined pathophysiology and may indeed result from multiple potential pathophysiological mechanisms (<a href="./references#CD003781-bbs2-0353" title="PeyronnetB , MironskaE , ChappleC , CardozoL , OelkeM , DmochowskiR , et al. A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment. European Urology2019;75(6):988-1000. [DOI: https://doi.org/10.1016/j.eururo.2019.02.038]">Peyronnet 2019</a>). One proposed factor is myogenic in nature, relating to spontaneous contraction of the detrusor smooth muscle (<a href="./references#CD003781-bbs2-0349" title='MengE , LinWY , LeeWC , ChuangYC . Pathophysiology of overactive bladder. LUTS: Lower Urinary Tract Symptoms2012;4:48-55. [DOI: &lt;a class="epub-doi" aria-label="Digital Object Identifier" href="https://doi.org/10.1111/j.1757-5672.2011.00122.x" style="box-sizing: border-box; background-color: rgb(255, 255, 255); cursor: pointer; color: rgb(0, 82, 116); text-decoration: none; font-weight: 600; overflow-wrap: break-word; outline: 0px; font-family: &amp;quot;Open Sans&amp;quot;, sans-serif; font-size: 14px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0phttps://doi.org/10.1111/j.1757-5672.2011.00122.x]'>Meng 2012</a>). </p> <p>The two main treatment options for overactive bladder syndrome are conservative management (e.g. bladder training (<a href="./references#CD003781-bbs2-0366" title="WallaceS , RoeB , WilliamsK , PalmerM . Bladder training for urinary incontinence in adults. Cochrane Database of Systematic Reviews2004, Issue 1. Art. No: CD001308. [DOI: 10.1002/14651858.CD001308.pub2]">Wallace 2004</a>), electrical stimulation (<a href="./references#CD003781-bbs2-0363" title="StewartF , GameiroLF , El DibR , GameiroMO , AmaroJL . Electrical stimulation with non-implanted electrodes for overactive bladder in adults. Cochrane Database of Systematic Reviews2016, Issue 12. Art. No: CD010098. [DOI: 10.1002/14651858.CD010098.pub4]">Stewart 2016</a>)), pharmacology (e.g. botulinum toxin injections (<a href="./references#CD003781-bbs2-0330" title="DuthieJB , VincentM , HerbisonGP , WilsonDI , WilsonD . Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database of Systematic Reviews2011, Issue 12. Art. No: CD005493. [DOI: 10.1002/14651858.CD005493.pub3]">Duthie 2011</a>)), or a combination of both. The mainstay of pharmacological treatment at present is anticholinergic medication and this review is one of several Cochrane Reviews investigating the effects of anticholinergic drugs. Alongside this review, which compares orally administered drugs to placebo or no treatment, other Cochrane Reviews have focused on whether different anticholinergic drugs have different effects (<a href="./references#CD003781-bbs2-0347" title="Madhuvrata P, Cody JD, Ellis G, HerbisonGP , Hay‐SmithEJ . Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database of Systematic Reviews2012, Issue 1. Art. No: CD005429. [DOI: 10.1002/14651858.CD005429.pub2]">Madhuvrata 2012</a>); whether anticholinergic drugs are better than active non‐drug therapies (<a href="./references#CD003781-bbs2-0354" title="RaiBP , CodyJD , AlhassoA , StewartL . Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD003193. [DOI: 10.1002/14651858.CD003193.pub4]">Rai 2012</a>); and whether anticholinergic drugs are better than other available drug treatments (<a href="./references#CD003781-bbs2-0359" title="RoxburghC , CookJ , DublinN . Anticholinergic drugs versus other medications for overactive bladder syndrome in adults. Cochrane Database of Systematic Reviews2007, Issue 4. Art. No: CD003190. [DOI: 10.1002/14651858.CD003190.pub4] [CD003190]">Roxburgh 2007</a>). </p> <p>At present, anticholinergic drugs are prescribed to be taken by mouth (the focus of investigation in this review), by intravesical injection or by transdermal skin patches with different dosage requirements depending on route of administration and the pharmaceutical properties of the drug. Imidafenacin, for example, has a range of accepted oral dosage between 0.1 mg and 0.2 mg twice daily, while propantheline has a therapeutic dosage range of 15 mg three times a day up to a maximum of 120 mg per day.  Further details on the individual drugs investigated in this Cochrane Review can be found in the <a href="#CD003781-sec-0019">Types of interventions</a> section.  </p> </section> <section id="CD003781-sec-0012"> <h3 class="title" id="CD003781-sec-0012">How the intervention might work</h3> <p>Anticholinergics work by blocking the muscarinic M3 receptors located on the bladder smooth muscle and as a result these muscles are relaxed. Muscarinic receptors are also found in other parts of the body (e.g. the gut, salivary glands and tear ducts). Due to the mode of action of the drug, this can lead to adverse effects. Commonly reported adverse effects include dry mouth, constipation, dyspepsia, abdominal pain, urinary retention, urinary tract infection, dry eyes, blurred vision, headache and dizziness. </p> </section> <section id="CD003781-sec-0013"> <h3 class="title" id="CD003781-sec-0013">Why it is important to do this review</h3> <p>In part due to the uncertainty around the pathophysiology or pathophysiologies of overactive bladder, there remains uncertainty as to whether orally administered anticholinergics are effective. Despite these uncertainties, anticholinergics are increasingly being used in primary and secondary care settings for the treatment of overactive bladder and this has considerable resource implications (e.g. <a href="./references#CD003781-bbs2-0364" title="TangDH , ColaycoDC , KhalafKM , PiercyJ , PatelV , GlobeD , et al . Impact of urinary incontinence on healthcare resource utilization, health related quality of life and productivity in patients with overactive bladder. BJU2014;113(3):484-91. [DOI: https://doi.org/10.1111/bju.12505]">Tang 2013</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003781-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003781-sec-0014"></div> <p>To assess the effects of anticholinergic drugs compared with placebo or no treatment for treating overactive bladder syndrome in adults. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003781-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003781-sec-0015"></div> <section id="CD003781-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003781-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included all randomised or quasi‐randomised controlled trials of anticholinergic drugs versus placebo or no treatment for treating overactive bladder syndrome. We excluded cluster‐randomised trials and cross‐over trials. This was because it was felt that direct comparisons of treatments in individually randomised trials would provide the strongest evidence to address this question. </p> </section> <section id="CD003781-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included studies of all adult men and women (aged 18 years and above) with a symptomatic diagnosis of overactive bladder syndrome, a urodynamic diagnosis of detrusor overactivity (either idiopathic or neurogenic), or both. </p> </section> <section id="CD003781-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included studies where at least one arm of the study used an anticholinergic drug and one other arm was placebo or no treatment. This comparison was used for the summary of findings table. </p> <p>To be included, the drug had to be a muscarinic antagonist (anticholinergic) given by mouth for the purpose of decreasing symptoms of overactive bladder. The group of drugs included darifenacin, fesoterodine, imidafenacin, oxybutynin, propantheline, propiverine, solifenacin, tolterodine and trospium. </p> <p>We focused on the standard therapeutic dosage ranges for adults in Europe and the UK. These areas follows: </p> <p> <ul id="CD003781-list-0001"> <li> <p>Darifenacin: initially 7.5 mg once daily, increased if necessary to 15 mg after 2 weeks. </p> </li> <li> <p>Fesoterodine: 4 mg once daily, increased if necessary up to 8 mg once daily.</p> </li> <li> <p>Imidafenacin: 0.1 mg twice daily, after breakfast and supper. The dosage may be increased if necessary to 0.2 mg twice daily. </p> </li> <li> <p>Oxybutynin: For adults: initially 5 mg two to three times daily, increased if necessary up to 5 mg four times daily. For elderly patients: initially 2.5 mg to 3 mg twice daily, increased if tolerated to 5 mg twice daily, adjusted according to response. </p> </li> <li> <p>Propantheline: 15 mg three times a day, dose to be taken at least one hour before food and 30 mg, dose to be taken at bedtime; maximum 120 mg per day. </p> </li> <li> <p>Propiverine: Immediate‐release medicines: 15 mg one to two times a day, increased if necessary up to 15 mg three times a day. Modified‐release capsules: 30 mg once daily. </p> </li> <li> <p>Solifenacin: 5 mg once daily, increased to 10 mg once daily if necessary.</p> </li> <li> <p>Tolterodine: Immediate‐release medicines: 2 mg twice daily, reduced if not tolerated to 1 mg twice daily. Modified‐release capsules: 4 mg once daily. </p> </li> <li> <p>Trospium: Immediate‐release medicines 20 mg twice daily, to be taken before food. Modified‐release medicines – adult ‐ 60 mg once daily. </p> </li> </ul> </p> <p>We excluded terodiline, an anticholinergic drug previously used in the treatment of overactive bladder, because it has been withdrawn from the market due to cardiovascular toxicities it can trigger. We also excluded emepronium as it is not recommended for use in clinical practice. </p> <p>We excluded trials of intravesical anticholinergic medication administration in this version of the review. We also excluded trials of other drugs with less direct anticholinergic effects (e.g. smooth muscle relaxants, flavoxate hydrochloride, calcium channel blockers, potassium channel openers, beta‐adrenoceptor agonists, alpha‐adrenoceptor antagonists, prostaglandin synthetase inhibitors and tricyclic antidepressants). </p> </section> <section id="CD003781-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD003781-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD003781-list-0002"> <li> <p>Mean change from baseline in condition‐specific quality of life (e.g. measured using the OAB‐Q‐SF or King's Health Questionnaire). </p> </li> <li> <p>Perception of cure or improvement (patient‐reported using a validated instrument, e.g. the Patient Perception of Bladder Condition (PPBC). The PPBC was used as the primary tool for meta‐analysis). </p> </li> <li> <p>Mean number of urinary urgency episodes per 24 hours (patient‐reported, e.g. by patient diary). </p> </li> </ul> </p> </section> <section id="CD003781-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD003781-list-0003"> <li> <p>Number of people experiencing one or more adverse effects (i.e. dry mouth, constipation, nausea, dyspepsia/indigestion, abdominal pain, urinary retention/high residual volume, urinary tract infection (UTI), dry eyes, blurred vision, headache, dizziness, flu‐like symptoms/fatigue, nasopharyngitis/sore throat, insomnia). </p> </li> <li> <p>Number of withdrawals due to adverse events.</p> </li> <li> <p>Mean number of micturitions per 24 hours.</p> </li> </ul> </p> </section> <section id="CD003781-sec-0023"> <h5 class="title">Timing of outcome assessment</h5> <p>All primary and secondary outcomes were measured post‐intervention. </p> </section> <section id="CD003781-sec-0024"> <h5 class="title">Main outcomes for summary of findings table</h5> <p>We included the following seven outcomes in the summary of findings table:</p> <p> <ul id="CD003781-list-0004"> <li> <p>Mean change from baseline in condition‐specific quality of life (e.g. measured using the OAB‐Q‐SF or King's Health Questionnaire). </p> </li> <li> <p>Perception of cure or improvement (patient‐reported, using a validated instrument, e.g. the PPBC). </p> </li> <li> <p>Number of urinary urgency episodes per 24 hours at the end of treatment.</p> </li> <li> <p>Adverse effects: dry mouth.</p> </li> <li> <p>Adverse effects: urinary retention.</p> </li> <li> <p>Number of withdrawals due to adverse events.</p> </li> <li> <p>Mean number of micturitions per 24 hours at the end of treatment.</p> </li> </ul> </p> <p>In terms of adverse effects, it was not possible to include all of those investigated in the summary of findings table so we selected the most commonly reported (dry mouth) and the most invasive to treat (urinary retention) to include as being of most use to patients and clinicians (however, full details of the adverse events occurring are reported in the results). </p> </section> </section> </section> <section id="CD003781-sec-0025"> <h3 class="title">Search methods for identification of studies</h3> <p>We did not impose any language or other limits on any of the searches described below.</p> <section id="CD003781-sec-0026"> <h4 class="title">Electronic searches</h4> <p>We identified relevant trials from the Cochrane Incontinence Specialised Register. For more details of the search methods used to build the Specialised Register, please see the Group's <a href="http://incontinence.cochrane.org/resources/specialised-register" target="_blank">web pages</a>. To summarise, the Register contains trials identified from the Cochrane Central Register of Controlled Trials (CENTRAL) (on CRS Web), MEDLINE (on Ovid), MEDLINE In‐Process (on Ovid), MEDLINE Epub Ahead of Print (on Ovid), MEDLINE Daily, <a href="https://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a>, World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">WHO ICTRP</a>), and handsearching of journals and conference proceedings. Many of the trials in the Cochrane Incontinence Specialised Register are also contained in CENTRAL. </p> <p>The date of the search of the Specialised Register for this review was: 14 January 2020. We performed a further updated search on 3 May 2022 the results of which have been added to <a href="./references#CD003781-bbs1-0003" title="">Studies awaiting classification</a> but have not been fully incorporated into the review. </p> <p>The terms used to search the Cochrane Incontinence Specialised Register and additional information about the content are given in <a href="./appendices#CD003781-sec-0108">Appendix 2</a>. </p> </section> <section id="CD003781-sec-0027"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of identified trials and other relevant articles.</p> </section> </section> <section id="CD003781-sec-0028"> <h3 class="title" id="CD003781-sec-0028">Data collection and analysis</h3> <p>We conducted data collection and analysis in accordance with methods specified in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003781-bbs2-0339" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook.">Higgins 2019</a>). </p> <section id="CD003781-sec-0029"> <h4 class="title">Selection of studies</h4> <p>Two review authors (EBM and AS) independently screened the list of titles and abstracts, retrieved the full‐text articles of potentially relevant trials and assessed them for eligibility. We resolved any disagreement through discussion or by involving a third party (MS). </p> </section> <section id="CD003781-sec-0030"> <h4 class="title">Data extraction and management</h4> <p>At least two review authors (EBM, AS, MS) independently abstracted and cross‐checked data using a pre‐piloted form. Any disagreements between the two review authors were resolved by consulting a third review author (either EBM, AS or MS depending on who was not involved in the original data extraction process). Where data were collected but were not reported, or were reported in a form not suitable for inclusion in the formal analysis, we sought further clarification from the trialists. We performed all data entry using Review Manager software (<a href="./references#CD003781-bbs2-0355" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). For condition‐specific quality of life measures, on some instruments a lower score represents a higher quality of life. However, for other instruments a lower score represents a lower quality of life. Where necessary to aid meta‐analysis, all quality of life scores were reinterpreted so that a lower score represented a higher quality of life. This was completed in reference to the instruments score range and assuming all scores were cardinal measures.  </p> </section> <section id="CD003781-sec-0031"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (from EBM, AS, MS) independently assessed the risk of bias of the included trials using Cochrane's risk of bias assessment tool (<a href="./references#CD003781-bbs2-0338" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). We assessed the following domains: random sequence generation (selection bias); allocation concealment (selection bias); blinding of participants or personnel (performance bias); blinding of outcome assessment (detection bias); completeness of outcome data (attrition bias); selective reporting (reporting bias); and other potential sources of bias. We resolved any differences in opinion by discussion. Where disagreement persisted, we consulted a third party (from either EBM, AS or MS depending on who was not involved in the original assessment). </p> </section> <section id="CD003781-sec-0032"> <h4 class="title">Measures of treatment effect</h4> <p>Where appropriate, we undertook meta‐analyses. For categorical outcomes, we related the numbers reporting an outcome to the numbers at risk in each group to derive a risk ratio (RR) and their corresponding 95% confidence intervals (CIs). For continuous variables, we used means and standard deviations (SDs) to derive a mean difference (MD) and their corresponding 95% CIs.  </p> </section> <section id="CD003781-sec-0033"> <h4 class="title">Unit of analysis issues</h4> <p>The primary analysis was per participant randomised. For multi‐arm studies, with binary outcomes, we combined two or more active (anticholinergic drug) treatment arms for comparison to placebo in the meta‐analyses. </p> <p>For combining two or more anticholinergics in the same study for continuous outcomes, we used this formula for standard deviation: SD=sqrt(SD<sup>2</sup>/number in first group+SD<sup>2</sup>/number in second group). The mean is the same as the mean is in group 1*(num in this group 1/number in groups 1 and 2) + mean in group 2*num in group 2/num in groups 1 and 2). </p> <p>To split the continuous outcomes, we split the number of participants in the groups and left the mean and SD as they were. </p> </section> <section id="CD003781-sec-0034"> <h4 class="title">Dealing with missing data</h4> <p>As far as possible, we analysed data on an intention‐to‐treat (ITT) basis, meaning that the analysis of participants was according to the groups to which they were originally randomised. However, if data were missing, we used the numbers as reported by the trialists. </p> <p>In terms of postintervention data for the outcomes 'mean number of micturitions per 24 hours' and 'urgency episodes per 24 hours', when the mean data were reported as baseline and change from baseline, we added the mean change from baseline to baseline data to get the postintervention score. SDs could not be recalculated because the correlation was not reported, therefore we borrowed them from the study in the same meta‐analysis with the largest reported post‐intervention SD. </p> </section> <section id="CD003781-sec-0035"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity between studies through visual inspection of plots of the data, the Chi² test for heterogeneity and the I² statistic (<a href="./references#CD003781-bbs2-0339" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook.">Higgins 2019</a>). We used the thresholds for interpretation of the I² statistic as defined by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003781-bbs2-0339" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook.">Higgins 2019</a>). The interpretations are: </p> <p> <ul id="CD003781-list-0005"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>40% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>60% to 90%: may represent substantial heterogeneity; and</p> </li> <li> <p>90% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>The threshold for whether the source of heterogeneity warranted exploration in a meta‐analysis was 40%, i.e. there was evidence of moderate heterogeneity between studies.  </p> </section> <section id="CD003781-sec-0036"> <h4 class="title">Assessment of reporting biases</h4> <p>We used funnel plots for detecting publication bias when there were more than 10 studies in a meta‐analysis. </p> </section> <section id="CD003781-sec-0037"> <h4 class="title">Data synthesis</h4> <p>We used a fixed‐effect model to calculate the pooled RRs, MDs and their 95% CIs unless there was substantial heterogeneity in which case we used a random‐effects model. In studies where different doses of the same drug were compared against placebo, we used what is considered to be the therapeutic dose in the UK or EU. In studies with two or more active (anticholinergic drug) treatment arms, we combined the data from the active treatments where possible for comparison with placebo, if it was clinically appropriate to do so. For the outcomes on urgency episodes and micturitions, we used postintervention data rather than the change from baseline.  </p> </section> <section id="CD003781-sec-0038"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We stratified data by the type of anticholinergic received by participants in meta‐analyses to investigate heterogeneity. In order to investigate differences in how people respond to anticholinergics, we had also planned other subgroup analyses based on age, sex, severity of symptoms and cause of overactive bladder symptoms (i.e. idiopathic versus neurogenic). Data were not reported in a useable form to conduct subgroup analyses and therefore these analyses were not undertaken.  </p> <p>We conducted the analysis for subgroup differences by stratifying each outcome by drug. The results of tests for subgroup differences were based on the I² value. We further explored the tests for subgroup differences indicating an I² value higher than 40% by deselecting drugs based on the overlapping CIs and effect sizes, and interpreted accordingly.  </p> </section> <section id="CD003781-sec-0039"> <h4 class="title">Sensitivity analysis</h4> <p>Had data allowed, we would have performed sensitivity analyses to determine the effects of including or excluding studies at an overall high risk of bias. </p> </section> <section id="CD003781-sec-0040"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We prepared a summary of findings table using the GRADEpro software for the main comparison pre‐stated in <a href="#CD003781-sec-0019">Types of interventions</a> (<a href="./references#CD003781-bbs2-0334" title="GRADEpro GDT. Version (accessed prior to 05 August 2021). Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a>). </p> <p>We used the GRADE approach to assess the certainty of evidence related to the 'Main outcomes for summary of findings table' as listed in the <a href="#CD003781-sec-0020">Types of outcome measures</a> (<a href="./references#CD003781-bbs2-0361" title="SchünemannHJ , HigginsJPT , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence Version 6.0 (updated July 2019). The Cochrane Collaboration, 2019. Available from handbook.cochrane.org.">Schünemann 2019</a>). We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias). We justified all decisions to downgrade the certainty of studies using footnotes. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003781-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003781-sec-0041"></div> <section id="CD003781-sec-0042"> <h3 class="title">Description of studies</h3> <section id="CD003781-sec-0043"> <h4 class="title">Results of the search</h4> <p>In this update we included 104 studies, 71 of which were new to the review or updated for this iteration (<a href="./references#CD003781-bbs2-0004" title="AbramsP , KelleherC , StaskinD , KayR , MartanA , MincikI , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World Journal of Urology2017;35(5):827-38. [NCT01340027] [sr-incont77897]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Cardiovascular safety of combination treatment with mirabegron and solifenacin in patients with overactive bladder in a randomised, double-blind, dose-ranging, Phase II study (Symphony) (Abstract). European Urology, Supplements2014;13(1):e574-e574a. [NCT01340027] [sr-incont67160]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB) - efficacy and safety results from a randomised phase II study (Symphony) (Abstract number 295). Neurourology and Urodynamics2013;32(6):930-1. [NCT01340027] [TrialID.SYMPHONY.] [sr-incont49188]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB): safety results from a phase 2 study (Abstract number MP-16.08). Urology2013;82(3 Suppl 1):S139. [NCT01340027] [sr-incont66675]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: Exploratory responder analyses of efficacy and evaluation of patient reported outcomes from a randomised, double-blind, dose-ranging, phase 2 study (Symphony) (Abstract number MP-24.11). Urology2014;84(4 Suppl 1):S145-6. [NCT01340027] [sr-incont67194]AbramsP , KelleherC , StaskinD , RechbergerT , KayR , MartinaR , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (SYMPHONY). European Urology2015;67(3):577-88. [NCT01340027] [sr-incont66674]NCT01340027, Bristol Urological Institute . A study to evaluate the efficacy, safety and tolerability of mirabegron and solifenacin succinate alone and in combination for the treatment of overactive bladder (symphony) [A randomized, double-blind, factorial, parallel-group, active and placebo-controlled, multicenter dose-ranging study to evaluate the efficacy, safety and tolerability of six dose combinations of solifenacin succinate and mirabegron compared to mirabegron and solifenacin succinate monotherapies in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01340027 (first received 21 April 2011). [178-CL-100] [2010-020601-32] [NCT01340027] [TrialID.SYMPHONY] [sr-incont44510]NittiV , AbramsP , StaskinD , AuerbachS , MartinaR , VanMR . Urinary retention in patients with overactive bladder treated with mirabegron alone and in combination with solifenacin: the results of two randomized, double-blind, phase II studies (Abstract number MP76-13). Journal of Urology2014;191(4 Suppl 1):e886-7. [NCT00410514] [NCT01340027] [TrialID.SYMPHONY] [sr-incont67453]">Abrams 2013</a>;  <a href="./references#CD003781-bbs2-0006" title="BaertL , Leuven, DijkmanG , Breda, the darifenacin study group. Darifenacin, a novel M3 muscarinic receptor antagonist in detrusor overactivity (Abstract  214). In: International Continence Society, 25th Annual Meeting; 1995 Oct 17-20;  Sydney, Australia. 1995:226-7. [sr-incont10890]">Baert 1995</a>; <a href="./references#CD003781-bbs2-0007" title="BrayR , CartwrightR , CardozoL , HillS , GuanZ , KhullarV . Tolterodine ER reduced increased bladder wall thickness in women with overactive bladder. A randomized, placebo-controlled, double-blind, parallel group study. Neurourology and  Urodynamics2018;37(1):237-43. [NCT00137397] [sr-incont74473]NCT00137397. A study to measure the effect of tolterodine extended release on the thickness of the bladder wall in patients with overactive bladder [A multi-centre, randomised, placebo controlled, double blind, parallel group study in female patients to evaluate whether tolterodine ER can reverse the increased bladder wall thickness in patients with overactive bladder]. clinicaltrials.gov/show/NCT00137397 (first received 29 August 2005). [NCT00137397] [sr-incont63809]">Bray 2018</a>; <a href="./references#CD003781-bbs2-0011" title="CardozoL , AdamikZ , GuimaraesM , KrhutJ , Labat J-J, PetrovS , et al. Patients with overactive bladder show progressive improvement in urgency and bladder condition during treatment with solifenacin in a randomised, double-blind, placebo-controlled study (SUNRISE) (Abstract number 115). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S67-8. [srincont-26595]CardozoL , AmarencoG , PushkarD , MikulasJ , DrogendijkT , WrightM , et al. Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE). BJU International2013;111(5):804-10. [NCT00801944] [TrialID.SUNRISE.] [sr-incont47554]CardozoL , DewildeT , FeyereislJ , WadieB , AmarencoG , LiapisA , et al. Solifenacin significantly reduces both urgency severity and bother: results from the flexible dose, placebo controlled, multinational SUNRISE study (Abstract number 281). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26641]CardozoL , DrogendijkT , BolodeokuJ . The efficacy of solifenacin 5/10 mg on 'urgency' endpoints in different OAB patient populations: subanalysis of results from the randomised, double-blind SUNRISE study (Abstract number 192). In: International Continence Society (ICS); 38th Annual Meeting; 2008 Oct 20-24; Cairo, Egypt. 2008. [srincont-31885]CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CardozoL , HessdörferE , MilaniR , ArañóP , DewildeL , SlackM , et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU International2008;102(9):1120-7. [NCT00801944] [TrialID.SUNRISE] [srincont-29249]">Cardozo 2008a</a>; <a href="./references#CD003781-bbs2-0015" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. ChappleC , RechbergerT , Al-ShukriS , MeffanP , EveraertK , RidderA . Results of a randomized phase 3 study comparing solifenacin succinate with tolterodine and placebo in patients with symptomatic overactive bladder (Abstract). Neurourology and Urodynamics2003;22(5):534-5. [sr-incont16991]ChappleCR , RechbergerT , Al ShukriS , MeffanP , EveraertK , HuangM , et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU International2004;93(3):303-10. [srincont-17270]">Chapple 2004c</a>; <a href="./references#CD003781-bbs2-0016" title="ChappleC , Van KerrebroeckP , TubaroA , Haag-MolkentellerC , ForstHT , MassowU , et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder [Erratum appears in: European Urology 2008,53(6):1319]. European Urology2007;52(4):1204-12. [NCT00220363] [SP583] [srincont-23875]ChappleC , Van KerrebroeckP , TubaroA , MillardR . Fesoterodine in non-neurogenic voiding dysfunction - results on efficacy and safety in a phase 3 trial (Abstract number 379). In: 21st Annual European Association of Urology (EAU) Congress; 2006 Apr 5-8; Paris, France. 2006. [srincont-41109]ChappleC , Van KerrebroeckP , TubaroA , WangJT , HvidstenK , BrodskyM . Efficacy of fesoterodine in patients with overactive bladder (OAB): improvements in OAB symptoms and health-related quality of life (HRQL) (Poster abstract number 1188). Journal of Urology2007;177(4 Suppl S):392. [srincont-31882]ChappleCR , vanKerrebroeckPE , JünemannKP , WangJT , BrodskyM . Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU International2008;102(9):1128-32. [srincont-29255]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. KelleherCJ , TubaroA , WangJT , KoppZ . Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU International2008;102(1):56-61. [srincont-27613]SandPK , MorrowJD , BavendamT , CreangaDL , NittiVW . Efficacy and tolerability of fesoterodine in women with overactive bladder. International Urogynecology Journal2009;20(7):827-35. [srincont-31351]">Chapple 2007a</a>; <a href="./references#CD003781-bbs2-0017" title="ChappleC , DuBeauC , EbingerU , RekedaL , ViegasA . Darifenacin treatment of patients &gt;or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Current Medical Research and Opinion2007;23(10):2347-58. [srincont-23921]">Chapple 2007b</a>; <a href="./references#CD003781-bbs2-0018" title="ChappleCR , DvorakV , RadziszewskiP , vanKerrebroeckP , WyndaeleJJ , BosmanB , et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder. International Urogynecology Journal2013;24(9):1447-58. [178-CL-044] [NCT00337090] [TrialID.DRAGON.] [sr-incont48549]NCT00337090 . A study of YM178 in patients with symptomatic overactive bladder (DRAGON) [A randomized, double-blind, parallel group, placebo and active controlled, multicenter dose ranging study with the beta-3 agonist YM178 in patients with symptomatic overactive bladder]. clinicaltrials.gov/show/NCT00337090 (first received 15 June 2006). [EudraCT2005-002256-17] [JapicCTI-R130350] [NCT00337090] [sr-incont63803]">Chapple 2013</a>; <a href="./references#CD003781-bbs2-0019" title="ChappleC , HaabF , SchneiderT , CarlssonM , ArumiD . Fesoterodine 8 mg versus fesoterodine 4 mg in patients with overactive bladder and a history of previous antimuscarinic therapy: Results from the EIGHT trial (Abstract number: Poster #M5). Neurourology and Urodynamics2015;34(S1):S20. [NCT01302067] [sr-incont68509]ChappleC , SchneiderT , HaabF , SunF , WhelanL , ScholfieldD , et al. Superiority of fesoterodine 8mg versus fesoterodine 4 mg in reducing urgency urinary incontinence episodes in subjects with overactive bladder: results of the randomized, double-blind, placebo-controlled EIGHT trial (Abstract number: Podium #48). Neurourology and Urodynamics2014;33(2):183-4. [NCT01302067] [sr-incont67484]ChappleC , SchneiderT , HaabF , SunF , WhelanL , ScholfieldD , et al. Superiority of fesoterodine 8mg vs 4mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial. BJU International2014;114(3):418-26. [A0221095] [NCT01302067] [TrialID.EIGHT] [srincont-62537]NCT01302067. A 12 week study to confirm the effectiveness of 8mg of Fesoterodine compared to 4mg of Fesoterodine [A 12-week, randomized, double-blind, placebo controlled, parallel group, multicenter trial in overactive bladder subjects to confirm the efficacy of 8 mg fesoterodine compared to 4 mg fesoterodine]. clinicaltrials.gov/show/NCT01302067 (first received 23 February 2011). [NCT01302067] [sr-incont63792]">Chapple 2014</a>; <a href="./references#CD003781-bbs2-0020" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. [sr-incont75259]ChuF , SmithN , UchidaT . Efficacy and safety of solifenacin succinate 10 mg once daily: a multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder. Current Therapeutic Research - Clinical and Experimental2009;70(6):405-20. [srincont-43324]">Chu 2009</a>; <a href="./references#CD003781-bbs2-0021" title="ChuaME , SeeMC , EsmeňaEB , BalingitJC , MoralesML . Efficacy and safety of gabapentin in comparison to solifenacin succinate in adult overactive bladder treatment. Lower Urinary Tract Symptoms2018;10(2):135-42. [NCT01486706] [sr-incont74529]NCT01486706, ChuaME . Efficacy and safety of gabapentin in treating overactive bladder (OAB). clinicaltrials.gov/show/NCT01486706 (first received 6 December 2011). [NCT01486706] [SLMC10-010] [sr-incont49864]">Chua 2018</a>; <a href="./references#CD003781-bbs2-0022" title="AmarencoG , SutoryM , FagertunH , WrightM , CompionG , De RidderD . Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Preliminary results from the SONIC urodynamic study (Abstract). European Urology, Supplements2012;11(1):e467-a. [EudraCT2006-005523-42] [NCT00629642] [sr-incont65392]AmarencoG , SutoryM , ZachovalR , AgarwalM , DelPG , TretterR , et al. Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study. Neurourology and Urodynamics2017;36(2):414-21. [EudraCT2006-005523-42] [JapicCTI-R130306] [NCT00629642] [sr-incont72248]De RidderD , AmarencoG , Finazzi-AgroE , AnguloJ , KurenkovA , WrightM , et al. Solifenacin treatment for neurogenic detrusor overactivity: patient-reported outcomes (PROs) from the randomised clinical trial SONIC (Abstract number 333). In: International Continence (ICS); 42nd Annual Meeting; 2012 Oct 15-19; Beijing, China. 2012. [905-EC-005] [EudraCT2006-005523-42] [NCT00629642] [TrialID.SONIC.] [srincont-49739]">De Ridder 2012</a>; <a href="./references#CD003781-bbs2-0023" title="ChancellorMB , OefeleinMG , VasavadaS . Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release. Neurourology and Urodynamics2010;29(4):551-4. [sr-incont39591]DmochowskiR , StaskinD , SandP , ZinnerN . Trospium chloride 60 mg once daily improves quality of life in subjects with overactive bladder syndrome (Abstract number 277). In: International Continence Society (ICS); 37th Annual Meeting; 2008 Aug 20-24; Rotterdam, the Netherlands. 2007. [srincont-26679]DmochowskiRR , RosenbergMT , ZinnerNR , StaskinDR , SandPK . Extended-release trospium chloride improves quality of life in overactive bladder. Value in Health2010;13(2):251-7. [srincont-40049]DmochowskiRR , SandPK , ZinnerNR , StaskinDR . Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology2008;71(3):449-54. [srincont-27107]DmochowskiRR , ZinnerNR , SandPK . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: Results from a multicenter, phase III, placebo-controlled study (Abstract). Neurourology and Urodynamics2007;26(Suppl 7):1105-6. [srincont-26692]GinsbergDA , OefeleinMG , EllsworthPI . Once-daily administration of trospium chloride extended release provides 24-hr coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials. Neurourology and Urodynamics2011;30(4):563-7. [sr-incont41531]RovnerE , DmochowskiR , WatanabeJ . Once daily (QD) trospium chloride 60 mg extended release (XR) is safe and effective in patients (PTS) with the overactive bladder (OAB) syndrome who use multiple concomitant medications (MEDS) (Abstract number: Poster #68). Neurourology and Urodynamics2009;28(2):146-7. [sr-incont31062]SandP , DmochowskiR , ZinnerN , StaskinD . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: results from a multicenter, phase III, placebo-controlled study (Abstract number 269). In: International Continence Society (ICS), 37th Annual Meeting; 2007 Aug 20-24; Rotterdam, the Netherlands. 2007. [srincont-26676]SandPK , DmochowskiRR , ZinnerNR , StaskinDR , AppellRA . Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome. International Urogynecology Journal and Pelvic Floor Dysfunction2009;20(12):1431-8. [sr-incont39648]SandPK , Johnson IiTM , RovnerES , EllsworthPI , OefeleinMG , StaskinDR . Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged &gt; 75 years) with overactive bladder syndrome. BJU International2011;107(4):612-20. [sr-incont41422]StaskinDR , RosenbergMT , SandPK , ZinnerNR , DmochowskiRR . Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials. International Journal of Clinical Practice2009;63(12):1715-23. [sr-incont35458]">Dmochowski 2008</a>; <a href="./references#CD003781-bbs2-0024" title="DmochowskiR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. A double-blind, placebo-controlled trial of flexible-dose fesoterodine for overactive bladder (Abstract number 715). In: International Continence Society (ICS); 39th Annual Meeting; 2009 Sep 29-Oct 03; San Francisco, CA. 2009. [sr-incont35627]DmochowskiRR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder [Errata appear in: Urology 2010 Jun;75(6):1519 and in Urology 2011 Jun;77(6):1513]. Urology2010;75(1):62-8. [A0221014] [NCT00536484] [sr-incont39548]DuBeauC , KrausSR , SunF , MorrowJD . Fesoterodine in older vs younger subjects with overactive bladder (Abstract number D87). Journal of the American Geriatrics Society2010;58:S218. [NCT00536484] [sr-incont64309]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. [sr-incont78640]NCT00536484. Fesoterodine flexible dose study [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with overactive bladder]. clinicaltrials.gov/show/NCT00536484 (first received 27 September 2007). [NCT00536484] [sr-incont49160]StaskinD , KhullarV , MichelMC , MorrowJD , SunF , GuanZ , et al. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. Neurourology and Urodynamics2011;30(8):1480-5. [sr-incont42686]">Dmochowski 2010</a>; <a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>; <a href="./references#CD003781-bbs2-0028" title="ElbasetM , TahaD , ZahranM , EzzatO , ElhefnawyAS , ElkenawyM , et al. Subjective and objective scales assessment after retreatment with anticholinergics post botox-faded effects in refractory idiopathic overactive bladder: a prospective single blinded randomized trial (Abstract number 132). European Urology, supplements2019;18(1):e172. [sr-incont78652]ElbasetMA , TahaDE , El-HefnawyAS , ZahranMH , ShokeirAA . Assessment of anticholinergic use after fading of BTX-A effects in refractory idiopathic overactive bladder: a prospective blinded randomized trial. International Neurourology Journal2019;23(3):240-8. [sr-incont78605]">Elbaset 2019</a>; <a href="./references#CD003781-bbs2-0029" title="EUCTR2004-001116-31-ES. Multicentre, randomised, double-blind, parallel group confirmatory Phase III study to compare the efficacy and safety of cizolirtine citrate 300 mg bid (600 mg/d), cizolirtine citrate 400 mg bid (800 mg/d), placebo, and tolterodine 2 mg bid (4 mg/d) in the treatment of urge urinary incontinence. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-001116-31 (first received 03 November 2004). [ESCLIN-002/04] [EUCTR2004-001116-31-ES] [sr-incont64643]">EUCTR2004‐001116‐31‐ES</a>; <a href="./references#CD003781-bbs2-0030" title="EUCTR2004-002143-27-AT. A double-blind, stratified, randomised, parallel, placebo-controlled, multi-centre study to compare the efficacy and safety of duloxetine hydrochloride (40mg twice a day) and tolterodine tartrate (XL) (4mg once daily) with placebo in patients with symptoms of Urge Urinary Incontinence. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-002143-27 (first received 15 February 2005). [1208.15] [EUCTR2004-002143-27-AT] [sr-incont64640]">EUCTR2004‐002143‐27‐AT</a>; <a href="./references#CD003781-bbs2-0031" title="EUCTR2007-004126-24-CZ. A placebo controlled randomized, 12-week, dose-ranging, double-blind study versus placebo using tolterodine as a study calibrator, to evaluate efficacy and safety of SSR240600C in women with overactive bladder including urge urinary incontinence. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-004126-24 (first received 12 December 2007). [DRI6271] [EUCTR2007-004126-24-CZ] [EudraCT2007-004126-24] [NCT00564226] [TrialID.BILADY] [sr-incont64596]NCT00564226. SSR240600C treatment in women with overactive bladder (BILADY) [A placebo controlled randomized, 12-week, dose-ranging, double-blind study versus placebo using tolterodine as a study calibrator, to evaluate efficacy and safety of SSR240600C in women with overactive bladder including urge urinary incontinence]. clinicaltrials.gov/show/NCT00564226 (first received 27 November 2007). [DRI6271] [EudraCT2007-004126-24] [NCT00564226] [TrialID.BILADY] [sr-incont63784]">EUCTR2007‐004126‐24‐CZ</a>; <a href="./references#CD003781-bbs2-0032" title="GellerE , DumondJ , BowlingJM , KhandelwalC , WuJ , Busby-WhiteheadJ , et al. Effect of an anticholinergic on cognitive function in postmenopausal women: a randomized trial (Abstract number: oral poster 52). Female Pelvic Medicine and Reconstructive Surgery2016;22(5):S61. [sr-incont78607]GellerEJ , DumondJB , BowlingJM , KhandelwalCM , WuJM , Busby-WhiteheadJ , et al. Effect of trospium chloride on cognitive function in women aged 50 and older: a randomized trial. Female Pelvic Medicine &amp; Reconstructive Surgery2017;23(2):118-23. [13-1352] [NCT01922115] [sr-incont74341]NCT01922115. The effect of anticholinergics on cognitive function in the elderly (ACE) [The effect of anticholinergics on cognitive function in the elderly: a randomized controlled trial]. clinicaltrials.gov/show/NCT01922115 (first received 14 August 2013). [13-1352] [NCT01922115] [TrialID.ACE] [sr-incont49282]">Geller 2013</a>; <a href="./references#CD003781-bbs2-0033" title="GotohM , HommaY , YokoyamaO , NishizawaO . Responsiveness and minimal clinically important change in overactive bladder symptom score. Urology2011;78(4):768-73. [srincont-42622]GotohM , YokoyamaO , MatsukawaY , NishizawaO . Responsiveness of overactive bladder symptom score (OABSS): verification based on data in a double-blinded, randomized placebo-controlled study of propiverine hydrochloride in Japanese patients (Abstract number 338). In: Joint Meeting of the International Continence Society (ICS) and the International Urogynecological Association; 2010 Aug 23-27; Toronto, Canada. 2010. [srincont-40173]GotohM , YokoyamaO , NishizawaO . Propiverine hydrochloride in Japanese patients with overactive bladder: A randomized, double-blind, placebo-controlled trial. International Journal of Urology2011;18(5):365-73. [srincont-41510]">Gotoh 2011</a>; <a href="./references#CD003781-bbs2-0034" title="GriebenowR , WienersF , LangeT . Possible induction of cardiac dysrhythmia in elderly patients under therapy with propiverine hydrochloride (Abstract). Neurourology and Urodynamics1994;13:430-2. [sr-incont2681]">Griebenow 1994</a>; <a href="./references#CD003781-bbs2-0036" title="HajebrahimiS , MotlaghRS , BazarganiHS , BabaieH . Efficacy of tadalafil in treatment of overactive bladder syndrome: a randomized controlled trial (Abstract number OP.3.6Dec.27). International Journal of Urology2014;21:A146. [IRCT2013030212668N1] [sr-incont67256]IRCT2013030212668N1. Effect of tadalafil in treatment of overactive bladder  [Comparison of the efficacy of tadalafil, toltrodine and placebo in reduction of symptoms severity of women with urgency, frequency syndrom / overactive bladder]. en.irct.ir/trial/12692 (first received 26 January 2013). [91189] [IRCT2013030212668N1] [sr-incont78643]">Hajebrahimi 2014</a>; <a href="./references#CD003781-bbs2-0038" title="HerschornS , HeesakkersJ , Castro-DiazD , WangJT , BrodskyM , GuanZ . Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*. Current Medical Research and Opinion2008;24(12):3513-21. [A6121122] [NCT00143377] [srincont-29250]HerschornS , HeesakkersJ , Castro-DiazD , WangJT , GuanZ , BrodskyM . Tolterodine extended release (TER) improves objective and subjective outcomes after 1 week of treatment in patients with overactive bladder (Abstract number 132). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S78-9. [srincont-26602]">Herschorn 2008</a>; <a href="./references#CD003781-bbs2-0039" title="CorcosJ , AnguloJC , GarelyAD , CarlssonM , GongJ , GuanZ . Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. Current Medical Research and Opinion2011;27(5):1059-65. [srincont-41596]EUCTR2006-006935-38-SE. 12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006935-38 (first received 16 April 2007). [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont64612]HerschornS , SwiftS , GuanZ , CarlssonM , BrodskyM , GongJ . Efficacy and safety of fesoterodine for overactive bladder in a double-blind, head-to-head comparison trial with tolterodine ER and placebo (Abstract number 710). In: International Continence Society (ICS), 39th Annual Meeting; 2009 Sep 29-Oct 3; San Francisco, CA. 2009. [srincont-35326]HerschornS , SwiftS , GuanZ , CarlssonM , MorrowJD , BrodskyM , et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU International2010;105(1):58-66. [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont39540]NCT00444925. Clinical trial to evaluate the efficacy and safety of Fesoterodine in comparison to Tolterodine for overactive bladder (OAB) [12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder (OAB)]. clinicaltrials.gov/show/NCT00444925 (first received 08 March 2007). [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont49159]">Herschorn 2009a</a>; <a href="./references#CD003781-bbs2-0040" title="EUCTR2012-005735-91-SK. A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-005735-91 (first received 12 November 2013). [178-CL-101] [EUCTR2012-005735-91-SK] [sr-incont78644]HerschornS , ChappleCR , AbramsP , ArlandisS , MitchesonD , LeeKS , et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU International2017;120(4):562-75. [NCT01972841] [sr-incont74470]MuellerER , RobinsonD , KelleherC , StaskinDR , FalconerC , WangJ , et al. Patient reported outcomes from synergy, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with mirabegron and solifenacin monotherapy (Abstract number - Podium #44). Neurourology and Urodynamics2017;36(Suppl S1):S151-2. [NCT01972841] [sr-incont75944]NCT01972841. This was a multinational study comparing the efficacy and safety of two medicines, solifenacin succinate and mirabegron taken together, or separately, or a mock treatment (placebo) in subjects with symptoms of overactive bladder (SYNERGY) [A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01972841 (first received 31 October 2013). [178-CL-101] [EUCTR2012-005735-91] [NCT01972841] [sr-incont63780]RobinsonD , KelleherC , StaskinD , MuellerER , FalconerC , WangJ , et al. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients. Neurourology and Urodynamics2018;37(1):394-406. [NCT01972841] [sr-incont76906]WeberMA , ChappleCR , GratzkeC , HerschornS , RobinsonD , FrankelJM , et al. A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial. Blood Pressure Monitoring2018;23(3):153-63. [NCT01972841] [sr-incont77899]WhiteWB , ChappleC , GratzkeC , HerschornS , RobinsonD , FrankelJ , et al. Cardiovascular safety of the beta3-adrenoceptor agonist mirabegron and the antimuscarinic agent solifenacin in the SYNERGY trial. Journal of Clinical Pharmacology2018;58(8):1084-91. [NCT01972841] [sr-incont78078]">Herschorn 2017a</a>; <a href="./references#CD003781-bbs2-0041" title="HerschornS , KohanA , AliottaP , McCammonK , SriramR , AbramsS , et al. The efficacy and safety of onabotulinumtoxin A or solifenacin compared with placebo in solifenacin naive patients with refractory overactive bladder: results from a multicenter, randomized, double-blind phase 3b trial. Journal of Urology2017;198(1):167-75. [NCT01767519] [sr-incont74491]NCT01767519. A study evaluating the efficacy and safety of BOTOX® or solifenacin in patients with overactive bladder and urinary incontinence. clinicaltrials.gov/show/NCT01767519 (first received 14 January 2013). [191622-125] [NCT01767519] [sr-incont49909]">Herschorn 2017b</a>; <a href="./references#CD003781-bbs2-0042" title="HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21072]HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21072]HillS , KhullarV , WyndaeleJJ , LheritierK , . Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. International Urogynecology Journal and Pelvic Floor2006;17(3):239-47. [srincont-22464]">Hill 2005</a>; <a href="./references#CD003781-bbs2-0044" title="HommaY , YamaguchiT , YamaguchiOA . A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2008;15(9):809-15. [srincont-27742]">Homma 2008</a>; <a href="./references#CD003781-bbs2-0045" title="HommaY , YamaguchiO , Imidafenacin Study Group. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2009;16(5):499-506. [NCT00212732] [ONO-8025-08] [srincont-31368]">Homma 2009</a>; <a href="./references#CD003781-bbs2-0046" title="HuangA , HessR , AryaL , RichterH , SubakL , BradleyC , et al. A randomized controlled trial of simple diagnosis and treatment for urgency urinary incontinence in women (Abstract). Journal of General Internal Medicine2011;26:S1. [NCT00862745] [sr-incont64391]HuangAJ , HessR , AryaLA , RichterHE , SubakLL , BradleyCS , et al. Pharmacologic treatment for urgency-predominant urinary incontinence in women diagnosed using a simplified algorithm: a randomized trial. American Journal of Obstetrics and Gynecology2012;206(5):444.e1-11. [GA0221IX] [NCT00862745] [TrialID.BRIDGES.] [srincont-44636]NCT00862745, BrownJ . Bringing simple urge incontinence diagnosis &amp; treatment to providers (BRIDGES)  [A multi-center, randomized, placebo-controlled clinical trial comparing fesoterodine to placebo in women diagnosed with urge urinary incontinence by the 3 Incontinence Questions (3IQ). Followed by a multi-center open label clinical cohort study of long-term effects of treatment with fesoterodine ]. clinicaltrials.gov/show/NCT00862745 (first received 17 March 2009). [NCT00862745] [sr-incont49836]WarsiQ , HuangA , BrownJS , SchembriM , HessR , AryaLA , et al. The effect of pharmacologic treatment of urgency urinary incontinence on sleep quality and daytime sleepiness (Abstract number: paper 37). Female Pelvic Medicine and Reconstructive Surgery2016;22(5 ):S17-8. [NCT00862745] [TrialID.BRIDGES.] [sr-incont78633]WarsiQA , HuangAJ , HessR , AryaLA , RichterHE , BradleyCS , et al. Association of pharmacologic treatment of urgency urinary incontinence with sleep quality and daytime sleepiness. Obstetrics and Gynecology2018;131(2):204-11. [NCT00862745] [sr-incont78239]WinkelmanW , HuangA , SchembriM , RogersRG , RichterHE , MyersDL , et al. Clinical variables moderating response to pharmacologic treatment of urgency-predominant urinary incontinence in a randomized controlled trial (Abstract number: poster 25). In: Female Pelvic Medicine and Reconstructive Surgery. 37th Annual Scientific Meeting of the American Urogynecologic Society; Aug 2016; United States. Vol. 22. Netherlands: Lippincott Williams and Wilkins, 2016:S81. [NCT00862745] [sr-incont78634]WinkelmanWD , HuangAJ , SchembriM , RogersRG , RichterH , MyersDL , et al. Modifiers of response to treatment with fesoterodine for urgency-predominant urinary incontinence in a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2017;23(2):151-6. [sr-incont74308]">Huang 2012</a>; <a href="./references#CD003781-bbs2-0050" title="JünemannKP , HessdörferE , Unamba‐OparahI , BerseM , BrünjesR , MadersbacherH . Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. Urologia Internationalis2006;77(4):334-9. [srincont-22199]">Junemann 2006</a>; <a href="./references#CD003781-bbs2-0051" title="EUCTR2007-006451-39-SE. 12-week, randomized, double-blind, double-dummy, placebo controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-006451-39 (first received 20 February 2008). [A0221046] [EUCTR2007-006451-39-SE] [sr-incont64591]KaplanSA , SchneiderT , FooteJ , GuanZ . Superior efficacy of fesoterodine over tolterodine with rapid onset: a prospective, head-to-head, placebo-controlled trial (Abstract number 67). Neurourology and Urodynamics2010;29(6):905-7. [srincont-40130]KaplanSA , SchneiderT , FooteJE , GuanZ , CarlssonM , GongJ . Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU International2011;107(9):1432-40. [A0221046] [NCT00611026] [srincont-41334]">Kaplan 2011</a>; <a href="./references#CD003781-bbs2-0052" title="CardozoL , KaplanS , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: results from the after study (Abstract number 740) [Erratum appears in: European Urology 2014;65(5):e78]. European Urology Supplements2013;12(1):e740-1. [NCT01302054] [sr-incont63732]CardozoL , KaplanS , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. Erratum: A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: results from the AFTER study [Erratum available in: European Urology Supplement 2013;2012:e740-1]. European Urology2014;65(5):e78 . [A0221094] [NCT01302054] [TrialID.AFTER.] [sr-incont61642]GrenaboL , HerschornS , KaplanSA , CardozoL , ScholfieldD , ArumiD , et al. Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptoms. Current Medical Research and Opinion2017;33(10):1731-6. [NCT01302054] [TrialID.AFTER.] [sr-incont76695]KaplanSA , CardozoL , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER. International Journal of Clinical Practice2014;68(9):1065-73. [A0221094] [NCT01302054] [TrialID.AFTER.] [srincont-63977]KaplanSA , HerschornS , CarlssonM , NtaniosF . Urgency urinary incontinence response rates in subjects with overactive bladder treated with fesoterodine 8 mg after suboptimal response to tolterodine extended release 4 mg: a randomized, double-blind, placebo-controlled trial (Abstract number 546). In: International Continence Society (ICS); 43rd Annual Meeting; 2013 Aug 26-30; Barcelona, Spain. 2013. [NCT01302054] [TrialID.AFTER.] [sr-incont49730]NCT01302054. A clinical study in patients with overactive bladder with leakage of urine, to find out if the medicine, Fesoterodine, works in those patients who did not have enough response to the medicine, tolterodine. [A 14 week randomized parallel group placebo-controlled double-blind multicentre study of fesoterodine 8 mg in overactive bladder patients with sub-optimal response to tolterodine 4 mg extended release (ER)]. clinicaltrials.gov/show/NCT01302054 (first received 23 February 2011). [A0221094] [NCT01302054] [TrialID.AFTER.] [sr-incont49845]">Kaplan 2014</a>; <a href="./references#CD003781-bbs2-0053" title="CapoJP , TogliaM , Forero-SchwanhaeuserS , HeW . Patients reporting severe overactive bladder symptoms: effects of solifenacin treatment on objective measures and patient-reported outcomes (Abstract number 582). In: International Continence Society (ICS), 38th Annual Meeting; 2008 Oct 20-24; Cairo, Egypt. 2008. [srincont-31844]CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. KarramMM , TogliaMR , SerelsSR , AndohM , FakhouryA , Forero-SchwanhaeuserS . Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology2009;73(1):14-8. [A0221094] [NCT00454896] [TrialID.VENUS.] [srincont-29219]SerelsSR , TogliaMR , Forero-SchwanhaeuserS , HeW . Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms. Current Medical Research and Opinion2010;26(10):2277-85. [srincont-40376]StaskinD , DmochowskiR , SerelsS , AndohM , SmithN . Report from a randomized, placebo-controlled study showing significant improvement in urgency and patient-reported outcomes in overactive bladder patients treated with solifenacin (Abstract number 124). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73-4. [srincont-26600]TogliaM , AndohM , HussainI . Solifenacin improved warning time significantly compared to placebo in patients with overactive bladder (Abstract number 123). Neurourology and Urodynamics2006;25(6):655. [srincont-26629]TogliaM , AndohM , HussainI . Solifenacin improves urgency symtoms as assessed by voiding diaries and patient-reported outcomes (PRO) in patients with overactive bladder (Abstract number 155). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26636]TogliaMR , OstergardDR , AppellRA , AndohM , FakhouryA , HussainIF . Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status. International Urogynecology Journal2010;21(7):847-54. [srincont-40094]TogliaMR , SerelsSR , LarameeC , KarramMM , NandyIM , AndohM , et al. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial. Postgraduate Medicine2009;121(5):151-8. [srincont-34204]ZinnerS , HerschornS , AndohM , HussainI . Responder analyses show statistically significant improvements in incontinence and urgency are associated with reduction in symptom bother and improvement in health-related quality of life: VENUS results (Abstract number 123). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73. [srincont-26599]">Karram 2009</a>; <a href="./references#CD003781-bbs2-0055" title="AballéaS , MamanK , ThokagevistkK , NazirJ , OdeyemiIA , HakimiZ , et al. Cost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United Kingdom. Clinical Drug Investigation2015;35(2):83-93. [NCT00689104] [sr-incont66445]Arlandis-GuzmánS , Brenes-BermúdezF , Jiménez-CidreMA , Rubio-RodríguezD , Rubio-TerrésC , MoraAM , et al. Cost effectiveness of Mirabegron and antimuscarinic drugs in patients with hiperactive bladder [Coste-efectividad de mirabegrón y los antimuscarínicos en pacientes con vejiga hiperactiva]. Archivos Espanoles de Urologia2018;71(10):809-24. [NCT00689104] [sr-incont78645]EUCTR2007-001451-19-ES. A randomized, double-blind, parallel group, placebo and active controlled, multicenter study to assess the efficacy and safety of the beta-3 agonist YM178 (50 mg qd and 100 mg qd) in subjects with symptoms of overactive bladder - SCORPIO [Estudio multicentrico, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo y tratamiento activo, para evaluar la eficacia y seguridad del agonista beta-3 YM178 (50 mg, una vez al dia y 100 mg, una vez al dia) en pacientes con sintomas de vejiga hiperactiva]. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-001451-19 (first received 05 June 2008). [EUCTR2007-001451-19-ES] [sr-incont78646]HerschornS , NazirJ , RamosB , HakimiZ . Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada. Canadian Urological Association Journal2017;11(3-4):123-30. [NCT00689104] [sr-incont76807]KhullarV , AmarencoG , AnguloJ , BoerrigterP , BlauwetM , HakimiZ . The potent and selective beta3-adrenoceptor agonist mirabegron improves patient-reported outcomes in the treatment of overactive bladder (Abstract number MP-12.16). Urology2012;80(3 Suppl 1):S123. [sr-incont65379]KhullarV , AmarencoG , AnguloJC , BlauwetMB , NazirJ , OdeyemiIA , et al. Patient-reported outcomes with the β3 beta3-adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder. Neurourology and Urodynamics2016;35(8):987-94. [NCT00689104] [sr-incont72221]KhullarV , AmarencoG , AnguloJC , CambroneroJ , HøyeK , MilsomI , et al. Efficacy and tolerability of mirabegron, a ß3-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. European Urology2013;63(2):283-95. [NCT00689104] [TrialID.SCORPIO.] [sr-incont46836]KhullarV , CambroneroJ , AnguloJ , WooningM , BlauwetM , SiddiquiE , et al. Onset of action of efficacy of the potent and selective beta-3-adrenoceptor agonist, mirabegron, for the treatment of overactive bladder (OAB) in a 12-week, multicentre, randomised, double-blind, parallel-group, placebo-and tolterodine slow release (SR)-controlled study in OAB patients (Abstract number 135). International Urogynecology Journal and Pelvic Floor Dysfunction2012;23(2 Suppl 1):S187-8. [NCT00689104] [sr-incont67382]KhullarV , CambroneroJ , AnguloJC , WooningM , BlauwetMB , DorrepaalC , et al. Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial. BMC Urology2013;13:45. [NCT00689104] [sr-incont49411]KhullarV , CambroneroJ , StroebergP , AnguloJ , BoerrigterP , WooningM . The efficacy and tolerability of mirabegron, a potent and selective B3-adrenoceptor agonist, compared with placebo and tolterodine slow release in patients with overactive bladder - results from a European-Australian phase III trial (Abstract number 328). In: International Continence Society (ICS); 41st Annual Meeting; 2011 Aug 29-Sept 2; Glasgow, Scotland. 2011. [NCT00689104] [sr-incont42211]NCT00689104. Study to assess the efficacy and safety of the beta-3 agonist mirabegron (ym178) in patients with symptoms of overactive bladder (SCORPIO) [A randomized, double-blind, parallel group, placebo and active controlled, multicenter study to assess the efficacy and safety of mirabegron in subjects with symptoms of overactive bladder (SCORPIO)]. clinicaltrials.gov/show/NCT00689104 (first received 03 June 2008). [NCT00689104] [sr-incont49843]NittiV , HerschornS , AuerbachS , KhullarV , AmarencoG , BlauwetMB , et al. The potent and selective ß3-adrenoceptor agonist mirabegron improves patient-reported outcomes in overactive bladder-results from two phase III studies (Abstract number 68). Neurourology and Urodynamics2012;31(6):813-5. [NCT00689104] [sr-incont46724]WielageRC , PerkS , CampbellNL , NgD , KleinTM , PostaLM , et al. The cost effectiveness of mirabegron for the treatment of overactive bladder: three US perspectives (Abstract number A142). Journal of the American Geriatrics Society2015;63:S67. [NCT00689104] [sr-incont70876]YamanishiT , YamanishiY , TajimaH , IkedaS . Cost-effectiveness of mirabegron and tolterodine for the treatment of overactive bladder in Japan-Which drug is more cost-effective if used as the first-line treatment? (Abstract number 504). International Urogynecology Journal2018;29:S252. [NCT00689104] [sr-incont78647]YamanishiY , YamanishiT , TajimaH , IkedaS . Mirabegron or tolterodine for the treatment of overactive bladder in Japan: Which drug is more cost-effective as the first-line treatment?International Journal of Urology2018;25(10):863-70. [NCT00689104] [sr-incont78648]">Khullar 2013</a>; <a href="./references#CD003781-bbs2-0056" title="KosilovKV , LoparevS , IvanovskayaM , KosilovaL . Treatment of overactive bladder in older women increased doses of antimuscarinic drugs safe and effective alternative to existing methods. Advances in Gerontology [Uspekhi Gerontologii]2014;27(1):149-55. [ISSN: 1561-9125] [sr-incont63914]">Kosilov 2014a</a>; <a href="./references#CD003781-bbs2-0057" title="KosilovK , LoparevS , IvanovskayaM , KosilovaL . A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron. Archives of Gerontology and Geriatrics2015;61(2):212-6. [sr-incont68133]">Kosilov 2015a</a>; <a href="./references#CD003781-bbs2-0058" title="KosilovKV , LoparevSA , IvanovskayaMA , KosilovaLV . The efficacy of different doses of solifenacin in elderly patients after treating a urinary tract infection. Arab Journal of Urology Print2015;13(3):203-8. [sr-incont69283]">Kosilov 2015b</a>; <a href="./references#CD003781-bbs2-0059" title="KrederK , PleilAM , ReesePR , KelleherJ . Effects of long-term tolterodine treatment on social and psychological aspects of health-related quality of life in overactive bladder patients (Abstract). Journal of Urology2002;167(Suppl 4):29. [sr-incont17591]">Kreder 2002</a>; <a href="./references#CD003781-bbs2-0060" title="HsiaoSM , ChangTC , ChenCH , WuWY , LinHH . Comparisons of the clinical outcomes and urodynamic effects of mirabegron versus tolterodine treatment for female overactive bladder syndrome: a subgroup analysis of a controlled, randomised, prospective study. Lower Urinary Tract Symptoms2018;10(3):215-20. [NCT01043666] [sr-incont74461]KuoHC , LeeKS , NaY , SoodR , NakajiS , KubotaY , et al. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourology and Urodynamics2015;34(7):685-92. [NCT01043666] [sr-incont68095]Kuo H‐C, Lin H‐H, Yu H‐J, Cheng C‐L, Hung M‐J, LinAT . Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials [Erratum available in: Urological Science 2015;26(2):148]. Urological Science2015;26(1):41-8 . [NCT01043666] [sr-incont68645]NCT01043666. A study of YM178 in subjects with symptoms of overactive bladder  [Phase III study of YM178: a randomized, double-blind, parallel group, placebo and active controlled, multi-center study in subjects with symptoms of overactive bladder]. clinicaltrials.gov/show/NCT01043666 (first received 07 January 2010). [178-CL-090] [NCT01043666] [sr-incont63781]">Kuo 2015</a>; <a href="./references#CD003781-bbs2-0061" title="LacknerTE , WymanJF , McCarthyTC , MonigoldM , DaveyC . Efficacy of oral extended-release oxybutynin in cognitively impaired older nursing home residents with urge urinary incontinence: a randomized placebo-controlled trial. Journal of the American Medical Directors Association2011;12(9):639-47. [sr-incont42677]LacknerTE , WymanJF , McCarthyTC , MonigoldM , DaveyC . Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. Journal of the American Geriatrics Society2008;56(5):862-70. [sr-incont27117]">Lackner 2011</a>; <a href="./references#CD003781-bbs2-0063" title="LeeKS , ChooMS , KimDY , KimJC , KimHJ , MinKS , et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. Journal of Urology2005;174(4 Pt 1):1334-8. [sr-incont21016]LeeKS , ChooMS , PaickJS , LeeJG , SeoJT , LeeJZ , et al. Propiverine hydrochloride reduced frequency and perception of urgency in treatment of overactive bladder: a 12 week prospective, randomized, double blind, placebo controlled study (Abstract number 279). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26640]LeeKS , LeeHW , ChooMS , PaickJS , LeeJG , SeoJT , et al. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'. BJU International2010;105(11):1565-70. [2005-01-08] [NCT00903045] [PROUD] [sr-incont39958]NCT00903045. Urinary urgency outcomes following propiverine treatment for an overactive bladder [Urinary urgency outcomes following propiverine treatment for an overactive bladder: propiverine study on overactive bladder including urgency data (PROUD)]. clinicaltrials.gov/show/NCT009030452005;(first received 15 May 2009). [2005-01-08] [NCT00903045] [TrialID.PROUD] [sr-incont49860]">Lee 2006</a>; <a href="./references#CD003781-bbs2-0064" title="LuisV , LoyolaJP , MelissaC , FelipeM , San MartinC . Efficacy of darifenacin use combined with pelvic floor physiotherapy in overactive bladder syndrome treatment in women (Abstract number 434). International Urogynecology Journal2018;29(Suppl 1):S220-1. [NCT02143570] [sr-incont78617]NCT02143570, CifuentesM , MartinezF . Efficacy of darifenacin and physiotherapy for the treatment of overactive bladder in women. clinicaltrials.gov/show/NCT02143570 (first received 21 May 2014). [NCT02143570] [sr-incont61781]">Luis 2018</a>; <a href="./references#CD003781-bbs2-0068" title="DmochowskiR , MitchesonD , FrenklT , BennettN , MuddPN . Durable efficacy and safety of long-term once-daily vibegron, a novel oral B-3 adrenergic receptor agonist: A 52-week phase 2 study in patients with overactive bladder syndrome (Abstract number PD50-03). Journal of Urology2018;199(4):e970-1. [sr-incont78091]EUCTR2010-022121-15-IT. A phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2 part clinical study of the efficacy and safety of MK-4618 in patients with overactive bladder - MK4618-008 [A 52-week extension to: a phase iib randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder]. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-022121-15 (first received 12 April 2011). [EUCTR2010-022121-15-IT] [MK4618-008] [NCT01314872] [sr-incont78639]MitchesonD , FrenklT , SamantaS , Anne PintoC , GreenS , BennettN , et al. Vibegron, a novel once daily oral beta-3 agonist, significantly reduces average daily micturitions, urge incontinence episodes and urgency episodes in patients with overactive bladder (Abstract number: podium #34). Neurourology and Urodynamics2018;37(Suppl 1):S565. [EUCTR2010-022121-15-IT] [NCT01314872] [sr-incont78618]MitchesonD , PintoCA , FrenklT , ChenL , PrasadM , MuddPN . Once daily vibegron improves quality of life measures in patients with overactive bladder (Abstract number PUK17). Value in Health2018;21(Suppl 1):S267-8. [EUCTR2010-022121-15-IT] [NCT01314872;] [sr-incont78619]MitchesonHD , SamantaS , MuldowneyK , PintoCA , RochaBA , GreenS , et al. Vibegron (RVT-901/MK-4618/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial. European Urology2019;75(2):274-82. [NCT01314872] [sr-incont78620]NCT01314872. A study of the efficacy and safety of Vibegron (MK-4618) in participants with overactive bladder (OAB) (MK-4618-008) [A phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder a 52-week extension to: a phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder]. clinicaltrials.gov/show/NCT01314872 (first received 15 March 2011). [NCT01314872] [sr-incont63793]UKCRN10391. A phase IIB randomised, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of MK-4618 in patients with overactive bladder . public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=10391 (accessed 28 June 2012). [CCRN525] [UKCRN10391] [sr-incont45046]">Mitcheson 2019</a>; <a href="./references#CD003781-bbs2-0069" title="Drug company. A phase 2, parallel group, stratified, randomized, double blind, placebo-controlled trial to investigate the efficacy and safety of 3 different dosages of sustained release fesoterodine in subjects with overactive bladder showing either involuntary detrusor contractions or normal findings during the baseline urodynamic assessment. Protocol numbers: A0221029 (SP668). ClinicalStudyResults.org (accessed 3 March 2011). [srincont-41111]NittiV , WiatrakM , KreitmanL , LipsitzD . Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB): results of a phase 2 trial (Abstract number 306). In: International Continence Society (ICS); 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21084]">Nitti 2005</a>; <a href="./references#CD003781-bbs2-0070" title="GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NittiVW , DmochowskiR , SandPK , ForstHT , Haag-MolkentellerC , MassowU , et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. Journal of Urology2007;178(6):2488-94. [NCT00138723] [SP584] [srincont-26313]">Nitti 2007</a>; <a href="./references#CD003781-bbs2-0071" title="OlshanskyB , FooteJ , ArguinzonizM , LheritierK , Quebe-FehlingE , SteelM . Cardiovascular safety of darifenacin and tolterodine in patients with overactive bladder (OAB) (Abstract number 49). International Urogynecology Journal and Pelvic Floor Dysfunction2006;17(Suppl 2):S86-7. [sr-incont34186]">Olshansky 2006</a>; <a href="./references#CD003781-bbs2-0072" title="OreskovićS , ButI , BanovićM , GoldstajnMS . The efficacy and safety of solifenacin in patients with overactive bladder syndrome. Collegium Antropologicum2012;36(1):243-8. [srincont-45056]">Oreskovic 2012</a>; <a href="./references#CD003781-bbs2-0073" title="NCT01302938. Web-based methodology trial to evaluate the efficacy and safety of tolterodine ER in subjects with overactive bladder (REMOTE) [Exploratory, randomized, double-blind, placebo-controlled, parallel-group, single center, web-based phase IV pilot methodolgy trial to evaluate the efficacy and safety of tolterodine ER in subjects with overactive bladder]. clinicaltrials.gov/ct2/show/NCT01302938 (first received 24 February 2011). [A6121195] [NCT01302938] [TrialID.REMOTE.] [sr-incont43314]OrriM , LipsetCH , JacobsBP , CostelloAJ , CummingsSR . Web-based trial to evaluate the efficacy and safety of tolterodine ER 4 mg in participants with overactive bladder: REMOTE trial. Contemporary Clinical Trials2014;38(2):190-7. [A6121195] [NCT01302938] [TrialID.REMOTE.] [sr-incont62536]">Orri 2014</a>; <a href="./references#CD003781-bbs2-0075" title="ISRCTN17856439, ResnickN . Pathophysiology of urge incontinence in older women. isrctn.org/ISRCTN17856439 (first received 09 March 2006). [1999P-001891] [94-6641-01] [ISRCTN17856439] [sr-incont64614]">Resnick 2006</a>; <a href="./references#CD003781-bbs2-0076" title="EUCTR2008-005215-17. A study to evaluate the overall effect of solifenacin 5mg and 10mg on bladder wall thickness and urinary nerve growth factor in female subjects with overactive bladder and a diagnosis of detrusor overactivity – a double-blind, randomized, placebo-controlled, parallel group, multicentre study - SHRINK. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-005215-17 (first received 14 September 2009). [EUCTR2008-005215-17] [NCT01093534] [sr-incont78650]NCT01093534. Study of 2 doses of solifenacin succinate in female subjects with overactive bladder (SHRINK) [A study to evaluate the overall effect of solifenacin 5mg and 10mg on bladder wall thickness and urinary nerve growth factor in female subjects with overactive bladder and a diagnosis of detrusor overactivity - a double-blind, randomised, placebo-controlled, parallel group, multi-centre study]. clinicaltrials.gov/show/NCT01093534 (first received 26 March 2010). [905-EC-007] [EUCTR2008-005215-17] [NCT01093534] [TrialID.SHRINK] [sr-incont63778]RobinsonD , KhullarV , OelkeM , WijkstraH , TretterR , StowB , et al. Effects of 12 weeks treatment with solifenacin on Bladder Wall Thickness (BWT) and clinical outcomes: results from the placebo-controlled SHRINK study (Abstract number 422). In: International Continence Society (ICS), 43rd Annual Meeting; 2013 Aug 26-30; Barcelona, Spain. 2013. [905-EC-007] [NCT01093534] [TrialID.SHRINK.] [srincont-49731]RobinsonD , OelkeM , KhullarV , WijkstraH , TretterR , StowB , et al. Bladder wall thickness in women with symptoms of overactive bladder and detrusor overactivity: results from the randomised, placebo-controlled SHRINK study. Neurourology and Urodynamics2016;35(7):819-25. [NCT01093534] [sr-incont72217]RobinsonD , OelkeM , TretterR , StowB , CompionG , TubaroA . The effect of solifenacin on bladder wall thickness in women with overactive bladder and detrusor overactivity: Results from the SHRINK study (Abstract number 782). European Urology Supplements2013;12(1):e782-3. [EUCTR2008-005215-17] [NCT01093534] [sr-incont67207]RobinsonD , TubaroA , KimbergM , PlummerM , DeVineJ , BouicP , et al. The effect of solifenacin on urinary nerve growth factor (UNGF) and brain-derived neurotropic factor (BDNF) in women with overactive bladder and detrusor overactivity: results from the SHRINK study (Abstract number PP 54). International Urogynecology Journal and Pelvic Floor Dysfunction2014;25(1 Suppl 1):S60-1. [EUCTR2008-005215-17] [NCT01093534] [sr-incont67200]TubaroA , KhullarV , OelkeM , WijkstraH , TretterR , StowB , et al. Intra- and inter-reader variability of transvaginal ultrasound bladder wall thickness measurements: results from the SHRINK study (Abstract number 136). Neurourology and Urodynamics2013;32(6):711-2. [EUCTR2008-005215-17] [NCT01093534] [sr-incont49211]">Robinson 2013</a>; <a href="./references#CD003781-bbs2-0077" title="RogersR , BachmannG , JumadilovaZ , SunF , MorrowJD , GuanZ , et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. International Urogynecology Journal and Pelvic Floor Dysfunction2008;19(11):1551-7. [A6121002] [NCT00143481] [srincont-27729]RogersRG , BachmannG , ScarperoH , JumadilovaZ , SunF , MorrowJD , et al. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. Current Medical Research and Opinion2009;25(9):2159-65. [srincont-32060]">Rogers 2008</a>; <a href="./references#CD003781-bbs2-0078" title="RomanziLJ , DelconteA , KralidisG . Impact of darifenacin compared with tolterodine on incontinence episodes in patients with overactive bladder (Abstract number A3522). Obstetrics and Gynecology2005;105(Suppl 4):88S. [sr-incont34187]">Romanzi 2005</a>; <a href="./references#CD003781-bbs2-0080" title="RudyD , ClineK , GoldbergK , HarrisR . A multicenter, randomized, placebo-controlled trial of trospium chloride in overactive bladder patients (Abstract). Neurourology and Urodynamics2004;23(5/6):600-1. [sr-incont19025]RudyD , ClineK , HarrisR , GoldbergK , DmochowskiR . Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology2006;67(2):275-80. [srincont-21604]RudyD , ClineK , HarrisR , GoldbergK , DmochowskiR . Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. BJU International2006;97(3):540-6. [sr-incont21593]">Rudy 2006</a>; <a href="./references#CD003781-bbs2-0081" title="StaskinDR , HarnettMD . Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder. Current Urology Reports2004;5(6):423-6. [sr-incont19422]">Staskin 2004</a>; <a href="./references#CD003781-bbs2-0082" title="ChancellorMB , OefeleinMG , VasavadaS . Obesity is associated with a more severe overactive bladder disease state that is effectively treated with one daily administration of trospium chloride extended release [Erratum available in: Neurourology and Urodynamics 2010;29(5):804]. Neurourology and Urodynamics2010;29(4):551-4. [sr-incont39591]GinsbergDA , OefeleinMG , EllsworthPI . Once-daily administration of trospium chloride extended release provides 24-hour coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials. Neurourology and Urodynamics2011;30(4):563-7. [sr-incont41531]RovnerE , DmochowskiR , WatanabeJ . Once daily (QD) trospium chloride 60mg extended release (XR) is safe and effective in patients (PTS) with the overactive bladder (OAB) syndrome who use multiple concomitant medications (MEDS) (Abstract number: Poster #68). Neurourology and Urodynamics2009;28(2):146-7. [sr-incont31062]SandP , DmochowskiR , ZinnerN , StaskinD . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: results from a multicenter, phase III, placebo-controlled study (Abstract number 269). In: International Continence Society (ICS), 37th Annual Meeting; 2007 Aug 20-24; Rotterdam, the Netherlands. 2007. [sr-incont26676]SandP , StaskinD , ZinnerN , DmochowskiR . Once-daily trospium chloride extended release is effective and well tolerated for the treatment of overactive bladder: results from a multicenter, phase III trial (Abstract number 57). Neurourology and Urodynamics2007;26(5):675. [sr-incont26661]StaskinD , SandP , ZinnerN , DmochowskiR , Trospium Study Group. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. Journal of Urology2007;178(3 Pt 1):978-83; discussion 983-4. [srincont-23909]StaskinDR , RosenbergMT , SandPK , ZinnerNR , DmochowskiRR . Trospium chloride once daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised phase III trials. International Journal of Clinical Practice2009;63(12):1715-23. [sr-incont35458]StaskinDR , SandPK , ZinnerNR . Once-daily trospium chloride extended release is effective and well tolerated for the treatment of overactive bladder: results from a multicenter, phase III trial (Abstract number - poster 22). Neurourology and Urodynamics2007;26(7 Suppl):1106. [srincont-27305]">Staskin 2007</a>; <a href="./references#CD003781-bbs2-0083" title="EUCTR2017-003293-14. Empowur (Empower OAB patients with vibegron for better urgency control) [An international phase 3, randomized, double-blind, placebo- and active (tolterodine)-controlled multicenter study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder]. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-003293-14 (first received 24 April 2018). [EUCTR2017-003293-14] [NCT03492281] [sr-incont78606]NCT03492281, JankowichR . A study to examine the safety and efficacy of a new drug in patients with symptoms of overactive bladder (OAB) [An international phase 3, randomized, double-blind, placebo- and active (tolterodine)-controlled multicenter study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder]. clinicaltrials.gov/show/NCT03492281 (first received 20 April 2018). [NCT03492281] [sr-incont78610]StaskinD , FrankelJ , VaranoS , ShortinoD , JankowichR , MuddPN . Vibegron demonstrates statistically significant improvement in efficacy measures in overactive bladder-key secondary results from the international phase 3 study in patients with overactive bladder (empowur) (Abstract number: long oral 40). Female Pelvic Medicine and Reconstructive Surgery2019;25(5):S20-1. [NCT03492281] [sr-incont78627]StaskinD , FrankelJ , VaranoS , ZhouJ , JankowichR , MuddPN . International phase 3, double-blind, placebo- and active (tolterodine)-controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: empowur (Abstract number LBA-02). Journal of Urology2019;201(4):e992. [NCT03492281] [sr-incont78628]StaskinD , VaranoS , FrankelJ , ShortinoD , JankowichR , MuddP . Once-daily vibegron 75 mg demonstrates statistically significant benefits on key secondary endpoints including quality of life in patients with OAB: data from an international phase 3 trial (EMPOWUR) (Abstract number 181). Neurourology and Urodynamics2019;38(S3):S115-7. [NCT03492281] [sr-incont78629]VaranoS , StaskinD , FrankelJ , ShortinoD , JankowichR , MuddPN . Vibegron statistically significantly improves measures of quality of life in patients with overactive bladder-data from the international phase 3 trial (Empowur) (Abstract number: long oral 38). Female Pelvic Medicine and Reconstructive Surgery2019;25(5):S19. [NCT03492281] [sr-incont78630]">Staskin 2019</a>; <a href="./references#CD003781-bbs2-0084" title="SteersW , CorcosJ . Efficacy, tolerability and safety of darifenacin, an M3 selective receptor antagonist for the treatment of overactive bladder, using a flexible dosing regimen (Abstract number 68). Progres en Urologie2004;14(3 Suppl 3):22. [srincont-22197]">Steers 2004</a>; <a href="./references#CD003781-bbs2-0088" title="TakayasuH , UenoA , TsutidaS , KoisoK , KuritaK , KawabeK , et al. Clinical effects of propiverine hydrochloride in the treatment of urinary frequency and incontinence associated with detrusor overactivity: a double blind, parallel, placebo controlled multicenter study. Igaku No Ayumi (Progress in Medicine)1990;153(8):459-71. [srincont-12896]TakayasuH , UenoA , TsutidaS , KoisoK , KuritaK , KawabeK , et al. Clinical effects of propiverine hydrochloride in the treatment of urinary frequency and incontinence associated with detrusor overactivity: a double blind, parallel, placebo controlled multicenter study. Igaku No Ayumi (Progress in Medicine)1990;153(8):459-71. [sr-incont12896]">Takayasu 1990</a>; <a href="./references#CD003781-bbs2-0092" title="ChancellorM , FreedmanS , MitchesonHD , AntociJ , PrimusG , WeinA . Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clinical Drug Investigation2000;19(2):83-91. [srincont-16326]FreemanR , HillS , MillardR , SlackM , SutherstJ , Tolterodine Study Group. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstetrics and Gynecology2003;102(3):605-11. [srincont-16494]GarelyA , Tolterodine Study Group. Once-daily tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder. International Urology Journal2001;12(Suppl 1):S18. [srincont-12012]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of life of patients with overactive bladder receiving tolterodine. Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of patients with overactive bladder receiving tolterodine (Abstract number 82). Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , ReesePR . Health related quality of life of patients with overactive bladder receiving tolterodine once-daily. Neurourology and Urodynamics2000;19(4):519-21. [srincont-9987]KelleherCJ , ReesePR , PleilAM , OkanoGJ . Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. American Journal of Managed Care2002;8(Suppl 19):S608-15. [srincont-17998]KelleherCJ , Tolterodine Study Group. Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2000;11(Suppl 1):S94. [srincont-11915]KrederKJ . Antimuscarinic therapy: relationship between efficacy and side effects in responders and non-responders. Journal of Urology2001;165(Suppl 5):S165. [srincont-16327]KrederKJ . Clinical effectiveness of antimuscarinic therapy: the relationship between efficacy and tolerability. In: Proceedings of the International Continence Society Annual Meeting(ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001:140. [srincont-14376]MallettV . Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2001;12(Suppl 1):4. [srincont-12011]MillardRJ , TamaddonK , Tolterodine Study Group. Randomized controlled trial to compare tolterodine prolonged release capsules and tolterodine immediate release tablets versus placebo in patients with symptoms of detrusor overactivity (Abstract number 57). Australian and New Zealand Journal of Surgery2002;Suppl 72:A140. [sr-incont22190]PleilAM , ReesePR , KelleherCJ , OkanoGJ . Health-related quality of life of patients with overactive bladder receiving immediate-release tolterodine. HEPAC Health Economics in Prevention and Care2001;2(2):69-75. [sr-incont18060]RoehrbornCG , AbramsP , RovnerES , KaplanSA , HerschornS , GuanZ . Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU International2006;97(5):1003-6. [sr-incont21882]SwiftS . Efficacy and tolerability of once-daily tolterodine for women with overactive bladder. In: International Continence Society Annual Meeting (ICS), 31st annual meeting; 2001 Sept 18-21; Seoul, Korea. 2001:No. 329. [srincont-14481]SwiftS . Once-daily tolterodine is effective and well tolerated in women with overactive bladder (Abstract 57). In: 2nd International Consultation on Incontinence; 2001 July 1-3; Paris, France. 2001. [srincont-16319]SwiftSE . Once-daily (OD) tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder (OAB). International Urogynecology Journal2000;11(Suppl 1):S15. [sr-incont11906]SwiftSE . Once-daily administration of extended-release tolterodine is effective and well-tolerated in patients with overactive bladder. In: XVI FIGO World Congress of Obstetrics and Gynecology; 2000 Sept 3-8; Washington DC. Vol. Book 1. 2000:40. [sr-incont12085]SwiftSE . Overactive bladder in females: treatment with once-daily tolterodine. International Urogynecology Journal2001;12(Suppl 3):S71. [sr-incont16328]Van KerrebroeckP , KrederK , JonasU , ZinnerN . Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology2001;57(3):414-21. [sr-incont11953]Van KerrebroeckPEV . Long-term (12 months) efficacy and tolerability of tolterodine once-daily in the treatment of overactive bladder. Neurourology and Urodynamics2001;20(4):401-2. [sr-incont15714]Van KerrebroeckPEVA , Tolterodine Study Group. Long-term tolerability and efficacy of once-daily (OD) tolterodine in the treatment of overactive bladder (OB). International Urogynecology Journal2001;12(Suppl 3):S49. [sr-incont16329]Van KerrebroeckPEVA , Tolterodine Study Group. Significant decreases in perception of urgency and urge incontinence episodes with once-daily tolterodine treatment in patients with overactive bladder (Abstract number 89). Neurourology and Urodynamics2000;19(4):493-4. [sr-incont9980]WeinAJ , KhullarV , WangJT , GuanZ . Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. BJU International2007;99(2):360-3. [sr-incont23180]vanKerrebroeckPE , KelleherCJ , CoyneKS , KoppZ , BrodskyM , WangJT . Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. Health and Quality of Life Outcomes2009;7(13):13. [10.1186/1477-7525-7-13] [sr-incont31438]vanKerrebroeckPE , WangJ , GuanZ . Effects of tolterodine extended release in patients with overactive bladder: perceived treatment benefits improve with efficacy (Abstract number 511). European Urology Supplements2004;3(2):130. [sr-incont31090]">Van Kerrebroeck 2001</a>; <a href="./references#CD003781-bbs2-0093" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CrosbyRD , MathiasSD , MarshallTS . Relationships between symptoms, symptom bother, and health-related quality of life in patients with overactive bladder taking solifenacin or placebo in the VIBRANT study. International Journal of Clinical Practice2011;65(2):211-8. [sr-incont41015]GollarKM , YoungDG , BailenJ , HeW , Forero-SchwanhaeuserS . Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: a secondary analysis of the VIBRANT study. Urologic Nursing2012;32(1):38-46. [TrialID.VIBRANT.] [sr-incont44571]Samuels T‐A, MitchesonHD , VardyM , Forero‐SchwanhaeuserS , MarshallT , HeW . Efficacy of solifenacin for symptom bother and other patient-reported outcomes in patients with overactive bladder (OAB): results of a large, double-blind, placebo-controlled trial (Abstract number: poster #74). Neurourology and Urodynamics2009;28(2):149. [sr-incont31063]VardyMD , MitchesonHD , SamuelsTA , Forero-SchwanhaeuserS , HeW . Efficacy of solifenacin on overactive bladder symptoms, symptom bother, and other patient-reported outcomes in subjects with or without incontinence: a post hoc analysis of data from VIBRANT. Female Pelvic Medicine and Reconstructive Surgery2011;17(1):24-9. [TrialID.VIBRANT.] [sr-incont44741]VardyMD , MitchesonHD , SamuelsTA , WegenkeJD , Forero-SchwanhaeuserS , MarshallTS , et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. International Journal of Clinical Practice2009;63(12):1702-14. [905-UC-010] [NCT00573508] [TrialID.VIBRANT.] [sr-incont35459]">Vardy 2009</a>; <a href="./references#CD003781-bbs2-0094" title="EUCTR2007-007087-17-SE. A 24-week, multicentre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-007087-17 (first received 13 June 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont64588]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00798434. A study to compare the effectiveness and safety of fesoterodine and placebo in an elderly population of patients who go to the toilet very frequently due to overactive bladder (SOFIA) [A 24-week, multi-centre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00798434 (first received 26 November 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont49847]SchneiderT , BergqvistA , WangJ , WaggA , Ebel-BitounC . Treatment with fesoterodine versus tolterodine for reducing symptom bother in elderly patients with overactive bladder including urgency urinary incontinence. European Urology, Supplements2012;11(1):e687-a. [sr-incont65389]WaggA , CarlssonM , ElsobkyM , FernetM . Effect of flexible dose fesoterodine on cognitive function in &gt;65 year old patients with OAB: data from two RCT (Abstract number 438). Neurourology and Urodynamics2019;38:S297-8. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78651]WaggA , DarekarA , ArumiD , KhullarV , OelkeM . Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people &gt;65 years of age: a post hoc analysis of data from the SOFIA study. Neurourology and Urodynamics2015;34(5):438-43. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont68100]WaggA , ElsobkyM , CarlssonM , FernetM . Response and cognitive safety of fesoterodine in patients &gt;65y old with OAB. Is there a relationship between cognition and treatment response? (Abstract number 183). Neurourology and Urodynamics2019;38:S118-20. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78632]WaggA , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. Journal of the American Geriatrics Society2013;61(2):185-93. [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TrialID.SOFIA.] [sr-incont48008]WaggAS , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Efficacy and tolerability of fesoterodine in older subjects with overactive bladder: results of SOFIA (Abstract number C33). Journal of the American Geriatrics Society2011;59:S124. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont65234]">Wagg 2013a</a>; <a href="./references#CD003781-bbs2-0095" title="GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00911937. A trial to evaluate the efficacy and safety of fesoterodine in patients with symptoms of overactive bladder including nocturnal urinary urgency [A randomized, double blind, placebo controlled, parallel group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with symptoms of overactive bladder including nocturnal urinary urgency]. clinicaltrials.gov/show/NCT00911937 (first received 03 June 2009). [NCT00911937] [sr-incont49848]WeissJ , JumadilovaZ , CarlssonM , FitzGeraldMP , MalhotraA , MartireDL . Effect of antimuscarinic treatment in subjects with overactive bladder, including nocturnal urinary urgency (Abstract number 1963). Journal of Urology2012;187(4 Suppl 1):e792. [NCT00911937] [sr-incont65184]WeissJP , CarlssonMR , ManganEK . Age, gender and nocturnal urgency severity predict response to antimuscarinic treatment (Abstract number 1962). Journal of Urology2013;189(4 Suppl 1):e805. [NCT00911937] [sr-incont65096]WeissJP , JumadilovaZ , JohnsonTM , FitzGeraldMP , CarlssonM , MartireDL , et al. Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency. Journal of Urology2013;189(4):1396-401. [A0221048] [NCT00911937] [sr-incont47568]">Weiss 2013</a>; <a href="./references#CD003781-bbs2-0096" title="YamaguchiO , MaruiE , KakizakiH , ItohN , YokotaT , OkadaH , et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU International2007;100(3):579-87. [sr-incont23865]YokoyamaO , YamaguchiO , KakizakiH , ItohN , YokotaT , OkadaH , et al. Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary. Journal of Urology2011;186(1):170-4. [sr-incont41734]">Yamaguchi 2007</a>; <a href="./references#CD003781-bbs2-0097" title="NCT00966004. A study to evaluate safety and efficacy of ym178 in patients with overactive bladder [Phase III study of YM178 - a placebo-controlled, double-blind, group comparison study in patients with overactive bladder]. clinicaltrials.gov/show/NCT00966004 (first received 26 August 2009). [178-CL-048] [JapicCTI-R130370] [NCT00966004] [sr-incont63783]YamaguchiO , HidehiroK , YukioH , YasuhikoI , MasayukiT , OsamuN , et al. A phase III, randomized, double-blind, placebo and active controlled study of once-daily mirabegron 50 mg in patients with overactive bladder (Abstract number POD-03.06). Urology2012;80(3 Suppl 1):S10-1. [NCT00966004] [sr-incont65380]YamaguchiO , MaruiE , KakizakiH , HommaY , IgawaY , TakedaM , et al. A phase III, randomized, double-blind, placebo-controlled study of the beta-adrenoceptor agonist, mirabegron 50 mg once-daily, in Japanese patients with overactive bladder. BJU International2014;113(6):951-60. [NCT00966004] [sr-incont50603]">Yamaguchi 2012</a>; <a href="./references#CD003781-bbs2-0098" title="YamaguchiO , UchidaE , HigoN , MinamiH , KobayashiS , SatoH , et al. Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: a randomized double-blind trial. International Journal of Urology2014;21(6):586-93. [JapicCTI-101309] [sr-incont62099]">Yamaguchi 2014</a>; <a href="./references#CD003781-bbs2-0099" title="YongucT , SefikE , InciI , KusbeciOY , CelikS , AydinME , et al. Randomized, controlled trial of fesoterodine fumarate for overactive bladder in Parkinson's disease. World Journal of Urology2019;38(8):2013-9. [sr-incont78635]">Yonguc 2019</a>; <a href="./references#CD003781-bbs2-0100" title="JapicCTI-152936. Phase III study of KRP-114V [A phase III, randomized, double-blind, parallel group, placebo controlled, multicenter study to assess the efficacy and safety of the beta-3 agonist KRP-114V in Japanese subjects with symptoms of overactive bladder]. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-152936 (first received 17 June 2015). [JapicCTI-152936] [sr-incont78653]YoshidaM , TakedaM , GotoM , NagaiS , KuroseT . Vibegron, a novel potent and selective beta3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study (Abstract number 1082). European Urology, Supplements2018;17(2):e1531-2. [JapicCTI-152936] [sr-incont78069]YoshidaM , TakedaM , GotohM , NagaiS , KuroseT . Vibegron, a novel potent and selective B3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study. European Urology2018;73(5):783-90. [JapicCTI-152936] [sr-incont77898]YoshidaM , TakedaM , GotohM , YokoyamaO , KakizakiH , TakahashiS , et al. Efficacy of novel beta3-adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: a post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study. International Journal of Urology2019;26(3):369-75. [JapicCTI-152936] [sr-incont78654]YoshidaM , TakedaM , GotohM , YokoyamaO , KakizakiH , TakahashiS , et al. Efficacy of vibegron, a novel selective I²3-adrenoreceptor agonist, on urgency urinary incontinence with overactive bladder: post-hoc analysis of phase iii study (Abstract number 180). Neurourology and Urodynamics2019;38(S3):S114-5. [JapicCTI-152936] [sr-incont78636]">Yoshida 2018</a>; <a href="./references#CD003781-bbs2-0101" title="NCT01018264, ZesiewiczT . Solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease (URGE-PD) [URGE-PD: a multi-site, double-blind, randomized, placebo controlled trial of solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease]. clinicaltrials.gov/show/NCT01018264 (first received 23 November 2009). [NCT01018264] [sr-incont63790]ZesiewiczTA , EvattM , JahanI , VaughanC , SingerC , OrdoricaR , et al. URGE-PD: a multi-site, double-blind, randomized, placebo controlled trial of solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease (Abstract number 745). Movement Disorders2014;29(Suppl 1):S276-7. [NCT01018264] [sr-incont66602]ZesiewiczTA , EvattM , VaughanCP , JahanI , SingerC , OrdoricaR , et al. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease. Parkinsonism and Related Disorders2015;21(5):514-20. [NCT01018264] [sr-incont66860]">Zesiewicz 2015</a>; <a href="./references#CD003781-bbs2-0104" title="ZinnerN , SussetJ , GittelmanM , ArguinzonizM , RekedaL , HaabF . Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. International Journal of Clinical Practice2006;60(1):119-26. [sr-incont21507]">Zinner 2006</a>). </p> <p>We screened the 1161 records identified by the literature search and obtained 495 full‐text articles for further assessment. A total of 218 reports of 104 studies met the inclusion criteria and are now included in the review. Additionally, five studies are ongoing and 14 studies are awaiting classification. We excluded 262 reports of 203 studies. The flow of literature through the assessment process is shown in the PRISMA diagram (<a href="#CD003781-fig-0001">Figure 1</a>) (covering from the inception of the review to the current version). </p> <div class="figure" id="CD003781-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA study flow diagram (covering searches from inception to this current version of the review) " data-id="CD003781-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA study flow diagram (covering searches from inception to this current version of the review)  </p> </div> </div> </div> <p>A further updated search on 3 May 2022 produced 70 records, which we screened for eligibility for this review. A total of 17 reports of six studies met the inclusion criteria but were not fully incorporated into the review (<a href="./references#CD003781-bbs2-0309" title="ChuangYC , LinCC , ChowPM , LienCS , TsuiKH , ChouCL , et al. A double-blind, randomized, placebo-controlled, parallel study to evaluate the efficacy and safety of imidafenacin in patients with overactive bladder in Taiwan. LUTS2021;13(1):108-17. ">Chuang 2021</a>; <a href="./references#CD003781-bbs2-0311" title="FrankelJ , StaskinD , VaranoS , KennellyM , NewmanDK , RosenbergMT , et al. Interpretation of the meaningfulness of symptom reduction with vibegron in patients with overactive bladder: analyses from EMPOWUR. Advances in Therapy2022;39(2):959-70. FrankelJ , StaskinD , VaranoS , ShortinoD , JankowichR , MuddP . Once-daily vibegron 75 mg for overactive bladder (OAB) is generally safe and well tolerated, and is efficacious in patients aged ≥65 or ≥75 years: EMPOWUR randomized, international, phase 3 study (Abstract C105). Journal of the American Geriatrics Society2020;68(Suppl 1):S217-8. FrankelJ , StaskinD , VaranoS , ShortinoD , JankowichR , MuddPN . PD21-02 efficacy of once-daily vibegron 75 mg for overactive bladder (OAB) in older patients: the EMPOWUR randomized, international, phase 3 study. Journal of Urology2020;203(Suppl 4):e453-4. FrankelJ , StaskinD , VaranoS , ShortinoD , JankowichR , MuddPN . Vibegron statistically significantly improves quality-of-life measures in patients with overactive bladder: empowur study (Abstract M11). Neurourology and Urodynamics2020;39(Suppl 1):S115-6. FrankelJ , VaranoS , StaskinD , ShortinoD , JankowichR , MuddPN . Vibegron improves quality-of-life measures in patients with overactive bladder: patient-reported outcomes from the EMPOWUR study. International Journal of Clinical Practice2021;75(5):e13937. NewmanD , VaranoS , ShortinoD , JankowichR , MuddP . Efficacy and safety of vibegron for the treatment of overactive bladder in women: a sub group analysis from the empowur trial (Abstract). Female Pelvic Medicine and Reconstructive Surgery2021;27(10 Suppl 1):S28-9. StaskinD , FrankelJ , VaranoS , KennellyM , NewmanDK , RosenbergMT , et al. Vibegron for the treatment of patients with dry overactive bladder: a subgroup analysis from the EMPOWUR trial (Abstract MP63-15). Journal of Urology2021;206(Suppl 3):e1107-8. StaskinD , FrankelJ , VaranoS , ShortinoD , JankowichR , MuddP . Once-daily vibegron 75 mg for overactive bladder (OAB): double-blind 52-week results from an extension study of the international phase 3 trial (EMPOWUR) (Abstract PD21-01). Journal of Urology2020;203(Suppl 4):e453. StaskinD , FrankelJ , VaranoS , ShortinoD , JankowichR , MuddPN . International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR. Journal of Urology2020;204(2):316-24. StaskinD , FrankelJ , VaranoS , ShortinoD , JankowichR , MuddPN . Once-daily vibegron 75 mg for overactive bladder: long-term safety and efficacy from a double-blind extension study of the international phase 3 trial (EMPOWUR). Journal of Urology2021;205(5):1421-9. StaskinD , FrankelJ , VaranoS , ShortinoD , JankowichR , MuddPN . Vibegron shows statistically significant improvement in secondary efficacy measures in overactive bladder: empowur study (Abstract 36). Neurourology and Urodynamics2020;39(Suppl 1):S96-7. VaranoS , StaskinD , FrankelJ , ShortinoD , JankowichR , MuddPN . Efficacy and safety of once-daily vibegron for treatment of overactive bladder in patients aged ≥ 65 and ≥ 75 years: subpopulation analysis from the EMPOWUR randomized, international, phase III study. Drugs and Aging2021;38(2):137-46. ">Frankel 2022</a>; <a href="./references#CD003781-bbs2-0315" title="JapicCTI-152936. Phase III study of KRP-114V [KRP-114V 第3相臨床試験] [A phase III, randomized, double-blind, parallel group, placebo controlled, multicenter study to assess the efficacy and safety of the beta-3 agonist krp-114v in Japanese subjects with symptoms of overactive bladder [KRP-114V 第3相臨床試験 −過活動膀胱患者を対象としたKRP-114Vの有効性及び安全性を検証するための二重盲検比較試験ー]]. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-152936 (first received 17 June 2015). ">JapicCTI‐152936</a>; <a href="./references#CD003781-bbs2-0316" title="KimJH , NCT05282069. A study to evaluate the efficacy and safety of DA-8010 in patients with overactive bladder [A multicenter, double-blind, placebo-controlled and active-reference, randomized, parallel, therapeutic confirmatory clinical study to evaluate the efficacy and safety of DA-8010 in patients with overactive bladder]. clinicaltrials.gov/show/NCT05282069 (first received 16 March 2022). ">Kim 2022</a>; <a href="./references#CD003781-bbs2-0320" title="SonHS , KimJC , KimHG , ShinDG , LeeKS , YooS , et al. Efficacy and safety of DA8010, a novel M3 antagonist, in patients with overactive bladder: randomized, double-blind, phase 2 study (Abstract MP02-18). Journal of Urology2021;206(Suppl 3):e19. ">Son 2021</a>; <a href="./references#CD003781-bbs2-0321" title="WaggA , GibsonWR , CarlssonM , ElsobkyM . Subjective and objective response to treatment of overactive bladder: a pooled analysis of randomised controlled trials of fesoterodine in patients of &gt;65 years (Abstract 514). European Urology Open Science2020;19(Suppl 2):e798-9. ">Wagg 2020</a>); these studies have been added to <a href="./references#CD003781-bbs1-0003" title="">Studies awaiting classification</a>. </p> </section> <section id="CD003781-sec-0044"> <h4 class="title">Included studies</h4> <p>Further details of the studies can be found in the <a href="./references#CD003781-sec-0123" title="">Characteristics of included studies</a>. </p> <p>A total of 29,682 participants received an anticholinergic drug compared to 17,424 participants who received a placebo. No studies were identified that compared an anticholinergic drug to no treatment. Twelve studies did not report group numbers (<a href="./references#CD003781-bbs2-0112" title="AssassaP , WilliamsK , LambertP , AbramsK , TurnerD , ShawC , et al. A double blind randomised placebo controlled trial of the effectiveness of bladder training with oxybutynin or imipramine in the management of detrusor overactivity (DO) (Abstract number 330). In: Joint Meeting of the International Continence Society (ICS) and the International Urogynecological Association; 2010 Aug 23-27; Toronto, Canada. 2010. [ISRCTN58226681] [sr-incont40171]ISRCTN58226681, McGrotherC . Evaluation of the efficacy of oxybutynin and imipramine in the management of detrusor instability. isrctn.org/ISRCTN58226681 (first received 25 October 2000). [DOI: https://doi.org/10.1186/ISRCTN58226681] [ISRCTN58226681] [sr-incont64656]">Assassa 2010</a>; <a href="./references#CD003781-bbs2-0012" title="ChalihaC , HalaskaM , StantonS . Trospium chloride for the treatment of detrusor instability: a placebo-controlled dose-finding study (Abstract 276). British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):92. [srincont-8452]">Chaliha 1998</a>; <a href="./references#CD003781-bbs2-0029" title="EUCTR2004-001116-31-ES. Multicentre, randomised, double-blind, parallel group confirmatory Phase III study to compare the efficacy and safety of cizolirtine citrate 300 mg bid (600 mg/d), cizolirtine citrate 400 mg bid (800 mg/d), placebo, and tolterodine 2 mg bid (4 mg/d) in the treatment of urge urinary incontinence. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-001116-31 (first received 03 November 2004). [ESCLIN-002/04] [EUCTR2004-001116-31-ES] [sr-incont64643]">EUCTR2004‐001116‐31‐ES</a>; <a href="./references#CD003781-bbs2-0031" title="EUCTR2007-004126-24-CZ. A placebo controlled randomized, 12-week, dose-ranging, double-blind study versus placebo using tolterodine as a study calibrator, to evaluate efficacy and safety of SSR240600C in women with overactive bladder including urge urinary incontinence. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-004126-24 (first received 12 December 2007). [DRI6271] [EUCTR2007-004126-24-CZ] [EudraCT2007-004126-24] [NCT00564226] [TrialID.BILADY] [sr-incont64596]NCT00564226. SSR240600C treatment in women with overactive bladder (BILADY) [A placebo controlled randomized, 12-week, dose-ranging, double-blind study versus placebo using tolterodine as a study calibrator, to evaluate efficacy and safety of SSR240600C in women with overactive bladder including urge urinary incontinence]. clinicaltrials.gov/show/NCT00564226 (first received 27 November 2007). [DRI6271] [EudraCT2007-004126-24] [NCT00564226] [TrialID.BILADY] [sr-incont63784]">EUCTR2007‐004126‐24‐CZ</a>; <a href="./references#CD003781-bbs2-0036" title="HajebrahimiS , MotlaghRS , BazarganiHS , BabaieH . Efficacy of tadalafil in treatment of overactive bladder syndrome: a randomized controlled trial (Abstract number OP.3.6Dec.27). International Journal of Urology2014;21:A146. [IRCT2013030212668N1] [sr-incont67256]IRCT2013030212668N1. Effect of tadalafil in treatment of overactive bladder  [Comparison of the efficacy of tadalafil, toltrodine and placebo in reduction of symptoms severity of women with urgency, frequency syndrom / overactive bladder]. en.irct.ir/trial/12692 (first received 26 January 2013). [91189] [IRCT2013030212668N1] [sr-incont78643]">Hajebrahimi 2014</a>; <a href="./references#CD003781-bbs2-0322" title="IRCT2015010720598N1. The effect of solifenacin succinate on intraocular pressure [Ocular effects of solifenacin succinate in women with narrow angle glaucoma and overactive bladder syndrome]. en.irct.ir/trial/18253 (first received 22 June 2015). [IRCT2015010720598N1] [sr-incont78608] [tbzmed.rec.1394.127]">Hajebrahimi 2015</a>; <a href="./references#CD003781-bbs2-0056" title="KosilovKV , LoparevS , IvanovskayaM , KosilovaL . Treatment of overactive bladder in older women increased doses of antimuscarinic drugs safe and effective alternative to existing methods. Advances in Gerontology [Uspekhi Gerontologii]2014;27(1):149-55. [ISSN: 1561-9125] [sr-incont63914]">Kosilov 2014a</a>; <a href="./references#CD003781-bbs2-0059" title="KrederK , PleilAM , ReesePR , KelleherJ . Effects of long-term tolterodine treatment on social and psychological aspects of health-related quality of life in overactive bladder patients (Abstract). Journal of Urology2002;167(Suppl 4):29. [sr-incont17591]">Kreder 2002</a>; <a href="./references#CD003781-bbs2-0323" title="NCT00553657. The study to test the effect of standardization of fluid intake in female patients with overactive bladder [A randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of standardization of fluid intake on the variability of measured voiding parameters in female patients with idiopathic overactive bladder]. clinicaltrials.gov/show/NCT00553657 (first received 04 November 2007). [NCT00553657] [sr-incont60907]">NCT00553657</a>; <a href="./references#CD003781-bbs2-0075" title="ISRCTN17856439, ResnickN . Pathophysiology of urge incontinence in older women. isrctn.org/ISRCTN17856439 (first received 09 March 2006). [1999P-001891] [94-6641-01] [ISRCTN17856439] [sr-incont64614]">Resnick 2006</a>; <a href="./references#CD003781-bbs2-0076" title="EUCTR2008-005215-17. A study to evaluate the overall effect of solifenacin 5mg and 10mg on bladder wall thickness and urinary nerve growth factor in female subjects with overactive bladder and a diagnosis of detrusor overactivity – a double-blind, randomized, placebo-controlled, parallel group, multicentre study - SHRINK. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-005215-17 (first received 14 September 2009). [EUCTR2008-005215-17] [NCT01093534] [sr-incont78650]NCT01093534. Study of 2 doses of solifenacin succinate in female subjects with overactive bladder (SHRINK) [A study to evaluate the overall effect of solifenacin 5mg and 10mg on bladder wall thickness and urinary nerve growth factor in female subjects with overactive bladder and a diagnosis of detrusor overactivity - a double-blind, randomised, placebo-controlled, parallel group, multi-centre study]. clinicaltrials.gov/show/NCT01093534 (first received 26 March 2010). [905-EC-007] [EUCTR2008-005215-17] [NCT01093534] [TrialID.SHRINK] [sr-incont63778]RobinsonD , KhullarV , OelkeM , WijkstraH , TretterR , StowB , et al. Effects of 12 weeks treatment with solifenacin on Bladder Wall Thickness (BWT) and clinical outcomes: results from the placebo-controlled SHRINK study (Abstract number 422). In: International Continence Society (ICS), 43rd Annual Meeting; 2013 Aug 26-30; Barcelona, Spain. 2013. [905-EC-007] [NCT01093534] [TrialID.SHRINK.] [srincont-49731]RobinsonD , OelkeM , KhullarV , WijkstraH , TretterR , StowB , et al. Bladder wall thickness in women with symptoms of overactive bladder and detrusor overactivity: results from the randomised, placebo-controlled SHRINK study. Neurourology and Urodynamics2016;35(7):819-25. [NCT01093534] [sr-incont72217]RobinsonD , OelkeM , TretterR , StowB , CompionG , TubaroA . The effect of solifenacin on bladder wall thickness in women with overactive bladder and detrusor overactivity: Results from the SHRINK study (Abstract number 782). European Urology Supplements2013;12(1):e782-3. [EUCTR2008-005215-17] [NCT01093534] [sr-incont67207]RobinsonD , TubaroA , KimbergM , PlummerM , DeVineJ , BouicP , et al. The effect of solifenacin on urinary nerve growth factor (UNGF) and brain-derived neurotropic factor (BDNF) in women with overactive bladder and detrusor overactivity: results from the SHRINK study (Abstract number PP 54). International Urogynecology Journal and Pelvic Floor Dysfunction2014;25(1 Suppl 1):S60-1. [EUCTR2008-005215-17] [NCT01093534] [sr-incont67200]TubaroA , KhullarV , OelkeM , WijkstraH , TretterR , StowB , et al. Intra- and inter-reader variability of transvaginal ultrasound bladder wall thickness measurements: results from the SHRINK study (Abstract number 136). Neurourology and Urodynamics2013;32(6):711-2. [EUCTR2008-005215-17] [NCT01093534] [sr-incont49211]">Robinson 2013</a>; <a href="./references#CD003781-bbs2-0087" title="TagoK , UenoA , TakayasuH . Clinical study of propiverine hydrochloride for the treatment of patients with urinary frequency and incontinence. Neurourology and Urodynamics1990;9(4):337-8. [srincont-5109]">Tago 1990</a>). One study was ended by the pharmaceutical company before any participants were recruited (<a href="./references#CD003781-bbs2-0030" title="EUCTR2004-002143-27-AT. A double-blind, stratified, randomised, parallel, placebo-controlled, multi-centre study to compare the efficacy and safety of duloxetine hydrochloride (40mg twice a day) and tolterodine tartrate (XL) (4mg once daily) with placebo in patients with symptoms of Urge Urinary Incontinence. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-002143-27 (first received 15 February 2005). [1208.15] [EUCTR2004-002143-27-AT] [sr-incont64640]">EUCTR2004‐002143‐27‐AT</a>). </p> <p>One study was published in Japanese (<a href="./references#CD003781-bbs2-0088" title="TakayasuH , UenoA , TsutidaS , KoisoK , KuritaK , KawabeK , et al. Clinical effects of propiverine hydrochloride in the treatment of urinary frequency and incontinence associated with detrusor overactivity: a double blind, parallel, placebo controlled multicenter study. Igaku No Ayumi (Progress in Medicine)1990;153(8):459-71. [srincont-12896]TakayasuH , UenoA , TsutidaS , KoisoK , KuritaK , KawabeK , et al. Clinical effects of propiverine hydrochloride in the treatment of urinary frequency and incontinence associated with detrusor overactivity: a double blind, parallel, placebo controlled multicenter study. Igaku No Ayumi (Progress in Medicine)1990;153(8):459-71. [sr-incont12896]">Takayasu 1990</a>), and one in Russian (<a href="./references#CD003781-bbs2-0056" title="KosilovKV , LoparevS , IvanovskayaM , KosilovaL . Treatment of overactive bladder in older women increased doses of antimuscarinic drugs safe and effective alternative to existing methods. Advances in Gerontology [Uspekhi Gerontologii]2014;27(1):149-55. [ISSN: 1561-9125] [sr-incont63914]">Kosilov 2014a</a>). We abstracted all information and data from the original papers. </p> <section id="CD003781-sec-0045"> <h5 class="title">Design</h5> <p>The studies were all randomised controlled trials (RCTs).</p> </section> <section id="CD003781-sec-0046"> <h5 class="title">Sample sizes</h5> <p>Sample sizes ranged from 18 (<a href="./references#CD003781-bbs2-0073" title="NCT01302938. Web-based methodology trial to evaluate the efficacy and safety of tolterodine ER in subjects with overactive bladder (REMOTE) [Exploratory, randomized, double-blind, placebo-controlled, parallel-group, single center, web-based phase IV pilot methodolgy trial to evaluate the efficacy and safety of tolterodine ER in subjects with overactive bladder]. clinicaltrials.gov/ct2/show/NCT01302938 (first received 24 February 2011). [A6121195] [NCT01302938] [TrialID.REMOTE.] [sr-incont43314]OrriM , LipsetCH , JacobsBP , CostelloAJ , CummingsSR . Web-based trial to evaluate the efficacy and safety of tolterodine ER 4 mg in participants with overactive bladder: REMOTE trial. Contemporary Clinical Trials2014;38(2):190-7. [A6121195] [NCT01302938] [TrialID.REMOTE.] [sr-incont62536]">Orri 2014</a>) to 2334 (<a href="./references#CD003781-bbs2-0051" title="EUCTR2007-006451-39-SE. 12-week, randomized, double-blind, double-dummy, placebo controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-006451-39 (first received 20 February 2008). [A0221046] [EUCTR2007-006451-39-SE] [sr-incont64591]KaplanSA , SchneiderT , FooteJ , GuanZ . Superior efficacy of fesoterodine over tolterodine with rapid onset: a prospective, head-to-head, placebo-controlled trial (Abstract number 67). Neurourology and Urodynamics2010;29(6):905-7. [srincont-40130]KaplanSA , SchneiderT , FooteJE , GuanZ , CarlssonM , GongJ . Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU International2011;107(9):1432-40. [A0221046] [NCT00611026] [srincont-41334]">Kaplan 2011</a>). </p> </section> <section id="CD003781-sec-0047"> <h5 class="title">Setting</h5> <p>Forty‐six trials stated that they were multinational (<a href="./references#CD003781-bbs2-0002" title="AbramsP , FreemanR , AnderströmC , MattiassonA . Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. British Journal of Urology1998;81(6):801-10. [srincont-7871]AbramsP , FreemanRN , AnderstromC , MattiassonA . Efficacy and tolerability of tolterodine vs. oxybutynin and placebo in patients with detrusor instability (Abstract). Journal of Urology1997;157(Suppl 4):103. [srincont-16321]">Abrams 1998</a>; <a href="./references#CD003781-bbs2-0004" title="AbramsP , KelleherC , StaskinD , KayR , MartanA , MincikI , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World Journal of Urology2017;35(5):827-38. [NCT01340027] [sr-incont77897]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Cardiovascular safety of combination treatment with mirabegron and solifenacin in patients with overactive bladder in a randomised, double-blind, dose-ranging, Phase II study (Symphony) (Abstract). European Urology, Supplements2014;13(1):e574-e574a. [NCT01340027] [sr-incont67160]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB) - efficacy and safety results from a randomised phase II study (Symphony) (Abstract number 295). Neurourology and Urodynamics2013;32(6):930-1. [NCT01340027] [TrialID.SYMPHONY.] [sr-incont49188]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB): safety results from a phase 2 study (Abstract number MP-16.08). Urology2013;82(3 Suppl 1):S139. [NCT01340027] [sr-incont66675]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: Exploratory responder analyses of efficacy and evaluation of patient reported outcomes from a randomised, double-blind, dose-ranging, phase 2 study (Symphony) (Abstract number MP-24.11). Urology2014;84(4 Suppl 1):S145-6. [NCT01340027] [sr-incont67194]AbramsP , KelleherC , StaskinD , RechbergerT , KayR , MartinaR , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (SYMPHONY). European Urology2015;67(3):577-88. [NCT01340027] [sr-incont66674]NCT01340027, Bristol Urological Institute . A study to evaluate the efficacy, safety and tolerability of mirabegron and solifenacin succinate alone and in combination for the treatment of overactive bladder (symphony) [A randomized, double-blind, factorial, parallel-group, active and placebo-controlled, multicenter dose-ranging study to evaluate the efficacy, safety and tolerability of six dose combinations of solifenacin succinate and mirabegron compared to mirabegron and solifenacin succinate monotherapies in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01340027 (first received 21 April 2011). [178-CL-100] [2010-020601-32] [NCT01340027] [TrialID.SYMPHONY] [sr-incont44510]NittiV , AbramsP , StaskinD , AuerbachS , MartinaR , VanMR . Urinary retention in patients with overactive bladder treated with mirabegron alone and in combination with solifenacin: the results of two randomized, double-blind, phase II studies (Abstract number MP76-13). Journal of Urology2014;191(4 Suppl 1):e886-7. [NCT00410514] [NCT01340027] [TrialID.SYMPHONY] [sr-incont67453]">Abrams 2013</a>; <a href="./references#CD003781-bbs2-0005" title="AlloussiS , Laval KU , Ballering-BruhlB , Grobe-FreeseM , BulittaM , SchaferM . Trospium chloride (Spasmo-lyt) in patients with motor urge syndrome (detrusor instability): a double-blind, randomised, multicentre, placebo-controlled study. Journal of Clinical Research1998;1:439-51. [srincont-12005]AlloussiS , Laval K-U, EckertR , Ballering-BruhlB , Grosse-FreeseM , BulittaM , et al. Trospium chloride (Spasmo-lyt(R)) in patients with motor urge syndrome (detrusor instability): a double-blind, randomised, multicentre, placebo-controlled study. Journal of Drug Assessment1999;2(1):27-39. [sr-incont18226]AlloussiS , Laval K-U, MertinsB . Efficacy and tolerability of trospium chloride (spasmo-lyt) versus placebo in patients with motor urge-syndrome. In: International Continence Society (ICS), 28th Annual Meeting; 1998 Sept 14-17; Jerusalem, Israel. 1998:109-10. [sr-incont5684]">Alloussi 1998</a>; <a href="./references#CD003781-bbs2-0009" title="CardozoL , ChappleCR , Toozs-HobsonP , Grosse-FreeseM , BulittaM , LehmacherW , et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomised, double-blind, multicentre clinical trial. British Journal of Urology International2000;85(6):659-64. [srincont-11732]">Cardozo 2000</a>; <a href="./references#CD003781-bbs2-0010" title="CardozoL , KuzminI , LisecML , MillardR , vanVierssen TripOB , RidderAM , et al. YM905: Results of a randomised, double-blind placebo-controlled trial in patients with symptomatic overactive bladder (Abstract number 104). European Urology Supplements2003;2(1):28. [sr-incont27407]CardozoL , KuzminI , LisecML , MillardRJ , vanVierssen TripOB , RidderAM , et al. A double-blind, randomised, placebo-controlled trial with YM905 in symptomatic overactive bladder (Abstract number P74). Journal of the American Geriatrics Society2003;51 (Suppl 4):S68-9. [sr-incont31100]CardozoL , LisecM , MillardR , vanVierssen TripO , KuzminI , DrogendijkTE , et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. Journal of Urology2004;172(5 (Pt 1 of 2)):1919-24. [srincont-19090]CardozoL . A randomised double-blind, placebo-controlled trial of the once-daily muscarinic receptor antagonist solifenacin succinate for symptoms of overactive bladder (Abstract number 211). International Urogynecology Journal2003;14 (Suppl 1):S64. [sr-incont31104]CardozoL . Solifenacin succinate improves symptoms of an overactive bladder (Abstract number TP77). International Journal of Gynecology and Obstetrics2003;83(Suppl 3):94. [sr-incont31096]KelleherCJ , CardozoL , ChappleCR , HaabF , RidderAM . Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU International2005;95(1):81-5. [srincont-20241]">Cardozo 2004a</a>; <a href="./references#CD003781-bbs2-0011" title="CardozoL , AdamikZ , GuimaraesM , KrhutJ , Labat J-J, PetrovS , et al. Patients with overactive bladder show progressive improvement in urgency and bladder condition during treatment with solifenacin in a randomised, double-blind, placebo-controlled study (SUNRISE) (Abstract number 115). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S67-8. [srincont-26595]CardozoL , AmarencoG , PushkarD , MikulasJ , DrogendijkT , WrightM , et al. Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE). BJU International2013;111(5):804-10. [NCT00801944] [TrialID.SUNRISE.] [sr-incont47554]CardozoL , DewildeT , FeyereislJ , WadieB , AmarencoG , LiapisA , et al. Solifenacin significantly reduces both urgency severity and bother: results from the flexible dose, placebo controlled, multinational SUNRISE study (Abstract number 281). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26641]CardozoL , DrogendijkT , BolodeokuJ . The efficacy of solifenacin 5/10 mg on 'urgency' endpoints in different OAB patient populations: subanalysis of results from the randomised, double-blind SUNRISE study (Abstract number 192). In: International Continence Society (ICS); 38th Annual Meeting; 2008 Oct 20-24; Cairo, Egypt. 2008. [srincont-31885]CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CardozoL , HessdörferE , MilaniR , ArañóP , DewildeL , SlackM , et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU International2008;102(9):1120-7. [NCT00801944] [TrialID.SUNRISE] [srincont-29249]">Cardozo 2008a</a>; <a href="./references#CD003781-bbs2-0013" title="ChappleC . Fesoterodine a new effective and well-tolerated antimuscarinic for the treatment of urgency-frequency syndrome: results of a phase 2 controlled study (Abstract 142). Neurourology and Urodynamics2004;23(5/6):598-9. [srincont-19023]Drug company. A Phase 2, parallel group, randomized, double-blind, placebo controlled dose-ranging trial to determine the optimal dose and the tolerability of sustained release SPM 8272 (fesoterodine) in subjects with non-neurogenic bladder overactivity. Protocol numbers: A0221027 (SP582). ClinicalStudyResults.org (accessed 3 March 2011)2002. [Protocol numbers: A0221027 (SP582)] [srincont-41110]">Chapple 2004a</a>; <a href="./references#CD003781-bbs2-0014" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. ChappleCR , AranoP , BoschJH , De RidderD , KramerG , RidderAM . YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo- and tolterodine-controlled, phase-II, dose-finding study (Abstract 75). Neurourology and Urodynamics2002;21(4):381-2. [srincont-14551]ChappleCR , ArañoP , BoschJL , De RidderD , KramerAE , RidderAM . Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU International2004;93(1):71-7. [srincont-17334]KelleherCJ , CardozoL , ChappleCR , HaabF , RidderAM . Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU International2005;95(1):81-5. [srincont-20241]SmithN , GrimesI , RidgeS , TempelD , UchidaT , YamanouchiUS . YM905 is effective and safe as treatment of overactive bladder in women and men: results from phase II study (Abstract). In: International Continence Society (ICS), 32nd Annual Meeting; 2002 Aug 28-30; Heidelberg, Germany. 2002:138-9. [sr-incont14508]">Chapple 2004b</a>; <a href="./references#CD003781-bbs2-0015" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. ChappleC , RechbergerT , Al-ShukriS , MeffanP , EveraertK , RidderA . Results of a randomized phase 3 study comparing solifenacin succinate with tolterodine and placebo in patients with symptomatic overactive bladder (Abstract). Neurourology and Urodynamics2003;22(5):534-5. [sr-incont16991]ChappleCR , RechbergerT , Al ShukriS , MeffanP , EveraertK , HuangM , et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU International2004;93(3):303-10. [srincont-17270]">Chapple 2004c</a>; <a href="./references#CD003781-bbs2-0016" title="ChappleC , Van KerrebroeckP , TubaroA , Haag-MolkentellerC , ForstHT , MassowU , et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder [Erratum appears in: European Urology 2008,53(6):1319]. European Urology2007;52(4):1204-12. [NCT00220363] [SP583] [srincont-23875]ChappleC , Van KerrebroeckP , TubaroA , MillardR . Fesoterodine in non-neurogenic voiding dysfunction - results on efficacy and safety in a phase 3 trial (Abstract number 379). In: 21st Annual European Association of Urology (EAU) Congress; 2006 Apr 5-8; Paris, France. 2006. [srincont-41109]ChappleC , Van KerrebroeckP , TubaroA , WangJT , HvidstenK , BrodskyM . Efficacy of fesoterodine in patients with overactive bladder (OAB): improvements in OAB symptoms and health-related quality of life (HRQL) (Poster abstract number 1188). Journal of Urology2007;177(4 Suppl S):392. [srincont-31882]ChappleCR , vanKerrebroeckPE , JünemannKP , WangJT , BrodskyM . Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU International2008;102(9):1128-32. [srincont-29255]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. KelleherCJ , TubaroA , WangJT , KoppZ . Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU International2008;102(1):56-61. [srincont-27613]SandPK , MorrowJD , BavendamT , CreangaDL , NittiVW . Efficacy and tolerability of fesoterodine in women with overactive bladder. International Urogynecology Journal2009;20(7):827-35. [srincont-31351]">Chapple 2007a</a>; <a href="./references#CD003781-bbs2-0017" title="ChappleC , DuBeauC , EbingerU , RekedaL , ViegasA . Darifenacin treatment of patients &gt;or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Current Medical Research and Opinion2007;23(10):2347-58. [srincont-23921]">Chapple 2007b</a>; <a href="./references#CD003781-bbs2-0018" title="ChappleCR , DvorakV , RadziszewskiP , vanKerrebroeckP , WyndaeleJJ , BosmanB , et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder. International Urogynecology Journal2013;24(9):1447-58. [178-CL-044] [NCT00337090] [TrialID.DRAGON.] [sr-incont48549]NCT00337090 . A study of YM178 in patients with symptomatic overactive bladder (DRAGON) [A randomized, double-blind, parallel group, placebo and active controlled, multicenter dose ranging study with the beta-3 agonist YM178 in patients with symptomatic overactive bladder]. clinicaltrials.gov/show/NCT00337090 (first received 15 June 2006). [EudraCT2005-002256-17] [JapicCTI-R130350] [NCT00337090] [sr-incont63803]">Chapple 2013</a>; <a href="./references#CD003781-bbs2-0019" title="ChappleC , HaabF , SchneiderT , CarlssonM , ArumiD . Fesoterodine 8 mg versus fesoterodine 4 mg in patients with overactive bladder and a history of previous antimuscarinic therapy: Results from the EIGHT trial (Abstract number: Poster #M5). Neurourology and Urodynamics2015;34(S1):S20. [NCT01302067] [sr-incont68509]ChappleC , SchneiderT , HaabF , SunF , WhelanL , ScholfieldD , et al. Superiority of fesoterodine 8mg versus fesoterodine 4 mg in reducing urgency urinary incontinence episodes in subjects with overactive bladder: results of the randomized, double-blind, placebo-controlled EIGHT trial (Abstract number: Podium #48). Neurourology and Urodynamics2014;33(2):183-4. [NCT01302067] [sr-incont67484]ChappleC , SchneiderT , HaabF , SunF , WhelanL , ScholfieldD , et al. Superiority of fesoterodine 8mg vs 4mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial. BJU International2014;114(3):418-26. [A0221095] [NCT01302067] [TrialID.EIGHT] [srincont-62537]NCT01302067. A 12 week study to confirm the effectiveness of 8mg of Fesoterodine compared to 4mg of Fesoterodine [A 12-week, randomized, double-blind, placebo controlled, parallel group, multicenter trial in overactive bladder subjects to confirm the efficacy of 8 mg fesoterodine compared to 4 mg fesoterodine]. clinicaltrials.gov/show/NCT01302067 (first received 23 February 2011). [NCT01302067] [sr-incont63792]">Chapple 2014</a>; <a href="./references#CD003781-bbs2-0022" title="AmarencoG , SutoryM , FagertunH , WrightM , CompionG , De RidderD . Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Preliminary results from the SONIC urodynamic study (Abstract). European Urology, Supplements2012;11(1):e467-a. [EudraCT2006-005523-42] [NCT00629642] [sr-incont65392]AmarencoG , SutoryM , ZachovalR , AgarwalM , DelPG , TretterR , et al. Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study. Neurourology and Urodynamics2017;36(2):414-21. [EudraCT2006-005523-42] [JapicCTI-R130306] [NCT00629642] [sr-incont72248]De RidderD , AmarencoG , Finazzi-AgroE , AnguloJ , KurenkovA , WrightM , et al. Solifenacin treatment for neurogenic detrusor overactivity: patient-reported outcomes (PROs) from the randomised clinical trial SONIC (Abstract number 333). In: International Continence (ICS); 42nd Annual Meeting; 2012 Oct 15-19; Beijing, China. 2012. [905-EC-005] [EudraCT2006-005523-42] [NCT00629642] [TrialID.SONIC.] [srincont-49739]">De Ridder 2012</a>; <a href="./references#CD003781-bbs2-0026" title="DrutzH , AppellRA . Clinical efficacy and safety of Tolterodine vs Oxybutynin and placebo in patients with unstable bladder. Acta Obstetrica et Gynecologica Scandinavica1997;Suppl 167(5):24. [srincont-6671]DrutzHP , AppellRA , GleasonD , KlimbergI , RadomskiS . Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. International Urogynecology Journal and Pelvic Floor Dysfunction1999;10(5):283-9. [srincont-8804]DrutzHP , AppellRA . Enhanced tolerability of tolterodine compared to oxybutynin in a controlled clinical study. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(1):S14. [srincont-5166]">Drutz 1999</a>; <a href="./references#CD003781-bbs2-0031" title="EUCTR2007-004126-24-CZ. A placebo controlled randomized, 12-week, dose-ranging, double-blind study versus placebo using tolterodine as a study calibrator, to evaluate efficacy and safety of SSR240600C in women with overactive bladder including urge urinary incontinence. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-004126-24 (first received 12 December 2007). [DRI6271] [EUCTR2007-004126-24-CZ] [EudraCT2007-004126-24] [NCT00564226] [TrialID.BILADY] [sr-incont64596]NCT00564226. SSR240600C treatment in women with overactive bladder (BILADY) [A placebo controlled randomized, 12-week, dose-ranging, double-blind study versus placebo using tolterodine as a study calibrator, to evaluate efficacy and safety of SSR240600C in women with overactive bladder including urge urinary incontinence]. clinicaltrials.gov/show/NCT00564226 (first received 27 November 2007). [DRI6271] [EudraCT2007-004126-24] [NCT00564226] [TrialID.BILADY] [sr-incont63784]">EUCTR2007‐004126‐24‐CZ</a>; <a href="./references#CD003781-bbs2-0029" title="EUCTR2004-001116-31-ES. Multicentre, randomised, double-blind, parallel group confirmatory Phase III study to compare the efficacy and safety of cizolirtine citrate 300 mg bid (600 mg/d), cizolirtine citrate 400 mg bid (800 mg/d), placebo, and tolterodine 2 mg bid (4 mg/d) in the treatment of urge urinary incontinence. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-001116-31 (first received 03 November 2004). [ESCLIN-002/04] [EUCTR2004-001116-31-ES] [sr-incont64643]">EUCTR2004‐001116‐31‐ES</a>; <a href="./references#CD003781-bbs2-0030" title="EUCTR2004-002143-27-AT. A double-blind, stratified, randomised, parallel, placebo-controlled, multi-centre study to compare the efficacy and safety of duloxetine hydrochloride (40mg twice a day) and tolterodine tartrate (XL) (4mg once daily) with placebo in patients with symptoms of Urge Urinary Incontinence. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-002143-27 (first received 15 February 2005). [1208.15] [EUCTR2004-002143-27-AT] [sr-incont64640]">EUCTR2004‐002143‐27‐AT</a>; <a href="./references#CD003781-bbs2-0035" title="HaabF , StewartL , DwyerP . Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. European Urology2004;45(4):420-9. [srincont-17428]">Haab 2004</a>; <a href="./references#CD003781-bbs2-0038" title="HerschornS , HeesakkersJ , Castro-DiazD , WangJT , BrodskyM , GuanZ . Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*. Current Medical Research and Opinion2008;24(12):3513-21. [A6121122] [NCT00143377] [srincont-29250]HerschornS , HeesakkersJ , Castro-DiazD , WangJT , GuanZ , BrodskyM . Tolterodine extended release (TER) improves objective and subjective outcomes after 1 week of treatment in patients with overactive bladder (Abstract number 132). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S78-9. [srincont-26602]">Herschorn 2008</a>; <a href="./references#CD003781-bbs2-0039" title="CorcosJ , AnguloJC , GarelyAD , CarlssonM , GongJ , GuanZ . Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. Current Medical Research and Opinion2011;27(5):1059-65. [srincont-41596]EUCTR2006-006935-38-SE. 12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006935-38 (first received 16 April 2007). [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont64612]HerschornS , SwiftS , GuanZ , CarlssonM , BrodskyM , GongJ . Efficacy and safety of fesoterodine for overactive bladder in a double-blind, head-to-head comparison trial with tolterodine ER and placebo (Abstract number 710). In: International Continence Society (ICS), 39th Annual Meeting; 2009 Sep 29-Oct 3; San Francisco, CA. 2009. [srincont-35326]HerschornS , SwiftS , GuanZ , CarlssonM , MorrowJD , BrodskyM , et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU International2010;105(1):58-66. [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont39540]NCT00444925. Clinical trial to evaluate the efficacy and safety of Fesoterodine in comparison to Tolterodine for overactive bladder (OAB) [12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder (OAB)]. clinicaltrials.gov/show/NCT00444925 (first received 08 March 2007). [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont49159]">Herschorn 2009a</a>; <a href="./references#CD003781-bbs2-0040" title="EUCTR2012-005735-91-SK. A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-005735-91 (first received 12 November 2013). [178-CL-101] [EUCTR2012-005735-91-SK] [sr-incont78644]HerschornS , ChappleCR , AbramsP , ArlandisS , MitchesonD , LeeKS , et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU International2017;120(4):562-75. [NCT01972841] [sr-incont74470]MuellerER , RobinsonD , KelleherC , StaskinDR , FalconerC , WangJ , et al. Patient reported outcomes from synergy, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with mirabegron and solifenacin monotherapy (Abstract number - Podium #44). Neurourology and Urodynamics2017;36(Suppl S1):S151-2. [NCT01972841] [sr-incont75944]NCT01972841. This was a multinational study comparing the efficacy and safety of two medicines, solifenacin succinate and mirabegron taken together, or separately, or a mock treatment (placebo) in subjects with symptoms of overactive bladder (SYNERGY) [A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01972841 (first received 31 October 2013). [178-CL-101] [EUCTR2012-005735-91] [NCT01972841] [sr-incont63780]RobinsonD , KelleherC , StaskinD , MuellerER , FalconerC , WangJ , et al. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients. Neurourology and Urodynamics2018;37(1):394-406. [NCT01972841] [sr-incont76906]WeberMA , ChappleCR , GratzkeC , HerschornS , RobinsonD , FrankelJM , et al. A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial. Blood Pressure Monitoring2018;23(3):153-63. [NCT01972841] [sr-incont77899]WhiteWB , ChappleC , GratzkeC , HerschornS , RobinsonD , FrankelJ , et al. Cardiovascular safety of the beta3-adrenoceptor agonist mirabegron and the antimuscarinic agent solifenacin in the SYNERGY trial. Journal of Clinical Pharmacology2018;58(8):1084-91. [NCT01972841] [sr-incont78078]">Herschorn 2017a</a>; <a href="./references#CD003781-bbs2-0041" title="HerschornS , KohanA , AliottaP , McCammonK , SriramR , AbramsS , et al. The efficacy and safety of onabotulinumtoxin A or solifenacin compared with placebo in solifenacin naive patients with refractory overactive bladder: results from a multicenter, randomized, double-blind phase 3b trial. Journal of Urology2017;198(1):167-75. [NCT01767519] [sr-incont74491]NCT01767519. A study evaluating the efficacy and safety of BOTOX® or solifenacin in patients with overactive bladder and urinary incontinence. clinicaltrials.gov/show/NCT01767519 (first received 14 January 2013). [191622-125] [NCT01767519] [sr-incont49909]">Herschorn 2017b</a>; <a href="./references#CD003781-bbs2-0042" title="HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21072]HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21072]HillS , KhullarV , WyndaeleJJ , LheritierK , . Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. International Urogynecology Journal and Pelvic Floor2006;17(3):239-47. [srincont-22464]">Hill 2005</a>; <a href="./references#CD003781-bbs2-0043" title="HommaY , KawabeK . Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World Journal of Urology2004;22(4):251-6. [srincont-19412]HommaY , PaickJS , LeeJG , KawabeK , Japanese and Korean Tolterodine Study Group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU International2003;92(7):741-7. [srincont-16418]">Homma 2003</a>; <a href="./references#CD003781-bbs2-0047" title="JacquetinB , WyndaeleJJ . Tolterodine reduces the number of incontinence episodes in patients with an overactive bladder. European Journal of Obstetrics and Gynecology and Reproductive Biology2001;98(1):97-102. [srincont-12200]JacquetinB , WyndaeleJJ . Tolterodine reduces the number of incontinence episodes in patients with detrusor overactivity. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(1):S30. [srincont-5167]">Jacquetin 2001</a>; <a href="./references#CD003781-bbs2-0048" title="JonasU , HofnerK , MadersbacherH , HolmdahlTH . Efficacy and safety of two doses of Tolterodine compared to placebo in patients with detrusor overactivity. Neurourology and Urodynamics1997;16(5):477-8. [srincont-5841]JonasU , HöfnerK , MadersbacherH , HolmdahlTH . Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group. World Journal of Urology1997;15(2):144-51. [srincont-5436]">Jonas 1997</a>; <a href="./references#CD003781-bbs2-0049" title="JunemannKP , Al-ShukriS . Efficacy and tolerability of trospium chloride and tolterodine in 234 patients with urge-syndrome: a double-blind, placebo-controlled, multicentre clinical trial (Abstract number 85B). Neurourology and Urodynamics2000;19(4):488-90. [srincont-9976]">Junemann 2000</a>; <a href="./references#CD003781-bbs2-0050" title="JünemannKP , HessdörferE , Unamba‐OparahI , BerseM , BrünjesR , MadersbacherH . Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. Urologia Internationalis2006;77(4):334-9. [srincont-22199]">Junemann 2006</a>; <a href="./references#CD003781-bbs2-0051" title="EUCTR2007-006451-39-SE. 12-week, randomized, double-blind, double-dummy, placebo controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-006451-39 (first received 20 February 2008). [A0221046] [EUCTR2007-006451-39-SE] [sr-incont64591]KaplanSA , SchneiderT , FooteJ , GuanZ . Superior efficacy of fesoterodine over tolterodine with rapid onset: a prospective, head-to-head, placebo-controlled trial (Abstract number 67). Neurourology and Urodynamics2010;29(6):905-7. [srincont-40130]KaplanSA , SchneiderT , FooteJE , GuanZ , CarlssonM , GongJ . Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU International2011;107(9):1432-40. [A0221046] [NCT00611026] [srincont-41334]">Kaplan 2011</a>; <a href="./references#CD003781-bbs2-0052" title="CardozoL , KaplanS , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: results from the after study (Abstract number 740) [Erratum appears in: European Urology 2014;65(5):e78]. European Urology Supplements2013;12(1):e740-1. [NCT01302054] [sr-incont63732]CardozoL , KaplanS , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. Erratum: A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: results from the AFTER study [Erratum available in: European Urology Supplement 2013;2012:e740-1]. European Urology2014;65(5):e78 . [A0221094] [NCT01302054] [TrialID.AFTER.] [sr-incont61642]GrenaboL , HerschornS , KaplanSA , CardozoL , ScholfieldD , ArumiD , et al. Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptoms. Current Medical Research and Opinion2017;33(10):1731-6. [NCT01302054] [TrialID.AFTER.] [sr-incont76695]KaplanSA , CardozoL , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER. International Journal of Clinical Practice2014;68(9):1065-73. [A0221094] [NCT01302054] [TrialID.AFTER.] [srincont-63977]KaplanSA , HerschornS , CarlssonM , NtaniosF . Urgency urinary incontinence response rates in subjects with overactive bladder treated with fesoterodine 8 mg after suboptimal response to tolterodine extended release 4 mg: a randomized, double-blind, placebo-controlled trial (Abstract number 546). In: International Continence Society (ICS); 43rd Annual Meeting; 2013 Aug 26-30; Barcelona, Spain. 2013. [NCT01302054] [TrialID.AFTER.] [sr-incont49730]NCT01302054. A clinical study in patients with overactive bladder with leakage of urine, to find out if the medicine, Fesoterodine, works in those patients who did not have enough response to the medicine, tolterodine. [A 14 week randomized parallel group placebo-controlled double-blind multicentre study of fesoterodine 8 mg in overactive bladder patients with sub-optimal response to tolterodine 4 mg extended release (ER)]. clinicaltrials.gov/show/NCT01302054 (first received 23 February 2011). [A0221094] [NCT01302054] [TrialID.AFTER.] [sr-incont49845]">Kaplan 2014</a>; <a href="./references#CD003781-bbs2-0054" title="KhullarV , HillS , LavalKU , SchiotzHA , JonasU , VersiE . Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology2004;64(2):269-74; discussion 274-5. [srincont-19498]KhullarV , HillS , SolankiJ . Assessment of health-related quality of life in patients with overactive bladder taking tolterodine extended release versus placebo (Abstract number 318). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21075]">Khullar 2004</a>; <a href="./references#CD003781-bbs2-0055" title="AballéaS , MamanK , ThokagevistkK , NazirJ , OdeyemiIA , HakimiZ , et al. Cost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United Kingdom. Clinical Drug Investigation2015;35(2):83-93. [NCT00689104] [sr-incont66445]Arlandis-GuzmánS , Brenes-BermúdezF , Jiménez-CidreMA , Rubio-RodríguezD , Rubio-TerrésC , MoraAM , et al. Cost effectiveness of Mirabegron and antimuscarinic drugs in patients with hiperactive bladder [Coste-efectividad de mirabegrón y los antimuscarínicos en pacientes con vejiga hiperactiva]. Archivos Espanoles de Urologia2018;71(10):809-24. [NCT00689104] [sr-incont78645]EUCTR2007-001451-19-ES. A randomized, double-blind, parallel group, placebo and active controlled, multicenter study to assess the efficacy and safety of the beta-3 agonist YM178 (50 mg qd and 100 mg qd) in subjects with symptoms of overactive bladder - SCORPIO [Estudio multicentrico, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo y tratamiento activo, para evaluar la eficacia y seguridad del agonista beta-3 YM178 (50 mg, una vez al dia y 100 mg, una vez al dia) en pacientes con sintomas de vejiga hiperactiva]. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-001451-19 (first received 05 June 2008). [EUCTR2007-001451-19-ES] [sr-incont78646]HerschornS , NazirJ , RamosB , HakimiZ . Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada. Canadian Urological Association Journal2017;11(3-4):123-30. [NCT00689104] [sr-incont76807]KhullarV , AmarencoG , AnguloJ , BoerrigterP , BlauwetM , HakimiZ . The potent and selective beta3-adrenoceptor agonist mirabegron improves patient-reported outcomes in the treatment of overactive bladder (Abstract number MP-12.16). Urology2012;80(3 Suppl 1):S123. [sr-incont65379]KhullarV , AmarencoG , AnguloJC , BlauwetMB , NazirJ , OdeyemiIA , et al. Patient-reported outcomes with the β3 beta3-adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder. Neurourology and Urodynamics2016;35(8):987-94. [NCT00689104] [sr-incont72221]KhullarV , AmarencoG , AnguloJC , CambroneroJ , HøyeK , MilsomI , et al. Efficacy and tolerability of mirabegron, a ß3-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. European Urology2013;63(2):283-95. [NCT00689104] [TrialID.SCORPIO.] [sr-incont46836]KhullarV , CambroneroJ , AnguloJ , WooningM , BlauwetM , SiddiquiE , et al. Onset of action of efficacy of the potent and selective beta-3-adrenoceptor agonist, mirabegron, for the treatment of overactive bladder (OAB) in a 12-week, multicentre, randomised, double-blind, parallel-group, placebo-and tolterodine slow release (SR)-controlled study in OAB patients (Abstract number 135). International Urogynecology Journal and Pelvic Floor Dysfunction2012;23(2 Suppl 1):S187-8. [NCT00689104] [sr-incont67382]KhullarV , CambroneroJ , AnguloJC , WooningM , BlauwetMB , DorrepaalC , et al. Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial. BMC Urology2013;13:45. [NCT00689104] [sr-incont49411]KhullarV , CambroneroJ , StroebergP , AnguloJ , BoerrigterP , WooningM . The efficacy and tolerability of mirabegron, a potent and selective B3-adrenoceptor agonist, compared with placebo and tolterodine slow release in patients with overactive bladder - results from a European-Australian phase III trial (Abstract number 328). In: International Continence Society (ICS); 41st Annual Meeting; 2011 Aug 29-Sept 2; Glasgow, Scotland. 2011. [NCT00689104] [sr-incont42211]NCT00689104. Study to assess the efficacy and safety of the beta-3 agonist mirabegron (ym178) in patients with symptoms of overactive bladder (SCORPIO) [A randomized, double-blind, parallel group, placebo and active controlled, multicenter study to assess the efficacy and safety of mirabegron in subjects with symptoms of overactive bladder (SCORPIO)]. clinicaltrials.gov/show/NCT00689104 (first received 03 June 2008). [NCT00689104] [sr-incont49843]NittiV , HerschornS , AuerbachS , KhullarV , AmarencoG , BlauwetMB , et al. The potent and selective ß3-adrenoceptor agonist mirabegron improves patient-reported outcomes in overactive bladder-results from two phase III studies (Abstract number 68). Neurourology and Urodynamics2012;31(6):813-5. [NCT00689104] [sr-incont46724]WielageRC , PerkS , CampbellNL , NgD , KleinTM , PostaLM , et al. The cost effectiveness of mirabegron for the treatment of overactive bladder: three US perspectives (Abstract number A142). Journal of the American Geriatrics Society2015;63:S67. [NCT00689104] [sr-incont70876]YamanishiT , YamanishiY , TajimaH , IkedaS . Cost-effectiveness of mirabegron and tolterodine for the treatment of overactive bladder in Japan-Which drug is more cost-effective if used as the first-line treatment? (Abstract number 504). International Urogynecology Journal2018;29:S252. [NCT00689104] [sr-incont78647]YamanishiY , YamanishiT , TajimaH , IkedaS . Mirabegron or tolterodine for the treatment of overactive bladder in Japan: Which drug is more cost-effective as the first-line treatment?International Journal of Urology2018;25(10):863-70. [NCT00689104] [sr-incont78648]">Khullar 2013</a>; <a href="./references#CD003781-bbs2-0059" title="KrederK , PleilAM , ReesePR , KelleherJ . Effects of long-term tolterodine treatment on social and psychological aspects of health-related quality of life in overactive bladder patients (Abstract). Journal of Urology2002;167(Suppl 4):29. [sr-incont17591]">Kreder 2002</a>; <a href="./references#CD003781-bbs2-0060" title="HsiaoSM , ChangTC , ChenCH , WuWY , LinHH . Comparisons of the clinical outcomes and urodynamic effects of mirabegron versus tolterodine treatment for female overactive bladder syndrome: a subgroup analysis of a controlled, randomised, prospective study. Lower Urinary Tract Symptoms2018;10(3):215-20. [NCT01043666] [sr-incont74461]KuoHC , LeeKS , NaY , SoodR , NakajiS , KubotaY , et al. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourology and Urodynamics2015;34(7):685-92. [NCT01043666] [sr-incont68095]Kuo H‐C, Lin H‐H, Yu H‐J, Cheng C‐L, Hung M‐J, LinAT . Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials [Erratum available in: Urological Science 2015;26(2):148]. Urological Science2015;26(1):41-8 . [NCT01043666] [sr-incont68645]NCT01043666. A study of YM178 in subjects with symptoms of overactive bladder  [Phase III study of YM178: a randomized, double-blind, parallel group, placebo and active controlled, multi-center study in subjects with symptoms of overactive bladder]. clinicaltrials.gov/show/NCT01043666 (first received 07 January 2010). [178-CL-090] [NCT01043666] [sr-incont63781]">Kuo 2015</a>; <a href="./references#CD003781-bbs2-0062" title="LandisJR , KaplanS , SwiftS , VersiE . Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity. Journal of Urology2004;171(2 Pt 1):752-6. [sr-incont17327]">Landis 2004</a>; <a href="./references#CD003781-bbs2-0066" title="Malone-LeeJG , WalshB , MaugourdMF , Tolterodine in the Elderly Study Group. The safety and clinical efficacy of two doses of tolterodine compared to placebo in elderly patients. In: International Continence Society (ICS), 27th Annual Meeting; 1997 Sep 23-26; Yokohama, Japan. 1997:155-6. [srincont-5855]Malone‐LeeJG , WalshJB , MaugourdMF . Tolterodine: A safe and effective treatment for older patients with overactive bladder. Journal of the American Geriatric Society2001;49(6):700-5. [srincont-12319]WaggA , Malone-LeeJ . Pressure-flow variables in patients treated with tolterodine for detrusor overactivity. BJU International2003;92(9):969-71. [sr-incont16659]">Malone‐Lee 2001</a>; <a href="./references#CD003781-bbs2-0068" title="DmochowskiR , MitchesonD , FrenklT , BennettN , MuddPN . Durable efficacy and safety of long-term once-daily vibegron, a novel oral B-3 adrenergic receptor agonist: A 52-week phase 2 study in patients with overactive bladder syndrome (Abstract number PD50-03). Journal of Urology2018;199(4):e970-1. [sr-incont78091]EUCTR2010-022121-15-IT. A phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2 part clinical study of the efficacy and safety of MK-4618 in patients with overactive bladder - MK4618-008 [A 52-week extension to: a phase iib randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder]. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-022121-15 (first received 12 April 2011). [EUCTR2010-022121-15-IT] [MK4618-008] [NCT01314872] [sr-incont78639]MitchesonD , FrenklT , SamantaS , Anne PintoC , GreenS , BennettN , et al. Vibegron, a novel once daily oral beta-3 agonist, significantly reduces average daily micturitions, urge incontinence episodes and urgency episodes in patients with overactive bladder (Abstract number: podium #34). Neurourology and Urodynamics2018;37(Suppl 1):S565. [EUCTR2010-022121-15-IT] [NCT01314872] [sr-incont78618]MitchesonD , PintoCA , FrenklT , ChenL , PrasadM , MuddPN . Once daily vibegron improves quality of life measures in patients with overactive bladder (Abstract number PUK17). Value in Health2018;21(Suppl 1):S267-8. [EUCTR2010-022121-15-IT] [NCT01314872;] [sr-incont78619]MitchesonHD , SamantaS , MuldowneyK , PintoCA , RochaBA , GreenS , et al. Vibegron (RVT-901/MK-4618/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial. European Urology2019;75(2):274-82. [NCT01314872] [sr-incont78620]NCT01314872. A study of the efficacy and safety of Vibegron (MK-4618) in participants with overactive bladder (OAB) (MK-4618-008) [A phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder a 52-week extension to: a phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder]. clinicaltrials.gov/show/NCT01314872 (first received 15 March 2011). [NCT01314872] [sr-incont63793]UKCRN10391. A phase IIB randomised, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of MK-4618 in patients with overactive bladder . public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=10391 (accessed 28 June 2012). [CCRN525] [UKCRN10391] [sr-incont45046]">Mitcheson 2019</a>; <a href="./references#CD003781-bbs2-0074" title="RentzhogSL , StantonL , CardozoL , NelsonE , FallM , AbramsP . Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. British Journal of Urology1998;81(1):42-8. [srincont-5461]">Rentzhog 1998</a>; <a href="./references#CD003781-bbs2-0076" title="EUCTR2008-005215-17. A study to evaluate the overall effect of solifenacin 5mg and 10mg on bladder wall thickness and urinary nerve growth factor in female subjects with overactive bladder and a diagnosis of detrusor overactivity – a double-blind, randomized, placebo-controlled, parallel group, multicentre study - SHRINK. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-005215-17 (first received 14 September 2009). [EUCTR2008-005215-17] [NCT01093534] [sr-incont78650]NCT01093534. Study of 2 doses of solifenacin succinate in female subjects with overactive bladder (SHRINK) [A study to evaluate the overall effect of solifenacin 5mg and 10mg on bladder wall thickness and urinary nerve growth factor in female subjects with overactive bladder and a diagnosis of detrusor overactivity - a double-blind, randomised, placebo-controlled, parallel group, multi-centre study]. clinicaltrials.gov/show/NCT01093534 (first received 26 March 2010). [905-EC-007] [EUCTR2008-005215-17] [NCT01093534] [TrialID.SHRINK] [sr-incont63778]RobinsonD , KhullarV , OelkeM , WijkstraH , TretterR , StowB , et al. Effects of 12 weeks treatment with solifenacin on Bladder Wall Thickness (BWT) and clinical outcomes: results from the placebo-controlled SHRINK study (Abstract number 422). In: International Continence Society (ICS), 43rd Annual Meeting; 2013 Aug 26-30; Barcelona, Spain. 2013. [905-EC-007] [NCT01093534] [TrialID.SHRINK.] [srincont-49731]RobinsonD , OelkeM , KhullarV , WijkstraH , TretterR , StowB , et al. Bladder wall thickness in women with symptoms of overactive bladder and detrusor overactivity: results from the randomised, placebo-controlled SHRINK study. Neurourology and Urodynamics2016;35(7):819-25. [NCT01093534] [sr-incont72217]RobinsonD , OelkeM , TretterR , StowB , CompionG , TubaroA . The effect of solifenacin on bladder wall thickness in women with overactive bladder and detrusor overactivity: Results from the SHRINK study (Abstract number 782). European Urology Supplements2013;12(1):e782-3. [EUCTR2008-005215-17] [NCT01093534] [sr-incont67207]RobinsonD , TubaroA , KimbergM , PlummerM , DeVineJ , BouicP , et al. The effect of solifenacin on urinary nerve growth factor (UNGF) and brain-derived neurotropic factor (BDNF) in women with overactive bladder and detrusor overactivity: results from the SHRINK study (Abstract number PP 54). International Urogynecology Journal and Pelvic Floor Dysfunction2014;25(1 Suppl 1):S60-1. [EUCTR2008-005215-17] [NCT01093534] [sr-incont67200]TubaroA , KhullarV , OelkeM , WijkstraH , TretterR , StowB , et al. Intra- and inter-reader variability of transvaginal ultrasound bladder wall thickness measurements: results from the SHRINK study (Abstract number 136). Neurourology and Urodynamics2013;32(6):711-2. [EUCTR2008-005215-17] [NCT01093534] [sr-incont49211]">Robinson 2013</a>; <a href="./references#CD003781-bbs2-0079" title="RovnerES , KaplanS , GuanZ , WangJT , RoehrbornCG . Clinical efficacy and safety of tolterodine extended release in male patients with overactive bladder and urgency urinary incontinence (Abstract number 188). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21091]">Rovner 2005</a>; <a href="./references#CD003781-bbs2-0083" title="EUCTR2017-003293-14. Empowur (Empower OAB patients with vibegron for better urgency control) [An international phase 3, randomized, double-blind, placebo- and active (tolterodine)-controlled multicenter study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder]. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-003293-14 (first received 24 April 2018). [EUCTR2017-003293-14] [NCT03492281] [sr-incont78606]NCT03492281, JankowichR . A study to examine the safety and efficacy of a new drug in patients with symptoms of overactive bladder (OAB) [An international phase 3, randomized, double-blind, placebo- and active (tolterodine)-controlled multicenter study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder]. clinicaltrials.gov/show/NCT03492281 (first received 20 April 2018). [NCT03492281] [sr-incont78610]StaskinD , FrankelJ , VaranoS , ShortinoD , JankowichR , MuddPN . Vibegron demonstrates statistically significant improvement in efficacy measures in overactive bladder-key secondary results from the international phase 3 study in patients with overactive bladder (empowur) (Abstract number: long oral 40). Female Pelvic Medicine and Reconstructive Surgery2019;25(5):S20-1. [NCT03492281] [sr-incont78627]StaskinD , FrankelJ , VaranoS , ZhouJ , JankowichR , MuddPN . International phase 3, double-blind, placebo- and active (tolterodine)-controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: empowur (Abstract number LBA-02). Journal of Urology2019;201(4):e992. [NCT03492281] [sr-incont78628]StaskinD , VaranoS , FrankelJ , ShortinoD , JankowichR , MuddP . Once-daily vibegron 75 mg demonstrates statistically significant benefits on key secondary endpoints including quality of life in patients with OAB: data from an international phase 3 trial (EMPOWUR) (Abstract number 181). Neurourology and Urodynamics2019;38(S3):S115-7. [NCT03492281] [sr-incont78629]VaranoS , StaskinD , FrankelJ , ShortinoD , JankowichR , MuddPN . Vibegron statistically significantly improves measures of quality of life in patients with overactive bladder-data from the international phase 3 trial (Empowur) (Abstract number: long oral 38). Female Pelvic Medicine and Reconstructive Surgery2019;25(5):S19. [NCT03492281] [sr-incont78630]">Staskin 2019</a>; <a href="./references#CD003781-bbs2-0091" title="MesselinkEJ , SolerJM , MadersbacherH , ThuroffJW , AmarencoG , Van KerrebroeckEV . Urodynamic aspects of the efficacy of tolterodine, a new anti muscarine drug in the treatment of detrusor hyperreflexia. In: International Continence Society (ICS), 25th Annual Meeting; 1995 Oct 17-20; Sydeney, Australia. 1995:95-6. [srincont-10883]Van KerrebroeckPE , AmarencoG , ThüroffJW , MadersbacherHG , LockMT , MesselinkEJ , et al. Dose-ranging study ot tolterodine in patients with detrusor hyperreflexia. Neurourology and Urodynamics1998;17(5):499-512. [srincont-7852]">Van Kerrebroeck 1998</a>; <a href="./references#CD003781-bbs2-0092" title="ChancellorM , FreedmanS , MitchesonHD , AntociJ , PrimusG , WeinA . Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clinical Drug Investigation2000;19(2):83-91. [srincont-16326]FreemanR , HillS , MillardR , SlackM , SutherstJ , Tolterodine Study Group. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstetrics and Gynecology2003;102(3):605-11. [srincont-16494]GarelyA , Tolterodine Study Group. Once-daily tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder. International Urology Journal2001;12(Suppl 1):S18. [srincont-12012]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of life of patients with overactive bladder receiving tolterodine. Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of patients with overactive bladder receiving tolterodine (Abstract number 82). Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , ReesePR . Health related quality of life of patients with overactive bladder receiving tolterodine once-daily. Neurourology and Urodynamics2000;19(4):519-21. [srincont-9987]KelleherCJ , ReesePR , PleilAM , OkanoGJ . Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. American Journal of Managed Care2002;8(Suppl 19):S608-15. [srincont-17998]KelleherCJ , Tolterodine Study Group. Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2000;11(Suppl 1):S94. [srincont-11915]KrederKJ . Antimuscarinic therapy: relationship between efficacy and side effects in responders and non-responders. Journal of Urology2001;165(Suppl 5):S165. [srincont-16327]KrederKJ . Clinical effectiveness of antimuscarinic therapy: the relationship between efficacy and tolerability. In: Proceedings of the International Continence Society Annual Meeting(ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001:140. [srincont-14376]MallettV . Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2001;12(Suppl 1):4. [srincont-12011]MillardRJ , TamaddonK , Tolterodine Study Group. Randomized controlled trial to compare tolterodine prolonged release capsules and tolterodine immediate release tablets versus placebo in patients with symptoms of detrusor overactivity (Abstract number 57). Australian and New Zealand Journal of Surgery2002;Suppl 72:A140. [sr-incont22190]PleilAM , ReesePR , KelleherCJ , OkanoGJ . Health-related quality of life of patients with overactive bladder receiving immediate-release tolterodine. HEPAC Health Economics in Prevention and Care2001;2(2):69-75. [sr-incont18060]RoehrbornCG , AbramsP , RovnerES , KaplanSA , HerschornS , GuanZ . Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU International2006;97(5):1003-6. [sr-incont21882]SwiftS . Efficacy and tolerability of once-daily tolterodine for women with overactive bladder. In: International Continence Society Annual Meeting (ICS), 31st annual meeting; 2001 Sept 18-21; Seoul, Korea. 2001:No. 329. [srincont-14481]SwiftS . Once-daily tolterodine is effective and well tolerated in women with overactive bladder (Abstract 57). In: 2nd International Consultation on Incontinence; 2001 July 1-3; Paris, France. 2001. [srincont-16319]SwiftSE . Once-daily (OD) tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder (OAB). International Urogynecology Journal2000;11(Suppl 1):S15. [sr-incont11906]SwiftSE . Once-daily administration of extended-release tolterodine is effective and well-tolerated in patients with overactive bladder. In: XVI FIGO World Congress of Obstetrics and Gynecology; 2000 Sept 3-8; Washington DC. Vol. Book 1. 2000:40. [sr-incont12085]SwiftSE . Overactive bladder in females: treatment with once-daily tolterodine. International Urogynecology Journal2001;12(Suppl 3):S71. [sr-incont16328]Van KerrebroeckP , KrederK , JonasU , ZinnerN . Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology2001;57(3):414-21. [sr-incont11953]Van KerrebroeckPEV . Long-term (12 months) efficacy and tolerability of tolterodine once-daily in the treatment of overactive bladder. Neurourology and Urodynamics2001;20(4):401-2. [sr-incont15714]Van KerrebroeckPEVA , Tolterodine Study Group. Long-term tolerability and efficacy of once-daily (OD) tolterodine in the treatment of overactive bladder (OB). International Urogynecology Journal2001;12(Suppl 3):S49. [sr-incont16329]Van KerrebroeckPEVA , Tolterodine Study Group. Significant decreases in perception of urgency and urge incontinence episodes with once-daily tolterodine treatment in patients with overactive bladder (Abstract number 89). Neurourology and Urodynamics2000;19(4):493-4. [sr-incont9980]WeinAJ , KhullarV , WangJT , GuanZ . Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. BJU International2007;99(2):360-3. [sr-incont23180]vanKerrebroeckPE , KelleherCJ , CoyneKS , KoppZ , BrodskyM , WangJT . Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. Health and Quality of Life Outcomes2009;7(13):13. [10.1186/1477-7525-7-13] [sr-incont31438]vanKerrebroeckPE , WangJ , GuanZ . Effects of tolterodine extended release in patients with overactive bladder: perceived treatment benefits improve with efficacy (Abstract number 511). European Urology Supplements2004;3(2):130. [sr-incont31090]">Van Kerrebroeck 2001</a>; <a href="./references#CD003781-bbs2-0094" title="EUCTR2007-007087-17-SE. A 24-week, multicentre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-007087-17 (first received 13 June 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont64588]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00798434. A study to compare the effectiveness and safety of fesoterodine and placebo in an elderly population of patients who go to the toilet very frequently due to overactive bladder (SOFIA) [A 24-week, multi-centre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00798434 (first received 26 November 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont49847]SchneiderT , BergqvistA , WangJ , WaggA , Ebel-BitounC . Treatment with fesoterodine versus tolterodine for reducing symptom bother in elderly patients with overactive bladder including urgency urinary incontinence. European Urology, Supplements2012;11(1):e687-a. [sr-incont65389]WaggA , CarlssonM , ElsobkyM , FernetM . Effect of flexible dose fesoterodine on cognitive function in &gt;65 year old patients with OAB: data from two RCT (Abstract number 438). Neurourology and Urodynamics2019;38:S297-8. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78651]WaggA , DarekarA , ArumiD , KhullarV , OelkeM . Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people &gt;65 years of age: a post hoc analysis of data from the SOFIA study. Neurourology and Urodynamics2015;34(5):438-43. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont68100]WaggA , ElsobkyM , CarlssonM , FernetM . Response and cognitive safety of fesoterodine in patients &gt;65y old with OAB. Is there a relationship between cognition and treatment response? (Abstract number 183). Neurourology and Urodynamics2019;38:S118-20. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78632]WaggA , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. Journal of the American Geriatrics Society2013;61(2):185-93. [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TrialID.SOFIA.] [sr-incont48008]WaggAS , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Efficacy and tolerability of fesoterodine in older subjects with overactive bladder: results of SOFIA (Abstract number C33). Journal of the American Geriatrics Society2011;59:S124. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont65234]">Wagg 2013a</a>; <a href="./references#CD003781-bbs2-0102" title="ZinnerNR , MattiassonA , StantonSL . Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. Journal of the American Geriatrics Society2002;50(5):799-807. [sr-incont14679]">Zinner 2002</a>). The total number of settings in a study ranged from two (<a href="./references#CD003781-bbs2-0009" title="CardozoL , ChappleCR , Toozs-HobsonP , Grosse-FreeseM , BulittaM , LehmacherW , et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomised, double-blind, multicentre clinical trial. British Journal of Urology International2000;85(6):659-64. [srincont-11732]">Cardozo 2000</a>; <a href="./references#CD003781-bbs2-0026" title="DrutzH , AppellRA . Clinical efficacy and safety of Tolterodine vs Oxybutynin and placebo in patients with unstable bladder. Acta Obstetrica et Gynecologica Scandinavica1997;Suppl 167(5):24. [srincont-6671]DrutzHP , AppellRA , GleasonD , KlimbergI , RadomskiS . Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. International Urogynecology Journal and Pelvic Floor Dysfunction1999;10(5):283-9. [srincont-8804]DrutzHP , AppellRA . Enhanced tolerability of tolterodine compared to oxybutynin in a controlled clinical study. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(1):S14. [srincont-5166]">Drutz 1999</a>; <a href="./references#CD003781-bbs2-0043" title="HommaY , KawabeK . Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World Journal of Urology2004;22(4):251-6. [srincont-19412]HommaY , PaickJS , LeeJG , KawabeK , Japanese and Korean Tolterodine Study Group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU International2003;92(7):741-7. [srincont-16418]">Homma 2003</a>; <a href="./references#CD003781-bbs2-0047" title="JacquetinB , WyndaeleJJ . Tolterodine reduces the number of incontinence episodes in patients with an overactive bladder. European Journal of Obstetrics and Gynecology and Reproductive Biology2001;98(1):97-102. [srincont-12200]JacquetinB , WyndaeleJJ . Tolterodine reduces the number of incontinence episodes in patients with detrusor overactivity. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(1):S30. [srincont-5167]">Jacquetin 2001</a>; <a href="./references#CD003781-bbs2-0074" title="RentzhogSL , StantonL , CardozoL , NelsonE , FallM , AbramsP . Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. British Journal of Urology1998;81(1):42-8. [srincont-5461]">Rentzhog 1998</a>) to 42 countries (<a href="./references#CD003781-bbs2-0040" title="EUCTR2012-005735-91-SK. A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-005735-91 (first received 12 November 2013). [178-CL-101] [EUCTR2012-005735-91-SK] [sr-incont78644]HerschornS , ChappleCR , AbramsP , ArlandisS , MitchesonD , LeeKS , et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU International2017;120(4):562-75. [NCT01972841] [sr-incont74470]MuellerER , RobinsonD , KelleherC , StaskinDR , FalconerC , WangJ , et al. Patient reported outcomes from synergy, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with mirabegron and solifenacin monotherapy (Abstract number - Podium #44). Neurourology and Urodynamics2017;36(Suppl S1):S151-2. [NCT01972841] [sr-incont75944]NCT01972841. This was a multinational study comparing the efficacy and safety of two medicines, solifenacin succinate and mirabegron taken together, or separately, or a mock treatment (placebo) in subjects with symptoms of overactive bladder (SYNERGY) [A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01972841 (first received 31 October 2013). [178-CL-101] [EUCTR2012-005735-91] [NCT01972841] [sr-incont63780]RobinsonD , KelleherC , StaskinD , MuellerER , FalconerC , WangJ , et al. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients. Neurourology and Urodynamics2018;37(1):394-406. [NCT01972841] [sr-incont76906]WeberMA , ChappleCR , GratzkeC , HerschornS , RobinsonD , FrankelJM , et al. A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial. Blood Pressure Monitoring2018;23(3):153-63. [NCT01972841] [sr-incont77899]WhiteWB , ChappleC , GratzkeC , HerschornS , RobinsonD , FrankelJ , et al. Cardiovascular safety of the beta3-adrenoceptor agonist mirabegron and the antimuscarinic agent solifenacin in the SYNERGY trial. Journal of Clinical Pharmacology2018;58(8):1084-91. [NCT01972841] [sr-incont78078]">Herschorn 2017a</a>). </p> <p>Thirty‐seven trials were conducted in single countries (<a href="./references#CD003781-bbs2-0007" title="BrayR , CartwrightR , CardozoL , HillS , GuanZ , KhullarV . Tolterodine ER reduced increased bladder wall thickness in women with overactive bladder. A randomized, placebo-controlled, double-blind, parallel group study. Neurourology and  Urodynamics2018;37(1):237-43. [NCT00137397] [sr-incont74473]NCT00137397. A study to measure the effect of tolterodine extended release on the thickness of the bladder wall in patients with overactive bladder [A multi-centre, randomised, placebo controlled, double blind, parallel group study in female patients to evaluate whether tolterodine ER can reverse the increased bladder wall thickness in patients with overactive bladder]. clinicaltrials.gov/show/NCT00137397 (first received 29 August 2005). [NCT00137397] [sr-incont63809]">Bray 2018</a>; <a href="./references#CD003781-bbs2-0008" title="BurgioKL , LocherJL , GoodePS , HardinJM , McDowellBJ , CandibD . Behavior vs drug therapy for urge incontinence in older women (Abstract number 26). In: American Urogynecology Society, 15th Annual Scientific Meeting; 1994 Sept 21-24; Toronto, Ontario. 1994:48. [sr-incont14585]BurgioKL , LocherJL , GoodePS , HardinM , McDowellBJ , Dombrowski M et al. Behavioral vs drug treatment for urge urinary incontinence in older women. A randomized controlled trial. JAMA1998;280(23):1995-2000. [srincont-5719]BurgioKL , LocherJL , GoodePS . Combined behavioral and drug therapy for urge incontinence in older women. Journal of the American Geriatrics Society2000;48(4):370-4. [srincont-9006]BurgioKL , LocherJL , RothDL , GoodePS . Psychological improvements associated with behavioral and drug treatment of urge incontinence in older women. Journal of Gerontology. Series B, Psychological Sciences and Social Sciences2001;56(1):P46-51. [srincont-11923]">Burgio 1998</a>; <a href="./references#CD003781-bbs2-0021" title="ChuaME , SeeMC , EsmeňaEB , BalingitJC , MoralesML . Efficacy and safety of gabapentin in comparison to solifenacin succinate in adult overactive bladder treatment. Lower Urinary Tract Symptoms2018;10(2):135-42. [NCT01486706] [sr-incont74529]NCT01486706, ChuaME . Efficacy and safety of gabapentin in treating overactive bladder (OAB). clinicaltrials.gov/show/NCT01486706 (first received 6 December 2011). [NCT01486706] [SLMC10-010] [sr-incont49864]">Chua 2018</a>; <a href="./references#CD003781-bbs2-0023" title="ChancellorMB , OefeleinMG , VasavadaS . Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release. Neurourology and Urodynamics2010;29(4):551-4. [sr-incont39591]DmochowskiR , StaskinD , SandP , ZinnerN . Trospium chloride 60 mg once daily improves quality of life in subjects with overactive bladder syndrome (Abstract number 277). In: International Continence Society (ICS); 37th Annual Meeting; 2008 Aug 20-24; Rotterdam, the Netherlands. 2007. [srincont-26679]DmochowskiRR , RosenbergMT , ZinnerNR , StaskinDR , SandPK . Extended-release trospium chloride improves quality of life in overactive bladder. Value in Health2010;13(2):251-7. [srincont-40049]DmochowskiRR , SandPK , ZinnerNR , StaskinDR . Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology2008;71(3):449-54. [srincont-27107]DmochowskiRR , ZinnerNR , SandPK . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: Results from a multicenter, phase III, placebo-controlled study (Abstract). Neurourology and Urodynamics2007;26(Suppl 7):1105-6. [srincont-26692]GinsbergDA , OefeleinMG , EllsworthPI . Once-daily administration of trospium chloride extended release provides 24-hr coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials. Neurourology and Urodynamics2011;30(4):563-7. [sr-incont41531]RovnerE , DmochowskiR , WatanabeJ . Once daily (QD) trospium chloride 60 mg extended release (XR) is safe and effective in patients (PTS) with the overactive bladder (OAB) syndrome who use multiple concomitant medications (MEDS) (Abstract number: Poster #68). Neurourology and Urodynamics2009;28(2):146-7. [sr-incont31062]SandP , DmochowskiR , ZinnerN , StaskinD . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: results from a multicenter, phase III, placebo-controlled study (Abstract number 269). In: International Continence Society (ICS), 37th Annual Meeting; 2007 Aug 20-24; Rotterdam, the Netherlands. 2007. [srincont-26676]SandPK , DmochowskiRR , ZinnerNR , StaskinDR , AppellRA . Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome. International Urogynecology Journal and Pelvic Floor Dysfunction2009;20(12):1431-8. [sr-incont39648]SandPK , Johnson IiTM , RovnerES , EllsworthPI , OefeleinMG , StaskinDR . Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged &gt; 75 years) with overactive bladder syndrome. BJU International2011;107(4):612-20. [sr-incont41422]StaskinDR , RosenbergMT , SandPK , ZinnerNR , DmochowskiRR . Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials. International Journal of Clinical Practice2009;63(12):1715-23. [sr-incont35458]">Dmochowski 2008</a>; <a href="./references#CD003781-bbs2-0024" title="DmochowskiR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. A double-blind, placebo-controlled trial of flexible-dose fesoterodine for overactive bladder (Abstract number 715). In: International Continence Society (ICS); 39th Annual Meeting; 2009 Sep 29-Oct 03; San Francisco, CA. 2009. [sr-incont35627]DmochowskiRR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder [Errata appear in: Urology 2010 Jun;75(6):1519 and in Urology 2011 Jun;77(6):1513]. Urology2010;75(1):62-8. [A0221014] [NCT00536484] [sr-incont39548]DuBeauC , KrausSR , SunF , MorrowJD . Fesoterodine in older vs younger subjects with overactive bladder (Abstract number D87). Journal of the American Geriatrics Society2010;58:S218. [NCT00536484] [sr-incont64309]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. [sr-incont78640]NCT00536484. Fesoterodine flexible dose study [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with overactive bladder]. clinicaltrials.gov/show/NCT00536484 (first received 27 September 2007). [NCT00536484] [sr-incont49160]StaskinD , KhullarV , MichelMC , MorrowJD , SunF , GuanZ , et al. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. Neurourology and Urodynamics2011;30(8):1480-5. [sr-incont42686]">Dmochowski 2010</a>; <a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>; <a href="./references#CD003781-bbs2-0028" title="ElbasetM , TahaD , ZahranM , EzzatO , ElhefnawyAS , ElkenawyM , et al. Subjective and objective scales assessment after retreatment with anticholinergics post botox-faded effects in refractory idiopathic overactive bladder: a prospective single blinded randomized trial (Abstract number 132). European Urology, supplements2019;18(1):e172. [sr-incont78652]ElbasetMA , TahaDE , El-HefnawyAS , ZahranMH , ShokeirAA . Assessment of anticholinergic use after fading of BTX-A effects in refractory idiopathic overactive bladder: a prospective blinded randomized trial. International Neurourology Journal2019;23(3):240-8. [sr-incont78605]">Elbaset 2019</a>; <a href="./references#CD003781-bbs2-0032" title="GellerE , DumondJ , BowlingJM , KhandelwalC , WuJ , Busby-WhiteheadJ , et al. Effect of an anticholinergic on cognitive function in postmenopausal women: a randomized trial (Abstract number: oral poster 52). Female Pelvic Medicine and Reconstructive Surgery2016;22(5):S61. [sr-incont78607]GellerEJ , DumondJB , BowlingJM , KhandelwalCM , WuJM , Busby-WhiteheadJ , et al. Effect of trospium chloride on cognitive function in women aged 50 and older: a randomized trial. Female Pelvic Medicine &amp; Reconstructive Surgery2017;23(2):118-23. [13-1352] [NCT01922115] [sr-incont74341]NCT01922115. The effect of anticholinergics on cognitive function in the elderly (ACE) [The effect of anticholinergics on cognitive function in the elderly: a randomized controlled trial]. clinicaltrials.gov/show/NCT01922115 (first received 14 August 2013). [13-1352] [NCT01922115] [TrialID.ACE] [sr-incont49282]">Geller 2013</a>; <a href="./references#CD003781-bbs2-0033" title="GotohM , HommaY , YokoyamaO , NishizawaO . Responsiveness and minimal clinically important change in overactive bladder symptom score. Urology2011;78(4):768-73. [srincont-42622]GotohM , YokoyamaO , MatsukawaY , NishizawaO . Responsiveness of overactive bladder symptom score (OABSS): verification based on data in a double-blinded, randomized placebo-controlled study of propiverine hydrochloride in Japanese patients (Abstract number 338). In: Joint Meeting of the International Continence Society (ICS) and the International Urogynecological Association; 2010 Aug 23-27; Toronto, Canada. 2010. [srincont-40173]GotohM , YokoyamaO , NishizawaO . Propiverine hydrochloride in Japanese patients with overactive bladder: A randomized, double-blind, placebo-controlled trial. International Journal of Urology2011;18(5):365-73. [srincont-41510]">Gotoh 2011</a>; <a href="./references#CD003781-bbs2-0036" title="HajebrahimiS , MotlaghRS , BazarganiHS , BabaieH . Efficacy of tadalafil in treatment of overactive bladder syndrome: a randomized controlled trial (Abstract number OP.3.6Dec.27). International Journal of Urology2014;21:A146. [IRCT2013030212668N1] [sr-incont67256]IRCT2013030212668N1. Effect of tadalafil in treatment of overactive bladder  [Comparison of the efficacy of tadalafil, toltrodine and placebo in reduction of symptoms severity of women with urgency, frequency syndrom / overactive bladder]. en.irct.ir/trial/12692 (first received 26 January 2013). [91189] [IRCT2013030212668N1] [sr-incont78643]">Hajebrahimi 2014</a>; <a href="./references#CD003781-bbs2-0322" title="IRCT2015010720598N1. The effect of solifenacin succinate on intraocular pressure [Ocular effects of solifenacin succinate in women with narrow angle glaucoma and overactive bladder syndrome]. en.irct.ir/trial/18253 (first received 22 June 2015). [IRCT2015010720598N1] [sr-incont78608] [tbzmed.rec.1394.127]">Hajebrahimi 2015</a>; <a href="./references#CD003781-bbs2-0044" title="HommaY , YamaguchiT , YamaguchiOA . A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2008;15(9):809-15. [srincont-27742]">Homma 2008</a>; <a href="./references#CD003781-bbs2-0045" title="HommaY , YamaguchiO , Imidafenacin Study Group. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2009;16(5):499-506. [NCT00212732] [ONO-8025-08] [srincont-31368]">Homma 2009</a>; <a href="./references#CD003781-bbs2-0046" title="HuangA , HessR , AryaL , RichterH , SubakL , BradleyC , et al. A randomized controlled trial of simple diagnosis and treatment for urgency urinary incontinence in women (Abstract). Journal of General Internal Medicine2011;26:S1. [NCT00862745] [sr-incont64391]HuangAJ , HessR , AryaLA , RichterHE , SubakLL , BradleyCS , et al. Pharmacologic treatment for urgency-predominant urinary incontinence in women diagnosed using a simplified algorithm: a randomized trial. American Journal of Obstetrics and Gynecology2012;206(5):444.e1-11. [GA0221IX] [NCT00862745] [TrialID.BRIDGES.] [srincont-44636]NCT00862745, BrownJ . Bringing simple urge incontinence diagnosis &amp; treatment to providers (BRIDGES)  [A multi-center, randomized, placebo-controlled clinical trial comparing fesoterodine to placebo in women diagnosed with urge urinary incontinence by the 3 Incontinence Questions (3IQ). Followed by a multi-center open label clinical cohort study of long-term effects of treatment with fesoterodine ]. clinicaltrials.gov/show/NCT00862745 (first received 17 March 2009). [NCT00862745] [sr-incont49836]WarsiQ , HuangA , BrownJS , SchembriM , HessR , AryaLA , et al. The effect of pharmacologic treatment of urgency urinary incontinence on sleep quality and daytime sleepiness (Abstract number: paper 37). Female Pelvic Medicine and Reconstructive Surgery2016;22(5 ):S17-8. [NCT00862745] [TrialID.BRIDGES.] [sr-incont78633]WarsiQA , HuangAJ , HessR , AryaLA , RichterHE , BradleyCS , et al. Association of pharmacologic treatment of urgency urinary incontinence with sleep quality and daytime sleepiness. Obstetrics and Gynecology2018;131(2):204-11. [NCT00862745] [sr-incont78239]WinkelmanW , HuangA , SchembriM , RogersRG , RichterHE , MyersDL , et al. Clinical variables moderating response to pharmacologic treatment of urgency-predominant urinary incontinence in a randomized controlled trial (Abstract number: poster 25). In: Female Pelvic Medicine and Reconstructive Surgery. 37th Annual Scientific Meeting of the American Urogynecologic Society; Aug 2016; United States. Vol. 22. Netherlands: Lippincott Williams and Wilkins, 2016:S81. [NCT00862745] [sr-incont78634]WinkelmanWD , HuangAJ , SchembriM , RogersRG , RichterH , MyersDL , et al. Modifiers of response to treatment with fesoterodine for urgency-predominant urinary incontinence in a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2017;23(2):151-6. [sr-incont74308]">Huang 2012</a>; <a href="./references#CD003781-bbs2-0056" title="KosilovKV , LoparevS , IvanovskayaM , KosilovaL . Treatment of overactive bladder in older women increased doses of antimuscarinic drugs safe and effective alternative to existing methods. Advances in Gerontology [Uspekhi Gerontologii]2014;27(1):149-55. [ISSN: 1561-9125] [sr-incont63914]">Kosilov 2014a</a>; <a href="./references#CD003781-bbs2-0057" title="KosilovK , LoparevS , IvanovskayaM , KosilovaL . A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron. Archives of Gerontology and Geriatrics2015;61(2):212-6. [sr-incont68133]">Kosilov 2015a</a>; <a href="./references#CD003781-bbs2-0058" title="KosilovKV , LoparevSA , IvanovskayaMA , KosilovaLV . The efficacy of different doses of solifenacin in elderly patients after treating a urinary tract infection. Arab Journal of Urology Print2015;13(3):203-8. [sr-incont69283]">Kosilov 2015b</a>; <a href="./references#CD003781-bbs2-0061" title="LacknerTE , WymanJF , McCarthyTC , MonigoldM , DaveyC . Efficacy of oral extended-release oxybutynin in cognitively impaired older nursing home residents with urge urinary incontinence: a randomized placebo-controlled trial. Journal of the American Medical Directors Association2011;12(9):639-47. [sr-incont42677]LacknerTE , WymanJF , McCarthyTC , MonigoldM , DaveyC . Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. Journal of the American Geriatrics Society2008;56(5):862-70. [sr-incont27117]">Lackner 2011</a>; <a href="./references#CD003781-bbs2-0063" title="LeeKS , ChooMS , KimDY , KimJC , KimHJ , MinKS , et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. Journal of Urology2005;174(4 Pt 1):1334-8. [sr-incont21016]LeeKS , ChooMS , PaickJS , LeeJG , SeoJT , LeeJZ , et al. Propiverine hydrochloride reduced frequency and perception of urgency in treatment of overactive bladder: a 12 week prospective, randomized, double blind, placebo controlled study (Abstract number 279). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26640]LeeKS , LeeHW , ChooMS , PaickJS , LeeJG , SeoJT , et al. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'. BJU International2010;105(11):1565-70. [2005-01-08] [NCT00903045] [PROUD] [sr-incont39958]NCT00903045. Urinary urgency outcomes following propiverine treatment for an overactive bladder [Urinary urgency outcomes following propiverine treatment for an overactive bladder: propiverine study on overactive bladder including urgency data (PROUD)]. clinicaltrials.gov/show/NCT009030452005;(first received 15 May 2009). [2005-01-08] [NCT00903045] [TrialID.PROUD] [sr-incont49860]">Lee 2006</a>; <a href="./references#CD003781-bbs2-0064" title="LuisV , LoyolaJP , MelissaC , FelipeM , San MartinC . Efficacy of darifenacin use combined with pelvic floor physiotherapy in overactive bladder syndrome treatment in women (Abstract number 434). International Urogynecology Journal2018;29(Suppl 1):S220-1. [NCT02143570] [sr-incont78617]NCT02143570, CifuentesM , MartinezF . Efficacy of darifenacin and physiotherapy for the treatment of overactive bladder in women. clinicaltrials.gov/show/NCT02143570 (first received 21 May 2014). [NCT02143570] [sr-incont61781]">Luis 2018</a>; <a href="./references#CD003781-bbs2-0112" title="AssassaP , WilliamsK , LambertP , AbramsK , TurnerD , ShawC , et al. A double blind randomised placebo controlled trial of the effectiveness of bladder training with oxybutynin or imipramine in the management of detrusor overactivity (DO) (Abstract number 330). In: Joint Meeting of the International Continence Society (ICS) and the International Urogynecological Association; 2010 Aug 23-27; Toronto, Canada. 2010. [ISRCTN58226681] [sr-incont40171]ISRCTN58226681, McGrotherC . Evaluation of the efficacy of oxybutynin and imipramine in the management of detrusor instability. isrctn.org/ISRCTN58226681 (first received 25 October 2000). [DOI: https://doi.org/10.1186/ISRCTN58226681] [ISRCTN58226681] [sr-incont64656]">Assassa 2010</a>; <a href="./references#CD003781-bbs2-0323" title="NCT00553657. The study to test the effect of standardization of fluid intake in female patients with overactive bladder [A randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of standardization of fluid intake on the variability of measured voiding parameters in female patients with idiopathic overactive bladder]. clinicaltrials.gov/show/NCT00553657 (first received 04 November 2007). [NCT00553657] [sr-incont60907]">NCT00553657</a>; <a href="./references#CD003781-bbs2-0069" title="Drug company. A phase 2, parallel group, stratified, randomized, double blind, placebo-controlled trial to investigate the efficacy and safety of 3 different dosages of sustained release fesoterodine in subjects with overactive bladder showing either involuntary detrusor contractions or normal findings during the baseline urodynamic assessment. Protocol numbers: A0221029 (SP668). ClinicalStudyResults.org (accessed 3 March 2011). [srincont-41111]NittiV , WiatrakM , KreitmanL , LipsitzD . Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB): results of a phase 2 trial (Abstract number 306). In: International Continence Society (ICS); 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21084]">Nitti 2005</a>; <a href="./references#CD003781-bbs2-0070" title="GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NittiVW , DmochowskiR , SandPK , ForstHT , Haag-MolkentellerC , MassowU , et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. Journal of Urology2007;178(6):2488-94. [NCT00138723] [SP584] [srincont-26313]">Nitti 2007</a>; <a href="./references#CD003781-bbs2-0073" title="NCT01302938. Web-based methodology trial to evaluate the efficacy and safety of tolterodine ER in subjects with overactive bladder (REMOTE) [Exploratory, randomized, double-blind, placebo-controlled, parallel-group, single center, web-based phase IV pilot methodolgy trial to evaluate the efficacy and safety of tolterodine ER in subjects with overactive bladder]. clinicaltrials.gov/ct2/show/NCT01302938 (first received 24 February 2011). [A6121195] [NCT01302938] [TrialID.REMOTE.] [sr-incont43314]OrriM , LipsetCH , JacobsBP , CostelloAJ , CummingsSR . Web-based trial to evaluate the efficacy and safety of tolterodine ER 4 mg in participants with overactive bladder: REMOTE trial. Contemporary Clinical Trials2014;38(2):190-7. [A6121195] [NCT01302938] [TrialID.REMOTE.] [sr-incont62536]">Orri 2014</a>; <a href="./references#CD003781-bbs2-0075" title="ISRCTN17856439, ResnickN . Pathophysiology of urge incontinence in older women. isrctn.org/ISRCTN17856439 (first received 09 March 2006). [1999P-001891] [94-6641-01] [ISRCTN17856439] [sr-incont64614]">Resnick 2006</a>; <a href="./references#CD003781-bbs2-0077" title="RogersR , BachmannG , JumadilovaZ , SunF , MorrowJD , GuanZ , et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. International Urogynecology Journal and Pelvic Floor Dysfunction2008;19(11):1551-7. [A6121002] [NCT00143481] [srincont-27729]RogersRG , BachmannG , ScarperoH , JumadilovaZ , SunF , MorrowJD , et al. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. Current Medical Research and Opinion2009;25(9):2159-65. [srincont-32060]">Rogers 2008</a>; <a href="./references#CD003781-bbs2-0080" title="RudyD , ClineK , GoldbergK , HarrisR . A multicenter, randomized, placebo-controlled trial of trospium chloride in overactive bladder patients (Abstract). Neurourology and Urodynamics2004;23(5/6):600-1. [sr-incont19025]RudyD , ClineK , HarrisR , GoldbergK , DmochowskiR . Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology2006;67(2):275-80. [srincont-21604]RudyD , ClineK , HarrisR , GoldbergK , DmochowskiR . Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. BJU International2006;97(3):540-6. [sr-incont21593]">Rudy 2006</a>; <a href="./references#CD003781-bbs2-0082" title="ChancellorMB , OefeleinMG , VasavadaS . Obesity is associated with a more severe overactive bladder disease state that is effectively treated with one daily administration of trospium chloride extended release [Erratum available in: Neurourology and Urodynamics 2010;29(5):804]. Neurourology and Urodynamics2010;29(4):551-4. [sr-incont39591]GinsbergDA , OefeleinMG , EllsworthPI . Once-daily administration of trospium chloride extended release provides 24-hour coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials. Neurourology and Urodynamics2011;30(4):563-7. [sr-incont41531]RovnerE , DmochowskiR , WatanabeJ . Once daily (QD) trospium chloride 60mg extended release (XR) is safe and effective in patients (PTS) with the overactive bladder (OAB) syndrome who use multiple concomitant medications (MEDS) (Abstract number: Poster #68). Neurourology and Urodynamics2009;28(2):146-7. [sr-incont31062]SandP , DmochowskiR , ZinnerN , StaskinD . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: results from a multicenter, phase III, placebo-controlled study (Abstract number 269). In: International Continence Society (ICS), 37th Annual Meeting; 2007 Aug 20-24; Rotterdam, the Netherlands. 2007. [sr-incont26676]SandP , StaskinD , ZinnerN , DmochowskiR . Once-daily trospium chloride extended release is effective and well tolerated for the treatment of overactive bladder: results from a multicenter, phase III trial (Abstract number 57). Neurourology and Urodynamics2007;26(5):675. [sr-incont26661]StaskinD , SandP , ZinnerN , DmochowskiR , Trospium Study Group. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. Journal of Urology2007;178(3 Pt 1):978-83; discussion 983-4. [srincont-23909]StaskinDR , RosenbergMT , SandPK , ZinnerNR , DmochowskiRR . Trospium chloride once daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised phase III trials. International Journal of Clinical Practice2009;63(12):1715-23. [sr-incont35458]StaskinDR , SandPK , ZinnerNR . Once-daily trospium chloride extended release is effective and well tolerated for the treatment of overactive bladder: results from a multicenter, phase III trial (Abstract number - poster 22). Neurourology and Urodynamics2007;26(7 Suppl):1106. [srincont-27305]">Staskin 2007</a>; <a href="./references#CD003781-bbs2-0093" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CrosbyRD , MathiasSD , MarshallTS . Relationships between symptoms, symptom bother, and health-related quality of life in patients with overactive bladder taking solifenacin or placebo in the VIBRANT study. International Journal of Clinical Practice2011;65(2):211-8. [sr-incont41015]GollarKM , YoungDG , BailenJ , HeW , Forero-SchwanhaeuserS . Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: a secondary analysis of the VIBRANT study. Urologic Nursing2012;32(1):38-46. [TrialID.VIBRANT.] [sr-incont44571]Samuels T‐A, MitchesonHD , VardyM , Forero‐SchwanhaeuserS , MarshallT , HeW . Efficacy of solifenacin for symptom bother and other patient-reported outcomes in patients with overactive bladder (OAB): results of a large, double-blind, placebo-controlled trial (Abstract number: poster #74). Neurourology and Urodynamics2009;28(2):149. [sr-incont31063]VardyMD , MitchesonHD , SamuelsTA , Forero-SchwanhaeuserS , HeW . Efficacy of solifenacin on overactive bladder symptoms, symptom bother, and other patient-reported outcomes in subjects with or without incontinence: a post hoc analysis of data from VIBRANT. Female Pelvic Medicine and Reconstructive Surgery2011;17(1):24-9. [TrialID.VIBRANT.] [sr-incont44741]VardyMD , MitchesonHD , SamuelsTA , WegenkeJD , Forero-SchwanhaeuserS , MarshallTS , et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. International Journal of Clinical Practice2009;63(12):1702-14. [905-UC-010] [NCT00573508] [TrialID.VIBRANT.] [sr-incont35459]">Vardy 2009</a>; <a href="./references#CD003781-bbs2-0095" title="GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00911937. A trial to evaluate the efficacy and safety of fesoterodine in patients with symptoms of overactive bladder including nocturnal urinary urgency [A randomized, double blind, placebo controlled, parallel group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with symptoms of overactive bladder including nocturnal urinary urgency]. clinicaltrials.gov/show/NCT00911937 (first received 03 June 2009). [NCT00911937] [sr-incont49848]WeissJ , JumadilovaZ , CarlssonM , FitzGeraldMP , MalhotraA , MartireDL . Effect of antimuscarinic treatment in subjects with overactive bladder, including nocturnal urinary urgency (Abstract number 1963). Journal of Urology2012;187(4 Suppl 1):e792. [NCT00911937] [sr-incont65184]WeissJP , CarlssonMR , ManganEK . Age, gender and nocturnal urgency severity predict response to antimuscarinic treatment (Abstract number 1962). Journal of Urology2013;189(4 Suppl 1):e805. [NCT00911937] [sr-incont65096]WeissJP , JumadilovaZ , JohnsonTM , FitzGeraldMP , CarlssonM , MartireDL , et al. Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency. Journal of Urology2013;189(4):1396-401. [A0221048] [NCT00911937] [sr-incont47568]">Weiss 2013</a>; <a href="./references#CD003781-bbs2-0096" title="YamaguchiO , MaruiE , KakizakiH , ItohN , YokotaT , OkadaH , et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU International2007;100(3):579-87. [sr-incont23865]YokoyamaO , YamaguchiO , KakizakiH , ItohN , YokotaT , OkadaH , et al. Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary. Journal of Urology2011;186(1):170-4. [sr-incont41734]">Yamaguchi 2007</a>; <a href="./references#CD003781-bbs2-0097" title="NCT00966004. A study to evaluate safety and efficacy of ym178 in patients with overactive bladder [Phase III study of YM178 - a placebo-controlled, double-blind, group comparison study in patients with overactive bladder]. clinicaltrials.gov/show/NCT00966004 (first received 26 August 2009). [178-CL-048] [JapicCTI-R130370] [NCT00966004] [sr-incont63783]YamaguchiO , HidehiroK , YukioH , YasuhikoI , MasayukiT , OsamuN , et al. A phase III, randomized, double-blind, placebo and active controlled study of once-daily mirabegron 50 mg in patients with overactive bladder (Abstract number POD-03.06). Urology2012;80(3 Suppl 1):S10-1. [NCT00966004] [sr-incont65380]YamaguchiO , MaruiE , KakizakiH , HommaY , IgawaY , TakedaM , et al. A phase III, randomized, double-blind, placebo-controlled study of the beta-adrenoceptor agonist, mirabegron 50 mg once-daily, in Japanese patients with overactive bladder. BJU International2014;113(6):951-60. [NCT00966004] [sr-incont50603]">Yamaguchi 2012</a>; <a href="./references#CD003781-bbs2-0098" title="YamaguchiO , UchidaE , HigoN , MinamiH , KobayashiS , SatoH , et al. Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: a randomized double-blind trial. International Journal of Urology2014;21(6):586-93. [JapicCTI-101309] [sr-incont62099]">Yamaguchi 2014</a>; <a href="./references#CD003781-bbs2-0100" title="JapicCTI-152936. Phase III study of KRP-114V [A phase III, randomized, double-blind, parallel group, placebo controlled, multicenter study to assess the efficacy and safety of the beta-3 agonist KRP-114V in Japanese subjects with symptoms of overactive bladder]. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-152936 (first received 17 June 2015). [JapicCTI-152936] [sr-incont78653]YoshidaM , TakedaM , GotoM , NagaiS , KuroseT . Vibegron, a novel potent and selective beta3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study (Abstract number 1082). European Urology, Supplements2018;17(2):e1531-2. [JapicCTI-152936] [sr-incont78069]YoshidaM , TakedaM , GotohM , NagaiS , KuroseT . Vibegron, a novel potent and selective B3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study. European Urology2018;73(5):783-90. [JapicCTI-152936] [sr-incont77898]YoshidaM , TakedaM , GotohM , YokoyamaO , KakizakiH , TakahashiS , et al. Efficacy of novel beta3-adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: a post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study. International Journal of Urology2019;26(3):369-75. [JapicCTI-152936] [sr-incont78654]YoshidaM , TakedaM , GotohM , YokoyamaO , KakizakiH , TakahashiS , et al. Efficacy of vibegron, a novel selective I²3-adrenoreceptor agonist, on urgency urinary incontinence with overactive bladder: post-hoc analysis of phase iii study (Abstract number 180). Neurourology and Urodynamics2019;38(S3):S114-5. [JapicCTI-152936] [sr-incont78636]">Yoshida 2018</a>; <a href="./references#CD003781-bbs2-0101" title="NCT01018264, ZesiewiczT . Solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease (URGE-PD) [URGE-PD: a multi-site, double-blind, randomized, placebo controlled trial of solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease]. clinicaltrials.gov/show/NCT01018264 (first received 23 November 2009). [NCT01018264] [sr-incont63790]ZesiewiczTA , EvattM , JahanI , VaughanC , SingerC , OrdoricaR , et al. URGE-PD: a multi-site, double-blind, randomized, placebo controlled trial of solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease (Abstract number 745). Movement Disorders2014;29(Suppl 1):S276-7. [NCT01018264] [sr-incont66602]ZesiewiczTA , EvattM , VaughanCP , JahanI , SingerC , OrdoricaR , et al. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease. Parkinsonism and Related Disorders2015;21(5):514-20. [NCT01018264] [sr-incont66860]">Zesiewicz 2015</a>; <a href="./references#CD003781-bbs2-0103" title="ZinnerN , GittelmanM , HarrisR , SussetJ , KanellosA , AuerbachS . Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial (Abstract number DP51). In: American Urological Association (AUA), 98th Annual Meeting; 2003 Apr 26-May 1; Chicago, Illinois. 2003. [sr-incont31101]ZinnerN , GittelmanM , HarrisR , SussetJ , KanelosA , AuerbachS , Trospium Study Group. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. Journal of Urology2004;171(6 Pt 1):2311-5. [sr-incont17376]">Zinner 2004</a>). </p> <p>Twenty‐two studies did not report details of the setting (<a href="./references#CD003781-bbs2-0001" title="AbramsP , JacksonS , MattiassonA , KrishnanK , HaendlerL . A randomised, double-blind, placebo controlled, dose ranging study of the safety and efficacy of tolterodine in patients with hyperreflexia (Abstract). In: International Continence Society 26th Annual Meeting; 1996 Aug 27-30; Athens, Greece. 1996:276-7. [sr-incont5135]">Abrams 1996</a>; <a href="./references#CD003781-bbs2-0003" title="AbramsP , KaplanS , MillardR . Tolterodine treatment is safe in men with bladder outlet obstruction (BOO) and symptomatic detrusor overactivity (DO) (Abstract). Neurourology and Urodynamics2001;20(4):547-8. [srincont-14372]">Abrams 2001</a>; <a href="./references#CD003781-bbs2-0006" title="BaertL , Leuven, DijkmanG , Breda, the darifenacin study group. Darifenacin, a novel M3 muscarinic receptor antagonist in detrusor overactivity (Abstract  214). In: International Continence Society, 25th Annual Meeting; 1995 Oct 17-20;  Sydney, Australia. 1995:226-7. [sr-incont10890]">Baert 1995</a>; <a href="./references#CD003781-bbs2-0012" title="ChalihaC , HalaskaM , StantonS . Trospium chloride for the treatment of detrusor instability: a placebo-controlled dose-finding study (Abstract 276). British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):92. [srincont-8452]">Chaliha 1998</a>; <a href="./references#CD003781-bbs2-0308" title="ChappleCR , MadersbacherH , DreikornK , DorschnerW , MurtzG . Urodynamics and frequency/volume chart - do they correlate? Treatment analysis of propiverine in comparison to oxybutynin and placebo in urge incontinence (Abstract number 224). In: International Continence Society (ICS), 31st Annual Meeting; 2001 Sep 18-21; Seoul, Korea. 2001. [sr-incont14474]">Chapple 2001</a>; <a href="./references#CD003781-bbs2-0020" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. [sr-incont75259]ChuF , SmithN , UchidaT . Efficacy and safety of solifenacin succinate 10 mg once daily: a multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder. Current Therapeutic Research - Clinical and Experimental2009;70(6):405-20. [srincont-43324]">Chu 2009</a>; <a href="./references#CD003781-bbs2-0025" title="ChappleCR , MadersbacherH , DreikornK , DorschnerW , MurtzG . Urodynamics and frequency/volume chart - do they correlate? Treatment analysis of propiverine in comparison to oxybutynin and placebo in urge incontinence (Abstract number 224). In: International Continence Society (ICS), 31st Annual Meeting; 2001 Sep 18-21; Seoul, Korea. 2001. [sr-incont14474]DorschnerW , StolzenburgJU , GriebenowR , HalaskaM , BrünjesR , FrankM , et al. The elderly patient with urge incontinence or urge-stress incontinence - efficacy and cardiac safety of propiverine [Der ältere Patient mit Drang-Symptomatik bzw. kombinierter Drang/Stress-Inkontinenz-Wirksamkeit und kardiale Sicherheit von Propiverin]. Aktuelle Urologie2003;34(2):102-8. [sr-incont16422]DorschnerW , StolzenburgJU , GriebenowR , HalaskaM , SchubertG , Mürtz G et al. Efficacy and cardiac safety of propiverine in elderly patients - a double-blind, placebo-controlled clinical study. European Urology2000;37(6):702-8. [srincont-11660]">Dorschner 2000</a>; <a href="./references#CD003781-bbs2-0034" title="GriebenowR , WienersF , LangeT . Possible induction of cardiac dysrhythmia in elderly patients under therapy with propiverine hydrochloride (Abstract). Neurourology and Urodynamics1994;13:430-2. [sr-incont2681]">Griebenow 1994</a>; <a href="./references#CD003781-bbs2-0037" title="HalaskaM , DorschnerW , FrankM . Treatment of urgency and incontinence in elderly patients with propiverine hydrochloride. Neurourology and Urodynamics1994;13(4):428-30. [srincont-2680]">Halaska 1994</a>; <a href="./references#CD003781-bbs2-0064" title="LuisV , LoyolaJP , MelissaC , FelipeM , San MartinC . Efficacy of darifenacin use combined with pelvic floor physiotherapy in overactive bladder syndrome treatment in women (Abstract number 434). International Urogynecology Journal2018;29(Suppl 1):S220-1. [NCT02143570] [sr-incont78617]NCT02143570, CifuentesM , MartinezF . Efficacy of darifenacin and physiotherapy for the treatment of overactive bladder in women. clinicaltrials.gov/show/NCT02143570 (first received 21 May 2014). [NCT02143570] [sr-incont61781]">Luis 2018</a>; <a href="./references#CD003781-bbs2-0065" title="ChappleCR , MadersbacherH , DreikornK , DorschnerW , MurtzG . Urodynamics and frequency/volume chart - do they correlate? Treatment analysis of propiverine in comparison to oxybutynin and placebo in urge incontinence (Abstract 224). In: International Continence Society (ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001. [sr-incont14474]HalaskaM , MadersbacherH , VoigtR , HofnerK , MartanA . Propiverine in patients with urgency and urge incontinence - a placebo controlled, multicentre study comparing its tolerability and efficacy with oxybutynin (Abstract number FDP36). International Urogynaecology Journal 2000;11(Suppl 1):S46. [srincont-11912]MadersbacherH , HalaskaM , VoigtR , AlloussiS , HofnerK . A urodynamically controlled multicenter study in patients with urge incontinence: tolerability and efficacy of propiverine hydrochloride in comparison to oxybutynin. In: International Continence Society (ICS), 27th Annual Meeting; 1997 Sep 23-26; Yokohama, Japan. 1997:153-4. [srincont-5854]MadersbacherH , HalaskaM , VoigtR , AlloussiS , HöfnerK . A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU International1999;84(6):646-51. [srincont-9166]">Madersbacher 1999</a>; <a href="./references#CD003781-bbs2-0067" title="MillardR , TuttleJ , MooreK , SussetJ , ClarkeB , DwyerP , et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. Journal of Urology1999;161(5):1551-5. [sr-incont8172]MooreK , MillardR , DwyerP , TuttleJ . A randomized controlled multicentre trial of tolterodine in detrusor instability/hyperreflexia. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(Suppl 1):S129. [sr-incont5171]RosamiliaA , DwyerPL , ClarkeB , MooreK , MillardRP , TuttleJ . The clinical efficacy and safety of two doses of Tolterodine in detrusor instability. Acta Obstetrica et Gynecologica Scandinavica1997;6(Suppl 167):24. [sr-incont6670]">Millard 1999</a>; <a href="./references#CD003781-bbs2-0071" title="OlshanskyB , FooteJ , ArguinzonizM , LheritierK , Quebe-FehlingE , SteelM . Cardiovascular safety of darifenacin and tolterodine in patients with overactive bladder (OAB) (Abstract number 49). International Urogynecology Journal and Pelvic Floor Dysfunction2006;17(Suppl 2):S86-7. [sr-incont34186]">Olshansky 2006</a>; <a href="./references#CD003781-bbs2-0078" title="RomanziLJ , DelconteA , KralidisG . Impact of darifenacin compared with tolterodine on incontinence episodes in patients with overactive bladder (Abstract number A3522). Obstetrics and Gynecology2005;105(Suppl 4):88S. [sr-incont34187]">Romanzi 2005</a>; <a href="./references#CD003781-bbs2-0084" title="SteersW , CorcosJ . Efficacy, tolerability and safety of darifenacin, an M3 selective receptor antagonist for the treatment of overactive bladder, using a flexible dosing regimen (Abstract number 68). Progres en Urologie2004;14(3 Suppl 3):22. [srincont-22197]">Steers 2004</a>; <a href="./references#CD003781-bbs2-0085" title="StohrerM , BauerP , GiannettiBM , RichterR , BurgdorferH , MurtzG . Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries. Urologia Internationalis1991;47(3):138-43. [srincont-236]">Stohrer 1991</a>; <a href="./references#CD003781-bbs2-0086" title="StohrerM , MadersbacherH , RichterR , WehnertJ , DreikornK . Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia - a double-blind, placebo-controlled clinical trial. Spinal Cord1999;37(3):196-200. [sr-incont8146]">Stohrer 1999</a>; <a href="./references#CD003781-bbs2-0087" title="TagoK , UenoA , TakayasuH . Clinical study of propiverine hydrochloride for the treatment of patients with urinary frequency and incontinence. Neurourology and Urodynamics1990;9(4):337-8. [srincont-5109]">Tago 1990</a>; <a href="./references#CD003781-bbs2-0089" title="ThuroffJW , BunkeB , EbnerA , FaberP , deGeeterP , HannappelJ , et al. Randomized, double-blind multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin vs. propantheline vs. placebo. Neurourology and Urodynamics1990;9(4):337-8. [srincont-5108]ThuroffJW , BunkeB , EbnerA , FaberP , deGeeterP , HannappelJ , et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. Journal of Urology1991;145(4):813-7. [srincont-1288]">Thuroff 1991</a>; <a href="./references#CD003781-bbs2-0090" title="UlshoferB , BihrAM , BodekerRH , SchwantesU , JahnHP . Randomised, double-blind, placebo-controlled study on the efficacy and tolerance of trospium chloride in patients with motor urge incontinence. Clinical Drug Investigation2001;21(8):563-9. [srincont-16324]UlshoferB , SchwantesU , BodekerRH , BihrAM , JahnHP . Efficacy and tolerance of trospium chloride in patients with motor urge incontinence - results of a randomised double-blind placebo-controlled study (Poster presentations). In: 2nd International Consultation on Incontinence (ICI); 2001 July 1-3; Paris, France. 2001:5. [srincont-16318]">Ulshofer 2001</a>; <a href="./references#CD003781-bbs2-0099" title="YongucT , SefikE , InciI , KusbeciOY , CelikS , AydinME , et al. Randomized, controlled trial of fesoterodine fumarate for overactive bladder in Parkinson's disease. World Journal of Urology2019;38(8):2013-9. [sr-incont78635]">Yonguc 2019</a>; <a href="./references#CD003781-bbs2-0104" title="ZinnerN , SussetJ , GittelmanM , ArguinzonizM , RekedaL , HaabF . Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. International Journal of Clinical Practice2006;60(1):119-26. [sr-incont21507]">Zinner 2006</a>). </p> </section> <section id="CD003781-sec-0048"> <h5 class="title">Participants</h5> <p>The inclusion or exclusion criteria, or both, were not always well described in the studies. A common exclusion criterion was evidence of voiding dysfunction or bladder outlet obstruction, although in one study inclusion was restricted to men with symptoms of bladder overactivity and bladder outlet obstruction (<a href="./references#CD003781-bbs2-0003" title="AbramsP , KaplanS , MillardR . Tolterodine treatment is safe in men with bladder outlet obstruction (BOO) and symptomatic detrusor overactivity (DO) (Abstract). Neurourology and Urodynamics2001;20(4):547-8. [srincont-14372]">Abrams 2001</a>). Further details on study inclusion and exclusion criteria can be found in the <a href="./references#CD003781-sec-0123" title="">Characteristics of included studies</a>. </p> <section id="CD003781-sec-0049"> <h6 class="title">Types of symptoms</h6> <p>People who had symptoms consistent with overactive bladder syndrome were included in 77 studies (<a href="./references#CD003781-bbs2-0002" title="AbramsP , FreemanR , AnderströmC , MattiassonA . Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. British Journal of Urology1998;81(6):801-10. [srincont-7871]AbramsP , FreemanRN , AnderstromC , MattiassonA . Efficacy and tolerability of tolterodine vs. oxybutynin and placebo in patients with detrusor instability (Abstract). Journal of Urology1997;157(Suppl 4):103. [srincont-16321]">Abrams 1998</a>; <a href="./references#CD003781-bbs2-0003" title="AbramsP , KaplanS , MillardR . Tolterodine treatment is safe in men with bladder outlet obstruction (BOO) and symptomatic detrusor overactivity (DO) (Abstract). Neurourology and Urodynamics2001;20(4):547-8. [srincont-14372]">Abrams 2001</a>; <a href="./references#CD003781-bbs2-0004" title="AbramsP , KelleherC , StaskinD , KayR , MartanA , MincikI , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World Journal of Urology2017;35(5):827-38. [NCT01340027] [sr-incont77897]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Cardiovascular safety of combination treatment with mirabegron and solifenacin in patients with overactive bladder in a randomised, double-blind, dose-ranging, Phase II study (Symphony) (Abstract). European Urology, Supplements2014;13(1):e574-e574a. [NCT01340027] [sr-incont67160]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB) - efficacy and safety results from a randomised phase II study (Symphony) (Abstract number 295). Neurourology and Urodynamics2013;32(6):930-1. [NCT01340027] [TrialID.SYMPHONY.] [sr-incont49188]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB): safety results from a phase 2 study (Abstract number MP-16.08). Urology2013;82(3 Suppl 1):S139. [NCT01340027] [sr-incont66675]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: Exploratory responder analyses of efficacy and evaluation of patient reported outcomes from a randomised, double-blind, dose-ranging, phase 2 study (Symphony) (Abstract number MP-24.11). Urology2014;84(4 Suppl 1):S145-6. [NCT01340027] [sr-incont67194]AbramsP , KelleherC , StaskinD , RechbergerT , KayR , MartinaR , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (SYMPHONY). European Urology2015;67(3):577-88. [NCT01340027] [sr-incont66674]NCT01340027, Bristol Urological Institute . A study to evaluate the efficacy, safety and tolerability of mirabegron and solifenacin succinate alone and in combination for the treatment of overactive bladder (symphony) [A randomized, double-blind, factorial, parallel-group, active and placebo-controlled, multicenter dose-ranging study to evaluate the efficacy, safety and tolerability of six dose combinations of solifenacin succinate and mirabegron compared to mirabegron and solifenacin succinate monotherapies in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01340027 (first received 21 April 2011). [178-CL-100] [2010-020601-32] [NCT01340027] [TrialID.SYMPHONY] [sr-incont44510]NittiV , AbramsP , StaskinD , AuerbachS , MartinaR , VanMR . Urinary retention in patients with overactive bladder treated with mirabegron alone and in combination with solifenacin: the results of two randomized, double-blind, phase II studies (Abstract number MP76-13). Journal of Urology2014;191(4 Suppl 1):e886-7. [NCT00410514] [NCT01340027] [TrialID.SYMPHONY] [sr-incont67453]">Abrams 2013</a>; <a href="./references#CD003781-bbs2-0006" title="BaertL , Leuven, DijkmanG , Breda, the darifenacin study group. Darifenacin, a novel M3 muscarinic receptor antagonist in detrusor overactivity (Abstract  214). In: International Continence Society, 25th Annual Meeting; 1995 Oct 17-20;  Sydney, Australia. 1995:226-7. [sr-incont10890]">Baert 1995</a>; <a href="./references#CD003781-bbs2-0007" title="BrayR , CartwrightR , CardozoL , HillS , GuanZ , KhullarV . Tolterodine ER reduced increased bladder wall thickness in women with overactive bladder. A randomized, placebo-controlled, double-blind, parallel group study. Neurourology and  Urodynamics2018;37(1):237-43. [NCT00137397] [sr-incont74473]NCT00137397. A study to measure the effect of tolterodine extended release on the thickness of the bladder wall in patients with overactive bladder [A multi-centre, randomised, placebo controlled, double blind, parallel group study in female patients to evaluate whether tolterodine ER can reverse the increased bladder wall thickness in patients with overactive bladder]. clinicaltrials.gov/show/NCT00137397 (first received 29 August 2005). [NCT00137397] [sr-incont63809]">Bray 2018</a>; <a href="./references#CD003781-bbs2-0008" title="BurgioKL , LocherJL , GoodePS , HardinJM , McDowellBJ , CandibD . Behavior vs drug therapy for urge incontinence in older women (Abstract number 26). In: American Urogynecology Society, 15th Annual Scientific Meeting; 1994 Sept 21-24; Toronto, Ontario. 1994:48. [sr-incont14585]BurgioKL , LocherJL , GoodePS , HardinM , McDowellBJ , Dombrowski M et al. Behavioral vs drug treatment for urge urinary incontinence in older women. A randomized controlled trial. JAMA1998;280(23):1995-2000. [srincont-5719]BurgioKL , LocherJL , GoodePS . Combined behavioral and drug therapy for urge incontinence in older women. Journal of the American Geriatrics Society2000;48(4):370-4. [srincont-9006]BurgioKL , LocherJL , RothDL , GoodePS . Psychological improvements associated with behavioral and drug treatment of urge incontinence in older women. Journal of Gerontology. Series B, Psychological Sciences and Social Sciences2001;56(1):P46-51. [srincont-11923]">Burgio 1998</a>; <a href="./references#CD003781-bbs2-0009" title="CardozoL , ChappleCR , Toozs-HobsonP , Grosse-FreeseM , BulittaM , LehmacherW , et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomised, double-blind, multicentre clinical trial. British Journal of Urology International2000;85(6):659-64. [srincont-11732]">Cardozo 2000</a>; <a href="./references#CD003781-bbs2-0011" title="CardozoL , AdamikZ , GuimaraesM , KrhutJ , Labat J-J, PetrovS , et al. Patients with overactive bladder show progressive improvement in urgency and bladder condition during treatment with solifenacin in a randomised, double-blind, placebo-controlled study (SUNRISE) (Abstract number 115). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S67-8. [srincont-26595]CardozoL , AmarencoG , PushkarD , MikulasJ , DrogendijkT , WrightM , et al. Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE). BJU International2013;111(5):804-10. [NCT00801944] [TrialID.SUNRISE.] [sr-incont47554]CardozoL , DewildeT , FeyereislJ , WadieB , AmarencoG , LiapisA , et al. Solifenacin significantly reduces both urgency severity and bother: results from the flexible dose, placebo controlled, multinational SUNRISE study (Abstract number 281). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26641]CardozoL , DrogendijkT , BolodeokuJ . The efficacy of solifenacin 5/10 mg on 'urgency' endpoints in different OAB patient populations: subanalysis of results from the randomised, double-blind SUNRISE study (Abstract number 192). In: International Continence Society (ICS); 38th Annual Meeting; 2008 Oct 20-24; Cairo, Egypt. 2008. [srincont-31885]CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CardozoL , HessdörferE , MilaniR , ArañóP , DewildeL , SlackM , et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU International2008;102(9):1120-7. [NCT00801944] [TrialID.SUNRISE] [srincont-29249]">Cardozo 2008a</a>; <a href="./references#CD003781-bbs2-0013" title="ChappleC . Fesoterodine a new effective and well-tolerated antimuscarinic for the treatment of urgency-frequency syndrome: results of a phase 2 controlled study (Abstract 142). Neurourology and Urodynamics2004;23(5/6):598-9. [srincont-19023]Drug company. A Phase 2, parallel group, randomized, double-blind, placebo controlled dose-ranging trial to determine the optimal dose and the tolerability of sustained release SPM 8272 (fesoterodine) in subjects with non-neurogenic bladder overactivity. Protocol numbers: A0221027 (SP582). ClinicalStudyResults.org (accessed 3 March 2011)2002. [Protocol numbers: A0221027 (SP582)] [srincont-41110]">Chapple 2004a</a>; <a href="./references#CD003781-bbs2-0016" title="ChappleC , Van KerrebroeckP , TubaroA , Haag-MolkentellerC , ForstHT , MassowU , et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder [Erratum appears in: European Urology 2008,53(6):1319]. European Urology2007;52(4):1204-12. [NCT00220363] [SP583] [srincont-23875]ChappleC , Van KerrebroeckP , TubaroA , MillardR . Fesoterodine in non-neurogenic voiding dysfunction - results on efficacy and safety in a phase 3 trial (Abstract number 379). In: 21st Annual European Association of Urology (EAU) Congress; 2006 Apr 5-8; Paris, France. 2006. [srincont-41109]ChappleC , Van KerrebroeckP , TubaroA , WangJT , HvidstenK , BrodskyM . Efficacy of fesoterodine in patients with overactive bladder (OAB): improvements in OAB symptoms and health-related quality of life (HRQL) (Poster abstract number 1188). Journal of Urology2007;177(4 Suppl S):392. [srincont-31882]ChappleCR , vanKerrebroeckPE , JünemannKP , WangJT , BrodskyM . Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU International2008;102(9):1128-32. [srincont-29255]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. KelleherCJ , TubaroA , WangJT , KoppZ . Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU International2008;102(1):56-61. [srincont-27613]SandPK , MorrowJD , BavendamT , CreangaDL , NittiVW . Efficacy and tolerability of fesoterodine in women with overactive bladder. International Urogynecology Journal2009;20(7):827-35. [srincont-31351]">Chapple 2007a</a>; <a href="./references#CD003781-bbs2-0017" title="ChappleC , DuBeauC , EbingerU , RekedaL , ViegasA . Darifenacin treatment of patients &gt;or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Current Medical Research and Opinion2007;23(10):2347-58. [srincont-23921]">Chapple 2007b</a>; <a href="./references#CD003781-bbs2-0018" title="ChappleCR , DvorakV , RadziszewskiP , vanKerrebroeckP , WyndaeleJJ , BosmanB , et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder. International Urogynecology Journal2013;24(9):1447-58. [178-CL-044] [NCT00337090] [TrialID.DRAGON.] [sr-incont48549]NCT00337090 . A study of YM178 in patients with symptomatic overactive bladder (DRAGON) [A randomized, double-blind, parallel group, placebo and active controlled, multicenter dose ranging study with the beta-3 agonist YM178 in patients with symptomatic overactive bladder]. clinicaltrials.gov/show/NCT00337090 (first received 15 June 2006). [EudraCT2005-002256-17] [JapicCTI-R130350] [NCT00337090] [sr-incont63803]">Chapple 2013</a>; <a href="./references#CD003781-bbs2-0019" title="ChappleC , HaabF , SchneiderT , CarlssonM , ArumiD . Fesoterodine 8 mg versus fesoterodine 4 mg in patients with overactive bladder and a history of previous antimuscarinic therapy: Results from the EIGHT trial (Abstract number: Poster #M5). Neurourology and Urodynamics2015;34(S1):S20. [NCT01302067] [sr-incont68509]ChappleC , SchneiderT , HaabF , SunF , WhelanL , ScholfieldD , et al. Superiority of fesoterodine 8mg versus fesoterodine 4 mg in reducing urgency urinary incontinence episodes in subjects with overactive bladder: results of the randomized, double-blind, placebo-controlled EIGHT trial (Abstract number: Podium #48). Neurourology and Urodynamics2014;33(2):183-4. [NCT01302067] [sr-incont67484]ChappleC , SchneiderT , HaabF , SunF , WhelanL , ScholfieldD , et al. Superiority of fesoterodine 8mg vs 4mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial. BJU International2014;114(3):418-26. [A0221095] [NCT01302067] [TrialID.EIGHT] [srincont-62537]NCT01302067. A 12 week study to confirm the effectiveness of 8mg of Fesoterodine compared to 4mg of Fesoterodine [A 12-week, randomized, double-blind, placebo controlled, parallel group, multicenter trial in overactive bladder subjects to confirm the efficacy of 8 mg fesoterodine compared to 4 mg fesoterodine]. clinicaltrials.gov/show/NCT01302067 (first received 23 February 2011). [NCT01302067] [sr-incont63792]">Chapple 2014</a>; <a href="./references#CD003781-bbs2-0020" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. [sr-incont75259]ChuF , SmithN , UchidaT . Efficacy and safety of solifenacin succinate 10 mg once daily: a multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder. Current Therapeutic Research - Clinical and Experimental2009;70(6):405-20. [srincont-43324]">Chu 2009</a>; <a href="./references#CD003781-bbs2-0021" title="ChuaME , SeeMC , EsmeňaEB , BalingitJC , MoralesML . Efficacy and safety of gabapentin in comparison to solifenacin succinate in adult overactive bladder treatment. Lower Urinary Tract Symptoms2018;10(2):135-42. [NCT01486706] [sr-incont74529]NCT01486706, ChuaME . Efficacy and safety of gabapentin in treating overactive bladder (OAB). clinicaltrials.gov/show/NCT01486706 (first received 6 December 2011). [NCT01486706] [SLMC10-010] [sr-incont49864]">Chua 2018</a>; <a href="./references#CD003781-bbs2-0023" title="ChancellorMB , OefeleinMG , VasavadaS . Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release. Neurourology and Urodynamics2010;29(4):551-4. [sr-incont39591]DmochowskiR , StaskinD , SandP , ZinnerN . Trospium chloride 60 mg once daily improves quality of life in subjects with overactive bladder syndrome (Abstract number 277). In: International Continence Society (ICS); 37th Annual Meeting; 2008 Aug 20-24; Rotterdam, the Netherlands. 2007. [srincont-26679]DmochowskiRR , RosenbergMT , ZinnerNR , StaskinDR , SandPK . Extended-release trospium chloride improves quality of life in overactive bladder. Value in Health2010;13(2):251-7. [srincont-40049]DmochowskiRR , SandPK , ZinnerNR , StaskinDR . Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology2008;71(3):449-54. [srincont-27107]DmochowskiRR , ZinnerNR , SandPK . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: Results from a multicenter, phase III, placebo-controlled study (Abstract). Neurourology and Urodynamics2007;26(Suppl 7):1105-6. [srincont-26692]GinsbergDA , OefeleinMG , EllsworthPI . Once-daily administration of trospium chloride extended release provides 24-hr coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials. Neurourology and Urodynamics2011;30(4):563-7. [sr-incont41531]RovnerE , DmochowskiR , WatanabeJ . Once daily (QD) trospium chloride 60 mg extended release (XR) is safe and effective in patients (PTS) with the overactive bladder (OAB) syndrome who use multiple concomitant medications (MEDS) (Abstract number: Poster #68). Neurourology and Urodynamics2009;28(2):146-7. [sr-incont31062]SandP , DmochowskiR , ZinnerN , StaskinD . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: results from a multicenter, phase III, placebo-controlled study (Abstract number 269). In: International Continence Society (ICS), 37th Annual Meeting; 2007 Aug 20-24; Rotterdam, the Netherlands. 2007. [srincont-26676]SandPK , DmochowskiRR , ZinnerNR , StaskinDR , AppellRA . Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome. International Urogynecology Journal and Pelvic Floor Dysfunction2009;20(12):1431-8. [sr-incont39648]SandPK , Johnson IiTM , RovnerES , EllsworthPI , OefeleinMG , StaskinDR . Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged &gt; 75 years) with overactive bladder syndrome. BJU International2011;107(4):612-20. [sr-incont41422]StaskinDR , RosenbergMT , SandPK , ZinnerNR , DmochowskiRR . Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials. International Journal of Clinical Practice2009;63(12):1715-23. [sr-incont35458]">Dmochowski 2008</a>; <a href="./references#CD003781-bbs2-0024" title="DmochowskiR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. A double-blind, placebo-controlled trial of flexible-dose fesoterodine for overactive bladder (Abstract number 715). In: International Continence Society (ICS); 39th Annual Meeting; 2009 Sep 29-Oct 03; San Francisco, CA. 2009. [sr-incont35627]DmochowskiRR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder [Errata appear in: Urology 2010 Jun;75(6):1519 and in Urology 2011 Jun;77(6):1513]. Urology2010;75(1):62-8. [A0221014] [NCT00536484] [sr-incont39548]DuBeauC , KrausSR , SunF , MorrowJD . Fesoterodine in older vs younger subjects with overactive bladder (Abstract number D87). Journal of the American Geriatrics Society2010;58:S218. [NCT00536484] [sr-incont64309]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. [sr-incont78640]NCT00536484. Fesoterodine flexible dose study [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with overactive bladder]. clinicaltrials.gov/show/NCT00536484 (first received 27 September 2007). [NCT00536484] [sr-incont49160]StaskinD , KhullarV , MichelMC , MorrowJD , SunF , GuanZ , et al. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. Neurourology and Urodynamics2011;30(8):1480-5. [sr-incont42686]">Dmochowski 2010</a>; <a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>; <a href="./references#CD003781-bbs2-0029" title="EUCTR2004-001116-31-ES. Multicentre, randomised, double-blind, parallel group confirmatory Phase III study to compare the efficacy and safety of cizolirtine citrate 300 mg bid (600 mg/d), cizolirtine citrate 400 mg bid (800 mg/d), placebo, and tolterodine 2 mg bid (4 mg/d) in the treatment of urge urinary incontinence. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-001116-31 (first received 03 November 2004). [ESCLIN-002/04] [EUCTR2004-001116-31-ES] [sr-incont64643]">EUCTR2004‐001116‐31‐ES</a>; <a href="./references#CD003781-bbs2-0030" title="EUCTR2004-002143-27-AT. A double-blind, stratified, randomised, parallel, placebo-controlled, multi-centre study to compare the efficacy and safety of duloxetine hydrochloride (40mg twice a day) and tolterodine tartrate (XL) (4mg once daily) with placebo in patients with symptoms of Urge Urinary Incontinence. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-002143-27 (first received 15 February 2005). [1208.15] [EUCTR2004-002143-27-AT] [sr-incont64640]">EUCTR2004‐002143‐27‐AT</a>; <a href="./references#CD003781-bbs2-0031" title="EUCTR2007-004126-24-CZ. A placebo controlled randomized, 12-week, dose-ranging, double-blind study versus placebo using tolterodine as a study calibrator, to evaluate efficacy and safety of SSR240600C in women with overactive bladder including urge urinary incontinence. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-004126-24 (first received 12 December 2007). [DRI6271] [EUCTR2007-004126-24-CZ] [EudraCT2007-004126-24] [NCT00564226] [TrialID.BILADY] [sr-incont64596]NCT00564226. SSR240600C treatment in women with overactive bladder (BILADY) [A placebo controlled randomized, 12-week, dose-ranging, double-blind study versus placebo using tolterodine as a study calibrator, to evaluate efficacy and safety of SSR240600C in women with overactive bladder including urge urinary incontinence]. clinicaltrials.gov/show/NCT00564226 (first received 27 November 2007). [DRI6271] [EudraCT2007-004126-24] [NCT00564226] [TrialID.BILADY] [sr-incont63784]">EUCTR2007‐004126‐24‐CZ</a>; <a href="./references#CD003781-bbs2-0032" title="GellerE , DumondJ , BowlingJM , KhandelwalC , WuJ , Busby-WhiteheadJ , et al. Effect of an anticholinergic on cognitive function in postmenopausal women: a randomized trial (Abstract number: oral poster 52). Female Pelvic Medicine and Reconstructive Surgery2016;22(5):S61. [sr-incont78607]GellerEJ , DumondJB , BowlingJM , KhandelwalCM , WuJM , Busby-WhiteheadJ , et al. Effect of trospium chloride on cognitive function in women aged 50 and older: a randomized trial. Female Pelvic Medicine &amp; Reconstructive Surgery2017;23(2):118-23. [13-1352] [NCT01922115] [sr-incont74341]NCT01922115. The effect of anticholinergics on cognitive function in the elderly (ACE) [The effect of anticholinergics on cognitive function in the elderly: a randomized controlled trial]. clinicaltrials.gov/show/NCT01922115 (first received 14 August 2013). [13-1352] [NCT01922115] [TrialID.ACE] [sr-incont49282]">Geller 2013</a>; <a href="./references#CD003781-bbs2-0033" title="GotohM , HommaY , YokoyamaO , NishizawaO . Responsiveness and minimal clinically important change in overactive bladder symptom score. Urology2011;78(4):768-73. [srincont-42622]GotohM , YokoyamaO , MatsukawaY , NishizawaO . Responsiveness of overactive bladder symptom score (OABSS): verification based on data in a double-blinded, randomized placebo-controlled study of propiverine hydrochloride in Japanese patients (Abstract number 338). In: Joint Meeting of the International Continence Society (ICS) and the International Urogynecological Association; 2010 Aug 23-27; Toronto, Canada. 2010. [srincont-40173]GotohM , YokoyamaO , NishizawaO . Propiverine hydrochloride in Japanese patients with overactive bladder: A randomized, double-blind, placebo-controlled trial. International Journal of Urology2011;18(5):365-73. [srincont-41510]">Gotoh 2011</a>; <a href="./references#CD003781-bbs2-0034" title="GriebenowR , WienersF , LangeT . Possible induction of cardiac dysrhythmia in elderly patients under therapy with propiverine hydrochloride (Abstract). Neurourology and Urodynamics1994;13:430-2. [sr-incont2681]">Griebenow 1994</a>; <a href="./references#CD003781-bbs2-0035" title="HaabF , StewartL , DwyerP . Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. European Urology2004;45(4):420-9. [srincont-17428]">Haab 2004</a>; <a href="./references#CD003781-bbs2-0036" title="HajebrahimiS , MotlaghRS , BazarganiHS , BabaieH . Efficacy of tadalafil in treatment of overactive bladder syndrome: a randomized controlled trial (Abstract number OP.3.6Dec.27). International Journal of Urology2014;21:A146. [IRCT2013030212668N1] [sr-incont67256]IRCT2013030212668N1. Effect of tadalafil in treatment of overactive bladder  [Comparison of the efficacy of tadalafil, toltrodine and placebo in reduction of symptoms severity of women with urgency, frequency syndrom / overactive bladder]. en.irct.ir/trial/12692 (first received 26 January 2013). [91189] [IRCT2013030212668N1] [sr-incont78643]">Hajebrahimi 2014</a>; <a href="./references#CD003781-bbs2-0322" title="IRCT2015010720598N1. The effect of solifenacin succinate on intraocular pressure [Ocular effects of solifenacin succinate in women with narrow angle glaucoma and overactive bladder syndrome]. en.irct.ir/trial/18253 (first received 22 June 2015). [IRCT2015010720598N1] [sr-incont78608] [tbzmed.rec.1394.127]">Hajebrahimi 2015</a>; <a href="./references#CD003781-bbs2-0037" title="HalaskaM , DorschnerW , FrankM . Treatment of urgency and incontinence in elderly patients with propiverine hydrochloride. Neurourology and Urodynamics1994;13(4):428-30. [srincont-2680]">Halaska 1994</a>; <a href="./references#CD003781-bbs2-0038" title="HerschornS , HeesakkersJ , Castro-DiazD , WangJT , BrodskyM , GuanZ . Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*. Current Medical Research and Opinion2008;24(12):3513-21. [A6121122] [NCT00143377] [srincont-29250]HerschornS , HeesakkersJ , Castro-DiazD , WangJT , GuanZ , BrodskyM . Tolterodine extended release (TER) improves objective and subjective outcomes after 1 week of treatment in patients with overactive bladder (Abstract number 132). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S78-9. [srincont-26602]">Herschorn 2008</a>; <a href="./references#CD003781-bbs2-0039" title="CorcosJ , AnguloJC , GarelyAD , CarlssonM , GongJ , GuanZ . Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. Current Medical Research and Opinion2011;27(5):1059-65. [srincont-41596]EUCTR2006-006935-38-SE. 12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006935-38 (first received 16 April 2007). [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont64612]HerschornS , SwiftS , GuanZ , CarlssonM , BrodskyM , GongJ . Efficacy and safety of fesoterodine for overactive bladder in a double-blind, head-to-head comparison trial with tolterodine ER and placebo (Abstract number 710). In: International Continence Society (ICS), 39th Annual Meeting; 2009 Sep 29-Oct 3; San Francisco, CA. 2009. [srincont-35326]HerschornS , SwiftS , GuanZ , CarlssonM , MorrowJD , BrodskyM , et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU International2010;105(1):58-66. [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont39540]NCT00444925. Clinical trial to evaluate the efficacy and safety of Fesoterodine in comparison to Tolterodine for overactive bladder (OAB) [12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder (OAB)]. clinicaltrials.gov/show/NCT00444925 (first received 08 March 2007). [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont49159]">Herschorn 2009a</a>; <a href="./references#CD003781-bbs2-0040" title="EUCTR2012-005735-91-SK. A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-005735-91 (first received 12 November 2013). [178-CL-101] [EUCTR2012-005735-91-SK] [sr-incont78644]HerschornS , ChappleCR , AbramsP , ArlandisS , MitchesonD , LeeKS , et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU International2017;120(4):562-75. [NCT01972841] [sr-incont74470]MuellerER , RobinsonD , KelleherC , StaskinDR , FalconerC , WangJ , et al. Patient reported outcomes from synergy, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with mirabegron and solifenacin monotherapy (Abstract number - Podium #44). Neurourology and Urodynamics2017;36(Suppl S1):S151-2. [NCT01972841] [sr-incont75944]NCT01972841. This was a multinational study comparing the efficacy and safety of two medicines, solifenacin succinate and mirabegron taken together, or separately, or a mock treatment (placebo) in subjects with symptoms of overactive bladder (SYNERGY) [A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01972841 (first received 31 October 2013). [178-CL-101] [EUCTR2012-005735-91] [NCT01972841] [sr-incont63780]RobinsonD , KelleherC , StaskinD , MuellerER , FalconerC , WangJ , et al. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients. Neurourology and Urodynamics2018;37(1):394-406. [NCT01972841] [sr-incont76906]WeberMA , ChappleCR , GratzkeC , HerschornS , RobinsonD , FrankelJM , et al. A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial. Blood Pressure Monitoring2018;23(3):153-63. [NCT01972841] [sr-incont77899]WhiteWB , ChappleC , GratzkeC , HerschornS , RobinsonD , FrankelJ , et al. Cardiovascular safety of the beta3-adrenoceptor agonist mirabegron and the antimuscarinic agent solifenacin in the SYNERGY trial. Journal of Clinical Pharmacology2018;58(8):1084-91. [NCT01972841] [sr-incont78078]">Herschorn 2017a</a>; <a href="./references#CD003781-bbs2-0041" title="HerschornS , KohanA , AliottaP , McCammonK , SriramR , AbramsS , et al. The efficacy and safety of onabotulinumtoxin A or solifenacin compared with placebo in solifenacin naive patients with refractory overactive bladder: results from a multicenter, randomized, double-blind phase 3b trial. Journal of Urology2017;198(1):167-75. [NCT01767519] [sr-incont74491]NCT01767519. A study evaluating the efficacy and safety of BOTOX® or solifenacin in patients with overactive bladder and urinary incontinence. clinicaltrials.gov/show/NCT01767519 (first received 14 January 2013). [191622-125] [NCT01767519] [sr-incont49909]">Herschorn 2017b</a>; <a href="./references#CD003781-bbs2-0042" title="HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21072]HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21072]HillS , KhullarV , WyndaeleJJ , LheritierK , . Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. International Urogynecology Journal and Pelvic Floor2006;17(3):239-47. [srincont-22464]">Hill 2005</a>; <a href="./references#CD003781-bbs2-0043" title="HommaY , KawabeK . Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World Journal of Urology2004;22(4):251-6. [srincont-19412]HommaY , PaickJS , LeeJG , KawabeK , Japanese and Korean Tolterodine Study Group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU International2003;92(7):741-7. [srincont-16418]">Homma 2003</a>; <a href="./references#CD003781-bbs2-0044" title="HommaY , YamaguchiT , YamaguchiOA . A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2008;15(9):809-15. [srincont-27742]">Homma 2008</a>; <a href="./references#CD003781-bbs2-0045" title="HommaY , YamaguchiO , Imidafenacin Study Group. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2009;16(5):499-506. [NCT00212732] [ONO-8025-08] [srincont-31368]">Homma 2009</a>; <a href="./references#CD003781-bbs2-0046" title="HuangA , HessR , AryaL , RichterH , SubakL , BradleyC , et al. A randomized controlled trial of simple diagnosis and treatment for urgency urinary incontinence in women (Abstract). Journal of General Internal Medicine2011;26:S1. [NCT00862745] [sr-incont64391]HuangAJ , HessR , AryaLA , RichterHE , SubakLL , BradleyCS , et al. Pharmacologic treatment for urgency-predominant urinary incontinence in women diagnosed using a simplified algorithm: a randomized trial. American Journal of Obstetrics and Gynecology2012;206(5):444.e1-11. [GA0221IX] [NCT00862745] [TrialID.BRIDGES.] [srincont-44636]NCT00862745, BrownJ . Bringing simple urge incontinence diagnosis &amp; treatment to providers (BRIDGES)  [A multi-center, randomized, placebo-controlled clinical trial comparing fesoterodine to placebo in women diagnosed with urge urinary incontinence by the 3 Incontinence Questions (3IQ). Followed by a multi-center open label clinical cohort study of long-term effects of treatment with fesoterodine ]. clinicaltrials.gov/show/NCT00862745 (first received 17 March 2009). [NCT00862745] [sr-incont49836]WarsiQ , HuangA , BrownJS , SchembriM , HessR , AryaLA , et al. The effect of pharmacologic treatment of urgency urinary incontinence on sleep quality and daytime sleepiness (Abstract number: paper 37). Female Pelvic Medicine and Reconstructive Surgery2016;22(5 ):S17-8. [NCT00862745] [TrialID.BRIDGES.] [sr-incont78633]WarsiQA , HuangAJ , HessR , AryaLA , RichterHE , BradleyCS , et al. Association of pharmacologic treatment of urgency urinary incontinence with sleep quality and daytime sleepiness. Obstetrics and Gynecology2018;131(2):204-11. [NCT00862745] [sr-incont78239]WinkelmanW , HuangA , SchembriM , RogersRG , RichterHE , MyersDL , et al. Clinical variables moderating response to pharmacologic treatment of urgency-predominant urinary incontinence in a randomized controlled trial (Abstract number: poster 25). In: Female Pelvic Medicine and Reconstructive Surgery. 37th Annual Scientific Meeting of the American Urogynecologic Society; Aug 2016; United States. Vol. 22. Netherlands: Lippincott Williams and Wilkins, 2016:S81. [NCT00862745] [sr-incont78634]WinkelmanWD , HuangAJ , SchembriM , RogersRG , RichterH , MyersDL , et al. Modifiers of response to treatment with fesoterodine for urgency-predominant urinary incontinence in a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2017;23(2):151-6. [sr-incont74308]">Huang 2012</a>; <a href="./references#CD003781-bbs2-0050" title="JünemannKP , HessdörferE , Unamba‐OparahI , BerseM , BrünjesR , MadersbacherH . Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. Urologia Internationalis2006;77(4):334-9. [srincont-22199]">Junemann 2006</a>; <a href="./references#CD003781-bbs2-0051" title="EUCTR2007-006451-39-SE. 12-week, randomized, double-blind, double-dummy, placebo controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-006451-39 (first received 20 February 2008). [A0221046] [EUCTR2007-006451-39-SE] [sr-incont64591]KaplanSA , SchneiderT , FooteJ , GuanZ . Superior efficacy of fesoterodine over tolterodine with rapid onset: a prospective, head-to-head, placebo-controlled trial (Abstract number 67). Neurourology and Urodynamics2010;29(6):905-7. [srincont-40130]KaplanSA , SchneiderT , FooteJE , GuanZ , CarlssonM , GongJ . Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU International2011;107(9):1432-40. [A0221046] [NCT00611026] [srincont-41334]">Kaplan 2011</a>; <a href="./references#CD003781-bbs2-0052" title="CardozoL , KaplanS , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: results from the after study (Abstract number 740) [Erratum appears in: European Urology 2014;65(5):e78]. European Urology Supplements2013;12(1):e740-1. [NCT01302054] [sr-incont63732]CardozoL , KaplanS , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. Erratum: A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: results from the AFTER study [Erratum available in: European Urology Supplement 2013;2012:e740-1]. European Urology2014;65(5):e78 . [A0221094] [NCT01302054] [TrialID.AFTER.] [sr-incont61642]GrenaboL , HerschornS , KaplanSA , CardozoL , ScholfieldD , ArumiD , et al. Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptoms. Current Medical Research and Opinion2017;33(10):1731-6. [NCT01302054] [TrialID.AFTER.] [sr-incont76695]KaplanSA , CardozoL , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER. International Journal of Clinical Practice2014;68(9):1065-73. [A0221094] [NCT01302054] [TrialID.AFTER.] [srincont-63977]KaplanSA , HerschornS , CarlssonM , NtaniosF . Urgency urinary incontinence response rates in subjects with overactive bladder treated with fesoterodine 8 mg after suboptimal response to tolterodine extended release 4 mg: a randomized, double-blind, placebo-controlled trial (Abstract number 546). In: International Continence Society (ICS); 43rd Annual Meeting; 2013 Aug 26-30; Barcelona, Spain. 2013. [NCT01302054] [TrialID.AFTER.] [sr-incont49730]NCT01302054. A clinical study in patients with overactive bladder with leakage of urine, to find out if the medicine, Fesoterodine, works in those patients who did not have enough response to the medicine, tolterodine. [A 14 week randomized parallel group placebo-controlled double-blind multicentre study of fesoterodine 8 mg in overactive bladder patients with sub-optimal response to tolterodine 4 mg extended release (ER)]. clinicaltrials.gov/show/NCT01302054 (first received 23 February 2011). [A0221094] [NCT01302054] [TrialID.AFTER.] [sr-incont49845]">Kaplan 2014</a>; <a href="./references#CD003781-bbs2-0053" title="CapoJP , TogliaM , Forero-SchwanhaeuserS , HeW . Patients reporting severe overactive bladder symptoms: effects of solifenacin treatment on objective measures and patient-reported outcomes (Abstract number 582). In: International Continence Society (ICS), 38th Annual Meeting; 2008 Oct 20-24; Cairo, Egypt. 2008. [srincont-31844]CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. KarramMM , TogliaMR , SerelsSR , AndohM , FakhouryA , Forero-SchwanhaeuserS . Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology2009;73(1):14-8. [A0221094] [NCT00454896] [TrialID.VENUS.] [srincont-29219]SerelsSR , TogliaMR , Forero-SchwanhaeuserS , HeW . Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms. Current Medical Research and Opinion2010;26(10):2277-85. [srincont-40376]StaskinD , DmochowskiR , SerelsS , AndohM , SmithN . Report from a randomized, placebo-controlled study showing significant improvement in urgency and patient-reported outcomes in overactive bladder patients treated with solifenacin (Abstract number 124). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73-4. [srincont-26600]TogliaM , AndohM , HussainI . Solifenacin improved warning time significantly compared to placebo in patients with overactive bladder (Abstract number 123). Neurourology and Urodynamics2006;25(6):655. [srincont-26629]TogliaM , AndohM , HussainI . Solifenacin improves urgency symtoms as assessed by voiding diaries and patient-reported outcomes (PRO) in patients with overactive bladder (Abstract number 155). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26636]TogliaMR , OstergardDR , AppellRA , AndohM , FakhouryA , HussainIF . Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status. International Urogynecology Journal2010;21(7):847-54. [srincont-40094]TogliaMR , SerelsSR , LarameeC , KarramMM , NandyIM , AndohM , et al. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial. Postgraduate Medicine2009;121(5):151-8. [srincont-34204]ZinnerS , HerschornS , AndohM , HussainI . Responder analyses show statistically significant improvements in incontinence and urgency are associated with reduction in symptom bother and improvement in health-related quality of life: VENUS results (Abstract number 123). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73. [srincont-26599]">Karram 2009</a>; <a href="./references#CD003781-bbs2-0054" title="KhullarV , HillS , LavalKU , SchiotzHA , JonasU , VersiE . Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology2004;64(2):269-74; discussion 274-5. [srincont-19498]KhullarV , HillS , SolankiJ . Assessment of health-related quality of life in patients with overactive bladder taking tolterodine extended release versus placebo (Abstract number 318). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21075]">Khullar 2004</a>; <a href="./references#CD003781-bbs2-0055" title="AballéaS , MamanK , ThokagevistkK , NazirJ , OdeyemiIA , HakimiZ , et al. Cost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United Kingdom. Clinical Drug Investigation2015;35(2):83-93. [NCT00689104] [sr-incont66445]Arlandis-GuzmánS , Brenes-BermúdezF , Jiménez-CidreMA , Rubio-RodríguezD , Rubio-TerrésC , MoraAM , et al. Cost effectiveness of Mirabegron and antimuscarinic drugs in patients with hiperactive bladder [Coste-efectividad de mirabegrón y los antimuscarínicos en pacientes con vejiga hiperactiva]. Archivos Espanoles de Urologia2018;71(10):809-24. [NCT00689104] [sr-incont78645]EUCTR2007-001451-19-ES. A randomized, double-blind, parallel group, placebo and active controlled, multicenter study to assess the efficacy and safety of the beta-3 agonist YM178 (50 mg qd and 100 mg qd) in subjects with symptoms of overactive bladder - SCORPIO [Estudio multicentrico, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo y tratamiento activo, para evaluar la eficacia y seguridad del agonista beta-3 YM178 (50 mg, una vez al dia y 100 mg, una vez al dia) en pacientes con sintomas de vejiga hiperactiva]. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-001451-19 (first received 05 June 2008). [EUCTR2007-001451-19-ES] [sr-incont78646]HerschornS , NazirJ , RamosB , HakimiZ . Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada. Canadian Urological Association Journal2017;11(3-4):123-30. [NCT00689104] [sr-incont76807]KhullarV , AmarencoG , AnguloJ , BoerrigterP , BlauwetM , HakimiZ . The potent and selective beta3-adrenoceptor agonist mirabegron improves patient-reported outcomes in the treatment of overactive bladder (Abstract number MP-12.16). Urology2012;80(3 Suppl 1):S123. [sr-incont65379]KhullarV , AmarencoG , AnguloJC , BlauwetMB , NazirJ , OdeyemiIA , et al. Patient-reported outcomes with the β3 beta3-adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder. Neurourology and Urodynamics2016;35(8):987-94. [NCT00689104] [sr-incont72221]KhullarV , AmarencoG , AnguloJC , CambroneroJ , HøyeK , MilsomI , et al. Efficacy and tolerability of mirabegron, a ß3-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. European Urology2013;63(2):283-95. [NCT00689104] [TrialID.SCORPIO.] [sr-incont46836]KhullarV , CambroneroJ , AnguloJ , WooningM , BlauwetM , SiddiquiE , et al. Onset of action of efficacy of the potent and selective beta-3-adrenoceptor agonist, mirabegron, for the treatment of overactive bladder (OAB) in a 12-week, multicentre, randomised, double-blind, parallel-group, placebo-and tolterodine slow release (SR)-controlled study in OAB patients (Abstract number 135). International Urogynecology Journal and Pelvic Floor Dysfunction2012;23(2 Suppl 1):S187-8. [NCT00689104] [sr-incont67382]KhullarV , CambroneroJ , AnguloJC , WooningM , BlauwetMB , DorrepaalC , et al. Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial. BMC Urology2013;13:45. [NCT00689104] [sr-incont49411]KhullarV , CambroneroJ , StroebergP , AnguloJ , BoerrigterP , WooningM . The efficacy and tolerability of mirabegron, a potent and selective B3-adrenoceptor agonist, compared with placebo and tolterodine slow release in patients with overactive bladder - results from a European-Australian phase III trial (Abstract number 328). In: International Continence Society (ICS); 41st Annual Meeting; 2011 Aug 29-Sept 2; Glasgow, Scotland. 2011. [NCT00689104] [sr-incont42211]NCT00689104. Study to assess the efficacy and safety of the beta-3 agonist mirabegron (ym178) in patients with symptoms of overactive bladder (SCORPIO) [A randomized, double-blind, parallel group, placebo and active controlled, multicenter study to assess the efficacy and safety of mirabegron in subjects with symptoms of overactive bladder (SCORPIO)]. clinicaltrials.gov/show/NCT00689104 (first received 03 June 2008). [NCT00689104] [sr-incont49843]NittiV , HerschornS , AuerbachS , KhullarV , AmarencoG , BlauwetMB , et al. The potent and selective ß3-adrenoceptor agonist mirabegron improves patient-reported outcomes in overactive bladder-results from two phase III studies (Abstract number 68). Neurourology and Urodynamics2012;31(6):813-5. [NCT00689104] [sr-incont46724]WielageRC , PerkS , CampbellNL , NgD , KleinTM , PostaLM , et al. The cost effectiveness of mirabegron for the treatment of overactive bladder: three US perspectives (Abstract number A142). Journal of the American Geriatrics Society2015;63:S67. [NCT00689104] [sr-incont70876]YamanishiT , YamanishiY , TajimaH , IkedaS . Cost-effectiveness of mirabegron and tolterodine for the treatment of overactive bladder in Japan-Which drug is more cost-effective if used as the first-line treatment? (Abstract number 504). International Urogynecology Journal2018;29:S252. [NCT00689104] [sr-incont78647]YamanishiY , YamanishiT , TajimaH , IkedaS . Mirabegron or tolterodine for the treatment of overactive bladder in Japan: Which drug is more cost-effective as the first-line treatment?International Journal of Urology2018;25(10):863-70. [NCT00689104] [sr-incont78648]">Khullar 2013</a>; <a href="./references#CD003781-bbs2-0057" title="KosilovK , LoparevS , IvanovskayaM , KosilovaL . A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron. Archives of Gerontology and Geriatrics2015;61(2):212-6. [sr-incont68133]">Kosilov 2015a</a>; <a href="./references#CD003781-bbs2-0058" title="KosilovKV , LoparevSA , IvanovskayaMA , KosilovaLV . The efficacy of different doses of solifenacin in elderly patients after treating a urinary tract infection. Arab Journal of Urology Print2015;13(3):203-8. [sr-incont69283]">Kosilov 2015b</a>; <a href="./references#CD003781-bbs2-0059" title="KrederK , PleilAM , ReesePR , KelleherJ . Effects of long-term tolterodine treatment on social and psychological aspects of health-related quality of life in overactive bladder patients (Abstract). Journal of Urology2002;167(Suppl 4):29. [sr-incont17591]">Kreder 2002</a>; <a href="./references#CD003781-bbs2-0060" title="HsiaoSM , ChangTC , ChenCH , WuWY , LinHH . Comparisons of the clinical outcomes and urodynamic effects of mirabegron versus tolterodine treatment for female overactive bladder syndrome: a subgroup analysis of a controlled, randomised, prospective study. Lower Urinary Tract Symptoms2018;10(3):215-20. [NCT01043666] [sr-incont74461]KuoHC , LeeKS , NaY , SoodR , NakajiS , KubotaY , et al. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourology and Urodynamics2015;34(7):685-92. [NCT01043666] [sr-incont68095]Kuo H‐C, Lin H‐H, Yu H‐J, Cheng C‐L, Hung M‐J, LinAT . Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials [Erratum available in: Urological Science 2015;26(2):148]. Urological Science2015;26(1):41-8 . [NCT01043666] [sr-incont68645]NCT01043666. A study of YM178 in subjects with symptoms of overactive bladder  [Phase III study of YM178: a randomized, double-blind, parallel group, placebo and active controlled, multi-center study in subjects with symptoms of overactive bladder]. clinicaltrials.gov/show/NCT01043666 (first received 07 January 2010). [178-CL-090] [NCT01043666] [sr-incont63781]">Kuo 2015</a>; <a href="./references#CD003781-bbs2-0061" title="LacknerTE , WymanJF , McCarthyTC , MonigoldM , DaveyC . Efficacy of oral extended-release oxybutynin in cognitively impaired older nursing home residents with urge urinary incontinence: a randomized placebo-controlled trial. Journal of the American Medical Directors Association2011;12(9):639-47. [sr-incont42677]LacknerTE , WymanJF , McCarthyTC , MonigoldM , DaveyC . Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. Journal of the American Geriatrics Society2008;56(5):862-70. [sr-incont27117]">Lackner 2011</a>; <a href="./references#CD003781-bbs2-0062" title="LandisJR , KaplanS , SwiftS , VersiE . Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity. Journal of Urology2004;171(2 Pt 1):752-6. [sr-incont17327]">Landis 2004</a>; <a href="./references#CD003781-bbs2-0063" title="LeeKS , ChooMS , KimDY , KimJC , KimHJ , MinKS , et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. Journal of Urology2005;174(4 Pt 1):1334-8. [sr-incont21016]LeeKS , ChooMS , PaickJS , LeeJG , SeoJT , LeeJZ , et al. Propiverine hydrochloride reduced frequency and perception of urgency in treatment of overactive bladder: a 12 week prospective, randomized, double blind, placebo controlled study (Abstract number 279). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26640]LeeKS , LeeHW , ChooMS , PaickJS , LeeJG , SeoJT , et al. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'. BJU International2010;105(11):1565-70. [2005-01-08] [NCT00903045] [PROUD] [sr-incont39958]NCT00903045. Urinary urgency outcomes following propiverine treatment for an overactive bladder [Urinary urgency outcomes following propiverine treatment for an overactive bladder: propiverine study on overactive bladder including urgency data (PROUD)]. clinicaltrials.gov/show/NCT009030452005;(first received 15 May 2009). [2005-01-08] [NCT00903045] [TrialID.PROUD] [sr-incont49860]">Lee 2006</a>; <a href="./references#CD003781-bbs2-0064" title="LuisV , LoyolaJP , MelissaC , FelipeM , San MartinC . Efficacy of darifenacin use combined with pelvic floor physiotherapy in overactive bladder syndrome treatment in women (Abstract number 434). International Urogynecology Journal2018;29(Suppl 1):S220-1. [NCT02143570] [sr-incont78617]NCT02143570, CifuentesM , MartinezF . Efficacy of darifenacin and physiotherapy for the treatment of overactive bladder in women. clinicaltrials.gov/show/NCT02143570 (first received 21 May 2014). [NCT02143570] [sr-incont61781]">Luis 2018</a>; <a href="./references#CD003781-bbs2-0066" title="Malone-LeeJG , WalshB , MaugourdMF , Tolterodine in the Elderly Study Group. The safety and clinical efficacy of two doses of tolterodine compared to placebo in elderly patients. In: International Continence Society (ICS), 27th Annual Meeting; 1997 Sep 23-26; Yokohama, Japan. 1997:155-6. [srincont-5855]Malone‐LeeJG , WalshJB , MaugourdMF . Tolterodine: A safe and effective treatment for older patients with overactive bladder. Journal of the American Geriatric Society2001;49(6):700-5. [srincont-12319]WaggA , Malone-LeeJ . Pressure-flow variables in patients treated with tolterodine for detrusor overactivity. BJU International2003;92(9):969-71. [sr-incont16659]">Malone‐Lee 2001</a>; <a href="./references#CD003781-bbs2-0068" title="DmochowskiR , MitchesonD , FrenklT , BennettN , MuddPN . Durable efficacy and safety of long-term once-daily vibegron, a novel oral B-3 adrenergic receptor agonist: A 52-week phase 2 study in patients with overactive bladder syndrome (Abstract number PD50-03). Journal of Urology2018;199(4):e970-1. [sr-incont78091]EUCTR2010-022121-15-IT. A phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2 part clinical study of the efficacy and safety of MK-4618 in patients with overactive bladder - MK4618-008 [A 52-week extension to: a phase iib randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder]. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-022121-15 (first received 12 April 2011). [EUCTR2010-022121-15-IT] [MK4618-008] [NCT01314872] [sr-incont78639]MitchesonD , FrenklT , SamantaS , Anne PintoC , GreenS , BennettN , et al. Vibegron, a novel once daily oral beta-3 agonist, significantly reduces average daily micturitions, urge incontinence episodes and urgency episodes in patients with overactive bladder (Abstract number: podium #34). Neurourology and Urodynamics2018;37(Suppl 1):S565. [EUCTR2010-022121-15-IT] [NCT01314872] [sr-incont78618]MitchesonD , PintoCA , FrenklT , ChenL , PrasadM , MuddPN . Once daily vibegron improves quality of life measures in patients with overactive bladder (Abstract number PUK17). Value in Health2018;21(Suppl 1):S267-8. [EUCTR2010-022121-15-IT] [NCT01314872;] [sr-incont78619]MitchesonHD , SamantaS , MuldowneyK , PintoCA , RochaBA , GreenS , et al. Vibegron (RVT-901/MK-4618/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial. European Urology2019;75(2):274-82. [NCT01314872] [sr-incont78620]NCT01314872. A study of the efficacy and safety of Vibegron (MK-4618) in participants with overactive bladder (OAB) (MK-4618-008) [A phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder a 52-week extension to: a phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder]. clinicaltrials.gov/show/NCT01314872 (first received 15 March 2011). [NCT01314872] [sr-incont63793]UKCRN10391. A phase IIB randomised, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of MK-4618 in patients with overactive bladder . public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=10391 (accessed 28 June 2012). [CCRN525] [UKCRN10391] [sr-incont45046]">Mitcheson 2019</a>; <a href="./references#CD003781-bbs2-0323" title="NCT00553657. The study to test the effect of standardization of fluid intake in female patients with overactive bladder [A randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of standardization of fluid intake on the variability of measured voiding parameters in female patients with idiopathic overactive bladder]. clinicaltrials.gov/show/NCT00553657 (first received 04 November 2007). [NCT00553657] [sr-incont60907]">NCT00553657</a>; <a href="./references#CD003781-bbs2-0069" title="Drug company. A phase 2, parallel group, stratified, randomized, double blind, placebo-controlled trial to investigate the efficacy and safety of 3 different dosages of sustained release fesoterodine in subjects with overactive bladder showing either involuntary detrusor contractions or normal findings during the baseline urodynamic assessment. Protocol numbers: A0221029 (SP668). ClinicalStudyResults.org (accessed 3 March 2011). [srincont-41111]NittiV , WiatrakM , KreitmanL , LipsitzD . Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB): results of a phase 2 trial (Abstract number 306). In: International Continence Society (ICS); 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21084]">Nitti 2005</a>; <a href="./references#CD003781-bbs2-0070" title="GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NittiVW , DmochowskiR , SandPK , ForstHT , Haag-MolkentellerC , MassowU , et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. Journal of Urology2007;178(6):2488-94. [NCT00138723] [SP584] [srincont-26313]">Nitti 2007</a>; <a href="./references#CD003781-bbs2-0071" title="OlshanskyB , FooteJ , ArguinzonizM , LheritierK , Quebe-FehlingE , SteelM . Cardiovascular safety of darifenacin and tolterodine in patients with overactive bladder (OAB) (Abstract number 49). International Urogynecology Journal and Pelvic Floor Dysfunction2006;17(Suppl 2):S86-7. [sr-incont34186]">Olshansky 2006</a>; <a href="./references#CD003781-bbs2-0072" title="OreskovićS , ButI , BanovićM , GoldstajnMS . The efficacy and safety of solifenacin in patients with overactive bladder syndrome. Collegium Antropologicum2012;36(1):243-8. [srincont-45056]">Oreskovic 2012</a>; <a href="./references#CD003781-bbs2-0073" title="NCT01302938. Web-based methodology trial to evaluate the efficacy and safety of tolterodine ER in subjects with overactive bladder (REMOTE) [Exploratory, randomized, double-blind, placebo-controlled, parallel-group, single center, web-based phase IV pilot methodolgy trial to evaluate the efficacy and safety of tolterodine ER in subjects with overactive bladder]. clinicaltrials.gov/ct2/show/NCT01302938 (first received 24 February 2011). [A6121195] [NCT01302938] [TrialID.REMOTE.] [sr-incont43314]OrriM , LipsetCH , JacobsBP , CostelloAJ , CummingsSR . Web-based trial to evaluate the efficacy and safety of tolterodine ER 4 mg in participants with overactive bladder: REMOTE trial. Contemporary Clinical Trials2014;38(2):190-7. [A6121195] [NCT01302938] [TrialID.REMOTE.] [sr-incont62536]">Orri 2014</a>; <a href="./references#CD003781-bbs2-0075" title="ISRCTN17856439, ResnickN . Pathophysiology of urge incontinence in older women. isrctn.org/ISRCTN17856439 (first received 09 March 2006). [1999P-001891] [94-6641-01] [ISRCTN17856439] [sr-incont64614]">Resnick 2006</a>; <a href="./references#CD003781-bbs2-0077" title="RogersR , BachmannG , JumadilovaZ , SunF , MorrowJD , GuanZ , et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. International Urogynecology Journal and Pelvic Floor Dysfunction2008;19(11):1551-7. [A6121002] [NCT00143481] [srincont-27729]RogersRG , BachmannG , ScarperoH , JumadilovaZ , SunF , MorrowJD , et al. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. Current Medical Research and Opinion2009;25(9):2159-65. [srincont-32060]">Rogers 2008</a>; <a href="./references#CD003781-bbs2-0079" title="RovnerES , KaplanS , GuanZ , WangJT , RoehrbornCG . Clinical efficacy and safety of tolterodine extended release in male patients with overactive bladder and urgency urinary incontinence (Abstract number 188). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21091]">Rovner 2005</a>; <a href="./references#CD003781-bbs2-0080" title="RudyD , ClineK , GoldbergK , HarrisR . A multicenter, randomized, placebo-controlled trial of trospium chloride in overactive bladder patients (Abstract). Neurourology and Urodynamics2004;23(5/6):600-1. [sr-incont19025]RudyD , ClineK , HarrisR , GoldbergK , DmochowskiR . Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology2006;67(2):275-80. [srincont-21604]RudyD , ClineK , HarrisR , GoldbergK , DmochowskiR . Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. BJU International2006;97(3):540-6. [sr-incont21593]">Rudy 2006</a>; <a href="./references#CD003781-bbs2-0082" title="ChancellorMB , OefeleinMG , VasavadaS . Obesity is associated with a more severe overactive bladder disease state that is effectively treated with one daily administration of trospium chloride extended release [Erratum available in: Neurourology and Urodynamics 2010;29(5):804]. Neurourology and Urodynamics2010;29(4):551-4. [sr-incont39591]GinsbergDA , OefeleinMG , EllsworthPI . Once-daily administration of trospium chloride extended release provides 24-hour coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials. Neurourology and Urodynamics2011;30(4):563-7. [sr-incont41531]RovnerE , DmochowskiR , WatanabeJ . Once daily (QD) trospium chloride 60mg extended release (XR) is safe and effective in patients (PTS) with the overactive bladder (OAB) syndrome who use multiple concomitant medications (MEDS) (Abstract number: Poster #68). Neurourology and Urodynamics2009;28(2):146-7. [sr-incont31062]SandP , DmochowskiR , ZinnerN , StaskinD . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: results from a multicenter, phase III, placebo-controlled study (Abstract number 269). In: International Continence Society (ICS), 37th Annual Meeting; 2007 Aug 20-24; Rotterdam, the Netherlands. 2007. [sr-incont26676]SandP , StaskinD , ZinnerN , DmochowskiR . Once-daily trospium chloride extended release is effective and well tolerated for the treatment of overactive bladder: results from a multicenter, phase III trial (Abstract number 57). Neurourology and Urodynamics2007;26(5):675. [sr-incont26661]StaskinD , SandP , ZinnerN , DmochowskiR , Trospium Study Group. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. Journal of Urology2007;178(3 Pt 1):978-83; discussion 983-4. [srincont-23909]StaskinDR , RosenbergMT , SandPK , ZinnerNR , DmochowskiRR . Trospium chloride once daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised phase III trials. International Journal of Clinical Practice2009;63(12):1715-23. [sr-incont35458]StaskinDR , SandPK , ZinnerNR . Once-daily trospium chloride extended release is effective and well tolerated for the treatment of overactive bladder: results from a multicenter, phase III trial (Abstract number - poster 22). Neurourology and Urodynamics2007;26(7 Suppl):1106. [srincont-27305]">Staskin 2007</a>; <a href="./references#CD003781-bbs2-0083" title="EUCTR2017-003293-14. Empowur (Empower OAB patients with vibegron for better urgency control) [An international phase 3, randomized, double-blind, placebo- and active (tolterodine)-controlled multicenter study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder]. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-003293-14 (first received 24 April 2018). [EUCTR2017-003293-14] [NCT03492281] [sr-incont78606]NCT03492281, JankowichR . A study to examine the safety and efficacy of a new drug in patients with symptoms of overactive bladder (OAB) [An international phase 3, randomized, double-blind, placebo- and active (tolterodine)-controlled multicenter study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder]. clinicaltrials.gov/show/NCT03492281 (first received 20 April 2018). [NCT03492281] [sr-incont78610]StaskinD , FrankelJ , VaranoS , ShortinoD , JankowichR , MuddPN . Vibegron demonstrates statistically significant improvement in efficacy measures in overactive bladder-key secondary results from the international phase 3 study in patients with overactive bladder (empowur) (Abstract number: long oral 40). Female Pelvic Medicine and Reconstructive Surgery2019;25(5):S20-1. [NCT03492281] [sr-incont78627]StaskinD , FrankelJ , VaranoS , ZhouJ , JankowichR , MuddPN . International phase 3, double-blind, placebo- and active (tolterodine)-controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: empowur (Abstract number LBA-02). Journal of Urology2019;201(4):e992. [NCT03492281] [sr-incont78628]StaskinD , VaranoS , FrankelJ , ShortinoD , JankowichR , MuddP . Once-daily vibegron 75 mg demonstrates statistically significant benefits on key secondary endpoints including quality of life in patients with OAB: data from an international phase 3 trial (EMPOWUR) (Abstract number 181). Neurourology and Urodynamics2019;38(S3):S115-7. [NCT03492281] [sr-incont78629]VaranoS , StaskinD , FrankelJ , ShortinoD , JankowichR , MuddPN . Vibegron statistically significantly improves measures of quality of life in patients with overactive bladder-data from the international phase 3 trial (Empowur) (Abstract number: long oral 38). Female Pelvic Medicine and Reconstructive Surgery2019;25(5):S19. [NCT03492281] [sr-incont78630]">Staskin 2019</a>; <a href="./references#CD003781-bbs2-0084" title="SteersW , CorcosJ . Efficacy, tolerability and safety of darifenacin, an M3 selective receptor antagonist for the treatment of overactive bladder, using a flexible dosing regimen (Abstract number 68). Progres en Urologie2004;14(3 Suppl 3):22. [srincont-22197]">Steers 2004</a>; <a href="./references#CD003781-bbs2-0088" title="TakayasuH , UenoA , TsutidaS , KoisoK , KuritaK , KawabeK , et al. Clinical effects of propiverine hydrochloride in the treatment of urinary frequency and incontinence associated with detrusor overactivity: a double blind, parallel, placebo controlled multicenter study. Igaku No Ayumi (Progress in Medicine)1990;153(8):459-71. [srincont-12896]TakayasuH , UenoA , TsutidaS , KoisoK , KuritaK , KawabeK , et al. Clinical effects of propiverine hydrochloride in the treatment of urinary frequency and incontinence associated with detrusor overactivity: a double blind, parallel, placebo controlled multicenter study. Igaku No Ayumi (Progress in Medicine)1990;153(8):459-71. [sr-incont12896]">Takayasu 1990</a>; <a href="./references#CD003781-bbs2-0090" title="UlshoferB , BihrAM , BodekerRH , SchwantesU , JahnHP . Randomised, double-blind, placebo-controlled study on the efficacy and tolerance of trospium chloride in patients with motor urge incontinence. Clinical Drug Investigation2001;21(8):563-9. [srincont-16324]UlshoferB , SchwantesU , BodekerRH , BihrAM , JahnHP . Efficacy and tolerance of trospium chloride in patients with motor urge incontinence - results of a randomised double-blind placebo-controlled study (Poster presentations). In: 2nd International Consultation on Incontinence (ICI); 2001 July 1-3; Paris, France. 2001:5. [srincont-16318]">Ulshofer 2001</a>; <a href="./references#CD003781-bbs2-0093" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CrosbyRD , MathiasSD , MarshallTS . Relationships between symptoms, symptom bother, and health-related quality of life in patients with overactive bladder taking solifenacin or placebo in the VIBRANT study. International Journal of Clinical Practice2011;65(2):211-8. [sr-incont41015]GollarKM , YoungDG , BailenJ , HeW , Forero-SchwanhaeuserS . Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: a secondary analysis of the VIBRANT study. Urologic Nursing2012;32(1):38-46. [TrialID.VIBRANT.] [sr-incont44571]Samuels T‐A, MitchesonHD , VardyM , Forero‐SchwanhaeuserS , MarshallT , HeW . Efficacy of solifenacin for symptom bother and other patient-reported outcomes in patients with overactive bladder (OAB): results of a large, double-blind, placebo-controlled trial (Abstract number: poster #74). Neurourology and Urodynamics2009;28(2):149. [sr-incont31063]VardyMD , MitchesonHD , SamuelsTA , Forero-SchwanhaeuserS , HeW . Efficacy of solifenacin on overactive bladder symptoms, symptom bother, and other patient-reported outcomes in subjects with or without incontinence: a post hoc analysis of data from VIBRANT. Female Pelvic Medicine and Reconstructive Surgery2011;17(1):24-9. [TrialID.VIBRANT.] [sr-incont44741]VardyMD , MitchesonHD , SamuelsTA , WegenkeJD , Forero-SchwanhaeuserS , MarshallTS , et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. International Journal of Clinical Practice2009;63(12):1702-14. [905-UC-010] [NCT00573508] [TrialID.VIBRANT.] [sr-incont35459]">Vardy 2009</a>; <a href="./references#CD003781-bbs2-0094" title="EUCTR2007-007087-17-SE. A 24-week, multicentre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-007087-17 (first received 13 June 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont64588]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00798434. A study to compare the effectiveness and safety of fesoterodine and placebo in an elderly population of patients who go to the toilet very frequently due to overactive bladder (SOFIA) [A 24-week, multi-centre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00798434 (first received 26 November 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont49847]SchneiderT , BergqvistA , WangJ , WaggA , Ebel-BitounC . Treatment with fesoterodine versus tolterodine for reducing symptom bother in elderly patients with overactive bladder including urgency urinary incontinence. European Urology, Supplements2012;11(1):e687-a. [sr-incont65389]WaggA , CarlssonM , ElsobkyM , FernetM . Effect of flexible dose fesoterodine on cognitive function in &gt;65 year old patients with OAB: data from two RCT (Abstract number 438). Neurourology and Urodynamics2019;38:S297-8. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78651]WaggA , DarekarA , ArumiD , KhullarV , OelkeM . Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people &gt;65 years of age: a post hoc analysis of data from the SOFIA study. Neurourology and Urodynamics2015;34(5):438-43. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont68100]WaggA , ElsobkyM , CarlssonM , FernetM . Response and cognitive safety of fesoterodine in patients &gt;65y old with OAB. Is there a relationship between cognition and treatment response? (Abstract number 183). Neurourology and Urodynamics2019;38:S118-20. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78632]WaggA , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. Journal of the American Geriatrics Society2013;61(2):185-93. [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TrialID.SOFIA.] [sr-incont48008]WaggAS , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Efficacy and tolerability of fesoterodine in older subjects with overactive bladder: results of SOFIA (Abstract number C33). Journal of the American Geriatrics Society2011;59:S124. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont65234]">Wagg 2013a</a>; <a href="./references#CD003781-bbs2-0095" title="GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00911937. A trial to evaluate the efficacy and safety of fesoterodine in patients with symptoms of overactive bladder including nocturnal urinary urgency [A randomized, double blind, placebo controlled, parallel group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with symptoms of overactive bladder including nocturnal urinary urgency]. clinicaltrials.gov/show/NCT00911937 (first received 03 June 2009). [NCT00911937] [sr-incont49848]WeissJ , JumadilovaZ , CarlssonM , FitzGeraldMP , MalhotraA , MartireDL . Effect of antimuscarinic treatment in subjects with overactive bladder, including nocturnal urinary urgency (Abstract number 1963). Journal of Urology2012;187(4 Suppl 1):e792. [NCT00911937] [sr-incont65184]WeissJP , CarlssonMR , ManganEK . Age, gender and nocturnal urgency severity predict response to antimuscarinic treatment (Abstract number 1962). Journal of Urology2013;189(4 Suppl 1):e805. [NCT00911937] [sr-incont65096]WeissJP , JumadilovaZ , JohnsonTM , FitzGeraldMP , CarlssonM , MartireDL , et al. Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency. Journal of Urology2013;189(4):1396-401. [A0221048] [NCT00911937] [sr-incont47568]">Weiss 2013</a>; <a href="./references#CD003781-bbs2-0096" title="YamaguchiO , MaruiE , KakizakiH , ItohN , YokotaT , OkadaH , et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU International2007;100(3):579-87. [sr-incont23865]YokoyamaO , YamaguchiO , KakizakiH , ItohN , YokotaT , OkadaH , et al. Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary. Journal of Urology2011;186(1):170-4. [sr-incont41734]">Yamaguchi 2007</a>; <a href="./references#CD003781-bbs2-0097" title="NCT00966004. A study to evaluate safety and efficacy of ym178 in patients with overactive bladder [Phase III study of YM178 - a placebo-controlled, double-blind, group comparison study in patients with overactive bladder]. clinicaltrials.gov/show/NCT00966004 (first received 26 August 2009). [178-CL-048] [JapicCTI-R130370] [NCT00966004] [sr-incont63783]YamaguchiO , HidehiroK , YukioH , YasuhikoI , MasayukiT , OsamuN , et al. A phase III, randomized, double-blind, placebo and active controlled study of once-daily mirabegron 50 mg in patients with overactive bladder (Abstract number POD-03.06). Urology2012;80(3 Suppl 1):S10-1. [NCT00966004] [sr-incont65380]YamaguchiO , MaruiE , KakizakiH , HommaY , IgawaY , TakedaM , et al. A phase III, randomized, double-blind, placebo-controlled study of the beta-adrenoceptor agonist, mirabegron 50 mg once-daily, in Japanese patients with overactive bladder. BJU International2014;113(6):951-60. [NCT00966004] [sr-incont50603]">Yamaguchi 2012</a>; <a href="./references#CD003781-bbs2-0098" title="YamaguchiO , UchidaE , HigoN , MinamiH , KobayashiS , SatoH , et al. Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: a randomized double-blind trial. International Journal of Urology2014;21(6):586-93. [JapicCTI-101309] [sr-incont62099]">Yamaguchi 2014</a>; <a href="./references#CD003781-bbs2-0100" title="JapicCTI-152936. Phase III study of KRP-114V [A phase III, randomized, double-blind, parallel group, placebo controlled, multicenter study to assess the efficacy and safety of the beta-3 agonist KRP-114V in Japanese subjects with symptoms of overactive bladder]. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-152936 (first received 17 June 2015). [JapicCTI-152936] [sr-incont78653]YoshidaM , TakedaM , GotoM , NagaiS , KuroseT . Vibegron, a novel potent and selective beta3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study (Abstract number 1082). European Urology, Supplements2018;17(2):e1531-2. [JapicCTI-152936] [sr-incont78069]YoshidaM , TakedaM , GotohM , NagaiS , KuroseT . Vibegron, a novel potent and selective B3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study. European Urology2018;73(5):783-90. [JapicCTI-152936] [sr-incont77898]YoshidaM , TakedaM , GotohM , YokoyamaO , KakizakiH , TakahashiS , et al. Efficacy of novel beta3-adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: a post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study. International Journal of Urology2019;26(3):369-75. [JapicCTI-152936] [sr-incont78654]YoshidaM , TakedaM , GotohM , YokoyamaO , KakizakiH , TakahashiS , et al. Efficacy of vibegron, a novel selective I²3-adrenoreceptor agonist, on urgency urinary incontinence with overactive bladder: post-hoc analysis of phase iii study (Abstract number 180). Neurourology and Urodynamics2019;38(S3):S114-5. [JapicCTI-152936] [sr-incont78636]">Yoshida 2018</a>; <a href="./references#CD003781-bbs2-0102" title="ZinnerNR , MattiassonA , StantonSL . Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. Journal of the American Geriatrics Society2002;50(5):799-807. [sr-incont14679]">Zinner 2002</a>; <a href="./references#CD003781-bbs2-0104" title="ZinnerN , SussetJ , GittelmanM , ArguinzonizM , RekedaL , HaabF . Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. International Journal of Clinical Practice2006;60(1):119-26. [sr-incont21507]">Zinner 2006</a>). </p> <p>Seven studies restricted participation to those with neurogenic detrusor overactivity, urodynamically confirmed or not (<a href="./references#CD003781-bbs2-0001" title="AbramsP , JacksonS , MattiassonA , KrishnanK , HaendlerL . A randomised, double-blind, placebo controlled, dose ranging study of the safety and efficacy of tolterodine in patients with hyperreflexia (Abstract). In: International Continence Society 26th Annual Meeting; 1996 Aug 27-30; Athens, Greece. 1996:276-7. [sr-incont5135]">Abrams 1996</a>; <a href="./references#CD003781-bbs2-0022" title="AmarencoG , SutoryM , FagertunH , WrightM , CompionG , De RidderD . Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Preliminary results from the SONIC urodynamic study (Abstract). European Urology, Supplements2012;11(1):e467-a. [EudraCT2006-005523-42] [NCT00629642] [sr-incont65392]AmarencoG , SutoryM , ZachovalR , AgarwalM , DelPG , TretterR , et al. Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study. Neurourology and Urodynamics2017;36(2):414-21. [EudraCT2006-005523-42] [JapicCTI-R130306] [NCT00629642] [sr-incont72248]De RidderD , AmarencoG , Finazzi-AgroE , AnguloJ , KurenkovA , WrightM , et al. Solifenacin treatment for neurogenic detrusor overactivity: patient-reported outcomes (PROs) from the randomised clinical trial SONIC (Abstract number 333). In: International Continence (ICS); 42nd Annual Meeting; 2012 Oct 15-19; Beijing, China. 2012. [905-EC-005] [EudraCT2006-005523-42] [NCT00629642] [TrialID.SONIC.] [srincont-49739]">De Ridder 2012</a>; <a href="./references#CD003781-bbs2-0085" title="StohrerM , BauerP , GiannettiBM , RichterR , BurgdorferH , MurtzG . Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries. Urologia Internationalis1991;47(3):138-43. [srincont-236]">Stohrer 1991</a>; <a href="./references#CD003781-bbs2-0086" title="StohrerM , MadersbacherH , RichterR , WehnertJ , DreikornK . Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia - a double-blind, placebo-controlled clinical trial. Spinal Cord1999;37(3):196-200. [sr-incont8146]">Stohrer 1999</a>; <a href="./references#CD003781-bbs2-0087" title="TagoK , UenoA , TakayasuH . Clinical study of propiverine hydrochloride for the treatment of patients with urinary frequency and incontinence. Neurourology and Urodynamics1990;9(4):337-8. [srincont-5109]">Tago 1990</a>; <a href="./references#CD003781-bbs2-0099" title="YongucT , SefikE , InciI , KusbeciOY , CelikS , AydinME , et al. Randomized, controlled trial of fesoterodine fumarate for overactive bladder in Parkinson's disease. World Journal of Urology2019;38(8):2013-9. [sr-incont78635]">Yonguc 2019</a>; <a href="./references#CD003781-bbs2-0101" title="NCT01018264, ZesiewiczT . Solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease (URGE-PD) [URGE-PD: a multi-site, double-blind, randomized, placebo controlled trial of solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease]. clinicaltrials.gov/show/NCT01018264 (first received 23 November 2009). [NCT01018264] [sr-incont63790]ZesiewiczTA , EvattM , JahanI , VaughanC , SingerC , OrdoricaR , et al. URGE-PD: a multi-site, double-blind, randomized, placebo controlled trial of solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease (Abstract number 745). Movement Disorders2014;29(Suppl 1):S276-7. [NCT01018264] [sr-incont66602]ZesiewiczTA , EvattM , VaughanCP , JahanI , SingerC , OrdoricaR , et al. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease. Parkinsonism and Related Disorders2015;21(5):514-20. [NCT01018264] [sr-incont66860]">Zesiewicz 2015</a>). Five studies included people with either idiopathic or neurogenic problems (<a href="./references#CD003781-bbs2-0014" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. ChappleCR , AranoP , BoschJH , De RidderD , KramerG , RidderAM . YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo- and tolterodine-controlled, phase-II, dose-finding study (Abstract 75). Neurourology and Urodynamics2002;21(4):381-2. [srincont-14551]ChappleCR , ArañoP , BoschJL , De RidderD , KramerAE , RidderAM . Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU International2004;93(1):71-7. [srincont-17334]KelleherCJ , CardozoL , ChappleCR , HaabF , RidderAM . Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU International2005;95(1):81-5. [srincont-20241]SmithN , GrimesI , RidgeS , TempelD , UchidaT , YamanouchiUS . YM905 is effective and safe as treatment of overactive bladder in women and men: results from phase II study (Abstract). In: International Continence Society (ICS), 32nd Annual Meeting; 2002 Aug 28-30; Heidelberg, Germany. 2002:138-9. [sr-incont14508]">Chapple 2004b</a>; <a href="./references#CD003781-bbs2-0015" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. ChappleC , RechbergerT , Al-ShukriS , MeffanP , EveraertK , RidderA . Results of a randomized phase 3 study comparing solifenacin succinate with tolterodine and placebo in patients with symptomatic overactive bladder (Abstract). Neurourology and Urodynamics2003;22(5):534-5. [sr-incont16991]ChappleCR , RechbergerT , Al ShukriS , MeffanP , EveraertK , HuangM , et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU International2004;93(3):303-10. [srincont-17270]">Chapple 2004c</a>; <a href="./references#CD003781-bbs2-0026" title="DrutzH , AppellRA . Clinical efficacy and safety of Tolterodine vs Oxybutynin and placebo in patients with unstable bladder. Acta Obstetrica et Gynecologica Scandinavica1997;Suppl 167(5):24. [srincont-6671]DrutzHP , AppellRA , GleasonD , KlimbergI , RadomskiS . Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. International Urogynecology Journal and Pelvic Floor Dysfunction1999;10(5):283-9. [srincont-8804]DrutzHP , AppellRA . Enhanced tolerability of tolterodine compared to oxybutynin in a controlled clinical study. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(1):S14. [srincont-5166]">Drutz 1999</a>; <a href="./references#CD003781-bbs2-0089" title="ThuroffJW , BunkeB , EbnerA , FaberP , deGeeterP , HannappelJ , et al. Randomized, double-blind multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin vs. propantheline vs. placebo. Neurourology and Urodynamics1990;9(4):337-8. [srincont-5108]ThuroffJW , BunkeB , EbnerA , FaberP , deGeeterP , HannappelJ , et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. Journal of Urology1991;145(4):813-7. [srincont-1288]">Thuroff 1991</a>; <a href="./references#CD003781-bbs2-0092" title="ChancellorM , FreedmanS , MitchesonHD , AntociJ , PrimusG , WeinA . Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clinical Drug Investigation2000;19(2):83-91. [srincont-16326]FreemanR , HillS , MillardR , SlackM , SutherstJ , Tolterodine Study Group. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstetrics and Gynecology2003;102(3):605-11. [srincont-16494]GarelyA , Tolterodine Study Group. Once-daily tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder. International Urology Journal2001;12(Suppl 1):S18. [srincont-12012]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of life of patients with overactive bladder receiving tolterodine. Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of patients with overactive bladder receiving tolterodine (Abstract number 82). Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , ReesePR . Health related quality of life of patients with overactive bladder receiving tolterodine once-daily. Neurourology and Urodynamics2000;19(4):519-21. [srincont-9987]KelleherCJ , ReesePR , PleilAM , OkanoGJ . Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. American Journal of Managed Care2002;8(Suppl 19):S608-15. [srincont-17998]KelleherCJ , Tolterodine Study Group. Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2000;11(Suppl 1):S94. [srincont-11915]KrederKJ . Antimuscarinic therapy: relationship between efficacy and side effects in responders and non-responders. Journal of Urology2001;165(Suppl 5):S165. [srincont-16327]KrederKJ . Clinical effectiveness of antimuscarinic therapy: the relationship between efficacy and tolerability. In: Proceedings of the International Continence Society Annual Meeting(ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001:140. [srincont-14376]MallettV . Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2001;12(Suppl 1):4. [srincont-12011]MillardRJ , TamaddonK , Tolterodine Study Group. Randomized controlled trial to compare tolterodine prolonged release capsules and tolterodine immediate release tablets versus placebo in patients with symptoms of detrusor overactivity (Abstract number 57). Australian and New Zealand Journal of Surgery2002;Suppl 72:A140. [sr-incont22190]PleilAM , ReesePR , KelleherCJ , OkanoGJ . Health-related quality of life of patients with overactive bladder receiving immediate-release tolterodine. HEPAC Health Economics in Prevention and Care2001;2(2):69-75. [sr-incont18060]RoehrbornCG , AbramsP , RovnerES , KaplanSA , HerschornS , GuanZ . Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU International2006;97(5):1003-6. [sr-incont21882]SwiftS . Efficacy and tolerability of once-daily tolterodine for women with overactive bladder. In: International Continence Society Annual Meeting (ICS), 31st annual meeting; 2001 Sept 18-21; Seoul, Korea. 2001:No. 329. [srincont-14481]SwiftS . Once-daily tolterodine is effective and well tolerated in women with overactive bladder (Abstract 57). In: 2nd International Consultation on Incontinence; 2001 July 1-3; Paris, France. 2001. [srincont-16319]SwiftSE . Once-daily (OD) tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder (OAB). International Urogynecology Journal2000;11(Suppl 1):S15. [sr-incont11906]SwiftSE . Once-daily administration of extended-release tolterodine is effective and well-tolerated in patients with overactive bladder. In: XVI FIGO World Congress of Obstetrics and Gynecology; 2000 Sept 3-8; Washington DC. Vol. Book 1. 2000:40. [sr-incont12085]SwiftSE . Overactive bladder in females: treatment with once-daily tolterodine. International Urogynecology Journal2001;12(Suppl 3):S71. [sr-incont16328]Van KerrebroeckP , KrederK , JonasU , ZinnerN . Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology2001;57(3):414-21. [sr-incont11953]Van KerrebroeckPEV . Long-term (12 months) efficacy and tolerability of tolterodine once-daily in the treatment of overactive bladder. Neurourology and Urodynamics2001;20(4):401-2. [sr-incont15714]Van KerrebroeckPEVA , Tolterodine Study Group. Long-term tolerability and efficacy of once-daily (OD) tolterodine in the treatment of overactive bladder (OB). International Urogynecology Journal2001;12(Suppl 3):S49. [sr-incont16329]Van KerrebroeckPEVA , Tolterodine Study Group. Significant decreases in perception of urgency and urge incontinence episodes with once-daily tolterodine treatment in patients with overactive bladder (Abstract number 89). Neurourology and Urodynamics2000;19(4):493-4. [sr-incont9980]WeinAJ , KhullarV , WangJT , GuanZ . Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. BJU International2007;99(2):360-3. [sr-incont23180]vanKerrebroeckPE , KelleherCJ , CoyneKS , KoppZ , BrodskyM , WangJT . Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. Health and Quality of Life Outcomes2009;7(13):13. [10.1186/1477-7525-7-13] [sr-incont31438]vanKerrebroeckPE , WangJ , GuanZ . Effects of tolterodine extended release in patients with overactive bladder: perceived treatment benefits improve with efficacy (Abstract number 511). European Urology Supplements2004;3(2):130. [sr-incont31090]">Van Kerrebroeck 2001</a>). </p> <p>Five studies did not report their inclusion criteria in a way that enabled us to judge the type of symptoms (<a href="./references#CD003781-bbs2-0308" title="ChappleCR , MadersbacherH , DreikornK , DorschnerW , MurtzG . Urodynamics and frequency/volume chart - do they correlate? Treatment analysis of propiverine in comparison to oxybutynin and placebo in urge incontinence (Abstract number 224). In: International Continence Society (ICS), 31st Annual Meeting; 2001 Sep 18-21; Seoul, Korea. 2001. [sr-incont14474]">Chapple 2001</a>; <a href="./references#CD003781-bbs2-0025" title="ChappleCR , MadersbacherH , DreikornK , DorschnerW , MurtzG . Urodynamics and frequency/volume chart - do they correlate? Treatment analysis of propiverine in comparison to oxybutynin and placebo in urge incontinence (Abstract number 224). In: International Continence Society (ICS), 31st Annual Meeting; 2001 Sep 18-21; Seoul, Korea. 2001. [sr-incont14474]DorschnerW , StolzenburgJU , GriebenowR , HalaskaM , BrünjesR , FrankM , et al. The elderly patient with urge incontinence or urge-stress incontinence - efficacy and cardiac safety of propiverine [Der ältere Patient mit Drang-Symptomatik bzw. kombinierter Drang/Stress-Inkontinenz-Wirksamkeit und kardiale Sicherheit von Propiverin]. Aktuelle Urologie2003;34(2):102-8. [sr-incont16422]DorschnerW , StolzenburgJU , GriebenowR , HalaskaM , SchubertG , Mürtz G et al. Efficacy and cardiac safety of propiverine in elderly patients - a double-blind, placebo-controlled clinical study. European Urology2000;37(6):702-8. [srincont-11660]">Dorschner 2000</a>; <a href="./references#CD003781-bbs2-0056" title="KosilovKV , LoparevS , IvanovskayaM , KosilovaL . Treatment of overactive bladder in older women increased doses of antimuscarinic drugs safe and effective alternative to existing methods. Advances in Gerontology [Uspekhi Gerontologii]2014;27(1):149-55. [ISSN: 1561-9125] [sr-incont63914]">Kosilov 2014a</a>; <a href="./references#CD003781-bbs2-0078" title="RomanziLJ , DelconteA , KralidisG . Impact of darifenacin compared with tolterodine on incontinence episodes in patients with overactive bladder (Abstract number A3522). Obstetrics and Gynecology2005;105(Suppl 4):88S. [sr-incont34187]">Romanzi 2005</a>; <a href="./references#CD003781-bbs2-0081" title="StaskinDR , HarnettMD . Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder. Current Urology Reports2004;5(6):423-6. [sr-incont19422]">Staskin 2004</a>). </p> </section> <section id="CD003781-sec-0050"> <h6 class="title">Sex</h6> <p>The majority of the studies included both men and women. Nine studies presented data for women only (<a href="./references#CD003781-bbs2-0008" title="BurgioKL , LocherJL , GoodePS , HardinJM , McDowellBJ , CandibD . Behavior vs drug therapy for urge incontinence in older women (Abstract number 26). In: American Urogynecology Society, 15th Annual Scientific Meeting; 1994 Sept 21-24; Toronto, Ontario. 1994:48. [sr-incont14585]BurgioKL , LocherJL , GoodePS , HardinM , McDowellBJ , Dombrowski M et al. Behavioral vs drug treatment for urge urinary incontinence in older women. A randomized controlled trial. JAMA1998;280(23):1995-2000. [srincont-5719]BurgioKL , LocherJL , GoodePS . Combined behavioral and drug therapy for urge incontinence in older women. Journal of the American Geriatrics Society2000;48(4):370-4. [srincont-9006]BurgioKL , LocherJL , RothDL , GoodePS . Psychological improvements associated with behavioral and drug treatment of urge incontinence in older women. Journal of Gerontology. Series B, Psychological Sciences and Social Sciences2001;56(1):P46-51. [srincont-11923]">Burgio 1998</a>; <a href="./references#CD003781-bbs2-0031" title="EUCTR2007-004126-24-CZ. A placebo controlled randomized, 12-week, dose-ranging, double-blind study versus placebo using tolterodine as a study calibrator, to evaluate efficacy and safety of SSR240600C in women with overactive bladder including urge urinary incontinence. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-004126-24 (first received 12 December 2007). [DRI6271] [EUCTR2007-004126-24-CZ] [EudraCT2007-004126-24] [NCT00564226] [TrialID.BILADY] [sr-incont64596]NCT00564226. SSR240600C treatment in women with overactive bladder (BILADY) [A placebo controlled randomized, 12-week, dose-ranging, double-blind study versus placebo using tolterodine as a study calibrator, to evaluate efficacy and safety of SSR240600C in women with overactive bladder including urge urinary incontinence]. clinicaltrials.gov/show/NCT00564226 (first received 27 November 2007). [DRI6271] [EudraCT2007-004126-24] [NCT00564226] [TrialID.BILADY] [sr-incont63784]">EUCTR2007‐004126‐24‐CZ</a>; <a href="./references#CD003781-bbs2-0032" title="GellerE , DumondJ , BowlingJM , KhandelwalC , WuJ , Busby-WhiteheadJ , et al. Effect of an anticholinergic on cognitive function in postmenopausal women: a randomized trial (Abstract number: oral poster 52). Female Pelvic Medicine and Reconstructive Surgery2016;22(5):S61. [sr-incont78607]GellerEJ , DumondJB , BowlingJM , KhandelwalCM , WuJM , Busby-WhiteheadJ , et al. Effect of trospium chloride on cognitive function in women aged 50 and older: a randomized trial. Female Pelvic Medicine &amp; Reconstructive Surgery2017;23(2):118-23. [13-1352] [NCT01922115] [sr-incont74341]NCT01922115. The effect of anticholinergics on cognitive function in the elderly (ACE) [The effect of anticholinergics on cognitive function in the elderly: a randomized controlled trial]. clinicaltrials.gov/show/NCT01922115 (first received 14 August 2013). [13-1352] [NCT01922115] [TrialID.ACE] [sr-incont49282]">Geller 2013</a>; <a href="./references#CD003781-bbs2-0046" title="HuangA , HessR , AryaL , RichterH , SubakL , BradleyC , et al. A randomized controlled trial of simple diagnosis and treatment for urgency urinary incontinence in women (Abstract). Journal of General Internal Medicine2011;26:S1. [NCT00862745] [sr-incont64391]HuangAJ , HessR , AryaLA , RichterHE , SubakLL , BradleyCS , et al. Pharmacologic treatment for urgency-predominant urinary incontinence in women diagnosed using a simplified algorithm: a randomized trial. American Journal of Obstetrics and Gynecology2012;206(5):444.e1-11. [GA0221IX] [NCT00862745] [TrialID.BRIDGES.] [srincont-44636]NCT00862745, BrownJ . Bringing simple urge incontinence diagnosis &amp; treatment to providers (BRIDGES)  [A multi-center, randomized, placebo-controlled clinical trial comparing fesoterodine to placebo in women diagnosed with urge urinary incontinence by the 3 Incontinence Questions (3IQ). Followed by a multi-center open label clinical cohort study of long-term effects of treatment with fesoterodine ]. clinicaltrials.gov/show/NCT00862745 (first received 17 March 2009). [NCT00862745] [sr-incont49836]WarsiQ , HuangA , BrownJS , SchembriM , HessR , AryaLA , et al. The effect of pharmacologic treatment of urgency urinary incontinence on sleep quality and daytime sleepiness (Abstract number: paper 37). Female Pelvic Medicine and Reconstructive Surgery2016;22(5 ):S17-8. [NCT00862745] [TrialID.BRIDGES.] [sr-incont78633]WarsiQA , HuangAJ , HessR , AryaLA , RichterHE , BradleyCS , et al. Association of pharmacologic treatment of urgency urinary incontinence with sleep quality and daytime sleepiness. Obstetrics and Gynecology2018;131(2):204-11. [NCT00862745] [sr-incont78239]WinkelmanW , HuangA , SchembriM , RogersRG , RichterHE , MyersDL , et al. Clinical variables moderating response to pharmacologic treatment of urgency-predominant urinary incontinence in a randomized controlled trial (Abstract number: poster 25). In: Female Pelvic Medicine and Reconstructive Surgery. 37th Annual Scientific Meeting of the American Urogynecologic Society; Aug 2016; United States. Vol. 22. Netherlands: Lippincott Williams and Wilkins, 2016:S81. [NCT00862745] [sr-incont78634]WinkelmanWD , HuangAJ , SchembriM , RogersRG , RichterH , MyersDL , et al. Modifiers of response to treatment with fesoterodine for urgency-predominant urinary incontinence in a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2017;23(2):151-6. [sr-incont74308]">Huang 2012</a>; <a href="./references#CD003781-bbs2-0061" title="LacknerTE , WymanJF , McCarthyTC , MonigoldM , DaveyC . Efficacy of oral extended-release oxybutynin in cognitively impaired older nursing home residents with urge urinary incontinence: a randomized placebo-controlled trial. Journal of the American Medical Directors Association2011;12(9):639-47. [sr-incont42677]LacknerTE , WymanJF , McCarthyTC , MonigoldM , DaveyC . Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. Journal of the American Geriatrics Society2008;56(5):862-70. [sr-incont27117]">Lackner 2011</a>; <a href="./references#CD003781-bbs2-0072" title="OreskovićS , ButI , BanovićM , GoldstajnMS . The efficacy and safety of solifenacin in patients with overactive bladder syndrome. Collegium Antropologicum2012;36(1):243-8. [srincont-45056]">Oreskovic 2012</a>; <a href="./references#CD003781-bbs2-0073" title="NCT01302938. Web-based methodology trial to evaluate the efficacy and safety of tolterodine ER in subjects with overactive bladder (REMOTE) [Exploratory, randomized, double-blind, placebo-controlled, parallel-group, single center, web-based phase IV pilot methodolgy trial to evaluate the efficacy and safety of tolterodine ER in subjects with overactive bladder]. clinicaltrials.gov/ct2/show/NCT01302938 (first received 24 February 2011). [A6121195] [NCT01302938] [TrialID.REMOTE.] [sr-incont43314]OrriM , LipsetCH , JacobsBP , CostelloAJ , CummingsSR . Web-based trial to evaluate the efficacy and safety of tolterodine ER 4 mg in participants with overactive bladder: REMOTE trial. Contemporary Clinical Trials2014;38(2):190-7. [A6121195] [NCT01302938] [TrialID.REMOTE.] [sr-incont62536]">Orri 2014</a>; <a href="./references#CD003781-bbs2-0076" title="EUCTR2008-005215-17. A study to evaluate the overall effect of solifenacin 5mg and 10mg on bladder wall thickness and urinary nerve growth factor in female subjects with overactive bladder and a diagnosis of detrusor overactivity – a double-blind, randomized, placebo-controlled, parallel group, multicentre study - SHRINK. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-005215-17 (first received 14 September 2009). [EUCTR2008-005215-17] [NCT01093534] [sr-incont78650]NCT01093534. Study of 2 doses of solifenacin succinate in female subjects with overactive bladder (SHRINK) [A study to evaluate the overall effect of solifenacin 5mg and 10mg on bladder wall thickness and urinary nerve growth factor in female subjects with overactive bladder and a diagnosis of detrusor overactivity - a double-blind, randomised, placebo-controlled, parallel group, multi-centre study]. clinicaltrials.gov/show/NCT01093534 (first received 26 March 2010). [905-EC-007] [EUCTR2008-005215-17] [NCT01093534] [TrialID.SHRINK] [sr-incont63778]RobinsonD , KhullarV , OelkeM , WijkstraH , TretterR , StowB , et al. Effects of 12 weeks treatment with solifenacin on Bladder Wall Thickness (BWT) and clinical outcomes: results from the placebo-controlled SHRINK study (Abstract number 422). In: International Continence Society (ICS), 43rd Annual Meeting; 2013 Aug 26-30; Barcelona, Spain. 2013. [905-EC-007] [NCT01093534] [TrialID.SHRINK.] [srincont-49731]RobinsonD , OelkeM , KhullarV , WijkstraH , TretterR , StowB , et al. Bladder wall thickness in women with symptoms of overactive bladder and detrusor overactivity: results from the randomised, placebo-controlled SHRINK study. Neurourology and Urodynamics2016;35(7):819-25. [NCT01093534] [sr-incont72217]RobinsonD , OelkeM , TretterR , StowB , CompionG , TubaroA . The effect of solifenacin on bladder wall thickness in women with overactive bladder and detrusor overactivity: Results from the SHRINK study (Abstract number 782). European Urology Supplements2013;12(1):e782-3. [EUCTR2008-005215-17] [NCT01093534] [sr-incont67207]RobinsonD , TubaroA , KimbergM , PlummerM , DeVineJ , BouicP , et al. The effect of solifenacin on urinary nerve growth factor (UNGF) and brain-derived neurotropic factor (BDNF) in women with overactive bladder and detrusor overactivity: results from the SHRINK study (Abstract number PP 54). International Urogynecology Journal and Pelvic Floor Dysfunction2014;25(1 Suppl 1):S60-1. [EUCTR2008-005215-17] [NCT01093534] [sr-incont67200]TubaroA , KhullarV , OelkeM , WijkstraH , TretterR , StowB , et al. Intra- and inter-reader variability of transvaginal ultrasound bladder wall thickness measurements: results from the SHRINK study (Abstract number 136). Neurourology and Urodynamics2013;32(6):711-2. [EUCTR2008-005215-17] [NCT01093534] [sr-incont49211]">Robinson 2013</a>; <a href="./references#CD003781-bbs2-0077" title="RogersR , BachmannG , JumadilovaZ , SunF , MorrowJD , GuanZ , et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. International Urogynecology Journal and Pelvic Floor Dysfunction2008;19(11):1551-7. [A6121002] [NCT00143481] [srincont-27729]RogersRG , BachmannG , ScarperoH , JumadilovaZ , SunF , MorrowJD , et al. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. Current Medical Research and Opinion2009;25(9):2159-65. [srincont-32060]">Rogers 2008</a>). One study presented data for men only (<a href="./references#CD003781-bbs2-0003" title="AbramsP , KaplanS , MillardR . Tolterodine treatment is safe in men with bladder outlet obstruction (BOO) and symptomatic detrusor overactivity (DO) (Abstract). Neurourology and Urodynamics2001;20(4):547-8. [srincont-14372]">Abrams 2001</a>). </p> </section> <section id="CD003781-sec-0051"> <h6 class="title">Age</h6> <p>The participants' age ranged from 21 to 93 years (<a href="./references#CD003781-bbs2-0071" title="OlshanskyB , FooteJ , ArguinzonizM , LheritierK , Quebe-FehlingE , SteelM . Cardiovascular safety of darifenacin and tolterodine in patients with overactive bladder (OAB) (Abstract number 49). International Urogynecology Journal and Pelvic Floor Dysfunction2006;17(Suppl 2):S86-7. [sr-incont34186]">Olshansky 2006</a>). However, it was only one study that included such a wide range of participant ages (<a href="./references#CD003781-bbs2-0071" title="OlshanskyB , FooteJ , ArguinzonizM , LheritierK , Quebe-FehlingE , SteelM . Cardiovascular safety of darifenacin and tolterodine in patients with overactive bladder (OAB) (Abstract number 49). International Urogynecology Journal and Pelvic Floor Dysfunction2006;17(Suppl 2):S86-7. [sr-incont34186]">Olshansky 2006</a>). There was only one more study that included participants aged younger than 30 (<a href="./references#CD003781-bbs2-0086" title="StohrerM , MadersbacherH , RichterR , WehnertJ , DreikornK . Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia - a double-blind, placebo-controlled clinical trial. Spinal Cord1999;37(3):196-200. [sr-incont8146]">Stohrer 1999</a>). No other studies that reported participants' ages included participants older than 90. Most other studies that reported participants' ages included participants in their 40s, 50s and 60s. Twenty studies did not report participants' ages (<a href="./references#CD003781-bbs2-0001" title="AbramsP , JacksonS , MattiassonA , KrishnanK , HaendlerL . A randomised, double-blind, placebo controlled, dose ranging study of the safety and efficacy of tolterodine in patients with hyperreflexia (Abstract). In: International Continence Society 26th Annual Meeting; 1996 Aug 27-30; Athens, Greece. 1996:276-7. [sr-incont5135]">Abrams 1996</a>; <a href="./references#CD003781-bbs2-0003" title="AbramsP , KaplanS , MillardR . Tolterodine treatment is safe in men with bladder outlet obstruction (BOO) and symptomatic detrusor overactivity (DO) (Abstract). Neurourology and Urodynamics2001;20(4):547-8. [srincont-14372]">Abrams 2001</a>; <a href="./references#CD003781-bbs2-0006" title="BaertL , Leuven, DijkmanG , Breda, the darifenacin study group. Darifenacin, a novel M3 muscarinic receptor antagonist in detrusor overactivity (Abstract  214). In: International Continence Society, 25th Annual Meeting; 1995 Oct 17-20;  Sydney, Australia. 1995:226-7. [sr-incont10890]">Baert 1995</a>; <a href="./references#CD003781-bbs2-0012" title="ChalihaC , HalaskaM , StantonS . Trospium chloride for the treatment of detrusor instability: a placebo-controlled dose-finding study (Abstract 276). British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):92. [srincont-8452]">Chaliha 1998</a>; <a href="./references#CD003781-bbs2-0308" title="ChappleCR , MadersbacherH , DreikornK , DorschnerW , MurtzG . Urodynamics and frequency/volume chart - do they correlate? Treatment analysis of propiverine in comparison to oxybutynin and placebo in urge incontinence (Abstract number 224). In: International Continence Society (ICS), 31st Annual Meeting; 2001 Sep 18-21; Seoul, Korea. 2001. [sr-incont14474]">Chapple 2001</a>; <a href="./references#CD003781-bbs2-0019" title="ChappleC , HaabF , SchneiderT , CarlssonM , ArumiD . Fesoterodine 8 mg versus fesoterodine 4 mg in patients with overactive bladder and a history of previous antimuscarinic therapy: Results from the EIGHT trial (Abstract number: Poster #M5). Neurourology and Urodynamics2015;34(S1):S20. [NCT01302067] [sr-incont68509]ChappleC , SchneiderT , HaabF , SunF , WhelanL , ScholfieldD , et al. Superiority of fesoterodine 8mg versus fesoterodine 4 mg in reducing urgency urinary incontinence episodes in subjects with overactive bladder: results of the randomized, double-blind, placebo-controlled EIGHT trial (Abstract number: Podium #48). Neurourology and Urodynamics2014;33(2):183-4. [NCT01302067] [sr-incont67484]ChappleC , SchneiderT , HaabF , SunF , WhelanL , ScholfieldD , et al. Superiority of fesoterodine 8mg vs 4mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial. BJU International2014;114(3):418-26. [A0221095] [NCT01302067] [TrialID.EIGHT] [srincont-62537]NCT01302067. A 12 week study to confirm the effectiveness of 8mg of Fesoterodine compared to 4mg of Fesoterodine [A 12-week, randomized, double-blind, placebo controlled, parallel group, multicenter trial in overactive bladder subjects to confirm the efficacy of 8 mg fesoterodine compared to 4 mg fesoterodine]. clinicaltrials.gov/show/NCT01302067 (first received 23 February 2011). [NCT01302067] [sr-incont63792]">Chapple 2014</a>; <a href="./references#CD003781-bbs2-0029" title="EUCTR2004-001116-31-ES. Multicentre, randomised, double-blind, parallel group confirmatory Phase III study to compare the efficacy and safety of cizolirtine citrate 300 mg bid (600 mg/d), cizolirtine citrate 400 mg bid (800 mg/d), placebo, and tolterodine 2 mg bid (4 mg/d) in the treatment of urge urinary incontinence. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-001116-31 (first received 03 November 2004). [ESCLIN-002/04] [EUCTR2004-001116-31-ES] [sr-incont64643]">EUCTR2004‐001116‐31‐ES</a>; <a href="./references#CD003781-bbs2-0030" title="EUCTR2004-002143-27-AT. A double-blind, stratified, randomised, parallel, placebo-controlled, multi-centre study to compare the efficacy and safety of duloxetine hydrochloride (40mg twice a day) and tolterodine tartrate (XL) (4mg once daily) with placebo in patients with symptoms of Urge Urinary Incontinence. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-002143-27 (first received 15 February 2005). [1208.15] [EUCTR2004-002143-27-AT] [sr-incont64640]">EUCTR2004‐002143‐27‐AT</a>; <a href="./references#CD003781-bbs2-0031" title="EUCTR2007-004126-24-CZ. A placebo controlled randomized, 12-week, dose-ranging, double-blind study versus placebo using tolterodine as a study calibrator, to evaluate efficacy and safety of SSR240600C in women with overactive bladder including urge urinary incontinence. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-004126-24 (first received 12 December 2007). [DRI6271] [EUCTR2007-004126-24-CZ] [EudraCT2007-004126-24] [NCT00564226] [TrialID.BILADY] [sr-incont64596]NCT00564226. SSR240600C treatment in women with overactive bladder (BILADY) [A placebo controlled randomized, 12-week, dose-ranging, double-blind study versus placebo using tolterodine as a study calibrator, to evaluate efficacy and safety of SSR240600C in women with overactive bladder including urge urinary incontinence]. clinicaltrials.gov/show/NCT00564226 (first received 27 November 2007). [DRI6271] [EudraCT2007-004126-24] [NCT00564226] [TrialID.BILADY] [sr-incont63784]">EUCTR2007‐004126‐24‐CZ</a>; <a href="./references#CD003781-bbs2-0034" title="GriebenowR , WienersF , LangeT . Possible induction of cardiac dysrhythmia in elderly patients under therapy with propiverine hydrochloride (Abstract). Neurourology and Urodynamics1994;13:430-2. [sr-incont2681]">Griebenow 1994</a>; <a href="./references#CD003781-bbs2-0036" title="HajebrahimiS , MotlaghRS , BazarganiHS , BabaieH . Efficacy of tadalafil in treatment of overactive bladder syndrome: a randomized controlled trial (Abstract number OP.3.6Dec.27). International Journal of Urology2014;21:A146. [IRCT2013030212668N1] [sr-incont67256]IRCT2013030212668N1. Effect of tadalafil in treatment of overactive bladder  [Comparison of the efficacy of tadalafil, toltrodine and placebo in reduction of symptoms severity of women with urgency, frequency syndrom / overactive bladder]. en.irct.ir/trial/12692 (first received 26 January 2013). [91189] [IRCT2013030212668N1] [sr-incont78643]">Hajebrahimi 2014</a>; <a href="./references#CD003781-bbs2-0037" title="HalaskaM , DorschnerW , FrankM . Treatment of urgency and incontinence in elderly patients with propiverine hydrochloride. Neurourology and Urodynamics1994;13(4):428-30. [srincont-2680]">Halaska 1994</a>; <a href="./references#CD003781-bbs2-0049" title="JunemannKP , Al-ShukriS . Efficacy and tolerability of trospium chloride and tolterodine in 234 patients with urge-syndrome: a double-blind, placebo-controlled, multicentre clinical trial (Abstract number 85B). Neurourology and Urodynamics2000;19(4):488-90. [srincont-9976]">Junemann 2000</a>; <a href="./references#CD003781-bbs2-0059" title="KrederK , PleilAM , ReesePR , KelleherJ . Effects of long-term tolterodine treatment on social and psychological aspects of health-related quality of life in overactive bladder patients (Abstract). Journal of Urology2002;167(Suppl 4):29. [sr-incont17591]">Kreder 2002</a>; <a href="./references#CD003781-bbs2-0074" title="RentzhogSL , StantonL , CardozoL , NelsonE , FallM , AbramsP . Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. British Journal of Urology1998;81(1):42-8. [srincont-5461]">Rentzhog 1998</a>; <a href="./references#CD003781-bbs2-0075" title="ISRCTN17856439, ResnickN . Pathophysiology of urge incontinence in older women. isrctn.org/ISRCTN17856439 (first received 09 March 2006). [1999P-001891] [94-6641-01] [ISRCTN17856439] [sr-incont64614]">Resnick 2006</a>; <a href="./references#CD003781-bbs2-0078" title="RomanziLJ , DelconteA , KralidisG . Impact of darifenacin compared with tolterodine on incontinence episodes in patients with overactive bladder (Abstract number A3522). Obstetrics and Gynecology2005;105(Suppl 4):88S. [sr-incont34187]">Romanzi 2005</a>; <a href="./references#CD003781-bbs2-0087" title="TagoK , UenoA , TakayasuH . Clinical study of propiverine hydrochloride for the treatment of patients with urinary frequency and incontinence. Neurourology and Urodynamics1990;9(4):337-8. [srincont-5109]">Tago 1990</a>; <a href="./references#CD003781-bbs2-0088" title="TakayasuH , UenoA , TsutidaS , KoisoK , KuritaK , KawabeK , et al. Clinical effects of propiverine hydrochloride in the treatment of urinary frequency and incontinence associated with detrusor overactivity: a double blind, parallel, placebo controlled multicenter study. Igaku No Ayumi (Progress in Medicine)1990;153(8):459-71. [srincont-12896]TakayasuH , UenoA , TsutidaS , KoisoK , KuritaK , KawabeK , et al. Clinical effects of propiverine hydrochloride in the treatment of urinary frequency and incontinence associated with detrusor overactivity: a double blind, parallel, placebo controlled multicenter study. Igaku No Ayumi (Progress in Medicine)1990;153(8):459-71. [sr-incont12896]">Takayasu 1990</a>; <a href="./references#CD003781-bbs2-0097" title="NCT00966004. A study to evaluate safety and efficacy of ym178 in patients with overactive bladder [Phase III study of YM178 - a placebo-controlled, double-blind, group comparison study in patients with overactive bladder]. clinicaltrials.gov/show/NCT00966004 (first received 26 August 2009). [178-CL-048] [JapicCTI-R130370] [NCT00966004] [sr-incont63783]YamaguchiO , HidehiroK , YukioH , YasuhikoI , MasayukiT , OsamuN , et al. A phase III, randomized, double-blind, placebo and active controlled study of once-daily mirabegron 50 mg in patients with overactive bladder (Abstract number POD-03.06). Urology2012;80(3 Suppl 1):S10-1. [NCT00966004] [sr-incont65380]YamaguchiO , MaruiE , KakizakiH , HommaY , IgawaY , TakedaM , et al. A phase III, randomized, double-blind, placebo-controlled study of the beta-adrenoceptor agonist, mirabegron 50 mg once-daily, in Japanese patients with overactive bladder. BJU International2014;113(6):951-60. [NCT00966004] [sr-incont50603]">Yamaguchi 2012</a>). </p> </section> </section> <section id="CD003781-sec-0052"> <h5 class="title">Interventions</h5> <p>All of the included studies were placebo‐controlled. No study made a comparison between an anticholinergic drug and no treatment. The studies compared the following active treatments with placebo (oral and immediate or extended release). </p> <p>Darifenacin was the intervention in nine studies (<a href="./references#CD003781-bbs2-0006" title="BaertL , Leuven, DijkmanG , Breda, the darifenacin study group. Darifenacin, a novel M3 muscarinic receptor antagonist in detrusor overactivity (Abstract  214). In: International Continence Society, 25th Annual Meeting; 1995 Oct 17-20;  Sydney, Australia. 1995:226-7. [sr-incont10890]">Baert 1995</a>; <a href="./references#CD003781-bbs2-0017" title="ChappleC , DuBeauC , EbingerU , RekedaL , ViegasA . Darifenacin treatment of patients &gt;or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Current Medical Research and Opinion2007;23(10):2347-58. [srincont-23921]">Chapple 2007b</a>; <a href="./references#CD003781-bbs2-0035" title="HaabF , StewartL , DwyerP . Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. European Urology2004;45(4):420-9. [srincont-17428]">Haab 2004</a>; <a href="./references#CD003781-bbs2-0042" title="HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21072]HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21072]HillS , KhullarV , WyndaeleJJ , LheritierK , . Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. International Urogynecology Journal and Pelvic Floor2006;17(3):239-47. [srincont-22464]">Hill 2005</a>; <a href="./references#CD003781-bbs2-0064" title="LuisV , LoyolaJP , MelissaC , FelipeM , San MartinC . Efficacy of darifenacin use combined with pelvic floor physiotherapy in overactive bladder syndrome treatment in women (Abstract number 434). International Urogynecology Journal2018;29(Suppl 1):S220-1. [NCT02143570] [sr-incont78617]NCT02143570, CifuentesM , MartinezF . Efficacy of darifenacin and physiotherapy for the treatment of overactive bladder in women. clinicaltrials.gov/show/NCT02143570 (first received 21 May 2014). [NCT02143570] [sr-incont61781]">Luis 2018</a>; <a href="./references#CD003781-bbs2-0071" title="OlshanskyB , FooteJ , ArguinzonizM , LheritierK , Quebe-FehlingE , SteelM . Cardiovascular safety of darifenacin and tolterodine in patients with overactive bladder (OAB) (Abstract number 49). International Urogynecology Journal and Pelvic Floor Dysfunction2006;17(Suppl 2):S86-7. [sr-incont34186]">Olshansky 2006</a>; <a href="./references#CD003781-bbs2-0078" title="RomanziLJ , DelconteA , KralidisG . Impact of darifenacin compared with tolterodine on incontinence episodes in patients with overactive bladder (Abstract number A3522). Obstetrics and Gynecology2005;105(Suppl 4):88S. [sr-incont34187]">Romanzi 2005</a>; <a href="./references#CD003781-bbs2-0084" title="SteersW , CorcosJ . Efficacy, tolerability and safety of darifenacin, an M3 selective receptor antagonist for the treatment of overactive bladder, using a flexible dosing regimen (Abstract number 68). Progres en Urologie2004;14(3 Suppl 3):22. [srincont-22197]">Steers 2004</a>; <a href="./references#CD003781-bbs2-0104" title="ZinnerN , SussetJ , GittelmanM , ArguinzonizM , RekedaL , HaabF . Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. International Journal of Clinical Practice2006;60(1):119-26. [sr-incont21507]">Zinner 2006</a>). </p> <p>Fourteen studies assessed the effects of fesoterodine compared with placebo (<a href="./references#CD003781-bbs2-0013" title="ChappleC . Fesoterodine a new effective and well-tolerated antimuscarinic for the treatment of urgency-frequency syndrome: results of a phase 2 controlled study (Abstract 142). Neurourology and Urodynamics2004;23(5/6):598-9. [srincont-19023]Drug company. A Phase 2, parallel group, randomized, double-blind, placebo controlled dose-ranging trial to determine the optimal dose and the tolerability of sustained release SPM 8272 (fesoterodine) in subjects with non-neurogenic bladder overactivity. Protocol numbers: A0221027 (SP582). ClinicalStudyResults.org (accessed 3 March 2011)2002. [Protocol numbers: A0221027 (SP582)] [srincont-41110]">Chapple 2004a</a>; <a href="./references#CD003781-bbs2-0016" title="ChappleC , Van KerrebroeckP , TubaroA , Haag-MolkentellerC , ForstHT , MassowU , et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder [Erratum appears in: European Urology 2008,53(6):1319]. European Urology2007;52(4):1204-12. [NCT00220363] [SP583] [srincont-23875]ChappleC , Van KerrebroeckP , TubaroA , MillardR . Fesoterodine in non-neurogenic voiding dysfunction - results on efficacy and safety in a phase 3 trial (Abstract number 379). In: 21st Annual European Association of Urology (EAU) Congress; 2006 Apr 5-8; Paris, France. 2006. [srincont-41109]ChappleC , Van KerrebroeckP , TubaroA , WangJT , HvidstenK , BrodskyM . Efficacy of fesoterodine in patients with overactive bladder (OAB): improvements in OAB symptoms and health-related quality of life (HRQL) (Poster abstract number 1188). Journal of Urology2007;177(4 Suppl S):392. [srincont-31882]ChappleCR , vanKerrebroeckPE , JünemannKP , WangJT , BrodskyM . Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU International2008;102(9):1128-32. [srincont-29255]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. KelleherCJ , TubaroA , WangJT , KoppZ . Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU International2008;102(1):56-61. [srincont-27613]SandPK , MorrowJD , BavendamT , CreangaDL , NittiVW . Efficacy and tolerability of fesoterodine in women with overactive bladder. International Urogynecology Journal2009;20(7):827-35. [srincont-31351]">Chapple 2007a</a>; <a href="./references#CD003781-bbs2-0019" title="ChappleC , HaabF , SchneiderT , CarlssonM , ArumiD . Fesoterodine 8 mg versus fesoterodine 4 mg in patients with overactive bladder and a history of previous antimuscarinic therapy: Results from the EIGHT trial (Abstract number: Poster #M5). Neurourology and Urodynamics2015;34(S1):S20. [NCT01302067] [sr-incont68509]ChappleC , SchneiderT , HaabF , SunF , WhelanL , ScholfieldD , et al. Superiority of fesoterodine 8mg versus fesoterodine 4 mg in reducing urgency urinary incontinence episodes in subjects with overactive bladder: results of the randomized, double-blind, placebo-controlled EIGHT trial (Abstract number: Podium #48). Neurourology and Urodynamics2014;33(2):183-4. [NCT01302067] [sr-incont67484]ChappleC , SchneiderT , HaabF , SunF , WhelanL , ScholfieldD , et al. Superiority of fesoterodine 8mg vs 4mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial. BJU International2014;114(3):418-26. [A0221095] [NCT01302067] [TrialID.EIGHT] [srincont-62537]NCT01302067. A 12 week study to confirm the effectiveness of 8mg of Fesoterodine compared to 4mg of Fesoterodine [A 12-week, randomized, double-blind, placebo controlled, parallel group, multicenter trial in overactive bladder subjects to confirm the efficacy of 8 mg fesoterodine compared to 4 mg fesoterodine]. clinicaltrials.gov/show/NCT01302067 (first received 23 February 2011). [NCT01302067] [sr-incont63792]">Chapple 2014</a>; <a href="./references#CD003781-bbs2-0024" title="DmochowskiR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. A double-blind, placebo-controlled trial of flexible-dose fesoterodine for overactive bladder (Abstract number 715). In: International Continence Society (ICS); 39th Annual Meeting; 2009 Sep 29-Oct 03; San Francisco, CA. 2009. [sr-incont35627]DmochowskiRR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder [Errata appear in: Urology 2010 Jun;75(6):1519 and in Urology 2011 Jun;77(6):1513]. Urology2010;75(1):62-8. [A0221014] [NCT00536484] [sr-incont39548]DuBeauC , KrausSR , SunF , MorrowJD . Fesoterodine in older vs younger subjects with overactive bladder (Abstract number D87). Journal of the American Geriatrics Society2010;58:S218. [NCT00536484] [sr-incont64309]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. [sr-incont78640]NCT00536484. Fesoterodine flexible dose study [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with overactive bladder]. clinicaltrials.gov/show/NCT00536484 (first received 27 September 2007). [NCT00536484] [sr-incont49160]StaskinD , KhullarV , MichelMC , MorrowJD , SunF , GuanZ , et al. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. Neurourology and Urodynamics2011;30(8):1480-5. [sr-incont42686]">Dmochowski 2010</a>; <a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>; <a href="./references#CD003781-bbs2-0039" title="CorcosJ , AnguloJC , GarelyAD , CarlssonM , GongJ , GuanZ . Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. Current Medical Research and Opinion2011;27(5):1059-65. [srincont-41596]EUCTR2006-006935-38-SE. 12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006935-38 (first received 16 April 2007). [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont64612]HerschornS , SwiftS , GuanZ , CarlssonM , BrodskyM , GongJ . Efficacy and safety of fesoterodine for overactive bladder in a double-blind, head-to-head comparison trial with tolterodine ER and placebo (Abstract number 710). In: International Continence Society (ICS), 39th Annual Meeting; 2009 Sep 29-Oct 3; San Francisco, CA. 2009. [srincont-35326]HerschornS , SwiftS , GuanZ , CarlssonM , MorrowJD , BrodskyM , et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU International2010;105(1):58-66. [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont39540]NCT00444925. Clinical trial to evaluate the efficacy and safety of Fesoterodine in comparison to Tolterodine for overactive bladder (OAB) [12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder (OAB)]. clinicaltrials.gov/show/NCT00444925 (first received 08 March 2007). [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont49159]">Herschorn 2009a</a>; <a href="./references#CD003781-bbs2-0046" title="HuangA , HessR , AryaL , RichterH , SubakL , BradleyC , et al. A randomized controlled trial of simple diagnosis and treatment for urgency urinary incontinence in women (Abstract). Journal of General Internal Medicine2011;26:S1. [NCT00862745] [sr-incont64391]HuangAJ , HessR , AryaLA , RichterHE , SubakLL , BradleyCS , et al. Pharmacologic treatment for urgency-predominant urinary incontinence in women diagnosed using a simplified algorithm: a randomized trial. American Journal of Obstetrics and Gynecology2012;206(5):444.e1-11. [GA0221IX] [NCT00862745] [TrialID.BRIDGES.] [srincont-44636]NCT00862745, BrownJ . Bringing simple urge incontinence diagnosis &amp; treatment to providers (BRIDGES)  [A multi-center, randomized, placebo-controlled clinical trial comparing fesoterodine to placebo in women diagnosed with urge urinary incontinence by the 3 Incontinence Questions (3IQ). Followed by a multi-center open label clinical cohort study of long-term effects of treatment with fesoterodine ]. clinicaltrials.gov/show/NCT00862745 (first received 17 March 2009). [NCT00862745] [sr-incont49836]WarsiQ , HuangA , BrownJS , SchembriM , HessR , AryaLA , et al. The effect of pharmacologic treatment of urgency urinary incontinence on sleep quality and daytime sleepiness (Abstract number: paper 37). Female Pelvic Medicine and Reconstructive Surgery2016;22(5 ):S17-8. [NCT00862745] [TrialID.BRIDGES.] [sr-incont78633]WarsiQA , HuangAJ , HessR , AryaLA , RichterHE , BradleyCS , et al. Association of pharmacologic treatment of urgency urinary incontinence with sleep quality and daytime sleepiness. Obstetrics and Gynecology2018;131(2):204-11. [NCT00862745] [sr-incont78239]WinkelmanW , HuangA , SchembriM , RogersRG , RichterHE , MyersDL , et al. Clinical variables moderating response to pharmacologic treatment of urgency-predominant urinary incontinence in a randomized controlled trial (Abstract number: poster 25). In: Female Pelvic Medicine and Reconstructive Surgery. 37th Annual Scientific Meeting of the American Urogynecologic Society; Aug 2016; United States. Vol. 22. Netherlands: Lippincott Williams and Wilkins, 2016:S81. [NCT00862745] [sr-incont78634]WinkelmanWD , HuangAJ , SchembriM , RogersRG , RichterH , MyersDL , et al. Modifiers of response to treatment with fesoterodine for urgency-predominant urinary incontinence in a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2017;23(2):151-6. [sr-incont74308]">Huang 2012</a>; <a href="./references#CD003781-bbs2-0051" title="EUCTR2007-006451-39-SE. 12-week, randomized, double-blind, double-dummy, placebo controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-006451-39 (first received 20 February 2008). [A0221046] [EUCTR2007-006451-39-SE] [sr-incont64591]KaplanSA , SchneiderT , FooteJ , GuanZ . Superior efficacy of fesoterodine over tolterodine with rapid onset: a prospective, head-to-head, placebo-controlled trial (Abstract number 67). Neurourology and Urodynamics2010;29(6):905-7. [srincont-40130]KaplanSA , SchneiderT , FooteJE , GuanZ , CarlssonM , GongJ . Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU International2011;107(9):1432-40. [A0221046] [NCT00611026] [srincont-41334]">Kaplan 2011</a>; <a href="./references#CD003781-bbs2-0052" title="CardozoL , KaplanS , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: results from the after study (Abstract number 740) [Erratum appears in: European Urology 2014;65(5):e78]. European Urology Supplements2013;12(1):e740-1. [NCT01302054] [sr-incont63732]CardozoL , KaplanS , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. Erratum: A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: results from the AFTER study [Erratum available in: European Urology Supplement 2013;2012:e740-1]. European Urology2014;65(5):e78 . [A0221094] [NCT01302054] [TrialID.AFTER.] [sr-incont61642]GrenaboL , HerschornS , KaplanSA , CardozoL , ScholfieldD , ArumiD , et al. Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptoms. Current Medical Research and Opinion2017;33(10):1731-6. [NCT01302054] [TrialID.AFTER.] [sr-incont76695]KaplanSA , CardozoL , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER. International Journal of Clinical Practice2014;68(9):1065-73. [A0221094] [NCT01302054] [TrialID.AFTER.] [srincont-63977]KaplanSA , HerschornS , CarlssonM , NtaniosF . Urgency urinary incontinence response rates in subjects with overactive bladder treated with fesoterodine 8 mg after suboptimal response to tolterodine extended release 4 mg: a randomized, double-blind, placebo-controlled trial (Abstract number 546). In: International Continence Society (ICS); 43rd Annual Meeting; 2013 Aug 26-30; Barcelona, Spain. 2013. [NCT01302054] [TrialID.AFTER.] [sr-incont49730]NCT01302054. A clinical study in patients with overactive bladder with leakage of urine, to find out if the medicine, Fesoterodine, works in those patients who did not have enough response to the medicine, tolterodine. [A 14 week randomized parallel group placebo-controlled double-blind multicentre study of fesoterodine 8 mg in overactive bladder patients with sub-optimal response to tolterodine 4 mg extended release (ER)]. clinicaltrials.gov/show/NCT01302054 (first received 23 February 2011). [A0221094] [NCT01302054] [TrialID.AFTER.] [sr-incont49845]">Kaplan 2014</a>; <a href="./references#CD003781-bbs2-0069" title="Drug company. A phase 2, parallel group, stratified, randomized, double blind, placebo-controlled trial to investigate the efficacy and safety of 3 different dosages of sustained release fesoterodine in subjects with overactive bladder showing either involuntary detrusor contractions or normal findings during the baseline urodynamic assessment. Protocol numbers: A0221029 (SP668). ClinicalStudyResults.org (accessed 3 March 2011). [srincont-41111]NittiV , WiatrakM , KreitmanL , LipsitzD . Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB): results of a phase 2 trial (Abstract number 306). In: International Continence Society (ICS); 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21084]">Nitti 2005</a>; <a href="./references#CD003781-bbs2-0070" title="GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NittiVW , DmochowskiR , SandPK , ForstHT , Haag-MolkentellerC , MassowU , et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. Journal of Urology2007;178(6):2488-94. [NCT00138723] [SP584] [srincont-26313]">Nitti 2007</a>; <a href="./references#CD003781-bbs2-0094" title="EUCTR2007-007087-17-SE. A 24-week, multicentre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-007087-17 (first received 13 June 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont64588]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00798434. A study to compare the effectiveness and safety of fesoterodine and placebo in an elderly population of patients who go to the toilet very frequently due to overactive bladder (SOFIA) [A 24-week, multi-centre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00798434 (first received 26 November 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont49847]SchneiderT , BergqvistA , WangJ , WaggA , Ebel-BitounC . Treatment with fesoterodine versus tolterodine for reducing symptom bother in elderly patients with overactive bladder including urgency urinary incontinence. European Urology, Supplements2012;11(1):e687-a. [sr-incont65389]WaggA , CarlssonM , ElsobkyM , FernetM . Effect of flexible dose fesoterodine on cognitive function in &gt;65 year old patients with OAB: data from two RCT (Abstract number 438). Neurourology and Urodynamics2019;38:S297-8. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78651]WaggA , DarekarA , ArumiD , KhullarV , OelkeM . Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people &gt;65 years of age: a post hoc analysis of data from the SOFIA study. Neurourology and Urodynamics2015;34(5):438-43. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont68100]WaggA , ElsobkyM , CarlssonM , FernetM . Response and cognitive safety of fesoterodine in patients &gt;65y old with OAB. Is there a relationship between cognition and treatment response? (Abstract number 183). Neurourology and Urodynamics2019;38:S118-20. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78632]WaggA , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. Journal of the American Geriatrics Society2013;61(2):185-93. [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TrialID.SOFIA.] [sr-incont48008]WaggAS , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Efficacy and tolerability of fesoterodine in older subjects with overactive bladder: results of SOFIA (Abstract number C33). Journal of the American Geriatrics Society2011;59:S124. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont65234]">Wagg 2013a</a>; <a href="./references#CD003781-bbs2-0095" title="GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00911937. A trial to evaluate the efficacy and safety of fesoterodine in patients with symptoms of overactive bladder including nocturnal urinary urgency [A randomized, double blind, placebo controlled, parallel group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with symptoms of overactive bladder including nocturnal urinary urgency]. clinicaltrials.gov/show/NCT00911937 (first received 03 June 2009). [NCT00911937] [sr-incont49848]WeissJ , JumadilovaZ , CarlssonM , FitzGeraldMP , MalhotraA , MartireDL . Effect of antimuscarinic treatment in subjects with overactive bladder, including nocturnal urinary urgency (Abstract number 1963). Journal of Urology2012;187(4 Suppl 1):e792. [NCT00911937] [sr-incont65184]WeissJP , CarlssonMR , ManganEK . Age, gender and nocturnal urgency severity predict response to antimuscarinic treatment (Abstract number 1962). Journal of Urology2013;189(4 Suppl 1):e805. [NCT00911937] [sr-incont65096]WeissJP , JumadilovaZ , JohnsonTM , FitzGeraldMP , CarlssonM , MartireDL , et al. Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency. Journal of Urology2013;189(4):1396-401. [A0221048] [NCT00911937] [sr-incont47568]">Weiss 2013</a>; <a href="./references#CD003781-bbs2-0099" title="YongucT , SefikE , InciI , KusbeciOY , CelikS , AydinME , et al. Randomized, controlled trial of fesoterodine fumarate for overactive bladder in Parkinson's disease. World Journal of Urology2019;38(8):2013-9. [sr-incont78635]">Yonguc 2019</a>). </p> <p>Imidafenacin was the intervention of interest in three studies (<a href="./references#CD003781-bbs2-0044" title="HommaY , YamaguchiT , YamaguchiOA . A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2008;15(9):809-15. [srincont-27742]">Homma 2008</a>; <a href="./references#CD003781-bbs2-0045" title="HommaY , YamaguchiO , Imidafenacin Study Group. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2009;16(5):499-506. [NCT00212732] [ONO-8025-08] [srincont-31368]">Homma 2009</a>; <a href="./references#CD003781-bbs2-0100" title="JapicCTI-152936. Phase III study of KRP-114V [A phase III, randomized, double-blind, parallel group, placebo controlled, multicenter study to assess the efficacy and safety of the beta-3 agonist KRP-114V in Japanese subjects with symptoms of overactive bladder]. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-152936 (first received 17 June 2015). [JapicCTI-152936] [sr-incont78653]YoshidaM , TakedaM , GotoM , NagaiS , KuroseT . Vibegron, a novel potent and selective beta3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study (Abstract number 1082). European Urology, Supplements2018;17(2):e1531-2. [JapicCTI-152936] [sr-incont78069]YoshidaM , TakedaM , GotohM , NagaiS , KuroseT . Vibegron, a novel potent and selective B3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study. European Urology2018;73(5):783-90. [JapicCTI-152936] [sr-incont77898]YoshidaM , TakedaM , GotohM , YokoyamaO , KakizakiH , TakahashiS , et al. Efficacy of novel beta3-adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: a post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study. International Journal of Urology2019;26(3):369-75. [JapicCTI-152936] [sr-incont78654]YoshidaM , TakedaM , GotohM , YokoyamaO , KakizakiH , TakahashiS , et al. Efficacy of vibegron, a novel selective I²3-adrenoreceptor agonist, on urgency urinary incontinence with overactive bladder: post-hoc analysis of phase iii study (Abstract number 180). Neurourology and Urodynamics2019;38(S3):S114-5. [JapicCTI-152936] [sr-incont78636]">Yoshida 2018</a>). </p> <p>Nine studies investigated the effects of oxybutynin compared with placebo (<a href="./references#CD003781-bbs2-0002" title="AbramsP , FreemanR , AnderströmC , MattiassonA . Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. British Journal of Urology1998;81(6):801-10. [srincont-7871]AbramsP , FreemanRN , AnderstromC , MattiassonA . Efficacy and tolerability of tolterodine vs. oxybutynin and placebo in patients with detrusor instability (Abstract). Journal of Urology1997;157(Suppl 4):103. [srincont-16321]">Abrams 1998</a>; <a href="./references#CD003781-bbs2-0008" title="BurgioKL , LocherJL , GoodePS , HardinJM , McDowellBJ , CandibD . Behavior vs drug therapy for urge incontinence in older women (Abstract number 26). In: American Urogynecology Society, 15th Annual Scientific Meeting; 1994 Sept 21-24; Toronto, Ontario. 1994:48. [sr-incont14585]BurgioKL , LocherJL , GoodePS , HardinM , McDowellBJ , Dombrowski M et al. Behavioral vs drug treatment for urge urinary incontinence in older women. A randomized controlled trial. JAMA1998;280(23):1995-2000. [srincont-5719]BurgioKL , LocherJL , GoodePS . Combined behavioral and drug therapy for urge incontinence in older women. Journal of the American Geriatrics Society2000;48(4):370-4. [srincont-9006]BurgioKL , LocherJL , RothDL , GoodePS . Psychological improvements associated with behavioral and drug treatment of urge incontinence in older women. Journal of Gerontology. Series B, Psychological Sciences and Social Sciences2001;56(1):P46-51. [srincont-11923]">Burgio 1998</a>; <a href="./references#CD003781-bbs2-0308" title="ChappleCR , MadersbacherH , DreikornK , DorschnerW , MurtzG . Urodynamics and frequency/volume chart - do they correlate? Treatment analysis of propiverine in comparison to oxybutynin and placebo in urge incontinence (Abstract number 224). In: International Continence Society (ICS), 31st Annual Meeting; 2001 Sep 18-21; Seoul, Korea. 2001. [sr-incont14474]">Chapple 2001</a>; <a href="./references#CD003781-bbs2-0026" title="DrutzH , AppellRA . Clinical efficacy and safety of Tolterodine vs Oxybutynin and placebo in patients with unstable bladder. Acta Obstetrica et Gynecologica Scandinavica1997;Suppl 167(5):24. [srincont-6671]DrutzHP , AppellRA , GleasonD , KlimbergI , RadomskiS . Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. International Urogynecology Journal and Pelvic Floor Dysfunction1999;10(5):283-9. [srincont-8804]DrutzHP , AppellRA . Enhanced tolerability of tolterodine compared to oxybutynin in a controlled clinical study. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(1):S14. [srincont-5166]">Drutz 1999</a>; <a href="./references#CD003781-bbs2-0043" title="HommaY , KawabeK . Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World Journal of Urology2004;22(4):251-6. [srincont-19412]HommaY , PaickJS , LeeJG , KawabeK , Japanese and Korean Tolterodine Study Group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU International2003;92(7):741-7. [srincont-16418]">Homma 2003</a>; <a href="./references#CD003781-bbs2-0061" title="LacknerTE , WymanJF , McCarthyTC , MonigoldM , DaveyC . Efficacy of oral extended-release oxybutynin in cognitively impaired older nursing home residents with urge urinary incontinence: a randomized placebo-controlled trial. Journal of the American Medical Directors Association2011;12(9):639-47. [sr-incont42677]LacknerTE , WymanJF , McCarthyTC , MonigoldM , DaveyC . Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. Journal of the American Geriatrics Society2008;56(5):862-70. [sr-incont27117]">Lackner 2011</a>; <a href="./references#CD003781-bbs2-0112" title="AssassaP , WilliamsK , LambertP , AbramsK , TurnerD , ShawC , et al. A double blind randomised placebo controlled trial of the effectiveness of bladder training with oxybutynin or imipramine in the management of detrusor overactivity (DO) (Abstract number 330). In: Joint Meeting of the International Continence Society (ICS) and the International Urogynecological Association; 2010 Aug 23-27; Toronto, Canada. 2010. [ISRCTN58226681] [sr-incont40171]ISRCTN58226681, McGrotherC . Evaluation of the efficacy of oxybutynin and imipramine in the management of detrusor instability. isrctn.org/ISRCTN58226681 (first received 25 October 2000). [DOI: https://doi.org/10.1186/ISRCTN58226681] [ISRCTN58226681] [sr-incont64656]">Assassa 2010</a>; <a href="./references#CD003781-bbs2-0075" title="ISRCTN17856439, ResnickN . Pathophysiology of urge incontinence in older women. isrctn.org/ISRCTN17856439 (first received 09 March 2006). [1999P-001891] [94-6641-01] [ISRCTN17856439] [sr-incont64614]">Resnick 2006</a>; <a href="./references#CD003781-bbs2-0089" title="ThuroffJW , BunkeB , EbnerA , FaberP , deGeeterP , HannappelJ , et al. Randomized, double-blind multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin vs. propantheline vs. placebo. Neurourology and Urodynamics1990;9(4):337-8. [srincont-5108]ThuroffJW , BunkeB , EbnerA , FaberP , deGeeterP , HannappelJ , et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. Journal of Urology1991;145(4):813-7. [srincont-1288]">Thuroff 1991</a>). </p> <p>Propiverine was studied in 12 studies (<a href="./references#CD003781-bbs2-0308" title="ChappleCR , MadersbacherH , DreikornK , DorschnerW , MurtzG . Urodynamics and frequency/volume chart - do they correlate? Treatment analysis of propiverine in comparison to oxybutynin and placebo in urge incontinence (Abstract number 224). In: International Continence Society (ICS), 31st Annual Meeting; 2001 Sep 18-21; Seoul, Korea. 2001. [sr-incont14474]">Chapple 2001</a>; <a href="./references#CD003781-bbs2-0025" title="ChappleCR , MadersbacherH , DreikornK , DorschnerW , MurtzG . Urodynamics and frequency/volume chart - do they correlate? Treatment analysis of propiverine in comparison to oxybutynin and placebo in urge incontinence (Abstract number 224). In: International Continence Society (ICS), 31st Annual Meeting; 2001 Sep 18-21; Seoul, Korea. 2001. [sr-incont14474]DorschnerW , StolzenburgJU , GriebenowR , HalaskaM , BrünjesR , FrankM , et al. The elderly patient with urge incontinence or urge-stress incontinence - efficacy and cardiac safety of propiverine [Der ältere Patient mit Drang-Symptomatik bzw. kombinierter Drang/Stress-Inkontinenz-Wirksamkeit und kardiale Sicherheit von Propiverin]. Aktuelle Urologie2003;34(2):102-8. [sr-incont16422]DorschnerW , StolzenburgJU , GriebenowR , HalaskaM , SchubertG , Mürtz G et al. Efficacy and cardiac safety of propiverine in elderly patients - a double-blind, placebo-controlled clinical study. European Urology2000;37(6):702-8. [srincont-11660]">Dorschner 2000</a>; <a href="./references#CD003781-bbs2-0033" title="GotohM , HommaY , YokoyamaO , NishizawaO . Responsiveness and minimal clinically important change in overactive bladder symptom score. Urology2011;78(4):768-73. [srincont-42622]GotohM , YokoyamaO , MatsukawaY , NishizawaO . Responsiveness of overactive bladder symptom score (OABSS): verification based on data in a double-blinded, randomized placebo-controlled study of propiverine hydrochloride in Japanese patients (Abstract number 338). In: Joint Meeting of the International Continence Society (ICS) and the International Urogynecological Association; 2010 Aug 23-27; Toronto, Canada. 2010. [srincont-40173]GotohM , YokoyamaO , NishizawaO . Propiverine hydrochloride in Japanese patients with overactive bladder: A randomized, double-blind, placebo-controlled trial. International Journal of Urology2011;18(5):365-73. [srincont-41510]">Gotoh 2011</a>; <a href="./references#CD003781-bbs2-0034" title="GriebenowR , WienersF , LangeT . Possible induction of cardiac dysrhythmia in elderly patients under therapy with propiverine hydrochloride (Abstract). Neurourology and Urodynamics1994;13:430-2. [sr-incont2681]">Griebenow 1994</a>; <a href="./references#CD003781-bbs2-0037" title="HalaskaM , DorschnerW , FrankM . Treatment of urgency and incontinence in elderly patients with propiverine hydrochloride. Neurourology and Urodynamics1994;13(4):428-30. [srincont-2680]">Halaska 1994</a>; <a href="./references#CD003781-bbs2-0050" title="JünemannKP , HessdörferE , Unamba‐OparahI , BerseM , BrünjesR , MadersbacherH . Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. Urologia Internationalis2006;77(4):334-9. [srincont-22199]">Junemann 2006</a>; <a href="./references#CD003781-bbs2-0063" title="LeeKS , ChooMS , KimDY , KimJC , KimHJ , MinKS , et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. Journal of Urology2005;174(4 Pt 1):1334-8. [sr-incont21016]LeeKS , ChooMS , PaickJS , LeeJG , SeoJT , LeeJZ , et al. Propiverine hydrochloride reduced frequency and perception of urgency in treatment of overactive bladder: a 12 week prospective, randomized, double blind, placebo controlled study (Abstract number 279). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26640]LeeKS , LeeHW , ChooMS , PaickJS , LeeJG , SeoJT , et al. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'. BJU International2010;105(11):1565-70. [2005-01-08] [NCT00903045] [PROUD] [sr-incont39958]NCT00903045. Urinary urgency outcomes following propiverine treatment for an overactive bladder [Urinary urgency outcomes following propiverine treatment for an overactive bladder: propiverine study on overactive bladder including urgency data (PROUD)]. clinicaltrials.gov/show/NCT009030452005;(first received 15 May 2009). [2005-01-08] [NCT00903045] [TrialID.PROUD] [sr-incont49860]">Lee 2006</a>; <a href="./references#CD003781-bbs2-0065" title="ChappleCR , MadersbacherH , DreikornK , DorschnerW , MurtzG . Urodynamics and frequency/volume chart - do they correlate? Treatment analysis of propiverine in comparison to oxybutynin and placebo in urge incontinence (Abstract 224). In: International Continence Society (ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001. [sr-incont14474]HalaskaM , MadersbacherH , VoigtR , HofnerK , MartanA . Propiverine in patients with urgency and urge incontinence - a placebo controlled, multicentre study comparing its tolerability and efficacy with oxybutynin (Abstract number FDP36). International Urogynaecology Journal 2000;11(Suppl 1):S46. [srincont-11912]MadersbacherH , HalaskaM , VoigtR , AlloussiS , HofnerK . A urodynamically controlled multicenter study in patients with urge incontinence: tolerability and efficacy of propiverine hydrochloride in comparison to oxybutynin. In: International Continence Society (ICS), 27th Annual Meeting; 1997 Sep 23-26; Yokohama, Japan. 1997:153-4. [srincont-5854]MadersbacherH , HalaskaM , VoigtR , AlloussiS , HöfnerK . A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU International1999;84(6):646-51. [srincont-9166]">Madersbacher 1999</a>; <a href="./references#CD003781-bbs2-0086" title="StohrerM , MadersbacherH , RichterR , WehnertJ , DreikornK . Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia - a double-blind, placebo-controlled clinical trial. Spinal Cord1999;37(3):196-200. [sr-incont8146]">Stohrer 1999</a>; <a href="./references#CD003781-bbs2-0087" title="TagoK , UenoA , TakayasuH . Clinical study of propiverine hydrochloride for the treatment of patients with urinary frequency and incontinence. Neurourology and Urodynamics1990;9(4):337-8. [srincont-5109]">Tago 1990</a>; <a href="./references#CD003781-bbs2-0096" title="YamaguchiO , MaruiE , KakizakiH , ItohN , YokotaT , OkadaH , et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU International2007;100(3):579-87. [sr-incont23865]YokoyamaO , YamaguchiO , KakizakiH , ItohN , YokotaT , OkadaH , et al. Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary. Journal of Urology2011;186(1):170-4. [sr-incont41734]">Yamaguchi 2007</a>; <a href="./references#CD003781-bbs2-0098" title="YamaguchiO , UchidaE , HigoN , MinamiH , KobayashiS , SatoH , et al. Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: a randomized double-blind trial. International Journal of Urology2014;21(6):586-93. [JapicCTI-101309] [sr-incont62099]">Yamaguchi 2014</a>). </p> <p>Solifenacin was the intervention of interest in 19 studies (<a href="./references#CD003781-bbs2-0004" title="AbramsP , KelleherC , StaskinD , KayR , MartanA , MincikI , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World Journal of Urology2017;35(5):827-38. [NCT01340027] [sr-incont77897]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Cardiovascular safety of combination treatment with mirabegron and solifenacin in patients with overactive bladder in a randomised, double-blind, dose-ranging, Phase II study (Symphony) (Abstract). European Urology, Supplements2014;13(1):e574-e574a. [NCT01340027] [sr-incont67160]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB) - efficacy and safety results from a randomised phase II study (Symphony) (Abstract number 295). Neurourology and Urodynamics2013;32(6):930-1. [NCT01340027] [TrialID.SYMPHONY.] [sr-incont49188]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB): safety results from a phase 2 study (Abstract number MP-16.08). Urology2013;82(3 Suppl 1):S139. [NCT01340027] [sr-incont66675]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: Exploratory responder analyses of efficacy and evaluation of patient reported outcomes from a randomised, double-blind, dose-ranging, phase 2 study (Symphony) (Abstract number MP-24.11). Urology2014;84(4 Suppl 1):S145-6. [NCT01340027] [sr-incont67194]AbramsP , KelleherC , StaskinD , RechbergerT , KayR , MartinaR , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (SYMPHONY). European Urology2015;67(3):577-88. [NCT01340027] [sr-incont66674]NCT01340027, Bristol Urological Institute . A study to evaluate the efficacy, safety and tolerability of mirabegron and solifenacin succinate alone and in combination for the treatment of overactive bladder (symphony) [A randomized, double-blind, factorial, parallel-group, active and placebo-controlled, multicenter dose-ranging study to evaluate the efficacy, safety and tolerability of six dose combinations of solifenacin succinate and mirabegron compared to mirabegron and solifenacin succinate monotherapies in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01340027 (first received 21 April 2011). [178-CL-100] [2010-020601-32] [NCT01340027] [TrialID.SYMPHONY] [sr-incont44510]NittiV , AbramsP , StaskinD , AuerbachS , MartinaR , VanMR . Urinary retention in patients with overactive bladder treated with mirabegron alone and in combination with solifenacin: the results of two randomized, double-blind, phase II studies (Abstract number MP76-13). Journal of Urology2014;191(4 Suppl 1):e886-7. [NCT00410514] [NCT01340027] [TrialID.SYMPHONY] [sr-incont67453]">Abrams 2013</a>; <a href="./references#CD003781-bbs2-0010" title="CardozoL , KuzminI , LisecML , MillardR , vanVierssen TripOB , RidderAM , et al. YM905: Results of a randomised, double-blind placebo-controlled trial in patients with symptomatic overactive bladder (Abstract number 104). European Urology Supplements2003;2(1):28. [sr-incont27407]CardozoL , KuzminI , LisecML , MillardRJ , vanVierssen TripOB , RidderAM , et al. A double-blind, randomised, placebo-controlled trial with YM905 in symptomatic overactive bladder (Abstract number P74). Journal of the American Geriatrics Society2003;51 (Suppl 4):S68-9. [sr-incont31100]CardozoL , LisecM , MillardR , vanVierssen TripO , KuzminI , DrogendijkTE , et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. Journal of Urology2004;172(5 (Pt 1 of 2)):1919-24. [srincont-19090]CardozoL . A randomised double-blind, placebo-controlled trial of the once-daily muscarinic receptor antagonist solifenacin succinate for symptoms of overactive bladder (Abstract number 211). International Urogynecology Journal2003;14 (Suppl 1):S64. [sr-incont31104]CardozoL . Solifenacin succinate improves symptoms of an overactive bladder (Abstract number TP77). International Journal of Gynecology and Obstetrics2003;83(Suppl 3):94. [sr-incont31096]KelleherCJ , CardozoL , ChappleCR , HaabF , RidderAM . Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU International2005;95(1):81-5. [srincont-20241]">Cardozo 2004a</a>; <a href="./references#CD003781-bbs2-0011" title="CardozoL , AdamikZ , GuimaraesM , KrhutJ , Labat J-J, PetrovS , et al. Patients with overactive bladder show progressive improvement in urgency and bladder condition during treatment with solifenacin in a randomised, double-blind, placebo-controlled study (SUNRISE) (Abstract number 115). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S67-8. [srincont-26595]CardozoL , AmarencoG , PushkarD , MikulasJ , DrogendijkT , WrightM , et al. Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE). BJU International2013;111(5):804-10. [NCT00801944] [TrialID.SUNRISE.] [sr-incont47554]CardozoL , DewildeT , FeyereislJ , WadieB , AmarencoG , LiapisA , et al. Solifenacin significantly reduces both urgency severity and bother: results from the flexible dose, placebo controlled, multinational SUNRISE study (Abstract number 281). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26641]CardozoL , DrogendijkT , BolodeokuJ . The efficacy of solifenacin 5/10 mg on 'urgency' endpoints in different OAB patient populations: subanalysis of results from the randomised, double-blind SUNRISE study (Abstract number 192). In: International Continence Society (ICS); 38th Annual Meeting; 2008 Oct 20-24; Cairo, Egypt. 2008. [srincont-31885]CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CardozoL , HessdörferE , MilaniR , ArañóP , DewildeL , SlackM , et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU International2008;102(9):1120-7. [NCT00801944] [TrialID.SUNRISE] [srincont-29249]">Cardozo 2008a</a>; <a href="./references#CD003781-bbs2-0014" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. ChappleCR , AranoP , BoschJH , De RidderD , KramerG , RidderAM . YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo- and tolterodine-controlled, phase-II, dose-finding study (Abstract 75). Neurourology and Urodynamics2002;21(4):381-2. [srincont-14551]ChappleCR , ArañoP , BoschJL , De RidderD , KramerAE , RidderAM . Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU International2004;93(1):71-7. [srincont-17334]KelleherCJ , CardozoL , ChappleCR , HaabF , RidderAM . Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU International2005;95(1):81-5. [srincont-20241]SmithN , GrimesI , RidgeS , TempelD , UchidaT , YamanouchiUS . YM905 is effective and safe as treatment of overactive bladder in women and men: results from phase II study (Abstract). In: International Continence Society (ICS), 32nd Annual Meeting; 2002 Aug 28-30; Heidelberg, Germany. 2002:138-9. [sr-incont14508]">Chapple 2004b</a>; <a href="./references#CD003781-bbs2-0015" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. ChappleC , RechbergerT , Al-ShukriS , MeffanP , EveraertK , RidderA . Results of a randomized phase 3 study comparing solifenacin succinate with tolterodine and placebo in patients with symptomatic overactive bladder (Abstract). Neurourology and Urodynamics2003;22(5):534-5. [sr-incont16991]ChappleCR , RechbergerT , Al ShukriS , MeffanP , EveraertK , HuangM , et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU International2004;93(3):303-10. [srincont-17270]">Chapple 2004c</a>; <a href="./references#CD003781-bbs2-0020" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. [sr-incont75259]ChuF , SmithN , UchidaT . Efficacy and safety of solifenacin succinate 10 mg once daily: a multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder. Current Therapeutic Research - Clinical and Experimental2009;70(6):405-20. [srincont-43324]">Chu 2009</a>; <a href="./references#CD003781-bbs2-0021" title="ChuaME , SeeMC , EsmeňaEB , BalingitJC , MoralesML . Efficacy and safety of gabapentin in comparison to solifenacin succinate in adult overactive bladder treatment. Lower Urinary Tract Symptoms2018;10(2):135-42. [NCT01486706] [sr-incont74529]NCT01486706, ChuaME . Efficacy and safety of gabapentin in treating overactive bladder (OAB). clinicaltrials.gov/show/NCT01486706 (first received 6 December 2011). [NCT01486706] [SLMC10-010] [sr-incont49864]">Chua 2018</a>; <a href="./references#CD003781-bbs2-0022" title="AmarencoG , SutoryM , FagertunH , WrightM , CompionG , De RidderD . Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Preliminary results from the SONIC urodynamic study (Abstract). European Urology, Supplements2012;11(1):e467-a. [EudraCT2006-005523-42] [NCT00629642] [sr-incont65392]AmarencoG , SutoryM , ZachovalR , AgarwalM , DelPG , TretterR , et al. Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study. Neurourology and Urodynamics2017;36(2):414-21. [EudraCT2006-005523-42] [JapicCTI-R130306] [NCT00629642] [sr-incont72248]De RidderD , AmarencoG , Finazzi-AgroE , AnguloJ , KurenkovA , WrightM , et al. Solifenacin treatment for neurogenic detrusor overactivity: patient-reported outcomes (PROs) from the randomised clinical trial SONIC (Abstract number 333). In: International Continence (ICS); 42nd Annual Meeting; 2012 Oct 15-19; Beijing, China. 2012. [905-EC-005] [EudraCT2006-005523-42] [NCT00629642] [TrialID.SONIC.] [srincont-49739]">De Ridder 2012</a>; <a href="./references#CD003781-bbs2-0028" title="ElbasetM , TahaD , ZahranM , EzzatO , ElhefnawyAS , ElkenawyM , et al. Subjective and objective scales assessment after retreatment with anticholinergics post botox-faded effects in refractory idiopathic overactive bladder: a prospective single blinded randomized trial (Abstract number 132). European Urology, supplements2019;18(1):e172. [sr-incont78652]ElbasetMA , TahaDE , El-HefnawyAS , ZahranMH , ShokeirAA . Assessment of anticholinergic use after fading of BTX-A effects in refractory idiopathic overactive bladder: a prospective blinded randomized trial. International Neurourology Journal2019;23(3):240-8. [sr-incont78605]">Elbaset 2019</a>; <a href="./references#CD003781-bbs2-0322" title="IRCT2015010720598N1. The effect of solifenacin succinate on intraocular pressure [Ocular effects of solifenacin succinate in women with narrow angle glaucoma and overactive bladder syndrome]. en.irct.ir/trial/18253 (first received 22 June 2015). [IRCT2015010720598N1] [sr-incont78608] [tbzmed.rec.1394.127]">Hajebrahimi 2015</a>; <a href="./references#CD003781-bbs2-0040" title="EUCTR2012-005735-91-SK. A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-005735-91 (first received 12 November 2013). [178-CL-101] [EUCTR2012-005735-91-SK] [sr-incont78644]HerschornS , ChappleCR , AbramsP , ArlandisS , MitchesonD , LeeKS , et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU International2017;120(4):562-75. [NCT01972841] [sr-incont74470]MuellerER , RobinsonD , KelleherC , StaskinDR , FalconerC , WangJ , et al. Patient reported outcomes from synergy, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with mirabegron and solifenacin monotherapy (Abstract number - Podium #44). Neurourology and Urodynamics2017;36(Suppl S1):S151-2. [NCT01972841] [sr-incont75944]NCT01972841. This was a multinational study comparing the efficacy and safety of two medicines, solifenacin succinate and mirabegron taken together, or separately, or a mock treatment (placebo) in subjects with symptoms of overactive bladder (SYNERGY) [A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01972841 (first received 31 October 2013). [178-CL-101] [EUCTR2012-005735-91] [NCT01972841] [sr-incont63780]RobinsonD , KelleherC , StaskinD , MuellerER , FalconerC , WangJ , et al. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients. Neurourology and Urodynamics2018;37(1):394-406. [NCT01972841] [sr-incont76906]WeberMA , ChappleCR , GratzkeC , HerschornS , RobinsonD , FrankelJM , et al. A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial. Blood Pressure Monitoring2018;23(3):153-63. [NCT01972841] [sr-incont77899]WhiteWB , ChappleC , GratzkeC , HerschornS , RobinsonD , FrankelJ , et al. Cardiovascular safety of the beta3-adrenoceptor agonist mirabegron and the antimuscarinic agent solifenacin in the SYNERGY trial. Journal of Clinical Pharmacology2018;58(8):1084-91. [NCT01972841] [sr-incont78078]">Herschorn 2017a</a>; <a href="./references#CD003781-bbs2-0041" title="HerschornS , KohanA , AliottaP , McCammonK , SriramR , AbramsS , et al. The efficacy and safety of onabotulinumtoxin A or solifenacin compared with placebo in solifenacin naive patients with refractory overactive bladder: results from a multicenter, randomized, double-blind phase 3b trial. Journal of Urology2017;198(1):167-75. [NCT01767519] [sr-incont74491]NCT01767519. A study evaluating the efficacy and safety of BOTOX® or solifenacin in patients with overactive bladder and urinary incontinence. clinicaltrials.gov/show/NCT01767519 (first received 14 January 2013). [191622-125] [NCT01767519] [sr-incont49909]">Herschorn 2017b</a>; <a href="./references#CD003781-bbs2-0053" title="CapoJP , TogliaM , Forero-SchwanhaeuserS , HeW . Patients reporting severe overactive bladder symptoms: effects of solifenacin treatment on objective measures and patient-reported outcomes (Abstract number 582). In: International Continence Society (ICS), 38th Annual Meeting; 2008 Oct 20-24; Cairo, Egypt. 2008. [srincont-31844]CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. KarramMM , TogliaMR , SerelsSR , AndohM , FakhouryA , Forero-SchwanhaeuserS . Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology2009;73(1):14-8. [A0221094] [NCT00454896] [TrialID.VENUS.] [srincont-29219]SerelsSR , TogliaMR , Forero-SchwanhaeuserS , HeW . Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms. Current Medical Research and Opinion2010;26(10):2277-85. [srincont-40376]StaskinD , DmochowskiR , SerelsS , AndohM , SmithN . Report from a randomized, placebo-controlled study showing significant improvement in urgency and patient-reported outcomes in overactive bladder patients treated with solifenacin (Abstract number 124). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73-4. [srincont-26600]TogliaM , AndohM , HussainI . Solifenacin improved warning time significantly compared to placebo in patients with overactive bladder (Abstract number 123). Neurourology and Urodynamics2006;25(6):655. [srincont-26629]TogliaM , AndohM , HussainI . Solifenacin improves urgency symtoms as assessed by voiding diaries and patient-reported outcomes (PRO) in patients with overactive bladder (Abstract number 155). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26636]TogliaMR , OstergardDR , AppellRA , AndohM , FakhouryA , HussainIF . Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status. International Urogynecology Journal2010;21(7):847-54. [srincont-40094]TogliaMR , SerelsSR , LarameeC , KarramMM , NandyIM , AndohM , et al. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial. Postgraduate Medicine2009;121(5):151-8. [srincont-34204]ZinnerS , HerschornS , AndohM , HussainI . Responder analyses show statistically significant improvements in incontinence and urgency are associated with reduction in symptom bother and improvement in health-related quality of life: VENUS results (Abstract number 123). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73. [srincont-26599]">Karram 2009</a>; <a href="./references#CD003781-bbs2-0057" title="KosilovK , LoparevS , IvanovskayaM , KosilovaL . A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron. Archives of Gerontology and Geriatrics2015;61(2):212-6. [sr-incont68133]">Kosilov 2015a</a>; <a href="./references#CD003781-bbs2-0072" title="OreskovićS , ButI , BanovićM , GoldstajnMS . The efficacy and safety of solifenacin in patients with overactive bladder syndrome. Collegium Antropologicum2012;36(1):243-8. [srincont-45056]">Oreskovic 2012</a>; <a href="./references#CD003781-bbs2-0076" title="EUCTR2008-005215-17. A study to evaluate the overall effect of solifenacin 5mg and 10mg on bladder wall thickness and urinary nerve growth factor in female subjects with overactive bladder and a diagnosis of detrusor overactivity – a double-blind, randomized, placebo-controlled, parallel group, multicentre study - SHRINK. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-005215-17 (first received 14 September 2009). [EUCTR2008-005215-17] [NCT01093534] [sr-incont78650]NCT01093534. Study of 2 doses of solifenacin succinate in female subjects with overactive bladder (SHRINK) [A study to evaluate the overall effect of solifenacin 5mg and 10mg on bladder wall thickness and urinary nerve growth factor in female subjects with overactive bladder and a diagnosis of detrusor overactivity - a double-blind, randomised, placebo-controlled, parallel group, multi-centre study]. clinicaltrials.gov/show/NCT01093534 (first received 26 March 2010). [905-EC-007] [EUCTR2008-005215-17] [NCT01093534] [TrialID.SHRINK] [sr-incont63778]RobinsonD , KhullarV , OelkeM , WijkstraH , TretterR , StowB , et al. Effects of 12 weeks treatment with solifenacin on Bladder Wall Thickness (BWT) and clinical outcomes: results from the placebo-controlled SHRINK study (Abstract number 422). In: International Continence Society (ICS), 43rd Annual Meeting; 2013 Aug 26-30; Barcelona, Spain. 2013. [905-EC-007] [NCT01093534] [TrialID.SHRINK.] [srincont-49731]RobinsonD , OelkeM , KhullarV , WijkstraH , TretterR , StowB , et al. Bladder wall thickness in women with symptoms of overactive bladder and detrusor overactivity: results from the randomised, placebo-controlled SHRINK study. Neurourology and Urodynamics2016;35(7):819-25. [NCT01093534] [sr-incont72217]RobinsonD , OelkeM , TretterR , StowB , CompionG , TubaroA . The effect of solifenacin on bladder wall thickness in women with overactive bladder and detrusor overactivity: Results from the SHRINK study (Abstract number 782). European Urology Supplements2013;12(1):e782-3. [EUCTR2008-005215-17] [NCT01093534] [sr-incont67207]RobinsonD , TubaroA , KimbergM , PlummerM , DeVineJ , BouicP , et al. The effect of solifenacin on urinary nerve growth factor (UNGF) and brain-derived neurotropic factor (BDNF) in women with overactive bladder and detrusor overactivity: results from the SHRINK study (Abstract number PP 54). International Urogynecology Journal and Pelvic Floor Dysfunction2014;25(1 Suppl 1):S60-1. [EUCTR2008-005215-17] [NCT01093534] [sr-incont67200]TubaroA , KhullarV , OelkeM , WijkstraH , TretterR , StowB , et al. Intra- and inter-reader variability of transvaginal ultrasound bladder wall thickness measurements: results from the SHRINK study (Abstract number 136). Neurourology and Urodynamics2013;32(6):711-2. [EUCTR2008-005215-17] [NCT01093534] [sr-incont49211]">Robinson 2013</a>; <a href="./references#CD003781-bbs2-0093" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CrosbyRD , MathiasSD , MarshallTS . Relationships between symptoms, symptom bother, and health-related quality of life in patients with overactive bladder taking solifenacin or placebo in the VIBRANT study. International Journal of Clinical Practice2011;65(2):211-8. [sr-incont41015]GollarKM , YoungDG , BailenJ , HeW , Forero-SchwanhaeuserS . Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: a secondary analysis of the VIBRANT study. Urologic Nursing2012;32(1):38-46. [TrialID.VIBRANT.] [sr-incont44571]Samuels T‐A, MitchesonHD , VardyM , Forero‐SchwanhaeuserS , MarshallT , HeW . Efficacy of solifenacin for symptom bother and other patient-reported outcomes in patients with overactive bladder (OAB): results of a large, double-blind, placebo-controlled trial (Abstract number: poster #74). Neurourology and Urodynamics2009;28(2):149. [sr-incont31063]VardyMD , MitchesonHD , SamuelsTA , Forero-SchwanhaeuserS , HeW . Efficacy of solifenacin on overactive bladder symptoms, symptom bother, and other patient-reported outcomes in subjects with or without incontinence: a post hoc analysis of data from VIBRANT. Female Pelvic Medicine and Reconstructive Surgery2011;17(1):24-9. [TrialID.VIBRANT.] [sr-incont44741]VardyMD , MitchesonHD , SamuelsTA , WegenkeJD , Forero-SchwanhaeuserS , MarshallTS , et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. International Journal of Clinical Practice2009;63(12):1702-14. [905-UC-010] [NCT00573508] [TrialID.VIBRANT.] [sr-incont35459]">Vardy 2009</a>; <a href="./references#CD003781-bbs2-0096" title="YamaguchiO , MaruiE , KakizakiH , ItohN , YokotaT , OkadaH , et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU International2007;100(3):579-87. [sr-incont23865]YokoyamaO , YamaguchiO , KakizakiH , ItohN , YokotaT , OkadaH , et al. Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary. Journal of Urology2011;186(1):170-4. [sr-incont41734]">Yamaguchi 2007</a>; <a href="./references#CD003781-bbs2-0101" title="NCT01018264, ZesiewiczT . Solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease (URGE-PD) [URGE-PD: a multi-site, double-blind, randomized, placebo controlled trial of solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease]. clinicaltrials.gov/show/NCT01018264 (first received 23 November 2009). [NCT01018264] [sr-incont63790]ZesiewiczTA , EvattM , JahanI , VaughanC , SingerC , OrdoricaR , et al. URGE-PD: a multi-site, double-blind, randomized, placebo controlled trial of solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease (Abstract number 745). Movement Disorders2014;29(Suppl 1):S276-7. [NCT01018264] [sr-incont66602]ZesiewiczTA , EvattM , VaughanCP , JahanI , SingerC , OrdoricaR , et al. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease. Parkinsonism and Related Disorders2015;21(5):514-20. [NCT01018264] [sr-incont66860]">Zesiewicz 2015</a>). </p> <p>Tolterodine was by far the most studied anticholinergic drug in the included studies, with 38 studies including this as the intervention (<a href="./references#CD003781-bbs2-0001" title="AbramsP , JacksonS , MattiassonA , KrishnanK , HaendlerL . A randomised, double-blind, placebo controlled, dose ranging study of the safety and efficacy of tolterodine in patients with hyperreflexia (Abstract). In: International Continence Society 26th Annual Meeting; 1996 Aug 27-30; Athens, Greece. 1996:276-7. [sr-incont5135]">Abrams 1996</a>; <a href="./references#CD003781-bbs2-0002" title="AbramsP , FreemanR , AnderströmC , MattiassonA . Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. British Journal of Urology1998;81(6):801-10. [srincont-7871]AbramsP , FreemanRN , AnderstromC , MattiassonA . Efficacy and tolerability of tolterodine vs. oxybutynin and placebo in patients with detrusor instability (Abstract). Journal of Urology1997;157(Suppl 4):103. [srincont-16321]">Abrams 1998</a>; <a href="./references#CD003781-bbs2-0003" title="AbramsP , KaplanS , MillardR . Tolterodine treatment is safe in men with bladder outlet obstruction (BOO) and symptomatic detrusor overactivity (DO) (Abstract). Neurourology and Urodynamics2001;20(4):547-8. [srincont-14372]">Abrams 2001</a>; <a href="./references#CD003781-bbs2-0007" title="BrayR , CartwrightR , CardozoL , HillS , GuanZ , KhullarV . Tolterodine ER reduced increased bladder wall thickness in women with overactive bladder. A randomized, placebo-controlled, double-blind, parallel group study. Neurourology and  Urodynamics2018;37(1):237-43. [NCT00137397] [sr-incont74473]NCT00137397. A study to measure the effect of tolterodine extended release on the thickness of the bladder wall in patients with overactive bladder [A multi-centre, randomised, placebo controlled, double blind, parallel group study in female patients to evaluate whether tolterodine ER can reverse the increased bladder wall thickness in patients with overactive bladder]. clinicaltrials.gov/show/NCT00137397 (first received 29 August 2005). [NCT00137397] [sr-incont63809]">Bray 2018</a>; <a href="./references#CD003781-bbs2-0009" title="CardozoL , ChappleCR , Toozs-HobsonP , Grosse-FreeseM , BulittaM , LehmacherW , et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomised, double-blind, multicentre clinical trial. British Journal of Urology International2000;85(6):659-64. [srincont-11732]">Cardozo 2000</a>; <a href="./references#CD003781-bbs2-0015" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. ChappleC , RechbergerT , Al-ShukriS , MeffanP , EveraertK , RidderA . Results of a randomized phase 3 study comparing solifenacin succinate with tolterodine and placebo in patients with symptomatic overactive bladder (Abstract). Neurourology and Urodynamics2003;22(5):534-5. [sr-incont16991]ChappleCR , RechbergerT , Al ShukriS , MeffanP , EveraertK , HuangM , et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU International2004;93(3):303-10. [srincont-17270]">Chapple 2004c</a>; <a href="./references#CD003781-bbs2-0018" title="ChappleCR , DvorakV , RadziszewskiP , vanKerrebroeckP , WyndaeleJJ , BosmanB , et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder. International Urogynecology Journal2013;24(9):1447-58. [178-CL-044] [NCT00337090] [TrialID.DRAGON.] [sr-incont48549]NCT00337090 . A study of YM178 in patients with symptomatic overactive bladder (DRAGON) [A randomized, double-blind, parallel group, placebo and active controlled, multicenter dose ranging study with the beta-3 agonist YM178 in patients with symptomatic overactive bladder]. clinicaltrials.gov/show/NCT00337090 (first received 15 June 2006). [EudraCT2005-002256-17] [JapicCTI-R130350] [NCT00337090] [sr-incont63803]">Chapple 2013</a>; <a href="./references#CD003781-bbs2-0026" title="DrutzH , AppellRA . Clinical efficacy and safety of Tolterodine vs Oxybutynin and placebo in patients with unstable bladder. Acta Obstetrica et Gynecologica Scandinavica1997;Suppl 167(5):24. [srincont-6671]DrutzHP , AppellRA , GleasonD , KlimbergI , RadomskiS . Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. International Urogynecology Journal and Pelvic Floor Dysfunction1999;10(5):283-9. [srincont-8804]DrutzHP , AppellRA . Enhanced tolerability of tolterodine compared to oxybutynin in a controlled clinical study. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(1):S14. [srincont-5166]">Drutz 1999</a>; <a href="./references#CD003781-bbs2-0029" title="EUCTR2004-001116-31-ES. Multicentre, randomised, double-blind, parallel group confirmatory Phase III study to compare the efficacy and safety of cizolirtine citrate 300 mg bid (600 mg/d), cizolirtine citrate 400 mg bid (800 mg/d), placebo, and tolterodine 2 mg bid (4 mg/d) in the treatment of urge urinary incontinence. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-001116-31 (first received 03 November 2004). [ESCLIN-002/04] [EUCTR2004-001116-31-ES] [sr-incont64643]">EUCTR2004‐001116‐31‐ES</a>; <a href="./references#CD003781-bbs2-0030" title="EUCTR2004-002143-27-AT. A double-blind, stratified, randomised, parallel, placebo-controlled, multi-centre study to compare the efficacy and safety of duloxetine hydrochloride (40mg twice a day) and tolterodine tartrate (XL) (4mg once daily) with placebo in patients with symptoms of Urge Urinary Incontinence. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-002143-27 (first received 15 February 2005). [1208.15] [EUCTR2004-002143-27-AT] [sr-incont64640]">EUCTR2004‐002143‐27‐AT</a>; <a href="./references#CD003781-bbs2-0031" title="EUCTR2007-004126-24-CZ. A placebo controlled randomized, 12-week, dose-ranging, double-blind study versus placebo using tolterodine as a study calibrator, to evaluate efficacy and safety of SSR240600C in women with overactive bladder including urge urinary incontinence. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-004126-24 (first received 12 December 2007). [DRI6271] [EUCTR2007-004126-24-CZ] [EudraCT2007-004126-24] [NCT00564226] [TrialID.BILADY] [sr-incont64596]NCT00564226. SSR240600C treatment in women with overactive bladder (BILADY) [A placebo controlled randomized, 12-week, dose-ranging, double-blind study versus placebo using tolterodine as a study calibrator, to evaluate efficacy and safety of SSR240600C in women with overactive bladder including urge urinary incontinence]. clinicaltrials.gov/show/NCT00564226 (first received 27 November 2007). [DRI6271] [EudraCT2007-004126-24] [NCT00564226] [TrialID.BILADY] [sr-incont63784]">EUCTR2007‐004126‐24‐CZ</a>; <a href="./references#CD003781-bbs2-0036" title="HajebrahimiS , MotlaghRS , BazarganiHS , BabaieH . Efficacy of tadalafil in treatment of overactive bladder syndrome: a randomized controlled trial (Abstract number OP.3.6Dec.27). International Journal of Urology2014;21:A146. [IRCT2013030212668N1] [sr-incont67256]IRCT2013030212668N1. Effect of tadalafil in treatment of overactive bladder  [Comparison of the efficacy of tadalafil, toltrodine and placebo in reduction of symptoms severity of women with urgency, frequency syndrom / overactive bladder]. en.irct.ir/trial/12692 (first received 26 January 2013). [91189] [IRCT2013030212668N1] [sr-incont78643]">Hajebrahimi 2014</a>; <a href="./references#CD003781-bbs2-0038" title="HerschornS , HeesakkersJ , Castro-DiazD , WangJT , BrodskyM , GuanZ . Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*. Current Medical Research and Opinion2008;24(12):3513-21. [A6121122] [NCT00143377] [srincont-29250]HerschornS , HeesakkersJ , Castro-DiazD , WangJT , GuanZ , BrodskyM . Tolterodine extended release (TER) improves objective and subjective outcomes after 1 week of treatment in patients with overactive bladder (Abstract number 132). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S78-9. [srincont-26602]">Herschorn 2008</a>; <a href="./references#CD003781-bbs2-0039" title="CorcosJ , AnguloJC , GarelyAD , CarlssonM , GongJ , GuanZ . Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. Current Medical Research and Opinion2011;27(5):1059-65. [srincont-41596]EUCTR2006-006935-38-SE. 12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006935-38 (first received 16 April 2007). [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont64612]HerschornS , SwiftS , GuanZ , CarlssonM , BrodskyM , GongJ . Efficacy and safety of fesoterodine for overactive bladder in a double-blind, head-to-head comparison trial with tolterodine ER and placebo (Abstract number 710). In: International Continence Society (ICS), 39th Annual Meeting; 2009 Sep 29-Oct 3; San Francisco, CA. 2009. [srincont-35326]HerschornS , SwiftS , GuanZ , CarlssonM , MorrowJD , BrodskyM , et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU International2010;105(1):58-66. [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont39540]NCT00444925. Clinical trial to evaluate the efficacy and safety of Fesoterodine in comparison to Tolterodine for overactive bladder (OAB) [12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder (OAB)]. clinicaltrials.gov/show/NCT00444925 (first received 08 March 2007). [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont49159]">Herschorn 2009a</a>; <a href="./references#CD003781-bbs2-0043" title="HommaY , KawabeK . Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World Journal of Urology2004;22(4):251-6. [srincont-19412]HommaY , PaickJS , LeeJG , KawabeK , Japanese and Korean Tolterodine Study Group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU International2003;92(7):741-7. [srincont-16418]">Homma 2003</a>; <a href="./references#CD003781-bbs2-0047" title="JacquetinB , WyndaeleJJ . Tolterodine reduces the number of incontinence episodes in patients with an overactive bladder. European Journal of Obstetrics and Gynecology and Reproductive Biology2001;98(1):97-102. [srincont-12200]JacquetinB , WyndaeleJJ . Tolterodine reduces the number of incontinence episodes in patients with detrusor overactivity. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(1):S30. [srincont-5167]">Jacquetin 2001</a>; <a href="./references#CD003781-bbs2-0048" title="JonasU , HofnerK , MadersbacherH , HolmdahlTH . Efficacy and safety of two doses of Tolterodine compared to placebo in patients with detrusor overactivity. Neurourology and Urodynamics1997;16(5):477-8. [srincont-5841]JonasU , HöfnerK , MadersbacherH , HolmdahlTH . Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group. World Journal of Urology1997;15(2):144-51. [srincont-5436]">Jonas 1997</a>; <a href="./references#CD003781-bbs2-0049" title="JunemannKP , Al-ShukriS . Efficacy and tolerability of trospium chloride and tolterodine in 234 patients with urge-syndrome: a double-blind, placebo-controlled, multicentre clinical trial (Abstract number 85B). Neurourology and Urodynamics2000;19(4):488-90. [srincont-9976]">Junemann 2000</a>; <a href="./references#CD003781-bbs2-0051" title="EUCTR2007-006451-39-SE. 12-week, randomized, double-blind, double-dummy, placebo controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-006451-39 (first received 20 February 2008). [A0221046] [EUCTR2007-006451-39-SE] [sr-incont64591]KaplanSA , SchneiderT , FooteJ , GuanZ . Superior efficacy of fesoterodine over tolterodine with rapid onset: a prospective, head-to-head, placebo-controlled trial (Abstract number 67). Neurourology and Urodynamics2010;29(6):905-7. [srincont-40130]KaplanSA , SchneiderT , FooteJE , GuanZ , CarlssonM , GongJ . Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU International2011;107(9):1432-40. [A0221046] [NCT00611026] [srincont-41334]">Kaplan 2011</a>; <a href="./references#CD003781-bbs2-0054" title="KhullarV , HillS , LavalKU , SchiotzHA , JonasU , VersiE . Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology2004;64(2):269-74; discussion 274-5. [srincont-19498]KhullarV , HillS , SolankiJ . Assessment of health-related quality of life in patients with overactive bladder taking tolterodine extended release versus placebo (Abstract number 318). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21075]">Khullar 2004</a>; <a href="./references#CD003781-bbs2-0055" title="AballéaS , MamanK , ThokagevistkK , NazirJ , OdeyemiIA , HakimiZ , et al. Cost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United Kingdom. Clinical Drug Investigation2015;35(2):83-93. [NCT00689104] [sr-incont66445]Arlandis-GuzmánS , Brenes-BermúdezF , Jiménez-CidreMA , Rubio-RodríguezD , Rubio-TerrésC , MoraAM , et al. Cost effectiveness of Mirabegron and antimuscarinic drugs in patients with hiperactive bladder [Coste-efectividad de mirabegrón y los antimuscarínicos en pacientes con vejiga hiperactiva]. Archivos Espanoles de Urologia2018;71(10):809-24. [NCT00689104] [sr-incont78645]EUCTR2007-001451-19-ES. A randomized, double-blind, parallel group, placebo and active controlled, multicenter study to assess the efficacy and safety of the beta-3 agonist YM178 (50 mg qd and 100 mg qd) in subjects with symptoms of overactive bladder - SCORPIO [Estudio multicentrico, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo y tratamiento activo, para evaluar la eficacia y seguridad del agonista beta-3 YM178 (50 mg, una vez al dia y 100 mg, una vez al dia) en pacientes con sintomas de vejiga hiperactiva]. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-001451-19 (first received 05 June 2008). [EUCTR2007-001451-19-ES] [sr-incont78646]HerschornS , NazirJ , RamosB , HakimiZ . Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada. Canadian Urological Association Journal2017;11(3-4):123-30. [NCT00689104] [sr-incont76807]KhullarV , AmarencoG , AnguloJ , BoerrigterP , BlauwetM , HakimiZ . The potent and selective beta3-adrenoceptor agonist mirabegron improves patient-reported outcomes in the treatment of overactive bladder (Abstract number MP-12.16). Urology2012;80(3 Suppl 1):S123. [sr-incont65379]KhullarV , AmarencoG , AnguloJC , BlauwetMB , NazirJ , OdeyemiIA , et al. Patient-reported outcomes with the β3 beta3-adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder. Neurourology and Urodynamics2016;35(8):987-94. [NCT00689104] [sr-incont72221]KhullarV , AmarencoG , AnguloJC , CambroneroJ , HøyeK , MilsomI , et al. Efficacy and tolerability of mirabegron, a ß3-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. European Urology2013;63(2):283-95. [NCT00689104] [TrialID.SCORPIO.] [sr-incont46836]KhullarV , CambroneroJ , AnguloJ , WooningM , BlauwetM , SiddiquiE , et al. Onset of action of efficacy of the potent and selective beta-3-adrenoceptor agonist, mirabegron, for the treatment of overactive bladder (OAB) in a 12-week, multicentre, randomised, double-blind, parallel-group, placebo-and tolterodine slow release (SR)-controlled study in OAB patients (Abstract number 135). International Urogynecology Journal and Pelvic Floor Dysfunction2012;23(2 Suppl 1):S187-8. [NCT00689104] [sr-incont67382]KhullarV , CambroneroJ , AnguloJC , WooningM , BlauwetMB , DorrepaalC , et al. Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial. BMC Urology2013;13:45. [NCT00689104] [sr-incont49411]KhullarV , CambroneroJ , StroebergP , AnguloJ , BoerrigterP , WooningM . The efficacy and tolerability of mirabegron, a potent and selective B3-adrenoceptor agonist, compared with placebo and tolterodine slow release in patients with overactive bladder - results from a European-Australian phase III trial (Abstract number 328). In: International Continence Society (ICS); 41st Annual Meeting; 2011 Aug 29-Sept 2; Glasgow, Scotland. 2011. [NCT00689104] [sr-incont42211]NCT00689104. Study to assess the efficacy and safety of the beta-3 agonist mirabegron (ym178) in patients with symptoms of overactive bladder (SCORPIO) [A randomized, double-blind, parallel group, placebo and active controlled, multicenter study to assess the efficacy and safety of mirabegron in subjects with symptoms of overactive bladder (SCORPIO)]. clinicaltrials.gov/show/NCT00689104 (first received 03 June 2008). [NCT00689104] [sr-incont49843]NittiV , HerschornS , AuerbachS , KhullarV , AmarencoG , BlauwetMB , et al. The potent and selective ß3-adrenoceptor agonist mirabegron improves patient-reported outcomes in overactive bladder-results from two phase III studies (Abstract number 68). Neurourology and Urodynamics2012;31(6):813-5. [NCT00689104] [sr-incont46724]WielageRC , PerkS , CampbellNL , NgD , KleinTM , PostaLM , et al. The cost effectiveness of mirabegron for the treatment of overactive bladder: three US perspectives (Abstract number A142). Journal of the American Geriatrics Society2015;63:S67. [NCT00689104] [sr-incont70876]YamanishiT , YamanishiY , TajimaH , IkedaS . Cost-effectiveness of mirabegron and tolterodine for the treatment of overactive bladder in Japan-Which drug is more cost-effective if used as the first-line treatment? (Abstract number 504). International Urogynecology Journal2018;29:S252. [NCT00689104] [sr-incont78647]YamanishiY , YamanishiT , TajimaH , IkedaS . Mirabegron or tolterodine for the treatment of overactive bladder in Japan: Which drug is more cost-effective as the first-line treatment?International Journal of Urology2018;25(10):863-70. [NCT00689104] [sr-incont78648]">Khullar 2013</a>; <a href="./references#CD003781-bbs2-0059" title="KrederK , PleilAM , ReesePR , KelleherJ . Effects of long-term tolterodine treatment on social and psychological aspects of health-related quality of life in overactive bladder patients (Abstract). Journal of Urology2002;167(Suppl 4):29. [sr-incont17591]">Kreder 2002</a>; <a href="./references#CD003781-bbs2-0060" title="HsiaoSM , ChangTC , ChenCH , WuWY , LinHH . Comparisons of the clinical outcomes and urodynamic effects of mirabegron versus tolterodine treatment for female overactive bladder syndrome: a subgroup analysis of a controlled, randomised, prospective study. Lower Urinary Tract Symptoms2018;10(3):215-20. [NCT01043666] [sr-incont74461]KuoHC , LeeKS , NaY , SoodR , NakajiS , KubotaY , et al. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourology and Urodynamics2015;34(7):685-92. [NCT01043666] [sr-incont68095]Kuo H‐C, Lin H‐H, Yu H‐J, Cheng C‐L, Hung M‐J, LinAT . Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials [Erratum available in: Urological Science 2015;26(2):148]. Urological Science2015;26(1):41-8 . [NCT01043666] [sr-incont68645]NCT01043666. A study of YM178 in subjects with symptoms of overactive bladder  [Phase III study of YM178: a randomized, double-blind, parallel group, placebo and active controlled, multi-center study in subjects with symptoms of overactive bladder]. clinicaltrials.gov/show/NCT01043666 (first received 07 January 2010). [178-CL-090] [NCT01043666] [sr-incont63781]">Kuo 2015</a>; <a href="./references#CD003781-bbs2-0062" title="LandisJR , KaplanS , SwiftS , VersiE . Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity. Journal of Urology2004;171(2 Pt 1):752-6. [sr-incont17327]">Landis 2004</a>; <a href="./references#CD003781-bbs2-0066" title="Malone-LeeJG , WalshB , MaugourdMF , Tolterodine in the Elderly Study Group. The safety and clinical efficacy of two doses of tolterodine compared to placebo in elderly patients. In: International Continence Society (ICS), 27th Annual Meeting; 1997 Sep 23-26; Yokohama, Japan. 1997:155-6. [srincont-5855]Malone‐LeeJG , WalshJB , MaugourdMF . Tolterodine: A safe and effective treatment for older patients with overactive bladder. Journal of the American Geriatric Society2001;49(6):700-5. [srincont-12319]WaggA , Malone-LeeJ . Pressure-flow variables in patients treated with tolterodine for detrusor overactivity. BJU International2003;92(9):969-71. [sr-incont16659]">Malone‐Lee 2001</a>; <a href="./references#CD003781-bbs2-0067" title="MillardR , TuttleJ , MooreK , SussetJ , ClarkeB , DwyerP , et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. Journal of Urology1999;161(5):1551-5. [sr-incont8172]MooreK , MillardR , DwyerP , TuttleJ . A randomized controlled multicentre trial of tolterodine in detrusor instability/hyperreflexia. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(Suppl 1):S129. [sr-incont5171]RosamiliaA , DwyerPL , ClarkeB , MooreK , MillardRP , TuttleJ . The clinical efficacy and safety of two doses of Tolterodine in detrusor instability. Acta Obstetrica et Gynecologica Scandinavica1997;6(Suppl 167):24. [sr-incont6670]">Millard 1999</a>; <a href="./references#CD003781-bbs2-0068" title="DmochowskiR , MitchesonD , FrenklT , BennettN , MuddPN . Durable efficacy and safety of long-term once-daily vibegron, a novel oral B-3 adrenergic receptor agonist: A 52-week phase 2 study in patients with overactive bladder syndrome (Abstract number PD50-03). Journal of Urology2018;199(4):e970-1. [sr-incont78091]EUCTR2010-022121-15-IT. A phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2 part clinical study of the efficacy and safety of MK-4618 in patients with overactive bladder - MK4618-008 [A 52-week extension to: a phase iib randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder]. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-022121-15 (first received 12 April 2011). [EUCTR2010-022121-15-IT] [MK4618-008] [NCT01314872] [sr-incont78639]MitchesonD , FrenklT , SamantaS , Anne PintoC , GreenS , BennettN , et al. Vibegron, a novel once daily oral beta-3 agonist, significantly reduces average daily micturitions, urge incontinence episodes and urgency episodes in patients with overactive bladder (Abstract number: podium #34). Neurourology and Urodynamics2018;37(Suppl 1):S565. [EUCTR2010-022121-15-IT] [NCT01314872] [sr-incont78618]MitchesonD , PintoCA , FrenklT , ChenL , PrasadM , MuddPN . Once daily vibegron improves quality of life measures in patients with overactive bladder (Abstract number PUK17). Value in Health2018;21(Suppl 1):S267-8. [EUCTR2010-022121-15-IT] [NCT01314872;] [sr-incont78619]MitchesonHD , SamantaS , MuldowneyK , PintoCA , RochaBA , GreenS , et al. Vibegron (RVT-901/MK-4618/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial. European Urology2019;75(2):274-82. [NCT01314872] [sr-incont78620]NCT01314872. A study of the efficacy and safety of Vibegron (MK-4618) in participants with overactive bladder (OAB) (MK-4618-008) [A phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder a 52-week extension to: a phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder]. clinicaltrials.gov/show/NCT01314872 (first received 15 March 2011). [NCT01314872] [sr-incont63793]UKCRN10391. A phase IIB randomised, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of MK-4618 in patients with overactive bladder . public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=10391 (accessed 28 June 2012). [CCRN525] [UKCRN10391] [sr-incont45046]">Mitcheson 2019</a>; <a href="./references#CD003781-bbs2-0323" title="NCT00553657. The study to test the effect of standardization of fluid intake in female patients with overactive bladder [A randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of standardization of fluid intake on the variability of measured voiding parameters in female patients with idiopathic overactive bladder]. clinicaltrials.gov/show/NCT00553657 (first received 04 November 2007). [NCT00553657] [sr-incont60907]">NCT00553657</a>; <a href="./references#CD003781-bbs2-0071" title="OlshanskyB , FooteJ , ArguinzonizM , LheritierK , Quebe-FehlingE , SteelM . Cardiovascular safety of darifenacin and tolterodine in patients with overactive bladder (OAB) (Abstract number 49). International Urogynecology Journal and Pelvic Floor Dysfunction2006;17(Suppl 2):S86-7. [sr-incont34186]">Olshansky 2006</a>; <a href="./references#CD003781-bbs2-0073" title="NCT01302938. Web-based methodology trial to evaluate the efficacy and safety of tolterodine ER in subjects with overactive bladder (REMOTE) [Exploratory, randomized, double-blind, placebo-controlled, parallel-group, single center, web-based phase IV pilot methodolgy trial to evaluate the efficacy and safety of tolterodine ER in subjects with overactive bladder]. clinicaltrials.gov/ct2/show/NCT01302938 (first received 24 February 2011). [A6121195] [NCT01302938] [TrialID.REMOTE.] [sr-incont43314]OrriM , LipsetCH , JacobsBP , CostelloAJ , CummingsSR . Web-based trial to evaluate the efficacy and safety of tolterodine ER 4 mg in participants with overactive bladder: REMOTE trial. Contemporary Clinical Trials2014;38(2):190-7. [A6121195] [NCT01302938] [TrialID.REMOTE.] [sr-incont62536]">Orri 2014</a>; <a href="./references#CD003781-bbs2-0074" title="RentzhogSL , StantonL , CardozoL , NelsonE , FallM , AbramsP . Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. British Journal of Urology1998;81(1):42-8. [srincont-5461]">Rentzhog 1998</a>; <a href="./references#CD003781-bbs2-0077" title="RogersR , BachmannG , JumadilovaZ , SunF , MorrowJD , GuanZ , et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. International Urogynecology Journal and Pelvic Floor Dysfunction2008;19(11):1551-7. [A6121002] [NCT00143481] [srincont-27729]RogersRG , BachmannG , ScarperoH , JumadilovaZ , SunF , MorrowJD , et al. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. Current Medical Research and Opinion2009;25(9):2159-65. [srincont-32060]">Rogers 2008</a>; <a href="./references#CD003781-bbs2-0078" title="RomanziLJ , DelconteA , KralidisG . Impact of darifenacin compared with tolterodine on incontinence episodes in patients with overactive bladder (Abstract number A3522). Obstetrics and Gynecology2005;105(Suppl 4):88S. [sr-incont34187]">Romanzi 2005</a>; <a href="./references#CD003781-bbs2-0083" title="EUCTR2017-003293-14. Empowur (Empower OAB patients with vibegron for better urgency control) [An international phase 3, randomized, double-blind, placebo- and active (tolterodine)-controlled multicenter study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder]. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-003293-14 (first received 24 April 2018). [EUCTR2017-003293-14] [NCT03492281] [sr-incont78606]NCT03492281, JankowichR . A study to examine the safety and efficacy of a new drug in patients with symptoms of overactive bladder (OAB) [An international phase 3, randomized, double-blind, placebo- and active (tolterodine)-controlled multicenter study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder]. clinicaltrials.gov/show/NCT03492281 (first received 20 April 2018). [NCT03492281] [sr-incont78610]StaskinD , FrankelJ , VaranoS , ShortinoD , JankowichR , MuddPN . Vibegron demonstrates statistically significant improvement in efficacy measures in overactive bladder-key secondary results from the international phase 3 study in patients with overactive bladder (empowur) (Abstract number: long oral 40). Female Pelvic Medicine and Reconstructive Surgery2019;25(5):S20-1. [NCT03492281] [sr-incont78627]StaskinD , FrankelJ , VaranoS , ZhouJ , JankowichR , MuddPN . International phase 3, double-blind, placebo- and active (tolterodine)-controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: empowur (Abstract number LBA-02). Journal of Urology2019;201(4):e992. [NCT03492281] [sr-incont78628]StaskinD , VaranoS , FrankelJ , ShortinoD , JankowichR , MuddP . Once-daily vibegron 75 mg demonstrates statistically significant benefits on key secondary endpoints including quality of life in patients with OAB: data from an international phase 3 trial (EMPOWUR) (Abstract number 181). Neurourology and Urodynamics2019;38(S3):S115-7. [NCT03492281] [sr-incont78629]VaranoS , StaskinD , FrankelJ , ShortinoD , JankowichR , MuddPN . Vibegron statistically significantly improves measures of quality of life in patients with overactive bladder-data from the international phase 3 trial (Empowur) (Abstract number: long oral 38). Female Pelvic Medicine and Reconstructive Surgery2019;25(5):S19. [NCT03492281] [sr-incont78630]">Staskin 2019</a>; <a href="./references#CD003781-bbs2-0091" title="MesselinkEJ , SolerJM , MadersbacherH , ThuroffJW , AmarencoG , Van KerrebroeckEV . Urodynamic aspects of the efficacy of tolterodine, a new anti muscarine drug in the treatment of detrusor hyperreflexia. In: International Continence Society (ICS), 25th Annual Meeting; 1995 Oct 17-20; Sydeney, Australia. 1995:95-6. [srincont-10883]Van KerrebroeckPE , AmarencoG , ThüroffJW , MadersbacherHG , LockMT , MesselinkEJ , et al. Dose-ranging study ot tolterodine in patients with detrusor hyperreflexia. Neurourology and Urodynamics1998;17(5):499-512. [srincont-7852]">Van Kerrebroeck 1998</a>; <a href="./references#CD003781-bbs2-0092" title="ChancellorM , FreedmanS , MitchesonHD , AntociJ , PrimusG , WeinA . Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clinical Drug Investigation2000;19(2):83-91. [srincont-16326]FreemanR , HillS , MillardR , SlackM , SutherstJ , Tolterodine Study Group. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstetrics and Gynecology2003;102(3):605-11. [srincont-16494]GarelyA , Tolterodine Study Group. Once-daily tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder. International Urology Journal2001;12(Suppl 1):S18. [srincont-12012]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of life of patients with overactive bladder receiving tolterodine. Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of patients with overactive bladder receiving tolterodine (Abstract number 82). Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , ReesePR . Health related quality of life of patients with overactive bladder receiving tolterodine once-daily. Neurourology and Urodynamics2000;19(4):519-21. [srincont-9987]KelleherCJ , ReesePR , PleilAM , OkanoGJ . Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. American Journal of Managed Care2002;8(Suppl 19):S608-15. [srincont-17998]KelleherCJ , Tolterodine Study Group. Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2000;11(Suppl 1):S94. [srincont-11915]KrederKJ . Antimuscarinic therapy: relationship between efficacy and side effects in responders and non-responders. Journal of Urology2001;165(Suppl 5):S165. [srincont-16327]KrederKJ . Clinical effectiveness of antimuscarinic therapy: the relationship between efficacy and tolerability. In: Proceedings of the International Continence Society Annual Meeting(ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001:140. [srincont-14376]MallettV . Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2001;12(Suppl 1):4. [srincont-12011]MillardRJ , TamaddonK , Tolterodine Study Group. Randomized controlled trial to compare tolterodine prolonged release capsules and tolterodine immediate release tablets versus placebo in patients with symptoms of detrusor overactivity (Abstract number 57). Australian and New Zealand Journal of Surgery2002;Suppl 72:A140. [sr-incont22190]PleilAM , ReesePR , KelleherCJ , OkanoGJ . Health-related quality of life of patients with overactive bladder receiving immediate-release tolterodine. HEPAC Health Economics in Prevention and Care2001;2(2):69-75. [sr-incont18060]RoehrbornCG , AbramsP , RovnerES , KaplanSA , HerschornS , GuanZ . Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU International2006;97(5):1003-6. [sr-incont21882]SwiftS . Efficacy and tolerability of once-daily tolterodine for women with overactive bladder. In: International Continence Society Annual Meeting (ICS), 31st annual meeting; 2001 Sept 18-21; Seoul, Korea. 2001:No. 329. [srincont-14481]SwiftS . Once-daily tolterodine is effective and well tolerated in women with overactive bladder (Abstract 57). In: 2nd International Consultation on Incontinence; 2001 July 1-3; Paris, France. 2001. [srincont-16319]SwiftSE . Once-daily (OD) tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder (OAB). International Urogynecology Journal2000;11(Suppl 1):S15. [sr-incont11906]SwiftSE . Once-daily administration of extended-release tolterodine is effective and well-tolerated in patients with overactive bladder. In: XVI FIGO World Congress of Obstetrics and Gynecology; 2000 Sept 3-8; Washington DC. Vol. Book 1. 2000:40. [sr-incont12085]SwiftSE . Overactive bladder in females: treatment with once-daily tolterodine. International Urogynecology Journal2001;12(Suppl 3):S71. [sr-incont16328]Van KerrebroeckP , KrederK , JonasU , ZinnerN . Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology2001;57(3):414-21. [sr-incont11953]Van KerrebroeckPEV . Long-term (12 months) efficacy and tolerability of tolterodine once-daily in the treatment of overactive bladder. Neurourology and Urodynamics2001;20(4):401-2. [sr-incont15714]Van KerrebroeckPEVA , Tolterodine Study Group. Long-term tolerability and efficacy of once-daily (OD) tolterodine in the treatment of overactive bladder (OB). International Urogynecology Journal2001;12(Suppl 3):S49. [sr-incont16329]Van KerrebroeckPEVA , Tolterodine Study Group. Significant decreases in perception of urgency and urge incontinence episodes with once-daily tolterodine treatment in patients with overactive bladder (Abstract number 89). Neurourology and Urodynamics2000;19(4):493-4. [sr-incont9980]WeinAJ , KhullarV , WangJT , GuanZ . Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. BJU International2007;99(2):360-3. [sr-incont23180]vanKerrebroeckPE , KelleherCJ , CoyneKS , KoppZ , BrodskyM , WangJT . Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. Health and Quality of Life Outcomes2009;7(13):13. [10.1186/1477-7525-7-13] [sr-incont31438]vanKerrebroeckPE , WangJ , GuanZ . Effects of tolterodine extended release in patients with overactive bladder: perceived treatment benefits improve with efficacy (Abstract number 511). European Urology Supplements2004;3(2):130. [sr-incont31090]">Van Kerrebroeck 2001</a>; <a href="./references#CD003781-bbs2-0097" title="NCT00966004. A study to evaluate safety and efficacy of ym178 in patients with overactive bladder [Phase III study of YM178 - a placebo-controlled, double-blind, group comparison study in patients with overactive bladder]. clinicaltrials.gov/show/NCT00966004 (first received 26 August 2009). [178-CL-048] [JapicCTI-R130370] [NCT00966004] [sr-incont63783]YamaguchiO , HidehiroK , YukioH , YasuhikoI , MasayukiT , OsamuN , et al. A phase III, randomized, double-blind, placebo and active controlled study of once-daily mirabegron 50 mg in patients with overactive bladder (Abstract number POD-03.06). Urology2012;80(3 Suppl 1):S10-1. [NCT00966004] [sr-incont65380]YamaguchiO , MaruiE , KakizakiH , HommaY , IgawaY , TakedaM , et al. A phase III, randomized, double-blind, placebo-controlled study of the beta-adrenoceptor agonist, mirabegron 50 mg once-daily, in Japanese patients with overactive bladder. BJU International2014;113(6):951-60. [NCT00966004] [sr-incont50603]">Yamaguchi 2012</a>; <a href="./references#CD003781-bbs2-0102" title="ZinnerNR , MattiassonA , StantonSL . Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. Journal of the American Geriatrics Society2002;50(5):799-807. [sr-incont14679]">Zinner 2002</a>). </p> <p>Only one study studied the effects of propantheline (<a href="./references#CD003781-bbs2-0089" title="ThuroffJW , BunkeB , EbnerA , FaberP , deGeeterP , HannappelJ , et al. Randomized, double-blind multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin vs. propantheline vs. placebo. Neurourology and Urodynamics1990;9(4):337-8. [srincont-5108]ThuroffJW , BunkeB , EbnerA , FaberP , deGeeterP , HannappelJ , et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. Journal of Urology1991;145(4):813-7. [srincont-1288]">Thuroff 1991</a>). </p> <p>Twenty‐two studies compared different doses of the same anticholinergic medication (<a href="./references#CD003781-bbs2-0001" title="AbramsP , JacksonS , MattiassonA , KrishnanK , HaendlerL . A randomised, double-blind, placebo controlled, dose ranging study of the safety and efficacy of tolterodine in patients with hyperreflexia (Abstract). In: International Continence Society 26th Annual Meeting; 1996 Aug 27-30; Athens, Greece. 1996:276-7. [sr-incont5135]">Abrams 1996</a>; <a href="./references#CD003781-bbs2-0004" title="AbramsP , KelleherC , StaskinD , KayR , MartanA , MincikI , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World Journal of Urology2017;35(5):827-38. [NCT01340027] [sr-incont77897]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Cardiovascular safety of combination treatment with mirabegron and solifenacin in patients with overactive bladder in a randomised, double-blind, dose-ranging, Phase II study (Symphony) (Abstract). European Urology, Supplements2014;13(1):e574-e574a. [NCT01340027] [sr-incont67160]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB) - efficacy and safety results from a randomised phase II study (Symphony) (Abstract number 295). Neurourology and Urodynamics2013;32(6):930-1. [NCT01340027] [TrialID.SYMPHONY.] [sr-incont49188]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB): safety results from a phase 2 study (Abstract number MP-16.08). Urology2013;82(3 Suppl 1):S139. [NCT01340027] [sr-incont66675]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: Exploratory responder analyses of efficacy and evaluation of patient reported outcomes from a randomised, double-blind, dose-ranging, phase 2 study (Symphony) (Abstract number MP-24.11). Urology2014;84(4 Suppl 1):S145-6. [NCT01340027] [sr-incont67194]AbramsP , KelleherC , StaskinD , RechbergerT , KayR , MartinaR , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (SYMPHONY). European Urology2015;67(3):577-88. [NCT01340027] [sr-incont66674]NCT01340027, Bristol Urological Institute . A study to evaluate the efficacy, safety and tolerability of mirabegron and solifenacin succinate alone and in combination for the treatment of overactive bladder (symphony) [A randomized, double-blind, factorial, parallel-group, active and placebo-controlled, multicenter dose-ranging study to evaluate the efficacy, safety and tolerability of six dose combinations of solifenacin succinate and mirabegron compared to mirabegron and solifenacin succinate monotherapies in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01340027 (first received 21 April 2011). [178-CL-100] [2010-020601-32] [NCT01340027] [TrialID.SYMPHONY] [sr-incont44510]NittiV , AbramsP , StaskinD , AuerbachS , MartinaR , VanMR . Urinary retention in patients with overactive bladder treated with mirabegron alone and in combination with solifenacin: the results of two randomized, double-blind, phase II studies (Abstract number MP76-13). Journal of Urology2014;191(4 Suppl 1):e886-7. [NCT00410514] [NCT01340027] [TrialID.SYMPHONY] [sr-incont67453]">Abrams 2013</a>; <a href="./references#CD003781-bbs2-0010" title="CardozoL , KuzminI , LisecML , MillardR , vanVierssen TripOB , RidderAM , et al. YM905: Results of a randomised, double-blind placebo-controlled trial in patients with symptomatic overactive bladder (Abstract number 104). European Urology Supplements2003;2(1):28. [sr-incont27407]CardozoL , KuzminI , LisecML , MillardRJ , vanVierssen TripOB , RidderAM , et al. A double-blind, randomised, placebo-controlled trial with YM905 in symptomatic overactive bladder (Abstract number P74). Journal of the American Geriatrics Society2003;51 (Suppl 4):S68-9. [sr-incont31100]CardozoL , LisecM , MillardR , vanVierssen TripO , KuzminI , DrogendijkTE , et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. Journal of Urology2004;172(5 (Pt 1 of 2)):1919-24. [srincont-19090]CardozoL . A randomised double-blind, placebo-controlled trial of the once-daily muscarinic receptor antagonist solifenacin succinate for symptoms of overactive bladder (Abstract number 211). International Urogynecology Journal2003;14 (Suppl 1):S64. [sr-incont31104]CardozoL . Solifenacin succinate improves symptoms of an overactive bladder (Abstract number TP77). International Journal of Gynecology and Obstetrics2003;83(Suppl 3):94. [sr-incont31096]KelleherCJ , CardozoL , ChappleCR , HaabF , RidderAM . Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU International2005;95(1):81-5. [srincont-20241]">Cardozo 2004a</a>; <a href="./references#CD003781-bbs2-0012" title="ChalihaC , HalaskaM , StantonS . Trospium chloride for the treatment of detrusor instability: a placebo-controlled dose-finding study (Abstract 276). British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):92. [srincont-8452]">Chaliha 1998</a>; <a href="./references#CD003781-bbs2-0013" title="ChappleC . Fesoterodine a new effective and well-tolerated antimuscarinic for the treatment of urgency-frequency syndrome: results of a phase 2 controlled study (Abstract 142). Neurourology and Urodynamics2004;23(5/6):598-9. [srincont-19023]Drug company. A Phase 2, parallel group, randomized, double-blind, placebo controlled dose-ranging trial to determine the optimal dose and the tolerability of sustained release SPM 8272 (fesoterodine) in subjects with non-neurogenic bladder overactivity. Protocol numbers: A0221027 (SP582). ClinicalStudyResults.org (accessed 3 March 2011)2002. [Protocol numbers: A0221027 (SP582)] [srincont-41110]">Chapple 2004a</a>; <a href="./references#CD003781-bbs2-0019" title="ChappleC , HaabF , SchneiderT , CarlssonM , ArumiD . Fesoterodine 8 mg versus fesoterodine 4 mg in patients with overactive bladder and a history of previous antimuscarinic therapy: Results from the EIGHT trial (Abstract number: Poster #M5). Neurourology and Urodynamics2015;34(S1):S20. [NCT01302067] [sr-incont68509]ChappleC , SchneiderT , HaabF , SunF , WhelanL , ScholfieldD , et al. Superiority of fesoterodine 8mg versus fesoterodine 4 mg in reducing urgency urinary incontinence episodes in subjects with overactive bladder: results of the randomized, double-blind, placebo-controlled EIGHT trial (Abstract number: Podium #48). Neurourology and Urodynamics2014;33(2):183-4. [NCT01302067] [sr-incont67484]ChappleC , SchneiderT , HaabF , SunF , WhelanL , ScholfieldD , et al. Superiority of fesoterodine 8mg vs 4mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial. BJU International2014;114(3):418-26. [A0221095] [NCT01302067] [TrialID.EIGHT] [srincont-62537]NCT01302067. A 12 week study to confirm the effectiveness of 8mg of Fesoterodine compared to 4mg of Fesoterodine [A 12-week, randomized, double-blind, placebo controlled, parallel group, multicenter trial in overactive bladder subjects to confirm the efficacy of 8 mg fesoterodine compared to 4 mg fesoterodine]. clinicaltrials.gov/show/NCT01302067 (first received 23 February 2011). [NCT01302067] [sr-incont63792]">Chapple 2014</a>; <a href="./references#CD003781-bbs2-0035" title="HaabF , StewartL , DwyerP . Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. European Urology2004;45(4):420-9. [srincont-17428]">Haab 2004</a>; <a href="./references#CD003781-bbs2-0042" title="HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21072]HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21072]HillS , KhullarV , WyndaeleJJ , LheritierK , . Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. International Urogynecology Journal and Pelvic Floor2006;17(3):239-47. [srincont-22464]">Hill 2005</a>; <a href="./references#CD003781-bbs2-0044" title="HommaY , YamaguchiT , YamaguchiOA . A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2008;15(9):809-15. [srincont-27742]">Homma 2008</a>; <a href="./references#CD003781-bbs2-0047" title="JacquetinB , WyndaeleJJ . Tolterodine reduces the number of incontinence episodes in patients with an overactive bladder. European Journal of Obstetrics and Gynecology and Reproductive Biology2001;98(1):97-102. [srincont-12200]JacquetinB , WyndaeleJJ . Tolterodine reduces the number of incontinence episodes in patients with detrusor overactivity. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(1):S30. [srincont-5167]">Jacquetin 2001</a>; <a href="./references#CD003781-bbs2-0048" title="JonasU , HofnerK , MadersbacherH , HolmdahlTH . Efficacy and safety of two doses of Tolterodine compared to placebo in patients with detrusor overactivity. Neurourology and Urodynamics1997;16(5):477-8. [srincont-5841]JonasU , HöfnerK , MadersbacherH , HolmdahlTH . Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group. World Journal of Urology1997;15(2):144-51. [srincont-5436]">Jonas 1997</a>; <a href="./references#CD003781-bbs2-0050" title="JünemannKP , HessdörferE , Unamba‐OparahI , BerseM , BrünjesR , MadersbacherH . Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. Urologia Internationalis2006;77(4):334-9. [srincont-22199]">Junemann 2006</a>; <a href="./references#CD003781-bbs2-0058" title="KosilovKV , LoparevSA , IvanovskayaMA , KosilovaLV . The efficacy of different doses of solifenacin in elderly patients after treating a urinary tract infection. Arab Journal of Urology Print2015;13(3):203-8. [sr-incont69283]">Kosilov 2015b</a>; <a href="./references#CD003781-bbs2-0066" title="Malone-LeeJG , WalshB , MaugourdMF , Tolterodine in the Elderly Study Group. The safety and clinical efficacy of two doses of tolterodine compared to placebo in elderly patients. In: International Continence Society (ICS), 27th Annual Meeting; 1997 Sep 23-26; Yokohama, Japan. 1997:155-6. [srincont-5855]Malone‐LeeJG , WalshJB , MaugourdMF . Tolterodine: A safe and effective treatment for older patients with overactive bladder. Journal of the American Geriatric Society2001;49(6):700-5. [srincont-12319]WaggA , Malone-LeeJ . Pressure-flow variables in patients treated with tolterodine for detrusor overactivity. BJU International2003;92(9):969-71. [sr-incont16659]">Malone‐Lee 2001</a>; <a href="./references#CD003781-bbs2-0067" title="MillardR , TuttleJ , MooreK , SussetJ , ClarkeB , DwyerP , et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. Journal of Urology1999;161(5):1551-5. [sr-incont8172]MooreK , MillardR , DwyerP , TuttleJ . A randomized controlled multicentre trial of tolterodine in detrusor instability/hyperreflexia. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(Suppl 1):S129. [sr-incont5171]RosamiliaA , DwyerPL , ClarkeB , MooreK , MillardRP , TuttleJ . The clinical efficacy and safety of two doses of Tolterodine in detrusor instability. Acta Obstetrica et Gynecologica Scandinavica1997;6(Suppl 167):24. [sr-incont6670]">Millard 1999</a>; <a href="./references#CD003781-bbs2-0069" title="Drug company. A phase 2, parallel group, stratified, randomized, double blind, placebo-controlled trial to investigate the efficacy and safety of 3 different dosages of sustained release fesoterodine in subjects with overactive bladder showing either involuntary detrusor contractions or normal findings during the baseline urodynamic assessment. Protocol numbers: A0221029 (SP668). ClinicalStudyResults.org (accessed 3 March 2011). [srincont-41111]NittiV , WiatrakM , KreitmanL , LipsitzD . Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB): results of a phase 2 trial (Abstract number 306). In: International Continence Society (ICS); 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21084]">Nitti 2005</a>; <a href="./references#CD003781-bbs2-0070" title="GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NittiVW , DmochowskiR , SandPK , ForstHT , Haag-MolkentellerC , MassowU , et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. Journal of Urology2007;178(6):2488-94. [NCT00138723] [SP584] [srincont-26313]">Nitti 2007</a>; <a href="./references#CD003781-bbs2-0074" title="RentzhogSL , StantonL , CardozoL , NelsonE , FallM , AbramsP . Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. British Journal of Urology1998;81(1):42-8. [srincont-5461]">Rentzhog 1998</a>; <a href="./references#CD003781-bbs2-0076" title="EUCTR2008-005215-17. A study to evaluate the overall effect of solifenacin 5mg and 10mg on bladder wall thickness and urinary nerve growth factor in female subjects with overactive bladder and a diagnosis of detrusor overactivity – a double-blind, randomized, placebo-controlled, parallel group, multicentre study - SHRINK. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-005215-17 (first received 14 September 2009). [EUCTR2008-005215-17] [NCT01093534] [sr-incont78650]NCT01093534. Study of 2 doses of solifenacin succinate in female subjects with overactive bladder (SHRINK) [A study to evaluate the overall effect of solifenacin 5mg and 10mg on bladder wall thickness and urinary nerve growth factor in female subjects with overactive bladder and a diagnosis of detrusor overactivity - a double-blind, randomised, placebo-controlled, parallel group, multi-centre study]. clinicaltrials.gov/show/NCT01093534 (first received 26 March 2010). [905-EC-007] [EUCTR2008-005215-17] [NCT01093534] [TrialID.SHRINK] [sr-incont63778]RobinsonD , KhullarV , OelkeM , WijkstraH , TretterR , StowB , et al. Effects of 12 weeks treatment with solifenacin on Bladder Wall Thickness (BWT) and clinical outcomes: results from the placebo-controlled SHRINK study (Abstract number 422). In: International Continence Society (ICS), 43rd Annual Meeting; 2013 Aug 26-30; Barcelona, Spain. 2013. [905-EC-007] [NCT01093534] [TrialID.SHRINK.] [srincont-49731]RobinsonD , OelkeM , KhullarV , WijkstraH , TretterR , StowB , et al. Bladder wall thickness in women with symptoms of overactive bladder and detrusor overactivity: results from the randomised, placebo-controlled SHRINK study. Neurourology and Urodynamics2016;35(7):819-25. [NCT01093534] [sr-incont72217]RobinsonD , OelkeM , TretterR , StowB , CompionG , TubaroA . The effect of solifenacin on bladder wall thickness in women with overactive bladder and detrusor overactivity: Results from the SHRINK study (Abstract number 782). European Urology Supplements2013;12(1):e782-3. [EUCTR2008-005215-17] [NCT01093534] [sr-incont67207]RobinsonD , TubaroA , KimbergM , PlummerM , DeVineJ , BouicP , et al. The effect of solifenacin on urinary nerve growth factor (UNGF) and brain-derived neurotropic factor (BDNF) in women with overactive bladder and detrusor overactivity: results from the SHRINK study (Abstract number PP 54). International Urogynecology Journal and Pelvic Floor Dysfunction2014;25(1 Suppl 1):S60-1. [EUCTR2008-005215-17] [NCT01093534] [sr-incont67200]TubaroA , KhullarV , OelkeM , WijkstraH , TretterR , StowB , et al. Intra- and inter-reader variability of transvaginal ultrasound bladder wall thickness measurements: results from the SHRINK study (Abstract number 136). Neurourology and Urodynamics2013;32(6):711-2. [EUCTR2008-005215-17] [NCT01093534] [sr-incont49211]">Robinson 2013</a>; <a href="./references#CD003781-bbs2-0084" title="SteersW , CorcosJ . Efficacy, tolerability and safety of darifenacin, an M3 selective receptor antagonist for the treatment of overactive bladder, using a flexible dosing regimen (Abstract number 68). Progres en Urologie2004;14(3 Suppl 3):22. [srincont-22197]">Steers 2004</a>; <a href="./references#CD003781-bbs2-0091" title="MesselinkEJ , SolerJM , MadersbacherH , ThuroffJW , AmarencoG , Van KerrebroeckEV . Urodynamic aspects of the efficacy of tolterodine, a new anti muscarine drug in the treatment of detrusor hyperreflexia. In: International Continence Society (ICS), 25th Annual Meeting; 1995 Oct 17-20; Sydeney, Australia. 1995:95-6. [srincont-10883]Van KerrebroeckPE , AmarencoG , ThüroffJW , MadersbacherHG , LockMT , MesselinkEJ , et al. Dose-ranging study ot tolterodine in patients with detrusor hyperreflexia. Neurourology and Urodynamics1998;17(5):499-512. [srincont-7852]">Van Kerrebroeck 1998</a>; <a href="./references#CD003781-bbs2-0092" title="ChancellorM , FreedmanS , MitchesonHD , AntociJ , PrimusG , WeinA . Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clinical Drug Investigation2000;19(2):83-91. [srincont-16326]FreemanR , HillS , MillardR , SlackM , SutherstJ , Tolterodine Study Group. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstetrics and Gynecology2003;102(3):605-11. [srincont-16494]GarelyA , Tolterodine Study Group. Once-daily tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder. International Urology Journal2001;12(Suppl 1):S18. [srincont-12012]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of life of patients with overactive bladder receiving tolterodine. Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of patients with overactive bladder receiving tolterodine (Abstract number 82). Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , ReesePR . Health related quality of life of patients with overactive bladder receiving tolterodine once-daily. Neurourology and Urodynamics2000;19(4):519-21. [srincont-9987]KelleherCJ , ReesePR , PleilAM , OkanoGJ . Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. American Journal of Managed Care2002;8(Suppl 19):S608-15. [srincont-17998]KelleherCJ , Tolterodine Study Group. Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2000;11(Suppl 1):S94. [srincont-11915]KrederKJ . Antimuscarinic therapy: relationship between efficacy and side effects in responders and non-responders. Journal of Urology2001;165(Suppl 5):S165. [srincont-16327]KrederKJ . Clinical effectiveness of antimuscarinic therapy: the relationship between efficacy and tolerability. In: Proceedings of the International Continence Society Annual Meeting(ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001:140. [srincont-14376]MallettV . Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2001;12(Suppl 1):4. [srincont-12011]MillardRJ , TamaddonK , Tolterodine Study Group. Randomized controlled trial to compare tolterodine prolonged release capsules and tolterodine immediate release tablets versus placebo in patients with symptoms of detrusor overactivity (Abstract number 57). Australian and New Zealand Journal of Surgery2002;Suppl 72:A140. [sr-incont22190]PleilAM , ReesePR , KelleherCJ , OkanoGJ . Health-related quality of life of patients with overactive bladder receiving immediate-release tolterodine. HEPAC Health Economics in Prevention and Care2001;2(2):69-75. [sr-incont18060]RoehrbornCG , AbramsP , RovnerES , KaplanSA , HerschornS , GuanZ . Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU International2006;97(5):1003-6. [sr-incont21882]SwiftS . Efficacy and tolerability of once-daily tolterodine for women with overactive bladder. In: International Continence Society Annual Meeting (ICS), 31st annual meeting; 2001 Sept 18-21; Seoul, Korea. 2001:No. 329. [srincont-14481]SwiftS . Once-daily tolterodine is effective and well tolerated in women with overactive bladder (Abstract 57). In: 2nd International Consultation on Incontinence; 2001 July 1-3; Paris, France. 2001. [srincont-16319]SwiftSE . Once-daily (OD) tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder (OAB). International Urogynecology Journal2000;11(Suppl 1):S15. [sr-incont11906]SwiftSE . Once-daily administration of extended-release tolterodine is effective and well-tolerated in patients with overactive bladder. In: XVI FIGO World Congress of Obstetrics and Gynecology; 2000 Sept 3-8; Washington DC. Vol. Book 1. 2000:40. [sr-incont12085]SwiftSE . Overactive bladder in females: treatment with once-daily tolterodine. International Urogynecology Journal2001;12(Suppl 3):S71. [sr-incont16328]Van KerrebroeckP , KrederK , JonasU , ZinnerN . Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology2001;57(3):414-21. [sr-incont11953]Van KerrebroeckPEV . Long-term (12 months) efficacy and tolerability of tolterodine once-daily in the treatment of overactive bladder. Neurourology and Urodynamics2001;20(4):401-2. [sr-incont15714]Van KerrebroeckPEVA , Tolterodine Study Group. Long-term tolerability and efficacy of once-daily (OD) tolterodine in the treatment of overactive bladder (OB). International Urogynecology Journal2001;12(Suppl 3):S49. [sr-incont16329]Van KerrebroeckPEVA , Tolterodine Study Group. Significant decreases in perception of urgency and urge incontinence episodes with once-daily tolterodine treatment in patients with overactive bladder (Abstract number 89). Neurourology and Urodynamics2000;19(4):493-4. [sr-incont9980]WeinAJ , KhullarV , WangJT , GuanZ . Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. BJU International2007;99(2):360-3. [sr-incont23180]vanKerrebroeckPE , KelleherCJ , CoyneKS , KoppZ , BrodskyM , WangJT . Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. Health and Quality of Life Outcomes2009;7(13):13. [10.1186/1477-7525-7-13] [sr-incont31438]vanKerrebroeckPE , WangJ , GuanZ . Effects of tolterodine extended release in patients with overactive bladder: perceived treatment benefits improve with efficacy (Abstract number 511). European Urology Supplements2004;3(2):130. [sr-incont31090]">Van Kerrebroeck 2001</a>). Of these, five studies included arms using dosages that were not considered therapeutic. These dosages were not combined for data extraction and analysis (<a href="./references#CD003781-bbs2-0012" title="ChalihaC , HalaskaM , StantonS . Trospium chloride for the treatment of detrusor instability: a placebo-controlled dose-finding study (Abstract 276). British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):92. [srincont-8452]">Chaliha 1998</a>; <a href="./references#CD003781-bbs2-0044" title="HommaY , YamaguchiT , YamaguchiOA . A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2008;15(9):809-15. [srincont-27742]">Homma 2008</a>; <a href="./references#CD003781-bbs2-0069" title="Drug company. A phase 2, parallel group, stratified, randomized, double blind, placebo-controlled trial to investigate the efficacy and safety of 3 different dosages of sustained release fesoterodine in subjects with overactive bladder showing either involuntary detrusor contractions or normal findings during the baseline urodynamic assessment. Protocol numbers: A0221029 (SP668). ClinicalStudyResults.org (accessed 3 March 2011). [srincont-41111]NittiV , WiatrakM , KreitmanL , LipsitzD . Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB): results of a phase 2 trial (Abstract number 306). In: International Continence Society (ICS); 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21084]">Nitti 2005</a>; <a href="./references#CD003781-bbs2-0074" title="RentzhogSL , StantonL , CardozoL , NelsonE , FallM , AbramsP . Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. British Journal of Urology1998;81(1):42-8. [srincont-5461]">Rentzhog 1998</a>; <a href="./references#CD003781-bbs2-0091" title="MesselinkEJ , SolerJM , MadersbacherH , ThuroffJW , AmarencoG , Van KerrebroeckEV . Urodynamic aspects of the efficacy of tolterodine, a new anti muscarine drug in the treatment of detrusor hyperreflexia. In: International Continence Society (ICS), 25th Annual Meeting; 1995 Oct 17-20; Sydeney, Australia. 1995:95-6. [srincont-10883]Van KerrebroeckPE , AmarencoG , ThüroffJW , MadersbacherHG , LockMT , MesselinkEJ , et al. Dose-ranging study ot tolterodine in patients with detrusor hyperreflexia. Neurourology and Urodynamics1998;17(5):499-512. [srincont-7852]">Van Kerrebroeck 1998</a>). </p> <p>Eighteen studies investigated two or more different anticholinergic drugs in comparison to placebo (<a href="./references#CD003781-bbs2-0002" title="AbramsP , FreemanR , AnderströmC , MattiassonA . Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. British Journal of Urology1998;81(6):801-10. [srincont-7871]AbramsP , FreemanRN , AnderstromC , MattiassonA . Efficacy and tolerability of tolterodine vs. oxybutynin and placebo in patients with detrusor instability (Abstract). Journal of Urology1997;157(Suppl 4):103. [srincont-16321]">Abrams 1998</a>; <a href="./references#CD003781-bbs2-0014" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. ChappleCR , AranoP , BoschJH , De RidderD , KramerG , RidderAM . YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo- and tolterodine-controlled, phase-II, dose-finding study (Abstract 75). Neurourology and Urodynamics2002;21(4):381-2. [srincont-14551]ChappleCR , ArañoP , BoschJL , De RidderD , KramerAE , RidderAM . Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU International2004;93(1):71-7. [srincont-17334]KelleherCJ , CardozoL , ChappleCR , HaabF , RidderAM . Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU International2005;95(1):81-5. [srincont-20241]SmithN , GrimesI , RidgeS , TempelD , UchidaT , YamanouchiUS . YM905 is effective and safe as treatment of overactive bladder in women and men: results from phase II study (Abstract). In: International Continence Society (ICS), 32nd Annual Meeting; 2002 Aug 28-30; Heidelberg, Germany. 2002:138-9. [sr-incont14508]">Chapple 2004b</a>; <a href="./references#CD003781-bbs2-0015" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. ChappleC , RechbergerT , Al-ShukriS , MeffanP , EveraertK , RidderA . Results of a randomized phase 3 study comparing solifenacin succinate with tolterodine and placebo in patients with symptomatic overactive bladder (Abstract). Neurourology and Urodynamics2003;22(5):534-5. [sr-incont16991]ChappleCR , RechbergerT , Al ShukriS , MeffanP , EveraertK , HuangM , et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU International2004;93(3):303-10. [srincont-17270]">Chapple 2004c</a>; <a href="./references#CD003781-bbs2-0016" title="ChappleC , Van KerrebroeckP , TubaroA , Haag-MolkentellerC , ForstHT , MassowU , et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder [Erratum appears in: European Urology 2008,53(6):1319]. European Urology2007;52(4):1204-12. [NCT00220363] [SP583] [srincont-23875]ChappleC , Van KerrebroeckP , TubaroA , MillardR . Fesoterodine in non-neurogenic voiding dysfunction - results on efficacy and safety in a phase 3 trial (Abstract number 379). In: 21st Annual European Association of Urology (EAU) Congress; 2006 Apr 5-8; Paris, France. 2006. [srincont-41109]ChappleC , Van KerrebroeckP , TubaroA , WangJT , HvidstenK , BrodskyM . Efficacy of fesoterodine in patients with overactive bladder (OAB): improvements in OAB symptoms and health-related quality of life (HRQL) (Poster abstract number 1188). Journal of Urology2007;177(4 Suppl S):392. [srincont-31882]ChappleCR , vanKerrebroeckPE , JünemannKP , WangJT , BrodskyM . Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU International2008;102(9):1128-32. [srincont-29255]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. KelleherCJ , TubaroA , WangJT , KoppZ . Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU International2008;102(1):56-61. [srincont-27613]SandPK , MorrowJD , BavendamT , CreangaDL , NittiVW . Efficacy and tolerability of fesoterodine in women with overactive bladder. International Urogynecology Journal2009;20(7):827-35. [srincont-31351]">Chapple 2007a</a>; <a href="./references#CD003781-bbs2-0022" title="AmarencoG , SutoryM , FagertunH , WrightM , CompionG , De RidderD . Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Preliminary results from the SONIC urodynamic study (Abstract). European Urology, Supplements2012;11(1):e467-a. [EudraCT2006-005523-42] [NCT00629642] [sr-incont65392]AmarencoG , SutoryM , ZachovalR , AgarwalM , DelPG , TretterR , et al. Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study. Neurourology and Urodynamics2017;36(2):414-21. [EudraCT2006-005523-42] [JapicCTI-R130306] [NCT00629642] [sr-incont72248]De RidderD , AmarencoG , Finazzi-AgroE , AnguloJ , KurenkovA , WrightM , et al. Solifenacin treatment for neurogenic detrusor overactivity: patient-reported outcomes (PROs) from the randomised clinical trial SONIC (Abstract number 333). In: International Continence (ICS); 42nd Annual Meeting; 2012 Oct 15-19; Beijing, China. 2012. [905-EC-005] [EudraCT2006-005523-42] [NCT00629642] [TrialID.SONIC.] [srincont-49739]">De Ridder 2012</a>; <a href="./references#CD003781-bbs2-0026" title="DrutzH , AppellRA . Clinical efficacy and safety of Tolterodine vs Oxybutynin and placebo in patients with unstable bladder. Acta Obstetrica et Gynecologica Scandinavica1997;Suppl 167(5):24. [srincont-6671]DrutzHP , AppellRA , GleasonD , KlimbergI , RadomskiS . Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. International Urogynecology Journal and Pelvic Floor Dysfunction1999;10(5):283-9. [srincont-8804]DrutzHP , AppellRA . Enhanced tolerability of tolterodine compared to oxybutynin in a controlled clinical study. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(1):S14. [srincont-5166]">Drutz 1999</a>; <a href="./references#CD003781-bbs2-0039" title="CorcosJ , AnguloJC , GarelyAD , CarlssonM , GongJ , GuanZ . Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. Current Medical Research and Opinion2011;27(5):1059-65. [srincont-41596]EUCTR2006-006935-38-SE. 12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006935-38 (first received 16 April 2007). [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont64612]HerschornS , SwiftS , GuanZ , CarlssonM , BrodskyM , GongJ . Efficacy and safety of fesoterodine for overactive bladder in a double-blind, head-to-head comparison trial with tolterodine ER and placebo (Abstract number 710). In: International Continence Society (ICS), 39th Annual Meeting; 2009 Sep 29-Oct 3; San Francisco, CA. 2009. [srincont-35326]HerschornS , SwiftS , GuanZ , CarlssonM , MorrowJD , BrodskyM , et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU International2010;105(1):58-66. [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont39540]NCT00444925. Clinical trial to evaluate the efficacy and safety of Fesoterodine in comparison to Tolterodine for overactive bladder (OAB) [12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder (OAB)]. clinicaltrials.gov/show/NCT00444925 (first received 08 March 2007). [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont49159]">Herschorn 2009a</a>; <a href="./references#CD003781-bbs2-0043" title="HommaY , KawabeK . Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World Journal of Urology2004;22(4):251-6. [srincont-19412]HommaY , PaickJS , LeeJG , KawabeK , Japanese and Korean Tolterodine Study Group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU International2003;92(7):741-7. [srincont-16418]">Homma 2003</a>; <a href="./references#CD003781-bbs2-0045" title="HommaY , YamaguchiO , Imidafenacin Study Group. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2009;16(5):499-506. [NCT00212732] [ONO-8025-08] [srincont-31368]">Homma 2009</a>; <a href="./references#CD003781-bbs2-0049" title="JunemannKP , Al-ShukriS . Efficacy and tolerability of trospium chloride and tolterodine in 234 patients with urge-syndrome: a double-blind, placebo-controlled, multicentre clinical trial (Abstract number 85B). Neurourology and Urodynamics2000;19(4):488-90. [srincont-9976]">Junemann 2000</a>; <a href="./references#CD003781-bbs2-0051" title="EUCTR2007-006451-39-SE. 12-week, randomized, double-blind, double-dummy, placebo controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-006451-39 (first received 20 February 2008). [A0221046] [EUCTR2007-006451-39-SE] [sr-incont64591]KaplanSA , SchneiderT , FooteJ , GuanZ . Superior efficacy of fesoterodine over tolterodine with rapid onset: a prospective, head-to-head, placebo-controlled trial (Abstract number 67). Neurourology and Urodynamics2010;29(6):905-7. [srincont-40130]KaplanSA , SchneiderT , FooteJE , GuanZ , CarlssonM , GongJ . Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU International2011;107(9):1432-40. [A0221046] [NCT00611026] [srincont-41334]">Kaplan 2011</a>; <a href="./references#CD003781-bbs2-0065" title="ChappleCR , MadersbacherH , DreikornK , DorschnerW , MurtzG . Urodynamics and frequency/volume chart - do they correlate? Treatment analysis of propiverine in comparison to oxybutynin and placebo in urge incontinence (Abstract 224). In: International Continence Society (ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001. [sr-incont14474]HalaskaM , MadersbacherH , VoigtR , HofnerK , MartanA . Propiverine in patients with urgency and urge incontinence - a placebo controlled, multicentre study comparing its tolerability and efficacy with oxybutynin (Abstract number FDP36). International Urogynaecology Journal 2000;11(Suppl 1):S46. [srincont-11912]MadersbacherH , HalaskaM , VoigtR , AlloussiS , HofnerK . A urodynamically controlled multicenter study in patients with urge incontinence: tolerability and efficacy of propiverine hydrochloride in comparison to oxybutynin. In: International Continence Society (ICS), 27th Annual Meeting; 1997 Sep 23-26; Yokohama, Japan. 1997:153-4. [srincont-5854]MadersbacherH , HalaskaM , VoigtR , AlloussiS , HöfnerK . A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU International1999;84(6):646-51. [srincont-9166]">Madersbacher 1999</a>; <a href="./references#CD003781-bbs2-0112" title="AssassaP , WilliamsK , LambertP , AbramsK , TurnerD , ShawC , et al. A double blind randomised placebo controlled trial of the effectiveness of bladder training with oxybutynin or imipramine in the management of detrusor overactivity (DO) (Abstract number 330). In: Joint Meeting of the International Continence Society (ICS) and the International Urogynecological Association; 2010 Aug 23-27; Toronto, Canada. 2010. [ISRCTN58226681] [sr-incont40171]ISRCTN58226681, McGrotherC . Evaluation of the efficacy of oxybutynin and imipramine in the management of detrusor instability. isrctn.org/ISRCTN58226681 (first received 25 October 2000). [DOI: https://doi.org/10.1186/ISRCTN58226681] [ISRCTN58226681] [sr-incont64656]">Assassa 2010</a>; <a href="./references#CD003781-bbs2-0071" title="OlshanskyB , FooteJ , ArguinzonizM , LheritierK , Quebe-FehlingE , SteelM . Cardiovascular safety of darifenacin and tolterodine in patients with overactive bladder (OAB) (Abstract number 49). International Urogynecology Journal and Pelvic Floor Dysfunction2006;17(Suppl 2):S86-7. [sr-incont34186]">Olshansky 2006</a>; <a href="./references#CD003781-bbs2-0078" title="RomanziLJ , DelconteA , KralidisG . Impact of darifenacin compared with tolterodine on incontinence episodes in patients with overactive bladder (Abstract number A3522). Obstetrics and Gynecology2005;105(Suppl 4):88S. [sr-incont34187]">Romanzi 2005</a>; <a href="./references#CD003781-bbs2-0089" title="ThuroffJW , BunkeB , EbnerA , FaberP , deGeeterP , HannappelJ , et al. Randomized, double-blind multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin vs. propantheline vs. placebo. Neurourology and Urodynamics1990;9(4):337-8. [srincont-5108]ThuroffJW , BunkeB , EbnerA , FaberP , deGeeterP , HannappelJ , et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. Journal of Urology1991;145(4):813-7. [srincont-1288]">Thuroff 1991</a>; <a href="./references#CD003781-bbs2-0096" title="YamaguchiO , MaruiE , KakizakiH , ItohN , YokotaT , OkadaH , et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU International2007;100(3):579-87. [sr-incont23865]YokoyamaO , YamaguchiO , KakizakiH , ItohN , YokotaT , OkadaH , et al. Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary. Journal of Urology2011;186(1):170-4. [sr-incont41734]">Yamaguchi 2007</a>; <a href="./references#CD003781-bbs2-0098" title="YamaguchiO , UchidaE , HigoN , MinamiH , KobayashiS , SatoH , et al. Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: a randomized double-blind trial. International Journal of Urology2014;21(6):586-93. [JapicCTI-101309] [sr-incont62099]">Yamaguchi 2014</a>). </p> <p>In the majority of studies, intervention was preceded by run‐in periods of varying lengths and treatment with co‐medications was specifically an exclusion criterion. However, for 20 of the included studies this information was not reported (<a href="./references#CD003781-bbs2-0008" title="BurgioKL , LocherJL , GoodePS , HardinJM , McDowellBJ , CandibD . Behavior vs drug therapy for urge incontinence in older women (Abstract number 26). In: American Urogynecology Society, 15th Annual Scientific Meeting; 1994 Sept 21-24; Toronto, Ontario. 1994:48. [sr-incont14585]BurgioKL , LocherJL , GoodePS , HardinM , McDowellBJ , Dombrowski M et al. Behavioral vs drug treatment for urge urinary incontinence in older women. A randomized controlled trial. JAMA1998;280(23):1995-2000. [srincont-5719]BurgioKL , LocherJL , GoodePS . Combined behavioral and drug therapy for urge incontinence in older women. Journal of the American Geriatrics Society2000;48(4):370-4. [srincont-9006]BurgioKL , LocherJL , RothDL , GoodePS . Psychological improvements associated with behavioral and drug treatment of urge incontinence in older women. Journal of Gerontology. Series B, Psychological Sciences and Social Sciences2001;56(1):P46-51. [srincont-11923]">Burgio 1998</a>; <a href="./references#CD003781-bbs2-0012" title="ChalihaC , HalaskaM , StantonS . Trospium chloride for the treatment of detrusor instability: a placebo-controlled dose-finding study (Abstract 276). British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):92. [srincont-8452]">Chaliha 1998</a>; <a href="./references#CD003781-bbs2-0014" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. ChappleCR , AranoP , BoschJH , De RidderD , KramerG , RidderAM . YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo- and tolterodine-controlled, phase-II, dose-finding study (Abstract 75). Neurourology and Urodynamics2002;21(4):381-2. [srincont-14551]ChappleCR , ArañoP , BoschJL , De RidderD , KramerAE , RidderAM . Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU International2004;93(1):71-7. [srincont-17334]KelleherCJ , CardozoL , ChappleCR , HaabF , RidderAM . Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU International2005;95(1):81-5. [srincont-20241]SmithN , GrimesI , RidgeS , TempelD , UchidaT , YamanouchiUS . YM905 is effective and safe as treatment of overactive bladder in women and men: results from phase II study (Abstract). In: International Continence Society (ICS), 32nd Annual Meeting; 2002 Aug 28-30; Heidelberg, Germany. 2002:138-9. [sr-incont14508]">Chapple 2004b</a>; <a href="./references#CD003781-bbs2-0023" title="ChancellorMB , OefeleinMG , VasavadaS . Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release. Neurourology and Urodynamics2010;29(4):551-4. [sr-incont39591]DmochowskiR , StaskinD , SandP , ZinnerN . Trospium chloride 60 mg once daily improves quality of life in subjects with overactive bladder syndrome (Abstract number 277). In: International Continence Society (ICS); 37th Annual Meeting; 2008 Aug 20-24; Rotterdam, the Netherlands. 2007. [srincont-26679]DmochowskiRR , RosenbergMT , ZinnerNR , StaskinDR , SandPK . Extended-release trospium chloride improves quality of life in overactive bladder. Value in Health2010;13(2):251-7. [srincont-40049]DmochowskiRR , SandPK , ZinnerNR , StaskinDR . Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology2008;71(3):449-54. [srincont-27107]DmochowskiRR , ZinnerNR , SandPK . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: Results from a multicenter, phase III, placebo-controlled study (Abstract). Neurourology and Urodynamics2007;26(Suppl 7):1105-6. [srincont-26692]GinsbergDA , OefeleinMG , EllsworthPI . Once-daily administration of trospium chloride extended release provides 24-hr coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials. Neurourology and Urodynamics2011;30(4):563-7. [sr-incont41531]RovnerE , DmochowskiR , WatanabeJ . Once daily (QD) trospium chloride 60 mg extended release (XR) is safe and effective in patients (PTS) with the overactive bladder (OAB) syndrome who use multiple concomitant medications (MEDS) (Abstract number: Poster #68). Neurourology and Urodynamics2009;28(2):146-7. [sr-incont31062]SandP , DmochowskiR , ZinnerN , StaskinD . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: results from a multicenter, phase III, placebo-controlled study (Abstract number 269). In: International Continence Society (ICS), 37th Annual Meeting; 2007 Aug 20-24; Rotterdam, the Netherlands. 2007. [srincont-26676]SandPK , DmochowskiRR , ZinnerNR , StaskinDR , AppellRA . Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome. International Urogynecology Journal and Pelvic Floor Dysfunction2009;20(12):1431-8. [sr-incont39648]SandPK , Johnson IiTM , RovnerES , EllsworthPI , OefeleinMG , StaskinDR . Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged &gt; 75 years) with overactive bladder syndrome. BJU International2011;107(4):612-20. [sr-incont41422]StaskinDR , RosenbergMT , SandPK , ZinnerNR , DmochowskiRR . Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials. International Journal of Clinical Practice2009;63(12):1715-23. [sr-incont35458]">Dmochowski 2008</a>; <a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>; <a href="./references#CD003781-bbs2-0038" title="HerschornS , HeesakkersJ , Castro-DiazD , WangJT , BrodskyM , GuanZ . Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*. Current Medical Research and Opinion2008;24(12):3513-21. [A6121122] [NCT00143377] [srincont-29250]HerschornS , HeesakkersJ , Castro-DiazD , WangJT , GuanZ , BrodskyM . Tolterodine extended release (TER) improves objective and subjective outcomes after 1 week of treatment in patients with overactive bladder (Abstract number 132). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S78-9. [srincont-26602]">Herschorn 2008</a>; <a href="./references#CD003781-bbs2-0043" title="HommaY , KawabeK . Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World Journal of Urology2004;22(4):251-6. [srincont-19412]HommaY , PaickJS , LeeJG , KawabeK , Japanese and Korean Tolterodine Study Group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU International2003;92(7):741-7. [srincont-16418]">Homma 2003</a>; <a href="./references#CD003781-bbs2-0046" title="HuangA , HessR , AryaL , RichterH , SubakL , BradleyC , et al. A randomized controlled trial of simple diagnosis and treatment for urgency urinary incontinence in women (Abstract). Journal of General Internal Medicine2011;26:S1. [NCT00862745] [sr-incont64391]HuangAJ , HessR , AryaLA , RichterHE , SubakLL , BradleyCS , et al. Pharmacologic treatment for urgency-predominant urinary incontinence in women diagnosed using a simplified algorithm: a randomized trial. American Journal of Obstetrics and Gynecology2012;206(5):444.e1-11. [GA0221IX] [NCT00862745] [TrialID.BRIDGES.] [srincont-44636]NCT00862745, BrownJ . Bringing simple urge incontinence diagnosis &amp; treatment to providers (BRIDGES)  [A multi-center, randomized, placebo-controlled clinical trial comparing fesoterodine to placebo in women diagnosed with urge urinary incontinence by the 3 Incontinence Questions (3IQ). Followed by a multi-center open label clinical cohort study of long-term effects of treatment with fesoterodine ]. clinicaltrials.gov/show/NCT00862745 (first received 17 March 2009). [NCT00862745] [sr-incont49836]WarsiQ , HuangA , BrownJS , SchembriM , HessR , AryaLA , et al. The effect of pharmacologic treatment of urgency urinary incontinence on sleep quality and daytime sleepiness (Abstract number: paper 37). Female Pelvic Medicine and Reconstructive Surgery2016;22(5 ):S17-8. [NCT00862745] [TrialID.BRIDGES.] [sr-incont78633]WarsiQA , HuangAJ , HessR , AryaLA , RichterHE , BradleyCS , et al. Association of pharmacologic treatment of urgency urinary incontinence with sleep quality and daytime sleepiness. Obstetrics and Gynecology2018;131(2):204-11. [NCT00862745] [sr-incont78239]WinkelmanW , HuangA , SchembriM , RogersRG , RichterHE , MyersDL , et al. Clinical variables moderating response to pharmacologic treatment of urgency-predominant urinary incontinence in a randomized controlled trial (Abstract number: poster 25). In: Female Pelvic Medicine and Reconstructive Surgery. 37th Annual Scientific Meeting of the American Urogynecologic Society; Aug 2016; United States. Vol. 22. Netherlands: Lippincott Williams and Wilkins, 2016:S81. [NCT00862745] [sr-incont78634]WinkelmanWD , HuangAJ , SchembriM , RogersRG , RichterH , MyersDL , et al. Modifiers of response to treatment with fesoterodine for urgency-predominant urinary incontinence in a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2017;23(2):151-6. [sr-incont74308]">Huang 2012</a>; <a href="./references#CD003781-bbs2-0053" title="CapoJP , TogliaM , Forero-SchwanhaeuserS , HeW . Patients reporting severe overactive bladder symptoms: effects of solifenacin treatment on objective measures and patient-reported outcomes (Abstract number 582). In: International Continence Society (ICS), 38th Annual Meeting; 2008 Oct 20-24; Cairo, Egypt. 2008. [srincont-31844]CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. KarramMM , TogliaMR , SerelsSR , AndohM , FakhouryA , Forero-SchwanhaeuserS . Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology2009;73(1):14-8. [A0221094] [NCT00454896] [TrialID.VENUS.] [srincont-29219]SerelsSR , TogliaMR , Forero-SchwanhaeuserS , HeW . Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms. Current Medical Research and Opinion2010;26(10):2277-85. [srincont-40376]StaskinD , DmochowskiR , SerelsS , AndohM , SmithN . Report from a randomized, placebo-controlled study showing significant improvement in urgency and patient-reported outcomes in overactive bladder patients treated with solifenacin (Abstract number 124). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73-4. [srincont-26600]TogliaM , AndohM , HussainI . Solifenacin improved warning time significantly compared to placebo in patients with overactive bladder (Abstract number 123). Neurourology and Urodynamics2006;25(6):655. [srincont-26629]TogliaM , AndohM , HussainI . Solifenacin improves urgency symtoms as assessed by voiding diaries and patient-reported outcomes (PRO) in patients with overactive bladder (Abstract number 155). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26636]TogliaMR , OstergardDR , AppellRA , AndohM , FakhouryA , HussainIF . Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status. International Urogynecology Journal2010;21(7):847-54. [srincont-40094]TogliaMR , SerelsSR , LarameeC , KarramMM , NandyIM , AndohM , et al. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial. Postgraduate Medicine2009;121(5):151-8. [srincont-34204]ZinnerS , HerschornS , AndohM , HussainI . Responder analyses show statistically significant improvements in incontinence and urgency are associated with reduction in symptom bother and improvement in health-related quality of life: VENUS results (Abstract number 123). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73. [srincont-26599]">Karram 2009</a>; <a href="./references#CD003781-bbs2-0063" title="LeeKS , ChooMS , KimDY , KimJC , KimHJ , MinKS , et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. Journal of Urology2005;174(4 Pt 1):1334-8. [sr-incont21016]LeeKS , ChooMS , PaickJS , LeeJG , SeoJT , LeeJZ , et al. Propiverine hydrochloride reduced frequency and perception of urgency in treatment of overactive bladder: a 12 week prospective, randomized, double blind, placebo controlled study (Abstract number 279). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26640]LeeKS , LeeHW , ChooMS , PaickJS , LeeJG , SeoJT , et al. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'. BJU International2010;105(11):1565-70. [2005-01-08] [NCT00903045] [PROUD] [sr-incont39958]NCT00903045. Urinary urgency outcomes following propiverine treatment for an overactive bladder [Urinary urgency outcomes following propiverine treatment for an overactive bladder: propiverine study on overactive bladder including urgency data (PROUD)]. clinicaltrials.gov/show/NCT009030452005;(first received 15 May 2009). [2005-01-08] [NCT00903045] [TrialID.PROUD] [sr-incont49860]">Lee 2006</a>; <a href="./references#CD003781-bbs2-0077" title="RogersR , BachmannG , JumadilovaZ , SunF , MorrowJD , GuanZ , et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. International Urogynecology Journal and Pelvic Floor Dysfunction2008;19(11):1551-7. [A6121002] [NCT00143481] [srincont-27729]RogersRG , BachmannG , ScarperoH , JumadilovaZ , SunF , MorrowJD , et al. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. Current Medical Research and Opinion2009;25(9):2159-65. [srincont-32060]">Rogers 2008</a>; <a href="./references#CD003781-bbs2-0078" title="RomanziLJ , DelconteA , KralidisG . Impact of darifenacin compared with tolterodine on incontinence episodes in patients with overactive bladder (Abstract number A3522). Obstetrics and Gynecology2005;105(Suppl 4):88S. [sr-incont34187]">Romanzi 2005</a>; <a href="./references#CD003781-bbs2-0080" title="RudyD , ClineK , GoldbergK , HarrisR . A multicenter, randomized, placebo-controlled trial of trospium chloride in overactive bladder patients (Abstract). Neurourology and Urodynamics2004;23(5/6):600-1. [sr-incont19025]RudyD , ClineK , HarrisR , GoldbergK , DmochowskiR . Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology2006;67(2):275-80. [srincont-21604]RudyD , ClineK , HarrisR , GoldbergK , DmochowskiR . Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. BJU International2006;97(3):540-6. [sr-incont21593]">Rudy 2006</a>; <a href="./references#CD003781-bbs2-0086" title="StohrerM , MadersbacherH , RichterR , WehnertJ , DreikornK . Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia - a double-blind, placebo-controlled clinical trial. Spinal Cord1999;37(3):196-200. [sr-incont8146]">Stohrer 1999</a>; <a href="./references#CD003781-bbs2-0087" title="TagoK , UenoA , TakayasuH . Clinical study of propiverine hydrochloride for the treatment of patients with urinary frequency and incontinence. Neurourology and Urodynamics1990;9(4):337-8. [srincont-5109]">Tago 1990</a>; <a href="./references#CD003781-bbs2-0093" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CrosbyRD , MathiasSD , MarshallTS . Relationships between symptoms, symptom bother, and health-related quality of life in patients with overactive bladder taking solifenacin or placebo in the VIBRANT study. International Journal of Clinical Practice2011;65(2):211-8. [sr-incont41015]GollarKM , YoungDG , BailenJ , HeW , Forero-SchwanhaeuserS . Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: a secondary analysis of the VIBRANT study. Urologic Nursing2012;32(1):38-46. [TrialID.VIBRANT.] [sr-incont44571]Samuels T‐A, MitchesonHD , VardyM , Forero‐SchwanhaeuserS , MarshallT , HeW . Efficacy of solifenacin for symptom bother and other patient-reported outcomes in patients with overactive bladder (OAB): results of a large, double-blind, placebo-controlled trial (Abstract number: poster #74). Neurourology and Urodynamics2009;28(2):149. [sr-incont31063]VardyMD , MitchesonHD , SamuelsTA , Forero-SchwanhaeuserS , HeW . Efficacy of solifenacin on overactive bladder symptoms, symptom bother, and other patient-reported outcomes in subjects with or without incontinence: a post hoc analysis of data from VIBRANT. Female Pelvic Medicine and Reconstructive Surgery2011;17(1):24-9. [TrialID.VIBRANT.] [sr-incont44741]VardyMD , MitchesonHD , SamuelsTA , WegenkeJD , Forero-SchwanhaeuserS , MarshallTS , et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. International Journal of Clinical Practice2009;63(12):1702-14. [905-UC-010] [NCT00573508] [TrialID.VIBRANT.] [sr-incont35459]">Vardy 2009</a>; <a href="./references#CD003781-bbs2-0094" title="EUCTR2007-007087-17-SE. A 24-week, multicentre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-007087-17 (first received 13 June 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont64588]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00798434. A study to compare the effectiveness and safety of fesoterodine and placebo in an elderly population of patients who go to the toilet very frequently due to overactive bladder (SOFIA) [A 24-week, multi-centre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00798434 (first received 26 November 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont49847]SchneiderT , BergqvistA , WangJ , WaggA , Ebel-BitounC . Treatment with fesoterodine versus tolterodine for reducing symptom bother in elderly patients with overactive bladder including urgency urinary incontinence. European Urology, Supplements2012;11(1):e687-a. [sr-incont65389]WaggA , CarlssonM , ElsobkyM , FernetM . Effect of flexible dose fesoterodine on cognitive function in &gt;65 year old patients with OAB: data from two RCT (Abstract number 438). Neurourology and Urodynamics2019;38:S297-8. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78651]WaggA , DarekarA , ArumiD , KhullarV , OelkeM . Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people &gt;65 years of age: a post hoc analysis of data from the SOFIA study. Neurourology and Urodynamics2015;34(5):438-43. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont68100]WaggA , ElsobkyM , CarlssonM , FernetM . Response and cognitive safety of fesoterodine in patients &gt;65y old with OAB. Is there a relationship between cognition and treatment response? (Abstract number 183). Neurourology and Urodynamics2019;38:S118-20. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78632]WaggA , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. Journal of the American Geriatrics Society2013;61(2):185-93. [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TrialID.SOFIA.] [sr-incont48008]WaggAS , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Efficacy and tolerability of fesoterodine in older subjects with overactive bladder: results of SOFIA (Abstract number C33). Journal of the American Geriatrics Society2011;59:S124. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont65234]">Wagg 2013a</a>; <a href="./references#CD003781-bbs2-0104" title="ZinnerN , SussetJ , GittelmanM , ArguinzonizM , RekedaL , HaabF . Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. International Journal of Clinical Practice2006;60(1):119-26. [sr-incont21507]">Zinner 2006</a>). </p> <p>In a majority of the studies, the length of the treatment was 12 weeks (<a href="./references#CD003781-bbs2-0002" title="AbramsP , FreemanR , AnderströmC , MattiassonA . Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. British Journal of Urology1998;81(6):801-10. [srincont-7871]AbramsP , FreemanRN , AnderstromC , MattiassonA . Efficacy and tolerability of tolterodine vs. oxybutynin and placebo in patients with detrusor instability (Abstract). Journal of Urology1997;157(Suppl 4):103. [srincont-16321]">Abrams 1998</a>; <a href="./references#CD003781-bbs2-0003" title="AbramsP , KaplanS , MillardR . Tolterodine treatment is safe in men with bladder outlet obstruction (BOO) and symptomatic detrusor overactivity (DO) (Abstract). Neurourology and Urodynamics2001;20(4):547-8. [srincont-14372]">Abrams 2001</a>; <a href="./references#CD003781-bbs2-0004" title="AbramsP , KelleherC , StaskinD , KayR , MartanA , MincikI , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World Journal of Urology2017;35(5):827-38. [NCT01340027] [sr-incont77897]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Cardiovascular safety of combination treatment with mirabegron and solifenacin in patients with overactive bladder in a randomised, double-blind, dose-ranging, Phase II study (Symphony) (Abstract). European Urology, Supplements2014;13(1):e574-e574a. [NCT01340027] [sr-incont67160]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB) - efficacy and safety results from a randomised phase II study (Symphony) (Abstract number 295). Neurourology and Urodynamics2013;32(6):930-1. [NCT01340027] [TrialID.SYMPHONY.] [sr-incont49188]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB): safety results from a phase 2 study (Abstract number MP-16.08). Urology2013;82(3 Suppl 1):S139. [NCT01340027] [sr-incont66675]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: Exploratory responder analyses of efficacy and evaluation of patient reported outcomes from a randomised, double-blind, dose-ranging, phase 2 study (Symphony) (Abstract number MP-24.11). Urology2014;84(4 Suppl 1):S145-6. [NCT01340027] [sr-incont67194]AbramsP , KelleherC , StaskinD , RechbergerT , KayR , MartinaR , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (SYMPHONY). European Urology2015;67(3):577-88. [NCT01340027] [sr-incont66674]NCT01340027, Bristol Urological Institute . A study to evaluate the efficacy, safety and tolerability of mirabegron and solifenacin succinate alone and in combination for the treatment of overactive bladder (symphony) [A randomized, double-blind, factorial, parallel-group, active and placebo-controlled, multicenter dose-ranging study to evaluate the efficacy, safety and tolerability of six dose combinations of solifenacin succinate and mirabegron compared to mirabegron and solifenacin succinate monotherapies in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01340027 (first received 21 April 2011). [178-CL-100] [2010-020601-32] [NCT01340027] [TrialID.SYMPHONY] [sr-incont44510]NittiV , AbramsP , StaskinD , AuerbachS , MartinaR , VanMR . Urinary retention in patients with overactive bladder treated with mirabegron alone and in combination with solifenacin: the results of two randomized, double-blind, phase II studies (Abstract number MP76-13). Journal of Urology2014;191(4 Suppl 1):e886-7. [NCT00410514] [NCT01340027] [TrialID.SYMPHONY] [sr-incont67453]">Abrams 2013</a>; <a href="./references#CD003781-bbs2-0007" title="BrayR , CartwrightR , CardozoL , HillS , GuanZ , KhullarV . Tolterodine ER reduced increased bladder wall thickness in women with overactive bladder. A randomized, placebo-controlled, double-blind, parallel group study. Neurourology and  Urodynamics2018;37(1):237-43. [NCT00137397] [sr-incont74473]NCT00137397. A study to measure the effect of tolterodine extended release on the thickness of the bladder wall in patients with overactive bladder [A multi-centre, randomised, placebo controlled, double blind, parallel group study in female patients to evaluate whether tolterodine ER can reverse the increased bladder wall thickness in patients with overactive bladder]. clinicaltrials.gov/show/NCT00137397 (first received 29 August 2005). [NCT00137397] [sr-incont63809]">Bray 2018</a>; <a href="./references#CD003781-bbs2-0010" title="CardozoL , KuzminI , LisecML , MillardR , vanVierssen TripOB , RidderAM , et al. YM905: Results of a randomised, double-blind placebo-controlled trial in patients with symptomatic overactive bladder (Abstract number 104). European Urology Supplements2003;2(1):28. [sr-incont27407]CardozoL , KuzminI , LisecML , MillardRJ , vanVierssen TripOB , RidderAM , et al. A double-blind, randomised, placebo-controlled trial with YM905 in symptomatic overactive bladder (Abstract number P74). Journal of the American Geriatrics Society2003;51 (Suppl 4):S68-9. [sr-incont31100]CardozoL , LisecM , MillardR , vanVierssen TripO , KuzminI , DrogendijkTE , et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. Journal of Urology2004;172(5 (Pt 1 of 2)):1919-24. [srincont-19090]CardozoL . A randomised double-blind, placebo-controlled trial of the once-daily muscarinic receptor antagonist solifenacin succinate for symptoms of overactive bladder (Abstract number 211). International Urogynecology Journal2003;14 (Suppl 1):S64. [sr-incont31104]CardozoL . Solifenacin succinate improves symptoms of an overactive bladder (Abstract number TP77). International Journal of Gynecology and Obstetrics2003;83(Suppl 3):94. [sr-incont31096]KelleherCJ , CardozoL , ChappleCR , HaabF , RidderAM . Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU International2005;95(1):81-5. [srincont-20241]">Cardozo 2004a</a>; <a href="./references#CD003781-bbs2-0013" title="ChappleC . Fesoterodine a new effective and well-tolerated antimuscarinic for the treatment of urgency-frequency syndrome: results of a phase 2 controlled study (Abstract 142). Neurourology and Urodynamics2004;23(5/6):598-9. [srincont-19023]Drug company. A Phase 2, parallel group, randomized, double-blind, placebo controlled dose-ranging trial to determine the optimal dose and the tolerability of sustained release SPM 8272 (fesoterodine) in subjects with non-neurogenic bladder overactivity. Protocol numbers: A0221027 (SP582). ClinicalStudyResults.org (accessed 3 March 2011)2002. [Protocol numbers: A0221027 (SP582)] [srincont-41110]">Chapple 2004a</a>; <a href="./references#CD003781-bbs2-0014" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. ChappleCR , AranoP , BoschJH , De RidderD , KramerG , RidderAM . YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo- and tolterodine-controlled, phase-II, dose-finding study (Abstract 75). Neurourology and Urodynamics2002;21(4):381-2. [srincont-14551]ChappleCR , ArañoP , BoschJL , De RidderD , KramerAE , RidderAM . Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU International2004;93(1):71-7. [srincont-17334]KelleherCJ , CardozoL , ChappleCR , HaabF , RidderAM . Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU International2005;95(1):81-5. [srincont-20241]SmithN , GrimesI , RidgeS , TempelD , UchidaT , YamanouchiUS . YM905 is effective and safe as treatment of overactive bladder in women and men: results from phase II study (Abstract). In: International Continence Society (ICS), 32nd Annual Meeting; 2002 Aug 28-30; Heidelberg, Germany. 2002:138-9. [sr-incont14508]">Chapple 2004b</a>; <a href="./references#CD003781-bbs2-0015" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. ChappleC , RechbergerT , Al-ShukriS , MeffanP , EveraertK , RidderA . Results of a randomized phase 3 study comparing solifenacin succinate with tolterodine and placebo in patients with symptomatic overactive bladder (Abstract). Neurourology and Urodynamics2003;22(5):534-5. [sr-incont16991]ChappleCR , RechbergerT , Al ShukriS , MeffanP , EveraertK , HuangM , et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU International2004;93(3):303-10. [srincont-17270]">Chapple 2004c</a>; <a href="./references#CD003781-bbs2-0016" title="ChappleC , Van KerrebroeckP , TubaroA , Haag-MolkentellerC , ForstHT , MassowU , et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder [Erratum appears in: European Urology 2008,53(6):1319]. European Urology2007;52(4):1204-12. [NCT00220363] [SP583] [srincont-23875]ChappleC , Van KerrebroeckP , TubaroA , MillardR . Fesoterodine in non-neurogenic voiding dysfunction - results on efficacy and safety in a phase 3 trial (Abstract number 379). In: 21st Annual European Association of Urology (EAU) Congress; 2006 Apr 5-8; Paris, France. 2006. [srincont-41109]ChappleC , Van KerrebroeckP , TubaroA , WangJT , HvidstenK , BrodskyM . Efficacy of fesoterodine in patients with overactive bladder (OAB): improvements in OAB symptoms and health-related quality of life (HRQL) (Poster abstract number 1188). Journal of Urology2007;177(4 Suppl S):392. [srincont-31882]ChappleCR , vanKerrebroeckPE , JünemannKP , WangJT , BrodskyM . Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU International2008;102(9):1128-32. [srincont-29255]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. KelleherCJ , TubaroA , WangJT , KoppZ . Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU International2008;102(1):56-61. [srincont-27613]SandPK , MorrowJD , BavendamT , CreangaDL , NittiVW . Efficacy and tolerability of fesoterodine in women with overactive bladder. International Urogynecology Journal2009;20(7):827-35. [srincont-31351]">Chapple 2007a</a>; <a href="./references#CD003781-bbs2-0017" title="ChappleC , DuBeauC , EbingerU , RekedaL , ViegasA . Darifenacin treatment of patients &gt;or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Current Medical Research and Opinion2007;23(10):2347-58. [srincont-23921]">Chapple 2007b</a>; <a href="./references#CD003781-bbs2-0020" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. [sr-incont75259]ChuF , SmithN , UchidaT . Efficacy and safety of solifenacin succinate 10 mg once daily: a multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder. Current Therapeutic Research - Clinical and Experimental2009;70(6):405-20. [srincont-43324]">Chu 2009</a>; <a href="./references#CD003781-bbs2-0021" title="ChuaME , SeeMC , EsmeňaEB , BalingitJC , MoralesML . Efficacy and safety of gabapentin in comparison to solifenacin succinate in adult overactive bladder treatment. Lower Urinary Tract Symptoms2018;10(2):135-42. [NCT01486706] [sr-incont74529]NCT01486706, ChuaME . Efficacy and safety of gabapentin in treating overactive bladder (OAB). clinicaltrials.gov/show/NCT01486706 (first received 6 December 2011). [NCT01486706] [SLMC10-010] [sr-incont49864]">Chua 2018</a>; <a href="./references#CD003781-bbs2-0023" title="ChancellorMB , OefeleinMG , VasavadaS . Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release. Neurourology and Urodynamics2010;29(4):551-4. [sr-incont39591]DmochowskiR , StaskinD , SandP , ZinnerN . Trospium chloride 60 mg once daily improves quality of life in subjects with overactive bladder syndrome (Abstract number 277). In: International Continence Society (ICS); 37th Annual Meeting; 2008 Aug 20-24; Rotterdam, the Netherlands. 2007. [srincont-26679]DmochowskiRR , RosenbergMT , ZinnerNR , StaskinDR , SandPK . Extended-release trospium chloride improves quality of life in overactive bladder. Value in Health2010;13(2):251-7. [srincont-40049]DmochowskiRR , SandPK , ZinnerNR , StaskinDR . Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology2008;71(3):449-54. [srincont-27107]DmochowskiRR , ZinnerNR , SandPK . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: Results from a multicenter, phase III, placebo-controlled study (Abstract). Neurourology and Urodynamics2007;26(Suppl 7):1105-6. [srincont-26692]GinsbergDA , OefeleinMG , EllsworthPI . Once-daily administration of trospium chloride extended release provides 24-hr coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials. Neurourology and Urodynamics2011;30(4):563-7. [sr-incont41531]RovnerE , DmochowskiR , WatanabeJ . Once daily (QD) trospium chloride 60 mg extended release (XR) is safe and effective in patients (PTS) with the overactive bladder (OAB) syndrome who use multiple concomitant medications (MEDS) (Abstract number: Poster #68). Neurourology and Urodynamics2009;28(2):146-7. [sr-incont31062]SandP , DmochowskiR , ZinnerN , StaskinD . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: results from a multicenter, phase III, placebo-controlled study (Abstract number 269). In: International Continence Society (ICS), 37th Annual Meeting; 2007 Aug 20-24; Rotterdam, the Netherlands. 2007. [srincont-26676]SandPK , DmochowskiRR , ZinnerNR , StaskinDR , AppellRA . Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome. International Urogynecology Journal and Pelvic Floor Dysfunction2009;20(12):1431-8. [sr-incont39648]SandPK , Johnson IiTM , RovnerES , EllsworthPI , OefeleinMG , StaskinDR . Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged &gt; 75 years) with overactive bladder syndrome. BJU International2011;107(4):612-20. [sr-incont41422]StaskinDR , RosenbergMT , SandPK , ZinnerNR , DmochowskiRR . Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials. International Journal of Clinical Practice2009;63(12):1715-23. [sr-incont35458]">Dmochowski 2008</a>; <a href="./references#CD003781-bbs2-0024" title="DmochowskiR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. A double-blind, placebo-controlled trial of flexible-dose fesoterodine for overactive bladder (Abstract number 715). In: International Continence Society (ICS); 39th Annual Meeting; 2009 Sep 29-Oct 03; San Francisco, CA. 2009. [sr-incont35627]DmochowskiRR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder [Errata appear in: Urology 2010 Jun;75(6):1519 and in Urology 2011 Jun;77(6):1513]. Urology2010;75(1):62-8. [A0221014] [NCT00536484] [sr-incont39548]DuBeauC , KrausSR , SunF , MorrowJD . Fesoterodine in older vs younger subjects with overactive bladder (Abstract number D87). Journal of the American Geriatrics Society2010;58:S218. [NCT00536484] [sr-incont64309]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. [sr-incont78640]NCT00536484. Fesoterodine flexible dose study [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with overactive bladder]. clinicaltrials.gov/show/NCT00536484 (first received 27 September 2007). [NCT00536484] [sr-incont49160]StaskinD , KhullarV , MichelMC , MorrowJD , SunF , GuanZ , et al. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. Neurourology and Urodynamics2011;30(8):1480-5. [sr-incont42686]">Dmochowski 2010</a>; <a href="./references#CD003781-bbs2-0026" title="DrutzH , AppellRA . Clinical efficacy and safety of Tolterodine vs Oxybutynin and placebo in patients with unstable bladder. Acta Obstetrica et Gynecologica Scandinavica1997;Suppl 167(5):24. [srincont-6671]DrutzHP , AppellRA , GleasonD , KlimbergI , RadomskiS . Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. International Urogynecology Journal and Pelvic Floor Dysfunction1999;10(5):283-9. [srincont-8804]DrutzHP , AppellRA . Enhanced tolerability of tolterodine compared to oxybutynin in a controlled clinical study. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(1):S14. [srincont-5166]">Drutz 1999</a>; <a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>; <a href="./references#CD003781-bbs2-0028" title="ElbasetM , TahaD , ZahranM , EzzatO , ElhefnawyAS , ElkenawyM , et al. Subjective and objective scales assessment after retreatment with anticholinergics post botox-faded effects in refractory idiopathic overactive bladder: a prospective single blinded randomized trial (Abstract number 132). European Urology, supplements2019;18(1):e172. [sr-incont78652]ElbasetMA , TahaDE , El-HefnawyAS , ZahranMH , ShokeirAA . Assessment of anticholinergic use after fading of BTX-A effects in refractory idiopathic overactive bladder: a prospective blinded randomized trial. International Neurourology Journal2019;23(3):240-8. [sr-incont78605]">Elbaset 2019</a>; <a href="./references#CD003781-bbs2-0033" title="GotohM , HommaY , YokoyamaO , NishizawaO . Responsiveness and minimal clinically important change in overactive bladder symptom score. Urology2011;78(4):768-73. [srincont-42622]GotohM , YokoyamaO , MatsukawaY , NishizawaO . Responsiveness of overactive bladder symptom score (OABSS): verification based on data in a double-blinded, randomized placebo-controlled study of propiverine hydrochloride in Japanese patients (Abstract number 338). In: Joint Meeting of the International Continence Society (ICS) and the International Urogynecological Association; 2010 Aug 23-27; Toronto, Canada. 2010. [srincont-40173]GotohM , YokoyamaO , NishizawaO . Propiverine hydrochloride in Japanese patients with overactive bladder: A randomized, double-blind, placebo-controlled trial. International Journal of Urology2011;18(5):365-73. [srincont-41510]">Gotoh 2011</a>; <a href="./references#CD003781-bbs2-0035" title="HaabF , StewartL , DwyerP . Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. European Urology2004;45(4):420-9. [srincont-17428]">Haab 2004</a>; <a href="./references#CD003781-bbs2-0038" title="HerschornS , HeesakkersJ , Castro-DiazD , WangJT , BrodskyM , GuanZ . Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*. Current Medical Research and Opinion2008;24(12):3513-21. [A6121122] [NCT00143377] [srincont-29250]HerschornS , HeesakkersJ , Castro-DiazD , WangJT , GuanZ , BrodskyM . Tolterodine extended release (TER) improves objective and subjective outcomes after 1 week of treatment in patients with overactive bladder (Abstract number 132). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S78-9. [srincont-26602]">Herschorn 2008</a>; <a href="./references#CD003781-bbs2-0039" title="CorcosJ , AnguloJC , GarelyAD , CarlssonM , GongJ , GuanZ . Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. Current Medical Research and Opinion2011;27(5):1059-65. [srincont-41596]EUCTR2006-006935-38-SE. 12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006935-38 (first received 16 April 2007). [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont64612]HerschornS , SwiftS , GuanZ , CarlssonM , BrodskyM , GongJ . Efficacy and safety of fesoterodine for overactive bladder in a double-blind, head-to-head comparison trial with tolterodine ER and placebo (Abstract number 710). In: International Continence Society (ICS), 39th Annual Meeting; 2009 Sep 29-Oct 3; San Francisco, CA. 2009. [srincont-35326]HerschornS , SwiftS , GuanZ , CarlssonM , MorrowJD , BrodskyM , et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU International2010;105(1):58-66. [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont39540]NCT00444925. Clinical trial to evaluate the efficacy and safety of Fesoterodine in comparison to Tolterodine for overactive bladder (OAB) [12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder (OAB)]. clinicaltrials.gov/show/NCT00444925 (first received 08 March 2007). [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont49159]">Herschorn 2009a</a>; <a href="./references#CD003781-bbs2-0040" title="EUCTR2012-005735-91-SK. A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-005735-91 (first received 12 November 2013). [178-CL-101] [EUCTR2012-005735-91-SK] [sr-incont78644]HerschornS , ChappleCR , AbramsP , ArlandisS , MitchesonD , LeeKS , et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU International2017;120(4):562-75. [NCT01972841] [sr-incont74470]MuellerER , RobinsonD , KelleherC , StaskinDR , FalconerC , WangJ , et al. Patient reported outcomes from synergy, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with mirabegron and solifenacin monotherapy (Abstract number - Podium #44). Neurourology and Urodynamics2017;36(Suppl S1):S151-2. [NCT01972841] [sr-incont75944]NCT01972841. This was a multinational study comparing the efficacy and safety of two medicines, solifenacin succinate and mirabegron taken together, or separately, or a mock treatment (placebo) in subjects with symptoms of overactive bladder (SYNERGY) [A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01972841 (first received 31 October 2013). [178-CL-101] [EUCTR2012-005735-91] [NCT01972841] [sr-incont63780]RobinsonD , KelleherC , StaskinD , MuellerER , FalconerC , WangJ , et al. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients. Neurourology and Urodynamics2018;37(1):394-406. [NCT01972841] [sr-incont76906]WeberMA , ChappleCR , GratzkeC , HerschornS , RobinsonD , FrankelJM , et al. A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial. Blood Pressure Monitoring2018;23(3):153-63. [NCT01972841] [sr-incont77899]WhiteWB , ChappleC , GratzkeC , HerschornS , RobinsonD , FrankelJ , et al. Cardiovascular safety of the beta3-adrenoceptor agonist mirabegron and the antimuscarinic agent solifenacin in the SYNERGY trial. Journal of Clinical Pharmacology2018;58(8):1084-91. [NCT01972841] [sr-incont78078]">Herschorn 2017a</a>; <a href="./references#CD003781-bbs2-0041" title="HerschornS , KohanA , AliottaP , McCammonK , SriramR , AbramsS , et al. The efficacy and safety of onabotulinumtoxin A or solifenacin compared with placebo in solifenacin naive patients with refractory overactive bladder: results from a multicenter, randomized, double-blind phase 3b trial. Journal of Urology2017;198(1):167-75. [NCT01767519] [sr-incont74491]NCT01767519. A study evaluating the efficacy and safety of BOTOX® or solifenacin in patients with overactive bladder and urinary incontinence. clinicaltrials.gov/show/NCT01767519 (first received 14 January 2013). [191622-125] [NCT01767519] [sr-incont49909]">Herschorn 2017b</a>; <a href="./references#CD003781-bbs2-0042" title="HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21072]HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21072]HillS , KhullarV , WyndaeleJJ , LheritierK , . Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. International Urogynecology Journal and Pelvic Floor2006;17(3):239-47. [srincont-22464]">Hill 2005</a>; <a href="./references#CD003781-bbs2-0043" title="HommaY , KawabeK . Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World Journal of Urology2004;22(4):251-6. [srincont-19412]HommaY , PaickJS , LeeJG , KawabeK , Japanese and Korean Tolterodine Study Group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU International2003;92(7):741-7. [srincont-16418]">Homma 2003</a>; <a href="./references#CD003781-bbs2-0044" title="HommaY , YamaguchiT , YamaguchiOA . A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2008;15(9):809-15. [srincont-27742]">Homma 2008</a>; <a href="./references#CD003781-bbs2-0045" title="HommaY , YamaguchiO , Imidafenacin Study Group. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2009;16(5):499-506. [NCT00212732] [ONO-8025-08] [srincont-31368]">Homma 2009</a>; <a href="./references#CD003781-bbs2-0046" title="HuangA , HessR , AryaL , RichterH , SubakL , BradleyC , et al. A randomized controlled trial of simple diagnosis and treatment for urgency urinary incontinence in women (Abstract). Journal of General Internal Medicine2011;26:S1. [NCT00862745] [sr-incont64391]HuangAJ , HessR , AryaLA , RichterHE , SubakLL , BradleyCS , et al. Pharmacologic treatment for urgency-predominant urinary incontinence in women diagnosed using a simplified algorithm: a randomized trial. American Journal of Obstetrics and Gynecology2012;206(5):444.e1-11. [GA0221IX] [NCT00862745] [TrialID.BRIDGES.] [srincont-44636]NCT00862745, BrownJ . Bringing simple urge incontinence diagnosis &amp; treatment to providers (BRIDGES)  [A multi-center, randomized, placebo-controlled clinical trial comparing fesoterodine to placebo in women diagnosed with urge urinary incontinence by the 3 Incontinence Questions (3IQ). Followed by a multi-center open label clinical cohort study of long-term effects of treatment with fesoterodine ]. clinicaltrials.gov/show/NCT00862745 (first received 17 March 2009). [NCT00862745] [sr-incont49836]WarsiQ , HuangA , BrownJS , SchembriM , HessR , AryaLA , et al. The effect of pharmacologic treatment of urgency urinary incontinence on sleep quality and daytime sleepiness (Abstract number: paper 37). Female Pelvic Medicine and Reconstructive Surgery2016;22(5 ):S17-8. [NCT00862745] [TrialID.BRIDGES.] [sr-incont78633]WarsiQA , HuangAJ , HessR , AryaLA , RichterHE , BradleyCS , et al. Association of pharmacologic treatment of urgency urinary incontinence with sleep quality and daytime sleepiness. Obstetrics and Gynecology2018;131(2):204-11. [NCT00862745] [sr-incont78239]WinkelmanW , HuangA , SchembriM , RogersRG , RichterHE , MyersDL , et al. Clinical variables moderating response to pharmacologic treatment of urgency-predominant urinary incontinence in a randomized controlled trial (Abstract number: poster 25). In: Female Pelvic Medicine and Reconstructive Surgery. 37th Annual Scientific Meeting of the American Urogynecologic Society; Aug 2016; United States. Vol. 22. Netherlands: Lippincott Williams and Wilkins, 2016:S81. [NCT00862745] [sr-incont78634]WinkelmanWD , HuangAJ , SchembriM , RogersRG , RichterH , MyersDL , et al. Modifiers of response to treatment with fesoterodine for urgency-predominant urinary incontinence in a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2017;23(2):151-6. [sr-incont74308]">Huang 2012</a>; <a href="./references#CD003781-bbs2-0051" title="EUCTR2007-006451-39-SE. 12-week, randomized, double-blind, double-dummy, placebo controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-006451-39 (first received 20 February 2008). [A0221046] [EUCTR2007-006451-39-SE] [sr-incont64591]KaplanSA , SchneiderT , FooteJ , GuanZ . Superior efficacy of fesoterodine over tolterodine with rapid onset: a prospective, head-to-head, placebo-controlled trial (Abstract number 67). Neurourology and Urodynamics2010;29(6):905-7. [srincont-40130]KaplanSA , SchneiderT , FooteJE , GuanZ , CarlssonM , GongJ . Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU International2011;107(9):1432-40. [A0221046] [NCT00611026] [srincont-41334]">Kaplan 2011</a>; <a href="./references#CD003781-bbs2-0052" title="CardozoL , KaplanS , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: results from the after study (Abstract number 740) [Erratum appears in: European Urology 2014;65(5):e78]. European Urology Supplements2013;12(1):e740-1. [NCT01302054] [sr-incont63732]CardozoL , KaplanS , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. Erratum: A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: results from the AFTER study [Erratum available in: European Urology Supplement 2013;2012:e740-1]. European Urology2014;65(5):e78 . [A0221094] [NCT01302054] [TrialID.AFTER.] [sr-incont61642]GrenaboL , HerschornS , KaplanSA , CardozoL , ScholfieldD , ArumiD , et al. Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptoms. Current Medical Research and Opinion2017;33(10):1731-6. [NCT01302054] [TrialID.AFTER.] [sr-incont76695]KaplanSA , CardozoL , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER. International Journal of Clinical Practice2014;68(9):1065-73. [A0221094] [NCT01302054] [TrialID.AFTER.] [srincont-63977]KaplanSA , HerschornS , CarlssonM , NtaniosF . Urgency urinary incontinence response rates in subjects with overactive bladder treated with fesoterodine 8 mg after suboptimal response to tolterodine extended release 4 mg: a randomized, double-blind, placebo-controlled trial (Abstract number 546). In: International Continence Society (ICS); 43rd Annual Meeting; 2013 Aug 26-30; Barcelona, Spain. 2013. [NCT01302054] [TrialID.AFTER.] [sr-incont49730]NCT01302054. A clinical study in patients with overactive bladder with leakage of urine, to find out if the medicine, Fesoterodine, works in those patients who did not have enough response to the medicine, tolterodine. [A 14 week randomized parallel group placebo-controlled double-blind multicentre study of fesoterodine 8 mg in overactive bladder patients with sub-optimal response to tolterodine 4 mg extended release (ER)]. clinicaltrials.gov/show/NCT01302054 (first received 23 February 2011). [A0221094] [NCT01302054] [TrialID.AFTER.] [sr-incont49845]">Kaplan 2014</a>; <a href="./references#CD003781-bbs2-0053" title="CapoJP , TogliaM , Forero-SchwanhaeuserS , HeW . Patients reporting severe overactive bladder symptoms: effects of solifenacin treatment on objective measures and patient-reported outcomes (Abstract number 582). In: International Continence Society (ICS), 38th Annual Meeting; 2008 Oct 20-24; Cairo, Egypt. 2008. [srincont-31844]CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. KarramMM , TogliaMR , SerelsSR , AndohM , FakhouryA , Forero-SchwanhaeuserS . Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology2009;73(1):14-8. [A0221094] [NCT00454896] [TrialID.VENUS.] [srincont-29219]SerelsSR , TogliaMR , Forero-SchwanhaeuserS , HeW . Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms. Current Medical Research and Opinion2010;26(10):2277-85. [srincont-40376]StaskinD , DmochowskiR , SerelsS , AndohM , SmithN . Report from a randomized, placebo-controlled study showing significant improvement in urgency and patient-reported outcomes in overactive bladder patients treated with solifenacin (Abstract number 124). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73-4. [srincont-26600]TogliaM , AndohM , HussainI . Solifenacin improved warning time significantly compared to placebo in patients with overactive bladder (Abstract number 123). Neurourology and Urodynamics2006;25(6):655. [srincont-26629]TogliaM , AndohM , HussainI . Solifenacin improves urgency symtoms as assessed by voiding diaries and patient-reported outcomes (PRO) in patients with overactive bladder (Abstract number 155). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26636]TogliaMR , OstergardDR , AppellRA , AndohM , FakhouryA , HussainIF . Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status. International Urogynecology Journal2010;21(7):847-54. [srincont-40094]TogliaMR , SerelsSR , LarameeC , KarramMM , NandyIM , AndohM , et al. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial. Postgraduate Medicine2009;121(5):151-8. [srincont-34204]ZinnerS , HerschornS , AndohM , HussainI . Responder analyses show statistically significant improvements in incontinence and urgency are associated with reduction in symptom bother and improvement in health-related quality of life: VENUS results (Abstract number 123). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73. [srincont-26599]">Karram 2009</a>; <a href="./references#CD003781-bbs2-0055" title="AballéaS , MamanK , ThokagevistkK , NazirJ , OdeyemiIA , HakimiZ , et al. Cost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United Kingdom. Clinical Drug Investigation2015;35(2):83-93. [NCT00689104] [sr-incont66445]Arlandis-GuzmánS , Brenes-BermúdezF , Jiménez-CidreMA , Rubio-RodríguezD , Rubio-TerrésC , MoraAM , et al. Cost effectiveness of Mirabegron and antimuscarinic drugs in patients with hiperactive bladder [Coste-efectividad de mirabegrón y los antimuscarínicos en pacientes con vejiga hiperactiva]. Archivos Espanoles de Urologia2018;71(10):809-24. [NCT00689104] [sr-incont78645]EUCTR2007-001451-19-ES. A randomized, double-blind, parallel group, placebo and active controlled, multicenter study to assess the efficacy and safety of the beta-3 agonist YM178 (50 mg qd and 100 mg qd) in subjects with symptoms of overactive bladder - SCORPIO [Estudio multicentrico, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo y tratamiento activo, para evaluar la eficacia y seguridad del agonista beta-3 YM178 (50 mg, una vez al dia y 100 mg, una vez al dia) en pacientes con sintomas de vejiga hiperactiva]. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-001451-19 (first received 05 June 2008). [EUCTR2007-001451-19-ES] [sr-incont78646]HerschornS , NazirJ , RamosB , HakimiZ . Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada. Canadian Urological Association Journal2017;11(3-4):123-30. [NCT00689104] [sr-incont76807]KhullarV , AmarencoG , AnguloJ , BoerrigterP , BlauwetM , HakimiZ . The potent and selective beta3-adrenoceptor agonist mirabegron improves patient-reported outcomes in the treatment of overactive bladder (Abstract number MP-12.16). Urology2012;80(3 Suppl 1):S123. [sr-incont65379]KhullarV , AmarencoG , AnguloJC , BlauwetMB , NazirJ , OdeyemiIA , et al. Patient-reported outcomes with the β3 beta3-adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder. Neurourology and Urodynamics2016;35(8):987-94. [NCT00689104] [sr-incont72221]KhullarV , AmarencoG , AnguloJC , CambroneroJ , HøyeK , MilsomI , et al. Efficacy and tolerability of mirabegron, a ß3-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. European Urology2013;63(2):283-95. [NCT00689104] [TrialID.SCORPIO.] [sr-incont46836]KhullarV , CambroneroJ , AnguloJ , WooningM , BlauwetM , SiddiquiE , et al. Onset of action of efficacy of the potent and selective beta-3-adrenoceptor agonist, mirabegron, for the treatment of overactive bladder (OAB) in a 12-week, multicentre, randomised, double-blind, parallel-group, placebo-and tolterodine slow release (SR)-controlled study in OAB patients (Abstract number 135). International Urogynecology Journal and Pelvic Floor Dysfunction2012;23(2 Suppl 1):S187-8. [NCT00689104] [sr-incont67382]KhullarV , CambroneroJ , AnguloJC , WooningM , BlauwetMB , DorrepaalC , et al. Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial. BMC Urology2013;13:45. [NCT00689104] [sr-incont49411]KhullarV , CambroneroJ , StroebergP , AnguloJ , BoerrigterP , WooningM . The efficacy and tolerability of mirabegron, a potent and selective B3-adrenoceptor agonist, compared with placebo and tolterodine slow release in patients with overactive bladder - results from a European-Australian phase III trial (Abstract number 328). In: International Continence Society (ICS); 41st Annual Meeting; 2011 Aug 29-Sept 2; Glasgow, Scotland. 2011. [NCT00689104] [sr-incont42211]NCT00689104. Study to assess the efficacy and safety of the beta-3 agonist mirabegron (ym178) in patients with symptoms of overactive bladder (SCORPIO) [A randomized, double-blind, parallel group, placebo and active controlled, multicenter study to assess the efficacy and safety of mirabegron in subjects with symptoms of overactive bladder (SCORPIO)]. clinicaltrials.gov/show/NCT00689104 (first received 03 June 2008). [NCT00689104] [sr-incont49843]NittiV , HerschornS , AuerbachS , KhullarV , AmarencoG , BlauwetMB , et al. The potent and selective ß3-adrenoceptor agonist mirabegron improves patient-reported outcomes in overactive bladder-results from two phase III studies (Abstract number 68). Neurourology and Urodynamics2012;31(6):813-5. [NCT00689104] [sr-incont46724]WielageRC , PerkS , CampbellNL , NgD , KleinTM , PostaLM , et al. The cost effectiveness of mirabegron for the treatment of overactive bladder: three US perspectives (Abstract number A142). Journal of the American Geriatrics Society2015;63:S67. [NCT00689104] [sr-incont70876]YamanishiT , YamanishiY , TajimaH , IkedaS . Cost-effectiveness of mirabegron and tolterodine for the treatment of overactive bladder in Japan-Which drug is more cost-effective if used as the first-line treatment? (Abstract number 504). International Urogynecology Journal2018;29:S252. [NCT00689104] [sr-incont78647]YamanishiY , YamanishiT , TajimaH , IkedaS . Mirabegron or tolterodine for the treatment of overactive bladder in Japan: Which drug is more cost-effective as the first-line treatment?International Journal of Urology2018;25(10):863-70. [NCT00689104] [sr-incont78648]">Khullar 2013</a>; <a href="./references#CD003781-bbs2-0058" title="KosilovKV , LoparevSA , IvanovskayaMA , KosilovaLV . The efficacy of different doses of solifenacin in elderly patients after treating a urinary tract infection. Arab Journal of Urology Print2015;13(3):203-8. [sr-incont69283]">Kosilov 2015b</a>; <a href="./references#CD003781-bbs2-0059" title="KrederK , PleilAM , ReesePR , KelleherJ . Effects of long-term tolterodine treatment on social and psychological aspects of health-related quality of life in overactive bladder patients (Abstract). Journal of Urology2002;167(Suppl 4):29. [sr-incont17591]">Kreder 2002</a>; <a href="./references#CD003781-bbs2-0060" title="HsiaoSM , ChangTC , ChenCH , WuWY , LinHH . Comparisons of the clinical outcomes and urodynamic effects of mirabegron versus tolterodine treatment for female overactive bladder syndrome: a subgroup analysis of a controlled, randomised, prospective study. Lower Urinary Tract Symptoms2018;10(3):215-20. [NCT01043666] [sr-incont74461]KuoHC , LeeKS , NaY , SoodR , NakajiS , KubotaY , et al. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourology and Urodynamics2015;34(7):685-92. [NCT01043666] [sr-incont68095]Kuo H‐C, Lin H‐H, Yu H‐J, Cheng C‐L, Hung M‐J, LinAT . Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials [Erratum available in: Urological Science 2015;26(2):148]. Urological Science2015;26(1):41-8 . [NCT01043666] [sr-incont68645]NCT01043666. A study of YM178 in subjects with symptoms of overactive bladder  [Phase III study of YM178: a randomized, double-blind, parallel group, placebo and active controlled, multi-center study in subjects with symptoms of overactive bladder]. clinicaltrials.gov/show/NCT01043666 (first received 07 January 2010). [178-CL-090] [NCT01043666] [sr-incont63781]">Kuo 2015</a>; <a href="./references#CD003781-bbs2-0062" title="LandisJR , KaplanS , SwiftS , VersiE . Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity. Journal of Urology2004;171(2 Pt 1):752-6. [sr-incont17327]">Landis 2004</a>; <a href="./references#CD003781-bbs2-0063" title="LeeKS , ChooMS , KimDY , KimJC , KimHJ , MinKS , et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. Journal of Urology2005;174(4 Pt 1):1334-8. [sr-incont21016]LeeKS , ChooMS , PaickJS , LeeJG , SeoJT , LeeJZ , et al. Propiverine hydrochloride reduced frequency and perception of urgency in treatment of overactive bladder: a 12 week prospective, randomized, double blind, placebo controlled study (Abstract number 279). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26640]LeeKS , LeeHW , ChooMS , PaickJS , LeeJG , SeoJT , et al. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'. BJU International2010;105(11):1565-70. [2005-01-08] [NCT00903045] [PROUD] [sr-incont39958]NCT00903045. Urinary urgency outcomes following propiverine treatment for an overactive bladder [Urinary urgency outcomes following propiverine treatment for an overactive bladder: propiverine study on overactive bladder including urgency data (PROUD)]. clinicaltrials.gov/show/NCT009030452005;(first received 15 May 2009). [2005-01-08] [NCT00903045] [TrialID.PROUD] [sr-incont49860]">Lee 2006</a>; <a href="./references#CD003781-bbs2-0064" title="LuisV , LoyolaJP , MelissaC , FelipeM , San MartinC . Efficacy of darifenacin use combined with pelvic floor physiotherapy in overactive bladder syndrome treatment in women (Abstract number 434). International Urogynecology Journal2018;29(Suppl 1):S220-1. [NCT02143570] [sr-incont78617]NCT02143570, CifuentesM , MartinezF . Efficacy of darifenacin and physiotherapy for the treatment of overactive bladder in women. clinicaltrials.gov/show/NCT02143570 (first received 21 May 2014). [NCT02143570] [sr-incont61781]">Luis 2018</a>; <a href="./references#CD003781-bbs2-0067" title="MillardR , TuttleJ , MooreK , SussetJ , ClarkeB , DwyerP , et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. Journal of Urology1999;161(5):1551-5. [sr-incont8172]MooreK , MillardR , DwyerP , TuttleJ . A randomized controlled multicentre trial of tolterodine in detrusor instability/hyperreflexia. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(Suppl 1):S129. [sr-incont5171]RosamiliaA , DwyerPL , ClarkeB , MooreK , MillardRP , TuttleJ . The clinical efficacy and safety of two doses of Tolterodine in detrusor instability. Acta Obstetrica et Gynecologica Scandinavica1997;6(Suppl 167):24. [sr-incont6670]">Millard 1999</a>; <a href="./references#CD003781-bbs2-0070" title="GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NittiVW , DmochowskiR , SandPK , ForstHT , Haag-MolkentellerC , MassowU , et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. Journal of Urology2007;178(6):2488-94. [NCT00138723] [SP584] [srincont-26313]">Nitti 2007</a>; <a href="./references#CD003781-bbs2-0071" title="OlshanskyB , FooteJ , ArguinzonizM , LheritierK , Quebe-FehlingE , SteelM . Cardiovascular safety of darifenacin and tolterodine in patients with overactive bladder (OAB) (Abstract number 49). International Urogynecology Journal and Pelvic Floor Dysfunction2006;17(Suppl 2):S86-7. [sr-incont34186]">Olshansky 2006</a>; <a href="./references#CD003781-bbs2-0073" title="NCT01302938. Web-based methodology trial to evaluate the efficacy and safety of tolterodine ER in subjects with overactive bladder (REMOTE) [Exploratory, randomized, double-blind, placebo-controlled, parallel-group, single center, web-based phase IV pilot methodolgy trial to evaluate the efficacy and safety of tolterodine ER in subjects with overactive bladder]. clinicaltrials.gov/ct2/show/NCT01302938 (first received 24 February 2011). [A6121195] [NCT01302938] [TrialID.REMOTE.] [sr-incont43314]OrriM , LipsetCH , JacobsBP , CostelloAJ , CummingsSR . Web-based trial to evaluate the efficacy and safety of tolterodine ER 4 mg in participants with overactive bladder: REMOTE trial. Contemporary Clinical Trials2014;38(2):190-7. [A6121195] [NCT01302938] [TrialID.REMOTE.] [sr-incont62536]">Orri 2014</a>; <a href="./references#CD003781-bbs2-0076" title="EUCTR2008-005215-17. A study to evaluate the overall effect of solifenacin 5mg and 10mg on bladder wall thickness and urinary nerve growth factor in female subjects with overactive bladder and a diagnosis of detrusor overactivity – a double-blind, randomized, placebo-controlled, parallel group, multicentre study - SHRINK. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-005215-17 (first received 14 September 2009). [EUCTR2008-005215-17] [NCT01093534] [sr-incont78650]NCT01093534. Study of 2 doses of solifenacin succinate in female subjects with overactive bladder (SHRINK) [A study to evaluate the overall effect of solifenacin 5mg and 10mg on bladder wall thickness and urinary nerve growth factor in female subjects with overactive bladder and a diagnosis of detrusor overactivity - a double-blind, randomised, placebo-controlled, parallel group, multi-centre study]. clinicaltrials.gov/show/NCT01093534 (first received 26 March 2010). [905-EC-007] [EUCTR2008-005215-17] [NCT01093534] [TrialID.SHRINK] [sr-incont63778]RobinsonD , KhullarV , OelkeM , WijkstraH , TretterR , StowB , et al. Effects of 12 weeks treatment with solifenacin on Bladder Wall Thickness (BWT) and clinical outcomes: results from the placebo-controlled SHRINK study (Abstract number 422). In: International Continence Society (ICS), 43rd Annual Meeting; 2013 Aug 26-30; Barcelona, Spain. 2013. [905-EC-007] [NCT01093534] [TrialID.SHRINK.] [srincont-49731]RobinsonD , OelkeM , KhullarV , WijkstraH , TretterR , StowB , et al. Bladder wall thickness in women with symptoms of overactive bladder and detrusor overactivity: results from the randomised, placebo-controlled SHRINK study. Neurourology and Urodynamics2016;35(7):819-25. [NCT01093534] [sr-incont72217]RobinsonD , OelkeM , TretterR , StowB , CompionG , TubaroA . The effect of solifenacin on bladder wall thickness in women with overactive bladder and detrusor overactivity: Results from the SHRINK study (Abstract number 782). European Urology Supplements2013;12(1):e782-3. [EUCTR2008-005215-17] [NCT01093534] [sr-incont67207]RobinsonD , TubaroA , KimbergM , PlummerM , DeVineJ , BouicP , et al. The effect of solifenacin on urinary nerve growth factor (UNGF) and brain-derived neurotropic factor (BDNF) in women with overactive bladder and detrusor overactivity: results from the SHRINK study (Abstract number PP 54). International Urogynecology Journal and Pelvic Floor Dysfunction2014;25(1 Suppl 1):S60-1. [EUCTR2008-005215-17] [NCT01093534] [sr-incont67200]TubaroA , KhullarV , OelkeM , WijkstraH , TretterR , StowB , et al. Intra- and inter-reader variability of transvaginal ultrasound bladder wall thickness measurements: results from the SHRINK study (Abstract number 136). Neurourology and Urodynamics2013;32(6):711-2. [EUCTR2008-005215-17] [NCT01093534] [sr-incont49211]">Robinson 2013</a>; <a href="./references#CD003781-bbs2-0077" title="RogersR , BachmannG , JumadilovaZ , SunF , MorrowJD , GuanZ , et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. International Urogynecology Journal and Pelvic Floor Dysfunction2008;19(11):1551-7. [A6121002] [NCT00143481] [srincont-27729]RogersRG , BachmannG , ScarperoH , JumadilovaZ , SunF , MorrowJD , et al. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. Current Medical Research and Opinion2009;25(9):2159-65. [srincont-32060]">Rogers 2008</a>; <a href="./references#CD003781-bbs2-0078" title="RomanziLJ , DelconteA , KralidisG . Impact of darifenacin compared with tolterodine on incontinence episodes in patients with overactive bladder (Abstract number A3522). Obstetrics and Gynecology2005;105(Suppl 4):88S. [sr-incont34187]">Romanzi 2005</a>; <a href="./references#CD003781-bbs2-0079" title="RovnerES , KaplanS , GuanZ , WangJT , RoehrbornCG . Clinical efficacy and safety of tolterodine extended release in male patients with overactive bladder and urgency urinary incontinence (Abstract number 188). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21091]">Rovner 2005</a>; <a href="./references#CD003781-bbs2-0080" title="RudyD , ClineK , GoldbergK , HarrisR . A multicenter, randomized, placebo-controlled trial of trospium chloride in overactive bladder patients (Abstract). Neurourology and Urodynamics2004;23(5/6):600-1. [sr-incont19025]RudyD , ClineK , HarrisR , GoldbergK , DmochowskiR . Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology2006;67(2):275-80. [srincont-21604]RudyD , ClineK , HarrisR , GoldbergK , DmochowskiR . Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. BJU International2006;97(3):540-6. [sr-incont21593]">Rudy 2006</a>; <a href="./references#CD003781-bbs2-0081" title="StaskinDR , HarnettMD . Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder. Current Urology Reports2004;5(6):423-6. [sr-incont19422]">Staskin 2004</a>; <a href="./references#CD003781-bbs2-0082" title="ChancellorMB , OefeleinMG , VasavadaS . Obesity is associated with a more severe overactive bladder disease state that is effectively treated with one daily administration of trospium chloride extended release [Erratum available in: Neurourology and Urodynamics 2010;29(5):804]. Neurourology and Urodynamics2010;29(4):551-4. [sr-incont39591]GinsbergDA , OefeleinMG , EllsworthPI . Once-daily administration of trospium chloride extended release provides 24-hour coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials. Neurourology and Urodynamics2011;30(4):563-7. [sr-incont41531]RovnerE , DmochowskiR , WatanabeJ . Once daily (QD) trospium chloride 60mg extended release (XR) is safe and effective in patients (PTS) with the overactive bladder (OAB) syndrome who use multiple concomitant medications (MEDS) (Abstract number: Poster #68). Neurourology and Urodynamics2009;28(2):146-7. [sr-incont31062]SandP , DmochowskiR , ZinnerN , StaskinD . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: results from a multicenter, phase III, placebo-controlled study (Abstract number 269). In: International Continence Society (ICS), 37th Annual Meeting; 2007 Aug 20-24; Rotterdam, the Netherlands. 2007. [sr-incont26676]SandP , StaskinD , ZinnerN , DmochowskiR . Once-daily trospium chloride extended release is effective and well tolerated for the treatment of overactive bladder: results from a multicenter, phase III trial (Abstract number 57). Neurourology and Urodynamics2007;26(5):675. [sr-incont26661]StaskinD , SandP , ZinnerN , DmochowskiR , Trospium Study Group. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. Journal of Urology2007;178(3 Pt 1):978-83; discussion 983-4. [srincont-23909]StaskinDR , RosenbergMT , SandPK , ZinnerNR , DmochowskiRR . Trospium chloride once daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised phase III trials. International Journal of Clinical Practice2009;63(12):1715-23. [sr-incont35458]StaskinDR , SandPK , ZinnerNR . Once-daily trospium chloride extended release is effective and well tolerated for the treatment of overactive bladder: results from a multicenter, phase III trial (Abstract number - poster 22). Neurourology and Urodynamics2007;26(7 Suppl):1106. [srincont-27305]">Staskin 2007</a>; <a href="./references#CD003781-bbs2-0083" title="EUCTR2017-003293-14. Empowur (Empower OAB patients with vibegron for better urgency control) [An international phase 3, randomized, double-blind, placebo- and active (tolterodine)-controlled multicenter study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder]. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-003293-14 (first received 24 April 2018). [EUCTR2017-003293-14] [NCT03492281] [sr-incont78606]NCT03492281, JankowichR . A study to examine the safety and efficacy of a new drug in patients with symptoms of overactive bladder (OAB) [An international phase 3, randomized, double-blind, placebo- and active (tolterodine)-controlled multicenter study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder]. clinicaltrials.gov/show/NCT03492281 (first received 20 April 2018). [NCT03492281] [sr-incont78610]StaskinD , FrankelJ , VaranoS , ShortinoD , JankowichR , MuddPN . Vibegron demonstrates statistically significant improvement in efficacy measures in overactive bladder-key secondary results from the international phase 3 study in patients with overactive bladder (empowur) (Abstract number: long oral 40). Female Pelvic Medicine and Reconstructive Surgery2019;25(5):S20-1. [NCT03492281] [sr-incont78627]StaskinD , FrankelJ , VaranoS , ZhouJ , JankowichR , MuddPN . International phase 3, double-blind, placebo- and active (tolterodine)-controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: empowur (Abstract number LBA-02). Journal of Urology2019;201(4):e992. [NCT03492281] [sr-incont78628]StaskinD , VaranoS , FrankelJ , ShortinoD , JankowichR , MuddP . Once-daily vibegron 75 mg demonstrates statistically significant benefits on key secondary endpoints including quality of life in patients with OAB: data from an international phase 3 trial (EMPOWUR) (Abstract number 181). Neurourology and Urodynamics2019;38(S3):S115-7. [NCT03492281] [sr-incont78629]VaranoS , StaskinD , FrankelJ , ShortinoD , JankowichR , MuddPN . Vibegron statistically significantly improves measures of quality of life in patients with overactive bladder-data from the international phase 3 trial (Empowur) (Abstract number: long oral 38). Female Pelvic Medicine and Reconstructive Surgery2019;25(5):S19. [NCT03492281] [sr-incont78630]">Staskin 2019</a>; <a href="./references#CD003781-bbs2-0084" title="SteersW , CorcosJ . Efficacy, tolerability and safety of darifenacin, an M3 selective receptor antagonist for the treatment of overactive bladder, using a flexible dosing regimen (Abstract number 68). Progres en Urologie2004;14(3 Suppl 3):22. [srincont-22197]">Steers 2004</a>; <a href="./references#CD003781-bbs2-0092" title="ChancellorM , FreedmanS , MitchesonHD , AntociJ , PrimusG , WeinA . Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clinical Drug Investigation2000;19(2):83-91. [srincont-16326]FreemanR , HillS , MillardR , SlackM , SutherstJ , Tolterodine Study Group. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstetrics and Gynecology2003;102(3):605-11. [srincont-16494]GarelyA , Tolterodine Study Group. Once-daily tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder. International Urology Journal2001;12(Suppl 1):S18. [srincont-12012]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of life of patients with overactive bladder receiving tolterodine. Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of patients with overactive bladder receiving tolterodine (Abstract number 82). Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , ReesePR . Health related quality of life of patients with overactive bladder receiving tolterodine once-daily. Neurourology and Urodynamics2000;19(4):519-21. [srincont-9987]KelleherCJ , ReesePR , PleilAM , OkanoGJ . Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. American Journal of Managed Care2002;8(Suppl 19):S608-15. [srincont-17998]KelleherCJ , Tolterodine Study Group. Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2000;11(Suppl 1):S94. [srincont-11915]KrederKJ . Antimuscarinic therapy: relationship between efficacy and side effects in responders and non-responders. Journal of Urology2001;165(Suppl 5):S165. [srincont-16327]KrederKJ . Clinical effectiveness of antimuscarinic therapy: the relationship between efficacy and tolerability. In: Proceedings of the International Continence Society Annual Meeting(ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001:140. [srincont-14376]MallettV . Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2001;12(Suppl 1):4. [srincont-12011]MillardRJ , TamaddonK , Tolterodine Study Group. Randomized controlled trial to compare tolterodine prolonged release capsules and tolterodine immediate release tablets versus placebo in patients with symptoms of detrusor overactivity (Abstract number 57). Australian and New Zealand Journal of Surgery2002;Suppl 72:A140. [sr-incont22190]PleilAM , ReesePR , KelleherCJ , OkanoGJ . Health-related quality of life of patients with overactive bladder receiving immediate-release tolterodine. HEPAC Health Economics in Prevention and Care2001;2(2):69-75. [sr-incont18060]RoehrbornCG , AbramsP , RovnerES , KaplanSA , HerschornS , GuanZ . Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU International2006;97(5):1003-6. [sr-incont21882]SwiftS . Efficacy and tolerability of once-daily tolterodine for women with overactive bladder. In: International Continence Society Annual Meeting (ICS), 31st annual meeting; 2001 Sept 18-21; Seoul, Korea. 2001:No. 329. [srincont-14481]SwiftS . Once-daily tolterodine is effective and well tolerated in women with overactive bladder (Abstract 57). In: 2nd International Consultation on Incontinence; 2001 July 1-3; Paris, France. 2001. [srincont-16319]SwiftSE . Once-daily (OD) tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder (OAB). International Urogynecology Journal2000;11(Suppl 1):S15. [sr-incont11906]SwiftSE . Once-daily administration of extended-release tolterodine is effective and well-tolerated in patients with overactive bladder. In: XVI FIGO World Congress of Obstetrics and Gynecology; 2000 Sept 3-8; Washington DC. Vol. Book 1. 2000:40. [sr-incont12085]SwiftSE . Overactive bladder in females: treatment with once-daily tolterodine. International Urogynecology Journal2001;12(Suppl 3):S71. [sr-incont16328]Van KerrebroeckP , KrederK , JonasU , ZinnerN . Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology2001;57(3):414-21. [sr-incont11953]Van KerrebroeckPEV . Long-term (12 months) efficacy and tolerability of tolterodine once-daily in the treatment of overactive bladder. Neurourology and Urodynamics2001;20(4):401-2. [sr-incont15714]Van KerrebroeckPEVA , Tolterodine Study Group. Long-term tolerability and efficacy of once-daily (OD) tolterodine in the treatment of overactive bladder (OB). International Urogynecology Journal2001;12(Suppl 3):S49. [sr-incont16329]Van KerrebroeckPEVA , Tolterodine Study Group. Significant decreases in perception of urgency and urge incontinence episodes with once-daily tolterodine treatment in patients with overactive bladder (Abstract number 89). Neurourology and Urodynamics2000;19(4):493-4. [sr-incont9980]WeinAJ , KhullarV , WangJT , GuanZ . Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. BJU International2007;99(2):360-3. [sr-incont23180]vanKerrebroeckPE , KelleherCJ , CoyneKS , KoppZ , BrodskyM , WangJT . Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. Health and Quality of Life Outcomes2009;7(13):13. [10.1186/1477-7525-7-13] [sr-incont31438]vanKerrebroeckPE , WangJ , GuanZ . Effects of tolterodine extended release in patients with overactive bladder: perceived treatment benefits improve with efficacy (Abstract number 511). European Urology Supplements2004;3(2):130. [sr-incont31090]">Van Kerrebroeck 2001</a>; <a href="./references#CD003781-bbs2-0093" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CrosbyRD , MathiasSD , MarshallTS . Relationships between symptoms, symptom bother, and health-related quality of life in patients with overactive bladder taking solifenacin or placebo in the VIBRANT study. International Journal of Clinical Practice2011;65(2):211-8. [sr-incont41015]GollarKM , YoungDG , BailenJ , HeW , Forero-SchwanhaeuserS . Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: a secondary analysis of the VIBRANT study. Urologic Nursing2012;32(1):38-46. [TrialID.VIBRANT.] [sr-incont44571]Samuels T‐A, MitchesonHD , VardyM , Forero‐SchwanhaeuserS , MarshallT , HeW . Efficacy of solifenacin for symptom bother and other patient-reported outcomes in patients with overactive bladder (OAB): results of a large, double-blind, placebo-controlled trial (Abstract number: poster #74). Neurourology and Urodynamics2009;28(2):149. [sr-incont31063]VardyMD , MitchesonHD , SamuelsTA , Forero-SchwanhaeuserS , HeW . Efficacy of solifenacin on overactive bladder symptoms, symptom bother, and other patient-reported outcomes in subjects with or without incontinence: a post hoc analysis of data from VIBRANT. Female Pelvic Medicine and Reconstructive Surgery2011;17(1):24-9. [TrialID.VIBRANT.] [sr-incont44741]VardyMD , MitchesonHD , SamuelsTA , WegenkeJD , Forero-SchwanhaeuserS , MarshallTS , et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. International Journal of Clinical Practice2009;63(12):1702-14. [905-UC-010] [NCT00573508] [TrialID.VIBRANT.] [sr-incont35459]">Vardy 2009</a>; <a href="./references#CD003781-bbs2-0094" title="EUCTR2007-007087-17-SE. A 24-week, multicentre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-007087-17 (first received 13 June 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont64588]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00798434. A study to compare the effectiveness and safety of fesoterodine and placebo in an elderly population of patients who go to the toilet very frequently due to overactive bladder (SOFIA) [A 24-week, multi-centre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00798434 (first received 26 November 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont49847]SchneiderT , BergqvistA , WangJ , WaggA , Ebel-BitounC . Treatment with fesoterodine versus tolterodine for reducing symptom bother in elderly patients with overactive bladder including urgency urinary incontinence. European Urology, Supplements2012;11(1):e687-a. [sr-incont65389]WaggA , CarlssonM , ElsobkyM , FernetM . Effect of flexible dose fesoterodine on cognitive function in &gt;65 year old patients with OAB: data from two RCT (Abstract number 438). Neurourology and Urodynamics2019;38:S297-8. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78651]WaggA , DarekarA , ArumiD , KhullarV , OelkeM . Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people &gt;65 years of age: a post hoc analysis of data from the SOFIA study. Neurourology and Urodynamics2015;34(5):438-43. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont68100]WaggA , ElsobkyM , CarlssonM , FernetM . Response and cognitive safety of fesoterodine in patients &gt;65y old with OAB. Is there a relationship between cognition and treatment response? (Abstract number 183). Neurourology and Urodynamics2019;38:S118-20. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78632]WaggA , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. Journal of the American Geriatrics Society2013;61(2):185-93. [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TrialID.SOFIA.] [sr-incont48008]WaggAS , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Efficacy and tolerability of fesoterodine in older subjects with overactive bladder: results of SOFIA (Abstract number C33). Journal of the American Geriatrics Society2011;59:S124. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont65234]">Wagg 2013a</a>; <a href="./references#CD003781-bbs2-0095" title="GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00911937. A trial to evaluate the efficacy and safety of fesoterodine in patients with symptoms of overactive bladder including nocturnal urinary urgency [A randomized, double blind, placebo controlled, parallel group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with symptoms of overactive bladder including nocturnal urinary urgency]. clinicaltrials.gov/show/NCT00911937 (first received 03 June 2009). [NCT00911937] [sr-incont49848]WeissJ , JumadilovaZ , CarlssonM , FitzGeraldMP , MalhotraA , MartireDL . Effect of antimuscarinic treatment in subjects with overactive bladder, including nocturnal urinary urgency (Abstract number 1963). Journal of Urology2012;187(4 Suppl 1):e792. [NCT00911937] [sr-incont65184]WeissJP , CarlssonMR , ManganEK . Age, gender and nocturnal urgency severity predict response to antimuscarinic treatment (Abstract number 1962). Journal of Urology2013;189(4 Suppl 1):e805. [NCT00911937] [sr-incont65096]WeissJP , JumadilovaZ , JohnsonTM , FitzGeraldMP , CarlssonM , MartireDL , et al. Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency. Journal of Urology2013;189(4):1396-401. [A0221048] [NCT00911937] [sr-incont47568]">Weiss 2013</a>; <a href="./references#CD003781-bbs2-0096" title="YamaguchiO , MaruiE , KakizakiH , ItohN , YokotaT , OkadaH , et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU International2007;100(3):579-87. [sr-incont23865]YokoyamaO , YamaguchiO , KakizakiH , ItohN , YokotaT , OkadaH , et al. Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary. Journal of Urology2011;186(1):170-4. [sr-incont41734]">Yamaguchi 2007</a>; <a href="./references#CD003781-bbs2-0097" title="NCT00966004. A study to evaluate safety and efficacy of ym178 in patients with overactive bladder [Phase III study of YM178 - a placebo-controlled, double-blind, group comparison study in patients with overactive bladder]. clinicaltrials.gov/show/NCT00966004 (first received 26 August 2009). [178-CL-048] [JapicCTI-R130370] [NCT00966004] [sr-incont63783]YamaguchiO , HidehiroK , YukioH , YasuhikoI , MasayukiT , OsamuN , et al. A phase III, randomized, double-blind, placebo and active controlled study of once-daily mirabegron 50 mg in patients with overactive bladder (Abstract number POD-03.06). Urology2012;80(3 Suppl 1):S10-1. [NCT00966004] [sr-incont65380]YamaguchiO , MaruiE , KakizakiH , HommaY , IgawaY , TakedaM , et al. A phase III, randomized, double-blind, placebo-controlled study of the beta-adrenoceptor agonist, mirabegron 50 mg once-daily, in Japanese patients with overactive bladder. BJU International2014;113(6):951-60. [NCT00966004] [sr-incont50603]">Yamaguchi 2012</a>; <a href="./references#CD003781-bbs2-0098" title="YamaguchiO , UchidaE , HigoN , MinamiH , KobayashiS , SatoH , et al. Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: a randomized double-blind trial. International Journal of Urology2014;21(6):586-93. [JapicCTI-101309] [sr-incont62099]">Yamaguchi 2014</a>; <a href="./references#CD003781-bbs2-0101" title="NCT01018264, ZesiewiczT . Solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease (URGE-PD) [URGE-PD: a multi-site, double-blind, randomized, placebo controlled trial of solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease]. clinicaltrials.gov/show/NCT01018264 (first received 23 November 2009). [NCT01018264] [sr-incont63790]ZesiewiczTA , EvattM , JahanI , VaughanC , SingerC , OrdoricaR , et al. URGE-PD: a multi-site, double-blind, randomized, placebo controlled trial of solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease (Abstract number 745). Movement Disorders2014;29(Suppl 1):S276-7. [NCT01018264] [sr-incont66602]ZesiewiczTA , EvattM , VaughanCP , JahanI , SingerC , OrdoricaR , et al. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease. Parkinsonism and Related Disorders2015;21(5):514-20. [NCT01018264] [sr-incont66860]">Zesiewicz 2015</a>; <a href="./references#CD003781-bbs2-0102" title="ZinnerNR , MattiassonA , StantonSL . Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. Journal of the American Geriatrics Society2002;50(5):799-807. [sr-incont14679]">Zinner 2002</a>; <a href="./references#CD003781-bbs2-0103" title="ZinnerN , GittelmanM , HarrisR , SussetJ , KanellosA , AuerbachS . Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial (Abstract number DP51). In: American Urological Association (AUA), 98th Annual Meeting; 2003 Apr 26-May 1; Chicago, Illinois. 2003. [sr-incont31101]ZinnerN , GittelmanM , HarrisR , SussetJ , KanelosA , AuerbachS , Trospium Study Group. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. Journal of Urology2004;171(6 Pt 1):2311-5. [sr-incont17376]">Zinner 2004</a>; <a href="./references#CD003781-bbs2-0104" title="ZinnerN , SussetJ , GittelmanM , ArguinzonizM , RekedaL , HaabF . Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. International Journal of Clinical Practice2006;60(1):119-26. [sr-incont21507]">Zinner 2006</a>). The remainder of the studies chose shorter treatment periods of two to four weeks in duration (<a href="./references#CD003781-bbs2-0001" title="AbramsP , JacksonS , MattiassonA , KrishnanK , HaendlerL . A randomised, double-blind, placebo controlled, dose ranging study of the safety and efficacy of tolterodine in patients with hyperreflexia (Abstract). In: International Continence Society 26th Annual Meeting; 1996 Aug 27-30; Athens, Greece. 1996:276-7. [sr-incont5135]">Abrams 1996</a>; <a href="./references#CD003781-bbs2-0002" title="AbramsP , FreemanR , AnderströmC , MattiassonA . Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. British Journal of Urology1998;81(6):801-10. [srincont-7871]AbramsP , FreemanRN , AnderstromC , MattiassonA . Efficacy and tolerability of tolterodine vs. oxybutynin and placebo in patients with detrusor instability (Abstract). Journal of Urology1997;157(Suppl 4):103. [srincont-16321]">Abrams 1998</a>; <a href="./references#CD003781-bbs2-0008" title="BurgioKL , LocherJL , GoodePS , HardinJM , McDowellBJ , CandibD . Behavior vs drug therapy for urge incontinence in older women (Abstract number 26). In: American Urogynecology Society, 15th Annual Scientific Meeting; 1994 Sept 21-24; Toronto, Ontario. 1994:48. [sr-incont14585]BurgioKL , LocherJL , GoodePS , HardinM , McDowellBJ , Dombrowski M et al. Behavioral vs drug treatment for urge urinary incontinence in older women. A randomized controlled trial. JAMA1998;280(23):1995-2000. [srincont-5719]BurgioKL , LocherJL , GoodePS . Combined behavioral and drug therapy for urge incontinence in older women. Journal of the American Geriatrics Society2000;48(4):370-4. [srincont-9006]BurgioKL , LocherJL , RothDL , GoodePS . Psychological improvements associated with behavioral and drug treatment of urge incontinence in older women. Journal of Gerontology. Series B, Psychological Sciences and Social Sciences2001;56(1):P46-51. [srincont-11923]">Burgio 1998</a>; <a href="./references#CD003781-bbs2-0009" title="CardozoL , ChappleCR , Toozs-HobsonP , Grosse-FreeseM , BulittaM , LehmacherW , et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomised, double-blind, multicentre clinical trial. British Journal of Urology International2000;85(6):659-64. [srincont-11732]">Cardozo 2000</a>; <a href="./references#CD003781-bbs2-0012" title="ChalihaC , HalaskaM , StantonS . Trospium chloride for the treatment of detrusor instability: a placebo-controlled dose-finding study (Abstract 276). British Journal of Obstetrics and Gynaecology1998;105(Suppl 17):92. [srincont-8452]">Chaliha 1998</a>; <a href="./references#CD003781-bbs2-0018" title="ChappleCR , DvorakV , RadziszewskiP , vanKerrebroeckP , WyndaeleJJ , BosmanB , et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder. International Urogynecology Journal2013;24(9):1447-58. [178-CL-044] [NCT00337090] [TrialID.DRAGON.] [sr-incont48549]NCT00337090 . A study of YM178 in patients with symptomatic overactive bladder (DRAGON) [A randomized, double-blind, parallel group, placebo and active controlled, multicenter dose ranging study with the beta-3 agonist YM178 in patients with symptomatic overactive bladder]. clinicaltrials.gov/show/NCT00337090 (first received 15 June 2006). [EudraCT2005-002256-17] [JapicCTI-R130350] [NCT00337090] [sr-incont63803]">Chapple 2013</a>; <a href="./references#CD003781-bbs2-0019" title="ChappleC , HaabF , SchneiderT , CarlssonM , ArumiD . Fesoterodine 8 mg versus fesoterodine 4 mg in patients with overactive bladder and a history of previous antimuscarinic therapy: Results from the EIGHT trial (Abstract number: Poster #M5). Neurourology and Urodynamics2015;34(S1):S20. [NCT01302067] [sr-incont68509]ChappleC , SchneiderT , HaabF , SunF , WhelanL , ScholfieldD , et al. Superiority of fesoterodine 8mg versus fesoterodine 4 mg in reducing urgency urinary incontinence episodes in subjects with overactive bladder: results of the randomized, double-blind, placebo-controlled EIGHT trial (Abstract number: Podium #48). Neurourology and Urodynamics2014;33(2):183-4. [NCT01302067] [sr-incont67484]ChappleC , SchneiderT , HaabF , SunF , WhelanL , ScholfieldD , et al. Superiority of fesoterodine 8mg vs 4mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial. BJU International2014;114(3):418-26. [A0221095] [NCT01302067] [TrialID.EIGHT] [srincont-62537]NCT01302067. A 12 week study to confirm the effectiveness of 8mg of Fesoterodine compared to 4mg of Fesoterodine [A 12-week, randomized, double-blind, placebo controlled, parallel group, multicenter trial in overactive bladder subjects to confirm the efficacy of 8 mg fesoterodine compared to 4 mg fesoterodine]. clinicaltrials.gov/show/NCT01302067 (first received 23 February 2011). [NCT01302067] [sr-incont63792]">Chapple 2014</a>; <a href="./references#CD003781-bbs2-0022" title="AmarencoG , SutoryM , FagertunH , WrightM , CompionG , De RidderD . Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Preliminary results from the SONIC urodynamic study (Abstract). European Urology, Supplements2012;11(1):e467-a. [EudraCT2006-005523-42] [NCT00629642] [sr-incont65392]AmarencoG , SutoryM , ZachovalR , AgarwalM , DelPG , TretterR , et al. Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study. Neurourology and Urodynamics2017;36(2):414-21. [EudraCT2006-005523-42] [JapicCTI-R130306] [NCT00629642] [sr-incont72248]De RidderD , AmarencoG , Finazzi-AgroE , AnguloJ , KurenkovA , WrightM , et al. Solifenacin treatment for neurogenic detrusor overactivity: patient-reported outcomes (PROs) from the randomised clinical trial SONIC (Abstract number 333). In: International Continence (ICS); 42nd Annual Meeting; 2012 Oct 15-19; Beijing, China. 2012. [905-EC-005] [EudraCT2006-005523-42] [NCT00629642] [TrialID.SONIC.] [srincont-49739]">De Ridder 2012</a>; <a href="./references#CD003781-bbs2-0025" title="ChappleCR , MadersbacherH , DreikornK , DorschnerW , MurtzG . Urodynamics and frequency/volume chart - do they correlate? Treatment analysis of propiverine in comparison to oxybutynin and placebo in urge incontinence (Abstract number 224). In: International Continence Society (ICS), 31st Annual Meeting; 2001 Sep 18-21; Seoul, Korea. 2001. [sr-incont14474]DorschnerW , StolzenburgJU , GriebenowR , HalaskaM , BrünjesR , FrankM , et al. The elderly patient with urge incontinence or urge-stress incontinence - efficacy and cardiac safety of propiverine [Der ältere Patient mit Drang-Symptomatik bzw. kombinierter Drang/Stress-Inkontinenz-Wirksamkeit und kardiale Sicherheit von Propiverin]. Aktuelle Urologie2003;34(2):102-8. [sr-incont16422]DorschnerW , StolzenburgJU , GriebenowR , HalaskaM , SchubertG , Mürtz G et al. Efficacy and cardiac safety of propiverine in elderly patients - a double-blind, placebo-controlled clinical study. European Urology2000;37(6):702-8. [srincont-11660]">Dorschner 2000</a>; <a href="./references#CD003781-bbs2-0029" title="EUCTR2004-001116-31-ES. Multicentre, randomised, double-blind, parallel group confirmatory Phase III study to compare the efficacy and safety of cizolirtine citrate 300 mg bid (600 mg/d), cizolirtine citrate 400 mg bid (800 mg/d), placebo, and tolterodine 2 mg bid (4 mg/d) in the treatment of urge urinary incontinence. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-001116-31 (first received 03 November 2004). [ESCLIN-002/04] [EUCTR2004-001116-31-ES] [sr-incont64643]">EUCTR2004‐001116‐31‐ES</a>; <a href="./references#CD003781-bbs2-0032" title="GellerE , DumondJ , BowlingJM , KhandelwalC , WuJ , Busby-WhiteheadJ , et al. Effect of an anticholinergic on cognitive function in postmenopausal women: a randomized trial (Abstract number: oral poster 52). Female Pelvic Medicine and Reconstructive Surgery2016;22(5):S61. [sr-incont78607]GellerEJ , DumondJB , BowlingJM , KhandelwalCM , WuJM , Busby-WhiteheadJ , et al. Effect of trospium chloride on cognitive function in women aged 50 and older: a randomized trial. Female Pelvic Medicine &amp; Reconstructive Surgery2017;23(2):118-23. [13-1352] [NCT01922115] [sr-incont74341]NCT01922115. The effect of anticholinergics on cognitive function in the elderly (ACE) [The effect of anticholinergics on cognitive function in the elderly: a randomized controlled trial]. clinicaltrials.gov/show/NCT01922115 (first received 14 August 2013). [13-1352] [NCT01922115] [TrialID.ACE] [sr-incont49282]">Geller 2013</a>; <a href="./references#CD003781-bbs2-0034" title="GriebenowR , WienersF , LangeT . Possible induction of cardiac dysrhythmia in elderly patients under therapy with propiverine hydrochloride (Abstract). Neurourology and Urodynamics1994;13:430-2. [sr-incont2681]">Griebenow 1994</a>; <a href="./references#CD003781-bbs2-0036" title="HajebrahimiS , MotlaghRS , BazarganiHS , BabaieH . Efficacy of tadalafil in treatment of overactive bladder syndrome: a randomized controlled trial (Abstract number OP.3.6Dec.27). International Journal of Urology2014;21:A146. [IRCT2013030212668N1] [sr-incont67256]IRCT2013030212668N1. Effect of tadalafil in treatment of overactive bladder  [Comparison of the efficacy of tadalafil, toltrodine and placebo in reduction of symptoms severity of women with urgency, frequency syndrom / overactive bladder]. en.irct.ir/trial/12692 (first received 26 January 2013). [91189] [IRCT2013030212668N1] [sr-incont78643]">Hajebrahimi 2014</a>; <a href="./references#CD003781-bbs2-0037" title="HalaskaM , DorschnerW , FrankM . Treatment of urgency and incontinence in elderly patients with propiverine hydrochloride. Neurourology and Urodynamics1994;13(4):428-30. [srincont-2680]">Halaska 1994</a>; <a href="./references#CD003781-bbs2-0047" title="JacquetinB , WyndaeleJJ . Tolterodine reduces the number of incontinence episodes in patients with an overactive bladder. European Journal of Obstetrics and Gynecology and Reproductive Biology2001;98(1):97-102. [srincont-12200]JacquetinB , WyndaeleJJ . Tolterodine reduces the number of incontinence episodes in patients with detrusor overactivity. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(1):S30. [srincont-5167]">Jacquetin 2001</a>; <a href="./references#CD003781-bbs2-0048" title="JonasU , HofnerK , MadersbacherH , HolmdahlTH . Efficacy and safety of two doses of Tolterodine compared to placebo in patients with detrusor overactivity. Neurourology and Urodynamics1997;16(5):477-8. [srincont-5841]JonasU , HöfnerK , MadersbacherH , HolmdahlTH . Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group. World Journal of Urology1997;15(2):144-51. [srincont-5436]">Jonas 1997</a>; <a href="./references#CD003781-bbs2-0049" title="JunemannKP , Al-ShukriS . Efficacy and tolerability of trospium chloride and tolterodine in 234 patients with urge-syndrome: a double-blind, placebo-controlled, multicentre clinical trial (Abstract number 85B). Neurourology and Urodynamics2000;19(4):488-90. [srincont-9976]">Junemann 2000</a>; <a href="./references#CD003781-bbs2-0050" title="JünemannKP , HessdörferE , Unamba‐OparahI , BerseM , BrünjesR , MadersbacherH . Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. Urologia Internationalis2006;77(4):334-9. [srincont-22199]">Junemann 2006</a>; <a href="./references#CD003781-bbs2-0061" title="LacknerTE , WymanJF , McCarthyTC , MonigoldM , DaveyC . Efficacy of oral extended-release oxybutynin in cognitively impaired older nursing home residents with urge urinary incontinence: a randomized placebo-controlled trial. Journal of the American Medical Directors Association2011;12(9):639-47. [sr-incont42677]LacknerTE , WymanJF , McCarthyTC , MonigoldM , DaveyC . Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. Journal of the American Geriatrics Society2008;56(5):862-70. [sr-incont27117]">Lackner 2011</a>; <a href="./references#CD003781-bbs2-0065" title="ChappleCR , MadersbacherH , DreikornK , DorschnerW , MurtzG . Urodynamics and frequency/volume chart - do they correlate? Treatment analysis of propiverine in comparison to oxybutynin and placebo in urge incontinence (Abstract 224). In: International Continence Society (ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001. [sr-incont14474]HalaskaM , MadersbacherH , VoigtR , HofnerK , MartanA . Propiverine in patients with urgency and urge incontinence - a placebo controlled, multicentre study comparing its tolerability and efficacy with oxybutynin (Abstract number FDP36). International Urogynaecology Journal 2000;11(Suppl 1):S46. [srincont-11912]MadersbacherH , HalaskaM , VoigtR , AlloussiS , HofnerK . A urodynamically controlled multicenter study in patients with urge incontinence: tolerability and efficacy of propiverine hydrochloride in comparison to oxybutynin. In: International Continence Society (ICS), 27th Annual Meeting; 1997 Sep 23-26; Yokohama, Japan. 1997:153-4. [srincont-5854]MadersbacherH , HalaskaM , VoigtR , AlloussiS , HöfnerK . A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU International1999;84(6):646-51. [srincont-9166]">Madersbacher 1999</a>; <a href="./references#CD003781-bbs2-0066" title="Malone-LeeJG , WalshB , MaugourdMF , Tolterodine in the Elderly Study Group. The safety and clinical efficacy of two doses of tolterodine compared to placebo in elderly patients. In: International Continence Society (ICS), 27th Annual Meeting; 1997 Sep 23-26; Yokohama, Japan. 1997:155-6. [srincont-5855]Malone‐LeeJG , WalshJB , MaugourdMF . Tolterodine: A safe and effective treatment for older patients with overactive bladder. Journal of the American Geriatric Society2001;49(6):700-5. [srincont-12319]WaggA , Malone-LeeJ . Pressure-flow variables in patients treated with tolterodine for detrusor overactivity. BJU International2003;92(9):969-71. [sr-incont16659]">Malone‐Lee 2001</a>; <a href="./references#CD003781-bbs2-0072" title="OreskovićS , ButI , BanovićM , GoldstajnMS . The efficacy and safety of solifenacin in patients with overactive bladder syndrome. Collegium Antropologicum2012;36(1):243-8. [srincont-45056]">Oreskovic 2012</a>; <a href="./references#CD003781-bbs2-0074" title="RentzhogSL , StantonL , CardozoL , NelsonE , FallM , AbramsP . Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. British Journal of Urology1998;81(1):42-8. [srincont-5461]">Rentzhog 1998</a>; <a href="./references#CD003781-bbs2-0085" title="StohrerM , BauerP , GiannettiBM , RichterR , BurgdorferH , MurtzG . Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries. Urologia Internationalis1991;47(3):138-43. [srincont-236]">Stohrer 1991</a>; <a href="./references#CD003781-bbs2-0086" title="StohrerM , MadersbacherH , RichterR , WehnertJ , DreikornK . Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia - a double-blind, placebo-controlled clinical trial. Spinal Cord1999;37(3):196-200. [sr-incont8146]">Stohrer 1999</a>; <a href="./references#CD003781-bbs2-0087" title="TagoK , UenoA , TakayasuH . Clinical study of propiverine hydrochloride for the treatment of patients with urinary frequency and incontinence. Neurourology and Urodynamics1990;9(4):337-8. [srincont-5109]">Tago 1990</a>; <a href="./references#CD003781-bbs2-0088" title="TakayasuH , UenoA , TsutidaS , KoisoK , KuritaK , KawabeK , et al. Clinical effects of propiverine hydrochloride in the treatment of urinary frequency and incontinence associated with detrusor overactivity: a double blind, parallel, placebo controlled multicenter study. Igaku No Ayumi (Progress in Medicine)1990;153(8):459-71. [srincont-12896]TakayasuH , UenoA , TsutidaS , KoisoK , KuritaK , KawabeK , et al. Clinical effects of propiverine hydrochloride in the treatment of urinary frequency and incontinence associated with detrusor overactivity: a double blind, parallel, placebo controlled multicenter study. Igaku No Ayumi (Progress in Medicine)1990;153(8):459-71. [sr-incont12896]">Takayasu 1990</a>; <a href="./references#CD003781-bbs2-0089" title="ThuroffJW , BunkeB , EbnerA , FaberP , deGeeterP , HannappelJ , et al. Randomized, double-blind multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin vs. propantheline vs. placebo. Neurourology and Urodynamics1990;9(4):337-8. [srincont-5108]ThuroffJW , BunkeB , EbnerA , FaberP , deGeeterP , HannappelJ , et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. Journal of Urology1991;145(4):813-7. [srincont-1288]">Thuroff 1991</a>; <a href="./references#CD003781-bbs2-0090" title="UlshoferB , BihrAM , BodekerRH , SchwantesU , JahnHP . Randomised, double-blind, placebo-controlled study on the efficacy and tolerance of trospium chloride in patients with motor urge incontinence. Clinical Drug Investigation2001;21(8):563-9. [srincont-16324]UlshoferB , SchwantesU , BodekerRH , BihrAM , JahnHP . Efficacy and tolerance of trospium chloride in patients with motor urge incontinence - results of a randomised double-blind placebo-controlled study (Poster presentations). In: 2nd International Consultation on Incontinence (ICI); 2001 July 1-3; Paris, France. 2001:5. [srincont-16318]">Ulshofer 2001</a>; <a href="./references#CD003781-bbs2-0091" title="MesselinkEJ , SolerJM , MadersbacherH , ThuroffJW , AmarencoG , Van KerrebroeckEV . Urodynamic aspects of the efficacy of tolterodine, a new anti muscarine drug in the treatment of detrusor hyperreflexia. In: International Continence Society (ICS), 25th Annual Meeting; 1995 Oct 17-20; Sydeney, Australia. 1995:95-6. [srincont-10883]Van KerrebroeckPE , AmarencoG , ThüroffJW , MadersbacherHG , LockMT , MesselinkEJ , et al. Dose-ranging study ot tolterodine in patients with detrusor hyperreflexia. Neurourology and Urodynamics1998;17(5):499-512. [srincont-7852]">Van Kerrebroeck 1998</a>; <a href="./references#CD003781-bbs2-0099" title="YongucT , SefikE , InciI , KusbeciOY , CelikS , AydinME , et al. Randomized, controlled trial of fesoterodine fumarate for overactive bladder in Parkinson's disease. World Journal of Urology2019;38(8):2013-9. [sr-incont78635]">Yonguc 2019</a>; <a href="./references#CD003781-bbs2-0100" title="JapicCTI-152936. Phase III study of KRP-114V [A phase III, randomized, double-blind, parallel group, placebo controlled, multicenter study to assess the efficacy and safety of the beta-3 agonist KRP-114V in Japanese subjects with symptoms of overactive bladder]. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-152936 (first received 17 June 2015). [JapicCTI-152936] [sr-incont78653]YoshidaM , TakedaM , GotoM , NagaiS , KuroseT . Vibegron, a novel potent and selective beta3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study (Abstract number 1082). European Urology, Supplements2018;17(2):e1531-2. [JapicCTI-152936] [sr-incont78069]YoshidaM , TakedaM , GotohM , NagaiS , KuroseT . Vibegron, a novel potent and selective B3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study. European Urology2018;73(5):783-90. [JapicCTI-152936] [sr-incont77898]YoshidaM , TakedaM , GotohM , YokoyamaO , KakizakiH , TakahashiS , et al. Efficacy of novel beta3-adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: a post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study. International Journal of Urology2019;26(3):369-75. [JapicCTI-152936] [sr-incont78654]YoshidaM , TakedaM , GotohM , YokoyamaO , KakizakiH , TakahashiS , et al. Efficacy of vibegron, a novel selective I²3-adrenoreceptor agonist, on urgency urinary incontinence with overactive bladder: post-hoc analysis of phase iii study (Abstract number 180). Neurourology and Urodynamics2019;38(S3):S114-5. [JapicCTI-152936] [sr-incont78636]">Yoshida 2018</a>). There were also three studies that lasted eight weeks (<a href="./references#CD003781-bbs2-0054" title="KhullarV , HillS , LavalKU , SchiotzHA , JonasU , VersiE . Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology2004;64(2):269-74; discussion 274-5. [srincont-19498]KhullarV , HillS , SolankiJ . Assessment of health-related quality of life in patients with overactive bladder taking tolterodine extended release versus placebo (Abstract number 318). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21075]">Khullar 2004</a>; <a href="./references#CD003781-bbs2-0068" title="DmochowskiR , MitchesonD , FrenklT , BennettN , MuddPN . Durable efficacy and safety of long-term once-daily vibegron, a novel oral B-3 adrenergic receptor agonist: A 52-week phase 2 study in patients with overactive bladder syndrome (Abstract number PD50-03). Journal of Urology2018;199(4):e970-1. [sr-incont78091]EUCTR2010-022121-15-IT. A phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2 part clinical study of the efficacy and safety of MK-4618 in patients with overactive bladder - MK4618-008 [A 52-week extension to: a phase iib randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder]. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-022121-15 (first received 12 April 2011). [EUCTR2010-022121-15-IT] [MK4618-008] [NCT01314872] [sr-incont78639]MitchesonD , FrenklT , SamantaS , Anne PintoC , GreenS , BennettN , et al. Vibegron, a novel once daily oral beta-3 agonist, significantly reduces average daily micturitions, urge incontinence episodes and urgency episodes in patients with overactive bladder (Abstract number: podium #34). Neurourology and Urodynamics2018;37(Suppl 1):S565. [EUCTR2010-022121-15-IT] [NCT01314872] [sr-incont78618]MitchesonD , PintoCA , FrenklT , ChenL , PrasadM , MuddPN . Once daily vibegron improves quality of life measures in patients with overactive bladder (Abstract number PUK17). Value in Health2018;21(Suppl 1):S267-8. [EUCTR2010-022121-15-IT] [NCT01314872;] [sr-incont78619]MitchesonHD , SamantaS , MuldowneyK , PintoCA , RochaBA , GreenS , et al. Vibegron (RVT-901/MK-4618/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial. European Urology2019;75(2):274-82. [NCT01314872] [sr-incont78620]NCT01314872. A study of the efficacy and safety of Vibegron (MK-4618) in participants with overactive bladder (OAB) (MK-4618-008) [A phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder a 52-week extension to: a phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder]. clinicaltrials.gov/show/NCT01314872 (first received 15 March 2011). [NCT01314872] [sr-incont63793]UKCRN10391. A phase IIB randomised, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of MK-4618 in patients with overactive bladder . public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=10391 (accessed 28 June 2012). [CCRN525] [UKCRN10391] [sr-incont45046]">Mitcheson 2019</a>; <a href="./references#CD003781-bbs2-0069" title="Drug company. A phase 2, parallel group, stratified, randomized, double blind, placebo-controlled trial to investigate the efficacy and safety of 3 different dosages of sustained release fesoterodine in subjects with overactive bladder showing either involuntary detrusor contractions or normal findings during the baseline urodynamic assessment. Protocol numbers: A0221029 (SP668). ClinicalStudyResults.org (accessed 3 March 2011). [srincont-41111]NittiV , WiatrakM , KreitmanL , LipsitzD . Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB): results of a phase 2 trial (Abstract number 306). In: International Continence Society (ICS); 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21084]">Nitti 2005</a>), one that lasted six weeks (<a href="./references#CD003781-bbs2-0057" title="KosilovK , LoparevS , IvanovskayaM , KosilovaL . A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron. Archives of Gerontology and Geriatrics2015;61(2):212-6. [sr-incont68133]">Kosilov 2015a</a>) and one that lasted 16 weeks (<a href="./references#CD003781-bbs2-0011" title="CardozoL , AdamikZ , GuimaraesM , KrhutJ , Labat J-J, PetrovS , et al. Patients with overactive bladder show progressive improvement in urgency and bladder condition during treatment with solifenacin in a randomised, double-blind, placebo-controlled study (SUNRISE) (Abstract number 115). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S67-8. [srincont-26595]CardozoL , AmarencoG , PushkarD , MikulasJ , DrogendijkT , WrightM , et al. Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE). BJU International2013;111(5):804-10. [NCT00801944] [TrialID.SUNRISE.] [sr-incont47554]CardozoL , DewildeT , FeyereislJ , WadieB , AmarencoG , LiapisA , et al. Solifenacin significantly reduces both urgency severity and bother: results from the flexible dose, placebo controlled, multinational SUNRISE study (Abstract number 281). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26641]CardozoL , DrogendijkT , BolodeokuJ . The efficacy of solifenacin 5/10 mg on 'urgency' endpoints in different OAB patient populations: subanalysis of results from the randomised, double-blind SUNRISE study (Abstract number 192). In: International Continence Society (ICS); 38th Annual Meeting; 2008 Oct 20-24; Cairo, Egypt. 2008. [srincont-31885]CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CardozoL , HessdörferE , MilaniR , ArañóP , DewildeL , SlackM , et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU International2008;102(9):1120-7. [NCT00801944] [TrialID.SUNRISE] [srincont-29249]">Cardozo 2008a</a>). </p> </section> <section id="CD003781-sec-0053"> <h5 class="title">Outcomes</h5> <p>Overall, there was a lack of consistency in the types of outcome measures reported by trialists and a lack of consistency in the way data were reported. Due to deficiencies in data reporting (e.g. point estimates without any measure of variation), many studies contributed only limited data to the review. The lack of similarity in measures reduced the possibilities for combining results from individual studies. </p> <section id="CD003781-sec-0054"> <h6 class="title">Patient perception of cure or improvement</h6> <p>Patient observations were rarely reported and, in reading study reports, it does not appear that these data were often collected. Where patient perception was reported, this was variable in terms of the measures used, ranging from a simple "yes/no" question to the Patient Perception of Bladder Condition (PPBC) instrument. We chose to only include studies in the meta‐analysis that used the PPBC as it has previously been validated (<a href="./references#CD003781-bbs2-0017" title="ChappleC , DuBeauC , EbingerU , RekedaL , ViegasA . Darifenacin treatment of patients &gt;or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Current Medical Research and Opinion2007;23(10):2347-58. [srincont-23921]">Chapple 2007b</a>; <a href="./references#CD003781-bbs2-0024" title="DmochowskiR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. A double-blind, placebo-controlled trial of flexible-dose fesoterodine for overactive bladder (Abstract number 715). In: International Continence Society (ICS); 39th Annual Meeting; 2009 Sep 29-Oct 03; San Francisco, CA. 2009. [sr-incont35627]DmochowskiRR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder [Errata appear in: Urology 2010 Jun;75(6):1519 and in Urology 2011 Jun;77(6):1513]. Urology2010;75(1):62-8. [A0221014] [NCT00536484] [sr-incont39548]DuBeauC , KrausSR , SunF , MorrowJD . Fesoterodine in older vs younger subjects with overactive bladder (Abstract number D87). Journal of the American Geriatrics Society2010;58:S218. [NCT00536484] [sr-incont64309]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. [sr-incont78640]NCT00536484. Fesoterodine flexible dose study [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with overactive bladder]. clinicaltrials.gov/show/NCT00536484 (first received 27 September 2007). [NCT00536484] [sr-incont49160]StaskinD , KhullarV , MichelMC , MorrowJD , SunF , GuanZ , et al. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. Neurourology and Urodynamics2011;30(8):1480-5. [sr-incont42686]">Dmochowski 2010</a>; <a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>; <a href="./references#CD003781-bbs2-0038" title="HerschornS , HeesakkersJ , Castro-DiazD , WangJT , BrodskyM , GuanZ . Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*. Current Medical Research and Opinion2008;24(12):3513-21. [A6121122] [NCT00143377] [srincont-29250]HerschornS , HeesakkersJ , Castro-DiazD , WangJT , GuanZ , BrodskyM . Tolterodine extended release (TER) improves objective and subjective outcomes after 1 week of treatment in patients with overactive bladder (Abstract number 132). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S78-9. [srincont-26602]">Herschorn 2008</a>; <a href="./references#CD003781-bbs2-0039" title="CorcosJ , AnguloJC , GarelyAD , CarlssonM , GongJ , GuanZ . Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. Current Medical Research and Opinion2011;27(5):1059-65. [srincont-41596]EUCTR2006-006935-38-SE. 12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006935-38 (first received 16 April 2007). [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont64612]HerschornS , SwiftS , GuanZ , CarlssonM , BrodskyM , GongJ . Efficacy and safety of fesoterodine for overactive bladder in a double-blind, head-to-head comparison trial with tolterodine ER and placebo (Abstract number 710). In: International Continence Society (ICS), 39th Annual Meeting; 2009 Sep 29-Oct 3; San Francisco, CA. 2009. [srincont-35326]HerschornS , SwiftS , GuanZ , CarlssonM , MorrowJD , BrodskyM , et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU International2010;105(1):58-66. [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont39540]NCT00444925. Clinical trial to evaluate the efficacy and safety of Fesoterodine in comparison to Tolterodine for overactive bladder (OAB) [12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder (OAB)]. clinicaltrials.gov/show/NCT00444925 (first received 08 March 2007). [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont49159]">Herschorn 2009a</a>; <a href="./references#CD003781-bbs2-0046" title="HuangA , HessR , AryaL , RichterH , SubakL , BradleyC , et al. A randomized controlled trial of simple diagnosis and treatment for urgency urinary incontinence in women (Abstract). Journal of General Internal Medicine2011;26:S1. [NCT00862745] [sr-incont64391]HuangAJ , HessR , AryaLA , RichterHE , SubakLL , BradleyCS , et al. Pharmacologic treatment for urgency-predominant urinary incontinence in women diagnosed using a simplified algorithm: a randomized trial. American Journal of Obstetrics and Gynecology2012;206(5):444.e1-11. [GA0221IX] [NCT00862745] [TrialID.BRIDGES.] [srincont-44636]NCT00862745, BrownJ . Bringing simple urge incontinence diagnosis &amp; treatment to providers (BRIDGES)  [A multi-center, randomized, placebo-controlled clinical trial comparing fesoterodine to placebo in women diagnosed with urge urinary incontinence by the 3 Incontinence Questions (3IQ). Followed by a multi-center open label clinical cohort study of long-term effects of treatment with fesoterodine ]. clinicaltrials.gov/show/NCT00862745 (first received 17 March 2009). [NCT00862745] [sr-incont49836]WarsiQ , HuangA , BrownJS , SchembriM , HessR , AryaLA , et al. The effect of pharmacologic treatment of urgency urinary incontinence on sleep quality and daytime sleepiness (Abstract number: paper 37). Female Pelvic Medicine and Reconstructive Surgery2016;22(5 ):S17-8. [NCT00862745] [TrialID.BRIDGES.] [sr-incont78633]WarsiQA , HuangAJ , HessR , AryaLA , RichterHE , BradleyCS , et al. Association of pharmacologic treatment of urgency urinary incontinence with sleep quality and daytime sleepiness. Obstetrics and Gynecology2018;131(2):204-11. [NCT00862745] [sr-incont78239]WinkelmanW , HuangA , SchembriM , RogersRG , RichterHE , MyersDL , et al. Clinical variables moderating response to pharmacologic treatment of urgency-predominant urinary incontinence in a randomized controlled trial (Abstract number: poster 25). In: Female Pelvic Medicine and Reconstructive Surgery. 37th Annual Scientific Meeting of the American Urogynecologic Society; Aug 2016; United States. Vol. 22. Netherlands: Lippincott Williams and Wilkins, 2016:S81. [NCT00862745] [sr-incont78634]WinkelmanWD , HuangAJ , SchembriM , RogersRG , RichterH , MyersDL , et al. Modifiers of response to treatment with fesoterodine for urgency-predominant urinary incontinence in a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2017;23(2):151-6. [sr-incont74308]">Huang 2012</a>; <a href="./references#CD003781-bbs2-0051" title="EUCTR2007-006451-39-SE. 12-week, randomized, double-blind, double-dummy, placebo controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-006451-39 (first received 20 February 2008). [A0221046] [EUCTR2007-006451-39-SE] [sr-incont64591]KaplanSA , SchneiderT , FooteJ , GuanZ . Superior efficacy of fesoterodine over tolterodine with rapid onset: a prospective, head-to-head, placebo-controlled trial (Abstract number 67). Neurourology and Urodynamics2010;29(6):905-7. [srincont-40130]KaplanSA , SchneiderT , FooteJE , GuanZ , CarlssonM , GongJ . Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU International2011;107(9):1432-40. [A0221046] [NCT00611026] [srincont-41334]">Kaplan 2011</a>; <a href="./references#CD003781-bbs2-0052" title="CardozoL , KaplanS , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: results from the after study (Abstract number 740) [Erratum appears in: European Urology 2014;65(5):e78]. European Urology Supplements2013;12(1):e740-1. [NCT01302054] [sr-incont63732]CardozoL , KaplanS , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. Erratum: A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: results from the AFTER study [Erratum available in: European Urology Supplement 2013;2012:e740-1]. European Urology2014;65(5):e78 . [A0221094] [NCT01302054] [TrialID.AFTER.] [sr-incont61642]GrenaboL , HerschornS , KaplanSA , CardozoL , ScholfieldD , ArumiD , et al. Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptoms. Current Medical Research and Opinion2017;33(10):1731-6. [NCT01302054] [TrialID.AFTER.] [sr-incont76695]KaplanSA , CardozoL , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER. International Journal of Clinical Practice2014;68(9):1065-73. [A0221094] [NCT01302054] [TrialID.AFTER.] [srincont-63977]KaplanSA , HerschornS , CarlssonM , NtaniosF . Urgency urinary incontinence response rates in subjects with overactive bladder treated with fesoterodine 8 mg after suboptimal response to tolterodine extended release 4 mg: a randomized, double-blind, placebo-controlled trial (Abstract number 546). In: International Continence Society (ICS); 43rd Annual Meeting; 2013 Aug 26-30; Barcelona, Spain. 2013. [NCT01302054] [TrialID.AFTER.] [sr-incont49730]NCT01302054. A clinical study in patients with overactive bladder with leakage of urine, to find out if the medicine, Fesoterodine, works in those patients who did not have enough response to the medicine, tolterodine. [A 14 week randomized parallel group placebo-controlled double-blind multicentre study of fesoterodine 8 mg in overactive bladder patients with sub-optimal response to tolterodine 4 mg extended release (ER)]. clinicaltrials.gov/show/NCT01302054 (first received 23 February 2011). [A0221094] [NCT01302054] [TrialID.AFTER.] [sr-incont49845]">Kaplan 2014</a>; <a href="./references#CD003781-bbs2-0094" title="EUCTR2007-007087-17-SE. A 24-week, multicentre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-007087-17 (first received 13 June 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont64588]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00798434. A study to compare the effectiveness and safety of fesoterodine and placebo in an elderly population of patients who go to the toilet very frequently due to overactive bladder (SOFIA) [A 24-week, multi-centre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00798434 (first received 26 November 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont49847]SchneiderT , BergqvistA , WangJ , WaggA , Ebel-BitounC . Treatment with fesoterodine versus tolterodine for reducing symptom bother in elderly patients with overactive bladder including urgency urinary incontinence. European Urology, Supplements2012;11(1):e687-a. [sr-incont65389]WaggA , CarlssonM , ElsobkyM , FernetM . Effect of flexible dose fesoterodine on cognitive function in &gt;65 year old patients with OAB: data from two RCT (Abstract number 438). Neurourology and Urodynamics2019;38:S297-8. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78651]WaggA , DarekarA , ArumiD , KhullarV , OelkeM . Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people &gt;65 years of age: a post hoc analysis of data from the SOFIA study. Neurourology and Urodynamics2015;34(5):438-43. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont68100]WaggA , ElsobkyM , CarlssonM , FernetM . Response and cognitive safety of fesoterodine in patients &gt;65y old with OAB. Is there a relationship between cognition and treatment response? (Abstract number 183). Neurourology and Urodynamics2019;38:S118-20. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78632]WaggA , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. Journal of the American Geriatrics Society2013;61(2):185-93. [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TrialID.SOFIA.] [sr-incont48008]WaggAS , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Efficacy and tolerability of fesoterodine in older subjects with overactive bladder: results of SOFIA (Abstract number C33). Journal of the American Geriatrics Society2011;59:S124. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont65234]">Wagg 2013a</a>). </p> </section> <section id="CD003781-sec-0055"> <h6 class="title">Quality of life</h6> <p>Measures of quality of life were reported in 25 studies. Eleven studies used the King's Health Questionnaire (KHQ) (<a href="./references#CD003781-bbs2-0014" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. ChappleCR , AranoP , BoschJH , De RidderD , KramerG , RidderAM . YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo- and tolterodine-controlled, phase-II, dose-finding study (Abstract 75). Neurourology and Urodynamics2002;21(4):381-2. [srincont-14551]ChappleCR , ArañoP , BoschJL , De RidderD , KramerAE , RidderAM . Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU International2004;93(1):71-7. [srincont-17334]KelleherCJ , CardozoL , ChappleCR , HaabF , RidderAM . Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU International2005;95(1):81-5. [srincont-20241]SmithN , GrimesI , RidgeS , TempelD , UchidaT , YamanouchiUS . YM905 is effective and safe as treatment of overactive bladder in women and men: results from phase II study (Abstract). In: International Continence Society (ICS), 32nd Annual Meeting; 2002 Aug 28-30; Heidelberg, Germany. 2002:138-9. [sr-incont14508]">Chapple 2004b</a>; <a href="./references#CD003781-bbs2-0015" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. ChappleC , RechbergerT , Al-ShukriS , MeffanP , EveraertK , RidderA . Results of a randomized phase 3 study comparing solifenacin succinate with tolterodine and placebo in patients with symptomatic overactive bladder (Abstract). Neurourology and Urodynamics2003;22(5):534-5. [sr-incont16991]ChappleCR , RechbergerT , Al ShukriS , MeffanP , EveraertK , HuangM , et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU International2004;93(3):303-10. [srincont-17270]">Chapple 2004c</a>; <a href="./references#CD003781-bbs2-0016" title="ChappleC , Van KerrebroeckP , TubaroA , Haag-MolkentellerC , ForstHT , MassowU , et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder [Erratum appears in: European Urology 2008,53(6):1319]. European Urology2007;52(4):1204-12. [NCT00220363] [SP583] [srincont-23875]ChappleC , Van KerrebroeckP , TubaroA , MillardR . Fesoterodine in non-neurogenic voiding dysfunction - results on efficacy and safety in a phase 3 trial (Abstract number 379). In: 21st Annual European Association of Urology (EAU) Congress; 2006 Apr 5-8; Paris, France. 2006. [srincont-41109]ChappleC , Van KerrebroeckP , TubaroA , WangJT , HvidstenK , BrodskyM . Efficacy of fesoterodine in patients with overactive bladder (OAB): improvements in OAB symptoms and health-related quality of life (HRQL) (Poster abstract number 1188). Journal of Urology2007;177(4 Suppl S):392. [srincont-31882]ChappleCR , vanKerrebroeckPE , JünemannKP , WangJT , BrodskyM . Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU International2008;102(9):1128-32. [srincont-29255]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. KelleherCJ , TubaroA , WangJT , KoppZ . Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU International2008;102(1):56-61. [srincont-27613]SandPK , MorrowJD , BavendamT , CreangaDL , NittiVW . Efficacy and tolerability of fesoterodine in women with overactive bladder. International Urogynecology Journal2009;20(7):827-35. [srincont-31351]">Chapple 2007a</a>; <a href="./references#CD003781-bbs2-0043" title="HommaY , KawabeK . Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World Journal of Urology2004;22(4):251-6. [srincont-19412]HommaY , PaickJS , LeeJG , KawabeK , Japanese and Korean Tolterodine Study Group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU International2003;92(7):741-7. [srincont-16418]">Homma 2003</a>; <a href="./references#CD003781-bbs2-0044" title="HommaY , YamaguchiT , YamaguchiOA . A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2008;15(9):809-15. [srincont-27742]">Homma 2008</a>; <a href="./references#CD003781-bbs2-0045" title="HommaY , YamaguchiO , Imidafenacin Study Group. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2009;16(5):499-506. [NCT00212732] [ONO-8025-08] [srincont-31368]">Homma 2009</a>; <a href="./references#CD003781-bbs2-0033" title="GotohM , HommaY , YokoyamaO , NishizawaO . Responsiveness and minimal clinically important change in overactive bladder symptom score. Urology2011;78(4):768-73. [srincont-42622]GotohM , YokoyamaO , MatsukawaY , NishizawaO . Responsiveness of overactive bladder symptom score (OABSS): verification based on data in a double-blinded, randomized placebo-controlled study of propiverine hydrochloride in Japanese patients (Abstract number 338). In: Joint Meeting of the International Continence Society (ICS) and the International Urogynecological Association; 2010 Aug 23-27; Toronto, Canada. 2010. [srincont-40173]GotohM , YokoyamaO , NishizawaO . Propiverine hydrochloride in Japanese patients with overactive bladder: A randomized, double-blind, placebo-controlled trial. International Journal of Urology2011;18(5):365-73. [srincont-41510]">Gotoh 2011</a>; <a href="./references#CD003781-bbs2-0050" title="JünemannKP , HessdörferE , Unamba‐OparahI , BerseM , BrünjesR , MadersbacherH . Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. Urologia Internationalis2006;77(4):334-9. [srincont-22199]">Junemann 2006</a>; <a href="./references#CD003781-bbs2-0054" title="KhullarV , HillS , LavalKU , SchiotzHA , JonasU , VersiE . Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology2004;64(2):269-74; discussion 274-5. [srincont-19498]KhullarV , HillS , SolankiJ . Assessment of health-related quality of life in patients with overactive bladder taking tolterodine extended release versus placebo (Abstract number 318). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21075]">Khullar 2004</a>;  <a href="./references#CD003781-bbs2-0096" title="YamaguchiO , MaruiE , KakizakiH , ItohN , YokotaT , OkadaH , et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU International2007;100(3):579-87. [sr-incont23865]YokoyamaO , YamaguchiO , KakizakiH , ItohN , YokotaT , OkadaH , et al. Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary. Journal of Urology2011;186(1):170-4. [sr-incont41734]">Yamaguchi 2007</a>; <a href="./references#CD003781-bbs2-0098" title="YamaguchiO , UchidaE , HigoN , MinamiH , KobayashiS , SatoH , et al. Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: a randomized double-blind trial. International Journal of Urology2014;21(6):586-93. [JapicCTI-101309] [sr-incont62099]">Yamaguchi 2014</a>). Fifteen studies used the overactive bladder questionnaire (OAB‐q) (<a href="./references#CD003781-bbs2-0017" title="ChappleC , DuBeauC , EbingerU , RekedaL , ViegasA . Darifenacin treatment of patients &gt;or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Current Medical Research and Opinion2007;23(10):2347-58. [srincont-23921]">Chapple 2007b</a>; <a href="./references#CD003781-bbs2-0019" title="ChappleC , HaabF , SchneiderT , CarlssonM , ArumiD . Fesoterodine 8 mg versus fesoterodine 4 mg in patients with overactive bladder and a history of previous antimuscarinic therapy: Results from the EIGHT trial (Abstract number: Poster #M5). Neurourology and Urodynamics2015;34(S1):S20. [NCT01302067] [sr-incont68509]ChappleC , SchneiderT , HaabF , SunF , WhelanL , ScholfieldD , et al. Superiority of fesoterodine 8mg versus fesoterodine 4 mg in reducing urgency urinary incontinence episodes in subjects with overactive bladder: results of the randomized, double-blind, placebo-controlled EIGHT trial (Abstract number: Podium #48). Neurourology and Urodynamics2014;33(2):183-4. [NCT01302067] [sr-incont67484]ChappleC , SchneiderT , HaabF , SunF , WhelanL , ScholfieldD , et al. Superiority of fesoterodine 8mg vs 4mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial. BJU International2014;114(3):418-26. [A0221095] [NCT01302067] [TrialID.EIGHT] [srincont-62537]NCT01302067. A 12 week study to confirm the effectiveness of 8mg of Fesoterodine compared to 4mg of Fesoterodine [A 12-week, randomized, double-blind, placebo controlled, parallel group, multicenter trial in overactive bladder subjects to confirm the efficacy of 8 mg fesoterodine compared to 4 mg fesoterodine]. clinicaltrials.gov/show/NCT01302067 (first received 23 February 2011). [NCT01302067] [sr-incont63792]">Chapple 2014</a>; <a href="./references#CD003781-bbs2-0021" title="ChuaME , SeeMC , EsmeňaEB , BalingitJC , MoralesML . Efficacy and safety of gabapentin in comparison to solifenacin succinate in adult overactive bladder treatment. Lower Urinary Tract Symptoms2018;10(2):135-42. [NCT01486706] [sr-incont74529]NCT01486706, ChuaME . Efficacy and safety of gabapentin in treating overactive bladder (OAB). clinicaltrials.gov/show/NCT01486706 (first received 6 December 2011). [NCT01486706] [SLMC10-010] [sr-incont49864]">Chua 2018</a> <a href="./references#CD003781-bbs2-0024" title="DmochowskiR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. A double-blind, placebo-controlled trial of flexible-dose fesoterodine for overactive bladder (Abstract number 715). In: International Continence Society (ICS); 39th Annual Meeting; 2009 Sep 29-Oct 03; San Francisco, CA. 2009. [sr-incont35627]DmochowskiRR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder [Errata appear in: Urology 2010 Jun;75(6):1519 and in Urology 2011 Jun;77(6):1513]. Urology2010;75(1):62-8. [A0221014] [NCT00536484] [sr-incont39548]DuBeauC , KrausSR , SunF , MorrowJD . Fesoterodine in older vs younger subjects with overactive bladder (Abstract number D87). Journal of the American Geriatrics Society2010;58:S218. [NCT00536484] [sr-incont64309]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. [sr-incont78640]NCT00536484. Fesoterodine flexible dose study [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with overactive bladder]. clinicaltrials.gov/show/NCT00536484 (first received 27 September 2007). [NCT00536484] [sr-incont49160]StaskinD , KhullarV , MichelMC , MorrowJD , SunF , GuanZ , et al. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. Neurourology and Urodynamics2011;30(8):1480-5. [sr-incont42686]">Dmochowski 2010</a>; <a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>; <a href="./references#CD003781-bbs2-0038" title="HerschornS , HeesakkersJ , Castro-DiazD , WangJT , BrodskyM , GuanZ . Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*. Current Medical Research and Opinion2008;24(12):3513-21. [A6121122] [NCT00143377] [srincont-29250]HerschornS , HeesakkersJ , Castro-DiazD , WangJT , GuanZ , BrodskyM . Tolterodine extended release (TER) improves objective and subjective outcomes after 1 week of treatment in patients with overactive bladder (Abstract number 132). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S78-9. [srincont-26602]">Herschorn 2008</a>; <a href="./references#CD003781-bbs2-0039" title="CorcosJ , AnguloJC , GarelyAD , CarlssonM , GongJ , GuanZ . Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. Current Medical Research and Opinion2011;27(5):1059-65. [srincont-41596]EUCTR2006-006935-38-SE. 12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006935-38 (first received 16 April 2007). [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont64612]HerschornS , SwiftS , GuanZ , CarlssonM , BrodskyM , GongJ . Efficacy and safety of fesoterodine for overactive bladder in a double-blind, head-to-head comparison trial with tolterodine ER and placebo (Abstract number 710). In: International Continence Society (ICS), 39th Annual Meeting; 2009 Sep 29-Oct 3; San Francisco, CA. 2009. [srincont-35326]HerschornS , SwiftS , GuanZ , CarlssonM , MorrowJD , BrodskyM , et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU International2010;105(1):58-66. [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont39540]NCT00444925. Clinical trial to evaluate the efficacy and safety of Fesoterodine in comparison to Tolterodine for overactive bladder (OAB) [12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder (OAB)]. clinicaltrials.gov/show/NCT00444925 (first received 08 March 2007). [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont49159]">Herschorn 2009a</a>; <a href="./references#CD003781-bbs2-0046" title="HuangA , HessR , AryaL , RichterH , SubakL , BradleyC , et al. A randomized controlled trial of simple diagnosis and treatment for urgency urinary incontinence in women (Abstract). Journal of General Internal Medicine2011;26:S1. [NCT00862745] [sr-incont64391]HuangAJ , HessR , AryaLA , RichterHE , SubakLL , BradleyCS , et al. Pharmacologic treatment for urgency-predominant urinary incontinence in women diagnosed using a simplified algorithm: a randomized trial. American Journal of Obstetrics and Gynecology2012;206(5):444.e1-11. [GA0221IX] [NCT00862745] [TrialID.BRIDGES.] [srincont-44636]NCT00862745, BrownJ . Bringing simple urge incontinence diagnosis &amp; treatment to providers (BRIDGES)  [A multi-center, randomized, placebo-controlled clinical trial comparing fesoterodine to placebo in women diagnosed with urge urinary incontinence by the 3 Incontinence Questions (3IQ). Followed by a multi-center open label clinical cohort study of long-term effects of treatment with fesoterodine ]. clinicaltrials.gov/show/NCT00862745 (first received 17 March 2009). [NCT00862745] [sr-incont49836]WarsiQ , HuangA , BrownJS , SchembriM , HessR , AryaLA , et al. The effect of pharmacologic treatment of urgency urinary incontinence on sleep quality and daytime sleepiness (Abstract number: paper 37). Female Pelvic Medicine and Reconstructive Surgery2016;22(5 ):S17-8. [NCT00862745] [TrialID.BRIDGES.] [sr-incont78633]WarsiQA , HuangAJ , HessR , AryaLA , RichterHE , BradleyCS , et al. Association of pharmacologic treatment of urgency urinary incontinence with sleep quality and daytime sleepiness. Obstetrics and Gynecology2018;131(2):204-11. [NCT00862745] [sr-incont78239]WinkelmanW , HuangA , SchembriM , RogersRG , RichterHE , MyersDL , et al. Clinical variables moderating response to pharmacologic treatment of urgency-predominant urinary incontinence in a randomized controlled trial (Abstract number: poster 25). In: Female Pelvic Medicine and Reconstructive Surgery. 37th Annual Scientific Meeting of the American Urogynecologic Society; Aug 2016; United States. Vol. 22. Netherlands: Lippincott Williams and Wilkins, 2016:S81. [NCT00862745] [sr-incont78634]WinkelmanWD , HuangAJ , SchembriM , RogersRG , RichterH , MyersDL , et al. Modifiers of response to treatment with fesoterodine for urgency-predominant urinary incontinence in a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2017;23(2):151-6. [sr-incont74308]">Huang 2012</a>; <a href="./references#CD003781-bbs2-0051" title="EUCTR2007-006451-39-SE. 12-week, randomized, double-blind, double-dummy, placebo controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-006451-39 (first received 20 February 2008). [A0221046] [EUCTR2007-006451-39-SE] [sr-incont64591]KaplanSA , SchneiderT , FooteJ , GuanZ . Superior efficacy of fesoterodine over tolterodine with rapid onset: a prospective, head-to-head, placebo-controlled trial (Abstract number 67). Neurourology and Urodynamics2010;29(6):905-7. [srincont-40130]KaplanSA , SchneiderT , FooteJE , GuanZ , CarlssonM , GongJ . Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU International2011;107(9):1432-40. [A0221046] [NCT00611026] [srincont-41334]">Kaplan 2011</a>; <a href="./references#CD003781-bbs2-0052" title="CardozoL , KaplanS , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: results from the after study (Abstract number 740) [Erratum appears in: European Urology 2014;65(5):e78]. European Urology Supplements2013;12(1):e740-1. [NCT01302054] [sr-incont63732]CardozoL , KaplanS , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. Erratum: A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: results from the AFTER study [Erratum available in: European Urology Supplement 2013;2012:e740-1]. European Urology2014;65(5):e78 . [A0221094] [NCT01302054] [TrialID.AFTER.] [sr-incont61642]GrenaboL , HerschornS , KaplanSA , CardozoL , ScholfieldD , ArumiD , et al. Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptoms. Current Medical Research and Opinion2017;33(10):1731-6. [NCT01302054] [TrialID.AFTER.] [sr-incont76695]KaplanSA , CardozoL , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER. International Journal of Clinical Practice2014;68(9):1065-73. [A0221094] [NCT01302054] [TrialID.AFTER.] [srincont-63977]KaplanSA , HerschornS , CarlssonM , NtaniosF . Urgency urinary incontinence response rates in subjects with overactive bladder treated with fesoterodine 8 mg after suboptimal response to tolterodine extended release 4 mg: a randomized, double-blind, placebo-controlled trial (Abstract number 546). In: International Continence Society (ICS); 43rd Annual Meeting; 2013 Aug 26-30; Barcelona, Spain. 2013. [NCT01302054] [TrialID.AFTER.] [sr-incont49730]NCT01302054. A clinical study in patients with overactive bladder with leakage of urine, to find out if the medicine, Fesoterodine, works in those patients who did not have enough response to the medicine, tolterodine. [A 14 week randomized parallel group placebo-controlled double-blind multicentre study of fesoterodine 8 mg in overactive bladder patients with sub-optimal response to tolterodine 4 mg extended release (ER)]. clinicaltrials.gov/show/NCT01302054 (first received 23 February 2011). [A0221094] [NCT01302054] [TrialID.AFTER.] [sr-incont49845]">Kaplan 2014</a>; <a href="./references#CD003781-bbs2-0053" title="CapoJP , TogliaM , Forero-SchwanhaeuserS , HeW . Patients reporting severe overactive bladder symptoms: effects of solifenacin treatment on objective measures and patient-reported outcomes (Abstract number 582). In: International Continence Society (ICS), 38th Annual Meeting; 2008 Oct 20-24; Cairo, Egypt. 2008. [srincont-31844]CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. KarramMM , TogliaMR , SerelsSR , AndohM , FakhouryA , Forero-SchwanhaeuserS . Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology2009;73(1):14-8. [A0221094] [NCT00454896] [TrialID.VENUS.] [srincont-29219]SerelsSR , TogliaMR , Forero-SchwanhaeuserS , HeW . Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms. Current Medical Research and Opinion2010;26(10):2277-85. [srincont-40376]StaskinD , DmochowskiR , SerelsS , AndohM , SmithN . Report from a randomized, placebo-controlled study showing significant improvement in urgency and patient-reported outcomes in overactive bladder patients treated with solifenacin (Abstract number 124). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73-4. [srincont-26600]TogliaM , AndohM , HussainI . Solifenacin improved warning time significantly compared to placebo in patients with overactive bladder (Abstract number 123). Neurourology and Urodynamics2006;25(6):655. [srincont-26629]TogliaM , AndohM , HussainI . Solifenacin improves urgency symtoms as assessed by voiding diaries and patient-reported outcomes (PRO) in patients with overactive bladder (Abstract number 155). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26636]TogliaMR , OstergardDR , AppellRA , AndohM , FakhouryA , HussainIF . Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status. International Urogynecology Journal2010;21(7):847-54. [srincont-40094]TogliaMR , SerelsSR , LarameeC , KarramMM , NandyIM , AndohM , et al. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial. Postgraduate Medicine2009;121(5):151-8. [srincont-34204]ZinnerS , HerschornS , AndohM , HussainI . Responder analyses show statistically significant improvements in incontinence and urgency are associated with reduction in symptom bother and improvement in health-related quality of life: VENUS results (Abstract number 123). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73. [srincont-26599]">Karram 2009</a>; <a href="./references#CD003781-bbs2-0077" title="RogersR , BachmannG , JumadilovaZ , SunF , MorrowJD , GuanZ , et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. International Urogynecology Journal and Pelvic Floor Dysfunction2008;19(11):1551-7. [A6121002] [NCT00143481] [srincont-27729]RogersRG , BachmannG , ScarperoH , JumadilovaZ , SunF , MorrowJD , et al. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. Current Medical Research and Opinion2009;25(9):2159-65. [srincont-32060]">Rogers 2008</a>; <a href="./references#CD003781-bbs2-0093" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CrosbyRD , MathiasSD , MarshallTS . Relationships between symptoms, symptom bother, and health-related quality of life in patients with overactive bladder taking solifenacin or placebo in the VIBRANT study. International Journal of Clinical Practice2011;65(2):211-8. [sr-incont41015]GollarKM , YoungDG , BailenJ , HeW , Forero-SchwanhaeuserS . Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: a secondary analysis of the VIBRANT study. Urologic Nursing2012;32(1):38-46. [TrialID.VIBRANT.] [sr-incont44571]Samuels T‐A, MitchesonHD , VardyM , Forero‐SchwanhaeuserS , MarshallT , HeW . Efficacy of solifenacin for symptom bother and other patient-reported outcomes in patients with overactive bladder (OAB): results of a large, double-blind, placebo-controlled trial (Abstract number: poster #74). Neurourology and Urodynamics2009;28(2):149. [sr-incont31063]VardyMD , MitchesonHD , SamuelsTA , Forero-SchwanhaeuserS , HeW . Efficacy of solifenacin on overactive bladder symptoms, symptom bother, and other patient-reported outcomes in subjects with or without incontinence: a post hoc analysis of data from VIBRANT. Female Pelvic Medicine and Reconstructive Surgery2011;17(1):24-9. [TrialID.VIBRANT.] [sr-incont44741]VardyMD , MitchesonHD , SamuelsTA , WegenkeJD , Forero-SchwanhaeuserS , MarshallTS , et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. International Journal of Clinical Practice2009;63(12):1702-14. [905-UC-010] [NCT00573508] [TrialID.VIBRANT.] [sr-incont35459]">Vardy 2009</a>; <a href="./references#CD003781-bbs2-0094" title="EUCTR2007-007087-17-SE. A 24-week, multicentre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-007087-17 (first received 13 June 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont64588]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00798434. A study to compare the effectiveness and safety of fesoterodine and placebo in an elderly population of patients who go to the toilet very frequently due to overactive bladder (SOFIA) [A 24-week, multi-centre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00798434 (first received 26 November 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont49847]SchneiderT , BergqvistA , WangJ , WaggA , Ebel-BitounC . Treatment with fesoterodine versus tolterodine for reducing symptom bother in elderly patients with overactive bladder including urgency urinary incontinence. European Urology, Supplements2012;11(1):e687-a. [sr-incont65389]WaggA , CarlssonM , ElsobkyM , FernetM . Effect of flexible dose fesoterodine on cognitive function in &gt;65 year old patients with OAB: data from two RCT (Abstract number 438). Neurourology and Urodynamics2019;38:S297-8. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78651]WaggA , DarekarA , ArumiD , KhullarV , OelkeM . Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people &gt;65 years of age: a post hoc analysis of data from the SOFIA study. Neurourology and Urodynamics2015;34(5):438-43. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont68100]WaggA , ElsobkyM , CarlssonM , FernetM . Response and cognitive safety of fesoterodine in patients &gt;65y old with OAB. Is there a relationship between cognition and treatment response? (Abstract number 183). Neurourology and Urodynamics2019;38:S118-20. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78632]WaggA , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. Journal of the American Geriatrics Society2013;61(2):185-93. [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TrialID.SOFIA.] [sr-incont48008]WaggAS , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Efficacy and tolerability of fesoterodine in older subjects with overactive bladder: results of SOFIA (Abstract number C33). Journal of the American Geriatrics Society2011;59:S124. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont65234]">Wagg 2013a</a>; <a href="./references#CD003781-bbs2-0095" title="GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00911937. A trial to evaluate the efficacy and safety of fesoterodine in patients with symptoms of overactive bladder including nocturnal urinary urgency [A randomized, double blind, placebo controlled, parallel group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with symptoms of overactive bladder including nocturnal urinary urgency]. clinicaltrials.gov/show/NCT00911937 (first received 03 June 2009). [NCT00911937] [sr-incont49848]WeissJ , JumadilovaZ , CarlssonM , FitzGeraldMP , MalhotraA , MartireDL . Effect of antimuscarinic treatment in subjects with overactive bladder, including nocturnal urinary urgency (Abstract number 1963). Journal of Urology2012;187(4 Suppl 1):e792. [NCT00911937] [sr-incont65184]WeissJP , CarlssonMR , ManganEK . Age, gender and nocturnal urgency severity predict response to antimuscarinic treatment (Abstract number 1962). Journal of Urology2013;189(4 Suppl 1):e805. [NCT00911937] [sr-incont65096]WeissJP , JumadilovaZ , JohnsonTM , FitzGeraldMP , CarlssonM , MartireDL , et al. Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency. Journal of Urology2013;189(4):1396-401. [A0221048] [NCT00911937] [sr-incont47568]">Weiss 2013</a>). One study used the Incontinence Impact Questionnaire (IIQ) (<a href="./references#CD003781-bbs2-0103" title="ZinnerN , GittelmanM , HarrisR , SussetJ , KanellosA , AuerbachS . Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial (Abstract number DP51). In: American Urological Association (AUA), 98th Annual Meeting; 2003 Apr 26-May 1; Chicago, Illinois. 2003. [sr-incont31101]ZinnerN , GittelmanM , HarrisR , SussetJ , KanelosA , AuerbachS , Trospium Study Group. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. Journal of Urology2004;171(6 Pt 1):2311-5. [sr-incont17376]">Zinner 2004</a>). One trial used the Giessen Complaint Survey and Basle Subjective Wellbeing Study (<a href="./references#CD003781-bbs2-0025" title="ChappleCR , MadersbacherH , DreikornK , DorschnerW , MurtzG . Urodynamics and frequency/volume chart - do they correlate? Treatment analysis of propiverine in comparison to oxybutynin and placebo in urge incontinence (Abstract number 224). In: International Continence Society (ICS), 31st Annual Meeting; 2001 Sep 18-21; Seoul, Korea. 2001. [sr-incont14474]DorschnerW , StolzenburgJU , GriebenowR , HalaskaM , BrünjesR , FrankM , et al. The elderly patient with urge incontinence or urge-stress incontinence - efficacy and cardiac safety of propiverine [Der ältere Patient mit Drang-Symptomatik bzw. kombinierter Drang/Stress-Inkontinenz-Wirksamkeit und kardiale Sicherheit von Propiverin]. Aktuelle Urologie2003;34(2):102-8. [sr-incont16422]DorschnerW , StolzenburgJU , GriebenowR , HalaskaM , SchubertG , Mürtz G et al. Efficacy and cardiac safety of propiverine in elderly patients - a double-blind, placebo-controlled clinical study. European Urology2000;37(6):702-8. [srincont-11660]">Dorschner 2000</a>). <a href="./references#CD003781-bbs2-0014" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. ChappleCR , AranoP , BoschJH , De RidderD , KramerG , RidderAM . YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo- and tolterodine-controlled, phase-II, dose-finding study (Abstract 75). Neurourology and Urodynamics2002;21(4):381-2. [srincont-14551]ChappleCR , ArañoP , BoschJL , De RidderD , KramerAE , RidderAM . Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU International2004;93(1):71-7. [srincont-17334]KelleherCJ , CardozoL , ChappleCR , HaabF , RidderAM . Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU International2005;95(1):81-5. [srincont-20241]SmithN , GrimesI , RidgeS , TempelD , UchidaT , YamanouchiUS . YM905 is effective and safe as treatment of overactive bladder in women and men: results from phase II study (Abstract). In: International Continence Society (ICS), 32nd Annual Meeting; 2002 Aug 28-30; Heidelberg, Germany. 2002:138-9. [sr-incont14508]">Chapple 2004b</a> also reported on quality life using the Contilife score. Seven studies used several measures of quality of life: Incontinence Quality of Life (IQOL) (<a href="./references#CD003781-bbs2-0022" title="AmarencoG , SutoryM , FagertunH , WrightM , CompionG , De RidderD . Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Preliminary results from the SONIC urodynamic study (Abstract). European Urology, Supplements2012;11(1):e467-a. [EudraCT2006-005523-42] [NCT00629642] [sr-incont65392]AmarencoG , SutoryM , ZachovalR , AgarwalM , DelPG , TretterR , et al. Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study. Neurourology and Urodynamics2017;36(2):414-21. [EudraCT2006-005523-42] [JapicCTI-R130306] [NCT00629642] [sr-incont72248]De RidderD , AmarencoG , Finazzi-AgroE , AnguloJ , KurenkovA , WrightM , et al. Solifenacin treatment for neurogenic detrusor overactivity: patient-reported outcomes (PROs) from the randomised clinical trial SONIC (Abstract number 333). In: International Continence (ICS); 42nd Annual Meeting; 2012 Oct 15-19; Beijing, China. 2012. [905-EC-005] [EudraCT2006-005523-42] [NCT00629642] [TrialID.SONIC.] [srincont-49739]">De Ridder 2012</a>); OAB‐q and KHQ (<a href="./references#CD003781-bbs2-0023" title="ChancellorMB , OefeleinMG , VasavadaS . Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release. Neurourology and Urodynamics2010;29(4):551-4. [sr-incont39591]DmochowskiR , StaskinD , SandP , ZinnerN . Trospium chloride 60 mg once daily improves quality of life in subjects with overactive bladder syndrome (Abstract number 277). In: International Continence Society (ICS); 37th Annual Meeting; 2008 Aug 20-24; Rotterdam, the Netherlands. 2007. [srincont-26679]DmochowskiRR , RosenbergMT , ZinnerNR , StaskinDR , SandPK . Extended-release trospium chloride improves quality of life in overactive bladder. Value in Health2010;13(2):251-7. [srincont-40049]DmochowskiRR , SandPK , ZinnerNR , StaskinDR . Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology2008;71(3):449-54. [srincont-27107]DmochowskiRR , ZinnerNR , SandPK . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: Results from a multicenter, phase III, placebo-controlled study (Abstract). Neurourology and Urodynamics2007;26(Suppl 7):1105-6. [srincont-26692]GinsbergDA , OefeleinMG , EllsworthPI . Once-daily administration of trospium chloride extended release provides 24-hr coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials. Neurourology and Urodynamics2011;30(4):563-7. [sr-incont41531]RovnerE , DmochowskiR , WatanabeJ . Once daily (QD) trospium chloride 60 mg extended release (XR) is safe and effective in patients (PTS) with the overactive bladder (OAB) syndrome who use multiple concomitant medications (MEDS) (Abstract number: Poster #68). Neurourology and Urodynamics2009;28(2):146-7. [sr-incont31062]SandP , DmochowskiR , ZinnerN , StaskinD . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: results from a multicenter, phase III, placebo-controlled study (Abstract number 269). In: International Continence Society (ICS), 37th Annual Meeting; 2007 Aug 20-24; Rotterdam, the Netherlands. 2007. [srincont-26676]SandPK , DmochowskiRR , ZinnerNR , StaskinDR , AppellRA . Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome. International Urogynecology Journal and Pelvic Floor Dysfunction2009;20(12):1431-8. [sr-incont39648]SandPK , Johnson IiTM , RovnerES , EllsworthPI , OefeleinMG , StaskinDR . Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged &gt; 75 years) with overactive bladder syndrome. BJU International2011;107(4):612-20. [sr-incont41422]StaskinDR , RosenbergMT , SandPK , ZinnerNR , DmochowskiRR . Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials. International Journal of Clinical Practice2009;63(12):1715-23. [sr-incont35458]">Dmochowski 2008</a>; <a href="./references#CD003781-bbs2-0082" title="ChancellorMB , OefeleinMG , VasavadaS . Obesity is associated with a more severe overactive bladder disease state that is effectively treated with one daily administration of trospium chloride extended release [Erratum available in: Neurourology and Urodynamics 2010;29(5):804]. Neurourology and Urodynamics2010;29(4):551-4. [sr-incont39591]GinsbergDA , OefeleinMG , EllsworthPI . Once-daily administration of trospium chloride extended release provides 24-hour coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials. Neurourology and Urodynamics2011;30(4):563-7. [sr-incont41531]RovnerE , DmochowskiR , WatanabeJ . Once daily (QD) trospium chloride 60mg extended release (XR) is safe and effective in patients (PTS) with the overactive bladder (OAB) syndrome who use multiple concomitant medications (MEDS) (Abstract number: Poster #68). Neurourology and Urodynamics2009;28(2):146-7. [sr-incont31062]SandP , DmochowskiR , ZinnerN , StaskinD . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: results from a multicenter, phase III, placebo-controlled study (Abstract number 269). In: International Continence Society (ICS), 37th Annual Meeting; 2007 Aug 20-24; Rotterdam, the Netherlands. 2007. [sr-incont26676]SandP , StaskinD , ZinnerN , DmochowskiR . Once-daily trospium chloride extended release is effective and well tolerated for the treatment of overactive bladder: results from a multicenter, phase III trial (Abstract number 57). Neurourology and Urodynamics2007;26(5):675. [sr-incont26661]StaskinD , SandP , ZinnerN , DmochowskiR , Trospium Study Group. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. Journal of Urology2007;178(3 Pt 1):978-83; discussion 983-4. [srincont-23909]StaskinDR , RosenbergMT , SandPK , ZinnerNR , DmochowskiRR . Trospium chloride once daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised phase III trials. International Journal of Clinical Practice2009;63(12):1715-23. [sr-incont35458]StaskinDR , SandPK , ZinnerNR . Once-daily trospium chloride extended release is effective and well tolerated for the treatment of overactive bladder: results from a multicenter, phase III trial (Abstract number - poster 22). Neurourology and Urodynamics2007;26(7 Suppl):1106. [srincont-27305]">Staskin 2007</a>); IIQ and Urogenital Distress Inventory (UDI) (<a href="./references#CD003781-bbs2-0072" title="OreskovićS , ButI , BanovićM , GoldstajnMS . The efficacy and safety of solifenacin in patients with overactive bladder syndrome. Collegium Antropologicum2012;36(1):243-8. [srincont-45056]">Oreskovic 2012</a>); S‐Qol and Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ) (<a href="./references#CD003781-bbs2-0077" title="RogersR , BachmannG , JumadilovaZ , SunF , MorrowJD , GuanZ , et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. International Urogynecology Journal and Pelvic Floor Dysfunction2008;19(11):1551-7. [A6121002] [NCT00143481] [srincont-27729]RogersRG , BachmannG , ScarperoH , JumadilovaZ , SunF , MorrowJD , et al. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. Current Medical Research and Opinion2009;25(9):2159-65. [srincont-32060]">Rogers 2008</a>); OAB‐q, KHQ and International Consultation of Incontinence Questionnaire (ICIQ) (<a href="./references#CD003781-bbs2-0104" title="ZinnerN , SussetJ , GittelmanM , ArguinzonizM , RekedaL , HaabF . Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. International Journal of Clinical Practice2006;60(1):119-26. [sr-incont21507]">Zinner 2006</a>). </p> </section> <section id="CD003781-sec-0056"> <h6 class="title">Urgency episodes per 24 hours at the end of treatment</h6> <p>Forty‐seven studies reported urgency episodes as an outcome. However, a total of 24 studies did not contribute to this analysis. Fifteen studies did not provide the data in a format sufficient to calculate the score at the end of treatment (<a href="./references#CD003781-bbs2-0004" title="AbramsP , KelleherC , StaskinD , KayR , MartanA , MincikI , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World Journal of Urology2017;35(5):827-38. [NCT01340027] [sr-incont77897]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Cardiovascular safety of combination treatment with mirabegron and solifenacin in patients with overactive bladder in a randomised, double-blind, dose-ranging, Phase II study (Symphony) (Abstract). European Urology, Supplements2014;13(1):e574-e574a. [NCT01340027] [sr-incont67160]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB) - efficacy and safety results from a randomised phase II study (Symphony) (Abstract number 295). Neurourology and Urodynamics2013;32(6):930-1. [NCT01340027] [TrialID.SYMPHONY.] [sr-incont49188]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB): safety results from a phase 2 study (Abstract number MP-16.08). Urology2013;82(3 Suppl 1):S139. [NCT01340027] [sr-incont66675]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: Exploratory responder analyses of efficacy and evaluation of patient reported outcomes from a randomised, double-blind, dose-ranging, phase 2 study (Symphony) (Abstract number MP-24.11). Urology2014;84(4 Suppl 1):S145-6. [NCT01340027] [sr-incont67194]AbramsP , KelleherC , StaskinD , RechbergerT , KayR , MartinaR , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (SYMPHONY). European Urology2015;67(3):577-88. [NCT01340027] [sr-incont66674]NCT01340027, Bristol Urological Institute . A study to evaluate the efficacy, safety and tolerability of mirabegron and solifenacin succinate alone and in combination for the treatment of overactive bladder (symphony) [A randomized, double-blind, factorial, parallel-group, active and placebo-controlled, multicenter dose-ranging study to evaluate the efficacy, safety and tolerability of six dose combinations of solifenacin succinate and mirabegron compared to mirabegron and solifenacin succinate monotherapies in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01340027 (first received 21 April 2011). [178-CL-100] [2010-020601-32] [NCT01340027] [TrialID.SYMPHONY] [sr-incont44510]NittiV , AbramsP , StaskinD , AuerbachS , MartinaR , VanMR . Urinary retention in patients with overactive bladder treated with mirabegron alone and in combination with solifenacin: the results of two randomized, double-blind, phase II studies (Abstract number MP76-13). Journal of Urology2014;191(4 Suppl 1):e886-7. [NCT00410514] [NCT01340027] [TrialID.SYMPHONY] [sr-incont67453]">Abrams 2013</a>; <a href="./references#CD003781-bbs2-0007" title="BrayR , CartwrightR , CardozoL , HillS , GuanZ , KhullarV . Tolterodine ER reduced increased bladder wall thickness in women with overactive bladder. A randomized, placebo-controlled, double-blind, parallel group study. Neurourology and  Urodynamics2018;37(1):237-43. [NCT00137397] [sr-incont74473]NCT00137397. A study to measure the effect of tolterodine extended release on the thickness of the bladder wall in patients with overactive bladder [A multi-centre, randomised, placebo controlled, double blind, parallel group study in female patients to evaluate whether tolterodine ER can reverse the increased bladder wall thickness in patients with overactive bladder]. clinicaltrials.gov/show/NCT00137397 (first received 29 August 2005). [NCT00137397] [sr-incont63809]">Bray 2018</a>; <a href="./references#CD003781-bbs2-0017" title="ChappleC , DuBeauC , EbingerU , RekedaL , ViegasA . Darifenacin treatment of patients &gt;or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Current Medical Research and Opinion2007;23(10):2347-58. [srincont-23921]">Chapple 2007b</a>; <a href="./references#CD003781-bbs2-0018" title="ChappleCR , DvorakV , RadziszewskiP , vanKerrebroeckP , WyndaeleJJ , BosmanB , et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder. International Urogynecology Journal2013;24(9):1447-58. [178-CL-044] [NCT00337090] [TrialID.DRAGON.] [sr-incont48549]NCT00337090 . A study of YM178 in patients with symptomatic overactive bladder (DRAGON) [A randomized, double-blind, parallel group, placebo and active controlled, multicenter dose ranging study with the beta-3 agonist YM178 in patients with symptomatic overactive bladder]. clinicaltrials.gov/show/NCT00337090 (first received 15 June 2006). [EudraCT2005-002256-17] [JapicCTI-R130350] [NCT00337090] [sr-incont63803]">Chapple 2013</a>; <a href="./references#CD003781-bbs2-0020" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. [sr-incont75259]ChuF , SmithN , UchidaT . Efficacy and safety of solifenacin succinate 10 mg once daily: a multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder. Current Therapeutic Research - Clinical and Experimental2009;70(6):405-20. [srincont-43324]">Chu 2009</a>; <a href="./references#CD003781-bbs2-0037" title="HalaskaM , DorschnerW , FrankM . Treatment of urgency and incontinence in elderly patients with propiverine hydrochloride. Neurourology and Urodynamics1994;13(4):428-30. [srincont-2680]">Halaska 1994</a>; <a href="./references#CD003781-bbs2-0038" title="HerschornS , HeesakkersJ , Castro-DiazD , WangJT , BrodskyM , GuanZ . Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*. Current Medical Research and Opinion2008;24(12):3513-21. [A6121122] [NCT00143377] [srincont-29250]HerschornS , HeesakkersJ , Castro-DiazD , WangJT , GuanZ , BrodskyM . Tolterodine extended release (TER) improves objective and subjective outcomes after 1 week of treatment in patients with overactive bladder (Abstract number 132). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S78-9. [srincont-26602]">Herschorn 2008</a>; <a href="./references#CD003781-bbs2-0040" title="EUCTR2012-005735-91-SK. A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-005735-91 (first received 12 November 2013). [178-CL-101] [EUCTR2012-005735-91-SK] [sr-incont78644]HerschornS , ChappleCR , AbramsP , ArlandisS , MitchesonD , LeeKS , et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU International2017;120(4):562-75. [NCT01972841] [sr-incont74470]MuellerER , RobinsonD , KelleherC , StaskinDR , FalconerC , WangJ , et al. Patient reported outcomes from synergy, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with mirabegron and solifenacin monotherapy (Abstract number - Podium #44). Neurourology and Urodynamics2017;36(Suppl S1):S151-2. [NCT01972841] [sr-incont75944]NCT01972841. This was a multinational study comparing the efficacy and safety of two medicines, solifenacin succinate and mirabegron taken together, or separately, or a mock treatment (placebo) in subjects with symptoms of overactive bladder (SYNERGY) [A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01972841 (first received 31 October 2013). [178-CL-101] [EUCTR2012-005735-91] [NCT01972841] [sr-incont63780]RobinsonD , KelleherC , StaskinD , MuellerER , FalconerC , WangJ , et al. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients. Neurourology and Urodynamics2018;37(1):394-406. [NCT01972841] [sr-incont76906]WeberMA , ChappleCR , GratzkeC , HerschornS , RobinsonD , FrankelJM , et al. A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial. Blood Pressure Monitoring2018;23(3):153-63. [NCT01972841] [sr-incont77899]WhiteWB , ChappleC , GratzkeC , HerschornS , RobinsonD , FrankelJ , et al. Cardiovascular safety of the beta3-adrenoceptor agonist mirabegron and the antimuscarinic agent solifenacin in the SYNERGY trial. Journal of Clinical Pharmacology2018;58(8):1084-91. [NCT01972841] [sr-incont78078]">Herschorn 2017a</a>; <a href="./references#CD003781-bbs2-0042" title="HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21072]HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21072]HillS , KhullarV , WyndaeleJJ , LheritierK , . Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. International Urogynecology Journal and Pelvic Floor2006;17(3):239-47. [srincont-22464]">Hill 2005</a>; <a href="./references#CD003781-bbs2-0062" title="LandisJR , KaplanS , SwiftS , VersiE . Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity. Journal of Urology2004;171(2 Pt 1):752-6. [sr-incont17327]">Landis 2004</a>; <a href="./references#CD003781-bbs2-0063" title="LeeKS , ChooMS , KimDY , KimJC , KimHJ , MinKS , et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. Journal of Urology2005;174(4 Pt 1):1334-8. [sr-incont21016]LeeKS , ChooMS , PaickJS , LeeJG , SeoJT , LeeJZ , et al. Propiverine hydrochloride reduced frequency and perception of urgency in treatment of overactive bladder: a 12 week prospective, randomized, double blind, placebo controlled study (Abstract number 279). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26640]LeeKS , LeeHW , ChooMS , PaickJS , LeeJG , SeoJT , et al. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'. BJU International2010;105(11):1565-70. [2005-01-08] [NCT00903045] [PROUD] [sr-incont39958]NCT00903045. Urinary urgency outcomes following propiverine treatment for an overactive bladder [Urinary urgency outcomes following propiverine treatment for an overactive bladder: propiverine study on overactive bladder including urgency data (PROUD)]. clinicaltrials.gov/show/NCT009030452005;(first received 15 May 2009). [2005-01-08] [NCT00903045] [TrialID.PROUD] [sr-incont49860]">Lee 2006</a>; <a href="./references#CD003781-bbs2-0068" title="DmochowskiR , MitchesonD , FrenklT , BennettN , MuddPN . Durable efficacy and safety of long-term once-daily vibegron, a novel oral B-3 adrenergic receptor agonist: A 52-week phase 2 study in patients with overactive bladder syndrome (Abstract number PD50-03). Journal of Urology2018;199(4):e970-1. [sr-incont78091]EUCTR2010-022121-15-IT. A phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2 part clinical study of the efficacy and safety of MK-4618 in patients with overactive bladder - MK4618-008 [A 52-week extension to: a phase iib randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder]. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-022121-15 (first received 12 April 2011). [EUCTR2010-022121-15-IT] [MK4618-008] [NCT01314872] [sr-incont78639]MitchesonD , FrenklT , SamantaS , Anne PintoC , GreenS , BennettN , et al. Vibegron, a novel once daily oral beta-3 agonist, significantly reduces average daily micturitions, urge incontinence episodes and urgency episodes in patients with overactive bladder (Abstract number: podium #34). Neurourology and Urodynamics2018;37(Suppl 1):S565. [EUCTR2010-022121-15-IT] [NCT01314872] [sr-incont78618]MitchesonD , PintoCA , FrenklT , ChenL , PrasadM , MuddPN . Once daily vibegron improves quality of life measures in patients with overactive bladder (Abstract number PUK17). Value in Health2018;21(Suppl 1):S267-8. [EUCTR2010-022121-15-IT] [NCT01314872;] [sr-incont78619]MitchesonHD , SamantaS , MuldowneyK , PintoCA , RochaBA , GreenS , et al. Vibegron (RVT-901/MK-4618/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial. European Urology2019;75(2):274-82. [NCT01314872] [sr-incont78620]NCT01314872. A study of the efficacy and safety of Vibegron (MK-4618) in participants with overactive bladder (OAB) (MK-4618-008) [A phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder a 52-week extension to: a phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder]. clinicaltrials.gov/show/NCT01314872 (first received 15 March 2011). [NCT01314872] [sr-incont63793]UKCRN10391. A phase IIB randomised, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of MK-4618 in patients with overactive bladder . public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=10391 (accessed 28 June 2012). [CCRN525] [UKCRN10391] [sr-incont45046]">Mitcheson 2019</a>; <a href="./references#CD003781-bbs2-0076" title="EUCTR2008-005215-17. A study to evaluate the overall effect of solifenacin 5mg and 10mg on bladder wall thickness and urinary nerve growth factor in female subjects with overactive bladder and a diagnosis of detrusor overactivity – a double-blind, randomized, placebo-controlled, parallel group, multicentre study - SHRINK. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-005215-17 (first received 14 September 2009). [EUCTR2008-005215-17] [NCT01093534] [sr-incont78650]NCT01093534. Study of 2 doses of solifenacin succinate in female subjects with overactive bladder (SHRINK) [A study to evaluate the overall effect of solifenacin 5mg and 10mg on bladder wall thickness and urinary nerve growth factor in female subjects with overactive bladder and a diagnosis of detrusor overactivity - a double-blind, randomised, placebo-controlled, parallel group, multi-centre study]. clinicaltrials.gov/show/NCT01093534 (first received 26 March 2010). [905-EC-007] [EUCTR2008-005215-17] [NCT01093534] [TrialID.SHRINK] [sr-incont63778]RobinsonD , KhullarV , OelkeM , WijkstraH , TretterR , StowB , et al. Effects of 12 weeks treatment with solifenacin on Bladder Wall Thickness (BWT) and clinical outcomes: results from the placebo-controlled SHRINK study (Abstract number 422). In: International Continence Society (ICS), 43rd Annual Meeting; 2013 Aug 26-30; Barcelona, Spain. 2013. [905-EC-007] [NCT01093534] [TrialID.SHRINK.] [srincont-49731]RobinsonD , OelkeM , KhullarV , WijkstraH , TretterR , StowB , et al. Bladder wall thickness in women with symptoms of overactive bladder and detrusor overactivity: results from the randomised, placebo-controlled SHRINK study. Neurourology and Urodynamics2016;35(7):819-25. [NCT01093534] [sr-incont72217]RobinsonD , OelkeM , TretterR , StowB , CompionG , TubaroA . The effect of solifenacin on bladder wall thickness in women with overactive bladder and detrusor overactivity: Results from the SHRINK study (Abstract number 782). European Urology Supplements2013;12(1):e782-3. [EUCTR2008-005215-17] [NCT01093534] [sr-incont67207]RobinsonD , TubaroA , KimbergM , PlummerM , DeVineJ , BouicP , et al. The effect of solifenacin on urinary nerve growth factor (UNGF) and brain-derived neurotropic factor (BDNF) in women with overactive bladder and detrusor overactivity: results from the SHRINK study (Abstract number PP 54). International Urogynecology Journal and Pelvic Floor Dysfunction2014;25(1 Suppl 1):S60-1. [EUCTR2008-005215-17] [NCT01093534] [sr-incont67200]TubaroA , KhullarV , OelkeM , WijkstraH , TretterR , StowB , et al. Intra- and inter-reader variability of transvaginal ultrasound bladder wall thickness measurements: results from the SHRINK study (Abstract number 136). Neurourology and Urodynamics2013;32(6):711-2. [EUCTR2008-005215-17] [NCT01093534] [sr-incont49211]">Robinson 2013</a>; <a href="./references#CD003781-bbs2-0083" title="EUCTR2017-003293-14. Empowur (Empower OAB patients with vibegron for better urgency control) [An international phase 3, randomized, double-blind, placebo- and active (tolterodine)-controlled multicenter study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder]. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-003293-14 (first received 24 April 2018). [EUCTR2017-003293-14] [NCT03492281] [sr-incont78606]NCT03492281, JankowichR . A study to examine the safety and efficacy of a new drug in patients with symptoms of overactive bladder (OAB) [An international phase 3, randomized, double-blind, placebo- and active (tolterodine)-controlled multicenter study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder]. clinicaltrials.gov/show/NCT03492281 (first received 20 April 2018). [NCT03492281] [sr-incont78610]StaskinD , FrankelJ , VaranoS , ShortinoD , JankowichR , MuddPN . Vibegron demonstrates statistically significant improvement in efficacy measures in overactive bladder-key secondary results from the international phase 3 study in patients with overactive bladder (empowur) (Abstract number: long oral 40). Female Pelvic Medicine and Reconstructive Surgery2019;25(5):S20-1. [NCT03492281] [sr-incont78627]StaskinD , FrankelJ , VaranoS , ZhouJ , JankowichR , MuddPN . International phase 3, double-blind, placebo- and active (tolterodine)-controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: empowur (Abstract number LBA-02). Journal of Urology2019;201(4):e992. [NCT03492281] [sr-incont78628]StaskinD , VaranoS , FrankelJ , ShortinoD , JankowichR , MuddP . Once-daily vibegron 75 mg demonstrates statistically significant benefits on key secondary endpoints including quality of life in patients with OAB: data from an international phase 3 trial (EMPOWUR) (Abstract number 181). Neurourology and Urodynamics2019;38(S3):S115-7. [NCT03492281] [sr-incont78629]VaranoS , StaskinD , FrankelJ , ShortinoD , JankowichR , MuddPN . Vibegron statistically significantly improves measures of quality of life in patients with overactive bladder-data from the international phase 3 trial (Empowur) (Abstract number: long oral 38). Female Pelvic Medicine and Reconstructive Surgery2019;25(5):S19. [NCT03492281] [sr-incont78630]">Staskin 2019</a>; <a href="./references#CD003781-bbs2-0084" title="SteersW , CorcosJ . Efficacy, tolerability and safety of darifenacin, an M3 selective receptor antagonist for the treatment of overactive bladder, using a flexible dosing regimen (Abstract number 68). Progres en Urologie2004;14(3 Suppl 3):22. [srincont-22197]">Steers 2004</a>). Other reasons for not including studies in the meta‐analysis were: change from baseline mean was calculated on a per‐patient basis and expressed as percentage change (<a href="./references#CD003781-bbs2-0010" title="CardozoL , KuzminI , LisecML , MillardR , vanVierssen TripOB , RidderAM , et al. YM905: Results of a randomised, double-blind placebo-controlled trial in patients with symptomatic overactive bladder (Abstract number 104). European Urology Supplements2003;2(1):28. [sr-incont27407]CardozoL , KuzminI , LisecML , MillardRJ , vanVierssen TripOB , RidderAM , et al. A double-blind, randomised, placebo-controlled trial with YM905 in symptomatic overactive bladder (Abstract number P74). Journal of the American Geriatrics Society2003;51 (Suppl 4):S68-9. [sr-incont31100]CardozoL , LisecM , MillardR , vanVierssen TripO , KuzminI , DrogendijkTE , et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. Journal of Urology2004;172(5 (Pt 1 of 2)):1919-24. [srincont-19090]CardozoL . A randomised double-blind, placebo-controlled trial of the once-daily muscarinic receptor antagonist solifenacin succinate for symptoms of overactive bladder (Abstract number 211). International Urogynecology Journal2003;14 (Suppl 1):S64. [sr-incont31104]CardozoL . Solifenacin succinate improves symptoms of an overactive bladder (Abstract number TP77). International Journal of Gynecology and Obstetrics2003;83(Suppl 3):94. [sr-incont31096]KelleherCJ , CardozoL , ChappleCR , HaabF , RidderAM . Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU International2005;95(1):81-5. [srincont-20241]">Cardozo 2004a</a>); baseline data were considered after eight weeks of the study beginning (<a href="./references#CD003781-bbs2-0011" title="CardozoL , AdamikZ , GuimaraesM , KrhutJ , Labat J-J, PetrovS , et al. Patients with overactive bladder show progressive improvement in urgency and bladder condition during treatment with solifenacin in a randomised, double-blind, placebo-controlled study (SUNRISE) (Abstract number 115). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S67-8. [srincont-26595]CardozoL , AmarencoG , PushkarD , MikulasJ , DrogendijkT , WrightM , et al. Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE). BJU International2013;111(5):804-10. [NCT00801944] [TrialID.SUNRISE.] [sr-incont47554]CardozoL , DewildeT , FeyereislJ , WadieB , AmarencoG , LiapisA , et al. Solifenacin significantly reduces both urgency severity and bother: results from the flexible dose, placebo controlled, multinational SUNRISE study (Abstract number 281). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26641]CardozoL , DrogendijkT , BolodeokuJ . The efficacy of solifenacin 5/10 mg on 'urgency' endpoints in different OAB patient populations: subanalysis of results from the randomised, double-blind SUNRISE study (Abstract number 192). In: International Continence Society (ICS); 38th Annual Meeting; 2008 Oct 20-24; Cairo, Egypt. 2008. [srincont-31885]CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CardozoL , HessdörferE , MilaniR , ArañóP , DewildeL , SlackM , et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU International2008;102(9):1120-7. [NCT00801944] [TrialID.SUNRISE] [srincont-29249]">Cardozo 2008a</a>); only severity of urgency was reported (<a href="./references#CD003781-bbs2-0035" title="HaabF , StewartL , DwyerP . Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. European Urology2004;45(4):420-9. [srincont-17428]">Haab 2004</a>; <a href="./references#CD003781-bbs2-0101" title="NCT01018264, ZesiewiczT . Solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease (URGE-PD) [URGE-PD: a multi-site, double-blind, randomized, placebo controlled trial of solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease]. clinicaltrials.gov/show/NCT01018264 (first received 23 November 2009). [NCT01018264] [sr-incont63790]ZesiewiczTA , EvattM , JahanI , VaughanC , SingerC , OrdoricaR , et al. URGE-PD: a multi-site, double-blind, randomized, placebo controlled trial of solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease (Abstract number 745). Movement Disorders2014;29(Suppl 1):S276-7. [NCT01018264] [sr-incont66602]ZesiewiczTA , EvattM , VaughanCP , JahanI , SingerC , OrdoricaR , et al. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease. Parkinsonism and Related Disorders2015;21(5):514-20. [NCT01018264] [sr-incont66860]">Zesiewicz 2015</a>); only results one month after the end of treatment were shown (<a href="./references#CD003781-bbs2-0058" title="KosilovKV , LoparevSA , IvanovskayaMA , KosilovaLV . The efficacy of different doses of solifenacin in elderly patients after treating a urinary tract infection. Arab Journal of Urology Print2015;13(3):203-8. [sr-incont69283]">Kosilov 2015b</a>); lack of time period indication for urgency episodes (<a href="./references#CD003781-bbs2-0065" title="ChappleCR , MadersbacherH , DreikornK , DorschnerW , MurtzG . Urodynamics and frequency/volume chart - do they correlate? Treatment analysis of propiverine in comparison to oxybutynin and placebo in urge incontinence (Abstract 224). In: International Continence Society (ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001. [sr-incont14474]HalaskaM , MadersbacherH , VoigtR , HofnerK , MartanA . Propiverine in patients with urgency and urge incontinence - a placebo controlled, multicentre study comparing its tolerability and efficacy with oxybutynin (Abstract number FDP36). International Urogynaecology Journal 2000;11(Suppl 1):S46. [srincont-11912]MadersbacherH , HalaskaM , VoigtR , AlloussiS , HofnerK . A urodynamically controlled multicenter study in patients with urge incontinence: tolerability and efficacy of propiverine hydrochloride in comparison to oxybutynin. In: International Continence Society (ICS), 27th Annual Meeting; 1997 Sep 23-26; Yokohama, Japan. 1997:153-4. [srincont-5854]MadersbacherH , HalaskaM , VoigtR , AlloussiS , HöfnerK . A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU International1999;84(6):646-51. [srincont-9166]">Madersbacher 1999</a>); results were not reported (<a href="./references#CD003781-bbs2-0323" title="NCT00553657. The study to test the effect of standardization of fluid intake in female patients with overactive bladder [A randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of standardization of fluid intake on the variability of measured voiding parameters in female patients with idiopathic overactive bladder]. clinicaltrials.gov/show/NCT00553657 (first received 04 November 2007). [NCT00553657] [sr-incont60907]">NCT00553657</a>); and urgency episodes were reported per week (<a href="./references#CD003781-bbs2-0069" title="Drug company. A phase 2, parallel group, stratified, randomized, double blind, placebo-controlled trial to investigate the efficacy and safety of 3 different dosages of sustained release fesoterodine in subjects with overactive bladder showing either involuntary detrusor contractions or normal findings during the baseline urodynamic assessment. Protocol numbers: A0221029 (SP668). ClinicalStudyResults.org (accessed 3 March 2011). [srincont-41111]NittiV , WiatrakM , KreitmanL , LipsitzD . Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB): results of a phase 2 trial (Abstract number 306). In: International Continence Society (ICS); 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21084]">Nitti 2005</a>; <a href="./references#CD003781-bbs2-0104" title="ZinnerN , SussetJ , GittelmanM , ArguinzonizM , RekedaL , HaabF . Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. International Journal of Clinical Practice2006;60(1):119-26. [sr-incont21507]">Zinner 2006</a>). Twenty‐three RCTs were included in the meta‐analysis for this outcome. </p> </section> <section id="CD003781-sec-0057"> <h6 class="title">Adverse events</h6> <p>The following adverse events were noted in the studies: dry mouth; constipation; nausea; dyspepsia/indigestion; abdominal pain; urinary retention/high residual volume; urinary tract infection (UTI); dry eyes; blurred vision; headache; dizziness; flu‐like symptoms/fatigue; nasopharyngitis/sore throat; and insomnia. Other adverse events that have previously been attributed to anticholinergics but not reported in any of the studies include: tachycardia/palpations; cognitive dysfunction; and memory loss. </p> <p>Adverse events were the most commonly reported secondary outcome of interest with 57 studies reporting side effects. Three studies did not make it clear whether they recorded the occurrence of adverse events (<a href="./references#CD003781-bbs2-0056" title="KosilovKV , LoparevS , IvanovskayaM , KosilovaL . Treatment of overactive bladder in older women increased doses of antimuscarinic drugs safe and effective alternative to existing methods. Advances in Gerontology [Uspekhi Gerontologii]2014;27(1):149-55. [ISSN: 1561-9125] [sr-incont63914]">Kosilov 2014a</a>; <a href="./references#CD003781-bbs2-0057" title="KosilovK , LoparevS , IvanovskayaM , KosilovaL . A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron. Archives of Gerontology and Geriatrics2015;61(2):212-6. [sr-incont68133]">Kosilov 2015a</a>; <a href="./references#CD003781-bbs2-0058" title="KosilovKV , LoparevSA , IvanovskayaMA , KosilovaLV . The efficacy of different doses of solifenacin in elderly patients after treating a urinary tract infection. Arab Journal of Urology Print2015;13(3):203-8. [sr-incont69283]">Kosilov 2015b</a>). Forty‐five studies did not report the above adverse events as an outcome (<a href="./references#CD003781-bbs2-0007" title="BrayR , CartwrightR , CardozoL , HillS , GuanZ , KhullarV . Tolterodine ER reduced increased bladder wall thickness in women with overactive bladder. A randomized, placebo-controlled, double-blind, parallel group study. Neurourology and  Urodynamics2018;37(1):237-43. [NCT00137397] [sr-incont74473]NCT00137397. A study to measure the effect of tolterodine extended release on the thickness of the bladder wall in patients with overactive bladder [A multi-centre, randomised, placebo controlled, double blind, parallel group study in female patients to evaluate whether tolterodine ER can reverse the increased bladder wall thickness in patients with overactive bladder]. clinicaltrials.gov/show/NCT00137397 (first received 29 August 2005). [NCT00137397] [sr-incont63809]">Bray 2018</a>; <a href="./references#CD003781-bbs2-0308" title="ChappleCR , MadersbacherH , DreikornK , DorschnerW , MurtzG . Urodynamics and frequency/volume chart - do they correlate? Treatment analysis of propiverine in comparison to oxybutynin and placebo in urge incontinence (Abstract number 224). In: International Continence Society (ICS), 31st Annual Meeting; 2001 Sep 18-21; Seoul, Korea. 2001. [sr-incont14474]">Chapple 2001</a>; <a href="./references#CD003781-bbs2-0017" title="ChappleC , DuBeauC , EbingerU , RekedaL , ViegasA . Darifenacin treatment of patients &gt;or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Current Medical Research and Opinion2007;23(10):2347-58. [srincont-23921]">Chapple 2007b</a>; <a href="./references#CD003781-bbs2-0019" title="ChappleC , HaabF , SchneiderT , CarlssonM , ArumiD . Fesoterodine 8 mg versus fesoterodine 4 mg in patients with overactive bladder and a history of previous antimuscarinic therapy: Results from the EIGHT trial (Abstract number: Poster #M5). Neurourology and Urodynamics2015;34(S1):S20. [NCT01302067] [sr-incont68509]ChappleC , SchneiderT , HaabF , SunF , WhelanL , ScholfieldD , et al. Superiority of fesoterodine 8mg versus fesoterodine 4 mg in reducing urgency urinary incontinence episodes in subjects with overactive bladder: results of the randomized, double-blind, placebo-controlled EIGHT trial (Abstract number: Podium #48). Neurourology and Urodynamics2014;33(2):183-4. [NCT01302067] [sr-incont67484]ChappleC , SchneiderT , HaabF , SunF , WhelanL , ScholfieldD , et al. Superiority of fesoterodine 8mg vs 4mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial. BJU International2014;114(3):418-26. [A0221095] [NCT01302067] [TrialID.EIGHT] [srincont-62537]NCT01302067. A 12 week study to confirm the effectiveness of 8mg of Fesoterodine compared to 4mg of Fesoterodine [A 12-week, randomized, double-blind, placebo controlled, parallel group, multicenter trial in overactive bladder subjects to confirm the efficacy of 8 mg fesoterodine compared to 4 mg fesoterodine]. clinicaltrials.gov/show/NCT01302067 (first received 23 February 2011). [NCT01302067] [sr-incont63792]">Chapple 2014</a>; <a href="./references#CD003781-bbs2-0021" title="ChuaME , SeeMC , EsmeňaEB , BalingitJC , MoralesML . Efficacy and safety of gabapentin in comparison to solifenacin succinate in adult overactive bladder treatment. Lower Urinary Tract Symptoms2018;10(2):135-42. [NCT01486706] [sr-incont74529]NCT01486706, ChuaME . Efficacy and safety of gabapentin in treating overactive bladder (OAB). clinicaltrials.gov/show/NCT01486706 (first received 6 December 2011). [NCT01486706] [SLMC10-010] [sr-incont49864]">Chua 2018</a>; <a href="./references#CD003781-bbs2-0022" title="AmarencoG , SutoryM , FagertunH , WrightM , CompionG , De RidderD . Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Preliminary results from the SONIC urodynamic study (Abstract). European Urology, Supplements2012;11(1):e467-a. [EudraCT2006-005523-42] [NCT00629642] [sr-incont65392]AmarencoG , SutoryM , ZachovalR , AgarwalM , DelPG , TretterR , et al. Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study. Neurourology and Urodynamics2017;36(2):414-21. [EudraCT2006-005523-42] [JapicCTI-R130306] [NCT00629642] [sr-incont72248]De RidderD , AmarencoG , Finazzi-AgroE , AnguloJ , KurenkovA , WrightM , et al. Solifenacin treatment for neurogenic detrusor overactivity: patient-reported outcomes (PROs) from the randomised clinical trial SONIC (Abstract number 333). In: International Continence (ICS); 42nd Annual Meeting; 2012 Oct 15-19; Beijing, China. 2012. [905-EC-005] [EudraCT2006-005523-42] [NCT00629642] [TrialID.SONIC.] [srincont-49739]">De Ridder 2012</a>; <a href="./references#CD003781-bbs2-0028" title="ElbasetM , TahaD , ZahranM , EzzatO , ElhefnawyAS , ElkenawyM , et al. Subjective and objective scales assessment after retreatment with anticholinergics post botox-faded effects in refractory idiopathic overactive bladder: a prospective single blinded randomized trial (Abstract number 132). European Urology, supplements2019;18(1):e172. [sr-incont78652]ElbasetMA , TahaDE , El-HefnawyAS , ZahranMH , ShokeirAA . Assessment of anticholinergic use after fading of BTX-A effects in refractory idiopathic overactive bladder: a prospective blinded randomized trial. International Neurourology Journal2019;23(3):240-8. [sr-incont78605]">Elbaset 2019</a>; <a href="./references#CD003781-bbs2-0029" title="EUCTR2004-001116-31-ES. Multicentre, randomised, double-blind, parallel group confirmatory Phase III study to compare the efficacy and safety of cizolirtine citrate 300 mg bid (600 mg/d), cizolirtine citrate 400 mg bid (800 mg/d), placebo, and tolterodine 2 mg bid (4 mg/d) in the treatment of urge urinary incontinence. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-001116-31 (first received 03 November 2004). [ESCLIN-002/04] [EUCTR2004-001116-31-ES] [sr-incont64643]">EUCTR2004‐001116‐31‐ES</a>; <a href="./references#CD003781-bbs2-0030" title="EUCTR2004-002143-27-AT. A double-blind, stratified, randomised, parallel, placebo-controlled, multi-centre study to compare the efficacy and safety of duloxetine hydrochloride (40mg twice a day) and tolterodine tartrate (XL) (4mg once daily) with placebo in patients with symptoms of Urge Urinary Incontinence. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-002143-27 (first received 15 February 2005). [1208.15] [EUCTR2004-002143-27-AT] [sr-incont64640]">EUCTR2004‐002143‐27‐AT</a>; <a href="./references#CD003781-bbs2-0031" title="EUCTR2007-004126-24-CZ. A placebo controlled randomized, 12-week, dose-ranging, double-blind study versus placebo using tolterodine as a study calibrator, to evaluate efficacy and safety of SSR240600C in women with overactive bladder including urge urinary incontinence. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-004126-24 (first received 12 December 2007). [DRI6271] [EUCTR2007-004126-24-CZ] [EudraCT2007-004126-24] [NCT00564226] [TrialID.BILADY] [sr-incont64596]NCT00564226. SSR240600C treatment in women with overactive bladder (BILADY) [A placebo controlled randomized, 12-week, dose-ranging, double-blind study versus placebo using tolterodine as a study calibrator, to evaluate efficacy and safety of SSR240600C in women with overactive bladder including urge urinary incontinence]. clinicaltrials.gov/show/NCT00564226 (first received 27 November 2007). [DRI6271] [EudraCT2007-004126-24] [NCT00564226] [TrialID.BILADY] [sr-incont63784]">EUCTR2007‐004126‐24‐CZ</a>; <a href="./references#CD003781-bbs2-0032" title="GellerE , DumondJ , BowlingJM , KhandelwalC , WuJ , Busby-WhiteheadJ , et al. Effect of an anticholinergic on cognitive function in postmenopausal women: a randomized trial (Abstract number: oral poster 52). Female Pelvic Medicine and Reconstructive Surgery2016;22(5):S61. [sr-incont78607]GellerEJ , DumondJB , BowlingJM , KhandelwalCM , WuJM , Busby-WhiteheadJ , et al. Effect of trospium chloride on cognitive function in women aged 50 and older: a randomized trial. Female Pelvic Medicine &amp; Reconstructive Surgery2017;23(2):118-23. [13-1352] [NCT01922115] [sr-incont74341]NCT01922115. The effect of anticholinergics on cognitive function in the elderly (ACE) [The effect of anticholinergics on cognitive function in the elderly: a randomized controlled trial]. clinicaltrials.gov/show/NCT01922115 (first received 14 August 2013). [13-1352] [NCT01922115] [TrialID.ACE] [sr-incont49282]">Geller 2013</a>; <a href="./references#CD003781-bbs2-0034" title="GriebenowR , WienersF , LangeT . Possible induction of cardiac dysrhythmia in elderly patients under therapy with propiverine hydrochloride (Abstract). Neurourology and Urodynamics1994;13:430-2. [sr-incont2681]">Griebenow 1994</a>; <a href="./references#CD003781-bbs2-0036" title="HajebrahimiS , MotlaghRS , BazarganiHS , BabaieH . Efficacy of tadalafil in treatment of overactive bladder syndrome: a randomized controlled trial (Abstract number OP.3.6Dec.27). International Journal of Urology2014;21:A146. [IRCT2013030212668N1] [sr-incont67256]IRCT2013030212668N1. Effect of tadalafil in treatment of overactive bladder  [Comparison of the efficacy of tadalafil, toltrodine and placebo in reduction of symptoms severity of women with urgency, frequency syndrom / overactive bladder]. en.irct.ir/trial/12692 (first received 26 January 2013). [91189] [IRCT2013030212668N1] [sr-incont78643]">Hajebrahimi 2014</a>; <a href="./references#CD003781-bbs2-0322" title="IRCT2015010720598N1. The effect of solifenacin succinate on intraocular pressure [Ocular effects of solifenacin succinate in women with narrow angle glaucoma and overactive bladder syndrome]. en.irct.ir/trial/18253 (first received 22 June 2015). [IRCT2015010720598N1] [sr-incont78608] [tbzmed.rec.1394.127]">Hajebrahimi 2015</a>; <a href="./references#CD003781-bbs2-0037" title="HalaskaM , DorschnerW , FrankM . Treatment of urgency and incontinence in elderly patients with propiverine hydrochloride. Neurourology and Urodynamics1994;13(4):428-30. [srincont-2680]">Halaska 1994</a>; <a href="./references#CD003781-bbs2-0040" title="EUCTR2012-005735-91-SK. A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-005735-91 (first received 12 November 2013). [178-CL-101] [EUCTR2012-005735-91-SK] [sr-incont78644]HerschornS , ChappleCR , AbramsP , ArlandisS , MitchesonD , LeeKS , et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU International2017;120(4):562-75. [NCT01972841] [sr-incont74470]MuellerER , RobinsonD , KelleherC , StaskinDR , FalconerC , WangJ , et al. Patient reported outcomes from synergy, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with mirabegron and solifenacin monotherapy (Abstract number - Podium #44). Neurourology and Urodynamics2017;36(Suppl S1):S151-2. [NCT01972841] [sr-incont75944]NCT01972841. This was a multinational study comparing the efficacy and safety of two medicines, solifenacin succinate and mirabegron taken together, or separately, or a mock treatment (placebo) in subjects with symptoms of overactive bladder (SYNERGY) [A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01972841 (first received 31 October 2013). [178-CL-101] [EUCTR2012-005735-91] [NCT01972841] [sr-incont63780]RobinsonD , KelleherC , StaskinD , MuellerER , FalconerC , WangJ , et al. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients. Neurourology and Urodynamics2018;37(1):394-406. [NCT01972841] [sr-incont76906]WeberMA , ChappleCR , GratzkeC , HerschornS , RobinsonD , FrankelJM , et al. A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial. Blood Pressure Monitoring2018;23(3):153-63. [NCT01972841] [sr-incont77899]WhiteWB , ChappleC , GratzkeC , HerschornS , RobinsonD , FrankelJ , et al. Cardiovascular safety of the beta3-adrenoceptor agonist mirabegron and the antimuscarinic agent solifenacin in the SYNERGY trial. Journal of Clinical Pharmacology2018;58(8):1084-91. [NCT01972841] [sr-incont78078]">Herschorn 2017a</a>; <a href="./references#CD003781-bbs2-0051" title="EUCTR2007-006451-39-SE. 12-week, randomized, double-blind, double-dummy, placebo controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-006451-39 (first received 20 February 2008). [A0221046] [EUCTR2007-006451-39-SE] [sr-incont64591]KaplanSA , SchneiderT , FooteJ , GuanZ . Superior efficacy of fesoterodine over tolterodine with rapid onset: a prospective, head-to-head, placebo-controlled trial (Abstract number 67). Neurourology and Urodynamics2010;29(6):905-7. [srincont-40130]KaplanSA , SchneiderT , FooteJE , GuanZ , CarlssonM , GongJ . Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU International2011;107(9):1432-40. [A0221046] [NCT00611026] [srincont-41334]">Kaplan 2011</a>; <a href="./references#CD003781-bbs2-0052" title="CardozoL , KaplanS , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: results from the after study (Abstract number 740) [Erratum appears in: European Urology 2014;65(5):e78]. European Urology Supplements2013;12(1):e740-1. [NCT01302054] [sr-incont63732]CardozoL , KaplanS , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. Erratum: A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: results from the AFTER study [Erratum available in: European Urology Supplement 2013;2012:e740-1]. European Urology2014;65(5):e78 . [A0221094] [NCT01302054] [TrialID.AFTER.] [sr-incont61642]GrenaboL , HerschornS , KaplanSA , CardozoL , ScholfieldD , ArumiD , et al. Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptoms. Current Medical Research and Opinion2017;33(10):1731-6. [NCT01302054] [TrialID.AFTER.] [sr-incont76695]KaplanSA , CardozoL , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER. International Journal of Clinical Practice2014;68(9):1065-73. [A0221094] [NCT01302054] [TrialID.AFTER.] [srincont-63977]KaplanSA , HerschornS , CarlssonM , NtaniosF . Urgency urinary incontinence response rates in subjects with overactive bladder treated with fesoterodine 8 mg after suboptimal response to tolterodine extended release 4 mg: a randomized, double-blind, placebo-controlled trial (Abstract number 546). In: International Continence Society (ICS); 43rd Annual Meeting; 2013 Aug 26-30; Barcelona, Spain. 2013. [NCT01302054] [TrialID.AFTER.] [sr-incont49730]NCT01302054. A clinical study in patients with overactive bladder with leakage of urine, to find out if the medicine, Fesoterodine, works in those patients who did not have enough response to the medicine, tolterodine. [A 14 week randomized parallel group placebo-controlled double-blind multicentre study of fesoterodine 8 mg in overactive bladder patients with sub-optimal response to tolterodine 4 mg extended release (ER)]. clinicaltrials.gov/show/NCT01302054 (first received 23 February 2011). [A0221094] [NCT01302054] [TrialID.AFTER.] [sr-incont49845]">Kaplan 2014</a>; <a href="./references#CD003781-bbs2-0053" title="CapoJP , TogliaM , Forero-SchwanhaeuserS , HeW . Patients reporting severe overactive bladder symptoms: effects of solifenacin treatment on objective measures and patient-reported outcomes (Abstract number 582). In: International Continence Society (ICS), 38th Annual Meeting; 2008 Oct 20-24; Cairo, Egypt. 2008. [srincont-31844]CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. KarramMM , TogliaMR , SerelsSR , AndohM , FakhouryA , Forero-SchwanhaeuserS . Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology2009;73(1):14-8. [A0221094] [NCT00454896] [TrialID.VENUS.] [srincont-29219]SerelsSR , TogliaMR , Forero-SchwanhaeuserS , HeW . Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms. Current Medical Research and Opinion2010;26(10):2277-85. [srincont-40376]StaskinD , DmochowskiR , SerelsS , AndohM , SmithN . Report from a randomized, placebo-controlled study showing significant improvement in urgency and patient-reported outcomes in overactive bladder patients treated with solifenacin (Abstract number 124). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73-4. [srincont-26600]TogliaM , AndohM , HussainI . Solifenacin improved warning time significantly compared to placebo in patients with overactive bladder (Abstract number 123). Neurourology and Urodynamics2006;25(6):655. [srincont-26629]TogliaM , AndohM , HussainI . Solifenacin improves urgency symtoms as assessed by voiding diaries and patient-reported outcomes (PRO) in patients with overactive bladder (Abstract number 155). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26636]TogliaMR , OstergardDR , AppellRA , AndohM , FakhouryA , HussainIF . Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status. International Urogynecology Journal2010;21(7):847-54. [srincont-40094]TogliaMR , SerelsSR , LarameeC , KarramMM , NandyIM , AndohM , et al. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial. Postgraduate Medicine2009;121(5):151-8. [srincont-34204]ZinnerS , HerschornS , AndohM , HussainI . Responder analyses show statistically significant improvements in incontinence and urgency are associated with reduction in symptom bother and improvement in health-related quality of life: VENUS results (Abstract number 123). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73. [srincont-26599]">Karram 2009</a>; <a href="./references#CD003781-bbs2-0055" title="AballéaS , MamanK , ThokagevistkK , NazirJ , OdeyemiIA , HakimiZ , et al. Cost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United Kingdom. Clinical Drug Investigation2015;35(2):83-93. [NCT00689104] [sr-incont66445]Arlandis-GuzmánS , Brenes-BermúdezF , Jiménez-CidreMA , Rubio-RodríguezD , Rubio-TerrésC , MoraAM , et al. Cost effectiveness of Mirabegron and antimuscarinic drugs in patients with hiperactive bladder [Coste-efectividad de mirabegrón y los antimuscarínicos en pacientes con vejiga hiperactiva]. Archivos Espanoles de Urologia2018;71(10):809-24. [NCT00689104] [sr-incont78645]EUCTR2007-001451-19-ES. A randomized, double-blind, parallel group, placebo and active controlled, multicenter study to assess the efficacy and safety of the beta-3 agonist YM178 (50 mg qd and 100 mg qd) in subjects with symptoms of overactive bladder - SCORPIO [Estudio multicentrico, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo y tratamiento activo, para evaluar la eficacia y seguridad del agonista beta-3 YM178 (50 mg, una vez al dia y 100 mg, una vez al dia) en pacientes con sintomas de vejiga hiperactiva]. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-001451-19 (first received 05 June 2008). [EUCTR2007-001451-19-ES] [sr-incont78646]HerschornS , NazirJ , RamosB , HakimiZ . Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada. Canadian Urological Association Journal2017;11(3-4):123-30. [NCT00689104] [sr-incont76807]KhullarV , AmarencoG , AnguloJ , BoerrigterP , BlauwetM , HakimiZ . The potent and selective beta3-adrenoceptor agonist mirabegron improves patient-reported outcomes in the treatment of overactive bladder (Abstract number MP-12.16). Urology2012;80(3 Suppl 1):S123. [sr-incont65379]KhullarV , AmarencoG , AnguloJC , BlauwetMB , NazirJ , OdeyemiIA , et al. Patient-reported outcomes with the β3 beta3-adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder. Neurourology and Urodynamics2016;35(8):987-94. [NCT00689104] [sr-incont72221]KhullarV , AmarencoG , AnguloJC , CambroneroJ , HøyeK , MilsomI , et al. Efficacy and tolerability of mirabegron, a ß3-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. European Urology2013;63(2):283-95. [NCT00689104] [TrialID.SCORPIO.] [sr-incont46836]KhullarV , CambroneroJ , AnguloJ , WooningM , BlauwetM , SiddiquiE , et al. Onset of action of efficacy of the potent and selective beta-3-adrenoceptor agonist, mirabegron, for the treatment of overactive bladder (OAB) in a 12-week, multicentre, randomised, double-blind, parallel-group, placebo-and tolterodine slow release (SR)-controlled study in OAB patients (Abstract number 135). International Urogynecology Journal and Pelvic Floor Dysfunction2012;23(2 Suppl 1):S187-8. [NCT00689104] [sr-incont67382]KhullarV , CambroneroJ , AnguloJC , WooningM , BlauwetMB , DorrepaalC , et al. Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial. BMC Urology2013;13:45. [NCT00689104] [sr-incont49411]KhullarV , CambroneroJ , StroebergP , AnguloJ , BoerrigterP , WooningM . The efficacy and tolerability of mirabegron, a potent and selective B3-adrenoceptor agonist, compared with placebo and tolterodine slow release in patients with overactive bladder - results from a European-Australian phase III trial (Abstract number 328). In: International Continence Society (ICS); 41st Annual Meeting; 2011 Aug 29-Sept 2; Glasgow, Scotland. 2011. [NCT00689104] [sr-incont42211]NCT00689104. Study to assess the efficacy and safety of the beta-3 agonist mirabegron (ym178) in patients with symptoms of overactive bladder (SCORPIO) [A randomized, double-blind, parallel group, placebo and active controlled, multicenter study to assess the efficacy and safety of mirabegron in subjects with symptoms of overactive bladder (SCORPIO)]. clinicaltrials.gov/show/NCT00689104 (first received 03 June 2008). [NCT00689104] [sr-incont49843]NittiV , HerschornS , AuerbachS , KhullarV , AmarencoG , BlauwetMB , et al. The potent and selective ß3-adrenoceptor agonist mirabegron improves patient-reported outcomes in overactive bladder-results from two phase III studies (Abstract number 68). Neurourology and Urodynamics2012;31(6):813-5. [NCT00689104] [sr-incont46724]WielageRC , PerkS , CampbellNL , NgD , KleinTM , PostaLM , et al. The cost effectiveness of mirabegron for the treatment of overactive bladder: three US perspectives (Abstract number A142). Journal of the American Geriatrics Society2015;63:S67. [NCT00689104] [sr-incont70876]YamanishiT , YamanishiY , TajimaH , IkedaS . Cost-effectiveness of mirabegron and tolterodine for the treatment of overactive bladder in Japan-Which drug is more cost-effective if used as the first-line treatment? (Abstract number 504). International Urogynecology Journal2018;29:S252. [NCT00689104] [sr-incont78647]YamanishiY , YamanishiT , TajimaH , IkedaS . Mirabegron or tolterodine for the treatment of overactive bladder in Japan: Which drug is more cost-effective as the first-line treatment?International Journal of Urology2018;25(10):863-70. [NCT00689104] [sr-incont78648]">Khullar 2013</a>; <a href="./references#CD003781-bbs2-0059" title="KrederK , PleilAM , ReesePR , KelleherJ . Effects of long-term tolterodine treatment on social and psychological aspects of health-related quality of life in overactive bladder patients (Abstract). Journal of Urology2002;167(Suppl 4):29. [sr-incont17591]">Kreder 2002</a>; <a href="./references#CD003781-bbs2-0060" title="HsiaoSM , ChangTC , ChenCH , WuWY , LinHH . Comparisons of the clinical outcomes and urodynamic effects of mirabegron versus tolterodine treatment for female overactive bladder syndrome: a subgroup analysis of a controlled, randomised, prospective study. Lower Urinary Tract Symptoms2018;10(3):215-20. [NCT01043666] [sr-incont74461]KuoHC , LeeKS , NaY , SoodR , NakajiS , KubotaY , et al. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourology and Urodynamics2015;34(7):685-92. [NCT01043666] [sr-incont68095]Kuo H‐C, Lin H‐H, Yu H‐J, Cheng C‐L, Hung M‐J, LinAT . Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials [Erratum available in: Urological Science 2015;26(2):148]. Urological Science2015;26(1):41-8 . [NCT01043666] [sr-incont68645]NCT01043666. A study of YM178 in subjects with symptoms of overactive bladder  [Phase III study of YM178: a randomized, double-blind, parallel group, placebo and active controlled, multi-center study in subjects with symptoms of overactive bladder]. clinicaltrials.gov/show/NCT01043666 (first received 07 January 2010). [178-CL-090] [NCT01043666] [sr-incont63781]">Kuo 2015</a>; <a href="./references#CD003781-bbs2-0061" title="LacknerTE , WymanJF , McCarthyTC , MonigoldM , DaveyC . Efficacy of oral extended-release oxybutynin in cognitively impaired older nursing home residents with urge urinary incontinence: a randomized placebo-controlled trial. Journal of the American Medical Directors Association2011;12(9):639-47. [sr-incont42677]LacknerTE , WymanJF , McCarthyTC , MonigoldM , DaveyC . Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. Journal of the American Geriatrics Society2008;56(5):862-70. [sr-incont27117]">Lackner 2011</a>; <a href="./references#CD003781-bbs2-0064" title="LuisV , LoyolaJP , MelissaC , FelipeM , San MartinC . Efficacy of darifenacin use combined with pelvic floor physiotherapy in overactive bladder syndrome treatment in women (Abstract number 434). International Urogynecology Journal2018;29(Suppl 1):S220-1. [NCT02143570] [sr-incont78617]NCT02143570, CifuentesM , MartinezF . Efficacy of darifenacin and physiotherapy for the treatment of overactive bladder in women. clinicaltrials.gov/show/NCT02143570 (first received 21 May 2014). [NCT02143570] [sr-incont61781]">Luis 2018</a>; <a href="./references#CD003781-bbs2-0065" title="ChappleCR , MadersbacherH , DreikornK , DorschnerW , MurtzG . Urodynamics and frequency/volume chart - do they correlate? Treatment analysis of propiverine in comparison to oxybutynin and placebo in urge incontinence (Abstract 224). In: International Continence Society (ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001. [sr-incont14474]HalaskaM , MadersbacherH , VoigtR , HofnerK , MartanA . Propiverine in patients with urgency and urge incontinence - a placebo controlled, multicentre study comparing its tolerability and efficacy with oxybutynin (Abstract number FDP36). International Urogynaecology Journal 2000;11(Suppl 1):S46. [srincont-11912]MadersbacherH , HalaskaM , VoigtR , AlloussiS , HofnerK . A urodynamically controlled multicenter study in patients with urge incontinence: tolerability and efficacy of propiverine hydrochloride in comparison to oxybutynin. In: International Continence Society (ICS), 27th Annual Meeting; 1997 Sep 23-26; Yokohama, Japan. 1997:153-4. [srincont-5854]MadersbacherH , HalaskaM , VoigtR , AlloussiS , HöfnerK . A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU International1999;84(6):646-51. [srincont-9166]">Madersbacher 1999</a>; <a href="./references#CD003781-bbs2-0112" title="AssassaP , WilliamsK , LambertP , AbramsK , TurnerD , ShawC , et al. A double blind randomised placebo controlled trial of the effectiveness of bladder training with oxybutynin or imipramine in the management of detrusor overactivity (DO) (Abstract number 330). In: Joint Meeting of the International Continence Society (ICS) and the International Urogynecological Association; 2010 Aug 23-27; Toronto, Canada. 2010. [ISRCTN58226681] [sr-incont40171]ISRCTN58226681, McGrotherC . Evaluation of the efficacy of oxybutynin and imipramine in the management of detrusor instability. isrctn.org/ISRCTN58226681 (first received 25 October 2000). [DOI: https://doi.org/10.1186/ISRCTN58226681] [ISRCTN58226681] [sr-incont64656]">Assassa 2010</a>; <a href="./references#CD003781-bbs2-0068" title="DmochowskiR , MitchesonD , FrenklT , BennettN , MuddPN . Durable efficacy and safety of long-term once-daily vibegron, a novel oral B-3 adrenergic receptor agonist: A 52-week phase 2 study in patients with overactive bladder syndrome (Abstract number PD50-03). Journal of Urology2018;199(4):e970-1. [sr-incont78091]EUCTR2010-022121-15-IT. A phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2 part clinical study of the efficacy and safety of MK-4618 in patients with overactive bladder - MK4618-008 [A 52-week extension to: a phase iib randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder]. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-022121-15 (first received 12 April 2011). [EUCTR2010-022121-15-IT] [MK4618-008] [NCT01314872] [sr-incont78639]MitchesonD , FrenklT , SamantaS , Anne PintoC , GreenS , BennettN , et al. Vibegron, a novel once daily oral beta-3 agonist, significantly reduces average daily micturitions, urge incontinence episodes and urgency episodes in patients with overactive bladder (Abstract number: podium #34). Neurourology and Urodynamics2018;37(Suppl 1):S565. [EUCTR2010-022121-15-IT] [NCT01314872] [sr-incont78618]MitchesonD , PintoCA , FrenklT , ChenL , PrasadM , MuddPN . Once daily vibegron improves quality of life measures in patients with overactive bladder (Abstract number PUK17). Value in Health2018;21(Suppl 1):S267-8. [EUCTR2010-022121-15-IT] [NCT01314872;] [sr-incont78619]MitchesonHD , SamantaS , MuldowneyK , PintoCA , RochaBA , GreenS , et al. Vibegron (RVT-901/MK-4618/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial. European Urology2019;75(2):274-82. [NCT01314872] [sr-incont78620]NCT01314872. A study of the efficacy and safety of Vibegron (MK-4618) in participants with overactive bladder (OAB) (MK-4618-008) [A phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder a 52-week extension to: a phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder]. clinicaltrials.gov/show/NCT01314872 (first received 15 March 2011). [NCT01314872] [sr-incont63793]UKCRN10391. A phase IIB randomised, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of MK-4618 in patients with overactive bladder . public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=10391 (accessed 28 June 2012). [CCRN525] [UKCRN10391] [sr-incont45046]">Mitcheson 2019</a>; <a href="./references#CD003781-bbs2-0323" title="NCT00553657. The study to test the effect of standardization of fluid intake in female patients with overactive bladder [A randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of standardization of fluid intake on the variability of measured voiding parameters in female patients with idiopathic overactive bladder]. clinicaltrials.gov/show/NCT00553657 (first received 04 November 2007). [NCT00553657] [sr-incont60907]">NCT00553657</a>; <a href="./references#CD003781-bbs2-0071" title="OlshanskyB , FooteJ , ArguinzonizM , LheritierK , Quebe-FehlingE , SteelM . Cardiovascular safety of darifenacin and tolterodine in patients with overactive bladder (OAB) (Abstract number 49). International Urogynecology Journal and Pelvic Floor Dysfunction2006;17(Suppl 2):S86-7. [sr-incont34186]">Olshansky 2006</a>; <a href="./references#CD003781-bbs2-0073" title="NCT01302938. Web-based methodology trial to evaluate the efficacy and safety of tolterodine ER in subjects with overactive bladder (REMOTE) [Exploratory, randomized, double-blind, placebo-controlled, parallel-group, single center, web-based phase IV pilot methodolgy trial to evaluate the efficacy and safety of tolterodine ER in subjects with overactive bladder]. clinicaltrials.gov/ct2/show/NCT01302938 (first received 24 February 2011). [A6121195] [NCT01302938] [TrialID.REMOTE.] [sr-incont43314]OrriM , LipsetCH , JacobsBP , CostelloAJ , CummingsSR . Web-based trial to evaluate the efficacy and safety of tolterodine ER 4 mg in participants with overactive bladder: REMOTE trial. Contemporary Clinical Trials2014;38(2):190-7. [A6121195] [NCT01302938] [TrialID.REMOTE.] [sr-incont62536]">Orri 2014</a>; <a href="./references#CD003781-bbs2-0075" title="ISRCTN17856439, ResnickN . Pathophysiology of urge incontinence in older women. isrctn.org/ISRCTN17856439 (first received 09 March 2006). [1999P-001891] [94-6641-01] [ISRCTN17856439] [sr-incont64614]">Resnick 2006</a>; <a href="./references#CD003781-bbs2-0076" title="EUCTR2008-005215-17. A study to evaluate the overall effect of solifenacin 5mg and 10mg on bladder wall thickness and urinary nerve growth factor in female subjects with overactive bladder and a diagnosis of detrusor overactivity – a double-blind, randomized, placebo-controlled, parallel group, multicentre study - SHRINK. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-005215-17 (first received 14 September 2009). [EUCTR2008-005215-17] [NCT01093534] [sr-incont78650]NCT01093534. Study of 2 doses of solifenacin succinate in female subjects with overactive bladder (SHRINK) [A study to evaluate the overall effect of solifenacin 5mg and 10mg on bladder wall thickness and urinary nerve growth factor in female subjects with overactive bladder and a diagnosis of detrusor overactivity - a double-blind, randomised, placebo-controlled, parallel group, multi-centre study]. clinicaltrials.gov/show/NCT01093534 (first received 26 March 2010). [905-EC-007] [EUCTR2008-005215-17] [NCT01093534] [TrialID.SHRINK] [sr-incont63778]RobinsonD , KhullarV , OelkeM , WijkstraH , TretterR , StowB , et al. Effects of 12 weeks treatment with solifenacin on Bladder Wall Thickness (BWT) and clinical outcomes: results from the placebo-controlled SHRINK study (Abstract number 422). In: International Continence Society (ICS), 43rd Annual Meeting; 2013 Aug 26-30; Barcelona, Spain. 2013. [905-EC-007] [NCT01093534] [TrialID.SHRINK.] [srincont-49731]RobinsonD , OelkeM , KhullarV , WijkstraH , TretterR , StowB , et al. Bladder wall thickness in women with symptoms of overactive bladder and detrusor overactivity: results from the randomised, placebo-controlled SHRINK study. Neurourology and Urodynamics2016;35(7):819-25. [NCT01093534] [sr-incont72217]RobinsonD , OelkeM , TretterR , StowB , CompionG , TubaroA . The effect of solifenacin on bladder wall thickness in women with overactive bladder and detrusor overactivity: Results from the SHRINK study (Abstract number 782). European Urology Supplements2013;12(1):e782-3. [EUCTR2008-005215-17] [NCT01093534] [sr-incont67207]RobinsonD , TubaroA , KimbergM , PlummerM , DeVineJ , BouicP , et al. The effect of solifenacin on urinary nerve growth factor (UNGF) and brain-derived neurotropic factor (BDNF) in women with overactive bladder and detrusor overactivity: results from the SHRINK study (Abstract number PP 54). International Urogynecology Journal and Pelvic Floor Dysfunction2014;25(1 Suppl 1):S60-1. [EUCTR2008-005215-17] [NCT01093534] [sr-incont67200]TubaroA , KhullarV , OelkeM , WijkstraH , TretterR , StowB , et al. Intra- and inter-reader variability of transvaginal ultrasound bladder wall thickness measurements: results from the SHRINK study (Abstract number 136). Neurourology and Urodynamics2013;32(6):711-2. [EUCTR2008-005215-17] [NCT01093534] [sr-incont49211]">Robinson 2013</a>; <a href="./references#CD003781-bbs2-0077" title="RogersR , BachmannG , JumadilovaZ , SunF , MorrowJD , GuanZ , et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. International Urogynecology Journal and Pelvic Floor Dysfunction2008;19(11):1551-7. [A6121002] [NCT00143481] [srincont-27729]RogersRG , BachmannG , ScarperoH , JumadilovaZ , SunF , MorrowJD , et al. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. Current Medical Research and Opinion2009;25(9):2159-65. [srincont-32060]">Rogers 2008</a>; <a href="./references#CD003781-bbs2-0081" title="StaskinDR , HarnettMD . Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder. Current Urology Reports2004;5(6):423-6. [sr-incont19422]">Staskin 2004</a>; <a href="./references#CD003781-bbs2-0083" title="EUCTR2017-003293-14. Empowur (Empower OAB patients with vibegron for better urgency control) [An international phase 3, randomized, double-blind, placebo- and active (tolterodine)-controlled multicenter study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder]. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-003293-14 (first received 24 April 2018). [EUCTR2017-003293-14] [NCT03492281] [sr-incont78606]NCT03492281, JankowichR . A study to examine the safety and efficacy of a new drug in patients with symptoms of overactive bladder (OAB) [An international phase 3, randomized, double-blind, placebo- and active (tolterodine)-controlled multicenter study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder]. clinicaltrials.gov/show/NCT03492281 (first received 20 April 2018). [NCT03492281] [sr-incont78610]StaskinD , FrankelJ , VaranoS , ShortinoD , JankowichR , MuddPN . Vibegron demonstrates statistically significant improvement in efficacy measures in overactive bladder-key secondary results from the international phase 3 study in patients with overactive bladder (empowur) (Abstract number: long oral 40). Female Pelvic Medicine and Reconstructive Surgery2019;25(5):S20-1. [NCT03492281] [sr-incont78627]StaskinD , FrankelJ , VaranoS , ZhouJ , JankowichR , MuddPN . International phase 3, double-blind, placebo- and active (tolterodine)-controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: empowur (Abstract number LBA-02). Journal of Urology2019;201(4):e992. [NCT03492281] [sr-incont78628]StaskinD , VaranoS , FrankelJ , ShortinoD , JankowichR , MuddP . Once-daily vibegron 75 mg demonstrates statistically significant benefits on key secondary endpoints including quality of life in patients with OAB: data from an international phase 3 trial (EMPOWUR) (Abstract number 181). Neurourology and Urodynamics2019;38(S3):S115-7. [NCT03492281] [sr-incont78629]VaranoS , StaskinD , FrankelJ , ShortinoD , JankowichR , MuddPN . Vibegron statistically significantly improves measures of quality of life in patients with overactive bladder-data from the international phase 3 trial (Empowur) (Abstract number: long oral 38). Female Pelvic Medicine and Reconstructive Surgery2019;25(5):S19. [NCT03492281] [sr-incont78630]">Staskin 2019</a>; <a href="./references#CD003781-bbs2-0088" title="TakayasuH , UenoA , TsutidaS , KoisoK , KuritaK , KawabeK , et al. Clinical effects of propiverine hydrochloride in the treatment of urinary frequency and incontinence associated with detrusor overactivity: a double blind, parallel, placebo controlled multicenter study. Igaku No Ayumi (Progress in Medicine)1990;153(8):459-71. [srincont-12896]TakayasuH , UenoA , TsutidaS , KoisoK , KuritaK , KawabeK , et al. Clinical effects of propiverine hydrochloride in the treatment of urinary frequency and incontinence associated with detrusor overactivity: a double blind, parallel, placebo controlled multicenter study. Igaku No Ayumi (Progress in Medicine)1990;153(8):459-71. [sr-incont12896]">Takayasu 1990</a>; <a href="./references#CD003781-bbs2-0090" title="UlshoferB , BihrAM , BodekerRH , SchwantesU , JahnHP . Randomised, double-blind, placebo-controlled study on the efficacy and tolerance of trospium chloride in patients with motor urge incontinence. Clinical Drug Investigation2001;21(8):563-9. [srincont-16324]UlshoferB , SchwantesU , BodekerRH , BihrAM , JahnHP . Efficacy and tolerance of trospium chloride in patients with motor urge incontinence - results of a randomised double-blind placebo-controlled study (Poster presentations). In: 2nd International Consultation on Incontinence (ICI); 2001 July 1-3; Paris, France. 2001:5. [srincont-16318]">Ulshofer 2001</a>; <a href="./references#CD003781-bbs2-0094" title="EUCTR2007-007087-17-SE. A 24-week, multicentre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-007087-17 (first received 13 June 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont64588]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00798434. A study to compare the effectiveness and safety of fesoterodine and placebo in an elderly population of patients who go to the toilet very frequently due to overactive bladder (SOFIA) [A 24-week, multi-centre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00798434 (first received 26 November 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont49847]SchneiderT , BergqvistA , WangJ , WaggA , Ebel-BitounC . Treatment with fesoterodine versus tolterodine for reducing symptom bother in elderly patients with overactive bladder including urgency urinary incontinence. European Urology, Supplements2012;11(1):e687-a. [sr-incont65389]WaggA , CarlssonM , ElsobkyM , FernetM . Effect of flexible dose fesoterodine on cognitive function in &gt;65 year old patients with OAB: data from two RCT (Abstract number 438). Neurourology and Urodynamics2019;38:S297-8. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78651]WaggA , DarekarA , ArumiD , KhullarV , OelkeM . Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people &gt;65 years of age: a post hoc analysis of data from the SOFIA study. Neurourology and Urodynamics2015;34(5):438-43. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont68100]WaggA , ElsobkyM , CarlssonM , FernetM . Response and cognitive safety of fesoterodine in patients &gt;65y old with OAB. Is there a relationship between cognition and treatment response? (Abstract number 183). Neurourology and Urodynamics2019;38:S118-20. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78632]WaggA , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. Journal of the American Geriatrics Society2013;61(2):185-93. [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TrialID.SOFIA.] [sr-incont48008]WaggAS , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Efficacy and tolerability of fesoterodine in older subjects with overactive bladder: results of SOFIA (Abstract number C33). Journal of the American Geriatrics Society2011;59:S124. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont65234]">Wagg 2013a</a>; <a href="./references#CD003781-bbs2-0095" title="GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00911937. A trial to evaluate the efficacy and safety of fesoterodine in patients with symptoms of overactive bladder including nocturnal urinary urgency [A randomized, double blind, placebo controlled, parallel group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with symptoms of overactive bladder including nocturnal urinary urgency]. clinicaltrials.gov/show/NCT00911937 (first received 03 June 2009). [NCT00911937] [sr-incont49848]WeissJ , JumadilovaZ , CarlssonM , FitzGeraldMP , MalhotraA , MartireDL . Effect of antimuscarinic treatment in subjects with overactive bladder, including nocturnal urinary urgency (Abstract number 1963). Journal of Urology2012;187(4 Suppl 1):e792. [NCT00911937] [sr-incont65184]WeissJP , CarlssonMR , ManganEK . Age, gender and nocturnal urgency severity predict response to antimuscarinic treatment (Abstract number 1962). Journal of Urology2013;189(4 Suppl 1):e805. [NCT00911937] [sr-incont65096]WeissJP , JumadilovaZ , JohnsonTM , FitzGeraldMP , CarlssonM , MartireDL , et al. Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency. Journal of Urology2013;189(4):1396-401. [A0221048] [NCT00911937] [sr-incont47568]">Weiss 2013</a>; <a href="./references#CD003781-bbs2-0097" title="NCT00966004. A study to evaluate safety and efficacy of ym178 in patients with overactive bladder [Phase III study of YM178 - a placebo-controlled, double-blind, group comparison study in patients with overactive bladder]. clinicaltrials.gov/show/NCT00966004 (first received 26 August 2009). [178-CL-048] [JapicCTI-R130370] [NCT00966004] [sr-incont63783]YamaguchiO , HidehiroK , YukioH , YasuhikoI , MasayukiT , OsamuN , et al. A phase III, randomized, double-blind, placebo and active controlled study of once-daily mirabegron 50 mg in patients with overactive bladder (Abstract number POD-03.06). Urology2012;80(3 Suppl 1):S10-1. [NCT00966004] [sr-incont65380]YamaguchiO , MaruiE , KakizakiH , HommaY , IgawaY , TakedaM , et al. A phase III, randomized, double-blind, placebo-controlled study of the beta-adrenoceptor agonist, mirabegron 50 mg once-daily, in Japanese patients with overactive bladder. BJU International2014;113(6):951-60. [NCT00966004] [sr-incont50603]">Yamaguchi 2012</a>; <a href="./references#CD003781-bbs2-0099" title="YongucT , SefikE , InciI , KusbeciOY , CelikS , AydinME , et al. Randomized, controlled trial of fesoterodine fumarate for overactive bladder in Parkinson's disease. World Journal of Urology2019;38(8):2013-9. [sr-incont78635]">Yonguc 2019</a>; <a href="./references#CD003781-bbs2-0100" title="JapicCTI-152936. Phase III study of KRP-114V [A phase III, randomized, double-blind, parallel group, placebo controlled, multicenter study to assess the efficacy and safety of the beta-3 agonist KRP-114V in Japanese subjects with symptoms of overactive bladder]. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-152936 (first received 17 June 2015). [JapicCTI-152936] [sr-incont78653]YoshidaM , TakedaM , GotoM , NagaiS , KuroseT . Vibegron, a novel potent and selective beta3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study (Abstract number 1082). European Urology, Supplements2018;17(2):e1531-2. [JapicCTI-152936] [sr-incont78069]YoshidaM , TakedaM , GotohM , NagaiS , KuroseT . Vibegron, a novel potent and selective B3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study. European Urology2018;73(5):783-90. [JapicCTI-152936] [sr-incont77898]YoshidaM , TakedaM , GotohM , YokoyamaO , KakizakiH , TakahashiS , et al. Efficacy of novel beta3-adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: a post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study. International Journal of Urology2019;26(3):369-75. [JapicCTI-152936] [sr-incont78654]YoshidaM , TakedaM , GotohM , YokoyamaO , KakizakiH , TakahashiS , et al. Efficacy of vibegron, a novel selective I²3-adrenoreceptor agonist, on urgency urinary incontinence with overactive bladder: post-hoc analysis of phase iii study (Abstract number 180). Neurourology and Urodynamics2019;38(S3):S114-5. [JapicCTI-152936] [sr-incont78636]">Yoshida 2018</a>; <a href="./references#CD003781-bbs2-0101" title="NCT01018264, ZesiewiczT . Solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease (URGE-PD) [URGE-PD: a multi-site, double-blind, randomized, placebo controlled trial of solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease]. clinicaltrials.gov/show/NCT01018264 (first received 23 November 2009). [NCT01018264] [sr-incont63790]ZesiewiczTA , EvattM , JahanI , VaughanC , SingerC , OrdoricaR , et al. URGE-PD: a multi-site, double-blind, randomized, placebo controlled trial of solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease (Abstract number 745). Movement Disorders2014;29(Suppl 1):S276-7. [NCT01018264] [sr-incont66602]ZesiewiczTA , EvattM , VaughanCP , JahanI , SingerC , OrdoricaR , et al. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease. Parkinsonism and Related Disorders2015;21(5):514-20. [NCT01018264] [sr-incont66860]">Zesiewicz 2015</a>; <a href="./references#CD003781-bbs2-0102" title="ZinnerNR , MattiassonA , StantonSL . Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. Journal of the American Geriatrics Society2002;50(5):799-807. [sr-incont14679]">Zinner 2002</a>; <a href="./references#CD003781-bbs2-0103" title="ZinnerN , GittelmanM , HarrisR , SussetJ , KanellosA , AuerbachS . Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial (Abstract number DP51). In: American Urological Association (AUA), 98th Annual Meeting; 2003 Apr 26-May 1; Chicago, Illinois. 2003. [sr-incont31101]ZinnerN , GittelmanM , HarrisR , SussetJ , KanelosA , AuerbachS , Trospium Study Group. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. Journal of Urology2004;171(6 Pt 1):2311-5. [sr-incont17376]">Zinner 2004</a>). </p> </section> <section id="CD003781-sec-0058"> <h6 class="title">Number of micturitions per 24 hours at the end of treatment</h6> <p>Fifty‐eight studies reported micturitions as an outcome. Twenty‐eight RCTs were not included in the meta‐analysis for the following reasons. Twenty‐six of them did not provide sufficient information to calculate end of treatment score (<a href="./references#CD003781-bbs2-0001" title="AbramsP , JacksonS , MattiassonA , KrishnanK , HaendlerL . A randomised, double-blind, placebo controlled, dose ranging study of the safety and efficacy of tolterodine in patients with hyperreflexia (Abstract). In: International Continence Society 26th Annual Meeting; 1996 Aug 27-30; Athens, Greece. 1996:276-7. [sr-incont5135]">Abrams 1996</a>; <a href="./references#CD003781-bbs2-0002" title="AbramsP , FreemanR , AnderströmC , MattiassonA . Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. British Journal of Urology1998;81(6):801-10. [srincont-7871]AbramsP , FreemanRN , AnderstromC , MattiassonA . Efficacy and tolerability of tolterodine vs. oxybutynin and placebo in patients with detrusor instability (Abstract). Journal of Urology1997;157(Suppl 4):103. [srincont-16321]">Abrams 1998</a>; <a href="./references#CD003781-bbs2-0007" title="BrayR , CartwrightR , CardozoL , HillS , GuanZ , KhullarV . Tolterodine ER reduced increased bladder wall thickness in women with overactive bladder. A randomized, placebo-controlled, double-blind, parallel group study. Neurourology and  Urodynamics2018;37(1):237-43. [NCT00137397] [sr-incont74473]NCT00137397. A study to measure the effect of tolterodine extended release on the thickness of the bladder wall in patients with overactive bladder [A multi-centre, randomised, placebo controlled, double blind, parallel group study in female patients to evaluate whether tolterodine ER can reverse the increased bladder wall thickness in patients with overactive bladder]. clinicaltrials.gov/show/NCT00137397 (first received 29 August 2005). [NCT00137397] [sr-incont63809]">Bray 2018</a>; <a href="./references#CD003781-bbs2-0010" title="CardozoL , KuzminI , LisecML , MillardR , vanVierssen TripOB , RidderAM , et al. YM905: Results of a randomised, double-blind placebo-controlled trial in patients with symptomatic overactive bladder (Abstract number 104). European Urology Supplements2003;2(1):28. [sr-incont27407]CardozoL , KuzminI , LisecML , MillardRJ , vanVierssen TripOB , RidderAM , et al. A double-blind, randomised, placebo-controlled trial with YM905 in symptomatic overactive bladder (Abstract number P74). Journal of the American Geriatrics Society2003;51 (Suppl 4):S68-9. [sr-incont31100]CardozoL , LisecM , MillardR , vanVierssen TripO , KuzminI , DrogendijkTE , et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. Journal of Urology2004;172(5 (Pt 1 of 2)):1919-24. [srincont-19090]CardozoL . A randomised double-blind, placebo-controlled trial of the once-daily muscarinic receptor antagonist solifenacin succinate for symptoms of overactive bladder (Abstract number 211). International Urogynecology Journal2003;14 (Suppl 1):S64. [sr-incont31104]CardozoL . Solifenacin succinate improves symptoms of an overactive bladder (Abstract number TP77). International Journal of Gynecology and Obstetrics2003;83(Suppl 3):94. [sr-incont31096]KelleherCJ , CardozoL , ChappleCR , HaabF , RidderAM . Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU International2005;95(1):81-5. [srincont-20241]">Cardozo 2004a</a>; <a href="./references#CD003781-bbs2-0011" title="CardozoL , AdamikZ , GuimaraesM , KrhutJ , Labat J-J, PetrovS , et al. Patients with overactive bladder show progressive improvement in urgency and bladder condition during treatment with solifenacin in a randomised, double-blind, placebo-controlled study (SUNRISE) (Abstract number 115). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S67-8. [srincont-26595]CardozoL , AmarencoG , PushkarD , MikulasJ , DrogendijkT , WrightM , et al. Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE). BJU International2013;111(5):804-10. [NCT00801944] [TrialID.SUNRISE.] [sr-incont47554]CardozoL , DewildeT , FeyereislJ , WadieB , AmarencoG , LiapisA , et al. Solifenacin significantly reduces both urgency severity and bother: results from the flexible dose, placebo controlled, multinational SUNRISE study (Abstract number 281). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26641]CardozoL , DrogendijkT , BolodeokuJ . The efficacy of solifenacin 5/10 mg on 'urgency' endpoints in different OAB patient populations: subanalysis of results from the randomised, double-blind SUNRISE study (Abstract number 192). In: International Continence Society (ICS); 38th Annual Meeting; 2008 Oct 20-24; Cairo, Egypt. 2008. [srincont-31885]CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CardozoL , HessdörferE , MilaniR , ArañóP , DewildeL , SlackM , et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU International2008;102(9):1120-7. [NCT00801944] [TrialID.SUNRISE] [srincont-29249]">Cardozo 2008a</a>; <a href="./references#CD003781-bbs2-0013" title="ChappleC . Fesoterodine a new effective and well-tolerated antimuscarinic for the treatment of urgency-frequency syndrome: results of a phase 2 controlled study (Abstract 142). Neurourology and Urodynamics2004;23(5/6):598-9. [srincont-19023]Drug company. A Phase 2, parallel group, randomized, double-blind, placebo controlled dose-ranging trial to determine the optimal dose and the tolerability of sustained release SPM 8272 (fesoterodine) in subjects with non-neurogenic bladder overactivity. Protocol numbers: A0221027 (SP582). ClinicalStudyResults.org (accessed 3 March 2011)2002. [Protocol numbers: A0221027 (SP582)] [srincont-41110]">Chapple 2004a</a>; <a href="./references#CD003781-bbs2-0017" title="ChappleC , DuBeauC , EbingerU , RekedaL , ViegasA . Darifenacin treatment of patients &gt;or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Current Medical Research and Opinion2007;23(10):2347-58. [srincont-23921]">Chapple 2007b</a>; <a href="./references#CD003781-bbs2-0018" title="ChappleCR , DvorakV , RadziszewskiP , vanKerrebroeckP , WyndaeleJJ , BosmanB , et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder. International Urogynecology Journal2013;24(9):1447-58. [178-CL-044] [NCT00337090] [TrialID.DRAGON.] [sr-incont48549]NCT00337090 . A study of YM178 in patients with symptomatic overactive bladder (DRAGON) [A randomized, double-blind, parallel group, placebo and active controlled, multicenter dose ranging study with the beta-3 agonist YM178 in patients with symptomatic overactive bladder]. clinicaltrials.gov/show/NCT00337090 (first received 15 June 2006). [EudraCT2005-002256-17] [JapicCTI-R130350] [NCT00337090] [sr-incont63803]">Chapple 2013</a>; <a href="./references#CD003781-bbs2-0020" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. [sr-incont75259]ChuF , SmithN , UchidaT . Efficacy and safety of solifenacin succinate 10 mg once daily: a multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder. Current Therapeutic Research - Clinical and Experimental2009;70(6):405-20. [srincont-43324]">Chu 2009</a>; <a href="./references#CD003781-bbs2-0035" title="HaabF , StewartL , DwyerP . Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. European Urology2004;45(4):420-9. [srincont-17428]">Haab 2004</a>; <a href="./references#CD003781-bbs2-0042" title="HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21072]HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21072]HillS , KhullarV , WyndaeleJJ , LheritierK , . Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. International Urogynecology Journal and Pelvic Floor2006;17(3):239-47. [srincont-22464]">Hill 2005</a>; <a href="./references#CD003781-bbs2-0043" title="HommaY , KawabeK . Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World Journal of Urology2004;22(4):251-6. [srincont-19412]HommaY , PaickJS , LeeJG , KawabeK , Japanese and Korean Tolterodine Study Group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU International2003;92(7):741-7. [srincont-16418]">Homma 2003</a>; <a href="./references#CD003781-bbs2-0049" title="JunemannKP , Al-ShukriS . Efficacy and tolerability of trospium chloride and tolterodine in 234 patients with urge-syndrome: a double-blind, placebo-controlled, multicentre clinical trial (Abstract number 85B). Neurourology and Urodynamics2000;19(4):488-90. [srincont-9976]">Junemann 2000</a>; <a href="./references#CD003781-bbs2-0062" title="LandisJR , KaplanS , SwiftS , VersiE . Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity. Journal of Urology2004;171(2 Pt 1):752-6. [sr-incont17327]">Landis 2004</a>; <a href="./references#CD003781-bbs2-0066" title="Malone-LeeJG , WalshB , MaugourdMF , Tolterodine in the Elderly Study Group. The safety and clinical efficacy of two doses of tolterodine compared to placebo in elderly patients. In: International Continence Society (ICS), 27th Annual Meeting; 1997 Sep 23-26; Yokohama, Japan. 1997:155-6. [srincont-5855]Malone‐LeeJG , WalshJB , MaugourdMF . Tolterodine: A safe and effective treatment for older patients with overactive bladder. Journal of the American Geriatric Society2001;49(6):700-5. [srincont-12319]WaggA , Malone-LeeJ . Pressure-flow variables in patients treated with tolterodine for detrusor overactivity. BJU International2003;92(9):969-71. [sr-incont16659]">Malone‐Lee 2001</a>; <a href="./references#CD003781-bbs2-0069" title="Drug company. A phase 2, parallel group, stratified, randomized, double blind, placebo-controlled trial to investigate the efficacy and safety of 3 different dosages of sustained release fesoterodine in subjects with overactive bladder showing either involuntary detrusor contractions or normal findings during the baseline urodynamic assessment. Protocol numbers: A0221029 (SP668). ClinicalStudyResults.org (accessed 3 March 2011). [srincont-41111]NittiV , WiatrakM , KreitmanL , LipsitzD . Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB): results of a phase 2 trial (Abstract number 306). In: International Continence Society (ICS); 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21084]">Nitti 2005</a>; <a href="./references#CD003781-bbs2-0072" title="OreskovićS , ButI , BanovićM , GoldstajnMS . The efficacy and safety of solifenacin in patients with overactive bladder syndrome. Collegium Antropologicum2012;36(1):243-8. [srincont-45056]">Oreskovic 2012</a>; <a href="./references#CD003781-bbs2-0074" title="RentzhogSL , StantonL , CardozoL , NelsonE , FallM , AbramsP . Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. British Journal of Urology1998;81(1):42-8. [srincont-5461]">Rentzhog 1998</a>; <a href="./references#CD003781-bbs2-0076" title="EUCTR2008-005215-17. A study to evaluate the overall effect of solifenacin 5mg and 10mg on bladder wall thickness and urinary nerve growth factor in female subjects with overactive bladder and a diagnosis of detrusor overactivity – a double-blind, randomized, placebo-controlled, parallel group, multicentre study - SHRINK. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-005215-17 (first received 14 September 2009). [EUCTR2008-005215-17] [NCT01093534] [sr-incont78650]NCT01093534. Study of 2 doses of solifenacin succinate in female subjects with overactive bladder (SHRINK) [A study to evaluate the overall effect of solifenacin 5mg and 10mg on bladder wall thickness and urinary nerve growth factor in female subjects with overactive bladder and a diagnosis of detrusor overactivity - a double-blind, randomised, placebo-controlled, parallel group, multi-centre study]. clinicaltrials.gov/show/NCT01093534 (first received 26 March 2010). [905-EC-007] [EUCTR2008-005215-17] [NCT01093534] [TrialID.SHRINK] [sr-incont63778]RobinsonD , KhullarV , OelkeM , WijkstraH , TretterR , StowB , et al. Effects of 12 weeks treatment with solifenacin on Bladder Wall Thickness (BWT) and clinical outcomes: results from the placebo-controlled SHRINK study (Abstract number 422). In: International Continence Society (ICS), 43rd Annual Meeting; 2013 Aug 26-30; Barcelona, Spain. 2013. [905-EC-007] [NCT01093534] [TrialID.SHRINK.] [srincont-49731]RobinsonD , OelkeM , KhullarV , WijkstraH , TretterR , StowB , et al. Bladder wall thickness in women with symptoms of overactive bladder and detrusor overactivity: results from the randomised, placebo-controlled SHRINK study. Neurourology and Urodynamics2016;35(7):819-25. [NCT01093534] [sr-incont72217]RobinsonD , OelkeM , TretterR , StowB , CompionG , TubaroA . The effect of solifenacin on bladder wall thickness in women with overactive bladder and detrusor overactivity: Results from the SHRINK study (Abstract number 782). European Urology Supplements2013;12(1):e782-3. [EUCTR2008-005215-17] [NCT01093534] [sr-incont67207]RobinsonD , TubaroA , KimbergM , PlummerM , DeVineJ , BouicP , et al. The effect of solifenacin on urinary nerve growth factor (UNGF) and brain-derived neurotropic factor (BDNF) in women with overactive bladder and detrusor overactivity: results from the SHRINK study (Abstract number PP 54). International Urogynecology Journal and Pelvic Floor Dysfunction2014;25(1 Suppl 1):S60-1. [EUCTR2008-005215-17] [NCT01093534] [sr-incont67200]TubaroA , KhullarV , OelkeM , WijkstraH , TretterR , StowB , et al. Intra- and inter-reader variability of transvaginal ultrasound bladder wall thickness measurements: results from the SHRINK study (Abstract number 136). Neurourology and Urodynamics2013;32(6):711-2. [EUCTR2008-005215-17] [NCT01093534] [sr-incont49211]">Robinson 2013</a>; <a href="./references#CD003781-bbs2-0079" title="RovnerES , KaplanS , GuanZ , WangJT , RoehrbornCG . Clinical efficacy and safety of tolterodine extended release in male patients with overactive bladder and urgency urinary incontinence (Abstract number 188). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21091]">Rovner 2005</a>; <a href="./references#CD003781-bbs2-0083" title="EUCTR2017-003293-14. Empowur (Empower OAB patients with vibegron for better urgency control) [An international phase 3, randomized, double-blind, placebo- and active (tolterodine)-controlled multicenter study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder]. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-003293-14 (first received 24 April 2018). [EUCTR2017-003293-14] [NCT03492281] [sr-incont78606]NCT03492281, JankowichR . A study to examine the safety and efficacy of a new drug in patients with symptoms of overactive bladder (OAB) [An international phase 3, randomized, double-blind, placebo- and active (tolterodine)-controlled multicenter study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder]. clinicaltrials.gov/show/NCT03492281 (first received 20 April 2018). [NCT03492281] [sr-incont78610]StaskinD , FrankelJ , VaranoS , ShortinoD , JankowichR , MuddPN . Vibegron demonstrates statistically significant improvement in efficacy measures in overactive bladder-key secondary results from the international phase 3 study in patients with overactive bladder (empowur) (Abstract number: long oral 40). Female Pelvic Medicine and Reconstructive Surgery2019;25(5):S20-1. [NCT03492281] [sr-incont78627]StaskinD , FrankelJ , VaranoS , ZhouJ , JankowichR , MuddPN . International phase 3, double-blind, placebo- and active (tolterodine)-controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: empowur (Abstract number LBA-02). Journal of Urology2019;201(4):e992. [NCT03492281] [sr-incont78628]StaskinD , VaranoS , FrankelJ , ShortinoD , JankowichR , MuddP . Once-daily vibegron 75 mg demonstrates statistically significant benefits on key secondary endpoints including quality of life in patients with OAB: data from an international phase 3 trial (EMPOWUR) (Abstract number 181). Neurourology and Urodynamics2019;38(S3):S115-7. [NCT03492281] [sr-incont78629]VaranoS , StaskinD , FrankelJ , ShortinoD , JankowichR , MuddPN . Vibegron statistically significantly improves measures of quality of life in patients with overactive bladder-data from the international phase 3 trial (Empowur) (Abstract number: long oral 38). Female Pelvic Medicine and Reconstructive Surgery2019;25(5):S19. [NCT03492281] [sr-incont78630]">Staskin 2019</a>; <a href="./references#CD003781-bbs2-0084" title="SteersW , CorcosJ . Efficacy, tolerability and safety of darifenacin, an M3 selective receptor antagonist for the treatment of overactive bladder, using a flexible dosing regimen (Abstract number 68). Progres en Urologie2004;14(3 Suppl 3):22. [srincont-22197]">Steers 2004</a>; <a href="./references#CD003781-bbs2-0089" title="ThuroffJW , BunkeB , EbnerA , FaberP , deGeeterP , HannappelJ , et al. Randomized, double-blind multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin vs. propantheline vs. placebo. Neurourology and Urodynamics1990;9(4):337-8. [srincont-5108]ThuroffJW , BunkeB , EbnerA , FaberP , deGeeterP , HannappelJ , et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. Journal of Urology1991;145(4):813-7. [srincont-1288]">Thuroff 1991</a>; <a href="./references#CD003781-bbs2-0092" title="ChancellorM , FreedmanS , MitchesonHD , AntociJ , PrimusG , WeinA . Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clinical Drug Investigation2000;19(2):83-91. [srincont-16326]FreemanR , HillS , MillardR , SlackM , SutherstJ , Tolterodine Study Group. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstetrics and Gynecology2003;102(3):605-11. [srincont-16494]GarelyA , Tolterodine Study Group. Once-daily tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder. International Urology Journal2001;12(Suppl 1):S18. [srincont-12012]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of life of patients with overactive bladder receiving tolterodine. Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of patients with overactive bladder receiving tolterodine (Abstract number 82). Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , ReesePR . Health related quality of life of patients with overactive bladder receiving tolterodine once-daily. Neurourology and Urodynamics2000;19(4):519-21. [srincont-9987]KelleherCJ , ReesePR , PleilAM , OkanoGJ . Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. American Journal of Managed Care2002;8(Suppl 19):S608-15. [srincont-17998]KelleherCJ , Tolterodine Study Group. Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2000;11(Suppl 1):S94. [srincont-11915]KrederKJ . Antimuscarinic therapy: relationship between efficacy and side effects in responders and non-responders. Journal of Urology2001;165(Suppl 5):S165. [srincont-16327]KrederKJ . Clinical effectiveness of antimuscarinic therapy: the relationship between efficacy and tolerability. In: Proceedings of the International Continence Society Annual Meeting(ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001:140. [srincont-14376]MallettV . Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2001;12(Suppl 1):4. [srincont-12011]MillardRJ , TamaddonK , Tolterodine Study Group. Randomized controlled trial to compare tolterodine prolonged release capsules and tolterodine immediate release tablets versus placebo in patients with symptoms of detrusor overactivity (Abstract number 57). Australian and New Zealand Journal of Surgery2002;Suppl 72:A140. [sr-incont22190]PleilAM , ReesePR , KelleherCJ , OkanoGJ . Health-related quality of life of patients with overactive bladder receiving immediate-release tolterodine. HEPAC Health Economics in Prevention and Care2001;2(2):69-75. [sr-incont18060]RoehrbornCG , AbramsP , RovnerES , KaplanSA , HerschornS , GuanZ . Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU International2006;97(5):1003-6. [sr-incont21882]SwiftS . Efficacy and tolerability of once-daily tolterodine for women with overactive bladder. In: International Continence Society Annual Meeting (ICS), 31st annual meeting; 2001 Sept 18-21; Seoul, Korea. 2001:No. 329. [srincont-14481]SwiftS . Once-daily tolterodine is effective and well tolerated in women with overactive bladder (Abstract 57). In: 2nd International Consultation on Incontinence; 2001 July 1-3; Paris, France. 2001. [srincont-16319]SwiftSE . Once-daily (OD) tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder (OAB). International Urogynecology Journal2000;11(Suppl 1):S15. [sr-incont11906]SwiftSE . Once-daily administration of extended-release tolterodine is effective and well-tolerated in patients with overactive bladder. In: XVI FIGO World Congress of Obstetrics and Gynecology; 2000 Sept 3-8; Washington DC. Vol. Book 1. 2000:40. [sr-incont12085]SwiftSE . Overactive bladder in females: treatment with once-daily tolterodine. International Urogynecology Journal2001;12(Suppl 3):S71. [sr-incont16328]Van KerrebroeckP , KrederK , JonasU , ZinnerN . Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology2001;57(3):414-21. [sr-incont11953]Van KerrebroeckPEV . Long-term (12 months) efficacy and tolerability of tolterodine once-daily in the treatment of overactive bladder. Neurourology and Urodynamics2001;20(4):401-2. [sr-incont15714]Van KerrebroeckPEVA , Tolterodine Study Group. Long-term tolerability and efficacy of once-daily (OD) tolterodine in the treatment of overactive bladder (OB). International Urogynecology Journal2001;12(Suppl 3):S49. [sr-incont16329]Van KerrebroeckPEVA , Tolterodine Study Group. Significant decreases in perception of urgency and urge incontinence episodes with once-daily tolterodine treatment in patients with overactive bladder (Abstract number 89). Neurourology and Urodynamics2000;19(4):493-4. [sr-incont9980]WeinAJ , KhullarV , WangJT , GuanZ . Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. BJU International2007;99(2):360-3. [sr-incont23180]vanKerrebroeckPE , KelleherCJ , CoyneKS , KoppZ , BrodskyM , WangJT . Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. Health and Quality of Life Outcomes2009;7(13):13. [10.1186/1477-7525-7-13] [sr-incont31438]vanKerrebroeckPE , WangJ , GuanZ . Effects of tolterodine extended release in patients with overactive bladder: perceived treatment benefits improve with efficacy (Abstract number 511). European Urology Supplements2004;3(2):130. [sr-incont31090]">Van Kerrebroeck 2001</a>; <a href="./references#CD003781-bbs2-0103" title="ZinnerN , GittelmanM , HarrisR , SussetJ , KanellosA , AuerbachS . Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial (Abstract number DP51). In: American Urological Association (AUA), 98th Annual Meeting; 2003 Apr 26-May 1; Chicago, Illinois. 2003. [sr-incont31101]ZinnerN , GittelmanM , HarrisR , SussetJ , KanelosA , AuerbachS , Trospium Study Group. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. Journal of Urology2004;171(6 Pt 1):2311-5. [sr-incont17376]">Zinner 2004</a>; <a href="./references#CD003781-bbs2-0104" title="ZinnerN , SussetJ , GittelmanM , ArguinzonizM , RekedaL , HaabF . Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. International Journal of Clinical Practice2006;60(1):119-26. [sr-incont21507]">Zinner 2006</a>). Two studies did not report the results (<a href="./references#CD003781-bbs2-0031" title="EUCTR2007-004126-24-CZ. A placebo controlled randomized, 12-week, dose-ranging, double-blind study versus placebo using tolterodine as a study calibrator, to evaluate efficacy and safety of SSR240600C in women with overactive bladder including urge urinary incontinence. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-004126-24 (first received 12 December 2007). [DRI6271] [EUCTR2007-004126-24-CZ] [EudraCT2007-004126-24] [NCT00564226] [TrialID.BILADY] [sr-incont64596]NCT00564226. SSR240600C treatment in women with overactive bladder (BILADY) [A placebo controlled randomized, 12-week, dose-ranging, double-blind study versus placebo using tolterodine as a study calibrator, to evaluate efficacy and safety of SSR240600C in women with overactive bladder including urge urinary incontinence]. clinicaltrials.gov/show/NCT00564226 (first received 27 November 2007). [DRI6271] [EudraCT2007-004126-24] [NCT00564226] [TrialID.BILADY] [sr-incont63784]">EUCTR2007‐004126‐24‐CZ</a>; <a href="./references#CD003781-bbs2-0323" title="NCT00553657. The study to test the effect of standardization of fluid intake in female patients with overactive bladder [A randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of standardization of fluid intake on the variability of measured voiding parameters in female patients with idiopathic overactive bladder]. clinicaltrials.gov/show/NCT00553657 (first received 04 November 2007). [NCT00553657] [sr-incont60907]">NCT00553657</a>). Thirty RCTs were included in the meta‐analysis for this outcome. </p> </section> </section> </section> <section id="CD003781-sec-0059"> <h4 class="title">Excluded studies</h4> <p>We excluded a total of 203 studies. Reasons for exclusion are listed in the <a href="./references#CD003781-sec-0124" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD003781-sec-0060"> <h3 class="title">Risk of bias in included studies</h3> <p>An overview of the risk of bias assessments is graphically represented in <a href="#CD003781-fig-0002">Figure 2</a> and <a href="#CD003781-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD003781-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003781-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD003781-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003781-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD003781-sec-0061"> <h4 class="title">Allocation</h4> <section id="CD003781-sec-0062"> <h5 class="title">Random sequence generation (selection bias)</h5> <p>Thirty‐five studies provided sufficient information about the methods of random sequence generation and we judged them to be at low risk of bias (<a href="./references#CD003781-bbs2-0004" title="AbramsP , KelleherC , StaskinD , KayR , MartanA , MincikI , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World Journal of Urology2017;35(5):827-38. [NCT01340027] [sr-incont77897]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Cardiovascular safety of combination treatment with mirabegron and solifenacin in patients with overactive bladder in a randomised, double-blind, dose-ranging, Phase II study (Symphony) (Abstract). European Urology, Supplements2014;13(1):e574-e574a. [NCT01340027] [sr-incont67160]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB) - efficacy and safety results from a randomised phase II study (Symphony) (Abstract number 295). Neurourology and Urodynamics2013;32(6):930-1. [NCT01340027] [TrialID.SYMPHONY.] [sr-incont49188]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB): safety results from a phase 2 study (Abstract number MP-16.08). Urology2013;82(3 Suppl 1):S139. [NCT01340027] [sr-incont66675]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: Exploratory responder analyses of efficacy and evaluation of patient reported outcomes from a randomised, double-blind, dose-ranging, phase 2 study (Symphony) (Abstract number MP-24.11). Urology2014;84(4 Suppl 1):S145-6. [NCT01340027] [sr-incont67194]AbramsP , KelleherC , StaskinD , RechbergerT , KayR , MartinaR , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (SYMPHONY). European Urology2015;67(3):577-88. [NCT01340027] [sr-incont66674]NCT01340027, Bristol Urological Institute . A study to evaluate the efficacy, safety and tolerability of mirabegron and solifenacin succinate alone and in combination for the treatment of overactive bladder (symphony) [A randomized, double-blind, factorial, parallel-group, active and placebo-controlled, multicenter dose-ranging study to evaluate the efficacy, safety and tolerability of six dose combinations of solifenacin succinate and mirabegron compared to mirabegron and solifenacin succinate monotherapies in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01340027 (first received 21 April 2011). [178-CL-100] [2010-020601-32] [NCT01340027] [TrialID.SYMPHONY] [sr-incont44510]NittiV , AbramsP , StaskinD , AuerbachS , MartinaR , VanMR . Urinary retention in patients with overactive bladder treated with mirabegron alone and in combination with solifenacin: the results of two randomized, double-blind, phase II studies (Abstract number MP76-13). Journal of Urology2014;191(4 Suppl 1):e886-7. [NCT00410514] [NCT01340027] [TrialID.SYMPHONY] [sr-incont67453]">Abrams 2013</a>; <a href="./references#CD003781-bbs2-0008" title="BurgioKL , LocherJL , GoodePS , HardinJM , McDowellBJ , CandibD . Behavior vs drug therapy for urge incontinence in older women (Abstract number 26). In: American Urogynecology Society, 15th Annual Scientific Meeting; 1994 Sept 21-24; Toronto, Ontario. 1994:48. [sr-incont14585]BurgioKL , LocherJL , GoodePS , HardinM , McDowellBJ , Dombrowski M et al. Behavioral vs drug treatment for urge urinary incontinence in older women. A randomized controlled trial. JAMA1998;280(23):1995-2000. [srincont-5719]BurgioKL , LocherJL , GoodePS . Combined behavioral and drug therapy for urge incontinence in older women. Journal of the American Geriatrics Society2000;48(4):370-4. [srincont-9006]BurgioKL , LocherJL , RothDL , GoodePS . Psychological improvements associated with behavioral and drug treatment of urge incontinence in older women. Journal of Gerontology. Series B, Psychological Sciences and Social Sciences2001;56(1):P46-51. [srincont-11923]">Burgio 1998</a>; <a href="./references#CD003781-bbs2-0009" title="CardozoL , ChappleCR , Toozs-HobsonP , Grosse-FreeseM , BulittaM , LehmacherW , et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomised, double-blind, multicentre clinical trial. British Journal of Urology International2000;85(6):659-64. [srincont-11732]">Cardozo 2000</a>; <a href="./references#CD003781-bbs2-0016" title="ChappleC , Van KerrebroeckP , TubaroA , Haag-MolkentellerC , ForstHT , MassowU , et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder [Erratum appears in: European Urology 2008,53(6):1319]. European Urology2007;52(4):1204-12. [NCT00220363] [SP583] [srincont-23875]ChappleC , Van KerrebroeckP , TubaroA , MillardR . Fesoterodine in non-neurogenic voiding dysfunction - results on efficacy and safety in a phase 3 trial (Abstract number 379). In: 21st Annual European Association of Urology (EAU) Congress; 2006 Apr 5-8; Paris, France. 2006. [srincont-41109]ChappleC , Van KerrebroeckP , TubaroA , WangJT , HvidstenK , BrodskyM . Efficacy of fesoterodine in patients with overactive bladder (OAB): improvements in OAB symptoms and health-related quality of life (HRQL) (Poster abstract number 1188). Journal of Urology2007;177(4 Suppl S):392. [srincont-31882]ChappleCR , vanKerrebroeckPE , JünemannKP , WangJT , BrodskyM . Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU International2008;102(9):1128-32. [srincont-29255]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. KelleherCJ , TubaroA , WangJT , KoppZ . Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU International2008;102(1):56-61. [srincont-27613]SandPK , MorrowJD , BavendamT , CreangaDL , NittiVW . Efficacy and tolerability of fesoterodine in women with overactive bladder. International Urogynecology Journal2009;20(7):827-35. [srincont-31351]">Chapple 2007a</a>; <a href="./references#CD003781-bbs2-0020" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. [sr-incont75259]ChuF , SmithN , UchidaT . Efficacy and safety of solifenacin succinate 10 mg once daily: a multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder. Current Therapeutic Research - Clinical and Experimental2009;70(6):405-20. [srincont-43324]">Chu 2009</a>; <a href="./references#CD003781-bbs2-0021" title="ChuaME , SeeMC , EsmeňaEB , BalingitJC , MoralesML . Efficacy and safety of gabapentin in comparison to solifenacin succinate in adult overactive bladder treatment. Lower Urinary Tract Symptoms2018;10(2):135-42. [NCT01486706] [sr-incont74529]NCT01486706, ChuaME . Efficacy and safety of gabapentin in treating overactive bladder (OAB). clinicaltrials.gov/show/NCT01486706 (first received 6 December 2011). [NCT01486706] [SLMC10-010] [sr-incont49864]">Chua 2018</a>; <a href="./references#CD003781-bbs2-0022" title="AmarencoG , SutoryM , FagertunH , WrightM , CompionG , De RidderD . Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Preliminary results from the SONIC urodynamic study (Abstract). European Urology, Supplements2012;11(1):e467-a. [EudraCT2006-005523-42] [NCT00629642] [sr-incont65392]AmarencoG , SutoryM , ZachovalR , AgarwalM , DelPG , TretterR , et al. Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study. Neurourology and Urodynamics2017;36(2):414-21. [EudraCT2006-005523-42] [JapicCTI-R130306] [NCT00629642] [sr-incont72248]De RidderD , AmarencoG , Finazzi-AgroE , AnguloJ , KurenkovA , WrightM , et al. Solifenacin treatment for neurogenic detrusor overactivity: patient-reported outcomes (PROs) from the randomised clinical trial SONIC (Abstract number 333). In: International Continence (ICS); 42nd Annual Meeting; 2012 Oct 15-19; Beijing, China. 2012. [905-EC-005] [EudraCT2006-005523-42] [NCT00629642] [TrialID.SONIC.] [srincont-49739]">De Ridder 2012</a>; <a href="./references#CD003781-bbs2-0024" title="DmochowskiR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. A double-blind, placebo-controlled trial of flexible-dose fesoterodine for overactive bladder (Abstract number 715). In: International Continence Society (ICS); 39th Annual Meeting; 2009 Sep 29-Oct 03; San Francisco, CA. 2009. [sr-incont35627]DmochowskiRR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder [Errata appear in: Urology 2010 Jun;75(6):1519 and in Urology 2011 Jun;77(6):1513]. Urology2010;75(1):62-8. [A0221014] [NCT00536484] [sr-incont39548]DuBeauC , KrausSR , SunF , MorrowJD . Fesoterodine in older vs younger subjects with overactive bladder (Abstract number D87). Journal of the American Geriatrics Society2010;58:S218. [NCT00536484] [sr-incont64309]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. [sr-incont78640]NCT00536484. Fesoterodine flexible dose study [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with overactive bladder]. clinicaltrials.gov/show/NCT00536484 (first received 27 September 2007). [NCT00536484] [sr-incont49160]StaskinD , KhullarV , MichelMC , MorrowJD , SunF , GuanZ , et al. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. Neurourology and Urodynamics2011;30(8):1480-5. [sr-incont42686]">Dmochowski 2010</a>; <a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>; <a href="./references#CD003781-bbs2-0028" title="ElbasetM , TahaD , ZahranM , EzzatO , ElhefnawyAS , ElkenawyM , et al. Subjective and objective scales assessment after retreatment with anticholinergics post botox-faded effects in refractory idiopathic overactive bladder: a prospective single blinded randomized trial (Abstract number 132). European Urology, supplements2019;18(1):e172. [sr-incont78652]ElbasetMA , TahaDE , El-HefnawyAS , ZahranMH , ShokeirAA . Assessment of anticholinergic use after fading of BTX-A effects in refractory idiopathic overactive bladder: a prospective blinded randomized trial. International Neurourology Journal2019;23(3):240-8. [sr-incont78605]">Elbaset 2019</a>; <a href="./references#CD003781-bbs2-0032" title="GellerE , DumondJ , BowlingJM , KhandelwalC , WuJ , Busby-WhiteheadJ , et al. Effect of an anticholinergic on cognitive function in postmenopausal women: a randomized trial (Abstract number: oral poster 52). Female Pelvic Medicine and Reconstructive Surgery2016;22(5):S61. [sr-incont78607]GellerEJ , DumondJB , BowlingJM , KhandelwalCM , WuJM , Busby-WhiteheadJ , et al. Effect of trospium chloride on cognitive function in women aged 50 and older: a randomized trial. Female Pelvic Medicine &amp; Reconstructive Surgery2017;23(2):118-23. [13-1352] [NCT01922115] [sr-incont74341]NCT01922115. The effect of anticholinergics on cognitive function in the elderly (ACE) [The effect of anticholinergics on cognitive function in the elderly: a randomized controlled trial]. clinicaltrials.gov/show/NCT01922115 (first received 14 August 2013). [13-1352] [NCT01922115] [TrialID.ACE] [sr-incont49282]">Geller 2013</a>; <a href="./references#CD003781-bbs2-0033" title="GotohM , HommaY , YokoyamaO , NishizawaO . Responsiveness and minimal clinically important change in overactive bladder symptom score. Urology2011;78(4):768-73. [srincont-42622]GotohM , YokoyamaO , MatsukawaY , NishizawaO . Responsiveness of overactive bladder symptom score (OABSS): verification based on data in a double-blinded, randomized placebo-controlled study of propiverine hydrochloride in Japanese patients (Abstract number 338). In: Joint Meeting of the International Continence Society (ICS) and the International Urogynecological Association; 2010 Aug 23-27; Toronto, Canada. 2010. [srincont-40173]GotohM , YokoyamaO , NishizawaO . Propiverine hydrochloride in Japanese patients with overactive bladder: A randomized, double-blind, placebo-controlled trial. International Journal of Urology2011;18(5):365-73. [srincont-41510]">Gotoh 2011</a>; <a href="./references#CD003781-bbs2-0035" title="HaabF , StewartL , DwyerP . Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. European Urology2004;45(4):420-9. [srincont-17428]">Haab 2004</a>; <a href="./references#CD003781-bbs2-0036" title="HajebrahimiS , MotlaghRS , BazarganiHS , BabaieH . Efficacy of tadalafil in treatment of overactive bladder syndrome: a randomized controlled trial (Abstract number OP.3.6Dec.27). International Journal of Urology2014;21:A146. [IRCT2013030212668N1] [sr-incont67256]IRCT2013030212668N1. Effect of tadalafil in treatment of overactive bladder  [Comparison of the efficacy of tadalafil, toltrodine and placebo in reduction of symptoms severity of women with urgency, frequency syndrom / overactive bladder]. en.irct.ir/trial/12692 (first received 26 January 2013). [91189] [IRCT2013030212668N1] [sr-incont78643]">Hajebrahimi 2014</a>; <a href="./references#CD003781-bbs2-0039" title="CorcosJ , AnguloJC , GarelyAD , CarlssonM , GongJ , GuanZ . Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. Current Medical Research and Opinion2011;27(5):1059-65. [srincont-41596]EUCTR2006-006935-38-SE. 12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006935-38 (first received 16 April 2007). [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont64612]HerschornS , SwiftS , GuanZ , CarlssonM , BrodskyM , GongJ . Efficacy and safety of fesoterodine for overactive bladder in a double-blind, head-to-head comparison trial with tolterodine ER and placebo (Abstract number 710). In: International Continence Society (ICS), 39th Annual Meeting; 2009 Sep 29-Oct 3; San Francisco, CA. 2009. [srincont-35326]HerschornS , SwiftS , GuanZ , CarlssonM , MorrowJD , BrodskyM , et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU International2010;105(1):58-66. [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont39540]NCT00444925. Clinical trial to evaluate the efficacy and safety of Fesoterodine in comparison to Tolterodine for overactive bladder (OAB) [12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder (OAB)]. clinicaltrials.gov/show/NCT00444925 (first received 08 March 2007). [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont49159]">Herschorn 2009a</a>; <a href="./references#CD003781-bbs2-0043" title="HommaY , KawabeK . Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World Journal of Urology2004;22(4):251-6. [srincont-19412]HommaY , PaickJS , LeeJG , KawabeK , Japanese and Korean Tolterodine Study Group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU International2003;92(7):741-7. [srincont-16418]">Homma 2003</a>; <a href="./references#CD003781-bbs2-0045" title="HommaY , YamaguchiO , Imidafenacin Study Group. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2009;16(5):499-506. [NCT00212732] [ONO-8025-08] [srincont-31368]">Homma 2009</a>; <a href="./references#CD003781-bbs2-0046" title="HuangA , HessR , AryaL , RichterH , SubakL , BradleyC , et al. A randomized controlled trial of simple diagnosis and treatment for urgency urinary incontinence in women (Abstract). Journal of General Internal Medicine2011;26:S1. [NCT00862745] [sr-incont64391]HuangAJ , HessR , AryaLA , RichterHE , SubakLL , BradleyCS , et al. Pharmacologic treatment for urgency-predominant urinary incontinence in women diagnosed using a simplified algorithm: a randomized trial. American Journal of Obstetrics and Gynecology2012;206(5):444.e1-11. [GA0221IX] [NCT00862745] [TrialID.BRIDGES.] [srincont-44636]NCT00862745, BrownJ . Bringing simple urge incontinence diagnosis &amp; treatment to providers (BRIDGES)  [A multi-center, randomized, placebo-controlled clinical trial comparing fesoterodine to placebo in women diagnosed with urge urinary incontinence by the 3 Incontinence Questions (3IQ). Followed by a multi-center open label clinical cohort study of long-term effects of treatment with fesoterodine ]. clinicaltrials.gov/show/NCT00862745 (first received 17 March 2009). [NCT00862745] [sr-incont49836]WarsiQ , HuangA , BrownJS , SchembriM , HessR , AryaLA , et al. The effect of pharmacologic treatment of urgency urinary incontinence on sleep quality and daytime sleepiness (Abstract number: paper 37). Female Pelvic Medicine and Reconstructive Surgery2016;22(5 ):S17-8. [NCT00862745] [TrialID.BRIDGES.] [sr-incont78633]WarsiQA , HuangAJ , HessR , AryaLA , RichterHE , BradleyCS , et al. Association of pharmacologic treatment of urgency urinary incontinence with sleep quality and daytime sleepiness. Obstetrics and Gynecology2018;131(2):204-11. [NCT00862745] [sr-incont78239]WinkelmanW , HuangA , SchembriM , RogersRG , RichterHE , MyersDL , et al. Clinical variables moderating response to pharmacologic treatment of urgency-predominant urinary incontinence in a randomized controlled trial (Abstract number: poster 25). In: Female Pelvic Medicine and Reconstructive Surgery. 37th Annual Scientific Meeting of the American Urogynecologic Society; Aug 2016; United States. Vol. 22. Netherlands: Lippincott Williams and Wilkins, 2016:S81. [NCT00862745] [sr-incont78634]WinkelmanWD , HuangAJ , SchembriM , RogersRG , RichterH , MyersDL , et al. Modifiers of response to treatment with fesoterodine for urgency-predominant urinary incontinence in a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2017;23(2):151-6. [sr-incont74308]">Huang 2012</a>; <a href="./references#CD003781-bbs2-0051" title="EUCTR2007-006451-39-SE. 12-week, randomized, double-blind, double-dummy, placebo controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-006451-39 (first received 20 February 2008). [A0221046] [EUCTR2007-006451-39-SE] [sr-incont64591]KaplanSA , SchneiderT , FooteJ , GuanZ . Superior efficacy of fesoterodine over tolterodine with rapid onset: a prospective, head-to-head, placebo-controlled trial (Abstract number 67). Neurourology and Urodynamics2010;29(6):905-7. [srincont-40130]KaplanSA , SchneiderT , FooteJE , GuanZ , CarlssonM , GongJ . Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU International2011;107(9):1432-40. [A0221046] [NCT00611026] [srincont-41334]">Kaplan 2011</a>; <a href="./references#CD003781-bbs2-0052" title="CardozoL , KaplanS , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: results from the after study (Abstract number 740) [Erratum appears in: European Urology 2014;65(5):e78]. European Urology Supplements2013;12(1):e740-1. [NCT01302054] [sr-incont63732]CardozoL , KaplanS , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. Erratum: A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: results from the AFTER study [Erratum available in: European Urology Supplement 2013;2012:e740-1]. European Urology2014;65(5):e78 . [A0221094] [NCT01302054] [TrialID.AFTER.] [sr-incont61642]GrenaboL , HerschornS , KaplanSA , CardozoL , ScholfieldD , ArumiD , et al. Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptoms. Current Medical Research and Opinion2017;33(10):1731-6. [NCT01302054] [TrialID.AFTER.] [sr-incont76695]KaplanSA , CardozoL , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER. International Journal of Clinical Practice2014;68(9):1065-73. [A0221094] [NCT01302054] [TrialID.AFTER.] [srincont-63977]KaplanSA , HerschornS , CarlssonM , NtaniosF . Urgency urinary incontinence response rates in subjects with overactive bladder treated with fesoterodine 8 mg after suboptimal response to tolterodine extended release 4 mg: a randomized, double-blind, placebo-controlled trial (Abstract number 546). In: International Continence Society (ICS); 43rd Annual Meeting; 2013 Aug 26-30; Barcelona, Spain. 2013. [NCT01302054] [TrialID.AFTER.] [sr-incont49730]NCT01302054. A clinical study in patients with overactive bladder with leakage of urine, to find out if the medicine, Fesoterodine, works in those patients who did not have enough response to the medicine, tolterodine. [A 14 week randomized parallel group placebo-controlled double-blind multicentre study of fesoterodine 8 mg in overactive bladder patients with sub-optimal response to tolterodine 4 mg extended release (ER)]. clinicaltrials.gov/show/NCT01302054 (first received 23 February 2011). [A0221094] [NCT01302054] [TrialID.AFTER.] [sr-incont49845]">Kaplan 2014</a>; <a href="./references#CD003781-bbs2-0054" title="KhullarV , HillS , LavalKU , SchiotzHA , JonasU , VersiE . Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology2004;64(2):269-74; discussion 274-5. [srincont-19498]KhullarV , HillS , SolankiJ . Assessment of health-related quality of life in patients with overactive bladder taking tolterodine extended release versus placebo (Abstract number 318). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21075]">Khullar 2004</a>; <a href="./references#CD003781-bbs2-0060" title="HsiaoSM , ChangTC , ChenCH , WuWY , LinHH . Comparisons of the clinical outcomes and urodynamic effects of mirabegron versus tolterodine treatment for female overactive bladder syndrome: a subgroup analysis of a controlled, randomised, prospective study. Lower Urinary Tract Symptoms2018;10(3):215-20. [NCT01043666] [sr-incont74461]KuoHC , LeeKS , NaY , SoodR , NakajiS , KubotaY , et al. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourology and Urodynamics2015;34(7):685-92. [NCT01043666] [sr-incont68095]Kuo H‐C, Lin H‐H, Yu H‐J, Cheng C‐L, Hung M‐J, LinAT . Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials [Erratum available in: Urological Science 2015;26(2):148]. Urological Science2015;26(1):41-8 . [NCT01043666] [sr-incont68645]NCT01043666. A study of YM178 in subjects with symptoms of overactive bladder  [Phase III study of YM178: a randomized, double-blind, parallel group, placebo and active controlled, multi-center study in subjects with symptoms of overactive bladder]. clinicaltrials.gov/show/NCT01043666 (first received 07 January 2010). [178-CL-090] [NCT01043666] [sr-incont63781]">Kuo 2015</a>; <a href="./references#CD003781-bbs2-0063" title="LeeKS , ChooMS , KimDY , KimJC , KimHJ , MinKS , et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. Journal of Urology2005;174(4 Pt 1):1334-8. [sr-incont21016]LeeKS , ChooMS , PaickJS , LeeJG , SeoJT , LeeJZ , et al. Propiverine hydrochloride reduced frequency and perception of urgency in treatment of overactive bladder: a 12 week prospective, randomized, double blind, placebo controlled study (Abstract number 279). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26640]LeeKS , LeeHW , ChooMS , PaickJS , LeeJG , SeoJT , et al. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'. BJU International2010;105(11):1565-70. [2005-01-08] [NCT00903045] [PROUD] [sr-incont39958]NCT00903045. Urinary urgency outcomes following propiverine treatment for an overactive bladder [Urinary urgency outcomes following propiverine treatment for an overactive bladder: propiverine study on overactive bladder including urgency data (PROUD)]. clinicaltrials.gov/show/NCT009030452005;(first received 15 May 2009). [2005-01-08] [NCT00903045] [TrialID.PROUD] [sr-incont49860]">Lee 2006</a>; <a href="./references#CD003781-bbs2-0068" title="DmochowskiR , MitchesonD , FrenklT , BennettN , MuddPN . Durable efficacy and safety of long-term once-daily vibegron, a novel oral B-3 adrenergic receptor agonist: A 52-week phase 2 study in patients with overactive bladder syndrome (Abstract number PD50-03). Journal of Urology2018;199(4):e970-1. [sr-incont78091]EUCTR2010-022121-15-IT. A phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2 part clinical study of the efficacy and safety of MK-4618 in patients with overactive bladder - MK4618-008 [A 52-week extension to: a phase iib randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder]. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-022121-15 (first received 12 April 2011). [EUCTR2010-022121-15-IT] [MK4618-008] [NCT01314872] [sr-incont78639]MitchesonD , FrenklT , SamantaS , Anne PintoC , GreenS , BennettN , et al. Vibegron, a novel once daily oral beta-3 agonist, significantly reduces average daily micturitions, urge incontinence episodes and urgency episodes in patients with overactive bladder (Abstract number: podium #34). Neurourology and Urodynamics2018;37(Suppl 1):S565. [EUCTR2010-022121-15-IT] [NCT01314872] [sr-incont78618]MitchesonD , PintoCA , FrenklT , ChenL , PrasadM , MuddPN . Once daily vibegron improves quality of life measures in patients with overactive bladder (Abstract number PUK17). Value in Health2018;21(Suppl 1):S267-8. [EUCTR2010-022121-15-IT] [NCT01314872;] [sr-incont78619]MitchesonHD , SamantaS , MuldowneyK , PintoCA , RochaBA , GreenS , et al. Vibegron (RVT-901/MK-4618/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial. European Urology2019;75(2):274-82. [NCT01314872] [sr-incont78620]NCT01314872. A study of the efficacy and safety of Vibegron (MK-4618) in participants with overactive bladder (OAB) (MK-4618-008) [A phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder a 52-week extension to: a phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder]. clinicaltrials.gov/show/NCT01314872 (first received 15 March 2011). [NCT01314872] [sr-incont63793]UKCRN10391. A phase IIB randomised, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of MK-4618 in patients with overactive bladder . public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=10391 (accessed 28 June 2012). [CCRN525] [UKCRN10391] [sr-incont45046]">Mitcheson 2019</a>; <a href="./references#CD003781-bbs2-0070" title="GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NittiVW , DmochowskiR , SandPK , ForstHT , Haag-MolkentellerC , MassowU , et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. Journal of Urology2007;178(6):2488-94. [NCT00138723] [SP584] [srincont-26313]">Nitti 2007</a>; <a href="./references#CD003781-bbs2-0073" title="NCT01302938. Web-based methodology trial to evaluate the efficacy and safety of tolterodine ER in subjects with overactive bladder (REMOTE) [Exploratory, randomized, double-blind, placebo-controlled, parallel-group, single center, web-based phase IV pilot methodolgy trial to evaluate the efficacy and safety of tolterodine ER in subjects with overactive bladder]. clinicaltrials.gov/ct2/show/NCT01302938 (first received 24 February 2011). [A6121195] [NCT01302938] [TrialID.REMOTE.] [sr-incont43314]OrriM , LipsetCH , JacobsBP , CostelloAJ , CummingsSR . Web-based trial to evaluate the efficacy and safety of tolterodine ER 4 mg in participants with overactive bladder: REMOTE trial. Contemporary Clinical Trials2014;38(2):190-7. [A6121195] [NCT01302938] [TrialID.REMOTE.] [sr-incont62536]">Orri 2014</a>; <a href="./references#CD003781-bbs2-0077" title="RogersR , BachmannG , JumadilovaZ , SunF , MorrowJD , GuanZ , et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. International Urogynecology Journal and Pelvic Floor Dysfunction2008;19(11):1551-7. [A6121002] [NCT00143481] [srincont-27729]RogersRG , BachmannG , ScarperoH , JumadilovaZ , SunF , MorrowJD , et al. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. Current Medical Research and Opinion2009;25(9):2159-65. [srincont-32060]">Rogers 2008</a>; <a href="./references#CD003781-bbs2-0082" title="ChancellorMB , OefeleinMG , VasavadaS . Obesity is associated with a more severe overactive bladder disease state that is effectively treated with one daily administration of trospium chloride extended release [Erratum available in: Neurourology and Urodynamics 2010;29(5):804]. Neurourology and Urodynamics2010;29(4):551-4. [sr-incont39591]GinsbergDA , OefeleinMG , EllsworthPI . Once-daily administration of trospium chloride extended release provides 24-hour coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials. Neurourology and Urodynamics2011;30(4):563-7. [sr-incont41531]RovnerE , DmochowskiR , WatanabeJ . Once daily (QD) trospium chloride 60mg extended release (XR) is safe and effective in patients (PTS) with the overactive bladder (OAB) syndrome who use multiple concomitant medications (MEDS) (Abstract number: Poster #68). Neurourology and Urodynamics2009;28(2):146-7. [sr-incont31062]SandP , DmochowskiR , ZinnerN , StaskinD . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: results from a multicenter, phase III, placebo-controlled study (Abstract number 269). In: International Continence Society (ICS), 37th Annual Meeting; 2007 Aug 20-24; Rotterdam, the Netherlands. 2007. [sr-incont26676]SandP , StaskinD , ZinnerN , DmochowskiR . Once-daily trospium chloride extended release is effective and well tolerated for the treatment of overactive bladder: results from a multicenter, phase III trial (Abstract number 57). Neurourology and Urodynamics2007;26(5):675. [sr-incont26661]StaskinD , SandP , ZinnerN , DmochowskiR , Trospium Study Group. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. Journal of Urology2007;178(3 Pt 1):978-83; discussion 983-4. [srincont-23909]StaskinDR , RosenbergMT , SandPK , ZinnerNR , DmochowskiRR . Trospium chloride once daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised phase III trials. International Journal of Clinical Practice2009;63(12):1715-23. [sr-incont35458]StaskinDR , SandPK , ZinnerNR . Once-daily trospium chloride extended release is effective and well tolerated for the treatment of overactive bladder: results from a multicenter, phase III trial (Abstract number - poster 22). Neurourology and Urodynamics2007;26(7 Suppl):1106. [srincont-27305]">Staskin 2007</a>; <a href="./references#CD003781-bbs2-0093" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CrosbyRD , MathiasSD , MarshallTS . Relationships between symptoms, symptom bother, and health-related quality of life in patients with overactive bladder taking solifenacin or placebo in the VIBRANT study. International Journal of Clinical Practice2011;65(2):211-8. [sr-incont41015]GollarKM , YoungDG , BailenJ , HeW , Forero-SchwanhaeuserS . Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: a secondary analysis of the VIBRANT study. Urologic Nursing2012;32(1):38-46. [TrialID.VIBRANT.] [sr-incont44571]Samuels T‐A, MitchesonHD , VardyM , Forero‐SchwanhaeuserS , MarshallT , HeW . Efficacy of solifenacin for symptom bother and other patient-reported outcomes in patients with overactive bladder (OAB): results of a large, double-blind, placebo-controlled trial (Abstract number: poster #74). Neurourology and Urodynamics2009;28(2):149. [sr-incont31063]VardyMD , MitchesonHD , SamuelsTA , Forero-SchwanhaeuserS , HeW . Efficacy of solifenacin on overactive bladder symptoms, symptom bother, and other patient-reported outcomes in subjects with or without incontinence: a post hoc analysis of data from VIBRANT. Female Pelvic Medicine and Reconstructive Surgery2011;17(1):24-9. [TrialID.VIBRANT.] [sr-incont44741]VardyMD , MitchesonHD , SamuelsTA , WegenkeJD , Forero-SchwanhaeuserS , MarshallTS , et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. International Journal of Clinical Practice2009;63(12):1702-14. [905-UC-010] [NCT00573508] [TrialID.VIBRANT.] [sr-incont35459]">Vardy 2009</a>; <a href="./references#CD003781-bbs2-0094" title="EUCTR2007-007087-17-SE. A 24-week, multicentre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-007087-17 (first received 13 June 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont64588]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00798434. A study to compare the effectiveness and safety of fesoterodine and placebo in an elderly population of patients who go to the toilet very frequently due to overactive bladder (SOFIA) [A 24-week, multi-centre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00798434 (first received 26 November 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont49847]SchneiderT , BergqvistA , WangJ , WaggA , Ebel-BitounC . Treatment with fesoterodine versus tolterodine for reducing symptom bother in elderly patients with overactive bladder including urgency urinary incontinence. European Urology, Supplements2012;11(1):e687-a. [sr-incont65389]WaggA , CarlssonM , ElsobkyM , FernetM . Effect of flexible dose fesoterodine on cognitive function in &gt;65 year old patients with OAB: data from two RCT (Abstract number 438). Neurourology and Urodynamics2019;38:S297-8. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78651]WaggA , DarekarA , ArumiD , KhullarV , OelkeM . Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people &gt;65 years of age: a post hoc analysis of data from the SOFIA study. Neurourology and Urodynamics2015;34(5):438-43. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont68100]WaggA , ElsobkyM , CarlssonM , FernetM . Response and cognitive safety of fesoterodine in patients &gt;65y old with OAB. Is there a relationship between cognition and treatment response? (Abstract number 183). Neurourology and Urodynamics2019;38:S118-20. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78632]WaggA , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. Journal of the American Geriatrics Society2013;61(2):185-93. [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TrialID.SOFIA.] [sr-incont48008]WaggAS , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Efficacy and tolerability of fesoterodine in older subjects with overactive bladder: results of SOFIA (Abstract number C33). Journal of the American Geriatrics Society2011;59:S124. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont65234]">Wagg 2013a</a>; <a href="./references#CD003781-bbs2-0095" title="GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00911937. A trial to evaluate the efficacy and safety of fesoterodine in patients with symptoms of overactive bladder including nocturnal urinary urgency [A randomized, double blind, placebo controlled, parallel group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with symptoms of overactive bladder including nocturnal urinary urgency]. clinicaltrials.gov/show/NCT00911937 (first received 03 June 2009). [NCT00911937] [sr-incont49848]WeissJ , JumadilovaZ , CarlssonM , FitzGeraldMP , MalhotraA , MartireDL . Effect of antimuscarinic treatment in subjects with overactive bladder, including nocturnal urinary urgency (Abstract number 1963). Journal of Urology2012;187(4 Suppl 1):e792. [NCT00911937] [sr-incont65184]WeissJP , CarlssonMR , ManganEK . Age, gender and nocturnal urgency severity predict response to antimuscarinic treatment (Abstract number 1962). Journal of Urology2013;189(4 Suppl 1):e805. [NCT00911937] [sr-incont65096]WeissJP , JumadilovaZ , JohnsonTM , FitzGeraldMP , CarlssonM , MartireDL , et al. Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency. Journal of Urology2013;189(4):1396-401. [A0221048] [NCT00911937] [sr-incont47568]">Weiss 2013</a>; <a href="./references#CD003781-bbs2-0098" title="YamaguchiO , UchidaE , HigoN , MinamiH , KobayashiS , SatoH , et al. Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: a randomized double-blind trial. International Journal of Urology2014;21(6):586-93. [JapicCTI-101309] [sr-incont62099]">Yamaguchi 2014</a>; <a href="./references#CD003781-bbs2-0099" title="YongucT , SefikE , InciI , KusbeciOY , CelikS , AydinME , et al. Randomized, controlled trial of fesoterodine fumarate for overactive bladder in Parkinson's disease. World Journal of Urology2019;38(8):2013-9. [sr-incont78635]">Yonguc 2019</a>; <a href="./references#CD003781-bbs2-0101" title="NCT01018264, ZesiewiczT . Solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease (URGE-PD) [URGE-PD: a multi-site, double-blind, randomized, placebo controlled trial of solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease]. clinicaltrials.gov/show/NCT01018264 (first received 23 November 2009). [NCT01018264] [sr-incont63790]ZesiewiczTA , EvattM , JahanI , VaughanC , SingerC , OrdoricaR , et al. URGE-PD: a multi-site, double-blind, randomized, placebo controlled trial of solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease (Abstract number 745). Movement Disorders2014;29(Suppl 1):S276-7. [NCT01018264] [sr-incont66602]ZesiewiczTA , EvattM , VaughanCP , JahanI , SingerC , OrdoricaR , et al. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease. Parkinsonism and Related Disorders2015;21(5):514-20. [NCT01018264] [sr-incont66860]">Zesiewicz 2015</a>; <a href="./references#CD003781-bbs2-0102" title="ZinnerNR , MattiassonA , StantonSL . Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. Journal of the American Geriatrics Society2002;50(5):799-807. [sr-incont14679]">Zinner 2002</a>). We deemed one study to be at high risk of bias as it used a simple probability sampling technique (<a href="./references#CD003781-bbs2-0057" title="KosilovK , LoparevS , IvanovskayaM , KosilovaL . A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron. Archives of Gerontology and Geriatrics2015;61(2):212-6. [sr-incont68133]">Kosilov 2015a</a>). The remaining 68 studies did not provide enough details about the methods used in sequence generation and we therefore judged them to be unclear. </p> </section> <section id="CD003781-sec-0063"> <h5 class="title">Allocation concealment (selection bias)</h5> <p>A total of 17 studies provided sufficient information to be sure there was adequate allocation concealment and we judged them to be at low risk of bias (<a href="./references#CD003781-bbs2-0002" title="AbramsP , FreemanR , AnderströmC , MattiassonA . Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. British Journal of Urology1998;81(6):801-10. [srincont-7871]AbramsP , FreemanRN , AnderstromC , MattiassonA . Efficacy and tolerability of tolterodine vs. oxybutynin and placebo in patients with detrusor instability (Abstract). Journal of Urology1997;157(Suppl 4):103. [srincont-16321]">Abrams 1998</a>; <a href="./references#CD003781-bbs2-0004" title="AbramsP , KelleherC , StaskinD , KayR , MartanA , MincikI , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World Journal of Urology2017;35(5):827-38. [NCT01340027] [sr-incont77897]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Cardiovascular safety of combination treatment with mirabegron and solifenacin in patients with overactive bladder in a randomised, double-blind, dose-ranging, Phase II study (Symphony) (Abstract). European Urology, Supplements2014;13(1):e574-e574a. [NCT01340027] [sr-incont67160]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB) - efficacy and safety results from a randomised phase II study (Symphony) (Abstract number 295). Neurourology and Urodynamics2013;32(6):930-1. [NCT01340027] [TrialID.SYMPHONY.] [sr-incont49188]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB): safety results from a phase 2 study (Abstract number MP-16.08). Urology2013;82(3 Suppl 1):S139. [NCT01340027] [sr-incont66675]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: Exploratory responder analyses of efficacy and evaluation of patient reported outcomes from a randomised, double-blind, dose-ranging, phase 2 study (Symphony) (Abstract number MP-24.11). Urology2014;84(4 Suppl 1):S145-6. [NCT01340027] [sr-incont67194]AbramsP , KelleherC , StaskinD , RechbergerT , KayR , MartinaR , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (SYMPHONY). European Urology2015;67(3):577-88. [NCT01340027] [sr-incont66674]NCT01340027, Bristol Urological Institute . A study to evaluate the efficacy, safety and tolerability of mirabegron and solifenacin succinate alone and in combination for the treatment of overactive bladder (symphony) [A randomized, double-blind, factorial, parallel-group, active and placebo-controlled, multicenter dose-ranging study to evaluate the efficacy, safety and tolerability of six dose combinations of solifenacin succinate and mirabegron compared to mirabegron and solifenacin succinate monotherapies in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01340027 (first received 21 April 2011). [178-CL-100] [2010-020601-32] [NCT01340027] [TrialID.SYMPHONY] [sr-incont44510]NittiV , AbramsP , StaskinD , AuerbachS , MartinaR , VanMR . Urinary retention in patients with overactive bladder treated with mirabegron alone and in combination with solifenacin: the results of two randomized, double-blind, phase II studies (Abstract number MP76-13). Journal of Urology2014;191(4 Suppl 1):e886-7. [NCT00410514] [NCT01340027] [TrialID.SYMPHONY] [sr-incont67453]">Abrams 2013</a>; <a href="./references#CD003781-bbs2-0021" title="ChuaME , SeeMC , EsmeňaEB , BalingitJC , MoralesML . Efficacy and safety of gabapentin in comparison to solifenacin succinate in adult overactive bladder treatment. Lower Urinary Tract Symptoms2018;10(2):135-42. [NCT01486706] [sr-incont74529]NCT01486706, ChuaME . Efficacy and safety of gabapentin in treating overactive bladder (OAB). clinicaltrials.gov/show/NCT01486706 (first received 6 December 2011). [NCT01486706] [SLMC10-010] [sr-incont49864]">Chua 2018</a>; <a href="./references#CD003781-bbs2-0032" title="GellerE , DumondJ , BowlingJM , KhandelwalC , WuJ , Busby-WhiteheadJ , et al. Effect of an anticholinergic on cognitive function in postmenopausal women: a randomized trial (Abstract number: oral poster 52). Female Pelvic Medicine and Reconstructive Surgery2016;22(5):S61. [sr-incont78607]GellerEJ , DumondJB , BowlingJM , KhandelwalCM , WuJM , Busby-WhiteheadJ , et al. Effect of trospium chloride on cognitive function in women aged 50 and older: a randomized trial. Female Pelvic Medicine &amp; Reconstructive Surgery2017;23(2):118-23. [13-1352] [NCT01922115] [sr-incont74341]NCT01922115. The effect of anticholinergics on cognitive function in the elderly (ACE) [The effect of anticholinergics on cognitive function in the elderly: a randomized controlled trial]. clinicaltrials.gov/show/NCT01922115 (first received 14 August 2013). [13-1352] [NCT01922115] [TrialID.ACE] [sr-incont49282]">Geller 2013</a>; <a href="./references#CD003781-bbs2-0033" title="GotohM , HommaY , YokoyamaO , NishizawaO . Responsiveness and minimal clinically important change in overactive bladder symptom score. Urology2011;78(4):768-73. [srincont-42622]GotohM , YokoyamaO , MatsukawaY , NishizawaO . Responsiveness of overactive bladder symptom score (OABSS): verification based on data in a double-blinded, randomized placebo-controlled study of propiverine hydrochloride in Japanese patients (Abstract number 338). In: Joint Meeting of the International Continence Society (ICS) and the International Urogynecological Association; 2010 Aug 23-27; Toronto, Canada. 2010. [srincont-40173]GotohM , YokoyamaO , NishizawaO . Propiverine hydrochloride in Japanese patients with overactive bladder: A randomized, double-blind, placebo-controlled trial. International Journal of Urology2011;18(5):365-73. [srincont-41510]">Gotoh 2011</a>; <a href="./references#CD003781-bbs2-0039" title="CorcosJ , AnguloJC , GarelyAD , CarlssonM , GongJ , GuanZ . Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. Current Medical Research and Opinion2011;27(5):1059-65. [srincont-41596]EUCTR2006-006935-38-SE. 12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006935-38 (first received 16 April 2007). [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont64612]HerschornS , SwiftS , GuanZ , CarlssonM , BrodskyM , GongJ . Efficacy and safety of fesoterodine for overactive bladder in a double-blind, head-to-head comparison trial with tolterodine ER and placebo (Abstract number 710). In: International Continence Society (ICS), 39th Annual Meeting; 2009 Sep 29-Oct 3; San Francisco, CA. 2009. [srincont-35326]HerschornS , SwiftS , GuanZ , CarlssonM , MorrowJD , BrodskyM , et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU International2010;105(1):58-66. [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont39540]NCT00444925. Clinical trial to evaluate the efficacy and safety of Fesoterodine in comparison to Tolterodine for overactive bladder (OAB) [12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder (OAB)]. clinicaltrials.gov/show/NCT00444925 (first received 08 March 2007). [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont49159]">Herschorn 2009a</a>; <a href="./references#CD003781-bbs2-0046" title="HuangA , HessR , AryaL , RichterH , SubakL , BradleyC , et al. A randomized controlled trial of simple diagnosis and treatment for urgency urinary incontinence in women (Abstract). Journal of General Internal Medicine2011;26:S1. [NCT00862745] [sr-incont64391]HuangAJ , HessR , AryaLA , RichterHE , SubakLL , BradleyCS , et al. Pharmacologic treatment for urgency-predominant urinary incontinence in women diagnosed using a simplified algorithm: a randomized trial. American Journal of Obstetrics and Gynecology2012;206(5):444.e1-11. [GA0221IX] [NCT00862745] [TrialID.BRIDGES.] [srincont-44636]NCT00862745, BrownJ . Bringing simple urge incontinence diagnosis &amp; treatment to providers (BRIDGES)  [A multi-center, randomized, placebo-controlled clinical trial comparing fesoterodine to placebo in women diagnosed with urge urinary incontinence by the 3 Incontinence Questions (3IQ). Followed by a multi-center open label clinical cohort study of long-term effects of treatment with fesoterodine ]. clinicaltrials.gov/show/NCT00862745 (first received 17 March 2009). [NCT00862745] [sr-incont49836]WarsiQ , HuangA , BrownJS , SchembriM , HessR , AryaLA , et al. The effect of pharmacologic treatment of urgency urinary incontinence on sleep quality and daytime sleepiness (Abstract number: paper 37). Female Pelvic Medicine and Reconstructive Surgery2016;22(5 ):S17-8. [NCT00862745] [TrialID.BRIDGES.] [sr-incont78633]WarsiQA , HuangAJ , HessR , AryaLA , RichterHE , BradleyCS , et al. Association of pharmacologic treatment of urgency urinary incontinence with sleep quality and daytime sleepiness. Obstetrics and Gynecology2018;131(2):204-11. [NCT00862745] [sr-incont78239]WinkelmanW , HuangA , SchembriM , RogersRG , RichterHE , MyersDL , et al. Clinical variables moderating response to pharmacologic treatment of urgency-predominant urinary incontinence in a randomized controlled trial (Abstract number: poster 25). In: Female Pelvic Medicine and Reconstructive Surgery. 37th Annual Scientific Meeting of the American Urogynecologic Society; Aug 2016; United States. Vol. 22. Netherlands: Lippincott Williams and Wilkins, 2016:S81. [NCT00862745] [sr-incont78634]WinkelmanWD , HuangAJ , SchembriM , RogersRG , RichterH , MyersDL , et al. Modifiers of response to treatment with fesoterodine for urgency-predominant urinary incontinence in a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2017;23(2):151-6. [sr-incont74308]">Huang 2012</a>; <a href="./references#CD003781-bbs2-0047" title="JacquetinB , WyndaeleJJ . Tolterodine reduces the number of incontinence episodes in patients with an overactive bladder. European Journal of Obstetrics and Gynecology and Reproductive Biology2001;98(1):97-102. [srincont-12200]JacquetinB , WyndaeleJJ . Tolterodine reduces the number of incontinence episodes in patients with detrusor overactivity. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(1):S30. [srincont-5167]">Jacquetin 2001</a>; <a href="./references#CD003781-bbs2-0051" title="EUCTR2007-006451-39-SE. 12-week, randomized, double-blind, double-dummy, placebo controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-006451-39 (first received 20 February 2008). [A0221046] [EUCTR2007-006451-39-SE] [sr-incont64591]KaplanSA , SchneiderT , FooteJ , GuanZ . Superior efficacy of fesoterodine over tolterodine with rapid onset: a prospective, head-to-head, placebo-controlled trial (Abstract number 67). Neurourology and Urodynamics2010;29(6):905-7. [srincont-40130]KaplanSA , SchneiderT , FooteJE , GuanZ , CarlssonM , GongJ . Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU International2011;107(9):1432-40. [A0221046] [NCT00611026] [srincont-41334]">Kaplan 2011</a>; <a href="./references#CD003781-bbs2-0054" title="KhullarV , HillS , LavalKU , SchiotzHA , JonasU , VersiE . Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology2004;64(2):269-74; discussion 274-5. [srincont-19498]KhullarV , HillS , SolankiJ . Assessment of health-related quality of life in patients with overactive bladder taking tolterodine extended release versus placebo (Abstract number 318). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21075]">Khullar 2004</a>; <a href="./references#CD003781-bbs2-0066" title="Malone-LeeJG , WalshB , MaugourdMF , Tolterodine in the Elderly Study Group. The safety and clinical efficacy of two doses of tolterodine compared to placebo in elderly patients. In: International Continence Society (ICS), 27th Annual Meeting; 1997 Sep 23-26; Yokohama, Japan. 1997:155-6. [srincont-5855]Malone‐LeeJG , WalshJB , MaugourdMF . Tolterodine: A safe and effective treatment for older patients with overactive bladder. Journal of the American Geriatric Society2001;49(6):700-5. [srincont-12319]WaggA , Malone-LeeJ . Pressure-flow variables in patients treated with tolterodine for detrusor overactivity. BJU International2003;92(9):969-71. [sr-incont16659]">Malone‐Lee 2001</a>; <a href="./references#CD003781-bbs2-0089" title="ThuroffJW , BunkeB , EbnerA , FaberP , deGeeterP , HannappelJ , et al. Randomized, double-blind multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin vs. propantheline vs. placebo. Neurourology and Urodynamics1990;9(4):337-8. [srincont-5108]ThuroffJW , BunkeB , EbnerA , FaberP , deGeeterP , HannappelJ , et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. Journal of Urology1991;145(4):813-7. [srincont-1288]">Thuroff 1991</a>; <a href="./references#CD003781-bbs2-0092" title="ChancellorM , FreedmanS , MitchesonHD , AntociJ , PrimusG , WeinA . Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clinical Drug Investigation2000;19(2):83-91. [srincont-16326]FreemanR , HillS , MillardR , SlackM , SutherstJ , Tolterodine Study Group. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstetrics and Gynecology2003;102(3):605-11. [srincont-16494]GarelyA , Tolterodine Study Group. Once-daily tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder. International Urology Journal2001;12(Suppl 1):S18. [srincont-12012]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of life of patients with overactive bladder receiving tolterodine. Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of patients with overactive bladder receiving tolterodine (Abstract number 82). Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , ReesePR . Health related quality of life of patients with overactive bladder receiving tolterodine once-daily. Neurourology and Urodynamics2000;19(4):519-21. [srincont-9987]KelleherCJ , ReesePR , PleilAM , OkanoGJ . Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. American Journal of Managed Care2002;8(Suppl 19):S608-15. [srincont-17998]KelleherCJ , Tolterodine Study Group. Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2000;11(Suppl 1):S94. [srincont-11915]KrederKJ . Antimuscarinic therapy: relationship between efficacy and side effects in responders and non-responders. Journal of Urology2001;165(Suppl 5):S165. [srincont-16327]KrederKJ . Clinical effectiveness of antimuscarinic therapy: the relationship between efficacy and tolerability. In: Proceedings of the International Continence Society Annual Meeting(ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001:140. [srincont-14376]MallettV . Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2001;12(Suppl 1):4. [srincont-12011]MillardRJ , TamaddonK , Tolterodine Study Group. Randomized controlled trial to compare tolterodine prolonged release capsules and tolterodine immediate release tablets versus placebo in patients with symptoms of detrusor overactivity (Abstract number 57). Australian and New Zealand Journal of Surgery2002;Suppl 72:A140. [sr-incont22190]PleilAM , ReesePR , KelleherCJ , OkanoGJ . Health-related quality of life of patients with overactive bladder receiving immediate-release tolterodine. HEPAC Health Economics in Prevention and Care2001;2(2):69-75. [sr-incont18060]RoehrbornCG , AbramsP , RovnerES , KaplanSA , HerschornS , GuanZ . Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU International2006;97(5):1003-6. [sr-incont21882]SwiftS . Efficacy and tolerability of once-daily tolterodine for women with overactive bladder. In: International Continence Society Annual Meeting (ICS), 31st annual meeting; 2001 Sept 18-21; Seoul, Korea. 2001:No. 329. [srincont-14481]SwiftS . Once-daily tolterodine is effective and well tolerated in women with overactive bladder (Abstract 57). In: 2nd International Consultation on Incontinence; 2001 July 1-3; Paris, France. 2001. [srincont-16319]SwiftSE . Once-daily (OD) tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder (OAB). International Urogynecology Journal2000;11(Suppl 1):S15. [sr-incont11906]SwiftSE . Once-daily administration of extended-release tolterodine is effective and well-tolerated in patients with overactive bladder. In: XVI FIGO World Congress of Obstetrics and Gynecology; 2000 Sept 3-8; Washington DC. Vol. Book 1. 2000:40. [sr-incont12085]SwiftSE . Overactive bladder in females: treatment with once-daily tolterodine. International Urogynecology Journal2001;12(Suppl 3):S71. [sr-incont16328]Van KerrebroeckP , KrederK , JonasU , ZinnerN . Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology2001;57(3):414-21. [sr-incont11953]Van KerrebroeckPEV . Long-term (12 months) efficacy and tolerability of tolterodine once-daily in the treatment of overactive bladder. Neurourology and Urodynamics2001;20(4):401-2. [sr-incont15714]Van KerrebroeckPEVA , Tolterodine Study Group. Long-term tolerability and efficacy of once-daily (OD) tolterodine in the treatment of overactive bladder (OB). International Urogynecology Journal2001;12(Suppl 3):S49. [sr-incont16329]Van KerrebroeckPEVA , Tolterodine Study Group. Significant decreases in perception of urgency and urge incontinence episodes with once-daily tolterodine treatment in patients with overactive bladder (Abstract number 89). Neurourology and Urodynamics2000;19(4):493-4. [sr-incont9980]WeinAJ , KhullarV , WangJT , GuanZ . Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. BJU International2007;99(2):360-3. [sr-incont23180]vanKerrebroeckPE , KelleherCJ , CoyneKS , KoppZ , BrodskyM , WangJT . Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. Health and Quality of Life Outcomes2009;7(13):13. [10.1186/1477-7525-7-13] [sr-incont31438]vanKerrebroeckPE , WangJ , GuanZ . Effects of tolterodine extended release in patients with overactive bladder: perceived treatment benefits improve with efficacy (Abstract number 511). European Urology Supplements2004;3(2):130. [sr-incont31090]">Van Kerrebroeck 2001</a>; <a href="./references#CD003781-bbs2-0093" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CrosbyRD , MathiasSD , MarshallTS . Relationships between symptoms, symptom bother, and health-related quality of life in patients with overactive bladder taking solifenacin or placebo in the VIBRANT study. International Journal of Clinical Practice2011;65(2):211-8. [sr-incont41015]GollarKM , YoungDG , BailenJ , HeW , Forero-SchwanhaeuserS . Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: a secondary analysis of the VIBRANT study. Urologic Nursing2012;32(1):38-46. [TrialID.VIBRANT.] [sr-incont44571]Samuels T‐A, MitchesonHD , VardyM , Forero‐SchwanhaeuserS , MarshallT , HeW . Efficacy of solifenacin for symptom bother and other patient-reported outcomes in patients with overactive bladder (OAB): results of a large, double-blind, placebo-controlled trial (Abstract number: poster #74). Neurourology and Urodynamics2009;28(2):149. [sr-incont31063]VardyMD , MitchesonHD , SamuelsTA , Forero-SchwanhaeuserS , HeW . Efficacy of solifenacin on overactive bladder symptoms, symptom bother, and other patient-reported outcomes in subjects with or without incontinence: a post hoc analysis of data from VIBRANT. Female Pelvic Medicine and Reconstructive Surgery2011;17(1):24-9. [TrialID.VIBRANT.] [sr-incont44741]VardyMD , MitchesonHD , SamuelsTA , WegenkeJD , Forero-SchwanhaeuserS , MarshallTS , et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. International Journal of Clinical Practice2009;63(12):1702-14. [905-UC-010] [NCT00573508] [TrialID.VIBRANT.] [sr-incont35459]">Vardy 2009</a>; <a href="./references#CD003781-bbs2-0094" title="EUCTR2007-007087-17-SE. A 24-week, multicentre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-007087-17 (first received 13 June 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont64588]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00798434. A study to compare the effectiveness and safety of fesoterodine and placebo in an elderly population of patients who go to the toilet very frequently due to overactive bladder (SOFIA) [A 24-week, multi-centre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00798434 (first received 26 November 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont49847]SchneiderT , BergqvistA , WangJ , WaggA , Ebel-BitounC . Treatment with fesoterodine versus tolterodine for reducing symptom bother in elderly patients with overactive bladder including urgency urinary incontinence. European Urology, Supplements2012;11(1):e687-a. [sr-incont65389]WaggA , CarlssonM , ElsobkyM , FernetM . Effect of flexible dose fesoterodine on cognitive function in &gt;65 year old patients with OAB: data from two RCT (Abstract number 438). Neurourology and Urodynamics2019;38:S297-8. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78651]WaggA , DarekarA , ArumiD , KhullarV , OelkeM . Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people &gt;65 years of age: a post hoc analysis of data from the SOFIA study. Neurourology and Urodynamics2015;34(5):438-43. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont68100]WaggA , ElsobkyM , CarlssonM , FernetM . Response and cognitive safety of fesoterodine in patients &gt;65y old with OAB. Is there a relationship between cognition and treatment response? (Abstract number 183). Neurourology and Urodynamics2019;38:S118-20. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78632]WaggA , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. Journal of the American Geriatrics Society2013;61(2):185-93. [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TrialID.SOFIA.] [sr-incont48008]WaggAS , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Efficacy and tolerability of fesoterodine in older subjects with overactive bladder: results of SOFIA (Abstract number C33). Journal of the American Geriatrics Society2011;59:S124. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont65234]">Wagg 2013a</a>; <a href="./references#CD003781-bbs2-0101" title="NCT01018264, ZesiewiczT . Solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease (URGE-PD) [URGE-PD: a multi-site, double-blind, randomized, placebo controlled trial of solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease]. clinicaltrials.gov/show/NCT01018264 (first received 23 November 2009). [NCT01018264] [sr-incont63790]ZesiewiczTA , EvattM , JahanI , VaughanC , SingerC , OrdoricaR , et al. URGE-PD: a multi-site, double-blind, randomized, placebo controlled trial of solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease (Abstract number 745). Movement Disorders2014;29(Suppl 1):S276-7. [NCT01018264] [sr-incont66602]ZesiewiczTA , EvattM , VaughanCP , JahanI , SingerC , OrdoricaR , et al. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease. Parkinsonism and Related Disorders2015;21(5):514-20. [NCT01018264] [sr-incont66860]">Zesiewicz 2015</a>; <a href="./references#CD003781-bbs2-0102" title="ZinnerNR , MattiassonA , StantonSL . Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. Journal of the American Geriatrics Society2002;50(5):799-807. [sr-incont14679]">Zinner 2002</a>). We judged two studies to be high risk of bias as "the randomisation schedule was generated, secured, distributed, and stored by Pfizer Global Clinical Data Services", the funder of the studies, raising concerns about independence (<a href="./references#CD003781-bbs2-0024" title="DmochowskiR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. A double-blind, placebo-controlled trial of flexible-dose fesoterodine for overactive bladder (Abstract number 715). In: International Continence Society (ICS); 39th Annual Meeting; 2009 Sep 29-Oct 03; San Francisco, CA. 2009. [sr-incont35627]DmochowskiRR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder [Errata appear in: Urology 2010 Jun;75(6):1519 and in Urology 2011 Jun;77(6):1513]. Urology2010;75(1):62-8. [A0221014] [NCT00536484] [sr-incont39548]DuBeauC , KrausSR , SunF , MorrowJD . Fesoterodine in older vs younger subjects with overactive bladder (Abstract number D87). Journal of the American Geriatrics Society2010;58:S218. [NCT00536484] [sr-incont64309]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. [sr-incont78640]NCT00536484. Fesoterodine flexible dose study [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with overactive bladder]. clinicaltrials.gov/show/NCT00536484 (first received 27 September 2007). [NCT00536484] [sr-incont49160]StaskinD , KhullarV , MichelMC , MorrowJD , SunF , GuanZ , et al. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. Neurourology and Urodynamics2011;30(8):1480-5. [sr-incont42686]">Dmochowski 2010</a>; <a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>). We judged all the remaining studies to be at unclear risk of bias as they did not provide sufficient detail about allocation concealment. </p> </section> </section> <section id="CD003781-sec-0064"> <h4 class="title">Blinding</h4> <section id="CD003781-sec-0065"> <h5 class="title">Blinding of participants and personnel (performance bias)</h5> <p>Blinding of participants and personnel was unclear in the majority of studies due to poor reporting of this aspect of the study. We did not judge any study to be at high risk. Thirty studies had a low risk of bias as they clearly documented their blinding process (<a href="./references#CD003781-bbs2-0004" title="AbramsP , KelleherC , StaskinD , KayR , MartanA , MincikI , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World Journal of Urology2017;35(5):827-38. [NCT01340027] [sr-incont77897]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Cardiovascular safety of combination treatment with mirabegron and solifenacin in patients with overactive bladder in a randomised, double-blind, dose-ranging, Phase II study (Symphony) (Abstract). European Urology, Supplements2014;13(1):e574-e574a. [NCT01340027] [sr-incont67160]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB) - efficacy and safety results from a randomised phase II study (Symphony) (Abstract number 295). Neurourology and Urodynamics2013;32(6):930-1. [NCT01340027] [TrialID.SYMPHONY.] [sr-incont49188]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB): safety results from a phase 2 study (Abstract number MP-16.08). Urology2013;82(3 Suppl 1):S139. [NCT01340027] [sr-incont66675]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: Exploratory responder analyses of efficacy and evaluation of patient reported outcomes from a randomised, double-blind, dose-ranging, phase 2 study (Symphony) (Abstract number MP-24.11). Urology2014;84(4 Suppl 1):S145-6. [NCT01340027] [sr-incont67194]AbramsP , KelleherC , StaskinD , RechbergerT , KayR , MartinaR , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (SYMPHONY). European Urology2015;67(3):577-88. [NCT01340027] [sr-incont66674]NCT01340027, Bristol Urological Institute . A study to evaluate the efficacy, safety and tolerability of mirabegron and solifenacin succinate alone and in combination for the treatment of overactive bladder (symphony) [A randomized, double-blind, factorial, parallel-group, active and placebo-controlled, multicenter dose-ranging study to evaluate the efficacy, safety and tolerability of six dose combinations of solifenacin succinate and mirabegron compared to mirabegron and solifenacin succinate monotherapies in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01340027 (first received 21 April 2011). [178-CL-100] [2010-020601-32] [NCT01340027] [TrialID.SYMPHONY] [sr-incont44510]NittiV , AbramsP , StaskinD , AuerbachS , MartinaR , VanMR . Urinary retention in patients with overactive bladder treated with mirabegron alone and in combination with solifenacin: the results of two randomized, double-blind, phase II studies (Abstract number MP76-13). Journal of Urology2014;191(4 Suppl 1):e886-7. [NCT00410514] [NCT01340027] [TrialID.SYMPHONY] [sr-incont67453]">Abrams 2013</a>; <a href="./references#CD003781-bbs2-0007" title="BrayR , CartwrightR , CardozoL , HillS , GuanZ , KhullarV . Tolterodine ER reduced increased bladder wall thickness in women with overactive bladder. A randomized, placebo-controlled, double-blind, parallel group study. Neurourology and  Urodynamics2018;37(1):237-43. [NCT00137397] [sr-incont74473]NCT00137397. A study to measure the effect of tolterodine extended release on the thickness of the bladder wall in patients with overactive bladder [A multi-centre, randomised, placebo controlled, double blind, parallel group study in female patients to evaluate whether tolterodine ER can reverse the increased bladder wall thickness in patients with overactive bladder]. clinicaltrials.gov/show/NCT00137397 (first received 29 August 2005). [NCT00137397] [sr-incont63809]">Bray 2018</a>; <a href="./references#CD003781-bbs2-0008" title="BurgioKL , LocherJL , GoodePS , HardinJM , McDowellBJ , CandibD . Behavior vs drug therapy for urge incontinence in older women (Abstract number 26). In: American Urogynecology Society, 15th Annual Scientific Meeting; 1994 Sept 21-24; Toronto, Ontario. 1994:48. [sr-incont14585]BurgioKL , LocherJL , GoodePS , HardinM , McDowellBJ , Dombrowski M et al. Behavioral vs drug treatment for urge urinary incontinence in older women. A randomized controlled trial. JAMA1998;280(23):1995-2000. [srincont-5719]BurgioKL , LocherJL , GoodePS . Combined behavioral and drug therapy for urge incontinence in older women. Journal of the American Geriatrics Society2000;48(4):370-4. [srincont-9006]BurgioKL , LocherJL , RothDL , GoodePS . Psychological improvements associated with behavioral and drug treatment of urge incontinence in older women. Journal of Gerontology. Series B, Psychological Sciences and Social Sciences2001;56(1):P46-51. [srincont-11923]">Burgio 1998</a>; <a href="./references#CD003781-bbs2-0017" title="ChappleC , DuBeauC , EbingerU , RekedaL , ViegasA . Darifenacin treatment of patients &gt;or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Current Medical Research and Opinion2007;23(10):2347-58. [srincont-23921]">Chapple 2007b</a>; <a href="./references#CD003781-bbs2-0019" title="ChappleC , HaabF , SchneiderT , CarlssonM , ArumiD . Fesoterodine 8 mg versus fesoterodine 4 mg in patients with overactive bladder and a history of previous antimuscarinic therapy: Results from the EIGHT trial (Abstract number: Poster #M5). Neurourology and Urodynamics2015;34(S1):S20. [NCT01302067] [sr-incont68509]ChappleC , SchneiderT , HaabF , SunF , WhelanL , ScholfieldD , et al. Superiority of fesoterodine 8mg versus fesoterodine 4 mg in reducing urgency urinary incontinence episodes in subjects with overactive bladder: results of the randomized, double-blind, placebo-controlled EIGHT trial (Abstract number: Podium #48). Neurourology and Urodynamics2014;33(2):183-4. [NCT01302067] [sr-incont67484]ChappleC , SchneiderT , HaabF , SunF , WhelanL , ScholfieldD , et al. Superiority of fesoterodine 8mg vs 4mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial. BJU International2014;114(3):418-26. [A0221095] [NCT01302067] [TrialID.EIGHT] [srincont-62537]NCT01302067. A 12 week study to confirm the effectiveness of 8mg of Fesoterodine compared to 4mg of Fesoterodine [A 12-week, randomized, double-blind, placebo controlled, parallel group, multicenter trial in overactive bladder subjects to confirm the efficacy of 8 mg fesoterodine compared to 4 mg fesoterodine]. clinicaltrials.gov/show/NCT01302067 (first received 23 February 2011). [NCT01302067] [sr-incont63792]">Chapple 2014</a>; <a href="./references#CD003781-bbs2-0020" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. [sr-incont75259]ChuF , SmithN , UchidaT . Efficacy and safety of solifenacin succinate 10 mg once daily: a multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder. Current Therapeutic Research - Clinical and Experimental2009;70(6):405-20. [srincont-43324]">Chu 2009</a>; <a href="./references#CD003781-bbs2-0021" title="ChuaME , SeeMC , EsmeňaEB , BalingitJC , MoralesML . Efficacy and safety of gabapentin in comparison to solifenacin succinate in adult overactive bladder treatment. Lower Urinary Tract Symptoms2018;10(2):135-42. [NCT01486706] [sr-incont74529]NCT01486706, ChuaME . Efficacy and safety of gabapentin in treating overactive bladder (OAB). clinicaltrials.gov/show/NCT01486706 (first received 6 December 2011). [NCT01486706] [SLMC10-010] [sr-incont49864]">Chua 2018</a>; <a href="./references#CD003781-bbs2-0022" title="AmarencoG , SutoryM , FagertunH , WrightM , CompionG , De RidderD . Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Preliminary results from the SONIC urodynamic study (Abstract). European Urology, Supplements2012;11(1):e467-a. [EudraCT2006-005523-42] [NCT00629642] [sr-incont65392]AmarencoG , SutoryM , ZachovalR , AgarwalM , DelPG , TretterR , et al. Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study. Neurourology and Urodynamics2017;36(2):414-21. [EudraCT2006-005523-42] [JapicCTI-R130306] [NCT00629642] [sr-incont72248]De RidderD , AmarencoG , Finazzi-AgroE , AnguloJ , KurenkovA , WrightM , et al. Solifenacin treatment for neurogenic detrusor overactivity: patient-reported outcomes (PROs) from the randomised clinical trial SONIC (Abstract number 333). In: International Continence (ICS); 42nd Annual Meeting; 2012 Oct 15-19; Beijing, China. 2012. [905-EC-005] [EudraCT2006-005523-42] [NCT00629642] [TrialID.SONIC.] [srincont-49739]">De Ridder 2012</a>; <a href="./references#CD003781-bbs2-0026" title="DrutzH , AppellRA . Clinical efficacy and safety of Tolterodine vs Oxybutynin and placebo in patients with unstable bladder. Acta Obstetrica et Gynecologica Scandinavica1997;Suppl 167(5):24. [srincont-6671]DrutzHP , AppellRA , GleasonD , KlimbergI , RadomskiS . Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. International Urogynecology Journal and Pelvic Floor Dysfunction1999;10(5):283-9. [srincont-8804]DrutzHP , AppellRA . Enhanced tolerability of tolterodine compared to oxybutynin in a controlled clinical study. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(1):S14. [srincont-5166]">Drutz 1999</a>; <a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>; <a href="./references#CD003781-bbs2-0032" title="GellerE , DumondJ , BowlingJM , KhandelwalC , WuJ , Busby-WhiteheadJ , et al. Effect of an anticholinergic on cognitive function in postmenopausal women: a randomized trial (Abstract number: oral poster 52). Female Pelvic Medicine and Reconstructive Surgery2016;22(5):S61. [sr-incont78607]GellerEJ , DumondJB , BowlingJM , KhandelwalCM , WuJM , Busby-WhiteheadJ , et al. Effect of trospium chloride on cognitive function in women aged 50 and older: a randomized trial. Female Pelvic Medicine &amp; Reconstructive Surgery2017;23(2):118-23. [13-1352] [NCT01922115] [sr-incont74341]NCT01922115. The effect of anticholinergics on cognitive function in the elderly (ACE) [The effect of anticholinergics on cognitive function in the elderly: a randomized controlled trial]. clinicaltrials.gov/show/NCT01922115 (first received 14 August 2013). [13-1352] [NCT01922115] [TrialID.ACE] [sr-incont49282]">Geller 2013</a> ; <a href="./references#CD003781-bbs2-0035" title="HaabF , StewartL , DwyerP . Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. European Urology2004;45(4):420-9. [srincont-17428]">Haab 2004</a>; <a href="./references#CD003781-bbs2-0039" title="CorcosJ , AnguloJC , GarelyAD , CarlssonM , GongJ , GuanZ . Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. Current Medical Research and Opinion2011;27(5):1059-65. [srincont-41596]EUCTR2006-006935-38-SE. 12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006935-38 (first received 16 April 2007). [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont64612]HerschornS , SwiftS , GuanZ , CarlssonM , BrodskyM , GongJ . Efficacy and safety of fesoterodine for overactive bladder in a double-blind, head-to-head comparison trial with tolterodine ER and placebo (Abstract number 710). In: International Continence Society (ICS), 39th Annual Meeting; 2009 Sep 29-Oct 3; San Francisco, CA. 2009. [srincont-35326]HerschornS , SwiftS , GuanZ , CarlssonM , MorrowJD , BrodskyM , et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU International2010;105(1):58-66. [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont39540]NCT00444925. Clinical trial to evaluate the efficacy and safety of Fesoterodine in comparison to Tolterodine for overactive bladder (OAB) [12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder (OAB)]. clinicaltrials.gov/show/NCT00444925 (first received 08 March 2007). [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont49159]">Herschorn 2009a</a>; <a href="./references#CD003781-bbs2-0042" title="HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21072]HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21072]HillS , KhullarV , WyndaeleJJ , LheritierK , . Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. International Urogynecology Journal and Pelvic Floor2006;17(3):239-47. [srincont-22464]">Hill 2005</a>; <a href="./references#CD003781-bbs2-0043" title="HommaY , KawabeK . Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World Journal of Urology2004;22(4):251-6. [srincont-19412]HommaY , PaickJS , LeeJG , KawabeK , Japanese and Korean Tolterodine Study Group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU International2003;92(7):741-7. [srincont-16418]">Homma 2003</a>; <a href="./references#CD003781-bbs2-0044" title="HommaY , YamaguchiT , YamaguchiOA . A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2008;15(9):809-15. [srincont-27742]">Homma 2008</a>; <a href="./references#CD003781-bbs2-0045" title="HommaY , YamaguchiO , Imidafenacin Study Group. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2009;16(5):499-506. [NCT00212732] [ONO-8025-08] [srincont-31368]">Homma 2009</a>; <a href="./references#CD003781-bbs2-0047" title="JacquetinB , WyndaeleJJ . Tolterodine reduces the number of incontinence episodes in patients with an overactive bladder. European Journal of Obstetrics and Gynecology and Reproductive Biology2001;98(1):97-102. [srincont-12200]JacquetinB , WyndaeleJJ . Tolterodine reduces the number of incontinence episodes in patients with detrusor overactivity. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(1):S30. [srincont-5167]">Jacquetin 2001</a>; <a href="./references#CD003781-bbs2-0050" title="JünemannKP , HessdörferE , Unamba‐OparahI , BerseM , BrünjesR , MadersbacherH . Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. Urologia Internationalis2006;77(4):334-9. [srincont-22199]">Junemann 2006</a>; <a href="./references#CD003781-bbs2-0051" title="EUCTR2007-006451-39-SE. 12-week, randomized, double-blind, double-dummy, placebo controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-006451-39 (first received 20 February 2008). [A0221046] [EUCTR2007-006451-39-SE] [sr-incont64591]KaplanSA , SchneiderT , FooteJ , GuanZ . Superior efficacy of fesoterodine over tolterodine with rapid onset: a prospective, head-to-head, placebo-controlled trial (Abstract number 67). Neurourology and Urodynamics2010;29(6):905-7. [srincont-40130]KaplanSA , SchneiderT , FooteJE , GuanZ , CarlssonM , GongJ . Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU International2011;107(9):1432-40. [A0221046] [NCT00611026] [srincont-41334]">Kaplan 2011</a>; <a href="./references#CD003781-bbs2-0054" title="KhullarV , HillS , LavalKU , SchiotzHA , JonasU , VersiE . Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology2004;64(2):269-74; discussion 274-5. [srincont-19498]KhullarV , HillS , SolankiJ . Assessment of health-related quality of life in patients with overactive bladder taking tolterodine extended release versus placebo (Abstract number 318). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21075]">Khullar 2004</a>; <a href="./references#CD003781-bbs2-0065" title="ChappleCR , MadersbacherH , DreikornK , DorschnerW , MurtzG . Urodynamics and frequency/volume chart - do they correlate? Treatment analysis of propiverine in comparison to oxybutynin and placebo in urge incontinence (Abstract 224). In: International Continence Society (ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001. [sr-incont14474]HalaskaM , MadersbacherH , VoigtR , HofnerK , MartanA . Propiverine in patients with urgency and urge incontinence - a placebo controlled, multicentre study comparing its tolerability and efficacy with oxybutynin (Abstract number FDP36). International Urogynaecology Journal 2000;11(Suppl 1):S46. [srincont-11912]MadersbacherH , HalaskaM , VoigtR , AlloussiS , HofnerK . A urodynamically controlled multicenter study in patients with urge incontinence: tolerability and efficacy of propiverine hydrochloride in comparison to oxybutynin. In: International Continence Society (ICS), 27th Annual Meeting; 1997 Sep 23-26; Yokohama, Japan. 1997:153-4. [srincont-5854]MadersbacherH , HalaskaM , VoigtR , AlloussiS , HöfnerK . A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU International1999;84(6):646-51. [srincont-9166]">Madersbacher 1999</a>; <a href="./references#CD003781-bbs2-0068" title="DmochowskiR , MitchesonD , FrenklT , BennettN , MuddPN . Durable efficacy and safety of long-term once-daily vibegron, a novel oral B-3 adrenergic receptor agonist: A 52-week phase 2 study in patients with overactive bladder syndrome (Abstract number PD50-03). Journal of Urology2018;199(4):e970-1. [sr-incont78091]EUCTR2010-022121-15-IT. A phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2 part clinical study of the efficacy and safety of MK-4618 in patients with overactive bladder - MK4618-008 [A 52-week extension to: a phase iib randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder]. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-022121-15 (first received 12 April 2011). [EUCTR2010-022121-15-IT] [MK4618-008] [NCT01314872] [sr-incont78639]MitchesonD , FrenklT , SamantaS , Anne PintoC , GreenS , BennettN , et al. Vibegron, a novel once daily oral beta-3 agonist, significantly reduces average daily micturitions, urge incontinence episodes and urgency episodes in patients with overactive bladder (Abstract number: podium #34). Neurourology and Urodynamics2018;37(Suppl 1):S565. [EUCTR2010-022121-15-IT] [NCT01314872] [sr-incont78618]MitchesonD , PintoCA , FrenklT , ChenL , PrasadM , MuddPN . Once daily vibegron improves quality of life measures in patients with overactive bladder (Abstract number PUK17). Value in Health2018;21(Suppl 1):S267-8. [EUCTR2010-022121-15-IT] [NCT01314872;] [sr-incont78619]MitchesonHD , SamantaS , MuldowneyK , PintoCA , RochaBA , GreenS , et al. Vibegron (RVT-901/MK-4618/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial. European Urology2019;75(2):274-82. [NCT01314872] [sr-incont78620]NCT01314872. A study of the efficacy and safety of Vibegron (MK-4618) in participants with overactive bladder (OAB) (MK-4618-008) [A phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder a 52-week extension to: a phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder]. clinicaltrials.gov/show/NCT01314872 (first received 15 March 2011). [NCT01314872] [sr-incont63793]UKCRN10391. A phase IIB randomised, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of MK-4618 in patients with overactive bladder . public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=10391 (accessed 28 June 2012). [CCRN525] [UKCRN10391] [sr-incont45046]">Mitcheson 2019</a>; <a href="./references#CD003781-bbs2-0061" title="LacknerTE , WymanJF , McCarthyTC , MonigoldM , DaveyC . Efficacy of oral extended-release oxybutynin in cognitively impaired older nursing home residents with urge urinary incontinence: a randomized placebo-controlled trial. Journal of the American Medical Directors Association2011;12(9):639-47. [sr-incont42677]LacknerTE , WymanJF , McCarthyTC , MonigoldM , DaveyC . Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. Journal of the American Geriatrics Society2008;56(5):862-70. [sr-incont27117]">Lackner 2011</a>; <a href="./references#CD003781-bbs2-0070" title="GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NittiVW , DmochowskiR , SandPK , ForstHT , Haag-MolkentellerC , MassowU , et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. Journal of Urology2007;178(6):2488-94. [NCT00138723] [SP584] [srincont-26313]">Nitti 2007</a>; <a href="./references#CD003781-bbs2-0092" title="ChancellorM , FreedmanS , MitchesonHD , AntociJ , PrimusG , WeinA . Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clinical Drug Investigation2000;19(2):83-91. [srincont-16326]FreemanR , HillS , MillardR , SlackM , SutherstJ , Tolterodine Study Group. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstetrics and Gynecology2003;102(3):605-11. [srincont-16494]GarelyA , Tolterodine Study Group. Once-daily tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder. International Urology Journal2001;12(Suppl 1):S18. [srincont-12012]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of life of patients with overactive bladder receiving tolterodine. Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of patients with overactive bladder receiving tolterodine (Abstract number 82). Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , ReesePR . Health related quality of life of patients with overactive bladder receiving tolterodine once-daily. Neurourology and Urodynamics2000;19(4):519-21. [srincont-9987]KelleherCJ , ReesePR , PleilAM , OkanoGJ . Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. American Journal of Managed Care2002;8(Suppl 19):S608-15. [srincont-17998]KelleherCJ , Tolterodine Study Group. Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2000;11(Suppl 1):S94. [srincont-11915]KrederKJ . Antimuscarinic therapy: relationship between efficacy and side effects in responders and non-responders. Journal of Urology2001;165(Suppl 5):S165. [srincont-16327]KrederKJ . Clinical effectiveness of antimuscarinic therapy: the relationship between efficacy and tolerability. In: Proceedings of the International Continence Society Annual Meeting(ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001:140. [srincont-14376]MallettV . Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2001;12(Suppl 1):4. [srincont-12011]MillardRJ , TamaddonK , Tolterodine Study Group. Randomized controlled trial to compare tolterodine prolonged release capsules and tolterodine immediate release tablets versus placebo in patients with symptoms of detrusor overactivity (Abstract number 57). Australian and New Zealand Journal of Surgery2002;Suppl 72:A140. [sr-incont22190]PleilAM , ReesePR , KelleherCJ , OkanoGJ . Health-related quality of life of patients with overactive bladder receiving immediate-release tolterodine. HEPAC Health Economics in Prevention and Care2001;2(2):69-75. [sr-incont18060]RoehrbornCG , AbramsP , RovnerES , KaplanSA , HerschornS , GuanZ . Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU International2006;97(5):1003-6. [sr-incont21882]SwiftS . Efficacy and tolerability of once-daily tolterodine for women with overactive bladder. In: International Continence Society Annual Meeting (ICS), 31st annual meeting; 2001 Sept 18-21; Seoul, Korea. 2001:No. 329. [srincont-14481]SwiftS . Once-daily tolterodine is effective and well tolerated in women with overactive bladder (Abstract 57). In: 2nd International Consultation on Incontinence; 2001 July 1-3; Paris, France. 2001. [srincont-16319]SwiftSE . Once-daily (OD) tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder (OAB). International Urogynecology Journal2000;11(Suppl 1):S15. [sr-incont11906]SwiftSE . Once-daily administration of extended-release tolterodine is effective and well-tolerated in patients with overactive bladder. In: XVI FIGO World Congress of Obstetrics and Gynecology; 2000 Sept 3-8; Washington DC. Vol. Book 1. 2000:40. [sr-incont12085]SwiftSE . Overactive bladder in females: treatment with once-daily tolterodine. International Urogynecology Journal2001;12(Suppl 3):S71. [sr-incont16328]Van KerrebroeckP , KrederK , JonasU , ZinnerN . Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology2001;57(3):414-21. [sr-incont11953]Van KerrebroeckPEV . Long-term (12 months) efficacy and tolerability of tolterodine once-daily in the treatment of overactive bladder. Neurourology and Urodynamics2001;20(4):401-2. [sr-incont15714]Van KerrebroeckPEVA , Tolterodine Study Group. Long-term tolerability and efficacy of once-daily (OD) tolterodine in the treatment of overactive bladder (OB). International Urogynecology Journal2001;12(Suppl 3):S49. [sr-incont16329]Van KerrebroeckPEVA , Tolterodine Study Group. Significant decreases in perception of urgency and urge incontinence episodes with once-daily tolterodine treatment in patients with overactive bladder (Abstract number 89). Neurourology and Urodynamics2000;19(4):493-4. [sr-incont9980]WeinAJ , KhullarV , WangJT , GuanZ . Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. BJU International2007;99(2):360-3. [sr-incont23180]vanKerrebroeckPE , KelleherCJ , CoyneKS , KoppZ , BrodskyM , WangJT . Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. Health and Quality of Life Outcomes2009;7(13):13. [10.1186/1477-7525-7-13] [sr-incont31438]vanKerrebroeckPE , WangJ , GuanZ . Effects of tolterodine extended release in patients with overactive bladder: perceived treatment benefits improve with efficacy (Abstract number 511). European Urology Supplements2004;3(2):130. [sr-incont31090]">Van Kerrebroeck 2001</a>; <a href="./references#CD003781-bbs2-0094" title="EUCTR2007-007087-17-SE. A 24-week, multicentre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-007087-17 (first received 13 June 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont64588]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00798434. A study to compare the effectiveness and safety of fesoterodine and placebo in an elderly population of patients who go to the toilet very frequently due to overactive bladder (SOFIA) [A 24-week, multi-centre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00798434 (first received 26 November 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont49847]SchneiderT , BergqvistA , WangJ , WaggA , Ebel-BitounC . Treatment with fesoterodine versus tolterodine for reducing symptom bother in elderly patients with overactive bladder including urgency urinary incontinence. European Urology, Supplements2012;11(1):e687-a. [sr-incont65389]WaggA , CarlssonM , ElsobkyM , FernetM . Effect of flexible dose fesoterodine on cognitive function in &gt;65 year old patients with OAB: data from two RCT (Abstract number 438). Neurourology and Urodynamics2019;38:S297-8. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78651]WaggA , DarekarA , ArumiD , KhullarV , OelkeM . Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people &gt;65 years of age: a post hoc analysis of data from the SOFIA study. Neurourology and Urodynamics2015;34(5):438-43. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont68100]WaggA , ElsobkyM , CarlssonM , FernetM . Response and cognitive safety of fesoterodine in patients &gt;65y old with OAB. Is there a relationship between cognition and treatment response? (Abstract number 183). Neurourology and Urodynamics2019;38:S118-20. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78632]WaggA , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. Journal of the American Geriatrics Society2013;61(2):185-93. [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TrialID.SOFIA.] [sr-incont48008]WaggAS , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Efficacy and tolerability of fesoterodine in older subjects with overactive bladder: results of SOFIA (Abstract number C33). Journal of the American Geriatrics Society2011;59:S124. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont65234]">Wagg 2013a</a>; <a href="./references#CD003781-bbs2-0099" title="YongucT , SefikE , InciI , KusbeciOY , CelikS , AydinME , et al. Randomized, controlled trial of fesoterodine fumarate for overactive bladder in Parkinson's disease. World Journal of Urology2019;38(8):2013-9. [sr-incont78635]">Yonguc 2019</a>; <a href="./references#CD003781-bbs2-0101" title="NCT01018264, ZesiewiczT . Solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease (URGE-PD) [URGE-PD: a multi-site, double-blind, randomized, placebo controlled trial of solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease]. clinicaltrials.gov/show/NCT01018264 (first received 23 November 2009). [NCT01018264] [sr-incont63790]ZesiewiczTA , EvattM , JahanI , VaughanC , SingerC , OrdoricaR , et al. URGE-PD: a multi-site, double-blind, randomized, placebo controlled trial of solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease (Abstract number 745). Movement Disorders2014;29(Suppl 1):S276-7. [NCT01018264] [sr-incont66602]ZesiewiczTA , EvattM , VaughanCP , JahanI , SingerC , OrdoricaR , et al. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease. Parkinsonism and Related Disorders2015;21(5):514-20. [NCT01018264] [sr-incont66860]">Zesiewicz 2015</a>). </p> </section> <section id="CD003781-sec-0066"> <h5 class="title">Blinding of outcome assessment (detection bias)</h5> <p>We considered blinding of outcome assessment to be adequate in nine studies, which we judged to be at low risk of bias (<a href="./references#CD003781-bbs2-0002" title="AbramsP , FreemanR , AnderströmC , MattiassonA . Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. British Journal of Urology1998;81(6):801-10. [srincont-7871]AbramsP , FreemanRN , AnderstromC , MattiassonA . Efficacy and tolerability of tolterodine vs. oxybutynin and placebo in patients with detrusor instability (Abstract). Journal of Urology1997;157(Suppl 4):103. [srincont-16321]">Abrams 1998</a>; <a href="./references#CD003781-bbs2-0004" title="AbramsP , KelleherC , StaskinD , KayR , MartanA , MincikI , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World Journal of Urology2017;35(5):827-38. [NCT01340027] [sr-incont77897]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Cardiovascular safety of combination treatment with mirabegron and solifenacin in patients with overactive bladder in a randomised, double-blind, dose-ranging, Phase II study (Symphony) (Abstract). European Urology, Supplements2014;13(1):e574-e574a. [NCT01340027] [sr-incont67160]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB) - efficacy and safety results from a randomised phase II study (Symphony) (Abstract number 295). Neurourology and Urodynamics2013;32(6):930-1. [NCT01340027] [TrialID.SYMPHONY.] [sr-incont49188]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB): safety results from a phase 2 study (Abstract number MP-16.08). Urology2013;82(3 Suppl 1):S139. [NCT01340027] [sr-incont66675]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: Exploratory responder analyses of efficacy and evaluation of patient reported outcomes from a randomised, double-blind, dose-ranging, phase 2 study (Symphony) (Abstract number MP-24.11). Urology2014;84(4 Suppl 1):S145-6. [NCT01340027] [sr-incont67194]AbramsP , KelleherC , StaskinD , RechbergerT , KayR , MartinaR , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (SYMPHONY). European Urology2015;67(3):577-88. [NCT01340027] [sr-incont66674]NCT01340027, Bristol Urological Institute . A study to evaluate the efficacy, safety and tolerability of mirabegron and solifenacin succinate alone and in combination for the treatment of overactive bladder (symphony) [A randomized, double-blind, factorial, parallel-group, active and placebo-controlled, multicenter dose-ranging study to evaluate the efficacy, safety and tolerability of six dose combinations of solifenacin succinate and mirabegron compared to mirabegron and solifenacin succinate monotherapies in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01340027 (first received 21 April 2011). [178-CL-100] [2010-020601-32] [NCT01340027] [TrialID.SYMPHONY] [sr-incont44510]NittiV , AbramsP , StaskinD , AuerbachS , MartinaR , VanMR . Urinary retention in patients with overactive bladder treated with mirabegron alone and in combination with solifenacin: the results of two randomized, double-blind, phase II studies (Abstract number MP76-13). Journal of Urology2014;191(4 Suppl 1):e886-7. [NCT00410514] [NCT01340027] [TrialID.SYMPHONY] [sr-incont67453]">Abrams 2013</a>; <a href="./references#CD003781-bbs2-0008" title="BurgioKL , LocherJL , GoodePS , HardinJM , McDowellBJ , CandibD . Behavior vs drug therapy for urge incontinence in older women (Abstract number 26). In: American Urogynecology Society, 15th Annual Scientific Meeting; 1994 Sept 21-24; Toronto, Ontario. 1994:48. [sr-incont14585]BurgioKL , LocherJL , GoodePS , HardinM , McDowellBJ , Dombrowski M et al. Behavioral vs drug treatment for urge urinary incontinence in older women. A randomized controlled trial. JAMA1998;280(23):1995-2000. [srincont-5719]BurgioKL , LocherJL , GoodePS . Combined behavioral and drug therapy for urge incontinence in older women. Journal of the American Geriatrics Society2000;48(4):370-4. [srincont-9006]BurgioKL , LocherJL , RothDL , GoodePS . Psychological improvements associated with behavioral and drug treatment of urge incontinence in older women. Journal of Gerontology. Series B, Psychological Sciences and Social Sciences2001;56(1):P46-51. [srincont-11923]">Burgio 1998</a>; <a href="./references#CD003781-bbs2-0017" title="ChappleC , DuBeauC , EbingerU , RekedaL , ViegasA . Darifenacin treatment of patients &gt;or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Current Medical Research and Opinion2007;23(10):2347-58. [srincont-23921]">Chapple 2007b</a>; <a href="./references#CD003781-bbs2-0021" title="ChuaME , SeeMC , EsmeňaEB , BalingitJC , MoralesML . Efficacy and safety of gabapentin in comparison to solifenacin succinate in adult overactive bladder treatment. Lower Urinary Tract Symptoms2018;10(2):135-42. [NCT01486706] [sr-incont74529]NCT01486706, ChuaME . Efficacy and safety of gabapentin in treating overactive bladder (OAB). clinicaltrials.gov/show/NCT01486706 (first received 6 December 2011). [NCT01486706] [SLMC10-010] [sr-incont49864]">Chua 2018</a>; <a href="./references#CD003781-bbs2-0032" title="GellerE , DumondJ , BowlingJM , KhandelwalC , WuJ , Busby-WhiteheadJ , et al. Effect of an anticholinergic on cognitive function in postmenopausal women: a randomized trial (Abstract number: oral poster 52). Female Pelvic Medicine and Reconstructive Surgery2016;22(5):S61. [sr-incont78607]GellerEJ , DumondJB , BowlingJM , KhandelwalCM , WuJM , Busby-WhiteheadJ , et al. Effect of trospium chloride on cognitive function in women aged 50 and older: a randomized trial. Female Pelvic Medicine &amp; Reconstructive Surgery2017;23(2):118-23. [13-1352] [NCT01922115] [sr-incont74341]NCT01922115. The effect of anticholinergics on cognitive function in the elderly (ACE) [The effect of anticholinergics on cognitive function in the elderly: a randomized controlled trial]. clinicaltrials.gov/show/NCT01922115 (first received 14 August 2013). [13-1352] [NCT01922115] [TrialID.ACE] [sr-incont49282]">Geller 2013</a>; <a href="./references#CD003781-bbs2-0094" title="EUCTR2007-007087-17-SE. A 24-week, multicentre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-007087-17 (first received 13 June 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont64588]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00798434. A study to compare the effectiveness and safety of fesoterodine and placebo in an elderly population of patients who go to the toilet very frequently due to overactive bladder (SOFIA) [A 24-week, multi-centre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00798434 (first received 26 November 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont49847]SchneiderT , BergqvistA , WangJ , WaggA , Ebel-BitounC . Treatment with fesoterodine versus tolterodine for reducing symptom bother in elderly patients with overactive bladder including urgency urinary incontinence. European Urology, Supplements2012;11(1):e687-a. [sr-incont65389]WaggA , CarlssonM , ElsobkyM , FernetM . Effect of flexible dose fesoterodine on cognitive function in &gt;65 year old patients with OAB: data from two RCT (Abstract number 438). Neurourology and Urodynamics2019;38:S297-8. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78651]WaggA , DarekarA , ArumiD , KhullarV , OelkeM . Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people &gt;65 years of age: a post hoc analysis of data from the SOFIA study. Neurourology and Urodynamics2015;34(5):438-43. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont68100]WaggA , ElsobkyM , CarlssonM , FernetM . Response and cognitive safety of fesoterodine in patients &gt;65y old with OAB. Is there a relationship between cognition and treatment response? (Abstract number 183). Neurourology and Urodynamics2019;38:S118-20. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78632]WaggA , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. Journal of the American Geriatrics Society2013;61(2):185-93. [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TrialID.SOFIA.] [sr-incont48008]WaggAS , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Efficacy and tolerability of fesoterodine in older subjects with overactive bladder: results of SOFIA (Abstract number C33). Journal of the American Geriatrics Society2011;59:S124. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont65234]">Wagg 2013a</a>; <a href="./references#CD003781-bbs2-0101" title="NCT01018264, ZesiewiczT . Solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease (URGE-PD) [URGE-PD: a multi-site, double-blind, randomized, placebo controlled trial of solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease]. clinicaltrials.gov/show/NCT01018264 (first received 23 November 2009). [NCT01018264] [sr-incont63790]ZesiewiczTA , EvattM , JahanI , VaughanC , SingerC , OrdoricaR , et al. URGE-PD: a multi-site, double-blind, randomized, placebo controlled trial of solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease (Abstract number 745). Movement Disorders2014;29(Suppl 1):S276-7. [NCT01018264] [sr-incont66602]ZesiewiczTA , EvattM , VaughanCP , JahanI , SingerC , OrdoricaR , et al. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease. Parkinsonism and Related Disorders2015;21(5):514-20. [NCT01018264] [sr-incont66860]">Zesiewicz 2015</a>). The remaining studies did not provide enough information to enable us to make an assessment and so we judged these to be at unclear risk of bias for this domain. </p> </section> </section> <section id="CD003781-sec-0067"> <h4 class="title">Incomplete outcome data</h4> <p>We judged 12 studies to have inadequately reported outcome data and thus were at high risk of bias (<a href="./references#CD003781-bbs2-0010" title="CardozoL , KuzminI , LisecML , MillardR , vanVierssen TripOB , RidderAM , et al. YM905: Results of a randomised, double-blind placebo-controlled trial in patients with symptomatic overactive bladder (Abstract number 104). European Urology Supplements2003;2(1):28. [sr-incont27407]CardozoL , KuzminI , LisecML , MillardRJ , vanVierssen TripOB , RidderAM , et al. A double-blind, randomised, placebo-controlled trial with YM905 in symptomatic overactive bladder (Abstract number P74). Journal of the American Geriatrics Society2003;51 (Suppl 4):S68-9. [sr-incont31100]CardozoL , LisecM , MillardR , vanVierssen TripO , KuzminI , DrogendijkTE , et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. Journal of Urology2004;172(5 (Pt 1 of 2)):1919-24. [srincont-19090]CardozoL . A randomised double-blind, placebo-controlled trial of the once-daily muscarinic receptor antagonist solifenacin succinate for symptoms of overactive bladder (Abstract number 211). International Urogynecology Journal2003;14 (Suppl 1):S64. [sr-incont31104]CardozoL . Solifenacin succinate improves symptoms of an overactive bladder (Abstract number TP77). International Journal of Gynecology and Obstetrics2003;83(Suppl 3):94. [sr-incont31096]KelleherCJ , CardozoL , ChappleCR , HaabF , RidderAM . Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU International2005;95(1):81-5. [srincont-20241]">Cardozo 2004a</a>; <a href="./references#CD003781-bbs2-0011" title="CardozoL , AdamikZ , GuimaraesM , KrhutJ , Labat J-J, PetrovS , et al. Patients with overactive bladder show progressive improvement in urgency and bladder condition during treatment with solifenacin in a randomised, double-blind, placebo-controlled study (SUNRISE) (Abstract number 115). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S67-8. [srincont-26595]CardozoL , AmarencoG , PushkarD , MikulasJ , DrogendijkT , WrightM , et al. Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE). BJU International2013;111(5):804-10. [NCT00801944] [TrialID.SUNRISE.] [sr-incont47554]CardozoL , DewildeT , FeyereislJ , WadieB , AmarencoG , LiapisA , et al. Solifenacin significantly reduces both urgency severity and bother: results from the flexible dose, placebo controlled, multinational SUNRISE study (Abstract number 281). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26641]CardozoL , DrogendijkT , BolodeokuJ . The efficacy of solifenacin 5/10 mg on 'urgency' endpoints in different OAB patient populations: subanalysis of results from the randomised, double-blind SUNRISE study (Abstract number 192). In: International Continence Society (ICS); 38th Annual Meeting; 2008 Oct 20-24; Cairo, Egypt. 2008. [srincont-31885]CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CardozoL , HessdörferE , MilaniR , ArañóP , DewildeL , SlackM , et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU International2008;102(9):1120-7. [NCT00801944] [TrialID.SUNRISE] [srincont-29249]">Cardozo 2008a</a>; <a href="./references#CD003781-bbs2-0023" title="ChancellorMB , OefeleinMG , VasavadaS . Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release. Neurourology and Urodynamics2010;29(4):551-4. [sr-incont39591]DmochowskiR , StaskinD , SandP , ZinnerN . Trospium chloride 60 mg once daily improves quality of life in subjects with overactive bladder syndrome (Abstract number 277). In: International Continence Society (ICS); 37th Annual Meeting; 2008 Aug 20-24; Rotterdam, the Netherlands. 2007. [srincont-26679]DmochowskiRR , RosenbergMT , ZinnerNR , StaskinDR , SandPK . Extended-release trospium chloride improves quality of life in overactive bladder. Value in Health2010;13(2):251-7. [srincont-40049]DmochowskiRR , SandPK , ZinnerNR , StaskinDR . Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology2008;71(3):449-54. [srincont-27107]DmochowskiRR , ZinnerNR , SandPK . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: Results from a multicenter, phase III, placebo-controlled study (Abstract). Neurourology and Urodynamics2007;26(Suppl 7):1105-6. [srincont-26692]GinsbergDA , OefeleinMG , EllsworthPI . Once-daily administration of trospium chloride extended release provides 24-hr coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials. Neurourology and Urodynamics2011;30(4):563-7. [sr-incont41531]RovnerE , DmochowskiR , WatanabeJ . Once daily (QD) trospium chloride 60 mg extended release (XR) is safe and effective in patients (PTS) with the overactive bladder (OAB) syndrome who use multiple concomitant medications (MEDS) (Abstract number: Poster #68). Neurourology and Urodynamics2009;28(2):146-7. [sr-incont31062]SandP , DmochowskiR , ZinnerN , StaskinD . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: results from a multicenter, phase III, placebo-controlled study (Abstract number 269). In: International Continence Society (ICS), 37th Annual Meeting; 2007 Aug 20-24; Rotterdam, the Netherlands. 2007. [srincont-26676]SandPK , DmochowskiRR , ZinnerNR , StaskinDR , AppellRA . Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome. International Urogynecology Journal and Pelvic Floor Dysfunction2009;20(12):1431-8. [sr-incont39648]SandPK , Johnson IiTM , RovnerES , EllsworthPI , OefeleinMG , StaskinDR . Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged &gt; 75 years) with overactive bladder syndrome. BJU International2011;107(4):612-20. [sr-incont41422]StaskinDR , RosenbergMT , SandPK , ZinnerNR , DmochowskiRR . Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials. International Journal of Clinical Practice2009;63(12):1715-23. [sr-incont35458]">Dmochowski 2008</a>; <a href="./references#CD003781-bbs2-0026" title="DrutzH , AppellRA . Clinical efficacy and safety of Tolterodine vs Oxybutynin and placebo in patients with unstable bladder. Acta Obstetrica et Gynecologica Scandinavica1997;Suppl 167(5):24. [srincont-6671]DrutzHP , AppellRA , GleasonD , KlimbergI , RadomskiS . Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. International Urogynecology Journal and Pelvic Floor Dysfunction1999;10(5):283-9. [srincont-8804]DrutzHP , AppellRA . Enhanced tolerability of tolterodine compared to oxybutynin in a controlled clinical study. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(1):S14. [srincont-5166]">Drutz 1999</a>; <a href="./references#CD003781-bbs2-0042" title="HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21072]HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21072]HillS , KhullarV , WyndaeleJJ , LheritierK , . Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. International Urogynecology Journal and Pelvic Floor2006;17(3):239-47. [srincont-22464]">Hill 2005</a>; <a href="./references#CD003781-bbs2-0044" title="HommaY , YamaguchiT , YamaguchiOA . A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2008;15(9):809-15. [srincont-27742]">Homma 2008</a>; <a href="./references#CD003781-bbs2-0052" title="CardozoL , KaplanS , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: results from the after study (Abstract number 740) [Erratum appears in: European Urology 2014;65(5):e78]. European Urology Supplements2013;12(1):e740-1. [NCT01302054] [sr-incont63732]CardozoL , KaplanS , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. Erratum: A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: results from the AFTER study [Erratum available in: European Urology Supplement 2013;2012:e740-1]. European Urology2014;65(5):e78 . [A0221094] [NCT01302054] [TrialID.AFTER.] [sr-incont61642]GrenaboL , HerschornS , KaplanSA , CardozoL , ScholfieldD , ArumiD , et al. Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptoms. Current Medical Research and Opinion2017;33(10):1731-6. [NCT01302054] [TrialID.AFTER.] [sr-incont76695]KaplanSA , CardozoL , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER. International Journal of Clinical Practice2014;68(9):1065-73. [A0221094] [NCT01302054] [TrialID.AFTER.] [srincont-63977]KaplanSA , HerschornS , CarlssonM , NtaniosF . Urgency urinary incontinence response rates in subjects with overactive bladder treated with fesoterodine 8 mg after suboptimal response to tolterodine extended release 4 mg: a randomized, double-blind, placebo-controlled trial (Abstract number 546). In: International Continence Society (ICS); 43rd Annual Meeting; 2013 Aug 26-30; Barcelona, Spain. 2013. [NCT01302054] [TrialID.AFTER.] [sr-incont49730]NCT01302054. A clinical study in patients with overactive bladder with leakage of urine, to find out if the medicine, Fesoterodine, works in those patients who did not have enough response to the medicine, tolterodine. [A 14 week randomized parallel group placebo-controlled double-blind multicentre study of fesoterodine 8 mg in overactive bladder patients with sub-optimal response to tolterodine 4 mg extended release (ER)]. clinicaltrials.gov/show/NCT01302054 (first received 23 February 2011). [A0221094] [NCT01302054] [TrialID.AFTER.] [sr-incont49845]">Kaplan 2014</a>; <a href="./references#CD003781-bbs2-0063" title="LeeKS , ChooMS , KimDY , KimJC , KimHJ , MinKS , et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. Journal of Urology2005;174(4 Pt 1):1334-8. [sr-incont21016]LeeKS , ChooMS , PaickJS , LeeJG , SeoJT , LeeJZ , et al. Propiverine hydrochloride reduced frequency and perception of urgency in treatment of overactive bladder: a 12 week prospective, randomized, double blind, placebo controlled study (Abstract number 279). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26640]LeeKS , LeeHW , ChooMS , PaickJS , LeeJG , SeoJT , et al. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'. BJU International2010;105(11):1565-70. [2005-01-08] [NCT00903045] [PROUD] [sr-incont39958]NCT00903045. Urinary urgency outcomes following propiverine treatment for an overactive bladder [Urinary urgency outcomes following propiverine treatment for an overactive bladder: propiverine study on overactive bladder including urgency data (PROUD)]. clinicaltrials.gov/show/NCT009030452005;(first received 15 May 2009). [2005-01-08] [NCT00903045] [TrialID.PROUD] [sr-incont49860]">Lee 2006</a>; <a href="./references#CD003781-bbs2-0074" title="RentzhogSL , StantonL , CardozoL , NelsonE , FallM , AbramsP . Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. British Journal of Urology1998;81(1):42-8. [srincont-5461]">Rentzhog 1998</a>; <a href="./references#CD003781-bbs2-0086" title="StohrerM , MadersbacherH , RichterR , WehnertJ , DreikornK . Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia - a double-blind, placebo-controlled clinical trial. Spinal Cord1999;37(3):196-200. [sr-incont8146]">Stohrer 1999</a>; <a href="./references#CD003781-bbs2-0091" title="MesselinkEJ , SolerJM , MadersbacherH , ThuroffJW , AmarencoG , Van KerrebroeckEV . Urodynamic aspects of the efficacy of tolterodine, a new anti muscarine drug in the treatment of detrusor hyperreflexia. In: International Continence Society (ICS), 25th Annual Meeting; 1995 Oct 17-20; Sydeney, Australia. 1995:95-6. [srincont-10883]Van KerrebroeckPE , AmarencoG , ThüroffJW , MadersbacherHG , LockMT , MesselinkEJ , et al. Dose-ranging study ot tolterodine in patients with detrusor hyperreflexia. Neurourology and Urodynamics1998;17(5):499-512. [srincont-7852]">Van Kerrebroeck 1998</a>; <a href="./references#CD003781-bbs2-0098" title="YamaguchiO , UchidaE , HigoN , MinamiH , KobayashiS , SatoH , et al. Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: a randomized double-blind trial. International Journal of Urology2014;21(6):586-93. [JapicCTI-101309] [sr-incont62099]">Yamaguchi 2014</a>). In contrast, we judged 52 studies to be at low risk of bias as they adequately reported attrition (<a href="./references#CD003781-bbs2-0002" title="AbramsP , FreemanR , AnderströmC , MattiassonA . Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. British Journal of Urology1998;81(6):801-10. [srincont-7871]AbramsP , FreemanRN , AnderstromC , MattiassonA . Efficacy and tolerability of tolterodine vs. oxybutynin and placebo in patients with detrusor instability (Abstract). Journal of Urology1997;157(Suppl 4):103. [srincont-16321]">Abrams 1998</a>; <a href="./references#CD003781-bbs2-0003" title="AbramsP , KaplanS , MillardR . Tolterodine treatment is safe in men with bladder outlet obstruction (BOO) and symptomatic detrusor overactivity (DO) (Abstract). Neurourology and Urodynamics2001;20(4):547-8. [srincont-14372]">Abrams 2001</a>; <a href="./references#CD003781-bbs2-0004" title="AbramsP , KelleherC , StaskinD , KayR , MartanA , MincikI , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World Journal of Urology2017;35(5):827-38. [NCT01340027] [sr-incont77897]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Cardiovascular safety of combination treatment with mirabegron and solifenacin in patients with overactive bladder in a randomised, double-blind, dose-ranging, Phase II study (Symphony) (Abstract). European Urology, Supplements2014;13(1):e574-e574a. [NCT01340027] [sr-incont67160]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB) - efficacy and safety results from a randomised phase II study (Symphony) (Abstract number 295). Neurourology and Urodynamics2013;32(6):930-1. [NCT01340027] [TrialID.SYMPHONY.] [sr-incont49188]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB): safety results from a phase 2 study (Abstract number MP-16.08). Urology2013;82(3 Suppl 1):S139. [NCT01340027] [sr-incont66675]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: Exploratory responder analyses of efficacy and evaluation of patient reported outcomes from a randomised, double-blind, dose-ranging, phase 2 study (Symphony) (Abstract number MP-24.11). Urology2014;84(4 Suppl 1):S145-6. [NCT01340027] [sr-incont67194]AbramsP , KelleherC , StaskinD , RechbergerT , KayR , MartinaR , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (SYMPHONY). European Urology2015;67(3):577-88. [NCT01340027] [sr-incont66674]NCT01340027, Bristol Urological Institute . A study to evaluate the efficacy, safety and tolerability of mirabegron and solifenacin succinate alone and in combination for the treatment of overactive bladder (symphony) [A randomized, double-blind, factorial, parallel-group, active and placebo-controlled, multicenter dose-ranging study to evaluate the efficacy, safety and tolerability of six dose combinations of solifenacin succinate and mirabegron compared to mirabegron and solifenacin succinate monotherapies in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01340027 (first received 21 April 2011). [178-CL-100] [2010-020601-32] [NCT01340027] [TrialID.SYMPHONY] [sr-incont44510]NittiV , AbramsP , StaskinD , AuerbachS , MartinaR , VanMR . Urinary retention in patients with overactive bladder treated with mirabegron alone and in combination with solifenacin: the results of two randomized, double-blind, phase II studies (Abstract number MP76-13). Journal of Urology2014;191(4 Suppl 1):e886-7. [NCT00410514] [NCT01340027] [TrialID.SYMPHONY] [sr-incont67453]">Abrams 2013</a>; <a href="./references#CD003781-bbs2-0005" title="AlloussiS , Laval KU , Ballering-BruhlB , Grobe-FreeseM , BulittaM , SchaferM . Trospium chloride (Spasmo-lyt) in patients with motor urge syndrome (detrusor instability): a double-blind, randomised, multicentre, placebo-controlled study. Journal of Clinical Research1998;1:439-51. [srincont-12005]AlloussiS , Laval K-U, EckertR , Ballering-BruhlB , Grosse-FreeseM , BulittaM , et al. Trospium chloride (Spasmo-lyt(R)) in patients with motor urge syndrome (detrusor instability): a double-blind, randomised, multicentre, placebo-controlled study. Journal of Drug Assessment1999;2(1):27-39. [sr-incont18226]AlloussiS , Laval K-U, MertinsB . Efficacy and tolerability of trospium chloride (spasmo-lyt) versus placebo in patients with motor urge-syndrome. In: International Continence Society (ICS), 28th Annual Meeting; 1998 Sept 14-17; Jerusalem, Israel. 1998:109-10. [sr-incont5684]">Alloussi 1998</a>; <a href="./references#CD003781-bbs2-0007" title="BrayR , CartwrightR , CardozoL , HillS , GuanZ , KhullarV . Tolterodine ER reduced increased bladder wall thickness in women with overactive bladder. A randomized, placebo-controlled, double-blind, parallel group study. Neurourology and  Urodynamics2018;37(1):237-43. [NCT00137397] [sr-incont74473]NCT00137397. A study to measure the effect of tolterodine extended release on the thickness of the bladder wall in patients with overactive bladder [A multi-centre, randomised, placebo controlled, double blind, parallel group study in female patients to evaluate whether tolterodine ER can reverse the increased bladder wall thickness in patients with overactive bladder]. clinicaltrials.gov/show/NCT00137397 (first received 29 August 2005). [NCT00137397] [sr-incont63809]">Bray 2018</a>; <a href="./references#CD003781-bbs2-0008" title="BurgioKL , LocherJL , GoodePS , HardinJM , McDowellBJ , CandibD . Behavior vs drug therapy for urge incontinence in older women (Abstract number 26). In: American Urogynecology Society, 15th Annual Scientific Meeting; 1994 Sept 21-24; Toronto, Ontario. 1994:48. [sr-incont14585]BurgioKL , LocherJL , GoodePS , HardinM , McDowellBJ , Dombrowski M et al. Behavioral vs drug treatment for urge urinary incontinence in older women. A randomized controlled trial. JAMA1998;280(23):1995-2000. [srincont-5719]BurgioKL , LocherJL , GoodePS . Combined behavioral and drug therapy for urge incontinence in older women. Journal of the American Geriatrics Society2000;48(4):370-4. [srincont-9006]BurgioKL , LocherJL , RothDL , GoodePS . Psychological improvements associated with behavioral and drug treatment of urge incontinence in older women. Journal of Gerontology. Series B, Psychological Sciences and Social Sciences2001;56(1):P46-51. [srincont-11923]">Burgio 1998</a>; <a href="./references#CD003781-bbs2-0009" title="CardozoL , ChappleCR , Toozs-HobsonP , Grosse-FreeseM , BulittaM , LehmacherW , et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomised, double-blind, multicentre clinical trial. British Journal of Urology International2000;85(6):659-64. [srincont-11732]">Cardozo 2000</a>; <a href="./references#CD003781-bbs2-0013" title="ChappleC . Fesoterodine a new effective and well-tolerated antimuscarinic for the treatment of urgency-frequency syndrome: results of a phase 2 controlled study (Abstract 142). Neurourology and Urodynamics2004;23(5/6):598-9. [srincont-19023]Drug company. A Phase 2, parallel group, randomized, double-blind, placebo controlled dose-ranging trial to determine the optimal dose and the tolerability of sustained release SPM 8272 (fesoterodine) in subjects with non-neurogenic bladder overactivity. Protocol numbers: A0221027 (SP582). ClinicalStudyResults.org (accessed 3 March 2011)2002. [Protocol numbers: A0221027 (SP582)] [srincont-41110]">Chapple 2004a</a>; <a href="./references#CD003781-bbs2-0014" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. ChappleCR , AranoP , BoschJH , De RidderD , KramerG , RidderAM . YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo- and tolterodine-controlled, phase-II, dose-finding study (Abstract 75). Neurourology and Urodynamics2002;21(4):381-2. [srincont-14551]ChappleCR , ArañoP , BoschJL , De RidderD , KramerAE , RidderAM . Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU International2004;93(1):71-7. [srincont-17334]KelleherCJ , CardozoL , ChappleCR , HaabF , RidderAM . Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU International2005;95(1):81-5. [srincont-20241]SmithN , GrimesI , RidgeS , TempelD , UchidaT , YamanouchiUS . YM905 is effective and safe as treatment of overactive bladder in women and men: results from phase II study (Abstract). In: International Continence Society (ICS), 32nd Annual Meeting; 2002 Aug 28-30; Heidelberg, Germany. 2002:138-9. [sr-incont14508]">Chapple 2004b</a>; <a href="./references#CD003781-bbs2-0015" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. ChappleC , RechbergerT , Al-ShukriS , MeffanP , EveraertK , RidderA . Results of a randomized phase 3 study comparing solifenacin succinate with tolterodine and placebo in patients with symptomatic overactive bladder (Abstract). Neurourology and Urodynamics2003;22(5):534-5. [sr-incont16991]ChappleCR , RechbergerT , Al ShukriS , MeffanP , EveraertK , HuangM , et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU International2004;93(3):303-10. [srincont-17270]">Chapple 2004c</a>; <a href="./references#CD003781-bbs2-0016" title="ChappleC , Van KerrebroeckP , TubaroA , Haag-MolkentellerC , ForstHT , MassowU , et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder [Erratum appears in: European Urology 2008,53(6):1319]. European Urology2007;52(4):1204-12. [NCT00220363] [SP583] [srincont-23875]ChappleC , Van KerrebroeckP , TubaroA , MillardR . Fesoterodine in non-neurogenic voiding dysfunction - results on efficacy and safety in a phase 3 trial (Abstract number 379). In: 21st Annual European Association of Urology (EAU) Congress; 2006 Apr 5-8; Paris, France. 2006. [srincont-41109]ChappleC , Van KerrebroeckP , TubaroA , WangJT , HvidstenK , BrodskyM . Efficacy of fesoterodine in patients with overactive bladder (OAB): improvements in OAB symptoms and health-related quality of life (HRQL) (Poster abstract number 1188). Journal of Urology2007;177(4 Suppl S):392. [srincont-31882]ChappleCR , vanKerrebroeckPE , JünemannKP , WangJT , BrodskyM . Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU International2008;102(9):1128-32. [srincont-29255]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. KelleherCJ , TubaroA , WangJT , KoppZ . Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU International2008;102(1):56-61. [srincont-27613]SandPK , MorrowJD , BavendamT , CreangaDL , NittiVW . Efficacy and tolerability of fesoterodine in women with overactive bladder. International Urogynecology Journal2009;20(7):827-35. [srincont-31351]">Chapple 2007a</a>; <a href="./references#CD003781-bbs2-0017" title="ChappleC , DuBeauC , EbingerU , RekedaL , ViegasA . Darifenacin treatment of patients &gt;or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Current Medical Research and Opinion2007;23(10):2347-58. [srincont-23921]">Chapple 2007b</a>; <a href="./references#CD003781-bbs2-0018" title="ChappleCR , DvorakV , RadziszewskiP , vanKerrebroeckP , WyndaeleJJ , BosmanB , et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder. International Urogynecology Journal2013;24(9):1447-58. [178-CL-044] [NCT00337090] [TrialID.DRAGON.] [sr-incont48549]NCT00337090 . A study of YM178 in patients with symptomatic overactive bladder (DRAGON) [A randomized, double-blind, parallel group, placebo and active controlled, multicenter dose ranging study with the beta-3 agonist YM178 in patients with symptomatic overactive bladder]. clinicaltrials.gov/show/NCT00337090 (first received 15 June 2006). [EudraCT2005-002256-17] [JapicCTI-R130350] [NCT00337090] [sr-incont63803]">Chapple 2013</a>; <a href="./references#CD003781-bbs2-0019" title="ChappleC , HaabF , SchneiderT , CarlssonM , ArumiD . Fesoterodine 8 mg versus fesoterodine 4 mg in patients with overactive bladder and a history of previous antimuscarinic therapy: Results from the EIGHT trial (Abstract number: Poster #M5). Neurourology and Urodynamics2015;34(S1):S20. [NCT01302067] [sr-incont68509]ChappleC , SchneiderT , HaabF , SunF , WhelanL , ScholfieldD , et al. Superiority of fesoterodine 8mg versus fesoterodine 4 mg in reducing urgency urinary incontinence episodes in subjects with overactive bladder: results of the randomized, double-blind, placebo-controlled EIGHT trial (Abstract number: Podium #48). Neurourology and Urodynamics2014;33(2):183-4. [NCT01302067] [sr-incont67484]ChappleC , SchneiderT , HaabF , SunF , WhelanL , ScholfieldD , et al. Superiority of fesoterodine 8mg vs 4mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial. BJU International2014;114(3):418-26. [A0221095] [NCT01302067] [TrialID.EIGHT] [srincont-62537]NCT01302067. A 12 week study to confirm the effectiveness of 8mg of Fesoterodine compared to 4mg of Fesoterodine [A 12-week, randomized, double-blind, placebo controlled, parallel group, multicenter trial in overactive bladder subjects to confirm the efficacy of 8 mg fesoterodine compared to 4 mg fesoterodine]. clinicaltrials.gov/show/NCT01302067 (first received 23 February 2011). [NCT01302067] [sr-incont63792]">Chapple 2014</a>; <a href="./references#CD003781-bbs2-0020" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. [sr-incont75259]ChuF , SmithN , UchidaT . Efficacy and safety of solifenacin succinate 10 mg once daily: a multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder. Current Therapeutic Research - Clinical and Experimental2009;70(6):405-20. [srincont-43324]">Chu 2009</a>; <a href="./references#CD003781-bbs2-0021" title="ChuaME , SeeMC , EsmeňaEB , BalingitJC , MoralesML . Efficacy and safety of gabapentin in comparison to solifenacin succinate in adult overactive bladder treatment. Lower Urinary Tract Symptoms2018;10(2):135-42. [NCT01486706] [sr-incont74529]NCT01486706, ChuaME . Efficacy and safety of gabapentin in treating overactive bladder (OAB). clinicaltrials.gov/show/NCT01486706 (first received 6 December 2011). [NCT01486706] [SLMC10-010] [sr-incont49864]">Chua 2018</a>; <a href="./references#CD003781-bbs2-0022" title="AmarencoG , SutoryM , FagertunH , WrightM , CompionG , De RidderD . Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Preliminary results from the SONIC urodynamic study (Abstract). European Urology, Supplements2012;11(1):e467-a. [EudraCT2006-005523-42] [NCT00629642] [sr-incont65392]AmarencoG , SutoryM , ZachovalR , AgarwalM , DelPG , TretterR , et al. Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study. Neurourology and Urodynamics2017;36(2):414-21. [EudraCT2006-005523-42] [JapicCTI-R130306] [NCT00629642] [sr-incont72248]De RidderD , AmarencoG , Finazzi-AgroE , AnguloJ , KurenkovA , WrightM , et al. Solifenacin treatment for neurogenic detrusor overactivity: patient-reported outcomes (PROs) from the randomised clinical trial SONIC (Abstract number 333). In: International Continence (ICS); 42nd Annual Meeting; 2012 Oct 15-19; Beijing, China. 2012. [905-EC-005] [EudraCT2006-005523-42] [NCT00629642] [TrialID.SONIC.] [srincont-49739]">De Ridder 2012</a>; <a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>; <a href="./references#CD003781-bbs2-0028" title="ElbasetM , TahaD , ZahranM , EzzatO , ElhefnawyAS , ElkenawyM , et al. Subjective and objective scales assessment after retreatment with anticholinergics post botox-faded effects in refractory idiopathic overactive bladder: a prospective single blinded randomized trial (Abstract number 132). European Urology, supplements2019;18(1):e172. [sr-incont78652]ElbasetMA , TahaDE , El-HefnawyAS , ZahranMH , ShokeirAA . Assessment of anticholinergic use after fading of BTX-A effects in refractory idiopathic overactive bladder: a prospective blinded randomized trial. International Neurourology Journal2019;23(3):240-8. [sr-incont78605]">Elbaset 2019</a>; <a href="./references#CD003781-bbs2-0032" title="GellerE , DumondJ , BowlingJM , KhandelwalC , WuJ , Busby-WhiteheadJ , et al. Effect of an anticholinergic on cognitive function in postmenopausal women: a randomized trial (Abstract number: oral poster 52). Female Pelvic Medicine and Reconstructive Surgery2016;22(5):S61. [sr-incont78607]GellerEJ , DumondJB , BowlingJM , KhandelwalCM , WuJM , Busby-WhiteheadJ , et al. Effect of trospium chloride on cognitive function in women aged 50 and older: a randomized trial. Female Pelvic Medicine &amp; Reconstructive Surgery2017;23(2):118-23. [13-1352] [NCT01922115] [sr-incont74341]NCT01922115. The effect of anticholinergics on cognitive function in the elderly (ACE) [The effect of anticholinergics on cognitive function in the elderly: a randomized controlled trial]. clinicaltrials.gov/show/NCT01922115 (first received 14 August 2013). [13-1352] [NCT01922115] [TrialID.ACE] [sr-incont49282]">Geller 2013</a>; <a href="./references#CD003781-bbs2-0033" title="GotohM , HommaY , YokoyamaO , NishizawaO . Responsiveness and minimal clinically important change in overactive bladder symptom score. Urology2011;78(4):768-73. [srincont-42622]GotohM , YokoyamaO , MatsukawaY , NishizawaO . Responsiveness of overactive bladder symptom score (OABSS): verification based on data in a double-blinded, randomized placebo-controlled study of propiverine hydrochloride in Japanese patients (Abstract number 338). In: Joint Meeting of the International Continence Society (ICS) and the International Urogynecological Association; 2010 Aug 23-27; Toronto, Canada. 2010. [srincont-40173]GotohM , YokoyamaO , NishizawaO . Propiverine hydrochloride in Japanese patients with overactive bladder: A randomized, double-blind, placebo-controlled trial. International Journal of Urology2011;18(5):365-73. [srincont-41510]">Gotoh 2011</a>; <a href="./references#CD003781-bbs2-0035" title="HaabF , StewartL , DwyerP . Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. European Urology2004;45(4):420-9. [srincont-17428]">Haab 2004</a>; <a href="./references#CD003781-bbs2-0038" title="HerschornS , HeesakkersJ , Castro-DiazD , WangJT , BrodskyM , GuanZ . Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*. Current Medical Research and Opinion2008;24(12):3513-21. [A6121122] [NCT00143377] [srincont-29250]HerschornS , HeesakkersJ , Castro-DiazD , WangJT , GuanZ , BrodskyM . Tolterodine extended release (TER) improves objective and subjective outcomes after 1 week of treatment in patients with overactive bladder (Abstract number 132). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S78-9. [srincont-26602]">Herschorn 2008</a>; <a href="./references#CD003781-bbs2-0039" title="CorcosJ , AnguloJC , GarelyAD , CarlssonM , GongJ , GuanZ . Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. Current Medical Research and Opinion2011;27(5):1059-65. [srincont-41596]EUCTR2006-006935-38-SE. 12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006935-38 (first received 16 April 2007). [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont64612]HerschornS , SwiftS , GuanZ , CarlssonM , BrodskyM , GongJ . Efficacy and safety of fesoterodine for overactive bladder in a double-blind, head-to-head comparison trial with tolterodine ER and placebo (Abstract number 710). In: International Continence Society (ICS), 39th Annual Meeting; 2009 Sep 29-Oct 3; San Francisco, CA. 2009. [srincont-35326]HerschornS , SwiftS , GuanZ , CarlssonM , MorrowJD , BrodskyM , et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU International2010;105(1):58-66. [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont39540]NCT00444925. Clinical trial to evaluate the efficacy and safety of Fesoterodine in comparison to Tolterodine for overactive bladder (OAB) [12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder (OAB)]. clinicaltrials.gov/show/NCT00444925 (first received 08 March 2007). [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont49159]">Herschorn 2009a</a>; <a href="./references#CD003781-bbs2-0040" title="EUCTR2012-005735-91-SK. A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-005735-91 (first received 12 November 2013). [178-CL-101] [EUCTR2012-005735-91-SK] [sr-incont78644]HerschornS , ChappleCR , AbramsP , ArlandisS , MitchesonD , LeeKS , et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU International2017;120(4):562-75. [NCT01972841] [sr-incont74470]MuellerER , RobinsonD , KelleherC , StaskinDR , FalconerC , WangJ , et al. Patient reported outcomes from synergy, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with mirabegron and solifenacin monotherapy (Abstract number - Podium #44). Neurourology and Urodynamics2017;36(Suppl S1):S151-2. [NCT01972841] [sr-incont75944]NCT01972841. This was a multinational study comparing the efficacy and safety of two medicines, solifenacin succinate and mirabegron taken together, or separately, or a mock treatment (placebo) in subjects with symptoms of overactive bladder (SYNERGY) [A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01972841 (first received 31 October 2013). [178-CL-101] [EUCTR2012-005735-91] [NCT01972841] [sr-incont63780]RobinsonD , KelleherC , StaskinD , MuellerER , FalconerC , WangJ , et al. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients. Neurourology and Urodynamics2018;37(1):394-406. [NCT01972841] [sr-incont76906]WeberMA , ChappleCR , GratzkeC , HerschornS , RobinsonD , FrankelJM , et al. A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial. Blood Pressure Monitoring2018;23(3):153-63. [NCT01972841] [sr-incont77899]WhiteWB , ChappleC , GratzkeC , HerschornS , RobinsonD , FrankelJ , et al. Cardiovascular safety of the beta3-adrenoceptor agonist mirabegron and the antimuscarinic agent solifenacin in the SYNERGY trial. Journal of Clinical Pharmacology2018;58(8):1084-91. [NCT01972841] [sr-incont78078]">Herschorn 2017a</a>; <a href="./references#CD003781-bbs2-0041" title="HerschornS , KohanA , AliottaP , McCammonK , SriramR , AbramsS , et al. The efficacy and safety of onabotulinumtoxin A or solifenacin compared with placebo in solifenacin naive patients with refractory overactive bladder: results from a multicenter, randomized, double-blind phase 3b trial. Journal of Urology2017;198(1):167-75. [NCT01767519] [sr-incont74491]NCT01767519. A study evaluating the efficacy and safety of BOTOX® or solifenacin in patients with overactive bladder and urinary incontinence. clinicaltrials.gov/show/NCT01767519 (first received 14 January 2013). [191622-125] [NCT01767519] [sr-incont49909]">Herschorn 2017b</a>; <a href="./references#CD003781-bbs2-0046" title="HuangA , HessR , AryaL , RichterH , SubakL , BradleyC , et al. A randomized controlled trial of simple diagnosis and treatment for urgency urinary incontinence in women (Abstract). Journal of General Internal Medicine2011;26:S1. [NCT00862745] [sr-incont64391]HuangAJ , HessR , AryaLA , RichterHE , SubakLL , BradleyCS , et al. Pharmacologic treatment for urgency-predominant urinary incontinence in women diagnosed using a simplified algorithm: a randomized trial. American Journal of Obstetrics and Gynecology2012;206(5):444.e1-11. [GA0221IX] [NCT00862745] [TrialID.BRIDGES.] [srincont-44636]NCT00862745, BrownJ . Bringing simple urge incontinence diagnosis &amp; treatment to providers (BRIDGES)  [A multi-center, randomized, placebo-controlled clinical trial comparing fesoterodine to placebo in women diagnosed with urge urinary incontinence by the 3 Incontinence Questions (3IQ). Followed by a multi-center open label clinical cohort study of long-term effects of treatment with fesoterodine ]. clinicaltrials.gov/show/NCT00862745 (first received 17 March 2009). [NCT00862745] [sr-incont49836]WarsiQ , HuangA , BrownJS , SchembriM , HessR , AryaLA , et al. The effect of pharmacologic treatment of urgency urinary incontinence on sleep quality and daytime sleepiness (Abstract number: paper 37). Female Pelvic Medicine and Reconstructive Surgery2016;22(5 ):S17-8. [NCT00862745] [TrialID.BRIDGES.] [sr-incont78633]WarsiQA , HuangAJ , HessR , AryaLA , RichterHE , BradleyCS , et al. Association of pharmacologic treatment of urgency urinary incontinence with sleep quality and daytime sleepiness. Obstetrics and Gynecology2018;131(2):204-11. [NCT00862745] [sr-incont78239]WinkelmanW , HuangA , SchembriM , RogersRG , RichterHE , MyersDL , et al. Clinical variables moderating response to pharmacologic treatment of urgency-predominant urinary incontinence in a randomized controlled trial (Abstract number: poster 25). In: Female Pelvic Medicine and Reconstructive Surgery. 37th Annual Scientific Meeting of the American Urogynecologic Society; Aug 2016; United States. Vol. 22. Netherlands: Lippincott Williams and Wilkins, 2016:S81. [NCT00862745] [sr-incont78634]WinkelmanWD , HuangAJ , SchembriM , RogersRG , RichterH , MyersDL , et al. Modifiers of response to treatment with fesoterodine for urgency-predominant urinary incontinence in a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2017;23(2):151-6. [sr-incont74308]">Huang 2012</a>; <a href="./references#CD003781-bbs2-0047" title="JacquetinB , WyndaeleJJ . Tolterodine reduces the number of incontinence episodes in patients with an overactive bladder. European Journal of Obstetrics and Gynecology and Reproductive Biology2001;98(1):97-102. [srincont-12200]JacquetinB , WyndaeleJJ . Tolterodine reduces the number of incontinence episodes in patients with detrusor overactivity. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(1):S30. [srincont-5167]">Jacquetin 2001</a>; <a href="./references#CD003781-bbs2-0048" title="JonasU , HofnerK , MadersbacherH , HolmdahlTH . Efficacy and safety of two doses of Tolterodine compared to placebo in patients with detrusor overactivity. Neurourology and Urodynamics1997;16(5):477-8. [srincont-5841]JonasU , HöfnerK , MadersbacherH , HolmdahlTH . Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group. World Journal of Urology1997;15(2):144-51. [srincont-5436]">Jonas 1997</a>; <a href="./references#CD003781-bbs2-0051" title="EUCTR2007-006451-39-SE. 12-week, randomized, double-blind, double-dummy, placebo controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-006451-39 (first received 20 February 2008). [A0221046] [EUCTR2007-006451-39-SE] [sr-incont64591]KaplanSA , SchneiderT , FooteJ , GuanZ . Superior efficacy of fesoterodine over tolterodine with rapid onset: a prospective, head-to-head, placebo-controlled trial (Abstract number 67). Neurourology and Urodynamics2010;29(6):905-7. [srincont-40130]KaplanSA , SchneiderT , FooteJE , GuanZ , CarlssonM , GongJ . Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU International2011;107(9):1432-40. [A0221046] [NCT00611026] [srincont-41334]">Kaplan 2011</a>; <a href="./references#CD003781-bbs2-0053" title="CapoJP , TogliaM , Forero-SchwanhaeuserS , HeW . Patients reporting severe overactive bladder symptoms: effects of solifenacin treatment on objective measures and patient-reported outcomes (Abstract number 582). In: International Continence Society (ICS), 38th Annual Meeting; 2008 Oct 20-24; Cairo, Egypt. 2008. [srincont-31844]CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. KarramMM , TogliaMR , SerelsSR , AndohM , FakhouryA , Forero-SchwanhaeuserS . Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology2009;73(1):14-8. [A0221094] [NCT00454896] [TrialID.VENUS.] [srincont-29219]SerelsSR , TogliaMR , Forero-SchwanhaeuserS , HeW . Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms. Current Medical Research and Opinion2010;26(10):2277-85. [srincont-40376]StaskinD , DmochowskiR , SerelsS , AndohM , SmithN . Report from a randomized, placebo-controlled study showing significant improvement in urgency and patient-reported outcomes in overactive bladder patients treated with solifenacin (Abstract number 124). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73-4. [srincont-26600]TogliaM , AndohM , HussainI . Solifenacin improved warning time significantly compared to placebo in patients with overactive bladder (Abstract number 123). Neurourology and Urodynamics2006;25(6):655. [srincont-26629]TogliaM , AndohM , HussainI . Solifenacin improves urgency symtoms as assessed by voiding diaries and patient-reported outcomes (PRO) in patients with overactive bladder (Abstract number 155). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26636]TogliaMR , OstergardDR , AppellRA , AndohM , FakhouryA , HussainIF . Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status. International Urogynecology Journal2010;21(7):847-54. [srincont-40094]TogliaMR , SerelsSR , LarameeC , KarramMM , NandyIM , AndohM , et al. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial. Postgraduate Medicine2009;121(5):151-8. [srincont-34204]ZinnerS , HerschornS , AndohM , HussainI . Responder analyses show statistically significant improvements in incontinence and urgency are associated with reduction in symptom bother and improvement in health-related quality of life: VENUS results (Abstract number 123). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73. [srincont-26599]">Karram 2009</a>; <a href="./references#CD003781-bbs2-0054" title="KhullarV , HillS , LavalKU , SchiotzHA , JonasU , VersiE . Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology2004;64(2):269-74; discussion 274-5. [srincont-19498]KhullarV , HillS , SolankiJ . Assessment of health-related quality of life in patients with overactive bladder taking tolterodine extended release versus placebo (Abstract number 318). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21075]">Khullar 2004</a>; <a href="./references#CD003781-bbs2-0058" title="KosilovKV , LoparevSA , IvanovskayaMA , KosilovaLV . The efficacy of different doses of solifenacin in elderly patients after treating a urinary tract infection. Arab Journal of Urology Print2015;13(3):203-8. [sr-incont69283]">Kosilov 2015b</a>; <a href="./references#CD003781-bbs2-0061" title="LacknerTE , WymanJF , McCarthyTC , MonigoldM , DaveyC . Efficacy of oral extended-release oxybutynin in cognitively impaired older nursing home residents with urge urinary incontinence: a randomized placebo-controlled trial. Journal of the American Medical Directors Association2011;12(9):639-47. [sr-incont42677]LacknerTE , WymanJF , McCarthyTC , MonigoldM , DaveyC . Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. Journal of the American Geriatrics Society2008;56(5):862-70. [sr-incont27117]">Lackner 2011</a>; <a href="./references#CD003781-bbs2-0065" title="ChappleCR , MadersbacherH , DreikornK , DorschnerW , MurtzG . Urodynamics and frequency/volume chart - do they correlate? Treatment analysis of propiverine in comparison to oxybutynin and placebo in urge incontinence (Abstract 224). In: International Continence Society (ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001. [sr-incont14474]HalaskaM , MadersbacherH , VoigtR , HofnerK , MartanA . Propiverine in patients with urgency and urge incontinence - a placebo controlled, multicentre study comparing its tolerability and efficacy with oxybutynin (Abstract number FDP36). International Urogynaecology Journal 2000;11(Suppl 1):S46. [srincont-11912]MadersbacherH , HalaskaM , VoigtR , AlloussiS , HofnerK . A urodynamically controlled multicenter study in patients with urge incontinence: tolerability and efficacy of propiverine hydrochloride in comparison to oxybutynin. In: International Continence Society (ICS), 27th Annual Meeting; 1997 Sep 23-26; Yokohama, Japan. 1997:153-4. [srincont-5854]MadersbacherH , HalaskaM , VoigtR , AlloussiS , HöfnerK . A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU International1999;84(6):646-51. [srincont-9166]">Madersbacher 1999</a>; <a href="./references#CD003781-bbs2-0066" title="Malone-LeeJG , WalshB , MaugourdMF , Tolterodine in the Elderly Study Group. The safety and clinical efficacy of two doses of tolterodine compared to placebo in elderly patients. In: International Continence Society (ICS), 27th Annual Meeting; 1997 Sep 23-26; Yokohama, Japan. 1997:155-6. [srincont-5855]Malone‐LeeJG , WalshJB , MaugourdMF . Tolterodine: A safe and effective treatment for older patients with overactive bladder. Journal of the American Geriatric Society2001;49(6):700-5. [srincont-12319]WaggA , Malone-LeeJ . Pressure-flow variables in patients treated with tolterodine for detrusor overactivity. BJU International2003;92(9):969-71. [sr-incont16659]">Malone‐Lee 2001</a>; <a href="./references#CD003781-bbs2-0067" title="MillardR , TuttleJ , MooreK , SussetJ , ClarkeB , DwyerP , et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. Journal of Urology1999;161(5):1551-5. [sr-incont8172]MooreK , MillardR , DwyerP , TuttleJ . A randomized controlled multicentre trial of tolterodine in detrusor instability/hyperreflexia. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(Suppl 1):S129. [sr-incont5171]RosamiliaA , DwyerPL , ClarkeB , MooreK , MillardRP , TuttleJ . The clinical efficacy and safety of two doses of Tolterodine in detrusor instability. Acta Obstetrica et Gynecologica Scandinavica1997;6(Suppl 167):24. [sr-incont6670]">Millard 1999</a>; <a href="./references#CD003781-bbs2-0069" title="Drug company. A phase 2, parallel group, stratified, randomized, double blind, placebo-controlled trial to investigate the efficacy and safety of 3 different dosages of sustained release fesoterodine in subjects with overactive bladder showing either involuntary detrusor contractions or normal findings during the baseline urodynamic assessment. Protocol numbers: A0221029 (SP668). ClinicalStudyResults.org (accessed 3 March 2011). [srincont-41111]NittiV , WiatrakM , KreitmanL , LipsitzD . Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB): results of a phase 2 trial (Abstract number 306). In: International Continence Society (ICS); 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21084]">Nitti 2005</a>; <a href="./references#CD003781-bbs2-0073" title="NCT01302938. Web-based methodology trial to evaluate the efficacy and safety of tolterodine ER in subjects with overactive bladder (REMOTE) [Exploratory, randomized, double-blind, placebo-controlled, parallel-group, single center, web-based phase IV pilot methodolgy trial to evaluate the efficacy and safety of tolterodine ER in subjects with overactive bladder]. clinicaltrials.gov/ct2/show/NCT01302938 (first received 24 February 2011). [A6121195] [NCT01302938] [TrialID.REMOTE.] [sr-incont43314]OrriM , LipsetCH , JacobsBP , CostelloAJ , CummingsSR . Web-based trial to evaluate the efficacy and safety of tolterodine ER 4 mg in participants with overactive bladder: REMOTE trial. Contemporary Clinical Trials2014;38(2):190-7. [A6121195] [NCT01302938] [TrialID.REMOTE.] [sr-incont62536]">Orri 2014</a>; <a href="./references#CD003781-bbs2-0077" title="RogersR , BachmannG , JumadilovaZ , SunF , MorrowJD , GuanZ , et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. International Urogynecology Journal and Pelvic Floor Dysfunction2008;19(11):1551-7. [A6121002] [NCT00143481] [srincont-27729]RogersRG , BachmannG , ScarperoH , JumadilovaZ , SunF , MorrowJD , et al. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. Current Medical Research and Opinion2009;25(9):2159-65. [srincont-32060]">Rogers 2008</a>; <a href="./references#CD003781-bbs2-0080" title="RudyD , ClineK , GoldbergK , HarrisR . A multicenter, randomized, placebo-controlled trial of trospium chloride in overactive bladder patients (Abstract). Neurourology and Urodynamics2004;23(5/6):600-1. [sr-incont19025]RudyD , ClineK , HarrisR , GoldbergK , DmochowskiR . Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology2006;67(2):275-80. [srincont-21604]RudyD , ClineK , HarrisR , GoldbergK , DmochowskiR . Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. BJU International2006;97(3):540-6. [sr-incont21593]">Rudy 2006</a>; <a href="./references#CD003781-bbs2-0081" title="StaskinDR , HarnettMD . Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder. Current Urology Reports2004;5(6):423-6. [sr-incont19422]">Staskin 2004</a>; <a href="./references#CD003781-bbs2-0082" title="ChancellorMB , OefeleinMG , VasavadaS . Obesity is associated with a more severe overactive bladder disease state that is effectively treated with one daily administration of trospium chloride extended release [Erratum available in: Neurourology and Urodynamics 2010;29(5):804]. Neurourology and Urodynamics2010;29(4):551-4. [sr-incont39591]GinsbergDA , OefeleinMG , EllsworthPI . Once-daily administration of trospium chloride extended release provides 24-hour coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials. Neurourology and Urodynamics2011;30(4):563-7. [sr-incont41531]RovnerE , DmochowskiR , WatanabeJ . Once daily (QD) trospium chloride 60mg extended release (XR) is safe and effective in patients (PTS) with the overactive bladder (OAB) syndrome who use multiple concomitant medications (MEDS) (Abstract number: Poster #68). Neurourology and Urodynamics2009;28(2):146-7. [sr-incont31062]SandP , DmochowskiR , ZinnerN , StaskinD . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: results from a multicenter, phase III, placebo-controlled study (Abstract number 269). In: International Continence Society (ICS), 37th Annual Meeting; 2007 Aug 20-24; Rotterdam, the Netherlands. 2007. [sr-incont26676]SandP , StaskinD , ZinnerN , DmochowskiR . Once-daily trospium chloride extended release is effective and well tolerated for the treatment of overactive bladder: results from a multicenter, phase III trial (Abstract number 57). Neurourology and Urodynamics2007;26(5):675. [sr-incont26661]StaskinD , SandP , ZinnerN , DmochowskiR , Trospium Study Group. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. Journal of Urology2007;178(3 Pt 1):978-83; discussion 983-4. [srincont-23909]StaskinDR , RosenbergMT , SandPK , ZinnerNR , DmochowskiRR . Trospium chloride once daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised phase III trials. International Journal of Clinical Practice2009;63(12):1715-23. [sr-incont35458]StaskinDR , SandPK , ZinnerNR . Once-daily trospium chloride extended release is effective and well tolerated for the treatment of overactive bladder: results from a multicenter, phase III trial (Abstract number - poster 22). Neurourology and Urodynamics2007;26(7 Suppl):1106. [srincont-27305]">Staskin 2007</a>; <a href="./references#CD003781-bbs2-0090" title="UlshoferB , BihrAM , BodekerRH , SchwantesU , JahnHP . Randomised, double-blind, placebo-controlled study on the efficacy and tolerance of trospium chloride in patients with motor urge incontinence. Clinical Drug Investigation2001;21(8):563-9. [srincont-16324]UlshoferB , SchwantesU , BodekerRH , BihrAM , JahnHP . Efficacy and tolerance of trospium chloride in patients with motor urge incontinence - results of a randomised double-blind placebo-controlled study (Poster presentations). In: 2nd International Consultation on Incontinence (ICI); 2001 July 1-3; Paris, France. 2001:5. [srincont-16318]">Ulshofer 2001</a>; <a href="./references#CD003781-bbs2-0094" title="EUCTR2007-007087-17-SE. A 24-week, multicentre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-007087-17 (first received 13 June 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont64588]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00798434. A study to compare the effectiveness and safety of fesoterodine and placebo in an elderly population of patients who go to the toilet very frequently due to overactive bladder (SOFIA) [A 24-week, multi-centre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00798434 (first received 26 November 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont49847]SchneiderT , BergqvistA , WangJ , WaggA , Ebel-BitounC . Treatment with fesoterodine versus tolterodine for reducing symptom bother in elderly patients with overactive bladder including urgency urinary incontinence. European Urology, Supplements2012;11(1):e687-a. [sr-incont65389]WaggA , CarlssonM , ElsobkyM , FernetM . Effect of flexible dose fesoterodine on cognitive function in &gt;65 year old patients with OAB: data from two RCT (Abstract number 438). Neurourology and Urodynamics2019;38:S297-8. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78651]WaggA , DarekarA , ArumiD , KhullarV , OelkeM . Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people &gt;65 years of age: a post hoc analysis of data from the SOFIA study. Neurourology and Urodynamics2015;34(5):438-43. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont68100]WaggA , ElsobkyM , CarlssonM , FernetM . Response and cognitive safety of fesoterodine in patients &gt;65y old with OAB. Is there a relationship between cognition and treatment response? (Abstract number 183). Neurourology and Urodynamics2019;38:S118-20. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78632]WaggA , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. Journal of the American Geriatrics Society2013;61(2):185-93. [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TrialID.SOFIA.] [sr-incont48008]WaggAS , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Efficacy and tolerability of fesoterodine in older subjects with overactive bladder: results of SOFIA (Abstract number C33). Journal of the American Geriatrics Society2011;59:S124. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont65234]">Wagg 2013a</a>; <a href="./references#CD003781-bbs2-0095" title="GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00911937. A trial to evaluate the efficacy and safety of fesoterodine in patients with symptoms of overactive bladder including nocturnal urinary urgency [A randomized, double blind, placebo controlled, parallel group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with symptoms of overactive bladder including nocturnal urinary urgency]. clinicaltrials.gov/show/NCT00911937 (first received 03 June 2009). [NCT00911937] [sr-incont49848]WeissJ , JumadilovaZ , CarlssonM , FitzGeraldMP , MalhotraA , MartireDL . Effect of antimuscarinic treatment in subjects with overactive bladder, including nocturnal urinary urgency (Abstract number 1963). Journal of Urology2012;187(4 Suppl 1):e792. [NCT00911937] [sr-incont65184]WeissJP , CarlssonMR , ManganEK . Age, gender and nocturnal urgency severity predict response to antimuscarinic treatment (Abstract number 1962). Journal of Urology2013;189(4 Suppl 1):e805. [NCT00911937] [sr-incont65096]WeissJP , JumadilovaZ , JohnsonTM , FitzGeraldMP , CarlssonM , MartireDL , et al. Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency. Journal of Urology2013;189(4):1396-401. [A0221048] [NCT00911937] [sr-incont47568]">Weiss 2013</a>; <a href="./references#CD003781-bbs2-0096" title="YamaguchiO , MaruiE , KakizakiH , ItohN , YokotaT , OkadaH , et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU International2007;100(3):579-87. [sr-incont23865]YokoyamaO , YamaguchiO , KakizakiH , ItohN , YokotaT , OkadaH , et al. Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary. Journal of Urology2011;186(1):170-4. [sr-incont41734]">Yamaguchi 2007</a>; <a href="./references#CD003781-bbs2-0097" title="NCT00966004. A study to evaluate safety and efficacy of ym178 in patients with overactive bladder [Phase III study of YM178 - a placebo-controlled, double-blind, group comparison study in patients with overactive bladder]. clinicaltrials.gov/show/NCT00966004 (first received 26 August 2009). [178-CL-048] [JapicCTI-R130370] [NCT00966004] [sr-incont63783]YamaguchiO , HidehiroK , YukioH , YasuhikoI , MasayukiT , OsamuN , et al. A phase III, randomized, double-blind, placebo and active controlled study of once-daily mirabegron 50 mg in patients with overactive bladder (Abstract number POD-03.06). Urology2012;80(3 Suppl 1):S10-1. [NCT00966004] [sr-incont65380]YamaguchiO , MaruiE , KakizakiH , HommaY , IgawaY , TakedaM , et al. A phase III, randomized, double-blind, placebo-controlled study of the beta-adrenoceptor agonist, mirabegron 50 mg once-daily, in Japanese patients with overactive bladder. BJU International2014;113(6):951-60. [NCT00966004] [sr-incont50603]">Yamaguchi 2012</a>; <a href="./references#CD003781-bbs2-0100" title="JapicCTI-152936. Phase III study of KRP-114V [A phase III, randomized, double-blind, parallel group, placebo controlled, multicenter study to assess the efficacy and safety of the beta-3 agonist KRP-114V in Japanese subjects with symptoms of overactive bladder]. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-152936 (first received 17 June 2015). [JapicCTI-152936] [sr-incont78653]YoshidaM , TakedaM , GotoM , NagaiS , KuroseT . Vibegron, a novel potent and selective beta3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study (Abstract number 1082). European Urology, Supplements2018;17(2):e1531-2. [JapicCTI-152936] [sr-incont78069]YoshidaM , TakedaM , GotohM , NagaiS , KuroseT . Vibegron, a novel potent and selective B3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study. European Urology2018;73(5):783-90. [JapicCTI-152936] [sr-incont77898]YoshidaM , TakedaM , GotohM , YokoyamaO , KakizakiH , TakahashiS , et al. Efficacy of novel beta3-adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: a post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study. International Journal of Urology2019;26(3):369-75. [JapicCTI-152936] [sr-incont78654]YoshidaM , TakedaM , GotohM , YokoyamaO , KakizakiH , TakahashiS , et al. Efficacy of vibegron, a novel selective I²3-adrenoreceptor agonist, on urgency urinary incontinence with overactive bladder: post-hoc analysis of phase iii study (Abstract number 180). Neurourology and Urodynamics2019;38(S3):S114-5. [JapicCTI-152936] [sr-incont78636]">Yoshida 2018</a>; <a href="./references#CD003781-bbs2-0101" title="NCT01018264, ZesiewiczT . Solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease (URGE-PD) [URGE-PD: a multi-site, double-blind, randomized, placebo controlled trial of solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease]. clinicaltrials.gov/show/NCT01018264 (first received 23 November 2009). [NCT01018264] [sr-incont63790]ZesiewiczTA , EvattM , JahanI , VaughanC , SingerC , OrdoricaR , et al. URGE-PD: a multi-site, double-blind, randomized, placebo controlled trial of solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease (Abstract number 745). Movement Disorders2014;29(Suppl 1):S276-7. [NCT01018264] [sr-incont66602]ZesiewiczTA , EvattM , VaughanCP , JahanI , SingerC , OrdoricaR , et al. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease. Parkinsonism and Related Disorders2015;21(5):514-20. [NCT01018264] [sr-incont66860]">Zesiewicz 2015</a>; <a href="./references#CD003781-bbs2-0103" title="ZinnerN , GittelmanM , HarrisR , SussetJ , KanellosA , AuerbachS . Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial (Abstract number DP51). In: American Urological Association (AUA), 98th Annual Meeting; 2003 Apr 26-May 1; Chicago, Illinois. 2003. [sr-incont31101]ZinnerN , GittelmanM , HarrisR , SussetJ , KanelosA , AuerbachS , Trospium Study Group. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. Journal of Urology2004;171(6 Pt 1):2311-5. [sr-incont17376]">Zinner 2004</a>; <a href="./references#CD003781-bbs2-0104" title="ZinnerN , SussetJ , GittelmanM , ArguinzonizM , RekedaL , HaabF . Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. International Journal of Clinical Practice2006;60(1):119-26. [sr-incont21507]">Zinner 2006</a>). We judged the remainder to be at unclear risk as there was not enough information provided to make another judgement. </p> </section> <section id="CD003781-sec-0068"> <h4 class="title">Selective reporting</h4> <p>Seven studies were at low risk of reporting bias because it was clear that the published reports included all expected outcomes (<a href="./references#CD003781-bbs2-0018" title="ChappleCR , DvorakV , RadziszewskiP , vanKerrebroeckP , WyndaeleJJ , BosmanB , et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder. International Urogynecology Journal2013;24(9):1447-58. [178-CL-044] [NCT00337090] [TrialID.DRAGON.] [sr-incont48549]NCT00337090 . A study of YM178 in patients with symptomatic overactive bladder (DRAGON) [A randomized, double-blind, parallel group, placebo and active controlled, multicenter dose ranging study with the beta-3 agonist YM178 in patients with symptomatic overactive bladder]. clinicaltrials.gov/show/NCT00337090 (first received 15 June 2006). [EudraCT2005-002256-17] [JapicCTI-R130350] [NCT00337090] [sr-incont63803]">Chapple 2013</a>; <a href="./references#CD003781-bbs2-0021" title="ChuaME , SeeMC , EsmeňaEB , BalingitJC , MoralesML . Efficacy and safety of gabapentin in comparison to solifenacin succinate in adult overactive bladder treatment. Lower Urinary Tract Symptoms2018;10(2):135-42. [NCT01486706] [sr-incont74529]NCT01486706, ChuaME . Efficacy and safety of gabapentin in treating overactive bladder (OAB). clinicaltrials.gov/show/NCT01486706 (first received 6 December 2011). [NCT01486706] [SLMC10-010] [sr-incont49864]">Chua 2018</a>; <a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>; <a href="./references#CD003781-bbs2-0028" title="ElbasetM , TahaD , ZahranM , EzzatO , ElhefnawyAS , ElkenawyM , et al. Subjective and objective scales assessment after retreatment with anticholinergics post botox-faded effects in refractory idiopathic overactive bladder: a prospective single blinded randomized trial (Abstract number 132). European Urology, supplements2019;18(1):e172. [sr-incont78652]ElbasetMA , TahaDE , El-HefnawyAS , ZahranMH , ShokeirAA . Assessment of anticholinergic use after fading of BTX-A effects in refractory idiopathic overactive bladder: a prospective blinded randomized trial. International Neurourology Journal2019;23(3):240-8. [sr-incont78605]">Elbaset 2019</a>; <a href="./references#CD003781-bbs2-0032" title="GellerE , DumondJ , BowlingJM , KhandelwalC , WuJ , Busby-WhiteheadJ , et al. Effect of an anticholinergic on cognitive function in postmenopausal women: a randomized trial (Abstract number: oral poster 52). Female Pelvic Medicine and Reconstructive Surgery2016;22(5):S61. [sr-incont78607]GellerEJ , DumondJB , BowlingJM , KhandelwalCM , WuJM , Busby-WhiteheadJ , et al. Effect of trospium chloride on cognitive function in women aged 50 and older: a randomized trial. Female Pelvic Medicine &amp; Reconstructive Surgery2017;23(2):118-23. [13-1352] [NCT01922115] [sr-incont74341]NCT01922115. The effect of anticholinergics on cognitive function in the elderly (ACE) [The effect of anticholinergics on cognitive function in the elderly: a randomized controlled trial]. clinicaltrials.gov/show/NCT01922115 (first received 14 August 2013). [13-1352] [NCT01922115] [TrialID.ACE] [sr-incont49282]">Geller 2013</a>; <a href="./references#CD003781-bbs2-0094" title="EUCTR2007-007087-17-SE. A 24-week, multicentre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-007087-17 (first received 13 June 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont64588]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00798434. A study to compare the effectiveness and safety of fesoterodine and placebo in an elderly population of patients who go to the toilet very frequently due to overactive bladder (SOFIA) [A 24-week, multi-centre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00798434 (first received 26 November 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont49847]SchneiderT , BergqvistA , WangJ , WaggA , Ebel-BitounC . Treatment with fesoterodine versus tolterodine for reducing symptom bother in elderly patients with overactive bladder including urgency urinary incontinence. European Urology, Supplements2012;11(1):e687-a. [sr-incont65389]WaggA , CarlssonM , ElsobkyM , FernetM . Effect of flexible dose fesoterodine on cognitive function in &gt;65 year old patients with OAB: data from two RCT (Abstract number 438). Neurourology and Urodynamics2019;38:S297-8. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78651]WaggA , DarekarA , ArumiD , KhullarV , OelkeM . Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people &gt;65 years of age: a post hoc analysis of data from the SOFIA study. Neurourology and Urodynamics2015;34(5):438-43. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont68100]WaggA , ElsobkyM , CarlssonM , FernetM . Response and cognitive safety of fesoterodine in patients &gt;65y old with OAB. Is there a relationship between cognition and treatment response? (Abstract number 183). Neurourology and Urodynamics2019;38:S118-20. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78632]WaggA , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. Journal of the American Geriatrics Society2013;61(2):185-93. [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TrialID.SOFIA.] [sr-incont48008]WaggAS , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Efficacy and tolerability of fesoterodine in older subjects with overactive bladder: results of SOFIA (Abstract number C33). Journal of the American Geriatrics Society2011;59:S124. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont65234]">Wagg 2013a</a>; <a href="./references#CD003781-bbs2-0101" title="NCT01018264, ZesiewiczT . Solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease (URGE-PD) [URGE-PD: a multi-site, double-blind, randomized, placebo controlled trial of solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease]. clinicaltrials.gov/show/NCT01018264 (first received 23 November 2009). [NCT01018264] [sr-incont63790]ZesiewiczTA , EvattM , JahanI , VaughanC , SingerC , OrdoricaR , et al. URGE-PD: a multi-site, double-blind, randomized, placebo controlled trial of solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease (Abstract number 745). Movement Disorders2014;29(Suppl 1):S276-7. [NCT01018264] [sr-incont66602]ZesiewiczTA , EvattM , VaughanCP , JahanI , SingerC , OrdoricaR , et al. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease. Parkinsonism and Related Disorders2015;21(5):514-20. [NCT01018264] [sr-incont66860]">Zesiewicz 2015</a>). We judged one study to be at a high risk of bias in this domain (<a href="./references#CD003781-bbs2-0048" title="JonasU , HofnerK , MadersbacherH , HolmdahlTH . Efficacy and safety of two doses of Tolterodine compared to placebo in patients with detrusor overactivity. Neurourology and Urodynamics1997;16(5):477-8. [srincont-5841]JonasU , HöfnerK , MadersbacherH , HolmdahlTH . Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group. World Journal of Urology1997;15(2):144-51. [srincont-5436]">Jonas 1997</a>). <a href="./references#CD003781-bbs2-0048" title="JonasU , HofnerK , MadersbacherH , HolmdahlTH . Efficacy and safety of two doses of Tolterodine compared to placebo in patients with detrusor overactivity. Neurourology and Urodynamics1997;16(5):477-8. [srincont-5841]JonasU , HöfnerK , MadersbacherH , HolmdahlTH . Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group. World Journal of Urology1997;15(2):144-51. [srincont-5436]">Jonas 1997</a> did not report three of the listed outcomes: empty resting pressure, full resting pressure and voided volume (5, 6, 11 on the list). The remaining studies were at an unclear risk of bias for this domain. </p> </section> <section id="CD003781-sec-0069"> <h4 class="title">Other potential sources of bias</h4> <p>Three studies were at high risk of other bias as they were stopped prematurely by the drug company involved and no reasons were given for these stoppages (<a href="./references#CD003781-bbs2-0029" title="EUCTR2004-001116-31-ES. Multicentre, randomised, double-blind, parallel group confirmatory Phase III study to compare the efficacy and safety of cizolirtine citrate 300 mg bid (600 mg/d), cizolirtine citrate 400 mg bid (800 mg/d), placebo, and tolterodine 2 mg bid (4 mg/d) in the treatment of urge urinary incontinence. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-001116-31 (first received 03 November 2004). [ESCLIN-002/04] [EUCTR2004-001116-31-ES] [sr-incont64643]">EUCTR2004‐001116‐31‐ES</a>; <a href="./references#CD003781-bbs2-0030" title="EUCTR2004-002143-27-AT. A double-blind, stratified, randomised, parallel, placebo-controlled, multi-centre study to compare the efficacy and safety of duloxetine hydrochloride (40mg twice a day) and tolterodine tartrate (XL) (4mg once daily) with placebo in patients with symptoms of Urge Urinary Incontinence. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-002143-27 (first received 15 February 2005). [1208.15] [EUCTR2004-002143-27-AT] [sr-incont64640]">EUCTR2004‐002143‐27‐AT</a>; <a href="./references#CD003781-bbs2-0031" title="EUCTR2007-004126-24-CZ. A placebo controlled randomized, 12-week, dose-ranging, double-blind study versus placebo using tolterodine as a study calibrator, to evaluate efficacy and safety of SSR240600C in women with overactive bladder including urge urinary incontinence. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-004126-24 (first received 12 December 2007). [DRI6271] [EUCTR2007-004126-24-CZ] [EudraCT2007-004126-24] [NCT00564226] [TrialID.BILADY] [sr-incont64596]NCT00564226. SSR240600C treatment in women with overactive bladder (BILADY) [A placebo controlled randomized, 12-week, dose-ranging, double-blind study versus placebo using tolterodine as a study calibrator, to evaluate efficacy and safety of SSR240600C in women with overactive bladder including urge urinary incontinence]. clinicaltrials.gov/show/NCT00564226 (first received 27 November 2007). [DRI6271] [EudraCT2007-004126-24] [NCT00564226] [TrialID.BILADY] [sr-incont63784]">EUCTR2007‐004126‐24‐CZ</a>). We judged 57 studies to be at low risk of other bias (<a href="./references#CD003781-bbs2-0002" title="AbramsP , FreemanR , AnderströmC , MattiassonA . Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. British Journal of Urology1998;81(6):801-10. [srincont-7871]AbramsP , FreemanRN , AnderstromC , MattiassonA . Efficacy and tolerability of tolterodine vs. oxybutynin and placebo in patients with detrusor instability (Abstract). Journal of Urology1997;157(Suppl 4):103. [srincont-16321]">Abrams 1998</a>; <a href="./references#CD003781-bbs2-0004" title="AbramsP , KelleherC , StaskinD , KayR , MartanA , MincikI , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World Journal of Urology2017;35(5):827-38. [NCT01340027] [sr-incont77897]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Cardiovascular safety of combination treatment with mirabegron and solifenacin in patients with overactive bladder in a randomised, double-blind, dose-ranging, Phase II study (Symphony) (Abstract). European Urology, Supplements2014;13(1):e574-e574a. [NCT01340027] [sr-incont67160]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB) - efficacy and safety results from a randomised phase II study (Symphony) (Abstract number 295). Neurourology and Urodynamics2013;32(6):930-1. [NCT01340027] [TrialID.SYMPHONY.] [sr-incont49188]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB): safety results from a phase 2 study (Abstract number MP-16.08). Urology2013;82(3 Suppl 1):S139. [NCT01340027] [sr-incont66675]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: Exploratory responder analyses of efficacy and evaluation of patient reported outcomes from a randomised, double-blind, dose-ranging, phase 2 study (Symphony) (Abstract number MP-24.11). Urology2014;84(4 Suppl 1):S145-6. [NCT01340027] [sr-incont67194]AbramsP , KelleherC , StaskinD , RechbergerT , KayR , MartinaR , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (SYMPHONY). European Urology2015;67(3):577-88. [NCT01340027] [sr-incont66674]NCT01340027, Bristol Urological Institute . A study to evaluate the efficacy, safety and tolerability of mirabegron and solifenacin succinate alone and in combination for the treatment of overactive bladder (symphony) [A randomized, double-blind, factorial, parallel-group, active and placebo-controlled, multicenter dose-ranging study to evaluate the efficacy, safety and tolerability of six dose combinations of solifenacin succinate and mirabegron compared to mirabegron and solifenacin succinate monotherapies in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01340027 (first received 21 April 2011). [178-CL-100] [2010-020601-32] [NCT01340027] [TrialID.SYMPHONY] [sr-incont44510]NittiV , AbramsP , StaskinD , AuerbachS , MartinaR , VanMR . Urinary retention in patients with overactive bladder treated with mirabegron alone and in combination with solifenacin: the results of two randomized, double-blind, phase II studies (Abstract number MP76-13). Journal of Urology2014;191(4 Suppl 1):e886-7. [NCT00410514] [NCT01340027] [TrialID.SYMPHONY] [sr-incont67453]">Abrams 2013</a>; <a href="./references#CD003781-bbs2-0005" title="AlloussiS , Laval KU , Ballering-BruhlB , Grobe-FreeseM , BulittaM , SchaferM . Trospium chloride (Spasmo-lyt) in patients with motor urge syndrome (detrusor instability): a double-blind, randomised, multicentre, placebo-controlled study. Journal of Clinical Research1998;1:439-51. [srincont-12005]AlloussiS , Laval K-U, EckertR , Ballering-BruhlB , Grosse-FreeseM , BulittaM , et al. Trospium chloride (Spasmo-lyt(R)) in patients with motor urge syndrome (detrusor instability): a double-blind, randomised, multicentre, placebo-controlled study. Journal of Drug Assessment1999;2(1):27-39. [sr-incont18226]AlloussiS , Laval K-U, MertinsB . Efficacy and tolerability of trospium chloride (spasmo-lyt) versus placebo in patients with motor urge-syndrome. In: International Continence Society (ICS), 28th Annual Meeting; 1998 Sept 14-17; Jerusalem, Israel. 1998:109-10. [sr-incont5684]">Alloussi 1998</a>; <a href="./references#CD003781-bbs2-0007" title="BrayR , CartwrightR , CardozoL , HillS , GuanZ , KhullarV . Tolterodine ER reduced increased bladder wall thickness in women with overactive bladder. A randomized, placebo-controlled, double-blind, parallel group study. Neurourology and  Urodynamics2018;37(1):237-43. [NCT00137397] [sr-incont74473]NCT00137397. A study to measure the effect of tolterodine extended release on the thickness of the bladder wall in patients with overactive bladder [A multi-centre, randomised, placebo controlled, double blind, parallel group study in female patients to evaluate whether tolterodine ER can reverse the increased bladder wall thickness in patients with overactive bladder]. clinicaltrials.gov/show/NCT00137397 (first received 29 August 2005). [NCT00137397] [sr-incont63809]">Bray 2018</a>; <a href="./references#CD003781-bbs2-0008" title="BurgioKL , LocherJL , GoodePS , HardinJM , McDowellBJ , CandibD . Behavior vs drug therapy for urge incontinence in older women (Abstract number 26). In: American Urogynecology Society, 15th Annual Scientific Meeting; 1994 Sept 21-24; Toronto, Ontario. 1994:48. [sr-incont14585]BurgioKL , LocherJL , GoodePS , HardinM , McDowellBJ , Dombrowski M et al. Behavioral vs drug treatment for urge urinary incontinence in older women. A randomized controlled trial. JAMA1998;280(23):1995-2000. [srincont-5719]BurgioKL , LocherJL , GoodePS . Combined behavioral and drug therapy for urge incontinence in older women. Journal of the American Geriatrics Society2000;48(4):370-4. [srincont-9006]BurgioKL , LocherJL , RothDL , GoodePS . Psychological improvements associated with behavioral and drug treatment of urge incontinence in older women. Journal of Gerontology. Series B, Psychological Sciences and Social Sciences2001;56(1):P46-51. [srincont-11923]">Burgio 1998</a>; <a href="./references#CD003781-bbs2-0009" title="CardozoL , ChappleCR , Toozs-HobsonP , Grosse-FreeseM , BulittaM , LehmacherW , et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomised, double-blind, multicentre clinical trial. British Journal of Urology International2000;85(6):659-64. [srincont-11732]">Cardozo 2000</a>; <a href="./references#CD003781-bbs2-0014" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. ChappleCR , AranoP , BoschJH , De RidderD , KramerG , RidderAM . YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo- and tolterodine-controlled, phase-II, dose-finding study (Abstract 75). Neurourology and Urodynamics2002;21(4):381-2. [srincont-14551]ChappleCR , ArañoP , BoschJL , De RidderD , KramerAE , RidderAM . Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU International2004;93(1):71-7. [srincont-17334]KelleherCJ , CardozoL , ChappleCR , HaabF , RidderAM . Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU International2005;95(1):81-5. [srincont-20241]SmithN , GrimesI , RidgeS , TempelD , UchidaT , YamanouchiUS . YM905 is effective and safe as treatment of overactive bladder in women and men: results from phase II study (Abstract). In: International Continence Society (ICS), 32nd Annual Meeting; 2002 Aug 28-30; Heidelberg, Germany. 2002:138-9. [sr-incont14508]">Chapple 2004b</a>; <a href="./references#CD003781-bbs2-0015" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. ChappleC , RechbergerT , Al-ShukriS , MeffanP , EveraertK , RidderA . Results of a randomized phase 3 study comparing solifenacin succinate with tolterodine and placebo in patients with symptomatic overactive bladder (Abstract). Neurourology and Urodynamics2003;22(5):534-5. [sr-incont16991]ChappleCR , RechbergerT , Al ShukriS , MeffanP , EveraertK , HuangM , et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU International2004;93(3):303-10. [srincont-17270]">Chapple 2004c</a>; <a href="./references#CD003781-bbs2-0016" title="ChappleC , Van KerrebroeckP , TubaroA , Haag-MolkentellerC , ForstHT , MassowU , et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder [Erratum appears in: European Urology 2008,53(6):1319]. European Urology2007;52(4):1204-12. [NCT00220363] [SP583] [srincont-23875]ChappleC , Van KerrebroeckP , TubaroA , MillardR . Fesoterodine in non-neurogenic voiding dysfunction - results on efficacy and safety in a phase 3 trial (Abstract number 379). In: 21st Annual European Association of Urology (EAU) Congress; 2006 Apr 5-8; Paris, France. 2006. [srincont-41109]ChappleC , Van KerrebroeckP , TubaroA , WangJT , HvidstenK , BrodskyM . Efficacy of fesoterodine in patients with overactive bladder (OAB): improvements in OAB symptoms and health-related quality of life (HRQL) (Poster abstract number 1188). Journal of Urology2007;177(4 Suppl S):392. [srincont-31882]ChappleCR , vanKerrebroeckPE , JünemannKP , WangJT , BrodskyM . Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU International2008;102(9):1128-32. [srincont-29255]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. KelleherCJ , TubaroA , WangJT , KoppZ . Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU International2008;102(1):56-61. [srincont-27613]SandPK , MorrowJD , BavendamT , CreangaDL , NittiVW . Efficacy and tolerability of fesoterodine in women with overactive bladder. International Urogynecology Journal2009;20(7):827-35. [srincont-31351]">Chapple 2007a</a>; <a href="./references#CD003781-bbs2-0017" title="ChappleC , DuBeauC , EbingerU , RekedaL , ViegasA . Darifenacin treatment of patients &gt;or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Current Medical Research and Opinion2007;23(10):2347-58. [srincont-23921]">Chapple 2007b</a>; <a href="./references#CD003781-bbs2-0018" title="ChappleCR , DvorakV , RadziszewskiP , vanKerrebroeckP , WyndaeleJJ , BosmanB , et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder. International Urogynecology Journal2013;24(9):1447-58. [178-CL-044] [NCT00337090] [TrialID.DRAGON.] [sr-incont48549]NCT00337090 . A study of YM178 in patients with symptomatic overactive bladder (DRAGON) [A randomized, double-blind, parallel group, placebo and active controlled, multicenter dose ranging study with the beta-3 agonist YM178 in patients with symptomatic overactive bladder]. clinicaltrials.gov/show/NCT00337090 (first received 15 June 2006). [EudraCT2005-002256-17] [JapicCTI-R130350] [NCT00337090] [sr-incont63803]">Chapple 2013</a>; <a href="./references#CD003781-bbs2-0019" title="ChappleC , HaabF , SchneiderT , CarlssonM , ArumiD . Fesoterodine 8 mg versus fesoterodine 4 mg in patients with overactive bladder and a history of previous antimuscarinic therapy: Results from the EIGHT trial (Abstract number: Poster #M5). Neurourology and Urodynamics2015;34(S1):S20. [NCT01302067] [sr-incont68509]ChappleC , SchneiderT , HaabF , SunF , WhelanL , ScholfieldD , et al. Superiority of fesoterodine 8mg versus fesoterodine 4 mg in reducing urgency urinary incontinence episodes in subjects with overactive bladder: results of the randomized, double-blind, placebo-controlled EIGHT trial (Abstract number: Podium #48). Neurourology and Urodynamics2014;33(2):183-4. [NCT01302067] [sr-incont67484]ChappleC , SchneiderT , HaabF , SunF , WhelanL , ScholfieldD , et al. Superiority of fesoterodine 8mg vs 4mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial. BJU International2014;114(3):418-26. [A0221095] [NCT01302067] [TrialID.EIGHT] [srincont-62537]NCT01302067. A 12 week study to confirm the effectiveness of 8mg of Fesoterodine compared to 4mg of Fesoterodine [A 12-week, randomized, double-blind, placebo controlled, parallel group, multicenter trial in overactive bladder subjects to confirm the efficacy of 8 mg fesoterodine compared to 4 mg fesoterodine]. clinicaltrials.gov/show/NCT01302067 (first received 23 February 2011). [NCT01302067] [sr-incont63792]">Chapple 2014</a>; <a href="./references#CD003781-bbs2-0020" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. [sr-incont75259]ChuF , SmithN , UchidaT . Efficacy and safety of solifenacin succinate 10 mg once daily: a multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder. Current Therapeutic Research - Clinical and Experimental2009;70(6):405-20. [srincont-43324]">Chu 2009</a>; <a href="./references#CD003781-bbs2-0021" title="ChuaME , SeeMC , EsmeňaEB , BalingitJC , MoralesML . Efficacy and safety of gabapentin in comparison to solifenacin succinate in adult overactive bladder treatment. Lower Urinary Tract Symptoms2018;10(2):135-42. [NCT01486706] [sr-incont74529]NCT01486706, ChuaME . Efficacy and safety of gabapentin in treating overactive bladder (OAB). clinicaltrials.gov/show/NCT01486706 (first received 6 December 2011). [NCT01486706] [SLMC10-010] [sr-incont49864]">Chua 2018</a>; <a href="./references#CD003781-bbs2-0022" title="AmarencoG , SutoryM , FagertunH , WrightM , CompionG , De RidderD . Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Preliminary results from the SONIC urodynamic study (Abstract). European Urology, Supplements2012;11(1):e467-a. [EudraCT2006-005523-42] [NCT00629642] [sr-incont65392]AmarencoG , SutoryM , ZachovalR , AgarwalM , DelPG , TretterR , et al. Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study. Neurourology and Urodynamics2017;36(2):414-21. [EudraCT2006-005523-42] [JapicCTI-R130306] [NCT00629642] [sr-incont72248]De RidderD , AmarencoG , Finazzi-AgroE , AnguloJ , KurenkovA , WrightM , et al. Solifenacin treatment for neurogenic detrusor overactivity: patient-reported outcomes (PROs) from the randomised clinical trial SONIC (Abstract number 333). In: International Continence (ICS); 42nd Annual Meeting; 2012 Oct 15-19; Beijing, China. 2012. [905-EC-005] [EudraCT2006-005523-42] [NCT00629642] [TrialID.SONIC.] [srincont-49739]">De Ridder 2012</a>; <a href="./references#CD003781-bbs2-0023" title="ChancellorMB , OefeleinMG , VasavadaS . Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release. Neurourology and Urodynamics2010;29(4):551-4. [sr-incont39591]DmochowskiR , StaskinD , SandP , ZinnerN . Trospium chloride 60 mg once daily improves quality of life in subjects with overactive bladder syndrome (Abstract number 277). In: International Continence Society (ICS); 37th Annual Meeting; 2008 Aug 20-24; Rotterdam, the Netherlands. 2007. [srincont-26679]DmochowskiRR , RosenbergMT , ZinnerNR , StaskinDR , SandPK . Extended-release trospium chloride improves quality of life in overactive bladder. Value in Health2010;13(2):251-7. [srincont-40049]DmochowskiRR , SandPK , ZinnerNR , StaskinDR . Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology2008;71(3):449-54. [srincont-27107]DmochowskiRR , ZinnerNR , SandPK . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: Results from a multicenter, phase III, placebo-controlled study (Abstract). Neurourology and Urodynamics2007;26(Suppl 7):1105-6. [srincont-26692]GinsbergDA , OefeleinMG , EllsworthPI . Once-daily administration of trospium chloride extended release provides 24-hr coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials. Neurourology and Urodynamics2011;30(4):563-7. [sr-incont41531]RovnerE , DmochowskiR , WatanabeJ . Once daily (QD) trospium chloride 60 mg extended release (XR) is safe and effective in patients (PTS) with the overactive bladder (OAB) syndrome who use multiple concomitant medications (MEDS) (Abstract number: Poster #68). Neurourology and Urodynamics2009;28(2):146-7. [sr-incont31062]SandP , DmochowskiR , ZinnerN , StaskinD . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: results from a multicenter, phase III, placebo-controlled study (Abstract number 269). In: International Continence Society (ICS), 37th Annual Meeting; 2007 Aug 20-24; Rotterdam, the Netherlands. 2007. [srincont-26676]SandPK , DmochowskiRR , ZinnerNR , StaskinDR , AppellRA . Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome. International Urogynecology Journal and Pelvic Floor Dysfunction2009;20(12):1431-8. [sr-incont39648]SandPK , Johnson IiTM , RovnerES , EllsworthPI , OefeleinMG , StaskinDR . Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged &gt; 75 years) with overactive bladder syndrome. BJU International2011;107(4):612-20. [sr-incont41422]StaskinDR , RosenbergMT , SandPK , ZinnerNR , DmochowskiRR . Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials. International Journal of Clinical Practice2009;63(12):1715-23. [sr-incont35458]">Dmochowski 2008</a>; <a href="./references#CD003781-bbs2-0024" title="DmochowskiR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. A double-blind, placebo-controlled trial of flexible-dose fesoterodine for overactive bladder (Abstract number 715). In: International Continence Society (ICS); 39th Annual Meeting; 2009 Sep 29-Oct 03; San Francisco, CA. 2009. [sr-incont35627]DmochowskiRR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder [Errata appear in: Urology 2010 Jun;75(6):1519 and in Urology 2011 Jun;77(6):1513]. Urology2010;75(1):62-8. [A0221014] [NCT00536484] [sr-incont39548]DuBeauC , KrausSR , SunF , MorrowJD . Fesoterodine in older vs younger subjects with overactive bladder (Abstract number D87). Journal of the American Geriatrics Society2010;58:S218. [NCT00536484] [sr-incont64309]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. [sr-incont78640]NCT00536484. Fesoterodine flexible dose study [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with overactive bladder]. clinicaltrials.gov/show/NCT00536484 (first received 27 September 2007). [NCT00536484] [sr-incont49160]StaskinD , KhullarV , MichelMC , MorrowJD , SunF , GuanZ , et al. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. Neurourology and Urodynamics2011;30(8):1480-5. [sr-incont42686]">Dmochowski 2010</a>; <a href="./references#CD003781-bbs2-0026" title="DrutzH , AppellRA . Clinical efficacy and safety of Tolterodine vs Oxybutynin and placebo in patients with unstable bladder. Acta Obstetrica et Gynecologica Scandinavica1997;Suppl 167(5):24. [srincont-6671]DrutzHP , AppellRA , GleasonD , KlimbergI , RadomskiS . Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. International Urogynecology Journal and Pelvic Floor Dysfunction1999;10(5):283-9. [srincont-8804]DrutzHP , AppellRA . Enhanced tolerability of tolterodine compared to oxybutynin in a controlled clinical study. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(1):S14. [srincont-5166]">Drutz 1999</a>; <a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>; <a href="./references#CD003781-bbs2-0028" title="ElbasetM , TahaD , ZahranM , EzzatO , ElhefnawyAS , ElkenawyM , et al. Subjective and objective scales assessment after retreatment with anticholinergics post botox-faded effects in refractory idiopathic overactive bladder: a prospective single blinded randomized trial (Abstract number 132). European Urology, supplements2019;18(1):e172. [sr-incont78652]ElbasetMA , TahaDE , El-HefnawyAS , ZahranMH , ShokeirAA . Assessment of anticholinergic use after fading of BTX-A effects in refractory idiopathic overactive bladder: a prospective blinded randomized trial. International Neurourology Journal2019;23(3):240-8. [sr-incont78605]">Elbaset 2019</a>; <a href="./references#CD003781-bbs2-0032" title="GellerE , DumondJ , BowlingJM , KhandelwalC , WuJ , Busby-WhiteheadJ , et al. Effect of an anticholinergic on cognitive function in postmenopausal women: a randomized trial (Abstract number: oral poster 52). Female Pelvic Medicine and Reconstructive Surgery2016;22(5):S61. [sr-incont78607]GellerEJ , DumondJB , BowlingJM , KhandelwalCM , WuJM , Busby-WhiteheadJ , et al. Effect of trospium chloride on cognitive function in women aged 50 and older: a randomized trial. Female Pelvic Medicine &amp; Reconstructive Surgery2017;23(2):118-23. [13-1352] [NCT01922115] [sr-incont74341]NCT01922115. The effect of anticholinergics on cognitive function in the elderly (ACE) [The effect of anticholinergics on cognitive function in the elderly: a randomized controlled trial]. clinicaltrials.gov/show/NCT01922115 (first received 14 August 2013). [13-1352] [NCT01922115] [TrialID.ACE] [sr-incont49282]">Geller 2013</a>; <a href="./references#CD003781-bbs2-0033" title="GotohM , HommaY , YokoyamaO , NishizawaO . Responsiveness and minimal clinically important change in overactive bladder symptom score. Urology2011;78(4):768-73. [srincont-42622]GotohM , YokoyamaO , MatsukawaY , NishizawaO . Responsiveness of overactive bladder symptom score (OABSS): verification based on data in a double-blinded, randomized placebo-controlled study of propiverine hydrochloride in Japanese patients (Abstract number 338). In: Joint Meeting of the International Continence Society (ICS) and the International Urogynecological Association; 2010 Aug 23-27; Toronto, Canada. 2010. [srincont-40173]GotohM , YokoyamaO , NishizawaO . Propiverine hydrochloride in Japanese patients with overactive bladder: A randomized, double-blind, placebo-controlled trial. International Journal of Urology2011;18(5):365-73. [srincont-41510]">Gotoh 2011</a>; <a href="./references#CD003781-bbs2-0035" title="HaabF , StewartL , DwyerP . Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. European Urology2004;45(4):420-9. [srincont-17428]">Haab 2004</a>; <a href="./references#CD003781-bbs2-0038" title="HerschornS , HeesakkersJ , Castro-DiazD , WangJT , BrodskyM , GuanZ . Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*. Current Medical Research and Opinion2008;24(12):3513-21. [A6121122] [NCT00143377] [srincont-29250]HerschornS , HeesakkersJ , Castro-DiazD , WangJT , GuanZ , BrodskyM . Tolterodine extended release (TER) improves objective and subjective outcomes after 1 week of treatment in patients with overactive bladder (Abstract number 132). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S78-9. [srincont-26602]">Herschorn 2008</a>; <a href="./references#CD003781-bbs2-0039" title="CorcosJ , AnguloJC , GarelyAD , CarlssonM , GongJ , GuanZ . Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. Current Medical Research and Opinion2011;27(5):1059-65. [srincont-41596]EUCTR2006-006935-38-SE. 12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006935-38 (first received 16 April 2007). [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont64612]HerschornS , SwiftS , GuanZ , CarlssonM , BrodskyM , GongJ . Efficacy and safety of fesoterodine for overactive bladder in a double-blind, head-to-head comparison trial with tolterodine ER and placebo (Abstract number 710). In: International Continence Society (ICS), 39th Annual Meeting; 2009 Sep 29-Oct 3; San Francisco, CA. 2009. [srincont-35326]HerschornS , SwiftS , GuanZ , CarlssonM , MorrowJD , BrodskyM , et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU International2010;105(1):58-66. [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont39540]NCT00444925. Clinical trial to evaluate the efficacy and safety of Fesoterodine in comparison to Tolterodine for overactive bladder (OAB) [12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder (OAB)]. clinicaltrials.gov/show/NCT00444925 (first received 08 March 2007). [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont49159]">Herschorn 2009a</a>; <a href="./references#CD003781-bbs2-0040" title="EUCTR2012-005735-91-SK. A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-005735-91 (first received 12 November 2013). [178-CL-101] [EUCTR2012-005735-91-SK] [sr-incont78644]HerschornS , ChappleCR , AbramsP , ArlandisS , MitchesonD , LeeKS , et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU International2017;120(4):562-75. [NCT01972841] [sr-incont74470]MuellerER , RobinsonD , KelleherC , StaskinDR , FalconerC , WangJ , et al. Patient reported outcomes from synergy, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with mirabegron and solifenacin monotherapy (Abstract number - Podium #44). Neurourology and Urodynamics2017;36(Suppl S1):S151-2. [NCT01972841] [sr-incont75944]NCT01972841. This was a multinational study comparing the efficacy and safety of two medicines, solifenacin succinate and mirabegron taken together, or separately, or a mock treatment (placebo) in subjects with symptoms of overactive bladder (SYNERGY) [A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01972841 (first received 31 October 2013). [178-CL-101] [EUCTR2012-005735-91] [NCT01972841] [sr-incont63780]RobinsonD , KelleherC , StaskinD , MuellerER , FalconerC , WangJ , et al. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients. Neurourology and Urodynamics2018;37(1):394-406. [NCT01972841] [sr-incont76906]WeberMA , ChappleCR , GratzkeC , HerschornS , RobinsonD , FrankelJM , et al. A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial. Blood Pressure Monitoring2018;23(3):153-63. [NCT01972841] [sr-incont77899]WhiteWB , ChappleC , GratzkeC , HerschornS , RobinsonD , FrankelJ , et al. Cardiovascular safety of the beta3-adrenoceptor agonist mirabegron and the antimuscarinic agent solifenacin in the SYNERGY trial. Journal of Clinical Pharmacology2018;58(8):1084-91. [NCT01972841] [sr-incont78078]">Herschorn 2017a</a>; <a href="./references#CD003781-bbs2-0041" title="HerschornS , KohanA , AliottaP , McCammonK , SriramR , AbramsS , et al. The efficacy and safety of onabotulinumtoxin A or solifenacin compared with placebo in solifenacin naive patients with refractory overactive bladder: results from a multicenter, randomized, double-blind phase 3b trial. Journal of Urology2017;198(1):167-75. [NCT01767519] [sr-incont74491]NCT01767519. A study evaluating the efficacy and safety of BOTOX® or solifenacin in patients with overactive bladder and urinary incontinence. clinicaltrials.gov/show/NCT01767519 (first received 14 January 2013). [191622-125] [NCT01767519] [sr-incont49909]">Herschorn 2017b</a>; <a href="./references#CD003781-bbs2-0042" title="HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21072]HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21072]HillS , KhullarV , WyndaeleJJ , LheritierK , . Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. International Urogynecology Journal and Pelvic Floor2006;17(3):239-47. [srincont-22464]">Hill 2005</a>; <a href="./references#CD003781-bbs2-0043" title="HommaY , KawabeK . Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World Journal of Urology2004;22(4):251-6. [srincont-19412]HommaY , PaickJS , LeeJG , KawabeK , Japanese and Korean Tolterodine Study Group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU International2003;92(7):741-7. [srincont-16418]">Homma 2003</a>; <a href="./references#CD003781-bbs2-0044" title="HommaY , YamaguchiT , YamaguchiOA . A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2008;15(9):809-15. [srincont-27742]">Homma 2008</a>; <a href="./references#CD003781-bbs2-0045" title="HommaY , YamaguchiO , Imidafenacin Study Group. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2009;16(5):499-506. [NCT00212732] [ONO-8025-08] [srincont-31368]">Homma 2009</a>; <a href="./references#CD003781-bbs2-0046" title="HuangA , HessR , AryaL , RichterH , SubakL , BradleyC , et al. A randomized controlled trial of simple diagnosis and treatment for urgency urinary incontinence in women (Abstract). Journal of General Internal Medicine2011;26:S1. [NCT00862745] [sr-incont64391]HuangAJ , HessR , AryaLA , RichterHE , SubakLL , BradleyCS , et al. Pharmacologic treatment for urgency-predominant urinary incontinence in women diagnosed using a simplified algorithm: a randomized trial. American Journal of Obstetrics and Gynecology2012;206(5):444.e1-11. [GA0221IX] [NCT00862745] [TrialID.BRIDGES.] [srincont-44636]NCT00862745, BrownJ . Bringing simple urge incontinence diagnosis &amp; treatment to providers (BRIDGES)  [A multi-center, randomized, placebo-controlled clinical trial comparing fesoterodine to placebo in women diagnosed with urge urinary incontinence by the 3 Incontinence Questions (3IQ). Followed by a multi-center open label clinical cohort study of long-term effects of treatment with fesoterodine ]. clinicaltrials.gov/show/NCT00862745 (first received 17 March 2009). [NCT00862745] [sr-incont49836]WarsiQ , HuangA , BrownJS , SchembriM , HessR , AryaLA , et al. The effect of pharmacologic treatment of urgency urinary incontinence on sleep quality and daytime sleepiness (Abstract number: paper 37). Female Pelvic Medicine and Reconstructive Surgery2016;22(5 ):S17-8. [NCT00862745] [TrialID.BRIDGES.] [sr-incont78633]WarsiQA , HuangAJ , HessR , AryaLA , RichterHE , BradleyCS , et al. Association of pharmacologic treatment of urgency urinary incontinence with sleep quality and daytime sleepiness. Obstetrics and Gynecology2018;131(2):204-11. [NCT00862745] [sr-incont78239]WinkelmanW , HuangA , SchembriM , RogersRG , RichterHE , MyersDL , et al. Clinical variables moderating response to pharmacologic treatment of urgency-predominant urinary incontinence in a randomized controlled trial (Abstract number: poster 25). In: Female Pelvic Medicine and Reconstructive Surgery. 37th Annual Scientific Meeting of the American Urogynecologic Society; Aug 2016; United States. Vol. 22. Netherlands: Lippincott Williams and Wilkins, 2016:S81. [NCT00862745] [sr-incont78634]WinkelmanWD , HuangAJ , SchembriM , RogersRG , RichterH , MyersDL , et al. Modifiers of response to treatment with fesoterodine for urgency-predominant urinary incontinence in a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2017;23(2):151-6. [sr-incont74308]">Huang 2012</a>; <a href="./references#CD003781-bbs2-0047" title="JacquetinB , WyndaeleJJ . Tolterodine reduces the number of incontinence episodes in patients with an overactive bladder. European Journal of Obstetrics and Gynecology and Reproductive Biology2001;98(1):97-102. [srincont-12200]JacquetinB , WyndaeleJJ . Tolterodine reduces the number of incontinence episodes in patients with detrusor overactivity. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(1):S30. [srincont-5167]">Jacquetin 2001</a>; <a href="./references#CD003781-bbs2-0048" title="JonasU , HofnerK , MadersbacherH , HolmdahlTH . Efficacy and safety of two doses of Tolterodine compared to placebo in patients with detrusor overactivity. Neurourology and Urodynamics1997;16(5):477-8. [srincont-5841]JonasU , HöfnerK , MadersbacherH , HolmdahlTH . Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group. World Journal of Urology1997;15(2):144-51. [srincont-5436]">Jonas 1997</a>; <a href="./references#CD003781-bbs2-0051" title="EUCTR2007-006451-39-SE. 12-week, randomized, double-blind, double-dummy, placebo controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-006451-39 (first received 20 February 2008). [A0221046] [EUCTR2007-006451-39-SE] [sr-incont64591]KaplanSA , SchneiderT , FooteJ , GuanZ . Superior efficacy of fesoterodine over tolterodine with rapid onset: a prospective, head-to-head, placebo-controlled trial (Abstract number 67). Neurourology and Urodynamics2010;29(6):905-7. [srincont-40130]KaplanSA , SchneiderT , FooteJE , GuanZ , CarlssonM , GongJ . Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU International2011;107(9):1432-40. [A0221046] [NCT00611026] [srincont-41334]">Kaplan 2011</a>; <a href="./references#CD003781-bbs2-0052" title="CardozoL , KaplanS , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: results from the after study (Abstract number 740) [Erratum appears in: European Urology 2014;65(5):e78]. European Urology Supplements2013;12(1):e740-1. [NCT01302054] [sr-incont63732]CardozoL , KaplanS , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. Erratum: A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: results from the AFTER study [Erratum available in: European Urology Supplement 2013;2012:e740-1]. European Urology2014;65(5):e78 . [A0221094] [NCT01302054] [TrialID.AFTER.] [sr-incont61642]GrenaboL , HerschornS , KaplanSA , CardozoL , ScholfieldD , ArumiD , et al. Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptoms. Current Medical Research and Opinion2017;33(10):1731-6. [NCT01302054] [TrialID.AFTER.] [sr-incont76695]KaplanSA , CardozoL , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER. International Journal of Clinical Practice2014;68(9):1065-73. [A0221094] [NCT01302054] [TrialID.AFTER.] [srincont-63977]KaplanSA , HerschornS , CarlssonM , NtaniosF . Urgency urinary incontinence response rates in subjects with overactive bladder treated with fesoterodine 8 mg after suboptimal response to tolterodine extended release 4 mg: a randomized, double-blind, placebo-controlled trial (Abstract number 546). In: International Continence Society (ICS); 43rd Annual Meeting; 2013 Aug 26-30; Barcelona, Spain. 2013. [NCT01302054] [TrialID.AFTER.] [sr-incont49730]NCT01302054. A clinical study in patients with overactive bladder with leakage of urine, to find out if the medicine, Fesoterodine, works in those patients who did not have enough response to the medicine, tolterodine. [A 14 week randomized parallel group placebo-controlled double-blind multicentre study of fesoterodine 8 mg in overactive bladder patients with sub-optimal response to tolterodine 4 mg extended release (ER)]. clinicaltrials.gov/show/NCT01302054 (first received 23 February 2011). [A0221094] [NCT01302054] [TrialID.AFTER.] [sr-incont49845]">Kaplan 2014</a>; <a href="./references#CD003781-bbs2-0054" title="KhullarV , HillS , LavalKU , SchiotzHA , JonasU , VersiE . Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology2004;64(2):269-74; discussion 274-5. [srincont-19498]KhullarV , HillS , SolankiJ . Assessment of health-related quality of life in patients with overactive bladder taking tolterodine extended release versus placebo (Abstract number 318). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21075]">Khullar 2004</a>; <a href="./references#CD003781-bbs2-0063" title="LeeKS , ChooMS , KimDY , KimJC , KimHJ , MinKS , et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. Journal of Urology2005;174(4 Pt 1):1334-8. [sr-incont21016]LeeKS , ChooMS , PaickJS , LeeJG , SeoJT , LeeJZ , et al. Propiverine hydrochloride reduced frequency and perception of urgency in treatment of overactive bladder: a 12 week prospective, randomized, double blind, placebo controlled study (Abstract number 279). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26640]LeeKS , LeeHW , ChooMS , PaickJS , LeeJG , SeoJT , et al. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'. BJU International2010;105(11):1565-70. [2005-01-08] [NCT00903045] [PROUD] [sr-incont39958]NCT00903045. Urinary urgency outcomes following propiverine treatment for an overactive bladder [Urinary urgency outcomes following propiverine treatment for an overactive bladder: propiverine study on overactive bladder including urgency data (PROUD)]. clinicaltrials.gov/show/NCT009030452005;(first received 15 May 2009). [2005-01-08] [NCT00903045] [TrialID.PROUD] [sr-incont49860]">Lee 2006</a>; <a href="./references#CD003781-bbs2-0065" title="ChappleCR , MadersbacherH , DreikornK , DorschnerW , MurtzG . Urodynamics and frequency/volume chart - do they correlate? Treatment analysis of propiverine in comparison to oxybutynin and placebo in urge incontinence (Abstract 224). In: International Continence Society (ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001. [sr-incont14474]HalaskaM , MadersbacherH , VoigtR , HofnerK , MartanA . Propiverine in patients with urgency and urge incontinence - a placebo controlled, multicentre study comparing its tolerability and efficacy with oxybutynin (Abstract number FDP36). International Urogynaecology Journal 2000;11(Suppl 1):S46. [srincont-11912]MadersbacherH , HalaskaM , VoigtR , AlloussiS , HofnerK . A urodynamically controlled multicenter study in patients with urge incontinence: tolerability and efficacy of propiverine hydrochloride in comparison to oxybutynin. In: International Continence Society (ICS), 27th Annual Meeting; 1997 Sep 23-26; Yokohama, Japan. 1997:153-4. [srincont-5854]MadersbacherH , HalaskaM , VoigtR , AlloussiS , HöfnerK . A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU International1999;84(6):646-51. [srincont-9166]">Madersbacher 1999</a>; <a href="./references#CD003781-bbs2-0066" title="Malone-LeeJG , WalshB , MaugourdMF , Tolterodine in the Elderly Study Group. The safety and clinical efficacy of two doses of tolterodine compared to placebo in elderly patients. In: International Continence Society (ICS), 27th Annual Meeting; 1997 Sep 23-26; Yokohama, Japan. 1997:155-6. [srincont-5855]Malone‐LeeJG , WalshJB , MaugourdMF . Tolterodine: A safe and effective treatment for older patients with overactive bladder. Journal of the American Geriatric Society2001;49(6):700-5. [srincont-12319]WaggA , Malone-LeeJ . Pressure-flow variables in patients treated with tolterodine for detrusor overactivity. BJU International2003;92(9):969-71. [sr-incont16659]">Malone‐Lee 2001</a>; <a href="./references#CD003781-bbs2-0067" title="MillardR , TuttleJ , MooreK , SussetJ , ClarkeB , DwyerP , et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. Journal of Urology1999;161(5):1551-5. [sr-incont8172]MooreK , MillardR , DwyerP , TuttleJ . A randomized controlled multicentre trial of tolterodine in detrusor instability/hyperreflexia. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(Suppl 1):S129. [sr-incont5171]RosamiliaA , DwyerPL , ClarkeB , MooreK , MillardRP , TuttleJ . The clinical efficacy and safety of two doses of Tolterodine in detrusor instability. Acta Obstetrica et Gynecologica Scandinavica1997;6(Suppl 167):24. [sr-incont6670]">Millard 1999</a>; <a href="./references#CD003781-bbs2-0068" title="DmochowskiR , MitchesonD , FrenklT , BennettN , MuddPN . Durable efficacy and safety of long-term once-daily vibegron, a novel oral B-3 adrenergic receptor agonist: A 52-week phase 2 study in patients with overactive bladder syndrome (Abstract number PD50-03). Journal of Urology2018;199(4):e970-1. [sr-incont78091]EUCTR2010-022121-15-IT. A phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2 part clinical study of the efficacy and safety of MK-4618 in patients with overactive bladder - MK4618-008 [A 52-week extension to: a phase iib randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder]. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-022121-15 (first received 12 April 2011). [EUCTR2010-022121-15-IT] [MK4618-008] [NCT01314872] [sr-incont78639]MitchesonD , FrenklT , SamantaS , Anne PintoC , GreenS , BennettN , et al. Vibegron, a novel once daily oral beta-3 agonist, significantly reduces average daily micturitions, urge incontinence episodes and urgency episodes in patients with overactive bladder (Abstract number: podium #34). Neurourology and Urodynamics2018;37(Suppl 1):S565. [EUCTR2010-022121-15-IT] [NCT01314872] [sr-incont78618]MitchesonD , PintoCA , FrenklT , ChenL , PrasadM , MuddPN . Once daily vibegron improves quality of life measures in patients with overactive bladder (Abstract number PUK17). Value in Health2018;21(Suppl 1):S267-8. [EUCTR2010-022121-15-IT] [NCT01314872;] [sr-incont78619]MitchesonHD , SamantaS , MuldowneyK , PintoCA , RochaBA , GreenS , et al. Vibegron (RVT-901/MK-4618/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial. European Urology2019;75(2):274-82. [NCT01314872] [sr-incont78620]NCT01314872. A study of the efficacy and safety of Vibegron (MK-4618) in participants with overactive bladder (OAB) (MK-4618-008) [A phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder a 52-week extension to: a phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder]. clinicaltrials.gov/show/NCT01314872 (first received 15 March 2011). [NCT01314872] [sr-incont63793]UKCRN10391. A phase IIB randomised, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of MK-4618 in patients with overactive bladder . public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=10391 (accessed 28 June 2012). [CCRN525] [UKCRN10391] [sr-incont45046]">Mitcheson 2019</a>; <a href="./references#CD003781-bbs2-0073" title="NCT01302938. Web-based methodology trial to evaluate the efficacy and safety of tolterodine ER in subjects with overactive bladder (REMOTE) [Exploratory, randomized, double-blind, placebo-controlled, parallel-group, single center, web-based phase IV pilot methodolgy trial to evaluate the efficacy and safety of tolterodine ER in subjects with overactive bladder]. clinicaltrials.gov/ct2/show/NCT01302938 (first received 24 February 2011). [A6121195] [NCT01302938] [TrialID.REMOTE.] [sr-incont43314]OrriM , LipsetCH , JacobsBP , CostelloAJ , CummingsSR . Web-based trial to evaluate the efficacy and safety of tolterodine ER 4 mg in participants with overactive bladder: REMOTE trial. Contemporary Clinical Trials2014;38(2):190-7. [A6121195] [NCT01302938] [TrialID.REMOTE.] [sr-incont62536]">Orri 2014</a>; <a href="./references#CD003781-bbs2-0077" title="RogersR , BachmannG , JumadilovaZ , SunF , MorrowJD , GuanZ , et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. International Urogynecology Journal and Pelvic Floor Dysfunction2008;19(11):1551-7. [A6121002] [NCT00143481] [srincont-27729]RogersRG , BachmannG , ScarperoH , JumadilovaZ , SunF , MorrowJD , et al. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. Current Medical Research and Opinion2009;25(9):2159-65. [srincont-32060]">Rogers 2008</a>; <a href="./references#CD003781-bbs2-0080" title="RudyD , ClineK , GoldbergK , HarrisR . A multicenter, randomized, placebo-controlled trial of trospium chloride in overactive bladder patients (Abstract). Neurourology and Urodynamics2004;23(5/6):600-1. [sr-incont19025]RudyD , ClineK , HarrisR , GoldbergK , DmochowskiR . Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology2006;67(2):275-80. [srincont-21604]RudyD , ClineK , HarrisR , GoldbergK , DmochowskiR . Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. BJU International2006;97(3):540-6. [sr-incont21593]">Rudy 2006</a>; <a href="./references#CD003781-bbs2-0082" title="ChancellorMB , OefeleinMG , VasavadaS . Obesity is associated with a more severe overactive bladder disease state that is effectively treated with one daily administration of trospium chloride extended release [Erratum available in: Neurourology and Urodynamics 2010;29(5):804]. Neurourology and Urodynamics2010;29(4):551-4. [sr-incont39591]GinsbergDA , OefeleinMG , EllsworthPI . Once-daily administration of trospium chloride extended release provides 24-hour coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials. Neurourology and Urodynamics2011;30(4):563-7. [sr-incont41531]RovnerE , DmochowskiR , WatanabeJ . Once daily (QD) trospium chloride 60mg extended release (XR) is safe and effective in patients (PTS) with the overactive bladder (OAB) syndrome who use multiple concomitant medications (MEDS) (Abstract number: Poster #68). Neurourology and Urodynamics2009;28(2):146-7. [sr-incont31062]SandP , DmochowskiR , ZinnerN , StaskinD . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: results from a multicenter, phase III, placebo-controlled study (Abstract number 269). In: International Continence Society (ICS), 37th Annual Meeting; 2007 Aug 20-24; Rotterdam, the Netherlands. 2007. [sr-incont26676]SandP , StaskinD , ZinnerN , DmochowskiR . Once-daily trospium chloride extended release is effective and well tolerated for the treatment of overactive bladder: results from a multicenter, phase III trial (Abstract number 57). Neurourology and Urodynamics2007;26(5):675. [sr-incont26661]StaskinD , SandP , ZinnerN , DmochowskiR , Trospium Study Group. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. Journal of Urology2007;178(3 Pt 1):978-83; discussion 983-4. [srincont-23909]StaskinDR , RosenbergMT , SandPK , ZinnerNR , DmochowskiRR . Trospium chloride once daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised phase III trials. International Journal of Clinical Practice2009;63(12):1715-23. [sr-incont35458]StaskinDR , SandPK , ZinnerNR . Once-daily trospium chloride extended release is effective and well tolerated for the treatment of overactive bladder: results from a multicenter, phase III trial (Abstract number - poster 22). Neurourology and Urodynamics2007;26(7 Suppl):1106. [srincont-27305]">Staskin 2007</a>; <a href="./references#CD003781-bbs2-0089" title="ThuroffJW , BunkeB , EbnerA , FaberP , deGeeterP , HannappelJ , et al. Randomized, double-blind multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin vs. propantheline vs. placebo. Neurourology and Urodynamics1990;9(4):337-8. [srincont-5108]ThuroffJW , BunkeB , EbnerA , FaberP , deGeeterP , HannappelJ , et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. Journal of Urology1991;145(4):813-7. [srincont-1288]">Thuroff 1991</a>; <a href="./references#CD003781-bbs2-0090" title="UlshoferB , BihrAM , BodekerRH , SchwantesU , JahnHP . Randomised, double-blind, placebo-controlled study on the efficacy and tolerance of trospium chloride in patients with motor urge incontinence. Clinical Drug Investigation2001;21(8):563-9. [srincont-16324]UlshoferB , SchwantesU , BodekerRH , BihrAM , JahnHP . Efficacy and tolerance of trospium chloride in patients with motor urge incontinence - results of a randomised double-blind placebo-controlled study (Poster presentations). In: 2nd International Consultation on Incontinence (ICI); 2001 July 1-3; Paris, France. 2001:5. [srincont-16318]">Ulshofer 2001</a>; <a href="./references#CD003781-bbs2-0092" title="ChancellorM , FreedmanS , MitchesonHD , AntociJ , PrimusG , WeinA . Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clinical Drug Investigation2000;19(2):83-91. [srincont-16326]FreemanR , HillS , MillardR , SlackM , SutherstJ , Tolterodine Study Group. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstetrics and Gynecology2003;102(3):605-11. [srincont-16494]GarelyA , Tolterodine Study Group. Once-daily tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder. International Urology Journal2001;12(Suppl 1):S18. [srincont-12012]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of life of patients with overactive bladder receiving tolterodine. Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of patients with overactive bladder receiving tolterodine (Abstract number 82). Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , ReesePR . Health related quality of life of patients with overactive bladder receiving tolterodine once-daily. Neurourology and Urodynamics2000;19(4):519-21. [srincont-9987]KelleherCJ , ReesePR , PleilAM , OkanoGJ . Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. American Journal of Managed Care2002;8(Suppl 19):S608-15. [srincont-17998]KelleherCJ , Tolterodine Study Group. Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2000;11(Suppl 1):S94. [srincont-11915]KrederKJ . Antimuscarinic therapy: relationship between efficacy and side effects in responders and non-responders. Journal of Urology2001;165(Suppl 5):S165. [srincont-16327]KrederKJ . Clinical effectiveness of antimuscarinic therapy: the relationship between efficacy and tolerability. In: Proceedings of the International Continence Society Annual Meeting(ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001:140. [srincont-14376]MallettV . Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2001;12(Suppl 1):4. [srincont-12011]MillardRJ , TamaddonK , Tolterodine Study Group. Randomized controlled trial to compare tolterodine prolonged release capsules and tolterodine immediate release tablets versus placebo in patients with symptoms of detrusor overactivity (Abstract number 57). Australian and New Zealand Journal of Surgery2002;Suppl 72:A140. [sr-incont22190]PleilAM , ReesePR , KelleherCJ , OkanoGJ . Health-related quality of life of patients with overactive bladder receiving immediate-release tolterodine. HEPAC Health Economics in Prevention and Care2001;2(2):69-75. [sr-incont18060]RoehrbornCG , AbramsP , RovnerES , KaplanSA , HerschornS , GuanZ . Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU International2006;97(5):1003-6. [sr-incont21882]SwiftS . Efficacy and tolerability of once-daily tolterodine for women with overactive bladder. In: International Continence Society Annual Meeting (ICS), 31st annual meeting; 2001 Sept 18-21; Seoul, Korea. 2001:No. 329. [srincont-14481]SwiftS . Once-daily tolterodine is effective and well tolerated in women with overactive bladder (Abstract 57). In: 2nd International Consultation on Incontinence; 2001 July 1-3; Paris, France. 2001. [srincont-16319]SwiftSE . Once-daily (OD) tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder (OAB). International Urogynecology Journal2000;11(Suppl 1):S15. [sr-incont11906]SwiftSE . Once-daily administration of extended-release tolterodine is effective and well-tolerated in patients with overactive bladder. In: XVI FIGO World Congress of Obstetrics and Gynecology; 2000 Sept 3-8; Washington DC. Vol. Book 1. 2000:40. [sr-incont12085]SwiftSE . Overactive bladder in females: treatment with once-daily tolterodine. International Urogynecology Journal2001;12(Suppl 3):S71. [sr-incont16328]Van KerrebroeckP , KrederK , JonasU , ZinnerN . Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology2001;57(3):414-21. [sr-incont11953]Van KerrebroeckPEV . Long-term (12 months) efficacy and tolerability of tolterodine once-daily in the treatment of overactive bladder. Neurourology and Urodynamics2001;20(4):401-2. [sr-incont15714]Van KerrebroeckPEVA , Tolterodine Study Group. Long-term tolerability and efficacy of once-daily (OD) tolterodine in the treatment of overactive bladder (OB). International Urogynecology Journal2001;12(Suppl 3):S49. [sr-incont16329]Van KerrebroeckPEVA , Tolterodine Study Group. Significant decreases in perception of urgency and urge incontinence episodes with once-daily tolterodine treatment in patients with overactive bladder (Abstract number 89). Neurourology and Urodynamics2000;19(4):493-4. [sr-incont9980]WeinAJ , KhullarV , WangJT , GuanZ . Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. BJU International2007;99(2):360-3. [sr-incont23180]vanKerrebroeckPE , KelleherCJ , CoyneKS , KoppZ , BrodskyM , WangJT . Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. Health and Quality of Life Outcomes2009;7(13):13. [10.1186/1477-7525-7-13] [sr-incont31438]vanKerrebroeckPE , WangJ , GuanZ . Effects of tolterodine extended release in patients with overactive bladder: perceived treatment benefits improve with efficacy (Abstract number 511). European Urology Supplements2004;3(2):130. [sr-incont31090]">Van Kerrebroeck 2001</a>; <a href="./references#CD003781-bbs2-0093" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CrosbyRD , MathiasSD , MarshallTS . Relationships between symptoms, symptom bother, and health-related quality of life in patients with overactive bladder taking solifenacin or placebo in the VIBRANT study. International Journal of Clinical Practice2011;65(2):211-8. [sr-incont41015]GollarKM , YoungDG , BailenJ , HeW , Forero-SchwanhaeuserS . Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: a secondary analysis of the VIBRANT study. Urologic Nursing2012;32(1):38-46. [TrialID.VIBRANT.] [sr-incont44571]Samuels T‐A, MitchesonHD , VardyM , Forero‐SchwanhaeuserS , MarshallT , HeW . Efficacy of solifenacin for symptom bother and other patient-reported outcomes in patients with overactive bladder (OAB): results of a large, double-blind, placebo-controlled trial (Abstract number: poster #74). Neurourology and Urodynamics2009;28(2):149. [sr-incont31063]VardyMD , MitchesonHD , SamuelsTA , Forero-SchwanhaeuserS , HeW . Efficacy of solifenacin on overactive bladder symptoms, symptom bother, and other patient-reported outcomes in subjects with or without incontinence: a post hoc analysis of data from VIBRANT. Female Pelvic Medicine and Reconstructive Surgery2011;17(1):24-9. [TrialID.VIBRANT.] [sr-incont44741]VardyMD , MitchesonHD , SamuelsTA , WegenkeJD , Forero-SchwanhaeuserS , MarshallTS , et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. International Journal of Clinical Practice2009;63(12):1702-14. [905-UC-010] [NCT00573508] [TrialID.VIBRANT.] [sr-incont35459]">Vardy 2009</a>; <a href="./references#CD003781-bbs2-0094" title="EUCTR2007-007087-17-SE. A 24-week, multicentre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-007087-17 (first received 13 June 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont64588]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00798434. A study to compare the effectiveness and safety of fesoterodine and placebo in an elderly population of patients who go to the toilet very frequently due to overactive bladder (SOFIA) [A 24-week, multi-centre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00798434 (first received 26 November 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont49847]SchneiderT , BergqvistA , WangJ , WaggA , Ebel-BitounC . Treatment with fesoterodine versus tolterodine for reducing symptom bother in elderly patients with overactive bladder including urgency urinary incontinence. European Urology, Supplements2012;11(1):e687-a. [sr-incont65389]WaggA , CarlssonM , ElsobkyM , FernetM . Effect of flexible dose fesoterodine on cognitive function in &gt;65 year old patients with OAB: data from two RCT (Abstract number 438). Neurourology and Urodynamics2019;38:S297-8. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78651]WaggA , DarekarA , ArumiD , KhullarV , OelkeM . Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people &gt;65 years of age: a post hoc analysis of data from the SOFIA study. Neurourology and Urodynamics2015;34(5):438-43. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont68100]WaggA , ElsobkyM , CarlssonM , FernetM . Response and cognitive safety of fesoterodine in patients &gt;65y old with OAB. Is there a relationship between cognition and treatment response? (Abstract number 183). Neurourology and Urodynamics2019;38:S118-20. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78632]WaggA , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. Journal of the American Geriatrics Society2013;61(2):185-93. [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TrialID.SOFIA.] [sr-incont48008]WaggAS , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Efficacy and tolerability of fesoterodine in older subjects with overactive bladder: results of SOFIA (Abstract number C33). Journal of the American Geriatrics Society2011;59:S124. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont65234]">Wagg 2013a</a>; <a href="./references#CD003781-bbs2-0096" title="YamaguchiO , MaruiE , KakizakiH , ItohN , YokotaT , OkadaH , et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU International2007;100(3):579-87. [sr-incont23865]YokoyamaO , YamaguchiO , KakizakiH , ItohN , YokotaT , OkadaH , et al. Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary. Journal of Urology2011;186(1):170-4. [sr-incont41734]">Yamaguchi 2007</a>; <a href="./references#CD003781-bbs2-0097" title="NCT00966004. A study to evaluate safety and efficacy of ym178 in patients with overactive bladder [Phase III study of YM178 - a placebo-controlled, double-blind, group comparison study in patients with overactive bladder]. clinicaltrials.gov/show/NCT00966004 (first received 26 August 2009). [178-CL-048] [JapicCTI-R130370] [NCT00966004] [sr-incont63783]YamaguchiO , HidehiroK , YukioH , YasuhikoI , MasayukiT , OsamuN , et al. A phase III, randomized, double-blind, placebo and active controlled study of once-daily mirabegron 50 mg in patients with overactive bladder (Abstract number POD-03.06). Urology2012;80(3 Suppl 1):S10-1. [NCT00966004] [sr-incont65380]YamaguchiO , MaruiE , KakizakiH , HommaY , IgawaY , TakedaM , et al. A phase III, randomized, double-blind, placebo-controlled study of the beta-adrenoceptor agonist, mirabegron 50 mg once-daily, in Japanese patients with overactive bladder. BJU International2014;113(6):951-60. [NCT00966004] [sr-incont50603]">Yamaguchi 2012</a>; <a href="./references#CD003781-bbs2-0098" title="YamaguchiO , UchidaE , HigoN , MinamiH , KobayashiS , SatoH , et al. Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: a randomized double-blind trial. International Journal of Urology2014;21(6):586-93. [JapicCTI-101309] [sr-incont62099]">Yamaguchi 2014</a>; <a href="./references#CD003781-bbs2-0099" title="YongucT , SefikE , InciI , KusbeciOY , CelikS , AydinME , et al. Randomized, controlled trial of fesoterodine fumarate for overactive bladder in Parkinson's disease. World Journal of Urology2019;38(8):2013-9. [sr-incont78635]">Yonguc 2019</a>; <a href="./references#CD003781-bbs2-0101" title="NCT01018264, ZesiewiczT . Solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease (URGE-PD) [URGE-PD: a multi-site, double-blind, randomized, placebo controlled trial of solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease]. clinicaltrials.gov/show/NCT01018264 (first received 23 November 2009). [NCT01018264] [sr-incont63790]ZesiewiczTA , EvattM , JahanI , VaughanC , SingerC , OrdoricaR , et al. URGE-PD: a multi-site, double-blind, randomized, placebo controlled trial of solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease (Abstract number 745). Movement Disorders2014;29(Suppl 1):S276-7. [NCT01018264] [sr-incont66602]ZesiewiczTA , EvattM , VaughanCP , JahanI , SingerC , OrdoricaR , et al. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease. Parkinsonism and Related Disorders2015;21(5):514-20. [NCT01018264] [sr-incont66860]">Zesiewicz 2015</a>; <a href="./references#CD003781-bbs2-0102" title="ZinnerNR , MattiassonA , StantonSL . Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. Journal of the American Geriatrics Society2002;50(5):799-807. [sr-incont14679]">Zinner 2002</a>).  </p> </section> </section> <section id="CD003781-sec-0070"> <h3 class="title" id="CD003781-sec-0070">Effects of interventions</h3> <p>See: <a href="./full#CD003781-tbl-0001"><b>Summary of findings 1</b> Anticholinergics compared to placebo for overactive bladder syndrome in adults</a> </p> <section id="CD003781-sec-0071"> <h4 class="title">Primary outcomes</h4> <section id="CD003781-sec-0072"> <h5 class="title">Mean change from baseline in condition‐specific quality of life</h5> <p>Twelve studies with a total of 6804 participants (3906 in the anticholinergic group and 2898 in the placebo group) contributed to the meta‐analysis of this outcome (<a href="./references#CD003781-bbs2-0017" title="ChappleC , DuBeauC , EbingerU , RekedaL , ViegasA . Darifenacin treatment of patients &gt;or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Current Medical Research and Opinion2007;23(10):2347-58. [srincont-23921]">Chapple 2007b</a>; <a href="./references#CD003781-bbs2-0021" title="ChuaME , SeeMC , EsmeňaEB , BalingitJC , MoralesML . Efficacy and safety of gabapentin in comparison to solifenacin succinate in adult overactive bladder treatment. Lower Urinary Tract Symptoms2018;10(2):135-42. [NCT01486706] [sr-incont74529]NCT01486706, ChuaME . Efficacy and safety of gabapentin in treating overactive bladder (OAB). clinicaltrials.gov/show/NCT01486706 (first received 6 December 2011). [NCT01486706] [SLMC10-010] [sr-incont49864]">Chua 2018</a>; <a href="./references#CD003781-bbs2-0022" title="AmarencoG , SutoryM , FagertunH , WrightM , CompionG , De RidderD . Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Preliminary results from the SONIC urodynamic study (Abstract). European Urology, Supplements2012;11(1):e467-a. [EudraCT2006-005523-42] [NCT00629642] [sr-incont65392]AmarencoG , SutoryM , ZachovalR , AgarwalM , DelPG , TretterR , et al. Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study. Neurourology and Urodynamics2017;36(2):414-21. [EudraCT2006-005523-42] [JapicCTI-R130306] [NCT00629642] [sr-incont72248]De RidderD , AmarencoG , Finazzi-AgroE , AnguloJ , KurenkovA , WrightM , et al. Solifenacin treatment for neurogenic detrusor overactivity: patient-reported outcomes (PROs) from the randomised clinical trial SONIC (Abstract number 333). In: International Continence (ICS); 42nd Annual Meeting; 2012 Oct 15-19; Beijing, China. 2012. [905-EC-005] [EudraCT2006-005523-42] [NCT00629642] [TrialID.SONIC.] [srincont-49739]">De Ridder 2012</a>; <a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>; <a href="./references#CD003781-bbs2-0038" title="HerschornS , HeesakkersJ , Castro-DiazD , WangJT , BrodskyM , GuanZ . Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*. Current Medical Research and Opinion2008;24(12):3513-21. [A6121122] [NCT00143377] [srincont-29250]HerschornS , HeesakkersJ , Castro-DiazD , WangJT , GuanZ , BrodskyM . Tolterodine extended release (TER) improves objective and subjective outcomes after 1 week of treatment in patients with overactive bladder (Abstract number 132). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S78-9. [srincont-26602]">Herschorn 2008</a>; <a href="./references#CD003781-bbs2-0040" title="EUCTR2012-005735-91-SK. A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-005735-91 (first received 12 November 2013). [178-CL-101] [EUCTR2012-005735-91-SK] [sr-incont78644]HerschornS , ChappleCR , AbramsP , ArlandisS , MitchesonD , LeeKS , et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU International2017;120(4):562-75. [NCT01972841] [sr-incont74470]MuellerER , RobinsonD , KelleherC , StaskinDR , FalconerC , WangJ , et al. Patient reported outcomes from synergy, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with mirabegron and solifenacin monotherapy (Abstract number - Podium #44). Neurourology and Urodynamics2017;36(Suppl S1):S151-2. [NCT01972841] [sr-incont75944]NCT01972841. This was a multinational study comparing the efficacy and safety of two medicines, solifenacin succinate and mirabegron taken together, or separately, or a mock treatment (placebo) in subjects with symptoms of overactive bladder (SYNERGY) [A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01972841 (first received 31 October 2013). [178-CL-101] [EUCTR2012-005735-91] [NCT01972841] [sr-incont63780]RobinsonD , KelleherC , StaskinD , MuellerER , FalconerC , WangJ , et al. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients. Neurourology and Urodynamics2018;37(1):394-406. [NCT01972841] [sr-incont76906]WeberMA , ChappleCR , GratzkeC , HerschornS , RobinsonD , FrankelJM , et al. A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial. Blood Pressure Monitoring2018;23(3):153-63. [NCT01972841] [sr-incont77899]WhiteWB , ChappleC , GratzkeC , HerschornS , RobinsonD , FrankelJ , et al. Cardiovascular safety of the beta3-adrenoceptor agonist mirabegron and the antimuscarinic agent solifenacin in the SYNERGY trial. Journal of Clinical Pharmacology2018;58(8):1084-91. [NCT01972841] [sr-incont78078]">Herschorn 2017a</a>; <a href="./references#CD003781-bbs2-0046" title="HuangA , HessR , AryaL , RichterH , SubakL , BradleyC , et al. A randomized controlled trial of simple diagnosis and treatment for urgency urinary incontinence in women (Abstract). Journal of General Internal Medicine2011;26:S1. [NCT00862745] [sr-incont64391]HuangAJ , HessR , AryaLA , RichterHE , SubakLL , BradleyCS , et al. Pharmacologic treatment for urgency-predominant urinary incontinence in women diagnosed using a simplified algorithm: a randomized trial. American Journal of Obstetrics and Gynecology2012;206(5):444.e1-11. [GA0221IX] [NCT00862745] [TrialID.BRIDGES.] [srincont-44636]NCT00862745, BrownJ . Bringing simple urge incontinence diagnosis &amp; treatment to providers (BRIDGES)  [A multi-center, randomized, placebo-controlled clinical trial comparing fesoterodine to placebo in women diagnosed with urge urinary incontinence by the 3 Incontinence Questions (3IQ). Followed by a multi-center open label clinical cohort study of long-term effects of treatment with fesoterodine ]. clinicaltrials.gov/show/NCT00862745 (first received 17 March 2009). [NCT00862745] [sr-incont49836]WarsiQ , HuangA , BrownJS , SchembriM , HessR , AryaLA , et al. The effect of pharmacologic treatment of urgency urinary incontinence on sleep quality and daytime sleepiness (Abstract number: paper 37). Female Pelvic Medicine and Reconstructive Surgery2016;22(5 ):S17-8. [NCT00862745] [TrialID.BRIDGES.] [sr-incont78633]WarsiQA , HuangAJ , HessR , AryaLA , RichterHE , BradleyCS , et al. Association of pharmacologic treatment of urgency urinary incontinence with sleep quality and daytime sleepiness. Obstetrics and Gynecology2018;131(2):204-11. [NCT00862745] [sr-incont78239]WinkelmanW , HuangA , SchembriM , RogersRG , RichterHE , MyersDL , et al. Clinical variables moderating response to pharmacologic treatment of urgency-predominant urinary incontinence in a randomized controlled trial (Abstract number: poster 25). In: Female Pelvic Medicine and Reconstructive Surgery. 37th Annual Scientific Meeting of the American Urogynecologic Society; Aug 2016; United States. Vol. 22. Netherlands: Lippincott Williams and Wilkins, 2016:S81. [NCT00862745] [sr-incont78634]WinkelmanWD , HuangAJ , SchembriM , RogersRG , RichterH , MyersDL , et al. Modifiers of response to treatment with fesoterodine for urgency-predominant urinary incontinence in a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2017;23(2):151-6. [sr-incont74308]">Huang 2012</a>; <a href="./references#CD003781-bbs2-0050" title="JünemannKP , HessdörferE , Unamba‐OparahI , BerseM , BrünjesR , MadersbacherH . Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. Urologia Internationalis2006;77(4):334-9. [srincont-22199]">Junemann 2006</a>;  <a href="./references#CD003781-bbs2-0052" title="CardozoL , KaplanS , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: results from the after study (Abstract number 740) [Erratum appears in: European Urology 2014;65(5):e78]. European Urology Supplements2013;12(1):e740-1. [NCT01302054] [sr-incont63732]CardozoL , KaplanS , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. Erratum: A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: results from the AFTER study [Erratum available in: European Urology Supplement 2013;2012:e740-1]. European Urology2014;65(5):e78 . [A0221094] [NCT01302054] [TrialID.AFTER.] [sr-incont61642]GrenaboL , HerschornS , KaplanSA , CardozoL , ScholfieldD , ArumiD , et al. Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptoms. Current Medical Research and Opinion2017;33(10):1731-6. [NCT01302054] [TrialID.AFTER.] [sr-incont76695]KaplanSA , CardozoL , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER. International Journal of Clinical Practice2014;68(9):1065-73. [A0221094] [NCT01302054] [TrialID.AFTER.] [srincont-63977]KaplanSA , HerschornS , CarlssonM , NtaniosF . Urgency urinary incontinence response rates in subjects with overactive bladder treated with fesoterodine 8 mg after suboptimal response to tolterodine extended release 4 mg: a randomized, double-blind, placebo-controlled trial (Abstract number 546). In: International Continence Society (ICS); 43rd Annual Meeting; 2013 Aug 26-30; Barcelona, Spain. 2013. [NCT01302054] [TrialID.AFTER.] [sr-incont49730]NCT01302054. A clinical study in patients with overactive bladder with leakage of urine, to find out if the medicine, Fesoterodine, works in those patients who did not have enough response to the medicine, tolterodine. [A 14 week randomized parallel group placebo-controlled double-blind multicentre study of fesoterodine 8 mg in overactive bladder patients with sub-optimal response to tolterodine 4 mg extended release (ER)]. clinicaltrials.gov/show/NCT01302054 (first received 23 February 2011). [A0221094] [NCT01302054] [TrialID.AFTER.] [sr-incont49845]">Kaplan 2014</a>; <a href="./references#CD003781-bbs2-0055" title="AballéaS , MamanK , ThokagevistkK , NazirJ , OdeyemiIA , HakimiZ , et al. Cost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United Kingdom. Clinical Drug Investigation2015;35(2):83-93. [NCT00689104] [sr-incont66445]Arlandis-GuzmánS , Brenes-BermúdezF , Jiménez-CidreMA , Rubio-RodríguezD , Rubio-TerrésC , MoraAM , et al. Cost effectiveness of Mirabegron and antimuscarinic drugs in patients with hiperactive bladder [Coste-efectividad de mirabegrón y los antimuscarínicos en pacientes con vejiga hiperactiva]. Archivos Espanoles de Urologia2018;71(10):809-24. [NCT00689104] [sr-incont78645]EUCTR2007-001451-19-ES. A randomized, double-blind, parallel group, placebo and active controlled, multicenter study to assess the efficacy and safety of the beta-3 agonist YM178 (50 mg qd and 100 mg qd) in subjects with symptoms of overactive bladder - SCORPIO [Estudio multicentrico, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo y tratamiento activo, para evaluar la eficacia y seguridad del agonista beta-3 YM178 (50 mg, una vez al dia y 100 mg, una vez al dia) en pacientes con sintomas de vejiga hiperactiva]. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-001451-19 (first received 05 June 2008). [EUCTR2007-001451-19-ES] [sr-incont78646]HerschornS , NazirJ , RamosB , HakimiZ . Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada. Canadian Urological Association Journal2017;11(3-4):123-30. [NCT00689104] [sr-incont76807]KhullarV , AmarencoG , AnguloJ , BoerrigterP , BlauwetM , HakimiZ . The potent and selective beta3-adrenoceptor agonist mirabegron improves patient-reported outcomes in the treatment of overactive bladder (Abstract number MP-12.16). Urology2012;80(3 Suppl 1):S123. [sr-incont65379]KhullarV , AmarencoG , AnguloJC , BlauwetMB , NazirJ , OdeyemiIA , et al. Patient-reported outcomes with the β3 beta3-adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder. Neurourology and Urodynamics2016;35(8):987-94. [NCT00689104] [sr-incont72221]KhullarV , AmarencoG , AnguloJC , CambroneroJ , HøyeK , MilsomI , et al. Efficacy and tolerability of mirabegron, a ß3-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. European Urology2013;63(2):283-95. [NCT00689104] [TrialID.SCORPIO.] [sr-incont46836]KhullarV , CambroneroJ , AnguloJ , WooningM , BlauwetM , SiddiquiE , et al. Onset of action of efficacy of the potent and selective beta-3-adrenoceptor agonist, mirabegron, for the treatment of overactive bladder (OAB) in a 12-week, multicentre, randomised, double-blind, parallel-group, placebo-and tolterodine slow release (SR)-controlled study in OAB patients (Abstract number 135). International Urogynecology Journal and Pelvic Floor Dysfunction2012;23(2 Suppl 1):S187-8. [NCT00689104] [sr-incont67382]KhullarV , CambroneroJ , AnguloJC , WooningM , BlauwetMB , DorrepaalC , et al. Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial. BMC Urology2013;13:45. [NCT00689104] [sr-incont49411]KhullarV , CambroneroJ , StroebergP , AnguloJ , BoerrigterP , WooningM . The efficacy and tolerability of mirabegron, a potent and selective B3-adrenoceptor agonist, compared with placebo and tolterodine slow release in patients with overactive bladder - results from a European-Australian phase III trial (Abstract number 328). In: International Continence Society (ICS); 41st Annual Meeting; 2011 Aug 29-Sept 2; Glasgow, Scotland. 2011. [NCT00689104] [sr-incont42211]NCT00689104. Study to assess the efficacy and safety of the beta-3 agonist mirabegron (ym178) in patients with symptoms of overactive bladder (SCORPIO) [A randomized, double-blind, parallel group, placebo and active controlled, multicenter study to assess the efficacy and safety of mirabegron in subjects with symptoms of overactive bladder (SCORPIO)]. clinicaltrials.gov/show/NCT00689104 (first received 03 June 2008). [NCT00689104] [sr-incont49843]NittiV , HerschornS , AuerbachS , KhullarV , AmarencoG , BlauwetMB , et al. The potent and selective ß3-adrenoceptor agonist mirabegron improves patient-reported outcomes in overactive bladder-results from two phase III studies (Abstract number 68). Neurourology and Urodynamics2012;31(6):813-5. [NCT00689104] [sr-incont46724]WielageRC , PerkS , CampbellNL , NgD , KleinTM , PostaLM , et al. The cost effectiveness of mirabegron for the treatment of overactive bladder: three US perspectives (Abstract number A142). Journal of the American Geriatrics Society2015;63:S67. [NCT00689104] [sr-incont70876]YamanishiT , YamanishiY , TajimaH , IkedaS . Cost-effectiveness of mirabegron and tolterodine for the treatment of overactive bladder in Japan-Which drug is more cost-effective if used as the first-line treatment? (Abstract number 504). International Urogynecology Journal2018;29:S252. [NCT00689104] [sr-incont78647]YamanishiY , YamanishiT , TajimaH , IkedaS . Mirabegron or tolterodine for the treatment of overactive bladder in Japan: Which drug is more cost-effective as the first-line treatment?International Journal of Urology2018;25(10):863-70. [NCT00689104] [sr-incont78648]">Khullar 2013</a>; <a href="./references#CD003781-bbs2-0077" title="RogersR , BachmannG , JumadilovaZ , SunF , MorrowJD , GuanZ , et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. International Urogynecology Journal and Pelvic Floor Dysfunction2008;19(11):1551-7. [A6121002] [NCT00143481] [srincont-27729]RogersRG , BachmannG , ScarperoH , JumadilovaZ , SunF , MorrowJD , et al. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. Current Medical Research and Opinion2009;25(9):2159-65. [srincont-32060]">Rogers 2008</a>; <a href="./references#CD003781-bbs2-0094" title="EUCTR2007-007087-17-SE. A 24-week, multicentre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-007087-17 (first received 13 June 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont64588]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00798434. A study to compare the effectiveness and safety of fesoterodine and placebo in an elderly population of patients who go to the toilet very frequently due to overactive bladder (SOFIA) [A 24-week, multi-centre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00798434 (first received 26 November 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont49847]SchneiderT , BergqvistA , WangJ , WaggA , Ebel-BitounC . Treatment with fesoterodine versus tolterodine for reducing symptom bother in elderly patients with overactive bladder including urgency urinary incontinence. European Urology, Supplements2012;11(1):e687-a. [sr-incont65389]WaggA , CarlssonM , ElsobkyM , FernetM . Effect of flexible dose fesoterodine on cognitive function in &gt;65 year old patients with OAB: data from two RCT (Abstract number 438). Neurourology and Urodynamics2019;38:S297-8. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78651]WaggA , DarekarA , ArumiD , KhullarV , OelkeM . Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people &gt;65 years of age: a post hoc analysis of data from the SOFIA study. Neurourology and Urodynamics2015;34(5):438-43. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont68100]WaggA , ElsobkyM , CarlssonM , FernetM . Response and cognitive safety of fesoterodine in patients &gt;65y old with OAB. Is there a relationship between cognition and treatment response? (Abstract number 183). Neurourology and Urodynamics2019;38:S118-20. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78632]WaggA , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. Journal of the American Geriatrics Society2013;61(2):185-93. [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TrialID.SOFIA.] [sr-incont48008]WaggAS , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Efficacy and tolerability of fesoterodine in older subjects with overactive bladder: results of SOFIA (Abstract number C33). Journal of the American Geriatrics Society2011;59:S124. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont65234]">Wagg 2013a</a>). Eight of these studies used the King's Health Questionnaire (KHQ) while one used the total score of the Incontinence Quality of Life measure (IQoL) (<a href="./references#CD003781-bbs2-0022" title="AmarencoG , SutoryM , FagertunH , WrightM , CompionG , De RidderD . Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Preliminary results from the SONIC urodynamic study (Abstract). European Urology, Supplements2012;11(1):e467-a. [EudraCT2006-005523-42] [NCT00629642] [sr-incont65392]AmarencoG , SutoryM , ZachovalR , AgarwalM , DelPG , TretterR , et al. Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study. Neurourology and Urodynamics2017;36(2):414-21. [EudraCT2006-005523-42] [JapicCTI-R130306] [NCT00629642] [sr-incont72248]De RidderD , AmarencoG , Finazzi-AgroE , AnguloJ , KurenkovA , WrightM , et al. Solifenacin treatment for neurogenic detrusor overactivity: patient-reported outcomes (PROs) from the randomised clinical trial SONIC (Abstract number 333). In: International Continence (ICS); 42nd Annual Meeting; 2012 Oct 15-19; Beijing, China. 2012. [905-EC-005] [EudraCT2006-005523-42] [NCT00629642] [TrialID.SONIC.] [srincont-49739]">De Ridder 2012</a>), and three studies used Overactive Bladder Questionnaire (OAB‐q) (<a href="./references#CD003781-bbs2-0046" title="HuangA , HessR , AryaL , RichterH , SubakL , BradleyC , et al. A randomized controlled trial of simple diagnosis and treatment for urgency urinary incontinence in women (Abstract). Journal of General Internal Medicine2011;26:S1. [NCT00862745] [sr-incont64391]HuangAJ , HessR , AryaLA , RichterHE , SubakLL , BradleyCS , et al. Pharmacologic treatment for urgency-predominant urinary incontinence in women diagnosed using a simplified algorithm: a randomized trial. American Journal of Obstetrics and Gynecology2012;206(5):444.e1-11. [GA0221IX] [NCT00862745] [TrialID.BRIDGES.] [srincont-44636]NCT00862745, BrownJ . Bringing simple urge incontinence diagnosis &amp; treatment to providers (BRIDGES)  [A multi-center, randomized, placebo-controlled clinical trial comparing fesoterodine to placebo in women diagnosed with urge urinary incontinence by the 3 Incontinence Questions (3IQ). Followed by a multi-center open label clinical cohort study of long-term effects of treatment with fesoterodine ]. clinicaltrials.gov/show/NCT00862745 (first received 17 March 2009). [NCT00862745] [sr-incont49836]WarsiQ , HuangA , BrownJS , SchembriM , HessR , AryaLA , et al. The effect of pharmacologic treatment of urgency urinary incontinence on sleep quality and daytime sleepiness (Abstract number: paper 37). Female Pelvic Medicine and Reconstructive Surgery2016;22(5 ):S17-8. [NCT00862745] [TrialID.BRIDGES.] [sr-incont78633]WarsiQA , HuangAJ , HessR , AryaLA , RichterHE , BradleyCS , et al. Association of pharmacologic treatment of urgency urinary incontinence with sleep quality and daytime sleepiness. Obstetrics and Gynecology2018;131(2):204-11. [NCT00862745] [sr-incont78239]WinkelmanW , HuangA , SchembriM , RogersRG , RichterHE , MyersDL , et al. Clinical variables moderating response to pharmacologic treatment of urgency-predominant urinary incontinence in a randomized controlled trial (Abstract number: poster 25). In: Female Pelvic Medicine and Reconstructive Surgery. 37th Annual Scientific Meeting of the American Urogynecologic Society; Aug 2016; United States. Vol. 22. Netherlands: Lippincott Williams and Wilkins, 2016:S81. [NCT00862745] [sr-incont78634]WinkelmanWD , HuangAJ , SchembriM , RogersRG , RichterH , MyersDL , et al. Modifiers of response to treatment with fesoterodine for urgency-predominant urinary incontinence in a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2017;23(2):151-6. [sr-incont74308]">Huang 2012</a>; <a href="./references#CD003781-bbs2-0052" title="CardozoL , KaplanS , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: results from the after study (Abstract number 740) [Erratum appears in: European Urology 2014;65(5):e78]. European Urology Supplements2013;12(1):e740-1. [NCT01302054] [sr-incont63732]CardozoL , KaplanS , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. Erratum: A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: results from the AFTER study [Erratum available in: European Urology Supplement 2013;2012:e740-1]. European Urology2014;65(5):e78 . [A0221094] [NCT01302054] [TrialID.AFTER.] [sr-incont61642]GrenaboL , HerschornS , KaplanSA , CardozoL , ScholfieldD , ArumiD , et al. Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptoms. Current Medical Research and Opinion2017;33(10):1731-6. [NCT01302054] [TrialID.AFTER.] [sr-incont76695]KaplanSA , CardozoL , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER. International Journal of Clinical Practice2014;68(9):1065-73. [A0221094] [NCT01302054] [TrialID.AFTER.] [srincont-63977]KaplanSA , HerschornS , CarlssonM , NtaniosF . Urgency urinary incontinence response rates in subjects with overactive bladder treated with fesoterodine 8 mg after suboptimal response to tolterodine extended release 4 mg: a randomized, double-blind, placebo-controlled trial (Abstract number 546). In: International Continence Society (ICS); 43rd Annual Meeting; 2013 Aug 26-30; Barcelona, Spain. 2013. [NCT01302054] [TrialID.AFTER.] [sr-incont49730]NCT01302054. A clinical study in patients with overactive bladder with leakage of urine, to find out if the medicine, Fesoterodine, works in those patients who did not have enough response to the medicine, tolterodine. [A 14 week randomized parallel group placebo-controlled double-blind multicentre study of fesoterodine 8 mg in overactive bladder patients with sub-optimal response to tolterodine 4 mg extended release (ER)]. clinicaltrials.gov/show/NCT01302054 (first received 23 February 2011). [A0221094] [NCT01302054] [TrialID.AFTER.] [sr-incont49845]">Kaplan 2014</a>; <a href="./references#CD003781-bbs2-0077" title="RogersR , BachmannG , JumadilovaZ , SunF , MorrowJD , GuanZ , et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. International Urogynecology Journal and Pelvic Floor Dysfunction2008;19(11):1551-7. [A6121002] [NCT00143481] [srincont-27729]RogersRG , BachmannG , ScarperoH , JumadilovaZ , SunF , MorrowJD , et al. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. Current Medical Research and Opinion2009;25(9):2159-65. [srincont-32060]">Rogers 2008</a>).  </p> <p>We used random‐effects meta‐analysis for this outcome due to high heterogeneity. As a reduction in score equals an improvement in quality of life for the instruments used in the studies that contributed to this meta‐analysis, anticholinergic drugs may improve condition‐specific quality of life compared to placebo (mean difference (MD) ‐4.41, 95% confidence interval (CI) ‐5.28 to ‐3.54; <a href="./references#CD003781-fig-0010" title="">Analysis 1.1</a>; <a href="./full#CD003781-tbl-0001">summary of findings Table 1</a>; low‐certainty evidence). </p> <p>Eighteen studies could not be included in the meta‐analysis because they reported different scales than OAB‐q or KHQ (<a href="./references#CD003781-bbs2-0014" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. ChappleCR , AranoP , BoschJH , De RidderD , KramerG , RidderAM . YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo- and tolterodine-controlled, phase-II, dose-finding study (Abstract 75). Neurourology and Urodynamics2002;21(4):381-2. [srincont-14551]ChappleCR , ArañoP , BoschJL , De RidderD , KramerAE , RidderAM . Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU International2004;93(1):71-7. [srincont-17334]KelleherCJ , CardozoL , ChappleCR , HaabF , RidderAM . Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU International2005;95(1):81-5. [srincont-20241]SmithN , GrimesI , RidgeS , TempelD , UchidaT , YamanouchiUS . YM905 is effective and safe as treatment of overactive bladder in women and men: results from phase II study (Abstract). In: International Continence Society (ICS), 32nd Annual Meeting; 2002 Aug 28-30; Heidelberg, Germany. 2002:138-9. [sr-incont14508]">Chapple 2004b</a>; <a href="./references#CD003781-bbs2-0018" title="ChappleCR , DvorakV , RadziszewskiP , vanKerrebroeckP , WyndaeleJJ , BosmanB , et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder. International Urogynecology Journal2013;24(9):1447-58. [178-CL-044] [NCT00337090] [TrialID.DRAGON.] [sr-incont48549]NCT00337090 . A study of YM178 in patients with symptomatic overactive bladder (DRAGON) [A randomized, double-blind, parallel group, placebo and active controlled, multicenter dose ranging study with the beta-3 agonist YM178 in patients with symptomatic overactive bladder]. clinicaltrials.gov/show/NCT00337090 (first received 15 June 2006). [EudraCT2005-002256-17] [JapicCTI-R130350] [NCT00337090] [sr-incont63803]">Chapple 2013</a>; <a href="./references#CD003781-bbs2-0072" title="OreskovićS , ButI , BanovićM , GoldstajnMS . The efficacy and safety of solifenacin in patients with overactive bladder syndrome. Collegium Antropologicum2012;36(1):243-8. [srincont-45056]">Oreskovic 2012</a>; <a href="./references#CD003781-bbs2-0103" title="ZinnerN , GittelmanM , HarrisR , SussetJ , KanellosA , AuerbachS . Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial (Abstract number DP51). In: American Urological Association (AUA), 98th Annual Meeting; 2003 Apr 26-May 1; Chicago, Illinois. 2003. [sr-incont31101]ZinnerN , GittelmanM , HarrisR , SussetJ , KanelosA , AuerbachS , Trospium Study Group. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. Journal of Urology2004;171(6 Pt 1):2311-5. [sr-incont17376]">Zinner 2004</a>), did not provide overall quality of life score (<a href="./references#CD003781-bbs2-0024" title="DmochowskiR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. A double-blind, placebo-controlled trial of flexible-dose fesoterodine for overactive bladder (Abstract number 715). In: International Continence Society (ICS); 39th Annual Meeting; 2009 Sep 29-Oct 03; San Francisco, CA. 2009. [sr-incont35627]DmochowskiRR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder [Errata appear in: Urology 2010 Jun;75(6):1519 and in Urology 2011 Jun;77(6):1513]. Urology2010;75(1):62-8. [A0221014] [NCT00536484] [sr-incont39548]DuBeauC , KrausSR , SunF , MorrowJD . Fesoterodine in older vs younger subjects with overactive bladder (Abstract number D87). Journal of the American Geriatrics Society2010;58:S218. [NCT00536484] [sr-incont64309]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. [sr-incont78640]NCT00536484. Fesoterodine flexible dose study [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with overactive bladder]. clinicaltrials.gov/show/NCT00536484 (first received 27 September 2007). [NCT00536484] [sr-incont49160]StaskinD , KhullarV , MichelMC , MorrowJD , SunF , GuanZ , et al. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. Neurourology and Urodynamics2011;30(8):1480-5. [sr-incont42686]">Dmochowski 2010</a>; <a href="./references#CD003781-bbs2-0033" title="GotohM , HommaY , YokoyamaO , NishizawaO . Responsiveness and minimal clinically important change in overactive bladder symptom score. Urology2011;78(4):768-73. [srincont-42622]GotohM , YokoyamaO , MatsukawaY , NishizawaO . Responsiveness of overactive bladder symptom score (OABSS): verification based on data in a double-blinded, randomized placebo-controlled study of propiverine hydrochloride in Japanese patients (Abstract number 338). In: Joint Meeting of the International Continence Society (ICS) and the International Urogynecological Association; 2010 Aug 23-27; Toronto, Canada. 2010. [srincont-40173]GotohM , YokoyamaO , NishizawaO . Propiverine hydrochloride in Japanese patients with overactive bladder: A randomized, double-blind, placebo-controlled trial. International Journal of Urology2011;18(5):365-73. [srincont-41510]">Gotoh 2011</a>; <a href="./references#CD003781-bbs2-0043" title="HommaY , KawabeK . Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World Journal of Urology2004;22(4):251-6. [srincont-19412]HommaY , PaickJS , LeeJG , KawabeK , Japanese and Korean Tolterodine Study Group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU International2003;92(7):741-7. [srincont-16418]">Homma 2003</a>; <a href="./references#CD003781-bbs2-0045" title="HommaY , YamaguchiO , Imidafenacin Study Group. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2009;16(5):499-506. [NCT00212732] [ONO-8025-08] [srincont-31368]">Homma 2009</a>; <a href="./references#CD003781-bbs2-0054" title="KhullarV , HillS , LavalKU , SchiotzHA , JonasU , VersiE . Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology2004;64(2):269-74; discussion 274-5. [srincont-19498]KhullarV , HillS , SolankiJ . Assessment of health-related quality of life in patients with overactive bladder taking tolterodine extended release versus placebo (Abstract number 318). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21075]">Khullar 2004</a>; <a href="./references#CD003781-bbs2-0096" title="YamaguchiO , MaruiE , KakizakiH , ItohN , YokotaT , OkadaH , et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU International2007;100(3):579-87. [sr-incont23865]YokoyamaO , YamaguchiO , KakizakiH , ItohN , YokotaT , OkadaH , et al. Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary. Journal of Urology2011;186(1):170-4. [sr-incont41734]">Yamaguchi 2007</a>; <a href="./references#CD003781-bbs2-0098" title="YamaguchiO , UchidaE , HigoN , MinamiH , KobayashiS , SatoH , et al. Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: a randomized double-blind trial. International Journal of Urology2014;21(6):586-93. [JapicCTI-101309] [sr-incont62099]">Yamaguchi 2014</a>), and/or did not report data necessary to conduct meta‐analysis (such as standard deviation (SD) or standard error (SE)) (<a href="./references#CD003781-bbs2-0018" title="ChappleCR , DvorakV , RadziszewskiP , vanKerrebroeckP , WyndaeleJJ , BosmanB , et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder. International Urogynecology Journal2013;24(9):1447-58. [178-CL-044] [NCT00337090] [TrialID.DRAGON.] [sr-incont48549]NCT00337090 . A study of YM178 in patients with symptomatic overactive bladder (DRAGON) [A randomized, double-blind, parallel group, placebo and active controlled, multicenter dose ranging study with the beta-3 agonist YM178 in patients with symptomatic overactive bladder]. clinicaltrials.gov/show/NCT00337090 (first received 15 June 2006). [EudraCT2005-002256-17] [JapicCTI-R130350] [NCT00337090] [sr-incont63803]">Chapple 2013</a>; <a href="./references#CD003781-bbs2-0019" title="ChappleC , HaabF , SchneiderT , CarlssonM , ArumiD . Fesoterodine 8 mg versus fesoterodine 4 mg in patients with overactive bladder and a history of previous antimuscarinic therapy: Results from the EIGHT trial (Abstract number: Poster #M5). Neurourology and Urodynamics2015;34(S1):S20. [NCT01302067] [sr-incont68509]ChappleC , SchneiderT , HaabF , SunF , WhelanL , ScholfieldD , et al. Superiority of fesoterodine 8mg versus fesoterodine 4 mg in reducing urgency urinary incontinence episodes in subjects with overactive bladder: results of the randomized, double-blind, placebo-controlled EIGHT trial (Abstract number: Podium #48). Neurourology and Urodynamics2014;33(2):183-4. [NCT01302067] [sr-incont67484]ChappleC , SchneiderT , HaabF , SunF , WhelanL , ScholfieldD , et al. Superiority of fesoterodine 8mg vs 4mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial. BJU International2014;114(3):418-26. [A0221095] [NCT01302067] [TrialID.EIGHT] [srincont-62537]NCT01302067. A 12 week study to confirm the effectiveness of 8mg of Fesoterodine compared to 4mg of Fesoterodine [A 12-week, randomized, double-blind, placebo controlled, parallel group, multicenter trial in overactive bladder subjects to confirm the efficacy of 8 mg fesoterodine compared to 4 mg fesoterodine]. clinicaltrials.gov/show/NCT01302067 (first received 23 February 2011). [NCT01302067] [sr-incont63792]">Chapple 2014</a>; <a href="./references#CD003781-bbs2-0033" title="GotohM , HommaY , YokoyamaO , NishizawaO . Responsiveness and minimal clinically important change in overactive bladder symptom score. Urology2011;78(4):768-73. [srincont-42622]GotohM , YokoyamaO , MatsukawaY , NishizawaO . Responsiveness of overactive bladder symptom score (OABSS): verification based on data in a double-blinded, randomized placebo-controlled study of propiverine hydrochloride in Japanese patients (Abstract number 338). In: Joint Meeting of the International Continence Society (ICS) and the International Urogynecological Association; 2010 Aug 23-27; Toronto, Canada. 2010. [srincont-40173]GotohM , YokoyamaO , NishizawaO . Propiverine hydrochloride in Japanese patients with overactive bladder: A randomized, double-blind, placebo-controlled trial. International Journal of Urology2011;18(5):365-73. [srincont-41510]">Gotoh 2011</a>; <a href="./references#CD003781-bbs2-0039" title="CorcosJ , AnguloJC , GarelyAD , CarlssonM , GongJ , GuanZ . Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. Current Medical Research and Opinion2011;27(5):1059-65. [srincont-41596]EUCTR2006-006935-38-SE. 12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006935-38 (first received 16 April 2007). [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont64612]HerschornS , SwiftS , GuanZ , CarlssonM , BrodskyM , GongJ . Efficacy and safety of fesoterodine for overactive bladder in a double-blind, head-to-head comparison trial with tolterodine ER and placebo (Abstract number 710). In: International Continence Society (ICS), 39th Annual Meeting; 2009 Sep 29-Oct 3; San Francisco, CA. 2009. [srincont-35326]HerschornS , SwiftS , GuanZ , CarlssonM , MorrowJD , BrodskyM , et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU International2010;105(1):58-66. [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont39540]NCT00444925. Clinical trial to evaluate the efficacy and safety of Fesoterodine in comparison to Tolterodine for overactive bladder (OAB) [12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder (OAB)]. clinicaltrials.gov/show/NCT00444925 (first received 08 March 2007). [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont49159]">Herschorn 2009a</a>; <a href="./references#CD003781-bbs2-0043" title="HommaY , KawabeK . Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World Journal of Urology2004;22(4):251-6. [srincont-19412]HommaY , PaickJS , LeeJG , KawabeK , Japanese and Korean Tolterodine Study Group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU International2003;92(7):741-7. [srincont-16418]">Homma 2003</a>; <a href="./references#CD003781-bbs2-0045" title="HommaY , YamaguchiO , Imidafenacin Study Group. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2009;16(5):499-506. [NCT00212732] [ONO-8025-08] [srincont-31368]">Homma 2009</a>; <a href="./references#CD003781-bbs2-0051" title="EUCTR2007-006451-39-SE. 12-week, randomized, double-blind, double-dummy, placebo controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-006451-39 (first received 20 February 2008). [A0221046] [EUCTR2007-006451-39-SE] [sr-incont64591]KaplanSA , SchneiderT , FooteJ , GuanZ . Superior efficacy of fesoterodine over tolterodine with rapid onset: a prospective, head-to-head, placebo-controlled trial (Abstract number 67). Neurourology and Urodynamics2010;29(6):905-7. [srincont-40130]KaplanSA , SchneiderT , FooteJE , GuanZ , CarlssonM , GongJ . Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU International2011;107(9):1432-40. [A0221046] [NCT00611026] [srincont-41334]">Kaplan 2011</a>; <a href="./references#CD003781-bbs2-0053" title="CapoJP , TogliaM , Forero-SchwanhaeuserS , HeW . Patients reporting severe overactive bladder symptoms: effects of solifenacin treatment on objective measures and patient-reported outcomes (Abstract number 582). In: International Continence Society (ICS), 38th Annual Meeting; 2008 Oct 20-24; Cairo, Egypt. 2008. [srincont-31844]CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. KarramMM , TogliaMR , SerelsSR , AndohM , FakhouryA , Forero-SchwanhaeuserS . Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology2009;73(1):14-8. [A0221094] [NCT00454896] [TrialID.VENUS.] [srincont-29219]SerelsSR , TogliaMR , Forero-SchwanhaeuserS , HeW . Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms. Current Medical Research and Opinion2010;26(10):2277-85. [srincont-40376]StaskinD , DmochowskiR , SerelsS , AndohM , SmithN . Report from a randomized, placebo-controlled study showing significant improvement in urgency and patient-reported outcomes in overactive bladder patients treated with solifenacin (Abstract number 124). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73-4. [srincont-26600]TogliaM , AndohM , HussainI . Solifenacin improved warning time significantly compared to placebo in patients with overactive bladder (Abstract number 123). Neurourology and Urodynamics2006;25(6):655. [srincont-26629]TogliaM , AndohM , HussainI . Solifenacin improves urgency symtoms as assessed by voiding diaries and patient-reported outcomes (PRO) in patients with overactive bladder (Abstract number 155). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26636]TogliaMR , OstergardDR , AppellRA , AndohM , FakhouryA , HussainIF . Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status. International Urogynecology Journal2010;21(7):847-54. [srincont-40094]TogliaMR , SerelsSR , LarameeC , KarramMM , NandyIM , AndohM , et al. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial. Postgraduate Medicine2009;121(5):151-8. [srincont-34204]ZinnerS , HerschornS , AndohM , HussainI . Responder analyses show statistically significant improvements in incontinence and urgency are associated with reduction in symptom bother and improvement in health-related quality of life: VENUS results (Abstract number 123). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73. [srincont-26599]">Karram 2009</a>; <a href="./references#CD003781-bbs2-0093" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CrosbyRD , MathiasSD , MarshallTS . Relationships between symptoms, symptom bother, and health-related quality of life in patients with overactive bladder taking solifenacin or placebo in the VIBRANT study. International Journal of Clinical Practice2011;65(2):211-8. [sr-incont41015]GollarKM , YoungDG , BailenJ , HeW , Forero-SchwanhaeuserS . Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: a secondary analysis of the VIBRANT study. Urologic Nursing2012;32(1):38-46. [TrialID.VIBRANT.] [sr-incont44571]Samuels T‐A, MitchesonHD , VardyM , Forero‐SchwanhaeuserS , MarshallT , HeW . Efficacy of solifenacin for symptom bother and other patient-reported outcomes in patients with overactive bladder (OAB): results of a large, double-blind, placebo-controlled trial (Abstract number: poster #74). Neurourology and Urodynamics2009;28(2):149. [sr-incont31063]VardyMD , MitchesonHD , SamuelsTA , Forero-SchwanhaeuserS , HeW . Efficacy of solifenacin on overactive bladder symptoms, symptom bother, and other patient-reported outcomes in subjects with or without incontinence: a post hoc analysis of data from VIBRANT. Female Pelvic Medicine and Reconstructive Surgery2011;17(1):24-9. [TrialID.VIBRANT.] [sr-incont44741]VardyMD , MitchesonHD , SamuelsTA , WegenkeJD , Forero-SchwanhaeuserS , MarshallTS , et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. International Journal of Clinical Practice2009;63(12):1702-14. [905-UC-010] [NCT00573508] [TrialID.VIBRANT.] [sr-incont35459]">Vardy 2009</a>; <a href="./references#CD003781-bbs2-0095" title="GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00911937. A trial to evaluate the efficacy and safety of fesoterodine in patients with symptoms of overactive bladder including nocturnal urinary urgency [A randomized, double blind, placebo controlled, parallel group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with symptoms of overactive bladder including nocturnal urinary urgency]. clinicaltrials.gov/show/NCT00911937 (first received 03 June 2009). [NCT00911937] [sr-incont49848]WeissJ , JumadilovaZ , CarlssonM , FitzGeraldMP , MalhotraA , MartireDL . Effect of antimuscarinic treatment in subjects with overactive bladder, including nocturnal urinary urgency (Abstract number 1963). Journal of Urology2012;187(4 Suppl 1):e792. [NCT00911937] [sr-incont65184]WeissJP , CarlssonMR , ManganEK . Age, gender and nocturnal urgency severity predict response to antimuscarinic treatment (Abstract number 1962). Journal of Urology2013;189(4 Suppl 1):e805. [NCT00911937] [sr-incont65096]WeissJP , JumadilovaZ , JohnsonTM , FitzGeraldMP , CarlssonM , MartireDL , et al. Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency. Journal of Urology2013;189(4):1396-401. [A0221048] [NCT00911937] [sr-incont47568]">Weiss 2013</a>; <a href="./references#CD003781-bbs2-0096" title="YamaguchiO , MaruiE , KakizakiH , ItohN , YokotaT , OkadaH , et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU International2007;100(3):579-87. [sr-incont23865]YokoyamaO , YamaguchiO , KakizakiH , ItohN , YokotaT , OkadaH , et al. Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary. Journal of Urology2011;186(1):170-4. [sr-incont41734]">Yamaguchi 2007</a>; <a href="./references#CD003781-bbs2-0098" title="YamaguchiO , UchidaE , HigoN , MinamiH , KobayashiS , SatoH , et al. Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: a randomized double-blind trial. International Journal of Urology2014;21(6):586-93. [JapicCTI-101309] [sr-incont62099]">Yamaguchi 2014</a>; <a href="./references#CD003781-bbs2-0104" title="ZinnerN , SussetJ , GittelmanM , ArguinzonizM , RekedaL , HaabF . Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. International Journal of Clinical Practice2006;60(1):119-26. [sr-incont21507]">Zinner 2006</a>). For the studies that did not provide an overall quality of life score, we used the incontinence impact change from baseline score as it is considered the most appropriate. However, a brief interpretation of other domains is also provided. Please see <a href="#CD003781-tbl-0002">Table 1</a> for quality of life results of the studies that could not be included in the meta‐analysis.  </p> <div class="table" id="CD003781-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Quality of life outcome of studies that were not included in meta‐analysis</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>QoL measure</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Direction and measurement of the scale, MCID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Result (mean change from baseline*)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Interpretation</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0014" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. ChappleCR , AranoP , BoschJH , De RidderD , KramerG , RidderAM . YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo- and tolterodine-controlled, phase-II, dose-finding study (Abstract 75). Neurourology and Urodynamics2002;21(4):381-2. [srincont-14551]ChappleCR , ArañoP , BoschJL , De RidderD , KramerAE , RidderAM . Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU International2004;93(1):71-7. [srincont-17334]KelleherCJ , CardozoL , ChappleCR , HaabF , RidderAM . Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU International2005;95(1):81-5. [srincont-20241]SmithN , GrimesI , RidgeS , TempelD , UchidaT , YamanouchiUS . YM905 is effective and safe as treatment of overactive bladder in women and men: results from phase II study (Abstract). In: International Continence Society (ICS), 32nd Annual Meeting; 2002 Aug 28-30; Heidelberg, Germany. 2002:138-9. [sr-incont14508]">Chapple 2004b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Contilife score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Scores range from 0 to 100, lower score indicates higher QoL<br/>MCID: unknown </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tolterodine (n = 37): 9.9</p> <p>Solifenacin (n = 70): 16.4</p> <p>Placebo (n = 36): 4.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticholinergics improve QoL compared to placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0018" title="ChappleCR , DvorakV , RadziszewskiP , vanKerrebroeckP , WyndaeleJJ , BosmanB , et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder. International Urogynecology Journal2013;24(9):1447-58. [178-CL-044] [NCT00337090] [TrialID.DRAGON.] [sr-incont48549]NCT00337090 . A study of YM178 in patients with symptomatic overactive bladder (DRAGON) [A randomized, double-blind, parallel group, placebo and active controlled, multicenter dose ranging study with the beta-3 agonist YM178 in patients with symptomatic overactive bladder]. clinicaltrials.gov/show/NCT00337090 (first received 15 June 2006). [EudraCT2005-002256-17] [JapicCTI-R130350] [NCT00337090] [sr-incont63803]">Chapple 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICIQ‐OABqol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 to 160 overall score with greater values indicating increased impact on QoL<br/>MCID: unknown/unclear </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tolterodine (n = 84): ‐17.42</p> <p>Placebo (n = 162): ‐ 16.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticholinergics improve QoL compared to placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0019" title="ChappleC , HaabF , SchneiderT , CarlssonM , ArumiD . Fesoterodine 8 mg versus fesoterodine 4 mg in patients with overactive bladder and a history of previous antimuscarinic therapy: Results from the EIGHT trial (Abstract number: Poster #M5). Neurourology and Urodynamics2015;34(S1):S20. [NCT01302067] [sr-incont68509]ChappleC , SchneiderT , HaabF , SunF , WhelanL , ScholfieldD , et al. Superiority of fesoterodine 8mg versus fesoterodine 4 mg in reducing urgency urinary incontinence episodes in subjects with overactive bladder: results of the randomized, double-blind, placebo-controlled EIGHT trial (Abstract number: Podium #48). Neurourology and Urodynamics2014;33(2):183-4. [NCT01302067] [sr-incont67484]ChappleC , SchneiderT , HaabF , SunF , WhelanL , ScholfieldD , et al. Superiority of fesoterodine 8mg vs 4mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial. BJU International2014;114(3):418-26. [A0221095] [NCT01302067] [TrialID.EIGHT] [srincont-62537]NCT01302067. A 12 week study to confirm the effectiveness of 8mg of Fesoterodine compared to 4mg of Fesoterodine [A 12-week, randomized, double-blind, placebo controlled, parallel group, multicenter trial in overactive bladder subjects to confirm the efficacy of 8 mg fesoterodine compared to 4 mg fesoterodine]. clinicaltrials.gov/show/NCT01302067 (first received 23 February 2011). [NCT01302067] [sr-incont63792]">Chapple 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OAB‐q (total HRQL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0‐ to 100‐point scale, higher HRQL scores indicate better HRQL<br/>MCID: 10 points </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fesoterodine (n = 1378): 26 </p> <p>Placebo (n = 347): 19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticholinergics improve QoL compared to placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0024" title="DmochowskiR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. A double-blind, placebo-controlled trial of flexible-dose fesoterodine for overactive bladder (Abstract number 715). In: International Continence Society (ICS); 39th Annual Meeting; 2009 Sep 29-Oct 03; San Francisco, CA. 2009. [sr-incont35627]DmochowskiRR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder [Errata appear in: Urology 2010 Jun;75(6):1519 and in Urology 2011 Jun;77(6):1513]. Urology2010;75(1):62-8. [A0221014] [NCT00536484] [sr-incont39548]DuBeauC , KrausSR , SunF , MorrowJD . Fesoterodine in older vs younger subjects with overactive bladder (Abstract number D87). Journal of the American Geriatrics Society2010;58:S218. [NCT00536484] [sr-incont64309]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. [sr-incont78640]NCT00536484. Fesoterodine flexible dose study [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with overactive bladder]. clinicaltrials.gov/show/NCT00536484 (first received 27 September 2007). [NCT00536484] [sr-incont49160]StaskinD , KhullarV , MichelMC , MorrowJD , SunF , GuanZ , et al. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. Neurourology and Urodynamics2011;30(8):1480-5. [sr-incont42686]">Dmochowski 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>KHQ incontinence impact score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0‐ to 100‐point scale, lower scores indicates higher QoL<br/>MCID: 5 points </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trospium (n = 530): ‐23</p> <p>Placebo (n = 556): ‐17 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The result shows improvement of QoL in terms of incontinence impact score, but the improvement was also demonstrated in all of the other KHQ domains </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0033" title="GotohM , HommaY , YokoyamaO , NishizawaO . Responsiveness and minimal clinically important change in overactive bladder symptom score. Urology2011;78(4):768-73. [srincont-42622]GotohM , YokoyamaO , MatsukawaY , NishizawaO . Responsiveness of overactive bladder symptom score (OABSS): verification based on data in a double-blinded, randomized placebo-controlled study of propiverine hydrochloride in Japanese patients (Abstract number 338). In: Joint Meeting of the International Continence Society (ICS) and the International Urogynecological Association; 2010 Aug 23-27; Toronto, Canada. 2010. [srincont-40173]GotohM , YokoyamaO , NishizawaO . Propiverine hydrochloride in Japanese patients with overactive bladder: A randomized, double-blind, placebo-controlled trial. International Journal of Urology2011;18(5):365-73. [srincont-41510]">Gotoh 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>KHQ incontinence impact score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0‐ to 100‐point scale, lower scores indicates higher QoL</p> <p>MCID: 5 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Propiverine (n = 284): ‐21</p> <p>Placebo (n = 270): ‐14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The result shows improvement of QoL in terms of incontinence impact score, but the improvement was also demonstrated in all of the other KHQ  domains </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0039" title="CorcosJ , AnguloJC , GarelyAD , CarlssonM , GongJ , GuanZ . Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. Current Medical Research and Opinion2011;27(5):1059-65. [srincont-41596]EUCTR2006-006935-38-SE. 12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006935-38 (first received 16 April 2007). [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont64612]HerschornS , SwiftS , GuanZ , CarlssonM , BrodskyM , GongJ . Efficacy and safety of fesoterodine for overactive bladder in a double-blind, head-to-head comparison trial with tolterodine ER and placebo (Abstract number 710). In: International Continence Society (ICS), 39th Annual Meeting; 2009 Sep 29-Oct 3; San Francisco, CA. 2009. [srincont-35326]HerschornS , SwiftS , GuanZ , CarlssonM , MorrowJD , BrodskyM , et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU International2010;105(1):58-66. [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont39540]NCT00444925. Clinical trial to evaluate the efficacy and safety of Fesoterodine in comparison to Tolterodine for overactive bladder (OAB) [12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder (OAB)]. clinicaltrials.gov/show/NCT00444925 (first received 08 March 2007). [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont49159]">Herschorn 2009a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OAB‐q (total HRQL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0– to 100‐point scale, higher HRQL scores indicate better HRQL</p> <p>MCID: 10 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tolterodine (n = 641): 16.3</p> <p>Fesoterodine (n = 636): 19.3</p> <p>Placebo (n = 313): 12.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticholinergics improve QoL compared to placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0043" title="HommaY , KawabeK . Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World Journal of Urology2004;22(4):251-6. [srincont-19412]HommaY , PaickJS , LeeJG , KawabeK , Japanese and Korean Tolterodine Study Group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU International2003;92(7):741-7. [srincont-16418]">Homma 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>KHQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable as data are not shown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Results are not presented in a table. In the text, oxybutynin and tolterodine are described as better than placebo according to P values. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticholinergics improve QoL compared to placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0045" title="HommaY , YamaguchiO , Imidafenacin Study Group. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2009;16(5):499-506. [NCT00212732] [ONO-8025-08] [srincont-31368]">Homma 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>KHQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable as data are not shown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Results are not presented in a table. In the text, imidafenacin and propiverine are described as better than placebo according to P values. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticholinergics improve QoL compared to placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0051" title="EUCTR2007-006451-39-SE. 12-week, randomized, double-blind, double-dummy, placebo controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-006451-39 (first received 20 February 2008). [A0221046] [EUCTR2007-006451-39-SE] [sr-incont64591]KaplanSA , SchneiderT , FooteJ , GuanZ . Superior efficacy of fesoterodine over tolterodine with rapid onset: a prospective, head-to-head, placebo-controlled trial (Abstract number 67). Neurourology and Urodynamics2010;29(6):905-7. [srincont-40130]KaplanSA , SchneiderT , FooteJE , GuanZ , CarlssonM , GongJ . Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU International2011;107(9):1432-40. [A0221046] [NCT00611026] [srincont-41334]">Kaplan 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OAB‐q (total HRQL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0– to 100‐point scale, higher HRQL scores indicate better HRQL</p> <p>MCID: 10 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tolterodine (n = 942): 19.5</p> <p>Fesoterodine (n = 930): 22.9</p> <p>Placebo (n = 462): 17.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticholinergics improve QoL compared to placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0053" title="CapoJP , TogliaM , Forero-SchwanhaeuserS , HeW . Patients reporting severe overactive bladder symptoms: effects of solifenacin treatment on objective measures and patient-reported outcomes (Abstract number 582). In: International Continence Society (ICS), 38th Annual Meeting; 2008 Oct 20-24; Cairo, Egypt. 2008. [srincont-31844]CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. KarramMM , TogliaMR , SerelsSR , AndohM , FakhouryA , Forero-SchwanhaeuserS . Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology2009;73(1):14-8. [A0221094] [NCT00454896] [TrialID.VENUS.] [srincont-29219]SerelsSR , TogliaMR , Forero-SchwanhaeuserS , HeW . Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms. Current Medical Research and Opinion2010;26(10):2277-85. [srincont-40376]StaskinD , DmochowskiR , SerelsS , AndohM , SmithN . Report from a randomized, placebo-controlled study showing significant improvement in urgency and patient-reported outcomes in overactive bladder patients treated with solifenacin (Abstract number 124). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73-4. [srincont-26600]TogliaM , AndohM , HussainI . Solifenacin improved warning time significantly compared to placebo in patients with overactive bladder (Abstract number 123). Neurourology and Urodynamics2006;25(6):655. [srincont-26629]TogliaM , AndohM , HussainI . Solifenacin improves urgency symtoms as assessed by voiding diaries and patient-reported outcomes (PRO) in patients with overactive bladder (Abstract number 155). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26636]TogliaMR , OstergardDR , AppellRA , AndohM , FakhouryA , HussainIF . Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status. International Urogynecology Journal2010;21(7):847-54. [srincont-40094]TogliaMR , SerelsSR , LarameeC , KarramMM , NandyIM , AndohM , et al. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial. Postgraduate Medicine2009;121(5):151-8. [srincont-34204]ZinnerS , HerschornS , AndohM , HussainI . Responder analyses show statistically significant improvements in incontinence and urgency are associated with reduction in symptom bother and improvement in health-related quality of life: VENUS results (Abstract number 123). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73. [srincont-26599]">Karram 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OAB‐q (total HRQL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0– to 100‐point scale, higher HRQL scores indicate better HRQL</p> <p>MCID: 10 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Solifenacin (n = 357): 22.6</p> <p>Placebo (n = 350): 17.2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticholinergics improve QoL compared to placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0054" title="KhullarV , HillS , LavalKU , SchiotzHA , JonasU , VersiE . Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology2004;64(2):269-74; discussion 274-5. [srincont-19498]KhullarV , HillS , SolankiJ . Assessment of health-related quality of life in patients with overactive bladder taking tolterodine extended release versus placebo (Abstract number 318). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21075]">Khullar 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>KHQ incontinence impact score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0‐ to 100‐point scale, lower scores indicates higher QoL</p> <p>MCID: 5 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tolterodine (n = 569): ‐20.4 </p> <p>Placebo (n = 285): ‐15.5 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The result shows improvement of QoL in terms of incontinence impact score, but the improvement was also demonstrated in all of the other KHQ domains </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0072" title="OreskovićS , ButI , BanovićM , GoldstajnMS . The efficacy and safety of solifenacin in patients with overactive bladder syndrome. Collegium Antropologicum2012;36(1):243-8. [srincont-45056]">Oreskovic 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UDI and IIQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UDI: range 0 to 300, lower scores indicate better QoL</p> <p>IIQ: 0 to 400, lower scores indicate better QoL</p> <p>MCID: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UDI score was significantly improved after solifenacin (22.26 ± 5.91 vs 29.61 ± 8.45) compared to placebo. IIQ score was decreased in patients with solifenacin (36.25 ± 10.34 vs 46.86 ± 6.81, P &lt; 0.001) compared to placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticholinergics improve QoL compared to placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0093" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CrosbyRD , MathiasSD , MarshallTS . Relationships between symptoms, symptom bother, and health-related quality of life in patients with overactive bladder taking solifenacin or placebo in the VIBRANT study. International Journal of Clinical Practice2011;65(2):211-8. [sr-incont41015]GollarKM , YoungDG , BailenJ , HeW , Forero-SchwanhaeuserS . Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: a secondary analysis of the VIBRANT study. Urologic Nursing2012;32(1):38-46. [TrialID.VIBRANT.] [sr-incont44571]Samuels T‐A, MitchesonHD , VardyM , Forero‐SchwanhaeuserS , MarshallT , HeW . Efficacy of solifenacin for symptom bother and other patient-reported outcomes in patients with overactive bladder (OAB): results of a large, double-blind, placebo-controlled trial (Abstract number: poster #74). Neurourology and Urodynamics2009;28(2):149. [sr-incont31063]VardyMD , MitchesonHD , SamuelsTA , Forero-SchwanhaeuserS , HeW . Efficacy of solifenacin on overactive bladder symptoms, symptom bother, and other patient-reported outcomes in subjects with or without incontinence: a post hoc analysis of data from VIBRANT. Female Pelvic Medicine and Reconstructive Surgery2011;17(1):24-9. [TrialID.VIBRANT.] [sr-incont44741]VardyMD , MitchesonHD , SamuelsTA , WegenkeJD , Forero-SchwanhaeuserS , MarshallTS , et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. International Journal of Clinical Practice2009;63(12):1702-14. [905-UC-010] [NCT00573508] [TrialID.VIBRANT.] [sr-incont35459]">Vardy 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OAB‐q (total HRQL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0– to 100‐point scale, higher HRQL scores indicate better HRQL</p> <p>MCID: 10 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Solifenacin (n = 374): 25.5</p> <p>Placebo (n = 374): 16.65 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticholinergics improve QoL compared to placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0095" title="GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00911937. A trial to evaluate the efficacy and safety of fesoterodine in patients with symptoms of overactive bladder including nocturnal urinary urgency [A randomized, double blind, placebo controlled, parallel group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with symptoms of overactive bladder including nocturnal urinary urgency]. clinicaltrials.gov/show/NCT00911937 (first received 03 June 2009). [NCT00911937] [sr-incont49848]WeissJ , JumadilovaZ , CarlssonM , FitzGeraldMP , MalhotraA , MartireDL . Effect of antimuscarinic treatment in subjects with overactive bladder, including nocturnal urinary urgency (Abstract number 1963). Journal of Urology2012;187(4 Suppl 1):e792. [NCT00911937] [sr-incont65184]WeissJP , CarlssonMR , ManganEK . Age, gender and nocturnal urgency severity predict response to antimuscarinic treatment (Abstract number 1962). Journal of Urology2013;189(4 Suppl 1):e805. [NCT00911937] [sr-incont65096]WeissJP , JumadilovaZ , JohnsonTM , FitzGeraldMP , CarlssonM , MartireDL , et al. Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency. Journal of Urology2013;189(4):1396-401. [A0221048] [NCT00911937] [sr-incont47568]">Weiss 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OAB‐q (total HRQL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0– to 100‐point scale, higher HRQL scores indicate better HRQL</p> <p>MCID: 10 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fesoterodine (n = 381): 17</p> <p>Placebo (n = 400): 14.9 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticholinergics improve QoL compared to placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0096" title="YamaguchiO , MaruiE , KakizakiH , ItohN , YokotaT , OkadaH , et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU International2007;100(3):579-87. [sr-incont23865]YokoyamaO , YamaguchiO , KakizakiH , ItohN , YokotaT , OkadaH , et al. Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary. Journal of Urology2011;186(1):170-4. [sr-incont41734]">Yamaguchi 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>KHQ incontinence impact score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0‐ to 100‐point scale, lower scores indicates higher QoL</p> <p>MCID: 5 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Solifenacin (n = 754): ‐21.5</p> <p>Propiverine (n = 384): ‐17</p> <p>Placebo (n = 395): ‐7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The result shows improvement of QoL in terms of incontinence impact score, but the improvement was also demonstrated in all of the other KHQ domains </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0098" title="YamaguchiO , UchidaE , HigoN , MinamiH , KobayashiS , SatoH , et al. Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: a randomized double-blind trial. International Journal of Urology2014;21(6):586-93. [JapicCTI-101309] [sr-incont62099]">Yamaguchi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>KHQ incontinence impact score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0‐ to 100‐point scale, lower scores indicates higher QoL</p> <p>MCID: 5 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Propiverine (n = 559): ‐16</p> <p>Placebo (n = 3737): ‐14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The result shows improvement of QoL in terms of incontinence impact score, but the improvement was also demonstrated in all of the other KHQ domains </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0103" title="ZinnerN , GittelmanM , HarrisR , SussetJ , KanellosA , AuerbachS . Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial (Abstract number DP51). In: American Urological Association (AUA), 98th Annual Meeting; 2003 Apr 26-May 1; Chicago, Illinois. 2003. [sr-incont31101]ZinnerN , GittelmanM , HarrisR , SussetJ , KanelosA , AuerbachS , Trospium Study Group. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. Journal of Urology2004;171(6 Pt 1):2311-5. [sr-incont17376]">Zinner 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IIQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 400, lower scores indicate better QoL MCID: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trospium change from baseline score indicated improvement in all IIQ domains (travel, social relationships, emotional health, physical activity) compared to placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticholinergics improve QoL compared to placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0104" title="ZinnerN , SussetJ , GittelmanM , ArguinzonizM , RekedaL , HaabF . Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. International Journal of Clinical Practice2006;60(1):119-26. [sr-incont21507]">Zinner 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OAB‐q, KHQ and ICIQ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable as data are not shown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Darifenacin showed improvement compared to placebo in all domains of all three measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticholinergics improve QoL compared to placebo</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*unless specified otherwise</p> <p>HRQL: health‐related quality of life<br/>ICIQ: International Consultation of Incontinence Questionnaire<br/>IIQ: Incontinence Impact Questionnaire<br/>KHQ: King's Health Questionnaire<br/>MCID: minimal clinically important difference<br/>OAB‐q: overactive bladder questionnaire<br/>QoL: quality of life<br/>UDI: Urogenital Distress Inventory </p> </div> </div> <p>All studies unequivocally reported improvement in quality of life compared to placebo, as illustrated in <a href="#CD003781-tbl-0002">Table 1</a>.  </p> </section> <section id="CD003781-sec-0073"> <h5 class="title">Patient perception of cure or improvement</h5> <p>Nine studies contributed to this outcome, with a total of 8457 participants (5367 in the anticholinergic group and 3090 in the placebo group) (<a href="./references#CD003781-bbs2-0017" title="ChappleC , DuBeauC , EbingerU , RekedaL , ViegasA . Darifenacin treatment of patients &gt;or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Current Medical Research and Opinion2007;23(10):2347-58. [srincont-23921]">Chapple 2007b</a>; <a href="./references#CD003781-bbs2-0024" title="DmochowskiR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. A double-blind, placebo-controlled trial of flexible-dose fesoterodine for overactive bladder (Abstract number 715). In: International Continence Society (ICS); 39th Annual Meeting; 2009 Sep 29-Oct 03; San Francisco, CA. 2009. [sr-incont35627]DmochowskiRR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder [Errata appear in: Urology 2010 Jun;75(6):1519 and in Urology 2011 Jun;77(6):1513]. Urology2010;75(1):62-8. [A0221014] [NCT00536484] [sr-incont39548]DuBeauC , KrausSR , SunF , MorrowJD . Fesoterodine in older vs younger subjects with overactive bladder (Abstract number D87). Journal of the American Geriatrics Society2010;58:S218. [NCT00536484] [sr-incont64309]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. [sr-incont78640]NCT00536484. Fesoterodine flexible dose study [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with overactive bladder]. clinicaltrials.gov/show/NCT00536484 (first received 27 September 2007). [NCT00536484] [sr-incont49160]StaskinD , KhullarV , MichelMC , MorrowJD , SunF , GuanZ , et al. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. Neurourology and Urodynamics2011;30(8):1480-5. [sr-incont42686]">Dmochowski 2010</a>; <a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>; <a href="./references#CD003781-bbs2-0038" title="HerschornS , HeesakkersJ , Castro-DiazD , WangJT , BrodskyM , GuanZ . Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*. Current Medical Research and Opinion2008;24(12):3513-21. [A6121122] [NCT00143377] [srincont-29250]HerschornS , HeesakkersJ , Castro-DiazD , WangJT , GuanZ , BrodskyM . Tolterodine extended release (TER) improves objective and subjective outcomes after 1 week of treatment in patients with overactive bladder (Abstract number 132). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S78-9. [srincont-26602]">Herschorn 2008</a>; <a href="./references#CD003781-bbs2-0039" title="CorcosJ , AnguloJC , GarelyAD , CarlssonM , GongJ , GuanZ . Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. Current Medical Research and Opinion2011;27(5):1059-65. [srincont-41596]EUCTR2006-006935-38-SE. 12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006935-38 (first received 16 April 2007). [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont64612]HerschornS , SwiftS , GuanZ , CarlssonM , BrodskyM , GongJ . Efficacy and safety of fesoterodine for overactive bladder in a double-blind, head-to-head comparison trial with tolterodine ER and placebo (Abstract number 710). In: International Continence Society (ICS), 39th Annual Meeting; 2009 Sep 29-Oct 3; San Francisco, CA. 2009. [srincont-35326]HerschornS , SwiftS , GuanZ , CarlssonM , MorrowJD , BrodskyM , et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU International2010;105(1):58-66. [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont39540]NCT00444925. Clinical trial to evaluate the efficacy and safety of Fesoterodine in comparison to Tolterodine for overactive bladder (OAB) [12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder (OAB)]. clinicaltrials.gov/show/NCT00444925 (first received 08 March 2007). [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont49159]">Herschorn 2009a</a>; <a href="./references#CD003781-bbs2-0046" title="HuangA , HessR , AryaL , RichterH , SubakL , BradleyC , et al. A randomized controlled trial of simple diagnosis and treatment for urgency urinary incontinence in women (Abstract). Journal of General Internal Medicine2011;26:S1. [NCT00862745] [sr-incont64391]HuangAJ , HessR , AryaLA , RichterHE , SubakLL , BradleyCS , et al. Pharmacologic treatment for urgency-predominant urinary incontinence in women diagnosed using a simplified algorithm: a randomized trial. American Journal of Obstetrics and Gynecology2012;206(5):444.e1-11. [GA0221IX] [NCT00862745] [TrialID.BRIDGES.] [srincont-44636]NCT00862745, BrownJ . Bringing simple urge incontinence diagnosis &amp; treatment to providers (BRIDGES)  [A multi-center, randomized, placebo-controlled clinical trial comparing fesoterodine to placebo in women diagnosed with urge urinary incontinence by the 3 Incontinence Questions (3IQ). Followed by a multi-center open label clinical cohort study of long-term effects of treatment with fesoterodine ]. clinicaltrials.gov/show/NCT00862745 (first received 17 March 2009). [NCT00862745] [sr-incont49836]WarsiQ , HuangA , BrownJS , SchembriM , HessR , AryaLA , et al. The effect of pharmacologic treatment of urgency urinary incontinence on sleep quality and daytime sleepiness (Abstract number: paper 37). Female Pelvic Medicine and Reconstructive Surgery2016;22(5 ):S17-8. [NCT00862745] [TrialID.BRIDGES.] [sr-incont78633]WarsiQA , HuangAJ , HessR , AryaLA , RichterHE , BradleyCS , et al. Association of pharmacologic treatment of urgency urinary incontinence with sleep quality and daytime sleepiness. Obstetrics and Gynecology2018;131(2):204-11. [NCT00862745] [sr-incont78239]WinkelmanW , HuangA , SchembriM , RogersRG , RichterHE , MyersDL , et al. Clinical variables moderating response to pharmacologic treatment of urgency-predominant urinary incontinence in a randomized controlled trial (Abstract number: poster 25). In: Female Pelvic Medicine and Reconstructive Surgery. 37th Annual Scientific Meeting of the American Urogynecologic Society; Aug 2016; United States. Vol. 22. Netherlands: Lippincott Williams and Wilkins, 2016:S81. [NCT00862745] [sr-incont78634]WinkelmanWD , HuangAJ , SchembriM , RogersRG , RichterH , MyersDL , et al. Modifiers of response to treatment with fesoterodine for urgency-predominant urinary incontinence in a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2017;23(2):151-6. [sr-incont74308]">Huang 2012</a>; <a href="./references#CD003781-bbs2-0051" title="EUCTR2007-006451-39-SE. 12-week, randomized, double-blind, double-dummy, placebo controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-006451-39 (first received 20 February 2008). [A0221046] [EUCTR2007-006451-39-SE] [sr-incont64591]KaplanSA , SchneiderT , FooteJ , GuanZ . Superior efficacy of fesoterodine over tolterodine with rapid onset: a prospective, head-to-head, placebo-controlled trial (Abstract number 67). Neurourology and Urodynamics2010;29(6):905-7. [srincont-40130]KaplanSA , SchneiderT , FooteJE , GuanZ , CarlssonM , GongJ . Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU International2011;107(9):1432-40. [A0221046] [NCT00611026] [srincont-41334]">Kaplan 2011</a>; <a href="./references#CD003781-bbs2-0052" title="CardozoL , KaplanS , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: results from the after study (Abstract number 740) [Erratum appears in: European Urology 2014;65(5):e78]. European Urology Supplements2013;12(1):e740-1. [NCT01302054] [sr-incont63732]CardozoL , KaplanS , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. Erratum: A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: results from the AFTER study [Erratum available in: European Urology Supplement 2013;2012:e740-1]. European Urology2014;65(5):e78 . [A0221094] [NCT01302054] [TrialID.AFTER.] [sr-incont61642]GrenaboL , HerschornS , KaplanSA , CardozoL , ScholfieldD , ArumiD , et al. Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptoms. Current Medical Research and Opinion2017;33(10):1731-6. [NCT01302054] [TrialID.AFTER.] [sr-incont76695]KaplanSA , CardozoL , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER. International Journal of Clinical Practice2014;68(9):1065-73. [A0221094] [NCT01302054] [TrialID.AFTER.] [srincont-63977]KaplanSA , HerschornS , CarlssonM , NtaniosF . Urgency urinary incontinence response rates in subjects with overactive bladder treated with fesoterodine 8 mg after suboptimal response to tolterodine extended release 4 mg: a randomized, double-blind, placebo-controlled trial (Abstract number 546). In: International Continence Society (ICS); 43rd Annual Meeting; 2013 Aug 26-30; Barcelona, Spain. 2013. [NCT01302054] [TrialID.AFTER.] [sr-incont49730]NCT01302054. A clinical study in patients with overactive bladder with leakage of urine, to find out if the medicine, Fesoterodine, works in those patients who did not have enough response to the medicine, tolterodine. [A 14 week randomized parallel group placebo-controlled double-blind multicentre study of fesoterodine 8 mg in overactive bladder patients with sub-optimal response to tolterodine 4 mg extended release (ER)]. clinicaltrials.gov/show/NCT01302054 (first received 23 February 2011). [A0221094] [NCT01302054] [TrialID.AFTER.] [sr-incont49845]">Kaplan 2014</a>; <a href="./references#CD003781-bbs2-0094" title="EUCTR2007-007087-17-SE. A 24-week, multicentre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-007087-17 (first received 13 June 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont64588]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00798434. A study to compare the effectiveness and safety of fesoterodine and placebo in an elderly population of patients who go to the toilet very frequently due to overactive bladder (SOFIA) [A 24-week, multi-centre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00798434 (first received 26 November 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont49847]SchneiderT , BergqvistA , WangJ , WaggA , Ebel-BitounC . Treatment with fesoterodine versus tolterodine for reducing symptom bother in elderly patients with overactive bladder including urgency urinary incontinence. European Urology, Supplements2012;11(1):e687-a. [sr-incont65389]WaggA , CarlssonM , ElsobkyM , FernetM . Effect of flexible dose fesoterodine on cognitive function in &gt;65 year old patients with OAB: data from two RCT (Abstract number 438). Neurourology and Urodynamics2019;38:S297-8. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78651]WaggA , DarekarA , ArumiD , KhullarV , OelkeM . Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people &gt;65 years of age: a post hoc analysis of data from the SOFIA study. Neurourology and Urodynamics2015;34(5):438-43. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont68100]WaggA , ElsobkyM , CarlssonM , FernetM . Response and cognitive safety of fesoterodine in patients &gt;65y old with OAB. Is there a relationship between cognition and treatment response? (Abstract number 183). Neurourology and Urodynamics2019;38:S118-20. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78632]WaggA , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. Journal of the American Geriatrics Society2013;61(2):185-93. [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TrialID.SOFIA.] [sr-incont48008]WaggAS , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Efficacy and tolerability of fesoterodine in older subjects with overactive bladder: results of SOFIA (Abstract number C33). Journal of the American Geriatrics Society2011;59:S124. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont65234]">Wagg 2013a</a>). </p> <p>Anticholinergic drugs probably lead to patients perceiving a greater sense of cure or improvement compared to placebo (risk ratio (RR) 1.38, 95% CI 1.15 to 1.66; P &lt; 0.00001; <a href="./references#CD003781-fig-0011" title="">Analysis 1.2</a>; <a href="./full#CD003781-tbl-0001">summary of findings Table 1</a>; moderate‐certainty evidence). </p> <p>There were 11 other studies that reported the patient perception of cure or improvement outcome but were not included in the meta‐analysis due to lack of information or different scales or outcome measures used (<a href="./references#CD003781-bbs2-0008" title="BurgioKL , LocherJL , GoodePS , HardinJM , McDowellBJ , CandibD . Behavior vs drug therapy for urge incontinence in older women (Abstract number 26). In: American Urogynecology Society, 15th Annual Scientific Meeting; 1994 Sept 21-24; Toronto, Ontario. 1994:48. [sr-incont14585]BurgioKL , LocherJL , GoodePS , HardinM , McDowellBJ , Dombrowski M et al. Behavioral vs drug treatment for urge urinary incontinence in older women. A randomized controlled trial. JAMA1998;280(23):1995-2000. [srincont-5719]BurgioKL , LocherJL , GoodePS . Combined behavioral and drug therapy for urge incontinence in older women. Journal of the American Geriatrics Society2000;48(4):370-4. [srincont-9006]BurgioKL , LocherJL , RothDL , GoodePS . Psychological improvements associated with behavioral and drug treatment of urge incontinence in older women. Journal of Gerontology. Series B, Psychological Sciences and Social Sciences2001;56(1):P46-51. [srincont-11923]">Burgio 1998</a>; <a href="./references#CD003781-bbs2-0022" title="AmarencoG , SutoryM , FagertunH , WrightM , CompionG , De RidderD . Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Preliminary results from the SONIC urodynamic study (Abstract). European Urology, Supplements2012;11(1):e467-a. [EudraCT2006-005523-42] [NCT00629642] [sr-incont65392]AmarencoG , SutoryM , ZachovalR , AgarwalM , DelPG , TretterR , et al. Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study. Neurourology and Urodynamics2017;36(2):414-21. [EudraCT2006-005523-42] [JapicCTI-R130306] [NCT00629642] [sr-incont72248]De RidderD , AmarencoG , Finazzi-AgroE , AnguloJ , KurenkovA , WrightM , et al. Solifenacin treatment for neurogenic detrusor overactivity: patient-reported outcomes (PROs) from the randomised clinical trial SONIC (Abstract number 333). In: International Continence (ICS); 42nd Annual Meeting; 2012 Oct 15-19; Beijing, China. 2012. [905-EC-005] [EudraCT2006-005523-42] [NCT00629642] [TrialID.SONIC.] [srincont-49739]">De Ridder 2012</a>; <a href="./references#CD003781-bbs2-0032" title="GellerE , DumondJ , BowlingJM , KhandelwalC , WuJ , Busby-WhiteheadJ , et al. Effect of an anticholinergic on cognitive function in postmenopausal women: a randomized trial (Abstract number: oral poster 52). Female Pelvic Medicine and Reconstructive Surgery2016;22(5):S61. [sr-incont78607]GellerEJ , DumondJB , BowlingJM , KhandelwalCM , WuJM , Busby-WhiteheadJ , et al. Effect of trospium chloride on cognitive function in women aged 50 and older: a randomized trial. Female Pelvic Medicine &amp; Reconstructive Surgery2017;23(2):118-23. [13-1352] [NCT01922115] [sr-incont74341]NCT01922115. The effect of anticholinergics on cognitive function in the elderly (ACE) [The effect of anticholinergics on cognitive function in the elderly: a randomized controlled trial]. clinicaltrials.gov/show/NCT01922115 (first received 14 August 2013). [13-1352] [NCT01922115] [TrialID.ACE] [sr-incont49282]">Geller 2013</a>; <a href="./references#CD003781-bbs2-0040" title="EUCTR2012-005735-91-SK. A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-005735-91 (first received 12 November 2013). [178-CL-101] [EUCTR2012-005735-91-SK] [sr-incont78644]HerschornS , ChappleCR , AbramsP , ArlandisS , MitchesonD , LeeKS , et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU International2017;120(4):562-75. [NCT01972841] [sr-incont74470]MuellerER , RobinsonD , KelleherC , StaskinDR , FalconerC , WangJ , et al. Patient reported outcomes from synergy, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with mirabegron and solifenacin monotherapy (Abstract number - Podium #44). Neurourology and Urodynamics2017;36(Suppl S1):S151-2. [NCT01972841] [sr-incont75944]NCT01972841. This was a multinational study comparing the efficacy and safety of two medicines, solifenacin succinate and mirabegron taken together, or separately, or a mock treatment (placebo) in subjects with symptoms of overactive bladder (SYNERGY) [A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01972841 (first received 31 October 2013). [178-CL-101] [EUCTR2012-005735-91] [NCT01972841] [sr-incont63780]RobinsonD , KelleherC , StaskinD , MuellerER , FalconerC , WangJ , et al. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients. Neurourology and Urodynamics2018;37(1):394-406. [NCT01972841] [sr-incont76906]WeberMA , ChappleCR , GratzkeC , HerschornS , RobinsonD , FrankelJM , et al. A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial. Blood Pressure Monitoring2018;23(3):153-63. [NCT01972841] [sr-incont77899]WhiteWB , ChappleC , GratzkeC , HerschornS , RobinsonD , FrankelJ , et al. Cardiovascular safety of the beta3-adrenoceptor agonist mirabegron and the antimuscarinic agent solifenacin in the SYNERGY trial. Journal of Clinical Pharmacology2018;58(8):1084-91. [NCT01972841] [sr-incont78078]">Herschorn 2017a</a>; <a href="./references#CD003781-bbs2-0054" title="KhullarV , HillS , LavalKU , SchiotzHA , JonasU , VersiE . Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology2004;64(2):269-74; discussion 274-5. [srincont-19498]KhullarV , HillS , SolankiJ . Assessment of health-related quality of life in patients with overactive bladder taking tolterodine extended release versus placebo (Abstract number 318). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21075]">Khullar 2004</a>; <a href="./references#CD003781-bbs2-0067" title="MillardR , TuttleJ , MooreK , SussetJ , ClarkeB , DwyerP , et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. Journal of Urology1999;161(5):1551-5. [sr-incont8172]MooreK , MillardR , DwyerP , TuttleJ . A randomized controlled multicentre trial of tolterodine in detrusor instability/hyperreflexia. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(Suppl 1):S129. [sr-incont5171]RosamiliaA , DwyerPL , ClarkeB , MooreK , MillardRP , TuttleJ . The clinical efficacy and safety of two doses of Tolterodine in detrusor instability. Acta Obstetrica et Gynecologica Scandinavica1997;6(Suppl 167):24. [sr-incont6670]">Millard 1999</a>; <a href="./references#CD003781-bbs2-0079" title="RovnerES , KaplanS , GuanZ , WangJT , RoehrbornCG . Clinical efficacy and safety of tolterodine extended release in male patients with overactive bladder and urgency urinary incontinence (Abstract number 188). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21091]">Rovner 2005</a>; <a href="./references#CD003781-bbs2-0088" title="TakayasuH , UenoA , TsutidaS , KoisoK , KuritaK , KawabeK , et al. Clinical effects of propiverine hydrochloride in the treatment of urinary frequency and incontinence associated with detrusor overactivity: a double blind, parallel, placebo controlled multicenter study. Igaku No Ayumi (Progress in Medicine)1990;153(8):459-71. [srincont-12896]TakayasuH , UenoA , TsutidaS , KoisoK , KuritaK , KawabeK , et al. Clinical effects of propiverine hydrochloride in the treatment of urinary frequency and incontinence associated with detrusor overactivity: a double blind, parallel, placebo controlled multicenter study. Igaku No Ayumi (Progress in Medicine)1990;153(8):459-71. [sr-incont12896]">Takayasu 1990</a>; <a href="./references#CD003781-bbs2-0093" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CrosbyRD , MathiasSD , MarshallTS . Relationships between symptoms, symptom bother, and health-related quality of life in patients with overactive bladder taking solifenacin or placebo in the VIBRANT study. International Journal of Clinical Practice2011;65(2):211-8. [sr-incont41015]GollarKM , YoungDG , BailenJ , HeW , Forero-SchwanhaeuserS . Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: a secondary analysis of the VIBRANT study. Urologic Nursing2012;32(1):38-46. [TrialID.VIBRANT.] [sr-incont44571]Samuels T‐A, MitchesonHD , VardyM , Forero‐SchwanhaeuserS , MarshallT , HeW . Efficacy of solifenacin for symptom bother and other patient-reported outcomes in patients with overactive bladder (OAB): results of a large, double-blind, placebo-controlled trial (Abstract number: poster #74). Neurourology and Urodynamics2009;28(2):149. [sr-incont31063]VardyMD , MitchesonHD , SamuelsTA , Forero-SchwanhaeuserS , HeW . Efficacy of solifenacin on overactive bladder symptoms, symptom bother, and other patient-reported outcomes in subjects with or without incontinence: a post hoc analysis of data from VIBRANT. Female Pelvic Medicine and Reconstructive Surgery2011;17(1):24-9. [TrialID.VIBRANT.] [sr-incont44741]VardyMD , MitchesonHD , SamuelsTA , WegenkeJD , Forero-SchwanhaeuserS , MarshallTS , et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. International Journal of Clinical Practice2009;63(12):1702-14. [905-UC-010] [NCT00573508] [TrialID.VIBRANT.] [sr-incont35459]">Vardy 2009</a>; <a href="./references#CD003781-bbs2-0101" title="NCT01018264, ZesiewiczT . Solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease (URGE-PD) [URGE-PD: a multi-site, double-blind, randomized, placebo controlled trial of solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease]. clinicaltrials.gov/show/NCT01018264 (first received 23 November 2009). [NCT01018264] [sr-incont63790]ZesiewiczTA , EvattM , JahanI , VaughanC , SingerC , OrdoricaR , et al. URGE-PD: a multi-site, double-blind, randomized, placebo controlled trial of solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease (Abstract number 745). Movement Disorders2014;29(Suppl 1):S276-7. [NCT01018264] [sr-incont66602]ZesiewiczTA , EvattM , VaughanCP , JahanI , SingerC , OrdoricaR , et al. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease. Parkinsonism and Related Disorders2015;21(5):514-20. [NCT01018264] [sr-incont66860]">Zesiewicz 2015</a>). These studies are described in this section.  </p> <p>Only two studies presented the change from baseline result with the Patient Perception of Bladder Condition (PPBC) scale (<a href="./references#CD003781-bbs2-0022" title="AmarencoG , SutoryM , FagertunH , WrightM , CompionG , De RidderD . Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Preliminary results from the SONIC urodynamic study (Abstract). European Urology, Supplements2012;11(1):e467-a. [EudraCT2006-005523-42] [NCT00629642] [sr-incont65392]AmarencoG , SutoryM , ZachovalR , AgarwalM , DelPG , TretterR , et al. Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study. Neurourology and Urodynamics2017;36(2):414-21. [EudraCT2006-005523-42] [JapicCTI-R130306] [NCT00629642] [sr-incont72248]De RidderD , AmarencoG , Finazzi-AgroE , AnguloJ , KurenkovA , WrightM , et al. Solifenacin treatment for neurogenic detrusor overactivity: patient-reported outcomes (PROs) from the randomised clinical trial SONIC (Abstract number 333). In: International Continence (ICS); 42nd Annual Meeting; 2012 Oct 15-19; Beijing, China. 2012. [905-EC-005] [EudraCT2006-005523-42] [NCT00629642] [TrialID.SONIC.] [srincont-49739]">De Ridder 2012</a>; <a href="./references#CD003781-bbs2-0040" title="EUCTR2012-005735-91-SK. A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-005735-91 (first received 12 November 2013). [178-CL-101] [EUCTR2012-005735-91-SK] [sr-incont78644]HerschornS , ChappleCR , AbramsP , ArlandisS , MitchesonD , LeeKS , et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU International2017;120(4):562-75. [NCT01972841] [sr-incont74470]MuellerER , RobinsonD , KelleherC , StaskinDR , FalconerC , WangJ , et al. Patient reported outcomes from synergy, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with mirabegron and solifenacin monotherapy (Abstract number - Podium #44). Neurourology and Urodynamics2017;36(Suppl S1):S151-2. [NCT01972841] [sr-incont75944]NCT01972841. This was a multinational study comparing the efficacy and safety of two medicines, solifenacin succinate and mirabegron taken together, or separately, or a mock treatment (placebo) in subjects with symptoms of overactive bladder (SYNERGY) [A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01972841 (first received 31 October 2013). [178-CL-101] [EUCTR2012-005735-91] [NCT01972841] [sr-incont63780]RobinsonD , KelleherC , StaskinD , MuellerER , FalconerC , WangJ , et al. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients. Neurourology and Urodynamics2018;37(1):394-406. [NCT01972841] [sr-incont76906]WeberMA , ChappleCR , GratzkeC , HerschornS , RobinsonD , FrankelJM , et al. A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial. Blood Pressure Monitoring2018;23(3):153-63. [NCT01972841] [sr-incont77899]WhiteWB , ChappleC , GratzkeC , HerschornS , RobinsonD , FrankelJ , et al. Cardiovascular safety of the beta3-adrenoceptor agonist mirabegron and the antimuscarinic agent solifenacin in the SYNERGY trial. Journal of Clinical Pharmacology2018;58(8):1084-91. [NCT01972841] [sr-incont78078]">Herschorn 2017a</a>). The results and interpretation of the results are shown in <a href="#CD003781-tbl-0003">Table 2</a>.  </p> <div class="table" id="CD003781-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Patient perception of cure or improvement outcome in studies that were not included in meta‐analysis (using PPBC measure)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Score/measure</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Interpretation</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0022" title="AmarencoG , SutoryM , FagertunH , WrightM , CompionG , De RidderD . Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Preliminary results from the SONIC urodynamic study (Abstract). European Urology, Supplements2012;11(1):e467-a. [EudraCT2006-005523-42] [NCT00629642] [sr-incont65392]AmarencoG , SutoryM , ZachovalR , AgarwalM , DelPG , TretterR , et al. Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study. Neurourology and Urodynamics2017;36(2):414-21. [EudraCT2006-005523-42] [JapicCTI-R130306] [NCT00629642] [sr-incont72248]De RidderD , AmarencoG , Finazzi-AgroE , AnguloJ , KurenkovA , WrightM , et al. Solifenacin treatment for neurogenic detrusor overactivity: patient-reported outcomes (PROs) from the randomised clinical trial SONIC (Abstract number 333). In: International Continence (ICS); 42nd Annual Meeting; 2012 Oct 15-19; Beijing, China. 2012. [905-EC-005] [EudraCT2006-005523-42] [NCT00629642] [TrialID.SONIC.] [srincont-49739]">De Ridder 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PPBC (change from baseline) </p> <p>Placebo: ‐0.1</p> <p>Solifenacin: ‐0.5 </p> <p>Oxybutynin: ‐0.5</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Solifenacin and oxybutynin may improve patient perception of bladder condition compared to placebo. </p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0040" title="EUCTR2012-005735-91-SK. A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-005735-91 (first received 12 November 2013). [178-CL-101] [EUCTR2012-005735-91-SK] [sr-incont78644]HerschornS , ChappleCR , AbramsP , ArlandisS , MitchesonD , LeeKS , et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU International2017;120(4):562-75. [NCT01972841] [sr-incont74470]MuellerER , RobinsonD , KelleherC , StaskinDR , FalconerC , WangJ , et al. Patient reported outcomes from synergy, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with mirabegron and solifenacin monotherapy (Abstract number - Podium #44). Neurourology and Urodynamics2017;36(Suppl S1):S151-2. [NCT01972841] [sr-incont75944]NCT01972841. This was a multinational study comparing the efficacy and safety of two medicines, solifenacin succinate and mirabegron taken together, or separately, or a mock treatment (placebo) in subjects with symptoms of overactive bladder (SYNERGY) [A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01972841 (first received 31 October 2013). [178-CL-101] [EUCTR2012-005735-91] [NCT01972841] [sr-incont63780]RobinsonD , KelleherC , StaskinD , MuellerER , FalconerC , WangJ , et al. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients. Neurourology and Urodynamics2018;37(1):394-406. [NCT01972841] [sr-incont76906]WeberMA , ChappleCR , GratzkeC , HerschornS , RobinsonD , FrankelJM , et al. A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial. Blood Pressure Monitoring2018;23(3):153-63. [NCT01972841] [sr-incont77899]WhiteWB , ChappleC , GratzkeC , HerschornS , RobinsonD , FrankelJ , et al. Cardiovascular safety of the beta3-adrenoceptor agonist mirabegron and the antimuscarinic agent solifenacin in the SYNERGY trial. Journal of Clinical Pharmacology2018;58(8):1084-91. [NCT01972841] [sr-incont78078]">Herschorn 2017a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PPBC (change from baseline)</p> <p>Placebo: ‐0.9</p> <p>Solifenacin: ‐1.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Solifenacin may improve patient perception of bladder condition compared to placebo.</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>PPBC: patient perception of cure or improvement.</p> <p>A decrease in PPBC score indicates improvement.</p> <p>Minimal clinically important difference is unclear.</p> </div> </div> <p>The remaining eight studies that were not included in either the meta‐analysis or the table are included in the direction of effect plot (<a href="#CD003781-tbl-0004">Table 3</a>), since different outcome measures and scales were used across the studies. We ranked the studies by risk of bias rating (those with more risk of bias domains rated as 'low' were closer the top, and those with fewer were closer to the bottom). All of the studies reported improvement with anticholinergic drugs compared with placebo. Nonetheless, since the exact calculation of the overall improvement cannot be estimated, the result should be interpreted with caution.  </p> <div class="table" id="CD003781-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Patient perception of cure or improvement ‐ direction of effect plot</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b>  </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study design</b>  </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Patient perception of cure or improvement</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0032" title="GellerE , DumondJ , BowlingJM , KhandelwalC , WuJ , Busby-WhiteheadJ , et al. Effect of an anticholinergic on cognitive function in postmenopausal women: a randomized trial (Abstract number: oral poster 52). Female Pelvic Medicine and Reconstructive Surgery2016;22(5):S61. [sr-incont78607]GellerEJ , DumondJB , BowlingJM , KhandelwalCM , WuJM , Busby-WhiteheadJ , et al. Effect of trospium chloride on cognitive function in women aged 50 and older: a randomized trial. Female Pelvic Medicine &amp; Reconstructive Surgery2017;23(2):118-23. [13-1352] [NCT01922115] [sr-incont74341]NCT01922115. The effect of anticholinergics on cognitive function in the elderly (ACE) [The effect of anticholinergics on cognitive function in the elderly: a randomized controlled trial]. clinicaltrials.gov/show/NCT01922115 (first received 14 August 2013). [13-1352] [NCT01922115] [TrialID.ACE] [sr-incont49282]">Geller 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>▲</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0101" title="NCT01018264, ZesiewiczT . Solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease (URGE-PD) [URGE-PD: a multi-site, double-blind, randomized, placebo controlled trial of solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease]. clinicaltrials.gov/show/NCT01018264 (first received 23 November 2009). [NCT01018264] [sr-incont63790]ZesiewiczTA , EvattM , JahanI , VaughanC , SingerC , OrdoricaR , et al. URGE-PD: a multi-site, double-blind, randomized, placebo controlled trial of solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease (Abstract number 745). Movement Disorders2014;29(Suppl 1):S276-7. [NCT01018264] [sr-incont66602]ZesiewiczTA , EvattM , VaughanCP , JahanI , SingerC , OrdoricaR , et al. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease. Parkinsonism and Related Disorders2015;21(5):514-20. [NCT01018264] [sr-incont66860]">Zesiewicz 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>▲</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0008" title="BurgioKL , LocherJL , GoodePS , HardinJM , McDowellBJ , CandibD . Behavior vs drug therapy for urge incontinence in older women (Abstract number 26). In: American Urogynecology Society, 15th Annual Scientific Meeting; 1994 Sept 21-24; Toronto, Ontario. 1994:48. [sr-incont14585]BurgioKL , LocherJL , GoodePS , HardinM , McDowellBJ , Dombrowski M et al. Behavioral vs drug treatment for urge urinary incontinence in older women. A randomized controlled trial. JAMA1998;280(23):1995-2000. [srincont-5719]BurgioKL , LocherJL , GoodePS . Combined behavioral and drug therapy for urge incontinence in older women. Journal of the American Geriatrics Society2000;48(4):370-4. [srincont-9006]BurgioKL , LocherJL , RothDL , GoodePS . Psychological improvements associated with behavioral and drug treatment of urge incontinence in older women. Journal of Gerontology. Series B, Psychological Sciences and Social Sciences2001;56(1):P46-51. [srincont-11923]">Burgio 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>▲</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0054" title="KhullarV , HillS , LavalKU , SchiotzHA , JonasU , VersiE . Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology2004;64(2):269-74; discussion 274-5. [srincont-19498]KhullarV , HillS , SolankiJ . Assessment of health-related quality of life in patients with overactive bladder taking tolterodine extended release versus placebo (Abstract number 318). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21075]">Khullar 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>▲</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0093" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CrosbyRD , MathiasSD , MarshallTS . Relationships between symptoms, symptom bother, and health-related quality of life in patients with overactive bladder taking solifenacin or placebo in the VIBRANT study. International Journal of Clinical Practice2011;65(2):211-8. [sr-incont41015]GollarKM , YoungDG , BailenJ , HeW , Forero-SchwanhaeuserS . Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: a secondary analysis of the VIBRANT study. Urologic Nursing2012;32(1):38-46. [TrialID.VIBRANT.] [sr-incont44571]Samuels T‐A, MitchesonHD , VardyM , Forero‐SchwanhaeuserS , MarshallT , HeW . Efficacy of solifenacin for symptom bother and other patient-reported outcomes in patients with overactive bladder (OAB): results of a large, double-blind, placebo-controlled trial (Abstract number: poster #74). Neurourology and Urodynamics2009;28(2):149. [sr-incont31063]VardyMD , MitchesonHD , SamuelsTA , Forero-SchwanhaeuserS , HeW . Efficacy of solifenacin on overactive bladder symptoms, symptom bother, and other patient-reported outcomes in subjects with or without incontinence: a post hoc analysis of data from VIBRANT. Female Pelvic Medicine and Reconstructive Surgery2011;17(1):24-9. [TrialID.VIBRANT.] [sr-incont44741]VardyMD , MitchesonHD , SamuelsTA , WegenkeJD , Forero-SchwanhaeuserS , MarshallTS , et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. International Journal of Clinical Practice2009;63(12):1702-14. [905-UC-010] [NCT00573508] [TrialID.VIBRANT.] [sr-incont35459]">Vardy 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>▲</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0067" title="MillardR , TuttleJ , MooreK , SussetJ , ClarkeB , DwyerP , et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. Journal of Urology1999;161(5):1551-5. [sr-incont8172]MooreK , MillardR , DwyerP , TuttleJ . A randomized controlled multicentre trial of tolterodine in detrusor instability/hyperreflexia. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(Suppl 1):S129. [sr-incont5171]RosamiliaA , DwyerPL , ClarkeB , MooreK , MillardRP , TuttleJ . The clinical efficacy and safety of two doses of Tolterodine in detrusor instability. Acta Obstetrica et Gynecologica Scandinavica1997;6(Suppl 167):24. [sr-incont6670]">Millard 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>▲</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0079" title="RovnerES , KaplanS , GuanZ , WangJT , RoehrbornCG . Clinical efficacy and safety of tolterodine extended release in male patients with overactive bladder and urgency urinary incontinence (Abstract number 188). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21091]">Rovner 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>▲</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0088" title="TakayasuH , UenoA , TsutidaS , KoisoK , KuritaK , KawabeK , et al. Clinical effects of propiverine hydrochloride in the treatment of urinary frequency and incontinence associated with detrusor overactivity: a double blind, parallel, placebo controlled multicenter study. Igaku No Ayumi (Progress in Medicine)1990;153(8):459-71. [srincont-12896]TakayasuH , UenoA , TsutidaS , KoisoK , KuritaK , KawabeK , et al. Clinical effects of propiverine hydrochloride in the treatment of urinary frequency and incontinence associated with detrusor overactivity: a double blind, parallel, placebo controlled multicenter study. Igaku No Ayumi (Progress in Medicine)1990;153(8):459-71. [sr-incont12896]">Takayasu 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>▲</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>▲ ‐ represents improvement</p> </div> </div> </section> <section id="CD003781-sec-0074"> <h5 class="title">Mean number of urgency episodes per 24 hours at the end of treatment</h5> <p>Twenty‐three studies reported this outcome with a total of 16,875 participants (10,951 in the anticholinergic group and 5924 in the placebo group) (<a href="./references#CD003781-bbs2-0014" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. ChappleCR , AranoP , BoschJH , De RidderD , KramerG , RidderAM . YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo- and tolterodine-controlled, phase-II, dose-finding study (Abstract 75). Neurourology and Urodynamics2002;21(4):381-2. [srincont-14551]ChappleCR , ArañoP , BoschJL , De RidderD , KramerAE , RidderAM . Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU International2004;93(1):71-7. [srincont-17334]KelleherCJ , CardozoL , ChappleCR , HaabF , RidderAM . Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU International2005;95(1):81-5. [srincont-20241]SmithN , GrimesI , RidgeS , TempelD , UchidaT , YamanouchiUS . YM905 is effective and safe as treatment of overactive bladder in women and men: results from phase II study (Abstract). In: International Continence Society (ICS), 32nd Annual Meeting; 2002 Aug 28-30; Heidelberg, Germany. 2002:138-9. [sr-incont14508]">Chapple 2004b</a>; <a href="./references#CD003781-bbs2-0016" title="ChappleC , Van KerrebroeckP , TubaroA , Haag-MolkentellerC , ForstHT , MassowU , et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder [Erratum appears in: European Urology 2008,53(6):1319]. European Urology2007;52(4):1204-12. [NCT00220363] [SP583] [srincont-23875]ChappleC , Van KerrebroeckP , TubaroA , MillardR . Fesoterodine in non-neurogenic voiding dysfunction - results on efficacy and safety in a phase 3 trial (Abstract number 379). In: 21st Annual European Association of Urology (EAU) Congress; 2006 Apr 5-8; Paris, France. 2006. [srincont-41109]ChappleC , Van KerrebroeckP , TubaroA , WangJT , HvidstenK , BrodskyM . Efficacy of fesoterodine in patients with overactive bladder (OAB): improvements in OAB symptoms and health-related quality of life (HRQL) (Poster abstract number 1188). Journal of Urology2007;177(4 Suppl S):392. [srincont-31882]ChappleCR , vanKerrebroeckPE , JünemannKP , WangJT , BrodskyM . Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU International2008;102(9):1128-32. [srincont-29255]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. KelleherCJ , TubaroA , WangJT , KoppZ . Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU International2008;102(1):56-61. [srincont-27613]SandPK , MorrowJD , BavendamT , CreangaDL , NittiVW . Efficacy and tolerability of fesoterodine in women with overactive bladder. International Urogynecology Journal2009;20(7):827-35. [srincont-31351]">Chapple 2007a</a>; <a href="./references#CD003781-bbs2-0021" title="ChuaME , SeeMC , EsmeňaEB , BalingitJC , MoralesML . Efficacy and safety of gabapentin in comparison to solifenacin succinate in adult overactive bladder treatment. Lower Urinary Tract Symptoms2018;10(2):135-42. [NCT01486706] [sr-incont74529]NCT01486706, ChuaME . Efficacy and safety of gabapentin in treating overactive bladder (OAB). clinicaltrials.gov/show/NCT01486706 (first received 6 December 2011). [NCT01486706] [SLMC10-010] [sr-incont49864]">Chua 2018</a>; <a href="./references#CD003781-bbs2-0024" title="DmochowskiR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. A double-blind, placebo-controlled trial of flexible-dose fesoterodine for overactive bladder (Abstract number 715). In: International Continence Society (ICS); 39th Annual Meeting; 2009 Sep 29-Oct 03; San Francisco, CA. 2009. [sr-incont35627]DmochowskiRR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder [Errata appear in: Urology 2010 Jun;75(6):1519 and in Urology 2011 Jun;77(6):1513]. Urology2010;75(1):62-8. [A0221014] [NCT00536484] [sr-incont39548]DuBeauC , KrausSR , SunF , MorrowJD . Fesoterodine in older vs younger subjects with overactive bladder (Abstract number D87). Journal of the American Geriatrics Society2010;58:S218. [NCT00536484] [sr-incont64309]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. [sr-incont78640]NCT00536484. Fesoterodine flexible dose study [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with overactive bladder]. clinicaltrials.gov/show/NCT00536484 (first received 27 September 2007). [NCT00536484] [sr-incont49160]StaskinD , KhullarV , MichelMC , MorrowJD , SunF , GuanZ , et al. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. Neurourology and Urodynamics2011;30(8):1480-5. [sr-incont42686]">Dmochowski 2010</a>; <a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>; <a href="./references#CD003781-bbs2-0033" title="GotohM , HommaY , YokoyamaO , NishizawaO . Responsiveness and minimal clinically important change in overactive bladder symptom score. Urology2011;78(4):768-73. [srincont-42622]GotohM , YokoyamaO , MatsukawaY , NishizawaO . Responsiveness of overactive bladder symptom score (OABSS): verification based on data in a double-blinded, randomized placebo-controlled study of propiverine hydrochloride in Japanese patients (Abstract number 338). In: Joint Meeting of the International Continence Society (ICS) and the International Urogynecological Association; 2010 Aug 23-27; Toronto, Canada. 2010. [srincont-40173]GotohM , YokoyamaO , NishizawaO . Propiverine hydrochloride in Japanese patients with overactive bladder: A randomized, double-blind, placebo-controlled trial. International Journal of Urology2011;18(5):365-73. [srincont-41510]">Gotoh 2011</a>; <a href="./references#CD003781-bbs2-0039" title="CorcosJ , AnguloJC , GarelyAD , CarlssonM , GongJ , GuanZ . Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. Current Medical Research and Opinion2011;27(5):1059-65. [srincont-41596]EUCTR2006-006935-38-SE. 12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006935-38 (first received 16 April 2007). [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont64612]HerschornS , SwiftS , GuanZ , CarlssonM , BrodskyM , GongJ . Efficacy and safety of fesoterodine for overactive bladder in a double-blind, head-to-head comparison trial with tolterodine ER and placebo (Abstract number 710). In: International Continence Society (ICS), 39th Annual Meeting; 2009 Sep 29-Oct 3; San Francisco, CA. 2009. [srincont-35326]HerschornS , SwiftS , GuanZ , CarlssonM , MorrowJD , BrodskyM , et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU International2010;105(1):58-66. [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont39540]NCT00444925. Clinical trial to evaluate the efficacy and safety of Fesoterodine in comparison to Tolterodine for overactive bladder (OAB) [12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder (OAB)]. clinicaltrials.gov/show/NCT00444925 (first received 08 March 2007). [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont49159]">Herschorn 2009a</a>; <a href="./references#CD003781-bbs2-0044" title="HommaY , YamaguchiT , YamaguchiOA . A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2008;15(9):809-15. [srincont-27742]">Homma 2008</a>; <a href="./references#CD003781-bbs2-0045" title="HommaY , YamaguchiO , Imidafenacin Study Group. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2009;16(5):499-506. [NCT00212732] [ONO-8025-08] [srincont-31368]">Homma 2009</a>; <a href="./references#CD003781-bbs2-0050" title="JünemannKP , HessdörferE , Unamba‐OparahI , BerseM , BrünjesR , MadersbacherH . Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. Urologia Internationalis2006;77(4):334-9. [srincont-22199]">Junemann 2006</a>; <a href="./references#CD003781-bbs2-0051" title="EUCTR2007-006451-39-SE. 12-week, randomized, double-blind, double-dummy, placebo controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-006451-39 (first received 20 February 2008). [A0221046] [EUCTR2007-006451-39-SE] [sr-incont64591]KaplanSA , SchneiderT , FooteJ , GuanZ . Superior efficacy of fesoterodine over tolterodine with rapid onset: a prospective, head-to-head, placebo-controlled trial (Abstract number 67). Neurourology and Urodynamics2010;29(6):905-7. [srincont-40130]KaplanSA , SchneiderT , FooteJE , GuanZ , CarlssonM , GongJ . Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU International2011;107(9):1432-40. [A0221046] [NCT00611026] [srincont-41334]">Kaplan 2011</a>; <a href="./references#CD003781-bbs2-0052" title="CardozoL , KaplanS , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: results from the after study (Abstract number 740) [Erratum appears in: European Urology 2014;65(5):e78]. European Urology Supplements2013;12(1):e740-1. [NCT01302054] [sr-incont63732]CardozoL , KaplanS , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. Erratum: A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: results from the AFTER study [Erratum available in: European Urology Supplement 2013;2012:e740-1]. European Urology2014;65(5):e78 . [A0221094] [NCT01302054] [TrialID.AFTER.] [sr-incont61642]GrenaboL , HerschornS , KaplanSA , CardozoL , ScholfieldD , ArumiD , et al. Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptoms. Current Medical Research and Opinion2017;33(10):1731-6. [NCT01302054] [TrialID.AFTER.] [sr-incont76695]KaplanSA , CardozoL , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER. International Journal of Clinical Practice2014;68(9):1065-73. [A0221094] [NCT01302054] [TrialID.AFTER.] [srincont-63977]KaplanSA , HerschornS , CarlssonM , NtaniosF . Urgency urinary incontinence response rates in subjects with overactive bladder treated with fesoterodine 8 mg after suboptimal response to tolterodine extended release 4 mg: a randomized, double-blind, placebo-controlled trial (Abstract number 546). In: International Continence Society (ICS); 43rd Annual Meeting; 2013 Aug 26-30; Barcelona, Spain. 2013. [NCT01302054] [TrialID.AFTER.] [sr-incont49730]NCT01302054. A clinical study in patients with overactive bladder with leakage of urine, to find out if the medicine, Fesoterodine, works in those patients who did not have enough response to the medicine, tolterodine. [A 14 week randomized parallel group placebo-controlled double-blind multicentre study of fesoterodine 8 mg in overactive bladder patients with sub-optimal response to tolterodine 4 mg extended release (ER)]. clinicaltrials.gov/show/NCT01302054 (first received 23 February 2011). [A0221094] [NCT01302054] [TrialID.AFTER.] [sr-incont49845]">Kaplan 2014</a>; <a href="./references#CD003781-bbs2-0053" title="CapoJP , TogliaM , Forero-SchwanhaeuserS , HeW . Patients reporting severe overactive bladder symptoms: effects of solifenacin treatment on objective measures and patient-reported outcomes (Abstract number 582). In: International Continence Society (ICS), 38th Annual Meeting; 2008 Oct 20-24; Cairo, Egypt. 2008. [srincont-31844]CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. KarramMM , TogliaMR , SerelsSR , AndohM , FakhouryA , Forero-SchwanhaeuserS . Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology2009;73(1):14-8. [A0221094] [NCT00454896] [TrialID.VENUS.] [srincont-29219]SerelsSR , TogliaMR , Forero-SchwanhaeuserS , HeW . Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms. Current Medical Research and Opinion2010;26(10):2277-85. [srincont-40376]StaskinD , DmochowskiR , SerelsS , AndohM , SmithN . Report from a randomized, placebo-controlled study showing significant improvement in urgency and patient-reported outcomes in overactive bladder patients treated with solifenacin (Abstract number 124). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73-4. [srincont-26600]TogliaM , AndohM , HussainI . Solifenacin improved warning time significantly compared to placebo in patients with overactive bladder (Abstract number 123). Neurourology and Urodynamics2006;25(6):655. [srincont-26629]TogliaM , AndohM , HussainI . Solifenacin improves urgency symtoms as assessed by voiding diaries and patient-reported outcomes (PRO) in patients with overactive bladder (Abstract number 155). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26636]TogliaMR , OstergardDR , AppellRA , AndohM , FakhouryA , HussainIF . Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status. International Urogynecology Journal2010;21(7):847-54. [srincont-40094]TogliaMR , SerelsSR , LarameeC , KarramMM , NandyIM , AndohM , et al. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial. Postgraduate Medicine2009;121(5):151-8. [srincont-34204]ZinnerS , HerschornS , AndohM , HussainI . Responder analyses show statistically significant improvements in incontinence and urgency are associated with reduction in symptom bother and improvement in health-related quality of life: VENUS results (Abstract number 123). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73. [srincont-26599]">Karram 2009</a>; <a href="./references#CD003781-bbs2-0060" title="HsiaoSM , ChangTC , ChenCH , WuWY , LinHH . Comparisons of the clinical outcomes and urodynamic effects of mirabegron versus tolterodine treatment for female overactive bladder syndrome: a subgroup analysis of a controlled, randomised, prospective study. Lower Urinary Tract Symptoms2018;10(3):215-20. [NCT01043666] [sr-incont74461]KuoHC , LeeKS , NaY , SoodR , NakajiS , KubotaY , et al. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourology and Urodynamics2015;34(7):685-92. [NCT01043666] [sr-incont68095]Kuo H‐C, Lin H‐H, Yu H‐J, Cheng C‐L, Hung M‐J, LinAT . Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials [Erratum available in: Urological Science 2015;26(2):148]. Urological Science2015;26(1):41-8 . [NCT01043666] [sr-incont68645]NCT01043666. A study of YM178 in subjects with symptoms of overactive bladder  [Phase III study of YM178: a randomized, double-blind, parallel group, placebo and active controlled, multi-center study in subjects with symptoms of overactive bladder]. clinicaltrials.gov/show/NCT01043666 (first received 07 January 2010). [178-CL-090] [NCT01043666] [sr-incont63781]">Kuo 2015</a>; <a href="./references#CD003781-bbs2-0070" title="GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NittiVW , DmochowskiR , SandPK , ForstHT , Haag-MolkentellerC , MassowU , et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. Journal of Urology2007;178(6):2488-94. [NCT00138723] [SP584] [srincont-26313]">Nitti 2007</a>; <a href="./references#CD003781-bbs2-0072" title="OreskovićS , ButI , BanovićM , GoldstajnMS . The efficacy and safety of solifenacin in patients with overactive bladder syndrome. Collegium Antropologicum2012;36(1):243-8. [srincont-45056]">Oreskovic 2012</a>, <a href="./references#CD003781-bbs2-0093" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CrosbyRD , MathiasSD , MarshallTS . Relationships between symptoms, symptom bother, and health-related quality of life in patients with overactive bladder taking solifenacin or placebo in the VIBRANT study. International Journal of Clinical Practice2011;65(2):211-8. [sr-incont41015]GollarKM , YoungDG , BailenJ , HeW , Forero-SchwanhaeuserS . Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: a secondary analysis of the VIBRANT study. Urologic Nursing2012;32(1):38-46. [TrialID.VIBRANT.] [sr-incont44571]Samuels T‐A, MitchesonHD , VardyM , Forero‐SchwanhaeuserS , MarshallT , HeW . Efficacy of solifenacin for symptom bother and other patient-reported outcomes in patients with overactive bladder (OAB): results of a large, double-blind, placebo-controlled trial (Abstract number: poster #74). Neurourology and Urodynamics2009;28(2):149. [sr-incont31063]VardyMD , MitchesonHD , SamuelsTA , Forero-SchwanhaeuserS , HeW . Efficacy of solifenacin on overactive bladder symptoms, symptom bother, and other patient-reported outcomes in subjects with or without incontinence: a post hoc analysis of data from VIBRANT. Female Pelvic Medicine and Reconstructive Surgery2011;17(1):24-9. [TrialID.VIBRANT.] [sr-incont44741]VardyMD , MitchesonHD , SamuelsTA , WegenkeJD , Forero-SchwanhaeuserS , MarshallTS , et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. International Journal of Clinical Practice2009;63(12):1702-14. [905-UC-010] [NCT00573508] [TrialID.VIBRANT.] [sr-incont35459]">Vardy 2009</a>; <a href="./references#CD003781-bbs2-0094" title="EUCTR2007-007087-17-SE. A 24-week, multicentre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-007087-17 (first received 13 June 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont64588]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00798434. A study to compare the effectiveness and safety of fesoterodine and placebo in an elderly population of patients who go to the toilet very frequently due to overactive bladder (SOFIA) [A 24-week, multi-centre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00798434 (first received 26 November 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont49847]SchneiderT , BergqvistA , WangJ , WaggA , Ebel-BitounC . Treatment with fesoterodine versus tolterodine for reducing symptom bother in elderly patients with overactive bladder including urgency urinary incontinence. European Urology, Supplements2012;11(1):e687-a. [sr-incont65389]WaggA , CarlssonM , ElsobkyM , FernetM . Effect of flexible dose fesoterodine on cognitive function in &gt;65 year old patients with OAB: data from two RCT (Abstract number 438). Neurourology and Urodynamics2019;38:S297-8. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78651]WaggA , DarekarA , ArumiD , KhullarV , OelkeM . Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people &gt;65 years of age: a post hoc analysis of data from the SOFIA study. Neurourology and Urodynamics2015;34(5):438-43. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont68100]WaggA , ElsobkyM , CarlssonM , FernetM . Response and cognitive safety of fesoterodine in patients &gt;65y old with OAB. Is there a relationship between cognition and treatment response? (Abstract number 183). Neurourology and Urodynamics2019;38:S118-20. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78632]WaggA , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. Journal of the American Geriatrics Society2013;61(2):185-93. [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TrialID.SOFIA.] [sr-incont48008]WaggAS , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Efficacy and tolerability of fesoterodine in older subjects with overactive bladder: results of SOFIA (Abstract number C33). Journal of the American Geriatrics Society2011;59:S124. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont65234]">Wagg 2013a</a>; <a href="./references#CD003781-bbs2-0096" title="YamaguchiO , MaruiE , KakizakiH , ItohN , YokotaT , OkadaH , et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU International2007;100(3):579-87. [sr-incont23865]YokoyamaO , YamaguchiO , KakizakiH , ItohN , YokotaT , OkadaH , et al. Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary. Journal of Urology2011;186(1):170-4. [sr-incont41734]">Yamaguchi 2007</a>; <a href="./references#CD003781-bbs2-0097" title="NCT00966004. A study to evaluate safety and efficacy of ym178 in patients with overactive bladder [Phase III study of YM178 - a placebo-controlled, double-blind, group comparison study in patients with overactive bladder]. clinicaltrials.gov/show/NCT00966004 (first received 26 August 2009). [178-CL-048] [JapicCTI-R130370] [NCT00966004] [sr-incont63783]YamaguchiO , HidehiroK , YukioH , YasuhikoI , MasayukiT , OsamuN , et al. A phase III, randomized, double-blind, placebo and active controlled study of once-daily mirabegron 50 mg in patients with overactive bladder (Abstract number POD-03.06). Urology2012;80(3 Suppl 1):S10-1. [NCT00966004] [sr-incont65380]YamaguchiO , MaruiE , KakizakiH , HommaY , IgawaY , TakedaM , et al. A phase III, randomized, double-blind, placebo-controlled study of the beta-adrenoceptor agonist, mirabegron 50 mg once-daily, in Japanese patients with overactive bladder. BJU International2014;113(6):951-60. [NCT00966004] [sr-incont50603]">Yamaguchi 2012</a>; <a href="./references#CD003781-bbs2-0098" title="YamaguchiO , UchidaE , HigoN , MinamiH , KobayashiS , SatoH , et al. Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: a randomized double-blind trial. International Journal of Urology2014;21(6):586-93. [JapicCTI-101309] [sr-incont62099]">Yamaguchi 2014</a>; <a href="./references#CD003781-bbs2-0099" title="YongucT , SefikE , InciI , KusbeciOY , CelikS , AydinME , et al. Randomized, controlled trial of fesoterodine fumarate for overactive bladder in Parkinson's disease. World Journal of Urology2019;38(8):2013-9. [sr-incont78635]">Yonguc 2019</a>; <a href="./references#CD003781-bbs2-0100" title="JapicCTI-152936. Phase III study of KRP-114V [A phase III, randomized, double-blind, parallel group, placebo controlled, multicenter study to assess the efficacy and safety of the beta-3 agonist KRP-114V in Japanese subjects with symptoms of overactive bladder]. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-152936 (first received 17 June 2015). [JapicCTI-152936] [sr-incont78653]YoshidaM , TakedaM , GotoM , NagaiS , KuroseT . Vibegron, a novel potent and selective beta3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study (Abstract number 1082). European Urology, Supplements2018;17(2):e1531-2. [JapicCTI-152936] [sr-incont78069]YoshidaM , TakedaM , GotohM , NagaiS , KuroseT . Vibegron, a novel potent and selective B3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study. European Urology2018;73(5):783-90. [JapicCTI-152936] [sr-incont77898]YoshidaM , TakedaM , GotohM , YokoyamaO , KakizakiH , TakahashiS , et al. Efficacy of novel beta3-adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: a post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study. International Journal of Urology2019;26(3):369-75. [JapicCTI-152936] [sr-incont78654]YoshidaM , TakedaM , GotohM , YokoyamaO , KakizakiH , TakahashiS , et al. Efficacy of vibegron, a novel selective I²3-adrenoreceptor agonist, on urgency urinary incontinence with overactive bladder: post-hoc analysis of phase iii study (Abstract number 180). Neurourology and Urodynamics2019;38(S3):S114-5. [JapicCTI-152936] [sr-incont78636]">Yoshida 2018</a>). </p> <p>Anticholinergic drugs probably lead to a slight reduction in urgency episodes per 24 hours at the end of treatment compared to placebo (MD ‐0.85, 95% CI ‐1.03 to ‐0.67; P &lt; 0.00001; <a href="./references#CD003781-fig-0012" title="">Analysis 1.3</a>; <a href="./full#CD003781-tbl-0001">summary of findings Table 1</a>; moderate‐certainty evidence). </p> </section> </section> <section id="CD003781-sec-0075"> <h4 class="title">Secondary outcomes</h4> <section id="CD003781-sec-0076"> <h5 class="title">Adverse events: dry mouth</h5> <p>Sixty‐six studies reported this outcome with total of 38,368 participants (24,523 in the anticholinergic group and 13,845 in the placebo group) (<a href="./references#CD003781-bbs2-0001" title="AbramsP , JacksonS , MattiassonA , KrishnanK , HaendlerL . A randomised, double-blind, placebo controlled, dose ranging study of the safety and efficacy of tolterodine in patients with hyperreflexia (Abstract). In: International Continence Society 26th Annual Meeting; 1996 Aug 27-30; Athens, Greece. 1996:276-7. [sr-incont5135]">Abrams 1996</a>; <a href="./references#CD003781-bbs2-0002" title="AbramsP , FreemanR , AnderströmC , MattiassonA . Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. British Journal of Urology1998;81(6):801-10. [srincont-7871]AbramsP , FreemanRN , AnderstromC , MattiassonA . Efficacy and tolerability of tolterodine vs. oxybutynin and placebo in patients with detrusor instability (Abstract). Journal of Urology1997;157(Suppl 4):103. [srincont-16321]">Abrams 1998</a>; <a href="./references#CD003781-bbs2-0004" title="AbramsP , KelleherC , StaskinD , KayR , MartanA , MincikI , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World Journal of Urology2017;35(5):827-38. [NCT01340027] [sr-incont77897]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Cardiovascular safety of combination treatment with mirabegron and solifenacin in patients with overactive bladder in a randomised, double-blind, dose-ranging, Phase II study (Symphony) (Abstract). European Urology, Supplements2014;13(1):e574-e574a. [NCT01340027] [sr-incont67160]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB) - efficacy and safety results from a randomised phase II study (Symphony) (Abstract number 295). Neurourology and Urodynamics2013;32(6):930-1. [NCT01340027] [TrialID.SYMPHONY.] [sr-incont49188]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB): safety results from a phase 2 study (Abstract number MP-16.08). Urology2013;82(3 Suppl 1):S139. [NCT01340027] [sr-incont66675]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: Exploratory responder analyses of efficacy and evaluation of patient reported outcomes from a randomised, double-blind, dose-ranging, phase 2 study (Symphony) (Abstract number MP-24.11). Urology2014;84(4 Suppl 1):S145-6. [NCT01340027] [sr-incont67194]AbramsP , KelleherC , StaskinD , RechbergerT , KayR , MartinaR , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (SYMPHONY). European Urology2015;67(3):577-88. [NCT01340027] [sr-incont66674]NCT01340027, Bristol Urological Institute . A study to evaluate the efficacy, safety and tolerability of mirabegron and solifenacin succinate alone and in combination for the treatment of overactive bladder (symphony) [A randomized, double-blind, factorial, parallel-group, active and placebo-controlled, multicenter dose-ranging study to evaluate the efficacy, safety and tolerability of six dose combinations of solifenacin succinate and mirabegron compared to mirabegron and solifenacin succinate monotherapies in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01340027 (first received 21 April 2011). [178-CL-100] [2010-020601-32] [NCT01340027] [TrialID.SYMPHONY] [sr-incont44510]NittiV , AbramsP , StaskinD , AuerbachS , MartinaR , VanMR . Urinary retention in patients with overactive bladder treated with mirabegron alone and in combination with solifenacin: the results of two randomized, double-blind, phase II studies (Abstract number MP76-13). Journal of Urology2014;191(4 Suppl 1):e886-7. [NCT00410514] [NCT01340027] [TrialID.SYMPHONY] [sr-incont67453]">Abrams 2013</a>; <a href="./references#CD003781-bbs2-0008" title="BurgioKL , LocherJL , GoodePS , HardinJM , McDowellBJ , CandibD . Behavior vs drug therapy for urge incontinence in older women (Abstract number 26). In: American Urogynecology Society, 15th Annual Scientific Meeting; 1994 Sept 21-24; Toronto, Ontario. 1994:48. [sr-incont14585]BurgioKL , LocherJL , GoodePS , HardinM , McDowellBJ , Dombrowski M et al. Behavioral vs drug treatment for urge urinary incontinence in older women. A randomized controlled trial. JAMA1998;280(23):1995-2000. [srincont-5719]BurgioKL , LocherJL , GoodePS . Combined behavioral and drug therapy for urge incontinence in older women. Journal of the American Geriatrics Society2000;48(4):370-4. [srincont-9006]BurgioKL , LocherJL , RothDL , GoodePS . Psychological improvements associated with behavioral and drug treatment of urge incontinence in older women. Journal of Gerontology. Series B, Psychological Sciences and Social Sciences2001;56(1):P46-51. [srincont-11923]">Burgio 1998</a>; <a href="./references#CD003781-bbs2-0009" title="CardozoL , ChappleCR , Toozs-HobsonP , Grosse-FreeseM , BulittaM , LehmacherW , et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomised, double-blind, multicentre clinical trial. British Journal of Urology International2000;85(6):659-64. [srincont-11732]">Cardozo 2000</a>; <a href="./references#CD003781-bbs2-0010" title="CardozoL , KuzminI , LisecML , MillardR , vanVierssen TripOB , RidderAM , et al. YM905: Results of a randomised, double-blind placebo-controlled trial in patients with symptomatic overactive bladder (Abstract number 104). European Urology Supplements2003;2(1):28. [sr-incont27407]CardozoL , KuzminI , LisecML , MillardRJ , vanVierssen TripOB , RidderAM , et al. A double-blind, randomised, placebo-controlled trial with YM905 in symptomatic overactive bladder (Abstract number P74). Journal of the American Geriatrics Society2003;51 (Suppl 4):S68-9. [sr-incont31100]CardozoL , LisecM , MillardR , vanVierssen TripO , KuzminI , DrogendijkTE , et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. Journal of Urology2004;172(5 (Pt 1 of 2)):1919-24. [srincont-19090]CardozoL . A randomised double-blind, placebo-controlled trial of the once-daily muscarinic receptor antagonist solifenacin succinate for symptoms of overactive bladder (Abstract number 211). International Urogynecology Journal2003;14 (Suppl 1):S64. [sr-incont31104]CardozoL . Solifenacin succinate improves symptoms of an overactive bladder (Abstract number TP77). International Journal of Gynecology and Obstetrics2003;83(Suppl 3):94. [sr-incont31096]KelleherCJ , CardozoL , ChappleCR , HaabF , RidderAM . Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU International2005;95(1):81-5. [srincont-20241]">Cardozo 2004a</a>; <a href="./references#CD003781-bbs2-0011" title="CardozoL , AdamikZ , GuimaraesM , KrhutJ , Labat J-J, PetrovS , et al. Patients with overactive bladder show progressive improvement in urgency and bladder condition during treatment with solifenacin in a randomised, double-blind, placebo-controlled study (SUNRISE) (Abstract number 115). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S67-8. [srincont-26595]CardozoL , AmarencoG , PushkarD , MikulasJ , DrogendijkT , WrightM , et al. Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE). BJU International2013;111(5):804-10. [NCT00801944] [TrialID.SUNRISE.] [sr-incont47554]CardozoL , DewildeT , FeyereislJ , WadieB , AmarencoG , LiapisA , et al. Solifenacin significantly reduces both urgency severity and bother: results from the flexible dose, placebo controlled, multinational SUNRISE study (Abstract number 281). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26641]CardozoL , DrogendijkT , BolodeokuJ . The efficacy of solifenacin 5/10 mg on 'urgency' endpoints in different OAB patient populations: subanalysis of results from the randomised, double-blind SUNRISE study (Abstract number 192). In: International Continence Society (ICS); 38th Annual Meeting; 2008 Oct 20-24; Cairo, Egypt. 2008. [srincont-31885]CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CardozoL , HessdörferE , MilaniR , ArañóP , DewildeL , SlackM , et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU International2008;102(9):1120-7. [NCT00801944] [TrialID.SUNRISE] [srincont-29249]">Cardozo 2008a</a>; <a href="./references#CD003781-bbs2-0013" title="ChappleC . Fesoterodine a new effective and well-tolerated antimuscarinic for the treatment of urgency-frequency syndrome: results of a phase 2 controlled study (Abstract 142). Neurourology and Urodynamics2004;23(5/6):598-9. [srincont-19023]Drug company. A Phase 2, parallel group, randomized, double-blind, placebo controlled dose-ranging trial to determine the optimal dose and the tolerability of sustained release SPM 8272 (fesoterodine) in subjects with non-neurogenic bladder overactivity. Protocol numbers: A0221027 (SP582). ClinicalStudyResults.org (accessed 3 March 2011)2002. [Protocol numbers: A0221027 (SP582)] [srincont-41110]">Chapple 2004a</a>; <a href="./references#CD003781-bbs2-0014" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. ChappleCR , AranoP , BoschJH , De RidderD , KramerG , RidderAM . YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo- and tolterodine-controlled, phase-II, dose-finding study (Abstract 75). Neurourology and Urodynamics2002;21(4):381-2. [srincont-14551]ChappleCR , ArañoP , BoschJL , De RidderD , KramerAE , RidderAM . Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU International2004;93(1):71-7. [srincont-17334]KelleherCJ , CardozoL , ChappleCR , HaabF , RidderAM . Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU International2005;95(1):81-5. [srincont-20241]SmithN , GrimesI , RidgeS , TempelD , UchidaT , YamanouchiUS . YM905 is effective and safe as treatment of overactive bladder in women and men: results from phase II study (Abstract). In: International Continence Society (ICS), 32nd Annual Meeting; 2002 Aug 28-30; Heidelberg, Germany. 2002:138-9. [sr-incont14508]">Chapple 2004b</a>; <a href="./references#CD003781-bbs2-0015" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. ChappleC , RechbergerT , Al-ShukriS , MeffanP , EveraertK , RidderA . Results of a randomized phase 3 study comparing solifenacin succinate with tolterodine and placebo in patients with symptomatic overactive bladder (Abstract). Neurourology and Urodynamics2003;22(5):534-5. [sr-incont16991]ChappleCR , RechbergerT , Al ShukriS , MeffanP , EveraertK , HuangM , et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU International2004;93(3):303-10. [srincont-17270]">Chapple 2004c</a>; <a href="./references#CD003781-bbs2-0016" title="ChappleC , Van KerrebroeckP , TubaroA , Haag-MolkentellerC , ForstHT , MassowU , et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder [Erratum appears in: European Urology 2008,53(6):1319]. European Urology2007;52(4):1204-12. [NCT00220363] [SP583] [srincont-23875]ChappleC , Van KerrebroeckP , TubaroA , MillardR . Fesoterodine in non-neurogenic voiding dysfunction - results on efficacy and safety in a phase 3 trial (Abstract number 379). In: 21st Annual European Association of Urology (EAU) Congress; 2006 Apr 5-8; Paris, France. 2006. [srincont-41109]ChappleC , Van KerrebroeckP , TubaroA , WangJT , HvidstenK , BrodskyM . Efficacy of fesoterodine in patients with overactive bladder (OAB): improvements in OAB symptoms and health-related quality of life (HRQL) (Poster abstract number 1188). Journal of Urology2007;177(4 Suppl S):392. [srincont-31882]ChappleCR , vanKerrebroeckPE , JünemannKP , WangJT , BrodskyM . Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU International2008;102(9):1128-32. [srincont-29255]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. KelleherCJ , TubaroA , WangJT , KoppZ . Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU International2008;102(1):56-61. [srincont-27613]SandPK , MorrowJD , BavendamT , CreangaDL , NittiVW . Efficacy and tolerability of fesoterodine in women with overactive bladder. International Urogynecology Journal2009;20(7):827-35. [srincont-31351]">Chapple 2007a</a>; <a href="./references#CD003781-bbs2-0017" title="ChappleC , DuBeauC , EbingerU , RekedaL , ViegasA . Darifenacin treatment of patients &gt;or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Current Medical Research and Opinion2007;23(10):2347-58. [srincont-23921]">Chapple 2007b</a>; <a href="./references#CD003781-bbs2-0019" title="ChappleC , HaabF , SchneiderT , CarlssonM , ArumiD . Fesoterodine 8 mg versus fesoterodine 4 mg in patients with overactive bladder and a history of previous antimuscarinic therapy: Results from the EIGHT trial (Abstract number: Poster #M5). Neurourology and Urodynamics2015;34(S1):S20. [NCT01302067] [sr-incont68509]ChappleC , SchneiderT , HaabF , SunF , WhelanL , ScholfieldD , et al. Superiority of fesoterodine 8mg versus fesoterodine 4 mg in reducing urgency urinary incontinence episodes in subjects with overactive bladder: results of the randomized, double-blind, placebo-controlled EIGHT trial (Abstract number: Podium #48). Neurourology and Urodynamics2014;33(2):183-4. [NCT01302067] [sr-incont67484]ChappleC , SchneiderT , HaabF , SunF , WhelanL , ScholfieldD , et al. Superiority of fesoterodine 8mg vs 4mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial. BJU International2014;114(3):418-26. [A0221095] [NCT01302067] [TrialID.EIGHT] [srincont-62537]NCT01302067. A 12 week study to confirm the effectiveness of 8mg of Fesoterodine compared to 4mg of Fesoterodine [A 12-week, randomized, double-blind, placebo controlled, parallel group, multicenter trial in overactive bladder subjects to confirm the efficacy of 8 mg fesoterodine compared to 4 mg fesoterodine]. clinicaltrials.gov/show/NCT01302067 (first received 23 February 2011). [NCT01302067] [sr-incont63792]">Chapple 2014</a>; <a href="./references#CD003781-bbs2-0020" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. [sr-incont75259]ChuF , SmithN , UchidaT . Efficacy and safety of solifenacin succinate 10 mg once daily: a multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder. Current Therapeutic Research - Clinical and Experimental2009;70(6):405-20. [srincont-43324]">Chu 2009</a>; <a href="./references#CD003781-bbs2-0021" title="ChuaME , SeeMC , EsmeňaEB , BalingitJC , MoralesML . Efficacy and safety of gabapentin in comparison to solifenacin succinate in adult overactive bladder treatment. Lower Urinary Tract Symptoms2018;10(2):135-42. [NCT01486706] [sr-incont74529]NCT01486706, ChuaME . Efficacy and safety of gabapentin in treating overactive bladder (OAB). clinicaltrials.gov/show/NCT01486706 (first received 6 December 2011). [NCT01486706] [SLMC10-010] [sr-incont49864]">Chua 2018</a>; <a href="./references#CD003781-bbs2-0023" title="ChancellorMB , OefeleinMG , VasavadaS . Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release. Neurourology and Urodynamics2010;29(4):551-4. [sr-incont39591]DmochowskiR , StaskinD , SandP , ZinnerN . Trospium chloride 60 mg once daily improves quality of life in subjects with overactive bladder syndrome (Abstract number 277). In: International Continence Society (ICS); 37th Annual Meeting; 2008 Aug 20-24; Rotterdam, the Netherlands. 2007. [srincont-26679]DmochowskiRR , RosenbergMT , ZinnerNR , StaskinDR , SandPK . Extended-release trospium chloride improves quality of life in overactive bladder. Value in Health2010;13(2):251-7. [srincont-40049]DmochowskiRR , SandPK , ZinnerNR , StaskinDR . Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology2008;71(3):449-54. [srincont-27107]DmochowskiRR , ZinnerNR , SandPK . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: Results from a multicenter, phase III, placebo-controlled study (Abstract). Neurourology and Urodynamics2007;26(Suppl 7):1105-6. [srincont-26692]GinsbergDA , OefeleinMG , EllsworthPI . Once-daily administration of trospium chloride extended release provides 24-hr coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials. Neurourology and Urodynamics2011;30(4):563-7. [sr-incont41531]RovnerE , DmochowskiR , WatanabeJ . Once daily (QD) trospium chloride 60 mg extended release (XR) is safe and effective in patients (PTS) with the overactive bladder (OAB) syndrome who use multiple concomitant medications (MEDS) (Abstract number: Poster #68). Neurourology and Urodynamics2009;28(2):146-7. [sr-incont31062]SandP , DmochowskiR , ZinnerN , StaskinD . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: results from a multicenter, phase III, placebo-controlled study (Abstract number 269). In: International Continence Society (ICS), 37th Annual Meeting; 2007 Aug 20-24; Rotterdam, the Netherlands. 2007. [srincont-26676]SandPK , DmochowskiRR , ZinnerNR , StaskinDR , AppellRA . Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome. International Urogynecology Journal and Pelvic Floor Dysfunction2009;20(12):1431-8. [sr-incont39648]SandPK , Johnson IiTM , RovnerES , EllsworthPI , OefeleinMG , StaskinDR . Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged &gt; 75 years) with overactive bladder syndrome. BJU International2011;107(4):612-20. [sr-incont41422]StaskinDR , RosenbergMT , SandPK , ZinnerNR , DmochowskiRR . Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials. International Journal of Clinical Practice2009;63(12):1715-23. [sr-incont35458]">Dmochowski 2008</a>; <a href="./references#CD003781-bbs2-0024" title="DmochowskiR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. A double-blind, placebo-controlled trial of flexible-dose fesoterodine for overactive bladder (Abstract number 715). In: International Continence Society (ICS); 39th Annual Meeting; 2009 Sep 29-Oct 03; San Francisco, CA. 2009. [sr-incont35627]DmochowskiRR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder [Errata appear in: Urology 2010 Jun;75(6):1519 and in Urology 2011 Jun;77(6):1513]. Urology2010;75(1):62-8. [A0221014] [NCT00536484] [sr-incont39548]DuBeauC , KrausSR , SunF , MorrowJD . Fesoterodine in older vs younger subjects with overactive bladder (Abstract number D87). Journal of the American Geriatrics Society2010;58:S218. [NCT00536484] [sr-incont64309]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. [sr-incont78640]NCT00536484. Fesoterodine flexible dose study [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with overactive bladder]. clinicaltrials.gov/show/NCT00536484 (first received 27 September 2007). [NCT00536484] [sr-incont49160]StaskinD , KhullarV , MichelMC , MorrowJD , SunF , GuanZ , et al. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. Neurourology and Urodynamics2011;30(8):1480-5. [sr-incont42686]">Dmochowski 2010</a>; <a href="./references#CD003781-bbs2-0026" title="DrutzH , AppellRA . Clinical efficacy and safety of Tolterodine vs Oxybutynin and placebo in patients with unstable bladder. Acta Obstetrica et Gynecologica Scandinavica1997;Suppl 167(5):24. [srincont-6671]DrutzHP , AppellRA , GleasonD , KlimbergI , RadomskiS . Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. International Urogynecology Journal and Pelvic Floor Dysfunction1999;10(5):283-9. [srincont-8804]DrutzHP , AppellRA . Enhanced tolerability of tolterodine compared to oxybutynin in a controlled clinical study. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(1):S14. [srincont-5166]">Drutz 1999</a>; <a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>; <a href="./references#CD003781-bbs2-0028" title="ElbasetM , TahaD , ZahranM , EzzatO , ElhefnawyAS , ElkenawyM , et al. Subjective and objective scales assessment after retreatment with anticholinergics post botox-faded effects in refractory idiopathic overactive bladder: a prospective single blinded randomized trial (Abstract number 132). European Urology, supplements2019;18(1):e172. [sr-incont78652]ElbasetMA , TahaDE , El-HefnawyAS , ZahranMH , ShokeirAA . Assessment of anticholinergic use after fading of BTX-A effects in refractory idiopathic overactive bladder: a prospective blinded randomized trial. International Neurourology Journal2019;23(3):240-8. [sr-incont78605]">Elbaset 2019</a>; <a href="./references#CD003781-bbs2-0033" title="GotohM , HommaY , YokoyamaO , NishizawaO . Responsiveness and minimal clinically important change in overactive bladder symptom score. Urology2011;78(4):768-73. [srincont-42622]GotohM , YokoyamaO , MatsukawaY , NishizawaO . Responsiveness of overactive bladder symptom score (OABSS): verification based on data in a double-blinded, randomized placebo-controlled study of propiverine hydrochloride in Japanese patients (Abstract number 338). In: Joint Meeting of the International Continence Society (ICS) and the International Urogynecological Association; 2010 Aug 23-27; Toronto, Canada. 2010. [srincont-40173]GotohM , YokoyamaO , NishizawaO . Propiverine hydrochloride in Japanese patients with overactive bladder: A randomized, double-blind, placebo-controlled trial. International Journal of Urology2011;18(5):365-73. [srincont-41510]">Gotoh 2011</a>; <a href="./references#CD003781-bbs2-0035" title="HaabF , StewartL , DwyerP . Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. European Urology2004;45(4):420-9. [srincont-17428]">Haab 2004</a>; <a href="./references#CD003781-bbs2-0038" title="HerschornS , HeesakkersJ , Castro-DiazD , WangJT , BrodskyM , GuanZ . Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*. Current Medical Research and Opinion2008;24(12):3513-21. [A6121122] [NCT00143377] [srincont-29250]HerschornS , HeesakkersJ , Castro-DiazD , WangJT , GuanZ , BrodskyM . Tolterodine extended release (TER) improves objective and subjective outcomes after 1 week of treatment in patients with overactive bladder (Abstract number 132). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S78-9. [srincont-26602]">Herschorn 2008</a>; <a href="./references#CD003781-bbs2-0039" title="CorcosJ , AnguloJC , GarelyAD , CarlssonM , GongJ , GuanZ . Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. Current Medical Research and Opinion2011;27(5):1059-65. [srincont-41596]EUCTR2006-006935-38-SE. 12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006935-38 (first received 16 April 2007). [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont64612]HerschornS , SwiftS , GuanZ , CarlssonM , BrodskyM , GongJ . Efficacy and safety of fesoterodine for overactive bladder in a double-blind, head-to-head comparison trial with tolterodine ER and placebo (Abstract number 710). In: International Continence Society (ICS), 39th Annual Meeting; 2009 Sep 29-Oct 3; San Francisco, CA. 2009. [srincont-35326]HerschornS , SwiftS , GuanZ , CarlssonM , MorrowJD , BrodskyM , et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU International2010;105(1):58-66. [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont39540]NCT00444925. Clinical trial to evaluate the efficacy and safety of Fesoterodine in comparison to Tolterodine for overactive bladder (OAB) [12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder (OAB)]. clinicaltrials.gov/show/NCT00444925 (first received 08 March 2007). [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont49159]">Herschorn 2009a</a>; <a href="./references#CD003781-bbs2-0040" title="EUCTR2012-005735-91-SK. A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-005735-91 (first received 12 November 2013). [178-CL-101] [EUCTR2012-005735-91-SK] [sr-incont78644]HerschornS , ChappleCR , AbramsP , ArlandisS , MitchesonD , LeeKS , et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU International2017;120(4):562-75. [NCT01972841] [sr-incont74470]MuellerER , RobinsonD , KelleherC , StaskinDR , FalconerC , WangJ , et al. Patient reported outcomes from synergy, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with mirabegron and solifenacin monotherapy (Abstract number - Podium #44). Neurourology and Urodynamics2017;36(Suppl S1):S151-2. [NCT01972841] [sr-incont75944]NCT01972841. This was a multinational study comparing the efficacy and safety of two medicines, solifenacin succinate and mirabegron taken together, or separately, or a mock treatment (placebo) in subjects with symptoms of overactive bladder (SYNERGY) [A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01972841 (first received 31 October 2013). [178-CL-101] [EUCTR2012-005735-91] [NCT01972841] [sr-incont63780]RobinsonD , KelleherC , StaskinD , MuellerER , FalconerC , WangJ , et al. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients. Neurourology and Urodynamics2018;37(1):394-406. [NCT01972841] [sr-incont76906]WeberMA , ChappleCR , GratzkeC , HerschornS , RobinsonD , FrankelJM , et al. A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial. Blood Pressure Monitoring2018;23(3):153-63. [NCT01972841] [sr-incont77899]WhiteWB , ChappleC , GratzkeC , HerschornS , RobinsonD , FrankelJ , et al. Cardiovascular safety of the beta3-adrenoceptor agonist mirabegron and the antimuscarinic agent solifenacin in the SYNERGY trial. Journal of Clinical Pharmacology2018;58(8):1084-91. [NCT01972841] [sr-incont78078]">Herschorn 2017a</a>; <a href="./references#CD003781-bbs2-0042" title="HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21072]HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21072]HillS , KhullarV , WyndaeleJJ , LheritierK , . Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. International Urogynecology Journal and Pelvic Floor2006;17(3):239-47. [srincont-22464]">Hill 2005</a>; <a href="./references#CD003781-bbs2-0043" title="HommaY , KawabeK . Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World Journal of Urology2004;22(4):251-6. [srincont-19412]HommaY , PaickJS , LeeJG , KawabeK , Japanese and Korean Tolterodine Study Group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU International2003;92(7):741-7. [srincont-16418]">Homma 2003</a>; <a href="./references#CD003781-bbs2-0044" title="HommaY , YamaguchiT , YamaguchiOA . A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2008;15(9):809-15. [srincont-27742]">Homma 2008</a>; <a href="./references#CD003781-bbs2-0045" title="HommaY , YamaguchiO , Imidafenacin Study Group. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2009;16(5):499-506. [NCT00212732] [ONO-8025-08] [srincont-31368]">Homma 2009</a>; <a href="./references#CD003781-bbs2-0047" title="JacquetinB , WyndaeleJJ . Tolterodine reduces the number of incontinence episodes in patients with an overactive bladder. European Journal of Obstetrics and Gynecology and Reproductive Biology2001;98(1):97-102. [srincont-12200]JacquetinB , WyndaeleJJ . Tolterodine reduces the number of incontinence episodes in patients with detrusor overactivity. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(1):S30. [srincont-5167]">Jacquetin 2001</a>; <a href="./references#CD003781-bbs2-0048" title="JonasU , HofnerK , MadersbacherH , HolmdahlTH . Efficacy and safety of two doses of Tolterodine compared to placebo in patients with detrusor overactivity. Neurourology and Urodynamics1997;16(5):477-8. [srincont-5841]JonasU , HöfnerK , MadersbacherH , HolmdahlTH . Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group. World Journal of Urology1997;15(2):144-51. [srincont-5436]">Jonas 1997</a>; <a href="./references#CD003781-bbs2-0049" title="JunemannKP , Al-ShukriS . Efficacy and tolerability of trospium chloride and tolterodine in 234 patients with urge-syndrome: a double-blind, placebo-controlled, multicentre clinical trial (Abstract number 85B). Neurourology and Urodynamics2000;19(4):488-90. [srincont-9976]">Junemann 2000</a>; <a href="./references#CD003781-bbs2-0050" title="JünemannKP , HessdörferE , Unamba‐OparahI , BerseM , BrünjesR , MadersbacherH . Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. Urologia Internationalis2006;77(4):334-9. [srincont-22199]">Junemann 2006</a>; <a href="./references#CD003781-bbs2-0051" title="EUCTR2007-006451-39-SE. 12-week, randomized, double-blind, double-dummy, placebo controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-006451-39 (first received 20 February 2008). [A0221046] [EUCTR2007-006451-39-SE] [sr-incont64591]KaplanSA , SchneiderT , FooteJ , GuanZ . Superior efficacy of fesoterodine over tolterodine with rapid onset: a prospective, head-to-head, placebo-controlled trial (Abstract number 67). Neurourology and Urodynamics2010;29(6):905-7. [srincont-40130]KaplanSA , SchneiderT , FooteJE , GuanZ , CarlssonM , GongJ . Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU International2011;107(9):1432-40. [A0221046] [NCT00611026] [srincont-41334]">Kaplan 2011</a>; <a href="./references#CD003781-bbs2-0052" title="CardozoL , KaplanS , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: results from the after study (Abstract number 740) [Erratum appears in: European Urology 2014;65(5):e78]. European Urology Supplements2013;12(1):e740-1. [NCT01302054] [sr-incont63732]CardozoL , KaplanS , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. Erratum: A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: results from the AFTER study [Erratum available in: European Urology Supplement 2013;2012:e740-1]. European Urology2014;65(5):e78 . [A0221094] [NCT01302054] [TrialID.AFTER.] [sr-incont61642]GrenaboL , HerschornS , KaplanSA , CardozoL , ScholfieldD , ArumiD , et al. Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptoms. Current Medical Research and Opinion2017;33(10):1731-6. [NCT01302054] [TrialID.AFTER.] [sr-incont76695]KaplanSA , CardozoL , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER. International Journal of Clinical Practice2014;68(9):1065-73. [A0221094] [NCT01302054] [TrialID.AFTER.] [srincont-63977]KaplanSA , HerschornS , CarlssonM , NtaniosF . Urgency urinary incontinence response rates in subjects with overactive bladder treated with fesoterodine 8 mg after suboptimal response to tolterodine extended release 4 mg: a randomized, double-blind, placebo-controlled trial (Abstract number 546). In: International Continence Society (ICS); 43rd Annual Meeting; 2013 Aug 26-30; Barcelona, Spain. 2013. [NCT01302054] [TrialID.AFTER.] [sr-incont49730]NCT01302054. A clinical study in patients with overactive bladder with leakage of urine, to find out if the medicine, Fesoterodine, works in those patients who did not have enough response to the medicine, tolterodine. [A 14 week randomized parallel group placebo-controlled double-blind multicentre study of fesoterodine 8 mg in overactive bladder patients with sub-optimal response to tolterodine 4 mg extended release (ER)]. clinicaltrials.gov/show/NCT01302054 (first received 23 February 2011). [A0221094] [NCT01302054] [TrialID.AFTER.] [sr-incont49845]">Kaplan 2014</a>; <a href="./references#CD003781-bbs2-0053" title="CapoJP , TogliaM , Forero-SchwanhaeuserS , HeW . Patients reporting severe overactive bladder symptoms: effects of solifenacin treatment on objective measures and patient-reported outcomes (Abstract number 582). In: International Continence Society (ICS), 38th Annual Meeting; 2008 Oct 20-24; Cairo, Egypt. 2008. [srincont-31844]CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. KarramMM , TogliaMR , SerelsSR , AndohM , FakhouryA , Forero-SchwanhaeuserS . Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology2009;73(1):14-8. [A0221094] [NCT00454896] [TrialID.VENUS.] [srincont-29219]SerelsSR , TogliaMR , Forero-SchwanhaeuserS , HeW . Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms. Current Medical Research and Opinion2010;26(10):2277-85. [srincont-40376]StaskinD , DmochowskiR , SerelsS , AndohM , SmithN . Report from a randomized, placebo-controlled study showing significant improvement in urgency and patient-reported outcomes in overactive bladder patients treated with solifenacin (Abstract number 124). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73-4. [srincont-26600]TogliaM , AndohM , HussainI . Solifenacin improved warning time significantly compared to placebo in patients with overactive bladder (Abstract number 123). Neurourology and Urodynamics2006;25(6):655. [srincont-26629]TogliaM , AndohM , HussainI . Solifenacin improves urgency symtoms as assessed by voiding diaries and patient-reported outcomes (PRO) in patients with overactive bladder (Abstract number 155). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26636]TogliaMR , OstergardDR , AppellRA , AndohM , FakhouryA , HussainIF . Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status. International Urogynecology Journal2010;21(7):847-54. [srincont-40094]TogliaMR , SerelsSR , LarameeC , KarramMM , NandyIM , AndohM , et al. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial. Postgraduate Medicine2009;121(5):151-8. [srincont-34204]ZinnerS , HerschornS , AndohM , HussainI . Responder analyses show statistically significant improvements in incontinence and urgency are associated with reduction in symptom bother and improvement in health-related quality of life: VENUS results (Abstract number 123). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73. [srincont-26599]">Karram 2009</a>; <a href="./references#CD003781-bbs2-0054" title="KhullarV , HillS , LavalKU , SchiotzHA , JonasU , VersiE . Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology2004;64(2):269-74; discussion 274-5. [srincont-19498]KhullarV , HillS , SolankiJ . Assessment of health-related quality of life in patients with overactive bladder taking tolterodine extended release versus placebo (Abstract number 318). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21075]">Khullar 2004</a>; <a href="./references#CD003781-bbs2-0057" title="KosilovK , LoparevS , IvanovskayaM , KosilovaL . A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron. Archives of Gerontology and Geriatrics2015;61(2):212-6. [sr-incont68133]">Kosilov 2015a</a>; <a href="./references#CD003781-bbs2-0058" title="KosilovKV , LoparevSA , IvanovskayaMA , KosilovaLV . The efficacy of different doses of solifenacin in elderly patients after treating a urinary tract infection. Arab Journal of Urology Print2015;13(3):203-8. [sr-incont69283]">Kosilov 2015b</a>; <a href="./references#CD003781-bbs2-0060" title="HsiaoSM , ChangTC , ChenCH , WuWY , LinHH . Comparisons of the clinical outcomes and urodynamic effects of mirabegron versus tolterodine treatment for female overactive bladder syndrome: a subgroup analysis of a controlled, randomised, prospective study. Lower Urinary Tract Symptoms2018;10(3):215-20. [NCT01043666] [sr-incont74461]KuoHC , LeeKS , NaY , SoodR , NakajiS , KubotaY , et al. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourology and Urodynamics2015;34(7):685-92. [NCT01043666] [sr-incont68095]Kuo H‐C, Lin H‐H, Yu H‐J, Cheng C‐L, Hung M‐J, LinAT . Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials [Erratum available in: Urological Science 2015;26(2):148]. Urological Science2015;26(1):41-8 . [NCT01043666] [sr-incont68645]NCT01043666. A study of YM178 in subjects with symptoms of overactive bladder  [Phase III study of YM178: a randomized, double-blind, parallel group, placebo and active controlled, multi-center study in subjects with symptoms of overactive bladder]. clinicaltrials.gov/show/NCT01043666 (first received 07 January 2010). [178-CL-090] [NCT01043666] [sr-incont63781]">Kuo 2015</a>; <a href="./references#CD003781-bbs2-0063" title="LeeKS , ChooMS , KimDY , KimJC , KimHJ , MinKS , et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. Journal of Urology2005;174(4 Pt 1):1334-8. [sr-incont21016]LeeKS , ChooMS , PaickJS , LeeJG , SeoJT , LeeJZ , et al. Propiverine hydrochloride reduced frequency and perception of urgency in treatment of overactive bladder: a 12 week prospective, randomized, double blind, placebo controlled study (Abstract number 279). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26640]LeeKS , LeeHW , ChooMS , PaickJS , LeeJG , SeoJT , et al. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'. BJU International2010;105(11):1565-70. [2005-01-08] [NCT00903045] [PROUD] [sr-incont39958]NCT00903045. Urinary urgency outcomes following propiverine treatment for an overactive bladder [Urinary urgency outcomes following propiverine treatment for an overactive bladder: propiverine study on overactive bladder including urgency data (PROUD)]. clinicaltrials.gov/show/NCT009030452005;(first received 15 May 2009). [2005-01-08] [NCT00903045] [TrialID.PROUD] [sr-incont49860]">Lee 2006</a>; <a href="./references#CD003781-bbs2-0065" title="ChappleCR , MadersbacherH , DreikornK , DorschnerW , MurtzG . Urodynamics and frequency/volume chart - do they correlate? Treatment analysis of propiverine in comparison to oxybutynin and placebo in urge incontinence (Abstract 224). In: International Continence Society (ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001. [sr-incont14474]HalaskaM , MadersbacherH , VoigtR , HofnerK , MartanA . Propiverine in patients with urgency and urge incontinence - a placebo controlled, multicentre study comparing its tolerability and efficacy with oxybutynin (Abstract number FDP36). International Urogynaecology Journal 2000;11(Suppl 1):S46. [srincont-11912]MadersbacherH , HalaskaM , VoigtR , AlloussiS , HofnerK . A urodynamically controlled multicenter study in patients with urge incontinence: tolerability and efficacy of propiverine hydrochloride in comparison to oxybutynin. In: International Continence Society (ICS), 27th Annual Meeting; 1997 Sep 23-26; Yokohama, Japan. 1997:153-4. [srincont-5854]MadersbacherH , HalaskaM , VoigtR , AlloussiS , HöfnerK . A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU International1999;84(6):646-51. [srincont-9166]">Madersbacher 1999</a>; <a href="./references#CD003781-bbs2-0066" title="Malone-LeeJG , WalshB , MaugourdMF , Tolterodine in the Elderly Study Group. The safety and clinical efficacy of two doses of tolterodine compared to placebo in elderly patients. In: International Continence Society (ICS), 27th Annual Meeting; 1997 Sep 23-26; Yokohama, Japan. 1997:155-6. [srincont-5855]Malone‐LeeJG , WalshJB , MaugourdMF . Tolterodine: A safe and effective treatment for older patients with overactive bladder. Journal of the American Geriatric Society2001;49(6):700-5. [srincont-12319]WaggA , Malone-LeeJ . Pressure-flow variables in patients treated with tolterodine for detrusor overactivity. BJU International2003;92(9):969-71. [sr-incont16659]">Malone‐Lee 2001</a>; <a href="./references#CD003781-bbs2-0067" title="MillardR , TuttleJ , MooreK , SussetJ , ClarkeB , DwyerP , et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. Journal of Urology1999;161(5):1551-5. [sr-incont8172]MooreK , MillardR , DwyerP , TuttleJ . A randomized controlled multicentre trial of tolterodine in detrusor instability/hyperreflexia. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(Suppl 1):S129. [sr-incont5171]RosamiliaA , DwyerPL , ClarkeB , MooreK , MillardRP , TuttleJ . The clinical efficacy and safety of two doses of Tolterodine in detrusor instability. Acta Obstetrica et Gynecologica Scandinavica1997;6(Suppl 167):24. [sr-incont6670]">Millard 1999</a>; <a href="./references#CD003781-bbs2-0068" title="DmochowskiR , MitchesonD , FrenklT , BennettN , MuddPN . Durable efficacy and safety of long-term once-daily vibegron, a novel oral B-3 adrenergic receptor agonist: A 52-week phase 2 study in patients with overactive bladder syndrome (Abstract number PD50-03). Journal of Urology2018;199(4):e970-1. [sr-incont78091]EUCTR2010-022121-15-IT. A phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2 part clinical study of the efficacy and safety of MK-4618 in patients with overactive bladder - MK4618-008 [A 52-week extension to: a phase iib randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder]. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-022121-15 (first received 12 April 2011). [EUCTR2010-022121-15-IT] [MK4618-008] [NCT01314872] [sr-incont78639]MitchesonD , FrenklT , SamantaS , Anne PintoC , GreenS , BennettN , et al. Vibegron, a novel once daily oral beta-3 agonist, significantly reduces average daily micturitions, urge incontinence episodes and urgency episodes in patients with overactive bladder (Abstract number: podium #34). Neurourology and Urodynamics2018;37(Suppl 1):S565. [EUCTR2010-022121-15-IT] [NCT01314872] [sr-incont78618]MitchesonD , PintoCA , FrenklT , ChenL , PrasadM , MuddPN . Once daily vibegron improves quality of life measures in patients with overactive bladder (Abstract number PUK17). Value in Health2018;21(Suppl 1):S267-8. [EUCTR2010-022121-15-IT] [NCT01314872;] [sr-incont78619]MitchesonHD , SamantaS , MuldowneyK , PintoCA , RochaBA , GreenS , et al. Vibegron (RVT-901/MK-4618/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial. European Urology2019;75(2):274-82. [NCT01314872] [sr-incont78620]NCT01314872. A study of the efficacy and safety of Vibegron (MK-4618) in participants with overactive bladder (OAB) (MK-4618-008) [A phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder a 52-week extension to: a phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder]. clinicaltrials.gov/show/NCT01314872 (first received 15 March 2011). [NCT01314872] [sr-incont63793]UKCRN10391. A phase IIB randomised, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of MK-4618 in patients with overactive bladder . public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=10391 (accessed 28 June 2012). [CCRN525] [UKCRN10391] [sr-incont45046]">Mitcheson 2019</a>; <a href="./references#CD003781-bbs2-0069" title="Drug company. A phase 2, parallel group, stratified, randomized, double blind, placebo-controlled trial to investigate the efficacy and safety of 3 different dosages of sustained release fesoterodine in subjects with overactive bladder showing either involuntary detrusor contractions or normal findings during the baseline urodynamic assessment. Protocol numbers: A0221029 (SP668). ClinicalStudyResults.org (accessed 3 March 2011). [srincont-41111]NittiV , WiatrakM , KreitmanL , LipsitzD . Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB): results of a phase 2 trial (Abstract number 306). In: International Continence Society (ICS); 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21084]">Nitti 2005</a>; <a href="./references#CD003781-bbs2-0070" title="GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NittiVW , DmochowskiR , SandPK , ForstHT , Haag-MolkentellerC , MassowU , et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. Journal of Urology2007;178(6):2488-94. [NCT00138723] [SP584] [srincont-26313]">Nitti 2007</a>; <a href="./references#CD003781-bbs2-0074" title="RentzhogSL , StantonL , CardozoL , NelsonE , FallM , AbramsP . Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. British Journal of Urology1998;81(1):42-8. [srincont-5461]">Rentzhog 1998</a>; <a href="./references#CD003781-bbs2-0077" title="RogersR , BachmannG , JumadilovaZ , SunF , MorrowJD , GuanZ , et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. International Urogynecology Journal and Pelvic Floor Dysfunction2008;19(11):1551-7. [A6121002] [NCT00143481] [srincont-27729]RogersRG , BachmannG , ScarperoH , JumadilovaZ , SunF , MorrowJD , et al. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. Current Medical Research and Opinion2009;25(9):2159-65. [srincont-32060]">Rogers 2008</a>; <a href="./references#CD003781-bbs2-0079" title="RovnerES , KaplanS , GuanZ , WangJT , RoehrbornCG . Clinical efficacy and safety of tolterodine extended release in male patients with overactive bladder and urgency urinary incontinence (Abstract number 188). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21091]">Rovner 2005</a>; <a href="./references#CD003781-bbs2-0080" title="RudyD , ClineK , GoldbergK , HarrisR . A multicenter, randomized, placebo-controlled trial of trospium chloride in overactive bladder patients (Abstract). Neurourology and Urodynamics2004;23(5/6):600-1. [sr-incont19025]RudyD , ClineK , HarrisR , GoldbergK , DmochowskiR . Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology2006;67(2):275-80. [srincont-21604]RudyD , ClineK , HarrisR , GoldbergK , DmochowskiR . Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. BJU International2006;97(3):540-6. [sr-incont21593]">Rudy 2006</a>; <a href="./references#CD003781-bbs2-0082" title="ChancellorMB , OefeleinMG , VasavadaS . Obesity is associated with a more severe overactive bladder disease state that is effectively treated with one daily administration of trospium chloride extended release [Erratum available in: Neurourology and Urodynamics 2010;29(5):804]. Neurourology and Urodynamics2010;29(4):551-4. [sr-incont39591]GinsbergDA , OefeleinMG , EllsworthPI . Once-daily administration of trospium chloride extended release provides 24-hour coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials. Neurourology and Urodynamics2011;30(4):563-7. [sr-incont41531]RovnerE , DmochowskiR , WatanabeJ . Once daily (QD) trospium chloride 60mg extended release (XR) is safe and effective in patients (PTS) with the overactive bladder (OAB) syndrome who use multiple concomitant medications (MEDS) (Abstract number: Poster #68). Neurourology and Urodynamics2009;28(2):146-7. [sr-incont31062]SandP , DmochowskiR , ZinnerN , StaskinD . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: results from a multicenter, phase III, placebo-controlled study (Abstract number 269). In: International Continence Society (ICS), 37th Annual Meeting; 2007 Aug 20-24; Rotterdam, the Netherlands. 2007. [sr-incont26676]SandP , StaskinD , ZinnerN , DmochowskiR . Once-daily trospium chloride extended release is effective and well tolerated for the treatment of overactive bladder: results from a multicenter, phase III trial (Abstract number 57). Neurourology and Urodynamics2007;26(5):675. [sr-incont26661]StaskinD , SandP , ZinnerN , DmochowskiR , Trospium Study Group. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. Journal of Urology2007;178(3 Pt 1):978-83; discussion 983-4. [srincont-23909]StaskinDR , RosenbergMT , SandPK , ZinnerNR , DmochowskiRR . Trospium chloride once daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised phase III trials. International Journal of Clinical Practice2009;63(12):1715-23. [sr-incont35458]StaskinDR , SandPK , ZinnerNR . Once-daily trospium chloride extended release is effective and well tolerated for the treatment of overactive bladder: results from a multicenter, phase III trial (Abstract number - poster 22). Neurourology and Urodynamics2007;26(7 Suppl):1106. [srincont-27305]">Staskin 2007</a>; <a href="./references#CD003781-bbs2-0084" title="SteersW , CorcosJ . Efficacy, tolerability and safety of darifenacin, an M3 selective receptor antagonist for the treatment of overactive bladder, using a flexible dosing regimen (Abstract number 68). Progres en Urologie2004;14(3 Suppl 3):22. [srincont-22197]">Steers 2004</a>; <a href="./references#CD003781-bbs2-0086" title="StohrerM , MadersbacherH , RichterR , WehnertJ , DreikornK . Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia - a double-blind, placebo-controlled clinical trial. Spinal Cord1999;37(3):196-200. [sr-incont8146]">Stohrer 1999</a>; <a href="./references#CD003781-bbs2-0089" title="ThuroffJW , BunkeB , EbnerA , FaberP , deGeeterP , HannappelJ , et al. Randomized, double-blind multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin vs. propantheline vs. placebo. Neurourology and Urodynamics1990;9(4):337-8. [srincont-5108]ThuroffJW , BunkeB , EbnerA , FaberP , deGeeterP , HannappelJ , et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. Journal of Urology1991;145(4):813-7. [srincont-1288]">Thuroff 1991</a>; <a href="./references#CD003781-bbs2-0091" title="MesselinkEJ , SolerJM , MadersbacherH , ThuroffJW , AmarencoG , Van KerrebroeckEV . Urodynamic aspects of the efficacy of tolterodine, a new anti muscarine drug in the treatment of detrusor hyperreflexia. In: International Continence Society (ICS), 25th Annual Meeting; 1995 Oct 17-20; Sydeney, Australia. 1995:95-6. [srincont-10883]Van KerrebroeckPE , AmarencoG , ThüroffJW , MadersbacherHG , LockMT , MesselinkEJ , et al. Dose-ranging study ot tolterodine in patients with detrusor hyperreflexia. Neurourology and Urodynamics1998;17(5):499-512. [srincont-7852]">Van Kerrebroeck 1998</a>; <a href="./references#CD003781-bbs2-0092" title="ChancellorM , FreedmanS , MitchesonHD , AntociJ , PrimusG , WeinA . Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clinical Drug Investigation2000;19(2):83-91. [srincont-16326]FreemanR , HillS , MillardR , SlackM , SutherstJ , Tolterodine Study Group. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstetrics and Gynecology2003;102(3):605-11. [srincont-16494]GarelyA , Tolterodine Study Group. Once-daily tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder. International Urology Journal2001;12(Suppl 1):S18. [srincont-12012]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of life of patients with overactive bladder receiving tolterodine. Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of patients with overactive bladder receiving tolterodine (Abstract number 82). Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , ReesePR . Health related quality of life of patients with overactive bladder receiving tolterodine once-daily. Neurourology and Urodynamics2000;19(4):519-21. [srincont-9987]KelleherCJ , ReesePR , PleilAM , OkanoGJ . Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. American Journal of Managed Care2002;8(Suppl 19):S608-15. [srincont-17998]KelleherCJ , Tolterodine Study Group. Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2000;11(Suppl 1):S94. [srincont-11915]KrederKJ . Antimuscarinic therapy: relationship between efficacy and side effects in responders and non-responders. Journal of Urology2001;165(Suppl 5):S165. [srincont-16327]KrederKJ . Clinical effectiveness of antimuscarinic therapy: the relationship between efficacy and tolerability. In: Proceedings of the International Continence Society Annual Meeting(ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001:140. [srincont-14376]MallettV . Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2001;12(Suppl 1):4. [srincont-12011]MillardRJ , TamaddonK , Tolterodine Study Group. Randomized controlled trial to compare tolterodine prolonged release capsules and tolterodine immediate release tablets versus placebo in patients with symptoms of detrusor overactivity (Abstract number 57). Australian and New Zealand Journal of Surgery2002;Suppl 72:A140. [sr-incont22190]PleilAM , ReesePR , KelleherCJ , OkanoGJ . Health-related quality of life of patients with overactive bladder receiving immediate-release tolterodine. HEPAC Health Economics in Prevention and Care2001;2(2):69-75. [sr-incont18060]RoehrbornCG , AbramsP , RovnerES , KaplanSA , HerschornS , GuanZ . Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU International2006;97(5):1003-6. [sr-incont21882]SwiftS . Efficacy and tolerability of once-daily tolterodine for women with overactive bladder. In: International Continence Society Annual Meeting (ICS), 31st annual meeting; 2001 Sept 18-21; Seoul, Korea. 2001:No. 329. [srincont-14481]SwiftS . Once-daily tolterodine is effective and well tolerated in women with overactive bladder (Abstract 57). In: 2nd International Consultation on Incontinence; 2001 July 1-3; Paris, France. 2001. [srincont-16319]SwiftSE . Once-daily (OD) tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder (OAB). International Urogynecology Journal2000;11(Suppl 1):S15. [sr-incont11906]SwiftSE . Once-daily administration of extended-release tolterodine is effective and well-tolerated in patients with overactive bladder. In: XVI FIGO World Congress of Obstetrics and Gynecology; 2000 Sept 3-8; Washington DC. Vol. Book 1. 2000:40. [sr-incont12085]SwiftSE . Overactive bladder in females: treatment with once-daily tolterodine. International Urogynecology Journal2001;12(Suppl 3):S71. [sr-incont16328]Van KerrebroeckP , KrederK , JonasU , ZinnerN . Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology2001;57(3):414-21. [sr-incont11953]Van KerrebroeckPEV . Long-term (12 months) efficacy and tolerability of tolterodine once-daily in the treatment of overactive bladder. Neurourology and Urodynamics2001;20(4):401-2. [sr-incont15714]Van KerrebroeckPEVA , Tolterodine Study Group. Long-term tolerability and efficacy of once-daily (OD) tolterodine in the treatment of overactive bladder (OB). International Urogynecology Journal2001;12(Suppl 3):S49. [sr-incont16329]Van KerrebroeckPEVA , Tolterodine Study Group. Significant decreases in perception of urgency and urge incontinence episodes with once-daily tolterodine treatment in patients with overactive bladder (Abstract number 89). Neurourology and Urodynamics2000;19(4):493-4. [sr-incont9980]WeinAJ , KhullarV , WangJT , GuanZ . Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. BJU International2007;99(2):360-3. [sr-incont23180]vanKerrebroeckPE , KelleherCJ , CoyneKS , KoppZ , BrodskyM , WangJT . Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. Health and Quality of Life Outcomes2009;7(13):13. [10.1186/1477-7525-7-13] [sr-incont31438]vanKerrebroeckPE , WangJ , GuanZ . Effects of tolterodine extended release in patients with overactive bladder: perceived treatment benefits improve with efficacy (Abstract number 511). European Urology Supplements2004;3(2):130. [sr-incont31090]">Van Kerrebroeck 2001</a>; <a href="./references#CD003781-bbs2-0093" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CrosbyRD , MathiasSD , MarshallTS . Relationships between symptoms, symptom bother, and health-related quality of life in patients with overactive bladder taking solifenacin or placebo in the VIBRANT study. International Journal of Clinical Practice2011;65(2):211-8. [sr-incont41015]GollarKM , YoungDG , BailenJ , HeW , Forero-SchwanhaeuserS . Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: a secondary analysis of the VIBRANT study. Urologic Nursing2012;32(1):38-46. [TrialID.VIBRANT.] [sr-incont44571]Samuels T‐A, MitchesonHD , VardyM , Forero‐SchwanhaeuserS , MarshallT , HeW . Efficacy of solifenacin for symptom bother and other patient-reported outcomes in patients with overactive bladder (OAB): results of a large, double-blind, placebo-controlled trial (Abstract number: poster #74). Neurourology and Urodynamics2009;28(2):149. [sr-incont31063]VardyMD , MitchesonHD , SamuelsTA , Forero-SchwanhaeuserS , HeW . Efficacy of solifenacin on overactive bladder symptoms, symptom bother, and other patient-reported outcomes in subjects with or without incontinence: a post hoc analysis of data from VIBRANT. Female Pelvic Medicine and Reconstructive Surgery2011;17(1):24-9. [TrialID.VIBRANT.] [sr-incont44741]VardyMD , MitchesonHD , SamuelsTA , WegenkeJD , Forero-SchwanhaeuserS , MarshallTS , et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. International Journal of Clinical Practice2009;63(12):1702-14. [905-UC-010] [NCT00573508] [TrialID.VIBRANT.] [sr-incont35459]">Vardy 2009</a>; <a href="./references#CD003781-bbs2-0094" title="EUCTR2007-007087-17-SE. A 24-week, multicentre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-007087-17 (first received 13 June 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont64588]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00798434. A study to compare the effectiveness and safety of fesoterodine and placebo in an elderly population of patients who go to the toilet very frequently due to overactive bladder (SOFIA) [A 24-week, multi-centre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00798434 (first received 26 November 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont49847]SchneiderT , BergqvistA , WangJ , WaggA , Ebel-BitounC . Treatment with fesoterodine versus tolterodine for reducing symptom bother in elderly patients with overactive bladder including urgency urinary incontinence. European Urology, Supplements2012;11(1):e687-a. [sr-incont65389]WaggA , CarlssonM , ElsobkyM , FernetM . Effect of flexible dose fesoterodine on cognitive function in &gt;65 year old patients with OAB: data from two RCT (Abstract number 438). Neurourology and Urodynamics2019;38:S297-8. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78651]WaggA , DarekarA , ArumiD , KhullarV , OelkeM . Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people &gt;65 years of age: a post hoc analysis of data from the SOFIA study. Neurourology and Urodynamics2015;34(5):438-43. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont68100]WaggA , ElsobkyM , CarlssonM , FernetM . Response and cognitive safety of fesoterodine in patients &gt;65y old with OAB. Is there a relationship between cognition and treatment response? (Abstract number 183). Neurourology and Urodynamics2019;38:S118-20. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78632]WaggA , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. Journal of the American Geriatrics Society2013;61(2):185-93. [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TrialID.SOFIA.] [sr-incont48008]WaggAS , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Efficacy and tolerability of fesoterodine in older subjects with overactive bladder: results of SOFIA (Abstract number C33). Journal of the American Geriatrics Society2011;59:S124. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont65234]">Wagg 2013a</a>; <a href="./references#CD003781-bbs2-0095" title="GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00911937. A trial to evaluate the efficacy and safety of fesoterodine in patients with symptoms of overactive bladder including nocturnal urinary urgency [A randomized, double blind, placebo controlled, parallel group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with symptoms of overactive bladder including nocturnal urinary urgency]. clinicaltrials.gov/show/NCT00911937 (first received 03 June 2009). [NCT00911937] [sr-incont49848]WeissJ , JumadilovaZ , CarlssonM , FitzGeraldMP , MalhotraA , MartireDL . Effect of antimuscarinic treatment in subjects with overactive bladder, including nocturnal urinary urgency (Abstract number 1963). Journal of Urology2012;187(4 Suppl 1):e792. [NCT00911937] [sr-incont65184]WeissJP , CarlssonMR , ManganEK . Age, gender and nocturnal urgency severity predict response to antimuscarinic treatment (Abstract number 1962). Journal of Urology2013;189(4 Suppl 1):e805. [NCT00911937] [sr-incont65096]WeissJP , JumadilovaZ , JohnsonTM , FitzGeraldMP , CarlssonM , MartireDL , et al. Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency. Journal of Urology2013;189(4):1396-401. [A0221048] [NCT00911937] [sr-incont47568]">Weiss 2013</a>; <a href="./references#CD003781-bbs2-0096" title="YamaguchiO , MaruiE , KakizakiH , ItohN , YokotaT , OkadaH , et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU International2007;100(3):579-87. [sr-incont23865]YokoyamaO , YamaguchiO , KakizakiH , ItohN , YokotaT , OkadaH , et al. Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary. Journal of Urology2011;186(1):170-4. [sr-incont41734]">Yamaguchi 2007</a>; <a href="./references#CD003781-bbs2-0098" title="YamaguchiO , UchidaE , HigoN , MinamiH , KobayashiS , SatoH , et al. Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: a randomized double-blind trial. International Journal of Urology2014;21(6):586-93. [JapicCTI-101309] [sr-incont62099]">Yamaguchi 2014</a>; <a href="./references#CD003781-bbs2-0100" title="JapicCTI-152936. Phase III study of KRP-114V [A phase III, randomized, double-blind, parallel group, placebo controlled, multicenter study to assess the efficacy and safety of the beta-3 agonist KRP-114V in Japanese subjects with symptoms of overactive bladder]. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-152936 (first received 17 June 2015). [JapicCTI-152936] [sr-incont78653]YoshidaM , TakedaM , GotoM , NagaiS , KuroseT . Vibegron, a novel potent and selective beta3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study (Abstract number 1082). European Urology, Supplements2018;17(2):e1531-2. [JapicCTI-152936] [sr-incont78069]YoshidaM , TakedaM , GotohM , NagaiS , KuroseT . Vibegron, a novel potent and selective B3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study. European Urology2018;73(5):783-90. [JapicCTI-152936] [sr-incont77898]YoshidaM , TakedaM , GotohM , YokoyamaO , KakizakiH , TakahashiS , et al. Efficacy of novel beta3-adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: a post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study. International Journal of Urology2019;26(3):369-75. [JapicCTI-152936] [sr-incont78654]YoshidaM , TakedaM , GotohM , YokoyamaO , KakizakiH , TakahashiS , et al. Efficacy of vibegron, a novel selective I²3-adrenoreceptor agonist, on urgency urinary incontinence with overactive bladder: post-hoc analysis of phase iii study (Abstract number 180). Neurourology and Urodynamics2019;38(S3):S114-5. [JapicCTI-152936] [sr-incont78636]">Yoshida 2018</a>; <a href="./references#CD003781-bbs2-0102" title="ZinnerNR , MattiassonA , StantonSL . Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. Journal of the American Geriatrics Society2002;50(5):799-807. [sr-incont14679]">Zinner 2002</a>; <a href="./references#CD003781-bbs2-0103" title="ZinnerN , GittelmanM , HarrisR , SussetJ , KanellosA , AuerbachS . Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial (Abstract number DP51). In: American Urological Association (AUA), 98th Annual Meeting; 2003 Apr 26-May 1; Chicago, Illinois. 2003. [sr-incont31101]ZinnerN , GittelmanM , HarrisR , SussetJ , KanelosA , AuerbachS , Trospium Study Group. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. Journal of Urology2004;171(6 Pt 1):2311-5. [sr-incont17376]">Zinner 2004</a>; <a href="./references#CD003781-bbs2-0104" title="ZinnerN , SussetJ , GittelmanM , ArguinzonizM , RekedaL , HaabF . Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. International Journal of Clinical Practice2006;60(1):119-26. [sr-incont21507]">Zinner 2006</a>). </p> <p>Anticholinergic drugs may result in an increase in dry mouth compared to placebo (RR 3.50, 95% CI 3.26 to 3.75; P &lt; 0.00001; <a href="./references#CD003781-fig-0013" title="">Analysis 1.4</a>; <a href="./full#CD003781-tbl-0001">summary of findings Table 1</a>; low‐certainty evidence). </p> <p>The I<sup>2</sup> value for subgroup differences for this outcome is 50.7%. When tolterodine was removed from the analyses, the I<sup>2</sup> value for subgroup differences was 19.2%. Additionally, without tolterodine the results changed to favour placebo more (RR 3.75, 95% CI 3.44 to 4.07). Hence, tolterodine might be better tolerated in terms of dry mouth compared to other drugs included in the review.   </p> </section> <section id="CD003781-sec-0077"> <h5 class="title">Adverse events: urinary retention</h5> <p>Seventeen included studies reported this outcome, with a total 7862 participants (4614 in the anticholinergics group and 3248 in the placebo group) (<a href="./references#CD003781-bbs2-0003" title="AbramsP , KaplanS , MillardR . Tolterodine treatment is safe in men with bladder outlet obstruction (BOO) and symptomatic detrusor overactivity (DO) (Abstract). Neurourology and Urodynamics2001;20(4):547-8. [srincont-14372]">Abrams 2001</a>; <a href="./references#CD003781-bbs2-0008" title="BurgioKL , LocherJL , GoodePS , HardinJM , McDowellBJ , CandibD . Behavior vs drug therapy for urge incontinence in older women (Abstract number 26). In: American Urogynecology Society, 15th Annual Scientific Meeting; 1994 Sept 21-24; Toronto, Ontario. 1994:48. [sr-incont14585]BurgioKL , LocherJL , GoodePS , HardinM , McDowellBJ , Dombrowski M et al. Behavioral vs drug treatment for urge urinary incontinence in older women. A randomized controlled trial. JAMA1998;280(23):1995-2000. [srincont-5719]BurgioKL , LocherJL , GoodePS . Combined behavioral and drug therapy for urge incontinence in older women. Journal of the American Geriatrics Society2000;48(4):370-4. [srincont-9006]BurgioKL , LocherJL , RothDL , GoodePS . Psychological improvements associated with behavioral and drug treatment of urge incontinence in older women. Journal of Gerontology. Series B, Psychological Sciences and Social Sciences2001;56(1):P46-51. [srincont-11923]">Burgio 1998</a>; <a href="./references#CD003781-bbs2-0014" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. ChappleCR , AranoP , BoschJH , De RidderD , KramerG , RidderAM . YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo- and tolterodine-controlled, phase-II, dose-finding study (Abstract 75). Neurourology and Urodynamics2002;21(4):381-2. [srincont-14551]ChappleCR , ArañoP , BoschJL , De RidderD , KramerAE , RidderAM . Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU International2004;93(1):71-7. [srincont-17334]KelleherCJ , CardozoL , ChappleCR , HaabF , RidderAM . Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU International2005;95(1):81-5. [srincont-20241]SmithN , GrimesI , RidgeS , TempelD , UchidaT , YamanouchiUS . YM905 is effective and safe as treatment of overactive bladder in women and men: results from phase II study (Abstract). In: International Continence Society (ICS), 32nd Annual Meeting; 2002 Aug 28-30; Heidelberg, Germany. 2002:138-9. [sr-incont14508]">Chapple 2004b</a>; <a href="./references#CD003781-bbs2-0020" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. [sr-incont75259]ChuF , SmithN , UchidaT . Efficacy and safety of solifenacin succinate 10 mg once daily: a multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder. Current Therapeutic Research - Clinical and Experimental2009;70(6):405-20. [srincont-43324]">Chu 2009</a>; <a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>; <a href="./references#CD003781-bbs2-0033" title="GotohM , HommaY , YokoyamaO , NishizawaO . Responsiveness and minimal clinically important change in overactive bladder symptom score. Urology2011;78(4):768-73. [srincont-42622]GotohM , YokoyamaO , MatsukawaY , NishizawaO . Responsiveness of overactive bladder symptom score (OABSS): verification based on data in a double-blinded, randomized placebo-controlled study of propiverine hydrochloride in Japanese patients (Abstract number 338). In: Joint Meeting of the International Continence Society (ICS) and the International Urogynecological Association; 2010 Aug 23-27; Toronto, Canada. 2010. [srincont-40173]GotohM , YokoyamaO , NishizawaO . Propiverine hydrochloride in Japanese patients with overactive bladder: A randomized, double-blind, placebo-controlled trial. International Journal of Urology2011;18(5):365-73. [srincont-41510]">Gotoh 2011</a>; <a href="./references#CD003781-bbs2-0040" title="EUCTR2012-005735-91-SK. A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-005735-91 (first received 12 November 2013). [178-CL-101] [EUCTR2012-005735-91-SK] [sr-incont78644]HerschornS , ChappleCR , AbramsP , ArlandisS , MitchesonD , LeeKS , et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU International2017;120(4):562-75. [NCT01972841] [sr-incont74470]MuellerER , RobinsonD , KelleherC , StaskinDR , FalconerC , WangJ , et al. Patient reported outcomes from synergy, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with mirabegron and solifenacin monotherapy (Abstract number - Podium #44). Neurourology and Urodynamics2017;36(Suppl S1):S151-2. [NCT01972841] [sr-incont75944]NCT01972841. This was a multinational study comparing the efficacy and safety of two medicines, solifenacin succinate and mirabegron taken together, or separately, or a mock treatment (placebo) in subjects with symptoms of overactive bladder (SYNERGY) [A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01972841 (first received 31 October 2013). [178-CL-101] [EUCTR2012-005735-91] [NCT01972841] [sr-incont63780]RobinsonD , KelleherC , StaskinD , MuellerER , FalconerC , WangJ , et al. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients. Neurourology and Urodynamics2018;37(1):394-406. [NCT01972841] [sr-incont76906]WeberMA , ChappleCR , GratzkeC , HerschornS , RobinsonD , FrankelJM , et al. A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial. Blood Pressure Monitoring2018;23(3):153-63. [NCT01972841] [sr-incont77899]WhiteWB , ChappleC , GratzkeC , HerschornS , RobinsonD , FrankelJ , et al. Cardiovascular safety of the beta3-adrenoceptor agonist mirabegron and the antimuscarinic agent solifenacin in the SYNERGY trial. Journal of Clinical Pharmacology2018;58(8):1084-91. [NCT01972841] [sr-incont78078]">Herschorn 2017a</a>; <a href="./references#CD003781-bbs2-0043" title="HommaY , KawabeK . Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World Journal of Urology2004;22(4):251-6. [srincont-19412]HommaY , PaickJS , LeeJG , KawabeK , Japanese and Korean Tolterodine Study Group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU International2003;92(7):741-7. [srincont-16418]">Homma 2003</a>; <a href="./references#CD003781-bbs2-0054" title="KhullarV , HillS , LavalKU , SchiotzHA , JonasU , VersiE . Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology2004;64(2):269-74; discussion 274-5. [srincont-19498]KhullarV , HillS , SolankiJ . Assessment of health-related quality of life in patients with overactive bladder taking tolterodine extended release versus placebo (Abstract number 318). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21075]">Khullar 2004</a>; <a href="./references#CD003781-bbs2-0057" title="KosilovK , LoparevS , IvanovskayaM , KosilovaL . A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron. Archives of Gerontology and Geriatrics2015;61(2):212-6. [sr-incont68133]">Kosilov 2015a</a>; <a href="./references#CD003781-bbs2-0058" title="KosilovKV , LoparevSA , IvanovskayaMA , KosilovaLV . The efficacy of different doses of solifenacin in elderly patients after treating a urinary tract infection. Arab Journal of Urology Print2015;13(3):203-8. [sr-incont69283]">Kosilov 2015b</a>; <a href="./references#CD003781-bbs2-0063" title="LeeKS , ChooMS , KimDY , KimJC , KimHJ , MinKS , et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. Journal of Urology2005;174(4 Pt 1):1334-8. [sr-incont21016]LeeKS , ChooMS , PaickJS , LeeJG , SeoJT , LeeJZ , et al. Propiverine hydrochloride reduced frequency and perception of urgency in treatment of overactive bladder: a 12 week prospective, randomized, double blind, placebo controlled study (Abstract number 279). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26640]LeeKS , LeeHW , ChooMS , PaickJS , LeeJG , SeoJT , et al. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'. BJU International2010;105(11):1565-70. [2005-01-08] [NCT00903045] [PROUD] [sr-incont39958]NCT00903045. Urinary urgency outcomes following propiverine treatment for an overactive bladder [Urinary urgency outcomes following propiverine treatment for an overactive bladder: propiverine study on overactive bladder including urgency data (PROUD)]. clinicaltrials.gov/show/NCT009030452005;(first received 15 May 2009). [2005-01-08] [NCT00903045] [TrialID.PROUD] [sr-incont49860]">Lee 2006</a>; <a href="./references#CD003781-bbs2-0070" title="GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NittiVW , DmochowskiR , SandPK , ForstHT , Haag-MolkentellerC , MassowU , et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. Journal of Urology2007;178(6):2488-94. [NCT00138723] [SP584] [srincont-26313]">Nitti 2007</a>; <a href="./references#CD003781-bbs2-0074" title="RentzhogSL , StantonL , CardozoL , NelsonE , FallM , AbramsP . Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. British Journal of Urology1998;81(1):42-8. [srincont-5461]">Rentzhog 1998</a>; <a href="./references#CD003781-bbs2-0082" title="ChancellorMB , OefeleinMG , VasavadaS . Obesity is associated with a more severe overactive bladder disease state that is effectively treated with one daily administration of trospium chloride extended release [Erratum available in: Neurourology and Urodynamics 2010;29(5):804]. Neurourology and Urodynamics2010;29(4):551-4. [sr-incont39591]GinsbergDA , OefeleinMG , EllsworthPI . Once-daily administration of trospium chloride extended release provides 24-hour coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials. Neurourology and Urodynamics2011;30(4):563-7. [sr-incont41531]RovnerE , DmochowskiR , WatanabeJ . Once daily (QD) trospium chloride 60mg extended release (XR) is safe and effective in patients (PTS) with the overactive bladder (OAB) syndrome who use multiple concomitant medications (MEDS) (Abstract number: Poster #68). Neurourology and Urodynamics2009;28(2):146-7. [sr-incont31062]SandP , DmochowskiR , ZinnerN , StaskinD . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: results from a multicenter, phase III, placebo-controlled study (Abstract number 269). In: International Continence Society (ICS), 37th Annual Meeting; 2007 Aug 20-24; Rotterdam, the Netherlands. 2007. [sr-incont26676]SandP , StaskinD , ZinnerN , DmochowskiR . Once-daily trospium chloride extended release is effective and well tolerated for the treatment of overactive bladder: results from a multicenter, phase III trial (Abstract number 57). Neurourology and Urodynamics2007;26(5):675. [sr-incont26661]StaskinD , SandP , ZinnerN , DmochowskiR , Trospium Study Group. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. Journal of Urology2007;178(3 Pt 1):978-83; discussion 983-4. [srincont-23909]StaskinDR , RosenbergMT , SandPK , ZinnerNR , DmochowskiRR . Trospium chloride once daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised phase III trials. International Journal of Clinical Practice2009;63(12):1715-23. [sr-incont35458]StaskinDR , SandPK , ZinnerNR . Once-daily trospium chloride extended release is effective and well tolerated for the treatment of overactive bladder: results from a multicenter, phase III trial (Abstract number - poster 22). Neurourology and Urodynamics2007;26(7 Suppl):1106. [srincont-27305]">Staskin 2007</a>; <a href="./references#CD003781-bbs2-0091" title="MesselinkEJ , SolerJM , MadersbacherH , ThuroffJW , AmarencoG , Van KerrebroeckEV . Urodynamic aspects of the efficacy of tolterodine, a new anti muscarine drug in the treatment of detrusor hyperreflexia. In: International Continence Society (ICS), 25th Annual Meeting; 1995 Oct 17-20; Sydeney, Australia. 1995:95-6. [srincont-10883]Van KerrebroeckPE , AmarencoG , ThüroffJW , MadersbacherHG , LockMT , MesselinkEJ , et al. Dose-ranging study ot tolterodine in patients with detrusor hyperreflexia. Neurourology and Urodynamics1998;17(5):499-512. [srincont-7852]">Van Kerrebroeck 1998</a>; <a href="./references#CD003781-bbs2-0102" title="ZinnerNR , MattiassonA , StantonSL . Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. Journal of the American Geriatrics Society2002;50(5):799-807. [sr-incont14679]">Zinner 2002</a>). Anticholinergic drugs may lead to an increased risk of urinary retention compared to placebo (RR 3.52, 95% CI 2.04 to 6.08; P &lt; 0.00001; <a href="./references#CD003781-fig-0014" title="">Analysis 1.5</a>; <a href="./full#CD003781-tbl-0001">summary of findings Table 1</a>; low‐certainty evidence). </p> </section> <section id="CD003781-sec-0078"> <h5 class="title">Adverse events: abdominal pain</h5> <p>Fifteen studies have been included in the analysis for abdominal pain, with a total of 8195 participants (5587 in the anticholinergic group, 2608 in the placebo group) (<a href="./references#CD003781-bbs2-0013" title="ChappleC . Fesoterodine a new effective and well-tolerated antimuscarinic for the treatment of urgency-frequency syndrome: results of a phase 2 controlled study (Abstract 142). Neurourology and Urodynamics2004;23(5/6):598-9. [srincont-19023]Drug company. A Phase 2, parallel group, randomized, double-blind, placebo controlled dose-ranging trial to determine the optimal dose and the tolerability of sustained release SPM 8272 (fesoterodine) in subjects with non-neurogenic bladder overactivity. Protocol numbers: A0221027 (SP582). ClinicalStudyResults.org (accessed 3 March 2011)2002. [Protocol numbers: A0221027 (SP582)] [srincont-41110]">Chapple 2004a</a>; <a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>; <a href="./references#CD003781-bbs2-0042" title="HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21072]HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21072]HillS , KhullarV , WyndaeleJJ , LheritierK , . Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. International Urogynecology Journal and Pelvic Floor2006;17(3):239-47. [srincont-22464]">Hill 2005</a>; <a href="./references#CD003781-bbs2-0043" title="HommaY , KawabeK . Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World Journal of Urology2004;22(4):251-6. [srincont-19412]HommaY , PaickJS , LeeJG , KawabeK , Japanese and Korean Tolterodine Study Group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU International2003;92(7):741-7. [srincont-16418]">Homma 2003</a>; <a href="./references#CD003781-bbs2-0045" title="HommaY , YamaguchiO , Imidafenacin Study Group. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2009;16(5):499-506. [NCT00212732] [ONO-8025-08] [srincont-31368]">Homma 2009</a>; <a href="./references#CD003781-bbs2-0047" title="JacquetinB , WyndaeleJJ . Tolterodine reduces the number of incontinence episodes in patients with an overactive bladder. European Journal of Obstetrics and Gynecology and Reproductive Biology2001;98(1):97-102. [srincont-12200]JacquetinB , WyndaeleJJ . Tolterodine reduces the number of incontinence episodes in patients with detrusor overactivity. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(1):S30. [srincont-5167]">Jacquetin 2001</a>; <a href="./references#CD003781-bbs2-0050" title="JünemannKP , HessdörferE , Unamba‐OparahI , BerseM , BrünjesR , MadersbacherH . Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. Urologia Internationalis2006;77(4):334-9. [srincont-22199]">Junemann 2006</a>; <a href="./references#CD003781-bbs2-0054" title="KhullarV , HillS , LavalKU , SchiotzHA , JonasU , VersiE . Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology2004;64(2):269-74; discussion 274-5. [srincont-19498]KhullarV , HillS , SolankiJ . Assessment of health-related quality of life in patients with overactive bladder taking tolterodine extended release versus placebo (Abstract number 318). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21075]">Khullar 2004</a>; <a href="./references#CD003781-bbs2-0057" title="KosilovK , LoparevS , IvanovskayaM , KosilovaL . A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron. Archives of Gerontology and Geriatrics2015;61(2):212-6. [sr-incont68133]">Kosilov 2015a</a>; <a href="./references#CD003781-bbs2-0066" title="Malone-LeeJG , WalshB , MaugourdMF , Tolterodine in the Elderly Study Group. The safety and clinical efficacy of two doses of tolterodine compared to placebo in elderly patients. In: International Continence Society (ICS), 27th Annual Meeting; 1997 Sep 23-26; Yokohama, Japan. 1997:155-6. [srincont-5855]Malone‐LeeJG , WalshJB , MaugourdMF . Tolterodine: A safe and effective treatment for older patients with overactive bladder. Journal of the American Geriatric Society2001;49(6):700-5. [srincont-12319]WaggA , Malone-LeeJ . Pressure-flow variables in patients treated with tolterodine for detrusor overactivity. BJU International2003;92(9):969-71. [sr-incont16659]">Malone‐Lee 2001</a>; <a href="./references#CD003781-bbs2-0069" title="Drug company. A phase 2, parallel group, stratified, randomized, double blind, placebo-controlled trial to investigate the efficacy and safety of 3 different dosages of sustained release fesoterodine in subjects with overactive bladder showing either involuntary detrusor contractions or normal findings during the baseline urodynamic assessment. Protocol numbers: A0221029 (SP668). ClinicalStudyResults.org (accessed 3 March 2011). [srincont-41111]NittiV , WiatrakM , KreitmanL , LipsitzD . Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB): results of a phase 2 trial (Abstract number 306). In: International Continence Society (ICS); 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21084]">Nitti 2005</a>; <a href="./references#CD003781-bbs2-0082" title="ChancellorMB , OefeleinMG , VasavadaS . Obesity is associated with a more severe overactive bladder disease state that is effectively treated with one daily administration of trospium chloride extended release [Erratum available in: Neurourology and Urodynamics 2010;29(5):804]. Neurourology and Urodynamics2010;29(4):551-4. [sr-incont39591]GinsbergDA , OefeleinMG , EllsworthPI . Once-daily administration of trospium chloride extended release provides 24-hour coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials. Neurourology and Urodynamics2011;30(4):563-7. [sr-incont41531]RovnerE , DmochowskiR , WatanabeJ . Once daily (QD) trospium chloride 60mg extended release (XR) is safe and effective in patients (PTS) with the overactive bladder (OAB) syndrome who use multiple concomitant medications (MEDS) (Abstract number: Poster #68). Neurourology and Urodynamics2009;28(2):146-7. [sr-incont31062]SandP , DmochowskiR , ZinnerN , StaskinD . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: results from a multicenter, phase III, placebo-controlled study (Abstract number 269). In: International Continence Society (ICS), 37th Annual Meeting; 2007 Aug 20-24; Rotterdam, the Netherlands. 2007. [sr-incont26676]SandP , StaskinD , ZinnerN , DmochowskiR . Once-daily trospium chloride extended release is effective and well tolerated for the treatment of overactive bladder: results from a multicenter, phase III trial (Abstract number 57). Neurourology and Urodynamics2007;26(5):675. [sr-incont26661]StaskinD , SandP , ZinnerN , DmochowskiR , Trospium Study Group. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. Journal of Urology2007;178(3 Pt 1):978-83; discussion 983-4. [srincont-23909]StaskinDR , RosenbergMT , SandPK , ZinnerNR , DmochowskiRR . Trospium chloride once daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised phase III trials. International Journal of Clinical Practice2009;63(12):1715-23. [sr-incont35458]StaskinDR , SandPK , ZinnerNR . Once-daily trospium chloride extended release is effective and well tolerated for the treatment of overactive bladder: results from a multicenter, phase III trial (Abstract number - poster 22). Neurourology and Urodynamics2007;26(7 Suppl):1106. [srincont-27305]">Staskin 2007</a>; <a href="./references#CD003781-bbs2-0091" title="MesselinkEJ , SolerJM , MadersbacherH , ThuroffJW , AmarencoG , Van KerrebroeckEV . Urodynamic aspects of the efficacy of tolterodine, a new anti muscarine drug in the treatment of detrusor hyperreflexia. In: International Continence Society (ICS), 25th Annual Meeting; 1995 Oct 17-20; Sydeney, Australia. 1995:95-6. [srincont-10883]Van KerrebroeckPE , AmarencoG , ThüroffJW , MadersbacherHG , LockMT , MesselinkEJ , et al. Dose-ranging study ot tolterodine in patients with detrusor hyperreflexia. Neurourology and Urodynamics1998;17(5):499-512. [srincont-7852]">Van Kerrebroeck 1998</a>; <a href="./references#CD003781-bbs2-0092" title="ChancellorM , FreedmanS , MitchesonHD , AntociJ , PrimusG , WeinA . Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clinical Drug Investigation2000;19(2):83-91. [srincont-16326]FreemanR , HillS , MillardR , SlackM , SutherstJ , Tolterodine Study Group. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstetrics and Gynecology2003;102(3):605-11. [srincont-16494]GarelyA , Tolterodine Study Group. Once-daily tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder. International Urology Journal2001;12(Suppl 1):S18. [srincont-12012]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of life of patients with overactive bladder receiving tolterodine. Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of patients with overactive bladder receiving tolterodine (Abstract number 82). Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , ReesePR . Health related quality of life of patients with overactive bladder receiving tolterodine once-daily. Neurourology and Urodynamics2000;19(4):519-21. [srincont-9987]KelleherCJ , ReesePR , PleilAM , OkanoGJ . Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. American Journal of Managed Care2002;8(Suppl 19):S608-15. [srincont-17998]KelleherCJ , Tolterodine Study Group. Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2000;11(Suppl 1):S94. [srincont-11915]KrederKJ . Antimuscarinic therapy: relationship between efficacy and side effects in responders and non-responders. Journal of Urology2001;165(Suppl 5):S165. [srincont-16327]KrederKJ . Clinical effectiveness of antimuscarinic therapy: the relationship between efficacy and tolerability. In: Proceedings of the International Continence Society Annual Meeting(ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001:140. [srincont-14376]MallettV . Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2001;12(Suppl 1):4. [srincont-12011]MillardRJ , TamaddonK , Tolterodine Study Group. Randomized controlled trial to compare tolterodine prolonged release capsules and tolterodine immediate release tablets versus placebo in patients with symptoms of detrusor overactivity (Abstract number 57). Australian and New Zealand Journal of Surgery2002;Suppl 72:A140. [sr-incont22190]PleilAM , ReesePR , KelleherCJ , OkanoGJ . Health-related quality of life of patients with overactive bladder receiving immediate-release tolterodine. HEPAC Health Economics in Prevention and Care2001;2(2):69-75. [sr-incont18060]RoehrbornCG , AbramsP , RovnerES , KaplanSA , HerschornS , GuanZ . Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU International2006;97(5):1003-6. [sr-incont21882]SwiftS . Efficacy and tolerability of once-daily tolterodine for women with overactive bladder. In: International Continence Society Annual Meeting (ICS), 31st annual meeting; 2001 Sept 18-21; Seoul, Korea. 2001:No. 329. [srincont-14481]SwiftS . Once-daily tolterodine is effective and well tolerated in women with overactive bladder (Abstract 57). In: 2nd International Consultation on Incontinence; 2001 July 1-3; Paris, France. 2001. [srincont-16319]SwiftSE . Once-daily (OD) tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder (OAB). International Urogynecology Journal2000;11(Suppl 1):S15. [sr-incont11906]SwiftSE . Once-daily administration of extended-release tolterodine is effective and well-tolerated in patients with overactive bladder. In: XVI FIGO World Congress of Obstetrics and Gynecology; 2000 Sept 3-8; Washington DC. Vol. Book 1. 2000:40. [sr-incont12085]SwiftSE . Overactive bladder in females: treatment with once-daily tolterodine. International Urogynecology Journal2001;12(Suppl 3):S71. [sr-incont16328]Van KerrebroeckP , KrederK , JonasU , ZinnerN . Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology2001;57(3):414-21. [sr-incont11953]Van KerrebroeckPEV . Long-term (12 months) efficacy and tolerability of tolterodine once-daily in the treatment of overactive bladder. Neurourology and Urodynamics2001;20(4):401-2. [sr-incont15714]Van KerrebroeckPEVA , Tolterodine Study Group. Long-term tolerability and efficacy of once-daily (OD) tolterodine in the treatment of overactive bladder (OB). International Urogynecology Journal2001;12(Suppl 3):S49. [sr-incont16329]Van KerrebroeckPEVA , Tolterodine Study Group. Significant decreases in perception of urgency and urge incontinence episodes with once-daily tolterodine treatment in patients with overactive bladder (Abstract number 89). Neurourology and Urodynamics2000;19(4):493-4. [sr-incont9980]WeinAJ , KhullarV , WangJT , GuanZ . Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. BJU International2007;99(2):360-3. [sr-incont23180]vanKerrebroeckPE , KelleherCJ , CoyneKS , KoppZ , BrodskyM , WangJT . Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. Health and Quality of Life Outcomes2009;7(13):13. [10.1186/1477-7525-7-13] [sr-incont31438]vanKerrebroeckPE , WangJ , GuanZ . Effects of tolterodine extended release in patients with overactive bladder: perceived treatment benefits improve with efficacy (Abstract number 511). European Urology Supplements2004;3(2):130. [sr-incont31090]">Van Kerrebroeck 2001</a>; <a href="./references#CD003781-bbs2-0103" title="ZinnerN , GittelmanM , HarrisR , SussetJ , KanellosA , AuerbachS . Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial (Abstract number DP51). In: American Urological Association (AUA), 98th Annual Meeting; 2003 Apr 26-May 1; Chicago, Illinois. 2003. [sr-incont31101]ZinnerN , GittelmanM , HarrisR , SussetJ , KanelosA , AuerbachS , Trospium Study Group. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. Journal of Urology2004;171(6 Pt 1):2311-5. [sr-incont17376]">Zinner 2004</a>). The risk of having abdominal pain is 67% higher in anticholinergics group compared to the placebo group (RR 1.67, 95% CI 1.20 to 2.33; P = 0.003; <a href="./references#CD003781-fig-0015" title="">Analysis 1.6</a>). </p> </section> <section id="CD003781-sec-0079"> <h5 class="title">Adverse events: blurred vision</h5> <p>Thirty‐two RCTs reported on blurred vision and were included in the analysis, with a total of 18,639 participants (12,437 in the anticholinergic group and 6202 in the placebo group) (<a href="./references#CD003781-bbs2-0004" title="AbramsP , KelleherC , StaskinD , KayR , MartanA , MincikI , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World Journal of Urology2017;35(5):827-38. [NCT01340027] [sr-incont77897]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Cardiovascular safety of combination treatment with mirabegron and solifenacin in patients with overactive bladder in a randomised, double-blind, dose-ranging, Phase II study (Symphony) (Abstract). European Urology, Supplements2014;13(1):e574-e574a. [NCT01340027] [sr-incont67160]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB) - efficacy and safety results from a randomised phase II study (Symphony) (Abstract number 295). Neurourology and Urodynamics2013;32(6):930-1. [NCT01340027] [TrialID.SYMPHONY.] [sr-incont49188]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB): safety results from a phase 2 study (Abstract number MP-16.08). Urology2013;82(3 Suppl 1):S139. [NCT01340027] [sr-incont66675]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: Exploratory responder analyses of efficacy and evaluation of patient reported outcomes from a randomised, double-blind, dose-ranging, phase 2 study (Symphony) (Abstract number MP-24.11). Urology2014;84(4 Suppl 1):S145-6. [NCT01340027] [sr-incont67194]AbramsP , KelleherC , StaskinD , RechbergerT , KayR , MartinaR , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (SYMPHONY). European Urology2015;67(3):577-88. [NCT01340027] [sr-incont66674]NCT01340027, Bristol Urological Institute . A study to evaluate the efficacy, safety and tolerability of mirabegron and solifenacin succinate alone and in combination for the treatment of overactive bladder (symphony) [A randomized, double-blind, factorial, parallel-group, active and placebo-controlled, multicenter dose-ranging study to evaluate the efficacy, safety and tolerability of six dose combinations of solifenacin succinate and mirabegron compared to mirabegron and solifenacin succinate monotherapies in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01340027 (first received 21 April 2011). [178-CL-100] [2010-020601-32] [NCT01340027] [TrialID.SYMPHONY] [sr-incont44510]NittiV , AbramsP , StaskinD , AuerbachS , MartinaR , VanMR . Urinary retention in patients with overactive bladder treated with mirabegron alone and in combination with solifenacin: the results of two randomized, double-blind, phase II studies (Abstract number MP76-13). Journal of Urology2014;191(4 Suppl 1):e886-7. [NCT00410514] [NCT01340027] [TrialID.SYMPHONY] [sr-incont67453]">Abrams 2013</a>; <a href="./references#CD003781-bbs2-0005" title="AlloussiS , Laval KU , Ballering-BruhlB , Grobe-FreeseM , BulittaM , SchaferM . Trospium chloride (Spasmo-lyt) in patients with motor urge syndrome (detrusor instability): a double-blind, randomised, multicentre, placebo-controlled study. Journal of Clinical Research1998;1:439-51. [srincont-12005]AlloussiS , Laval K-U, EckertR , Ballering-BruhlB , Grosse-FreeseM , BulittaM , et al. Trospium chloride (Spasmo-lyt(R)) in patients with motor urge syndrome (detrusor instability): a double-blind, randomised, multicentre, placebo-controlled study. Journal of Drug Assessment1999;2(1):27-39. [sr-incont18226]AlloussiS , Laval K-U, MertinsB . Efficacy and tolerability of trospium chloride (spasmo-lyt) versus placebo in patients with motor urge-syndrome. In: International Continence Society (ICS), 28th Annual Meeting; 1998 Sept 14-17; Jerusalem, Israel. 1998:109-10. [sr-incont5684]">Alloussi 1998</a>; <a href="./references#CD003781-bbs2-0008" title="BurgioKL , LocherJL , GoodePS , HardinJM , McDowellBJ , CandibD . Behavior vs drug therapy for urge incontinence in older women (Abstract number 26). In: American Urogynecology Society, 15th Annual Scientific Meeting; 1994 Sept 21-24; Toronto, Ontario. 1994:48. [sr-incont14585]BurgioKL , LocherJL , GoodePS , HardinM , McDowellBJ , Dombrowski M et al. Behavioral vs drug treatment for urge urinary incontinence in older women. A randomized controlled trial. JAMA1998;280(23):1995-2000. [srincont-5719]BurgioKL , LocherJL , GoodePS . Combined behavioral and drug therapy for urge incontinence in older women. Journal of the American Geriatrics Society2000;48(4):370-4. [srincont-9006]BurgioKL , LocherJL , RothDL , GoodePS . Psychological improvements associated with behavioral and drug treatment of urge incontinence in older women. Journal of Gerontology. Series B, Psychological Sciences and Social Sciences2001;56(1):P46-51. [srincont-11923]">Burgio 1998</a>; <a href="./references#CD003781-bbs2-0010" title="CardozoL , KuzminI , LisecML , MillardR , vanVierssen TripOB , RidderAM , et al. YM905: Results of a randomised, double-blind placebo-controlled trial in patients with symptomatic overactive bladder (Abstract number 104). European Urology Supplements2003;2(1):28. [sr-incont27407]CardozoL , KuzminI , LisecML , MillardRJ , vanVierssen TripOB , RidderAM , et al. A double-blind, randomised, placebo-controlled trial with YM905 in symptomatic overactive bladder (Abstract number P74). Journal of the American Geriatrics Society2003;51 (Suppl 4):S68-9. [sr-incont31100]CardozoL , LisecM , MillardR , vanVierssen TripO , KuzminI , DrogendijkTE , et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. Journal of Urology2004;172(5 (Pt 1 of 2)):1919-24. [srincont-19090]CardozoL . A randomised double-blind, placebo-controlled trial of the once-daily muscarinic receptor antagonist solifenacin succinate for symptoms of overactive bladder (Abstract number 211). International Urogynecology Journal2003;14 (Suppl 1):S64. [sr-incont31104]CardozoL . Solifenacin succinate improves symptoms of an overactive bladder (Abstract number TP77). International Journal of Gynecology and Obstetrics2003;83(Suppl 3):94. [sr-incont31096]KelleherCJ , CardozoL , ChappleCR , HaabF , RidderAM . Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU International2005;95(1):81-5. [srincont-20241]">Cardozo 2004a</a>; <a href="./references#CD003781-bbs2-0011" title="CardozoL , AdamikZ , GuimaraesM , KrhutJ , Labat J-J, PetrovS , et al. Patients with overactive bladder show progressive improvement in urgency and bladder condition during treatment with solifenacin in a randomised, double-blind, placebo-controlled study (SUNRISE) (Abstract number 115). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S67-8. [srincont-26595]CardozoL , AmarencoG , PushkarD , MikulasJ , DrogendijkT , WrightM , et al. Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE). BJU International2013;111(5):804-10. [NCT00801944] [TrialID.SUNRISE.] [sr-incont47554]CardozoL , DewildeT , FeyereislJ , WadieB , AmarencoG , LiapisA , et al. Solifenacin significantly reduces both urgency severity and bother: results from the flexible dose, placebo controlled, multinational SUNRISE study (Abstract number 281). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26641]CardozoL , DrogendijkT , BolodeokuJ . The efficacy of solifenacin 5/10 mg on 'urgency' endpoints in different OAB patient populations: subanalysis of results from the randomised, double-blind SUNRISE study (Abstract number 192). In: International Continence Society (ICS); 38th Annual Meeting; 2008 Oct 20-24; Cairo, Egypt. 2008. [srincont-31885]CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CardozoL , HessdörferE , MilaniR , ArañóP , DewildeL , SlackM , et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU International2008;102(9):1120-7. [NCT00801944] [TrialID.SUNRISE] [srincont-29249]">Cardozo 2008a</a>; <a href="./references#CD003781-bbs2-0014" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. ChappleCR , AranoP , BoschJH , De RidderD , KramerG , RidderAM . YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo- and tolterodine-controlled, phase-II, dose-finding study (Abstract 75). Neurourology and Urodynamics2002;21(4):381-2. [srincont-14551]ChappleCR , ArañoP , BoschJL , De RidderD , KramerAE , RidderAM . Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU International2004;93(1):71-7. [srincont-17334]KelleherCJ , CardozoL , ChappleCR , HaabF , RidderAM . Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU International2005;95(1):81-5. [srincont-20241]SmithN , GrimesI , RidgeS , TempelD , UchidaT , YamanouchiUS . YM905 is effective and safe as treatment of overactive bladder in women and men: results from phase II study (Abstract). In: International Continence Society (ICS), 32nd Annual Meeting; 2002 Aug 28-30; Heidelberg, Germany. 2002:138-9. [sr-incont14508]">Chapple 2004b</a>; <a href="./references#CD003781-bbs2-0015" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. ChappleC , RechbergerT , Al-ShukriS , MeffanP , EveraertK , RidderA . Results of a randomized phase 3 study comparing solifenacin succinate with tolterodine and placebo in patients with symptomatic overactive bladder (Abstract). Neurourology and Urodynamics2003;22(5):534-5. [sr-incont16991]ChappleCR , RechbergerT , Al ShukriS , MeffanP , EveraertK , HuangM , et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU International2004;93(3):303-10. [srincont-17270]">Chapple 2004c</a>; <a href="./references#CD003781-bbs2-0020" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. [sr-incont75259]ChuF , SmithN , UchidaT . Efficacy and safety of solifenacin succinate 10 mg once daily: a multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder. Current Therapeutic Research - Clinical and Experimental2009;70(6):405-20. [srincont-43324]">Chu 2009</a>; <a href="./references#CD003781-bbs2-0021" title="ChuaME , SeeMC , EsmeňaEB , BalingitJC , MoralesML . Efficacy and safety of gabapentin in comparison to solifenacin succinate in adult overactive bladder treatment. Lower Urinary Tract Symptoms2018;10(2):135-42. [NCT01486706] [sr-incont74529]NCT01486706, ChuaME . Efficacy and safety of gabapentin in treating overactive bladder (OAB). clinicaltrials.gov/show/NCT01486706 (first received 6 December 2011). [NCT01486706] [SLMC10-010] [sr-incont49864]">Chua 2018</a>; <a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>; <a href="./references#CD003781-bbs2-0033" title="GotohM , HommaY , YokoyamaO , NishizawaO . Responsiveness and minimal clinically important change in overactive bladder symptom score. Urology2011;78(4):768-73. [srincont-42622]GotohM , YokoyamaO , MatsukawaY , NishizawaO . Responsiveness of overactive bladder symptom score (OABSS): verification based on data in a double-blinded, randomized placebo-controlled study of propiverine hydrochloride in Japanese patients (Abstract number 338). In: Joint Meeting of the International Continence Society (ICS) and the International Urogynecological Association; 2010 Aug 23-27; Toronto, Canada. 2010. [srincont-40173]GotohM , YokoyamaO , NishizawaO . Propiverine hydrochloride in Japanese patients with overactive bladder: A randomized, double-blind, placebo-controlled trial. International Journal of Urology2011;18(5):365-73. [srincont-41510]">Gotoh 2011</a>; <a href="./references#CD003781-bbs2-0040" title="EUCTR2012-005735-91-SK. A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-005735-91 (first received 12 November 2013). [178-CL-101] [EUCTR2012-005735-91-SK] [sr-incont78644]HerschornS , ChappleCR , AbramsP , ArlandisS , MitchesonD , LeeKS , et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU International2017;120(4):562-75. [NCT01972841] [sr-incont74470]MuellerER , RobinsonD , KelleherC , StaskinDR , FalconerC , WangJ , et al. Patient reported outcomes from synergy, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with mirabegron and solifenacin monotherapy (Abstract number - Podium #44). Neurourology and Urodynamics2017;36(Suppl S1):S151-2. [NCT01972841] [sr-incont75944]NCT01972841. This was a multinational study comparing the efficacy and safety of two medicines, solifenacin succinate and mirabegron taken together, or separately, or a mock treatment (placebo) in subjects with symptoms of overactive bladder (SYNERGY) [A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01972841 (first received 31 October 2013). [178-CL-101] [EUCTR2012-005735-91] [NCT01972841] [sr-incont63780]RobinsonD , KelleherC , StaskinD , MuellerER , FalconerC , WangJ , et al. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients. Neurourology and Urodynamics2018;37(1):394-406. [NCT01972841] [sr-incont76906]WeberMA , ChappleCR , GratzkeC , HerschornS , RobinsonD , FrankelJM , et al. A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial. Blood Pressure Monitoring2018;23(3):153-63. [NCT01972841] [sr-incont77899]WhiteWB , ChappleC , GratzkeC , HerschornS , RobinsonD , FrankelJ , et al. Cardiovascular safety of the beta3-adrenoceptor agonist mirabegron and the antimuscarinic agent solifenacin in the SYNERGY trial. Journal of Clinical Pharmacology2018;58(8):1084-91. [NCT01972841] [sr-incont78078]">Herschorn 2017a</a>; <a href="./references#CD003781-bbs2-0042" title="HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21072]HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21072]HillS , KhullarV , WyndaeleJJ , LheritierK , . Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. International Urogynecology Journal and Pelvic Floor2006;17(3):239-47. [srincont-22464]">Hill 2005</a>; <a href="./references#CD003781-bbs2-0043" title="HommaY , KawabeK . Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World Journal of Urology2004;22(4):251-6. [srincont-19412]HommaY , PaickJS , LeeJG , KawabeK , Japanese and Korean Tolterodine Study Group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU International2003;92(7):741-7. [srincont-16418]">Homma 2003</a>; <a href="./references#CD003781-bbs2-0044" title="HommaY , YamaguchiT , YamaguchiOA . A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2008;15(9):809-15. [srincont-27742]">Homma 2008</a>; <a href="./references#CD003781-bbs2-0045" title="HommaY , YamaguchiO , Imidafenacin Study Group. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2009;16(5):499-506. [NCT00212732] [ONO-8025-08] [srincont-31368]">Homma 2009</a>; <a href="./references#CD003781-bbs2-0048" title="JonasU , HofnerK , MadersbacherH , HolmdahlTH . Efficacy and safety of two doses of Tolterodine compared to placebo in patients with detrusor overactivity. Neurourology and Urodynamics1997;16(5):477-8. [srincont-5841]JonasU , HöfnerK , MadersbacherH , HolmdahlTH . Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group. World Journal of Urology1997;15(2):144-51. [srincont-5436]">Jonas 1997</a>; <a href="./references#CD003781-bbs2-0050" title="JünemannKP , HessdörferE , Unamba‐OparahI , BerseM , BrünjesR , MadersbacherH . Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. Urologia Internationalis2006;77(4):334-9. [srincont-22199]">Junemann 2006</a>; <a href="./references#CD003781-bbs2-0053" title="CapoJP , TogliaM , Forero-SchwanhaeuserS , HeW . Patients reporting severe overactive bladder symptoms: effects of solifenacin treatment on objective measures and patient-reported outcomes (Abstract number 582). In: International Continence Society (ICS), 38th Annual Meeting; 2008 Oct 20-24; Cairo, Egypt. 2008. [srincont-31844]CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. KarramMM , TogliaMR , SerelsSR , AndohM , FakhouryA , Forero-SchwanhaeuserS . Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology2009;73(1):14-8. [A0221094] [NCT00454896] [TrialID.VENUS.] [srincont-29219]SerelsSR , TogliaMR , Forero-SchwanhaeuserS , HeW . Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms. Current Medical Research and Opinion2010;26(10):2277-85. [srincont-40376]StaskinD , DmochowskiR , SerelsS , AndohM , SmithN . Report from a randomized, placebo-controlled study showing significant improvement in urgency and patient-reported outcomes in overactive bladder patients treated with solifenacin (Abstract number 124). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73-4. [srincont-26600]TogliaM , AndohM , HussainI . Solifenacin improved warning time significantly compared to placebo in patients with overactive bladder (Abstract number 123). Neurourology and Urodynamics2006;25(6):655. [srincont-26629]TogliaM , AndohM , HussainI . Solifenacin improves urgency symtoms as assessed by voiding diaries and patient-reported outcomes (PRO) in patients with overactive bladder (Abstract number 155). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26636]TogliaMR , OstergardDR , AppellRA , AndohM , FakhouryA , HussainIF . Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status. International Urogynecology Journal2010;21(7):847-54. [srincont-40094]TogliaMR , SerelsSR , LarameeC , KarramMM , NandyIM , AndohM , et al. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial. Postgraduate Medicine2009;121(5):151-8. [srincont-34204]ZinnerS , HerschornS , AndohM , HussainI . Responder analyses show statistically significant improvements in incontinence and urgency are associated with reduction in symptom bother and improvement in health-related quality of life: VENUS results (Abstract number 123). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73. [srincont-26599]">Karram 2009</a>; <a href="./references#CD003781-bbs2-0054" title="KhullarV , HillS , LavalKU , SchiotzHA , JonasU , VersiE . Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology2004;64(2):269-74; discussion 274-5. [srincont-19498]KhullarV , HillS , SolankiJ . Assessment of health-related quality of life in patients with overactive bladder taking tolterodine extended release versus placebo (Abstract number 318). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21075]">Khullar 2004</a>; <a href="./references#CD003781-bbs2-0057" title="KosilovK , LoparevS , IvanovskayaM , KosilovaL . A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron. Archives of Gerontology and Geriatrics2015;61(2):212-6. [sr-incont68133]">Kosilov 2015a</a>; <a href="./references#CD003781-bbs2-0065" title="ChappleCR , MadersbacherH , DreikornK , DorschnerW , MurtzG . Urodynamics and frequency/volume chart - do they correlate? Treatment analysis of propiverine in comparison to oxybutynin and placebo in urge incontinence (Abstract 224). In: International Continence Society (ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001. [sr-incont14474]HalaskaM , MadersbacherH , VoigtR , HofnerK , MartanA . Propiverine in patients with urgency and urge incontinence - a placebo controlled, multicentre study comparing its tolerability and efficacy with oxybutynin (Abstract number FDP36). International Urogynaecology Journal 2000;11(Suppl 1):S46. [srincont-11912]MadersbacherH , HalaskaM , VoigtR , AlloussiS , HofnerK . A urodynamically controlled multicenter study in patients with urge incontinence: tolerability and efficacy of propiverine hydrochloride in comparison to oxybutynin. In: International Continence Society (ICS), 27th Annual Meeting; 1997 Sep 23-26; Yokohama, Japan. 1997:153-4. [srincont-5854]MadersbacherH , HalaskaM , VoigtR , AlloussiS , HöfnerK . A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU International1999;84(6):646-51. [srincont-9166]">Madersbacher 1999</a>; <a href="./references#CD003781-bbs2-0066" title="Malone-LeeJG , WalshB , MaugourdMF , Tolterodine in the Elderly Study Group. The safety and clinical efficacy of two doses of tolterodine compared to placebo in elderly patients. In: International Continence Society (ICS), 27th Annual Meeting; 1997 Sep 23-26; Yokohama, Japan. 1997:155-6. [srincont-5855]Malone‐LeeJG , WalshJB , MaugourdMF . Tolterodine: A safe and effective treatment for older patients with overactive bladder. Journal of the American Geriatric Society2001;49(6):700-5. [srincont-12319]WaggA , Malone-LeeJ . Pressure-flow variables in patients treated with tolterodine for detrusor overactivity. BJU International2003;92(9):969-71. [sr-incont16659]">Malone‐Lee 2001</a>; <a href="./references#CD003781-bbs2-0069" title="Drug company. A phase 2, parallel group, stratified, randomized, double blind, placebo-controlled trial to investigate the efficacy and safety of 3 different dosages of sustained release fesoterodine in subjects with overactive bladder showing either involuntary detrusor contractions or normal findings during the baseline urodynamic assessment. Protocol numbers: A0221029 (SP668). ClinicalStudyResults.org (accessed 3 March 2011). [srincont-41111]NittiV , WiatrakM , KreitmanL , LipsitzD . Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB): results of a phase 2 trial (Abstract number 306). In: International Continence Society (ICS); 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21084]">Nitti 2005</a>; <a href="./references#CD003781-bbs2-0074" title="RentzhogSL , StantonL , CardozoL , NelsonE , FallM , AbramsP . Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. British Journal of Urology1998;81(1):42-8. [srincont-5461]">Rentzhog 1998</a>; <a href="./references#CD003781-bbs2-0082" title="ChancellorMB , OefeleinMG , VasavadaS . Obesity is associated with a more severe overactive bladder disease state that is effectively treated with one daily administration of trospium chloride extended release [Erratum available in: Neurourology and Urodynamics 2010;29(5):804]. Neurourology and Urodynamics2010;29(4):551-4. [sr-incont39591]GinsbergDA , OefeleinMG , EllsworthPI . Once-daily administration of trospium chloride extended release provides 24-hour coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials. Neurourology and Urodynamics2011;30(4):563-7. [sr-incont41531]RovnerE , DmochowskiR , WatanabeJ . Once daily (QD) trospium chloride 60mg extended release (XR) is safe and effective in patients (PTS) with the overactive bladder (OAB) syndrome who use multiple concomitant medications (MEDS) (Abstract number: Poster #68). Neurourology and Urodynamics2009;28(2):146-7. [sr-incont31062]SandP , DmochowskiR , ZinnerN , StaskinD . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: results from a multicenter, phase III, placebo-controlled study (Abstract number 269). In: International Continence Society (ICS), 37th Annual Meeting; 2007 Aug 20-24; Rotterdam, the Netherlands. 2007. [sr-incont26676]SandP , StaskinD , ZinnerN , DmochowskiR . Once-daily trospium chloride extended release is effective and well tolerated for the treatment of overactive bladder: results from a multicenter, phase III trial (Abstract number 57). Neurourology and Urodynamics2007;26(5):675. [sr-incont26661]StaskinD , SandP , ZinnerN , DmochowskiR , Trospium Study Group. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. Journal of Urology2007;178(3 Pt 1):978-83; discussion 983-4. [srincont-23909]StaskinDR , RosenbergMT , SandPK , ZinnerNR , DmochowskiRR . Trospium chloride once daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised phase III trials. International Journal of Clinical Practice2009;63(12):1715-23. [sr-incont35458]StaskinDR , SandPK , ZinnerNR . Once-daily trospium chloride extended release is effective and well tolerated for the treatment of overactive bladder: results from a multicenter, phase III trial (Abstract number - poster 22). Neurourology and Urodynamics2007;26(7 Suppl):1106. [srincont-27305]">Staskin 2007</a>; <a href="./references#CD003781-bbs2-0089" title="ThuroffJW , BunkeB , EbnerA , FaberP , deGeeterP , HannappelJ , et al. Randomized, double-blind multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin vs. propantheline vs. placebo. Neurourology and Urodynamics1990;9(4):337-8. [srincont-5108]ThuroffJW , BunkeB , EbnerA , FaberP , deGeeterP , HannappelJ , et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. Journal of Urology1991;145(4):813-7. [srincont-1288]">Thuroff 1991</a>; <a href="./references#CD003781-bbs2-0091" title="MesselinkEJ , SolerJM , MadersbacherH , ThuroffJW , AmarencoG , Van KerrebroeckEV . Urodynamic aspects of the efficacy of tolterodine, a new anti muscarine drug in the treatment of detrusor hyperreflexia. In: International Continence Society (ICS), 25th Annual Meeting; 1995 Oct 17-20; Sydeney, Australia. 1995:95-6. [srincont-10883]Van KerrebroeckPE , AmarencoG , ThüroffJW , MadersbacherHG , LockMT , MesselinkEJ , et al. Dose-ranging study ot tolterodine in patients with detrusor hyperreflexia. Neurourology and Urodynamics1998;17(5):499-512. [srincont-7852]">Van Kerrebroeck 1998</a>; <a href="./references#CD003781-bbs2-0092" title="ChancellorM , FreedmanS , MitchesonHD , AntociJ , PrimusG , WeinA . Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clinical Drug Investigation2000;19(2):83-91. [srincont-16326]FreemanR , HillS , MillardR , SlackM , SutherstJ , Tolterodine Study Group. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstetrics and Gynecology2003;102(3):605-11. [srincont-16494]GarelyA , Tolterodine Study Group. Once-daily tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder. International Urology Journal2001;12(Suppl 1):S18. [srincont-12012]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of life of patients with overactive bladder receiving tolterodine. Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of patients with overactive bladder receiving tolterodine (Abstract number 82). Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , ReesePR . Health related quality of life of patients with overactive bladder receiving tolterodine once-daily. Neurourology and Urodynamics2000;19(4):519-21. [srincont-9987]KelleherCJ , ReesePR , PleilAM , OkanoGJ . Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. American Journal of Managed Care2002;8(Suppl 19):S608-15. [srincont-17998]KelleherCJ , Tolterodine Study Group. Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2000;11(Suppl 1):S94. [srincont-11915]KrederKJ . Antimuscarinic therapy: relationship between efficacy and side effects in responders and non-responders. Journal of Urology2001;165(Suppl 5):S165. [srincont-16327]KrederKJ . Clinical effectiveness of antimuscarinic therapy: the relationship between efficacy and tolerability. In: Proceedings of the International Continence Society Annual Meeting(ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001:140. [srincont-14376]MallettV . Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2001;12(Suppl 1):4. [srincont-12011]MillardRJ , TamaddonK , Tolterodine Study Group. Randomized controlled trial to compare tolterodine prolonged release capsules and tolterodine immediate release tablets versus placebo in patients with symptoms of detrusor overactivity (Abstract number 57). Australian and New Zealand Journal of Surgery2002;Suppl 72:A140. [sr-incont22190]PleilAM , ReesePR , KelleherCJ , OkanoGJ . Health-related quality of life of patients with overactive bladder receiving immediate-release tolterodine. HEPAC Health Economics in Prevention and Care2001;2(2):69-75. [sr-incont18060]RoehrbornCG , AbramsP , RovnerES , KaplanSA , HerschornS , GuanZ . Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU International2006;97(5):1003-6. [sr-incont21882]SwiftS . Efficacy and tolerability of once-daily tolterodine for women with overactive bladder. In: International Continence Society Annual Meeting (ICS), 31st annual meeting; 2001 Sept 18-21; Seoul, Korea. 2001:No. 329. [srincont-14481]SwiftS . Once-daily tolterodine is effective and well tolerated in women with overactive bladder (Abstract 57). In: 2nd International Consultation on Incontinence; 2001 July 1-3; Paris, France. 2001. [srincont-16319]SwiftSE . Once-daily (OD) tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder (OAB). International Urogynecology Journal2000;11(Suppl 1):S15. [sr-incont11906]SwiftSE . Once-daily administration of extended-release tolterodine is effective and well-tolerated in patients with overactive bladder. In: XVI FIGO World Congress of Obstetrics and Gynecology; 2000 Sept 3-8; Washington DC. Vol. Book 1. 2000:40. [sr-incont12085]SwiftSE . Overactive bladder in females: treatment with once-daily tolterodine. International Urogynecology Journal2001;12(Suppl 3):S71. [sr-incont16328]Van KerrebroeckP , KrederK , JonasU , ZinnerN . Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology2001;57(3):414-21. [sr-incont11953]Van KerrebroeckPEV . Long-term (12 months) efficacy and tolerability of tolterodine once-daily in the treatment of overactive bladder. Neurourology and Urodynamics2001;20(4):401-2. [sr-incont15714]Van KerrebroeckPEVA , Tolterodine Study Group. Long-term tolerability and efficacy of once-daily (OD) tolterodine in the treatment of overactive bladder (OB). International Urogynecology Journal2001;12(Suppl 3):S49. [sr-incont16329]Van KerrebroeckPEVA , Tolterodine Study Group. Significant decreases in perception of urgency and urge incontinence episodes with once-daily tolterodine treatment in patients with overactive bladder (Abstract number 89). Neurourology and Urodynamics2000;19(4):493-4. [sr-incont9980]WeinAJ , KhullarV , WangJT , GuanZ . Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. BJU International2007;99(2):360-3. [sr-incont23180]vanKerrebroeckPE , KelleherCJ , CoyneKS , KoppZ , BrodskyM , WangJT . Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. Health and Quality of Life Outcomes2009;7(13):13. [10.1186/1477-7525-7-13] [sr-incont31438]vanKerrebroeckPE , WangJ , GuanZ . Effects of tolterodine extended release in patients with overactive bladder: perceived treatment benefits improve with efficacy (Abstract number 511). European Urology Supplements2004;3(2):130. [sr-incont31090]">Van Kerrebroeck 2001</a>; <a href="./references#CD003781-bbs2-0093" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CrosbyRD , MathiasSD , MarshallTS . Relationships between symptoms, symptom bother, and health-related quality of life in patients with overactive bladder taking solifenacin or placebo in the VIBRANT study. International Journal of Clinical Practice2011;65(2):211-8. [sr-incont41015]GollarKM , YoungDG , BailenJ , HeW , Forero-SchwanhaeuserS . Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: a secondary analysis of the VIBRANT study. Urologic Nursing2012;32(1):38-46. [TrialID.VIBRANT.] [sr-incont44571]Samuels T‐A, MitchesonHD , VardyM , Forero‐SchwanhaeuserS , MarshallT , HeW . Efficacy of solifenacin for symptom bother and other patient-reported outcomes in patients with overactive bladder (OAB): results of a large, double-blind, placebo-controlled trial (Abstract number: poster #74). Neurourology and Urodynamics2009;28(2):149. [sr-incont31063]VardyMD , MitchesonHD , SamuelsTA , Forero-SchwanhaeuserS , HeW . Efficacy of solifenacin on overactive bladder symptoms, symptom bother, and other patient-reported outcomes in subjects with or without incontinence: a post hoc analysis of data from VIBRANT. Female Pelvic Medicine and Reconstructive Surgery2011;17(1):24-9. [TrialID.VIBRANT.] [sr-incont44741]VardyMD , MitchesonHD , SamuelsTA , WegenkeJD , Forero-SchwanhaeuserS , MarshallTS , et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. International Journal of Clinical Practice2009;63(12):1702-14. [905-UC-010] [NCT00573508] [TrialID.VIBRANT.] [sr-incont35459]">Vardy 2009</a>; <a href="./references#CD003781-bbs2-0096" title="YamaguchiO , MaruiE , KakizakiH , ItohN , YokotaT , OkadaH , et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU International2007;100(3):579-87. [sr-incont23865]YokoyamaO , YamaguchiO , KakizakiH , ItohN , YokotaT , OkadaH , et al. Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary. Journal of Urology2011;186(1):170-4. [sr-incont41734]">Yamaguchi 2007</a>; <a href="./references#CD003781-bbs2-0102" title="ZinnerNR , MattiassonA , StantonSL . Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. Journal of the American Geriatrics Society2002;50(5):799-807. [sr-incont14679]">Zinner 2002</a>). Participants taking anticholinergic drugs are 58% more likely to experience blurred vision adverse event than participants in the placebo group (RR 1.58, 95% CI 1.26 to 1.99; P &lt; 0.0001; <a href="./references#CD003781-fig-0016" title="">Analysis 1.7</a>). </p> </section> <section id="CD003781-sec-0080"> <h5 class="title">Adverse events: constipation</h5> <p>Fifty‐three studies were included in the analysis that reported on constipation, with a total of 37,317 participants (24,756 in the anticholinergic group and 12,561 in the placebo group) (<a href="./references#CD003781-bbs2-0004" title="AbramsP , KelleherC , StaskinD , KayR , MartanA , MincikI , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World Journal of Urology2017;35(5):827-38. [NCT01340027] [sr-incont77897]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Cardiovascular safety of combination treatment with mirabegron and solifenacin in patients with overactive bladder in a randomised, double-blind, dose-ranging, Phase II study (Symphony) (Abstract). European Urology, Supplements2014;13(1):e574-e574a. [NCT01340027] [sr-incont67160]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB) - efficacy and safety results from a randomised phase II study (Symphony) (Abstract number 295). Neurourology and Urodynamics2013;32(6):930-1. [NCT01340027] [TrialID.SYMPHONY.] [sr-incont49188]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB): safety results from a phase 2 study (Abstract number MP-16.08). Urology2013;82(3 Suppl 1):S139. [NCT01340027] [sr-incont66675]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: Exploratory responder analyses of efficacy and evaluation of patient reported outcomes from a randomised, double-blind, dose-ranging, phase 2 study (Symphony) (Abstract number MP-24.11). Urology2014;84(4 Suppl 1):S145-6. [NCT01340027] [sr-incont67194]AbramsP , KelleherC , StaskinD , RechbergerT , KayR , MartinaR , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (SYMPHONY). European Urology2015;67(3):577-88. [NCT01340027] [sr-incont66674]NCT01340027, Bristol Urological Institute . A study to evaluate the efficacy, safety and tolerability of mirabegron and solifenacin succinate alone and in combination for the treatment of overactive bladder (symphony) [A randomized, double-blind, factorial, parallel-group, active and placebo-controlled, multicenter dose-ranging study to evaluate the efficacy, safety and tolerability of six dose combinations of solifenacin succinate and mirabegron compared to mirabegron and solifenacin succinate monotherapies in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01340027 (first received 21 April 2011). [178-CL-100] [2010-020601-32] [NCT01340027] [TrialID.SYMPHONY] [sr-incont44510]NittiV , AbramsP , StaskinD , AuerbachS , MartinaR , VanMR . Urinary retention in patients with overactive bladder treated with mirabegron alone and in combination with solifenacin: the results of two randomized, double-blind, phase II studies (Abstract number MP76-13). Journal of Urology2014;191(4 Suppl 1):e886-7. [NCT00410514] [NCT01340027] [TrialID.SYMPHONY] [sr-incont67453]">Abrams 2013</a>; <a href="./references#CD003781-bbs2-0008" title="BurgioKL , LocherJL , GoodePS , HardinJM , McDowellBJ , CandibD . Behavior vs drug therapy for urge incontinence in older women (Abstract number 26). In: American Urogynecology Society, 15th Annual Scientific Meeting; 1994 Sept 21-24; Toronto, Ontario. 1994:48. [sr-incont14585]BurgioKL , LocherJL , GoodePS , HardinM , McDowellBJ , Dombrowski M et al. Behavioral vs drug treatment for urge urinary incontinence in older women. A randomized controlled trial. JAMA1998;280(23):1995-2000. [srincont-5719]BurgioKL , LocherJL , GoodePS . Combined behavioral and drug therapy for urge incontinence in older women. Journal of the American Geriatrics Society2000;48(4):370-4. [srincont-9006]BurgioKL , LocherJL , RothDL , GoodePS . Psychological improvements associated with behavioral and drug treatment of urge incontinence in older women. Journal of Gerontology. Series B, Psychological Sciences and Social Sciences2001;56(1):P46-51. [srincont-11923]">Burgio 1998</a>; <a href="./references#CD003781-bbs2-0010" title="CardozoL , KuzminI , LisecML , MillardR , vanVierssen TripOB , RidderAM , et al. YM905: Results of a randomised, double-blind placebo-controlled trial in patients with symptomatic overactive bladder (Abstract number 104). European Urology Supplements2003;2(1):28. [sr-incont27407]CardozoL , KuzminI , LisecML , MillardRJ , vanVierssen TripOB , RidderAM , et al. A double-blind, randomised, placebo-controlled trial with YM905 in symptomatic overactive bladder (Abstract number P74). Journal of the American Geriatrics Society2003;51 (Suppl 4):S68-9. [sr-incont31100]CardozoL , LisecM , MillardR , vanVierssen TripO , KuzminI , DrogendijkTE , et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. Journal of Urology2004;172(5 (Pt 1 of 2)):1919-24. [srincont-19090]CardozoL . A randomised double-blind, placebo-controlled trial of the once-daily muscarinic receptor antagonist solifenacin succinate for symptoms of overactive bladder (Abstract number 211). International Urogynecology Journal2003;14 (Suppl 1):S64. [sr-incont31104]CardozoL . Solifenacin succinate improves symptoms of an overactive bladder (Abstract number TP77). International Journal of Gynecology and Obstetrics2003;83(Suppl 3):94. [sr-incont31096]KelleherCJ , CardozoL , ChappleCR , HaabF , RidderAM . Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU International2005;95(1):81-5. [srincont-20241]">Cardozo 2004a</a>; <a href="./references#CD003781-bbs2-0011" title="CardozoL , AdamikZ , GuimaraesM , KrhutJ , Labat J-J, PetrovS , et al. Patients with overactive bladder show progressive improvement in urgency and bladder condition during treatment with solifenacin in a randomised, double-blind, placebo-controlled study (SUNRISE) (Abstract number 115). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S67-8. [srincont-26595]CardozoL , AmarencoG , PushkarD , MikulasJ , DrogendijkT , WrightM , et al. Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE). BJU International2013;111(5):804-10. [NCT00801944] [TrialID.SUNRISE.] [sr-incont47554]CardozoL , DewildeT , FeyereislJ , WadieB , AmarencoG , LiapisA , et al. Solifenacin significantly reduces both urgency severity and bother: results from the flexible dose, placebo controlled, multinational SUNRISE study (Abstract number 281). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26641]CardozoL , DrogendijkT , BolodeokuJ . The efficacy of solifenacin 5/10 mg on 'urgency' endpoints in different OAB patient populations: subanalysis of results from the randomised, double-blind SUNRISE study (Abstract number 192). In: International Continence Society (ICS); 38th Annual Meeting; 2008 Oct 20-24; Cairo, Egypt. 2008. [srincont-31885]CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CardozoL , HessdörferE , MilaniR , ArañóP , DewildeL , SlackM , et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU International2008;102(9):1120-7. [NCT00801944] [TrialID.SUNRISE] [srincont-29249]">Cardozo 2008a</a>; <a href="./references#CD003781-bbs2-0013" title="ChappleC . Fesoterodine a new effective and well-tolerated antimuscarinic for the treatment of urgency-frequency syndrome: results of a phase 2 controlled study (Abstract 142). Neurourology and Urodynamics2004;23(5/6):598-9. [srincont-19023]Drug company. A Phase 2, parallel group, randomized, double-blind, placebo controlled dose-ranging trial to determine the optimal dose and the tolerability of sustained release SPM 8272 (fesoterodine) in subjects with non-neurogenic bladder overactivity. Protocol numbers: A0221027 (SP582). ClinicalStudyResults.org (accessed 3 March 2011)2002. [Protocol numbers: A0221027 (SP582)] [srincont-41110]">Chapple 2004a</a>; <a href="./references#CD003781-bbs2-0014" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. ChappleCR , AranoP , BoschJH , De RidderD , KramerG , RidderAM . YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo- and tolterodine-controlled, phase-II, dose-finding study (Abstract 75). Neurourology and Urodynamics2002;21(4):381-2. [srincont-14551]ChappleCR , ArañoP , BoschJL , De RidderD , KramerAE , RidderAM . Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU International2004;93(1):71-7. [srincont-17334]KelleherCJ , CardozoL , ChappleCR , HaabF , RidderAM . Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU International2005;95(1):81-5. [srincont-20241]SmithN , GrimesI , RidgeS , TempelD , UchidaT , YamanouchiUS . YM905 is effective and safe as treatment of overactive bladder in women and men: results from phase II study (Abstract). In: International Continence Society (ICS), 32nd Annual Meeting; 2002 Aug 28-30; Heidelberg, Germany. 2002:138-9. [sr-incont14508]">Chapple 2004b</a>; <a href="./references#CD003781-bbs2-0015" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. ChappleC , RechbergerT , Al-ShukriS , MeffanP , EveraertK , RidderA . Results of a randomized phase 3 study comparing solifenacin succinate with tolterodine and placebo in patients with symptomatic overactive bladder (Abstract). Neurourology and Urodynamics2003;22(5):534-5. [sr-incont16991]ChappleCR , RechbergerT , Al ShukriS , MeffanP , EveraertK , HuangM , et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU International2004;93(3):303-10. [srincont-17270]">Chapple 2004c</a>; <a href="./references#CD003781-bbs2-0016" title="ChappleC , Van KerrebroeckP , TubaroA , Haag-MolkentellerC , ForstHT , MassowU , et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder [Erratum appears in: European Urology 2008,53(6):1319]. European Urology2007;52(4):1204-12. [NCT00220363] [SP583] [srincont-23875]ChappleC , Van KerrebroeckP , TubaroA , MillardR . Fesoterodine in non-neurogenic voiding dysfunction - results on efficacy and safety in a phase 3 trial (Abstract number 379). In: 21st Annual European Association of Urology (EAU) Congress; 2006 Apr 5-8; Paris, France. 2006. [srincont-41109]ChappleC , Van KerrebroeckP , TubaroA , WangJT , HvidstenK , BrodskyM . Efficacy of fesoterodine in patients with overactive bladder (OAB): improvements in OAB symptoms and health-related quality of life (HRQL) (Poster abstract number 1188). Journal of Urology2007;177(4 Suppl S):392. [srincont-31882]ChappleCR , vanKerrebroeckPE , JünemannKP , WangJT , BrodskyM . Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU International2008;102(9):1128-32. [srincont-29255]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. KelleherCJ , TubaroA , WangJT , KoppZ . Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU International2008;102(1):56-61. [srincont-27613]SandPK , MorrowJD , BavendamT , CreangaDL , NittiVW . Efficacy and tolerability of fesoterodine in women with overactive bladder. International Urogynecology Journal2009;20(7):827-35. [srincont-31351]">Chapple 2007a</a>; <a href="./references#CD003781-bbs2-0017" title="ChappleC , DuBeauC , EbingerU , RekedaL , ViegasA . Darifenacin treatment of patients &gt;or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Current Medical Research and Opinion2007;23(10):2347-58. [srincont-23921]">Chapple 2007b</a>; <a href="./references#CD003781-bbs2-0019" title="ChappleC , HaabF , SchneiderT , CarlssonM , ArumiD . Fesoterodine 8 mg versus fesoterodine 4 mg in patients with overactive bladder and a history of previous antimuscarinic therapy: Results from the EIGHT trial (Abstract number: Poster #M5). Neurourology and Urodynamics2015;34(S1):S20. [NCT01302067] [sr-incont68509]ChappleC , SchneiderT , HaabF , SunF , WhelanL , ScholfieldD , et al. Superiority of fesoterodine 8mg versus fesoterodine 4 mg in reducing urgency urinary incontinence episodes in subjects with overactive bladder: results of the randomized, double-blind, placebo-controlled EIGHT trial (Abstract number: Podium #48). Neurourology and Urodynamics2014;33(2):183-4. [NCT01302067] [sr-incont67484]ChappleC , SchneiderT , HaabF , SunF , WhelanL , ScholfieldD , et al. Superiority of fesoterodine 8mg vs 4mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial. BJU International2014;114(3):418-26. [A0221095] [NCT01302067] [TrialID.EIGHT] [srincont-62537]NCT01302067. A 12 week study to confirm the effectiveness of 8mg of Fesoterodine compared to 4mg of Fesoterodine [A 12-week, randomized, double-blind, placebo controlled, parallel group, multicenter trial in overactive bladder subjects to confirm the efficacy of 8 mg fesoterodine compared to 4 mg fesoterodine]. clinicaltrials.gov/show/NCT01302067 (first received 23 February 2011). [NCT01302067] [sr-incont63792]">Chapple 2014</a>; <a href="./references#CD003781-bbs2-0021" title="ChuaME , SeeMC , EsmeňaEB , BalingitJC , MoralesML . Efficacy and safety of gabapentin in comparison to solifenacin succinate in adult overactive bladder treatment. Lower Urinary Tract Symptoms2018;10(2):135-42. [NCT01486706] [sr-incont74529]NCT01486706, ChuaME . Efficacy and safety of gabapentin in treating overactive bladder (OAB). clinicaltrials.gov/show/NCT01486706 (first received 6 December 2011). [NCT01486706] [SLMC10-010] [sr-incont49864]">Chua 2018</a>; <a href="./references#CD003781-bbs2-0023" title="ChancellorMB , OefeleinMG , VasavadaS . Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release. Neurourology and Urodynamics2010;29(4):551-4. [sr-incont39591]DmochowskiR , StaskinD , SandP , ZinnerN . Trospium chloride 60 mg once daily improves quality of life in subjects with overactive bladder syndrome (Abstract number 277). In: International Continence Society (ICS); 37th Annual Meeting; 2008 Aug 20-24; Rotterdam, the Netherlands. 2007. [srincont-26679]DmochowskiRR , RosenbergMT , ZinnerNR , StaskinDR , SandPK . Extended-release trospium chloride improves quality of life in overactive bladder. Value in Health2010;13(2):251-7. [srincont-40049]DmochowskiRR , SandPK , ZinnerNR , StaskinDR . Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology2008;71(3):449-54. [srincont-27107]DmochowskiRR , ZinnerNR , SandPK . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: Results from a multicenter, phase III, placebo-controlled study (Abstract). Neurourology and Urodynamics2007;26(Suppl 7):1105-6. [srincont-26692]GinsbergDA , OefeleinMG , EllsworthPI . Once-daily administration of trospium chloride extended release provides 24-hr coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials. Neurourology and Urodynamics2011;30(4):563-7. [sr-incont41531]RovnerE , DmochowskiR , WatanabeJ . Once daily (QD) trospium chloride 60 mg extended release (XR) is safe and effective in patients (PTS) with the overactive bladder (OAB) syndrome who use multiple concomitant medications (MEDS) (Abstract number: Poster #68). Neurourology and Urodynamics2009;28(2):146-7. [sr-incont31062]SandP , DmochowskiR , ZinnerN , StaskinD . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: results from a multicenter, phase III, placebo-controlled study (Abstract number 269). In: International Continence Society (ICS), 37th Annual Meeting; 2007 Aug 20-24; Rotterdam, the Netherlands. 2007. [srincont-26676]SandPK , DmochowskiRR , ZinnerNR , StaskinDR , AppellRA . Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome. International Urogynecology Journal and Pelvic Floor Dysfunction2009;20(12):1431-8. [sr-incont39648]SandPK , Johnson IiTM , RovnerES , EllsworthPI , OefeleinMG , StaskinDR . Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged &gt; 75 years) with overactive bladder syndrome. BJU International2011;107(4):612-20. [sr-incont41422]StaskinDR , RosenbergMT , SandPK , ZinnerNR , DmochowskiRR . Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials. International Journal of Clinical Practice2009;63(12):1715-23. [sr-incont35458]">Dmochowski 2008</a>; <a href="./references#CD003781-bbs2-0024" title="DmochowskiR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. A double-blind, placebo-controlled trial of flexible-dose fesoterodine for overactive bladder (Abstract number 715). In: International Continence Society (ICS); 39th Annual Meeting; 2009 Sep 29-Oct 03; San Francisco, CA. 2009. [sr-incont35627]DmochowskiRR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder [Errata appear in: Urology 2010 Jun;75(6):1519 and in Urology 2011 Jun;77(6):1513]. Urology2010;75(1):62-8. [A0221014] [NCT00536484] [sr-incont39548]DuBeauC , KrausSR , SunF , MorrowJD . Fesoterodine in older vs younger subjects with overactive bladder (Abstract number D87). Journal of the American Geriatrics Society2010;58:S218. [NCT00536484] [sr-incont64309]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. [sr-incont78640]NCT00536484. Fesoterodine flexible dose study [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with overactive bladder]. clinicaltrials.gov/show/NCT00536484 (first received 27 September 2007). [NCT00536484] [sr-incont49160]StaskinD , KhullarV , MichelMC , MorrowJD , SunF , GuanZ , et al. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. Neurourology and Urodynamics2011;30(8):1480-5. [sr-incont42686]">Dmochowski 2010</a>; <a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>; <a href="./references#CD003781-bbs2-0033" title="GotohM , HommaY , YokoyamaO , NishizawaO . Responsiveness and minimal clinically important change in overactive bladder symptom score. Urology2011;78(4):768-73. [srincont-42622]GotohM , YokoyamaO , MatsukawaY , NishizawaO . Responsiveness of overactive bladder symptom score (OABSS): verification based on data in a double-blinded, randomized placebo-controlled study of propiverine hydrochloride in Japanese patients (Abstract number 338). In: Joint Meeting of the International Continence Society (ICS) and the International Urogynecological Association; 2010 Aug 23-27; Toronto, Canada. 2010. [srincont-40173]GotohM , YokoyamaO , NishizawaO . Propiverine hydrochloride in Japanese patients with overactive bladder: A randomized, double-blind, placebo-controlled trial. International Journal of Urology2011;18(5):365-73. [srincont-41510]">Gotoh 2011</a>; <a href="./references#CD003781-bbs2-0035" title="HaabF , StewartL , DwyerP . Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. European Urology2004;45(4):420-9. [srincont-17428]">Haab 2004</a>; <a href="./references#CD003781-bbs2-0038" title="HerschornS , HeesakkersJ , Castro-DiazD , WangJT , BrodskyM , GuanZ . Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*. Current Medical Research and Opinion2008;24(12):3513-21. [A6121122] [NCT00143377] [srincont-29250]HerschornS , HeesakkersJ , Castro-DiazD , WangJT , GuanZ , BrodskyM . Tolterodine extended release (TER) improves objective and subjective outcomes after 1 week of treatment in patients with overactive bladder (Abstract number 132). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S78-9. [srincont-26602]">Herschorn 2008</a>; <a href="./references#CD003781-bbs2-0039" title="CorcosJ , AnguloJC , GarelyAD , CarlssonM , GongJ , GuanZ . Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. Current Medical Research and Opinion2011;27(5):1059-65. [srincont-41596]EUCTR2006-006935-38-SE. 12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006935-38 (first received 16 April 2007). [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont64612]HerschornS , SwiftS , GuanZ , CarlssonM , BrodskyM , GongJ . Efficacy and safety of fesoterodine for overactive bladder in a double-blind, head-to-head comparison trial with tolterodine ER and placebo (Abstract number 710). In: International Continence Society (ICS), 39th Annual Meeting; 2009 Sep 29-Oct 3; San Francisco, CA. 2009. [srincont-35326]HerschornS , SwiftS , GuanZ , CarlssonM , MorrowJD , BrodskyM , et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU International2010;105(1):58-66. [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont39540]NCT00444925. Clinical trial to evaluate the efficacy and safety of Fesoterodine in comparison to Tolterodine for overactive bladder (OAB) [12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder (OAB)]. clinicaltrials.gov/show/NCT00444925 (first received 08 March 2007). [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont49159]">Herschorn 2009a</a>; <a href="./references#CD003781-bbs2-0040" title="EUCTR2012-005735-91-SK. A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-005735-91 (first received 12 November 2013). [178-CL-101] [EUCTR2012-005735-91-SK] [sr-incont78644]HerschornS , ChappleCR , AbramsP , ArlandisS , MitchesonD , LeeKS , et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU International2017;120(4):562-75. [NCT01972841] [sr-incont74470]MuellerER , RobinsonD , KelleherC , StaskinDR , FalconerC , WangJ , et al. Patient reported outcomes from synergy, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with mirabegron and solifenacin monotherapy (Abstract number - Podium #44). Neurourology and Urodynamics2017;36(Suppl S1):S151-2. [NCT01972841] [sr-incont75944]NCT01972841. This was a multinational study comparing the efficacy and safety of two medicines, solifenacin succinate and mirabegron taken together, or separately, or a mock treatment (placebo) in subjects with symptoms of overactive bladder (SYNERGY) [A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01972841 (first received 31 October 2013). [178-CL-101] [EUCTR2012-005735-91] [NCT01972841] [sr-incont63780]RobinsonD , KelleherC , StaskinD , MuellerER , FalconerC , WangJ , et al. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients. Neurourology and Urodynamics2018;37(1):394-406. [NCT01972841] [sr-incont76906]WeberMA , ChappleCR , GratzkeC , HerschornS , RobinsonD , FrankelJM , et al. A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial. Blood Pressure Monitoring2018;23(3):153-63. [NCT01972841] [sr-incont77899]WhiteWB , ChappleC , GratzkeC , HerschornS , RobinsonD , FrankelJ , et al. Cardiovascular safety of the beta3-adrenoceptor agonist mirabegron and the antimuscarinic agent solifenacin in the SYNERGY trial. Journal of Clinical Pharmacology2018;58(8):1084-91. [NCT01972841] [sr-incont78078]">Herschorn 2017a</a>; <a href="./references#CD003781-bbs2-0042" title="HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21072]HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21072]HillS , KhullarV , WyndaeleJJ , LheritierK , . Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. International Urogynecology Journal and Pelvic Floor2006;17(3):239-47. [srincont-22464]">Hill 2005</a>; <a href="./references#CD003781-bbs2-0043" title="HommaY , KawabeK . Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World Journal of Urology2004;22(4):251-6. [srincont-19412]HommaY , PaickJS , LeeJG , KawabeK , Japanese and Korean Tolterodine Study Group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU International2003;92(7):741-7. [srincont-16418]">Homma 2003</a>; <a href="./references#CD003781-bbs2-0044" title="HommaY , YamaguchiT , YamaguchiOA . A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2008;15(9):809-15. [srincont-27742]">Homma 2008</a>; <a href="./references#CD003781-bbs2-0045" title="HommaY , YamaguchiO , Imidafenacin Study Group. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2009;16(5):499-506. [NCT00212732] [ONO-8025-08] [srincont-31368]">Homma 2009</a>; <a href="./references#CD003781-bbs2-0047" title="JacquetinB , WyndaeleJJ . Tolterodine reduces the number of incontinence episodes in patients with an overactive bladder. European Journal of Obstetrics and Gynecology and Reproductive Biology2001;98(1):97-102. [srincont-12200]JacquetinB , WyndaeleJJ . Tolterodine reduces the number of incontinence episodes in patients with detrusor overactivity. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(1):S30. [srincont-5167]">Jacquetin 2001</a>; <a href="./references#CD003781-bbs2-0048" title="JonasU , HofnerK , MadersbacherH , HolmdahlTH . Efficacy and safety of two doses of Tolterodine compared to placebo in patients with detrusor overactivity. Neurourology and Urodynamics1997;16(5):477-8. [srincont-5841]JonasU , HöfnerK , MadersbacherH , HolmdahlTH . Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group. World Journal of Urology1997;15(2):144-51. [srincont-5436]">Jonas 1997</a>; <a href="./references#CD003781-bbs2-0050" title="JünemannKP , HessdörferE , Unamba‐OparahI , BerseM , BrünjesR , MadersbacherH . Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. Urologia Internationalis2006;77(4):334-9. [srincont-22199]">Junemann 2006</a>; <a href="./references#CD003781-bbs2-0051" title="EUCTR2007-006451-39-SE. 12-week, randomized, double-blind, double-dummy, placebo controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-006451-39 (first received 20 February 2008). [A0221046] [EUCTR2007-006451-39-SE] [sr-incont64591]KaplanSA , SchneiderT , FooteJ , GuanZ . Superior efficacy of fesoterodine over tolterodine with rapid onset: a prospective, head-to-head, placebo-controlled trial (Abstract number 67). Neurourology and Urodynamics2010;29(6):905-7. [srincont-40130]KaplanSA , SchneiderT , FooteJE , GuanZ , CarlssonM , GongJ . Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU International2011;107(9):1432-40. [A0221046] [NCT00611026] [srincont-41334]">Kaplan 2011</a>; <a href="./references#CD003781-bbs2-0052" title="CardozoL , KaplanS , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: results from the after study (Abstract number 740) [Erratum appears in: European Urology 2014;65(5):e78]. European Urology Supplements2013;12(1):e740-1. [NCT01302054] [sr-incont63732]CardozoL , KaplanS , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. Erratum: A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: results from the AFTER study [Erratum available in: European Urology Supplement 2013;2012:e740-1]. European Urology2014;65(5):e78 . [A0221094] [NCT01302054] [TrialID.AFTER.] [sr-incont61642]GrenaboL , HerschornS , KaplanSA , CardozoL , ScholfieldD , ArumiD , et al. Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptoms. Current Medical Research and Opinion2017;33(10):1731-6. [NCT01302054] [TrialID.AFTER.] [sr-incont76695]KaplanSA , CardozoL , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER. International Journal of Clinical Practice2014;68(9):1065-73. [A0221094] [NCT01302054] [TrialID.AFTER.] [srincont-63977]KaplanSA , HerschornS , CarlssonM , NtaniosF . Urgency urinary incontinence response rates in subjects with overactive bladder treated with fesoterodine 8 mg after suboptimal response to tolterodine extended release 4 mg: a randomized, double-blind, placebo-controlled trial (Abstract number 546). In: International Continence Society (ICS); 43rd Annual Meeting; 2013 Aug 26-30; Barcelona, Spain. 2013. [NCT01302054] [TrialID.AFTER.] [sr-incont49730]NCT01302054. A clinical study in patients with overactive bladder with leakage of urine, to find out if the medicine, Fesoterodine, works in those patients who did not have enough response to the medicine, tolterodine. [A 14 week randomized parallel group placebo-controlled double-blind multicentre study of fesoterodine 8 mg in overactive bladder patients with sub-optimal response to tolterodine 4 mg extended release (ER)]. clinicaltrials.gov/show/NCT01302054 (first received 23 February 2011). [A0221094] [NCT01302054] [TrialID.AFTER.] [sr-incont49845]">Kaplan 2014</a>; <a href="./references#CD003781-bbs2-0053" title="CapoJP , TogliaM , Forero-SchwanhaeuserS , HeW . Patients reporting severe overactive bladder symptoms: effects of solifenacin treatment on objective measures and patient-reported outcomes (Abstract number 582). In: International Continence Society (ICS), 38th Annual Meeting; 2008 Oct 20-24; Cairo, Egypt. 2008. [srincont-31844]CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. KarramMM , TogliaMR , SerelsSR , AndohM , FakhouryA , Forero-SchwanhaeuserS . Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology2009;73(1):14-8. [A0221094] [NCT00454896] [TrialID.VENUS.] [srincont-29219]SerelsSR , TogliaMR , Forero-SchwanhaeuserS , HeW . Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms. Current Medical Research and Opinion2010;26(10):2277-85. [srincont-40376]StaskinD , DmochowskiR , SerelsS , AndohM , SmithN . Report from a randomized, placebo-controlled study showing significant improvement in urgency and patient-reported outcomes in overactive bladder patients treated with solifenacin (Abstract number 124). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73-4. [srincont-26600]TogliaM , AndohM , HussainI . Solifenacin improved warning time significantly compared to placebo in patients with overactive bladder (Abstract number 123). Neurourology and Urodynamics2006;25(6):655. [srincont-26629]TogliaM , AndohM , HussainI . Solifenacin improves urgency symtoms as assessed by voiding diaries and patient-reported outcomes (PRO) in patients with overactive bladder (Abstract number 155). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26636]TogliaMR , OstergardDR , AppellRA , AndohM , FakhouryA , HussainIF . Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status. International Urogynecology Journal2010;21(7):847-54. [srincont-40094]TogliaMR , SerelsSR , LarameeC , KarramMM , NandyIM , AndohM , et al. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial. Postgraduate Medicine2009;121(5):151-8. [srincont-34204]ZinnerS , HerschornS , AndohM , HussainI . Responder analyses show statistically significant improvements in incontinence and urgency are associated with reduction in symptom bother and improvement in health-related quality of life: VENUS results (Abstract number 123). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73. [srincont-26599]">Karram 2009</a>; <a href="./references#CD003781-bbs2-0054" title="KhullarV , HillS , LavalKU , SchiotzHA , JonasU , VersiE . Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology2004;64(2):269-74; discussion 274-5. [srincont-19498]KhullarV , HillS , SolankiJ . Assessment of health-related quality of life in patients with overactive bladder taking tolterodine extended release versus placebo (Abstract number 318). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21075]">Khullar 2004</a>; <a href="./references#CD003781-bbs2-0060" title="HsiaoSM , ChangTC , ChenCH , WuWY , LinHH . Comparisons of the clinical outcomes and urodynamic effects of mirabegron versus tolterodine treatment for female overactive bladder syndrome: a subgroup analysis of a controlled, randomised, prospective study. Lower Urinary Tract Symptoms2018;10(3):215-20. [NCT01043666] [sr-incont74461]KuoHC , LeeKS , NaY , SoodR , NakajiS , KubotaY , et al. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourology and Urodynamics2015;34(7):685-92. [NCT01043666] [sr-incont68095]Kuo H‐C, Lin H‐H, Yu H‐J, Cheng C‐L, Hung M‐J, LinAT . Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials [Erratum available in: Urological Science 2015;26(2):148]. Urological Science2015;26(1):41-8 . [NCT01043666] [sr-incont68645]NCT01043666. A study of YM178 in subjects with symptoms of overactive bladder  [Phase III study of YM178: a randomized, double-blind, parallel group, placebo and active controlled, multi-center study in subjects with symptoms of overactive bladder]. clinicaltrials.gov/show/NCT01043666 (first received 07 January 2010). [178-CL-090] [NCT01043666] [sr-incont63781]">Kuo 2015</a>; <a href="./references#CD003781-bbs2-0063" title="LeeKS , ChooMS , KimDY , KimJC , KimHJ , MinKS , et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. Journal of Urology2005;174(4 Pt 1):1334-8. [sr-incont21016]LeeKS , ChooMS , PaickJS , LeeJG , SeoJT , LeeJZ , et al. Propiverine hydrochloride reduced frequency and perception of urgency in treatment of overactive bladder: a 12 week prospective, randomized, double blind, placebo controlled study (Abstract number 279). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26640]LeeKS , LeeHW , ChooMS , PaickJS , LeeJG , SeoJT , et al. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'. BJU International2010;105(11):1565-70. [2005-01-08] [NCT00903045] [PROUD] [sr-incont39958]NCT00903045. Urinary urgency outcomes following propiverine treatment for an overactive bladder [Urinary urgency outcomes following propiverine treatment for an overactive bladder: propiverine study on overactive bladder including urgency data (PROUD)]. clinicaltrials.gov/show/NCT009030452005;(first received 15 May 2009). [2005-01-08] [NCT00903045] [TrialID.PROUD] [sr-incont49860]">Lee 2006</a>; <a href="./references#CD003781-bbs2-0066" title="Malone-LeeJG , WalshB , MaugourdMF , Tolterodine in the Elderly Study Group. The safety and clinical efficacy of two doses of tolterodine compared to placebo in elderly patients. In: International Continence Society (ICS), 27th Annual Meeting; 1997 Sep 23-26; Yokohama, Japan. 1997:155-6. [srincont-5855]Malone‐LeeJG , WalshJB , MaugourdMF . Tolterodine: A safe and effective treatment for older patients with overactive bladder. Journal of the American Geriatric Society2001;49(6):700-5. [srincont-12319]WaggA , Malone-LeeJ . Pressure-flow variables in patients treated with tolterodine for detrusor overactivity. BJU International2003;92(9):969-71. [sr-incont16659]">Malone‐Lee 2001</a>; <a href="./references#CD003781-bbs2-0068" title="DmochowskiR , MitchesonD , FrenklT , BennettN , MuddPN . Durable efficacy and safety of long-term once-daily vibegron, a novel oral B-3 adrenergic receptor agonist: A 52-week phase 2 study in patients with overactive bladder syndrome (Abstract number PD50-03). Journal of Urology2018;199(4):e970-1. [sr-incont78091]EUCTR2010-022121-15-IT. A phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2 part clinical study of the efficacy and safety of MK-4618 in patients with overactive bladder - MK4618-008 [A 52-week extension to: a phase iib randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder]. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-022121-15 (first received 12 April 2011). [EUCTR2010-022121-15-IT] [MK4618-008] [NCT01314872] [sr-incont78639]MitchesonD , FrenklT , SamantaS , Anne PintoC , GreenS , BennettN , et al. Vibegron, a novel once daily oral beta-3 agonist, significantly reduces average daily micturitions, urge incontinence episodes and urgency episodes in patients with overactive bladder (Abstract number: podium #34). Neurourology and Urodynamics2018;37(Suppl 1):S565. [EUCTR2010-022121-15-IT] [NCT01314872] [sr-incont78618]MitchesonD , PintoCA , FrenklT , ChenL , PrasadM , MuddPN . Once daily vibegron improves quality of life measures in patients with overactive bladder (Abstract number PUK17). Value in Health2018;21(Suppl 1):S267-8. [EUCTR2010-022121-15-IT] [NCT01314872;] [sr-incont78619]MitchesonHD , SamantaS , MuldowneyK , PintoCA , RochaBA , GreenS , et al. Vibegron (RVT-901/MK-4618/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial. European Urology2019;75(2):274-82. [NCT01314872] [sr-incont78620]NCT01314872. A study of the efficacy and safety of Vibegron (MK-4618) in participants with overactive bladder (OAB) (MK-4618-008) [A phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder a 52-week extension to: a phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder]. clinicaltrials.gov/show/NCT01314872 (first received 15 March 2011). [NCT01314872] [sr-incont63793]UKCRN10391. A phase IIB randomised, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of MK-4618 in patients with overactive bladder . public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=10391 (accessed 28 June 2012). [CCRN525] [UKCRN10391] [sr-incont45046]">Mitcheson 2019</a>; <a href="./references#CD003781-bbs2-0069" title="Drug company. A phase 2, parallel group, stratified, randomized, double blind, placebo-controlled trial to investigate the efficacy and safety of 3 different dosages of sustained release fesoterodine in subjects with overactive bladder showing either involuntary detrusor contractions or normal findings during the baseline urodynamic assessment. Protocol numbers: A0221029 (SP668). ClinicalStudyResults.org (accessed 3 March 2011). [srincont-41111]NittiV , WiatrakM , KreitmanL , LipsitzD . Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB): results of a phase 2 trial (Abstract number 306). In: International Continence Society (ICS); 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21084]">Nitti 2005</a>; <a href="./references#CD003781-bbs2-0070" title="GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NittiVW , DmochowskiR , SandPK , ForstHT , Haag-MolkentellerC , MassowU , et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. Journal of Urology2007;178(6):2488-94. [NCT00138723] [SP584] [srincont-26313]">Nitti 2007</a>; <a href="./references#CD003781-bbs2-0074" title="RentzhogSL , StantonL , CardozoL , NelsonE , FallM , AbramsP . Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. British Journal of Urology1998;81(1):42-8. [srincont-5461]">Rentzhog 1998</a>; <a href="./references#CD003781-bbs2-0077" title="RogersR , BachmannG , JumadilovaZ , SunF , MorrowJD , GuanZ , et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. International Urogynecology Journal and Pelvic Floor Dysfunction2008;19(11):1551-7. [A6121002] [NCT00143481] [srincont-27729]RogersRG , BachmannG , ScarperoH , JumadilovaZ , SunF , MorrowJD , et al. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. Current Medical Research and Opinion2009;25(9):2159-65. [srincont-32060]">Rogers 2008</a>; <a href="./references#CD003781-bbs2-0079" title="RovnerES , KaplanS , GuanZ , WangJT , RoehrbornCG . Clinical efficacy and safety of tolterodine extended release in male patients with overactive bladder and urgency urinary incontinence (Abstract number 188). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21091]">Rovner 2005</a>; <a href="./references#CD003781-bbs2-0080" title="RudyD , ClineK , GoldbergK , HarrisR . A multicenter, randomized, placebo-controlled trial of trospium chloride in overactive bladder patients (Abstract). Neurourology and Urodynamics2004;23(5/6):600-1. [sr-incont19025]RudyD , ClineK , HarrisR , GoldbergK , DmochowskiR . Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology2006;67(2):275-80. [srincont-21604]RudyD , ClineK , HarrisR , GoldbergK , DmochowskiR . Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. BJU International2006;97(3):540-6. [sr-incont21593]">Rudy 2006</a>; <a href="./references#CD003781-bbs2-0082" title="ChancellorMB , OefeleinMG , VasavadaS . Obesity is associated with a more severe overactive bladder disease state that is effectively treated with one daily administration of trospium chloride extended release [Erratum available in: Neurourology and Urodynamics 2010;29(5):804]. Neurourology and Urodynamics2010;29(4):551-4. [sr-incont39591]GinsbergDA , OefeleinMG , EllsworthPI . Once-daily administration of trospium chloride extended release provides 24-hour coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials. Neurourology and Urodynamics2011;30(4):563-7. [sr-incont41531]RovnerE , DmochowskiR , WatanabeJ . Once daily (QD) trospium chloride 60mg extended release (XR) is safe and effective in patients (PTS) with the overactive bladder (OAB) syndrome who use multiple concomitant medications (MEDS) (Abstract number: Poster #68). Neurourology and Urodynamics2009;28(2):146-7. [sr-incont31062]SandP , DmochowskiR , ZinnerN , StaskinD . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: results from a multicenter, phase III, placebo-controlled study (Abstract number 269). In: International Continence Society (ICS), 37th Annual Meeting; 2007 Aug 20-24; Rotterdam, the Netherlands. 2007. [sr-incont26676]SandP , StaskinD , ZinnerN , DmochowskiR . Once-daily trospium chloride extended release is effective and well tolerated for the treatment of overactive bladder: results from a multicenter, phase III trial (Abstract number 57). Neurourology and Urodynamics2007;26(5):675. [sr-incont26661]StaskinD , SandP , ZinnerN , DmochowskiR , Trospium Study Group. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. Journal of Urology2007;178(3 Pt 1):978-83; discussion 983-4. [srincont-23909]StaskinDR , RosenbergMT , SandPK , ZinnerNR , DmochowskiRR . Trospium chloride once daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised phase III trials. International Journal of Clinical Practice2009;63(12):1715-23. [sr-incont35458]StaskinDR , SandPK , ZinnerNR . Once-daily trospium chloride extended release is effective and well tolerated for the treatment of overactive bladder: results from a multicenter, phase III trial (Abstract number - poster 22). Neurourology and Urodynamics2007;26(7 Suppl):1106. [srincont-27305]">Staskin 2007</a>; <a href="./references#CD003781-bbs2-0084" title="SteersW , CorcosJ . Efficacy, tolerability and safety of darifenacin, an M3 selective receptor antagonist for the treatment of overactive bladder, using a flexible dosing regimen (Abstract number 68). Progres en Urologie2004;14(3 Suppl 3):22. [srincont-22197]">Steers 2004</a>; <a href="./references#CD003781-bbs2-0089" title="ThuroffJW , BunkeB , EbnerA , FaberP , deGeeterP , HannappelJ , et al. Randomized, double-blind multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin vs. propantheline vs. placebo. Neurourology and Urodynamics1990;9(4):337-8. [srincont-5108]ThuroffJW , BunkeB , EbnerA , FaberP , deGeeterP , HannappelJ , et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. Journal of Urology1991;145(4):813-7. [srincont-1288]">Thuroff 1991</a>; <a href="./references#CD003781-bbs2-0092" title="ChancellorM , FreedmanS , MitchesonHD , AntociJ , PrimusG , WeinA . Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clinical Drug Investigation2000;19(2):83-91. [srincont-16326]FreemanR , HillS , MillardR , SlackM , SutherstJ , Tolterodine Study Group. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstetrics and Gynecology2003;102(3):605-11. [srincont-16494]GarelyA , Tolterodine Study Group. Once-daily tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder. International Urology Journal2001;12(Suppl 1):S18. [srincont-12012]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of life of patients with overactive bladder receiving tolterodine. Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of patients with overactive bladder receiving tolterodine (Abstract number 82). Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , ReesePR . Health related quality of life of patients with overactive bladder receiving tolterodine once-daily. Neurourology and Urodynamics2000;19(4):519-21. [srincont-9987]KelleherCJ , ReesePR , PleilAM , OkanoGJ . Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. American Journal of Managed Care2002;8(Suppl 19):S608-15. [srincont-17998]KelleherCJ , Tolterodine Study Group. Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2000;11(Suppl 1):S94. [srincont-11915]KrederKJ . Antimuscarinic therapy: relationship between efficacy and side effects in responders and non-responders. Journal of Urology2001;165(Suppl 5):S165. [srincont-16327]KrederKJ . Clinical effectiveness of antimuscarinic therapy: the relationship between efficacy and tolerability. In: Proceedings of the International Continence Society Annual Meeting(ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001:140. [srincont-14376]MallettV . Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2001;12(Suppl 1):4. [srincont-12011]MillardRJ , TamaddonK , Tolterodine Study Group. Randomized controlled trial to compare tolterodine prolonged release capsules and tolterodine immediate release tablets versus placebo in patients with symptoms of detrusor overactivity (Abstract number 57). Australian and New Zealand Journal of Surgery2002;Suppl 72:A140. [sr-incont22190]PleilAM , ReesePR , KelleherCJ , OkanoGJ . Health-related quality of life of patients with overactive bladder receiving immediate-release tolterodine. HEPAC Health Economics in Prevention and Care2001;2(2):69-75. [sr-incont18060]RoehrbornCG , AbramsP , RovnerES , KaplanSA , HerschornS , GuanZ . Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU International2006;97(5):1003-6. [sr-incont21882]SwiftS . Efficacy and tolerability of once-daily tolterodine for women with overactive bladder. In: International Continence Society Annual Meeting (ICS), 31st annual meeting; 2001 Sept 18-21; Seoul, Korea. 2001:No. 329. [srincont-14481]SwiftS . Once-daily tolterodine is effective and well tolerated in women with overactive bladder (Abstract 57). In: 2nd International Consultation on Incontinence; 2001 July 1-3; Paris, France. 2001. [srincont-16319]SwiftSE . Once-daily (OD) tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder (OAB). International Urogynecology Journal2000;11(Suppl 1):S15. [sr-incont11906]SwiftSE . Once-daily administration of extended-release tolterodine is effective and well-tolerated in patients with overactive bladder. In: XVI FIGO World Congress of Obstetrics and Gynecology; 2000 Sept 3-8; Washington DC. Vol. Book 1. 2000:40. [sr-incont12085]SwiftSE . Overactive bladder in females: treatment with once-daily tolterodine. International Urogynecology Journal2001;12(Suppl 3):S71. [sr-incont16328]Van KerrebroeckP , KrederK , JonasU , ZinnerN . Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology2001;57(3):414-21. [sr-incont11953]Van KerrebroeckPEV . Long-term (12 months) efficacy and tolerability of tolterodine once-daily in the treatment of overactive bladder. Neurourology and Urodynamics2001;20(4):401-2. [sr-incont15714]Van KerrebroeckPEVA , Tolterodine Study Group. Long-term tolerability and efficacy of once-daily (OD) tolterodine in the treatment of overactive bladder (OB). International Urogynecology Journal2001;12(Suppl 3):S49. [sr-incont16329]Van KerrebroeckPEVA , Tolterodine Study Group. Significant decreases in perception of urgency and urge incontinence episodes with once-daily tolterodine treatment in patients with overactive bladder (Abstract number 89). Neurourology and Urodynamics2000;19(4):493-4. [sr-incont9980]WeinAJ , KhullarV , WangJT , GuanZ . Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. BJU International2007;99(2):360-3. [sr-incont23180]vanKerrebroeckPE , KelleherCJ , CoyneKS , KoppZ , BrodskyM , WangJT . Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. Health and Quality of Life Outcomes2009;7(13):13. [10.1186/1477-7525-7-13] [sr-incont31438]vanKerrebroeckPE , WangJ , GuanZ . Effects of tolterodine extended release in patients with overactive bladder: perceived treatment benefits improve with efficacy (Abstract number 511). European Urology Supplements2004;3(2):130. [sr-incont31090]">Van Kerrebroeck 2001</a>; <a href="./references#CD003781-bbs2-0093" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CrosbyRD , MathiasSD , MarshallTS . Relationships between symptoms, symptom bother, and health-related quality of life in patients with overactive bladder taking solifenacin or placebo in the VIBRANT study. International Journal of Clinical Practice2011;65(2):211-8. [sr-incont41015]GollarKM , YoungDG , BailenJ , HeW , Forero-SchwanhaeuserS . Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: a secondary analysis of the VIBRANT study. Urologic Nursing2012;32(1):38-46. [TrialID.VIBRANT.] [sr-incont44571]Samuels T‐A, MitchesonHD , VardyM , Forero‐SchwanhaeuserS , MarshallT , HeW . Efficacy of solifenacin for symptom bother and other patient-reported outcomes in patients with overactive bladder (OAB): results of a large, double-blind, placebo-controlled trial (Abstract number: poster #74). Neurourology and Urodynamics2009;28(2):149. [sr-incont31063]VardyMD , MitchesonHD , SamuelsTA , Forero-SchwanhaeuserS , HeW . Efficacy of solifenacin on overactive bladder symptoms, symptom bother, and other patient-reported outcomes in subjects with or without incontinence: a post hoc analysis of data from VIBRANT. Female Pelvic Medicine and Reconstructive Surgery2011;17(1):24-9. [TrialID.VIBRANT.] [sr-incont44741]VardyMD , MitchesonHD , SamuelsTA , WegenkeJD , Forero-SchwanhaeuserS , MarshallTS , et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. International Journal of Clinical Practice2009;63(12):1702-14. [905-UC-010] [NCT00573508] [TrialID.VIBRANT.] [sr-incont35459]">Vardy 2009</a>; <a href="./references#CD003781-bbs2-0094" title="EUCTR2007-007087-17-SE. A 24-week, multicentre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-007087-17 (first received 13 June 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont64588]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00798434. A study to compare the effectiveness and safety of fesoterodine and placebo in an elderly population of patients who go to the toilet very frequently due to overactive bladder (SOFIA) [A 24-week, multi-centre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00798434 (first received 26 November 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont49847]SchneiderT , BergqvistA , WangJ , WaggA , Ebel-BitounC . Treatment with fesoterodine versus tolterodine for reducing symptom bother in elderly patients with overactive bladder including urgency urinary incontinence. European Urology, Supplements2012;11(1):e687-a. [sr-incont65389]WaggA , CarlssonM , ElsobkyM , FernetM . Effect of flexible dose fesoterodine on cognitive function in &gt;65 year old patients with OAB: data from two RCT (Abstract number 438). Neurourology and Urodynamics2019;38:S297-8. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78651]WaggA , DarekarA , ArumiD , KhullarV , OelkeM . Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people &gt;65 years of age: a post hoc analysis of data from the SOFIA study. Neurourology and Urodynamics2015;34(5):438-43. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont68100]WaggA , ElsobkyM , CarlssonM , FernetM . Response and cognitive safety of fesoterodine in patients &gt;65y old with OAB. Is there a relationship between cognition and treatment response? (Abstract number 183). Neurourology and Urodynamics2019;38:S118-20. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78632]WaggA , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. Journal of the American Geriatrics Society2013;61(2):185-93. [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TrialID.SOFIA.] [sr-incont48008]WaggAS , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Efficacy and tolerability of fesoterodine in older subjects with overactive bladder: results of SOFIA (Abstract number C33). Journal of the American Geriatrics Society2011;59:S124. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont65234]">Wagg 2013a</a>; <a href="./references#CD003781-bbs2-0095" title="GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00911937. A trial to evaluate the efficacy and safety of fesoterodine in patients with symptoms of overactive bladder including nocturnal urinary urgency [A randomized, double blind, placebo controlled, parallel group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with symptoms of overactive bladder including nocturnal urinary urgency]. clinicaltrials.gov/show/NCT00911937 (first received 03 June 2009). [NCT00911937] [sr-incont49848]WeissJ , JumadilovaZ , CarlssonM , FitzGeraldMP , MalhotraA , MartireDL . Effect of antimuscarinic treatment in subjects with overactive bladder, including nocturnal urinary urgency (Abstract number 1963). Journal of Urology2012;187(4 Suppl 1):e792. [NCT00911937] [sr-incont65184]WeissJP , CarlssonMR , ManganEK . Age, gender and nocturnal urgency severity predict response to antimuscarinic treatment (Abstract number 1962). Journal of Urology2013;189(4 Suppl 1):e805. [NCT00911937] [sr-incont65096]WeissJP , JumadilovaZ , JohnsonTM , FitzGeraldMP , CarlssonM , MartireDL , et al. Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency. Journal of Urology2013;189(4):1396-401. [A0221048] [NCT00911937] [sr-incont47568]">Weiss 2013</a>; <a href="./references#CD003781-bbs2-0096" title="YamaguchiO , MaruiE , KakizakiH , ItohN , YokotaT , OkadaH , et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU International2007;100(3):579-87. [sr-incont23865]YokoyamaO , YamaguchiO , KakizakiH , ItohN , YokotaT , OkadaH , et al. Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary. Journal of Urology2011;186(1):170-4. [sr-incont41734]">Yamaguchi 2007</a>; <a href="./references#CD003781-bbs2-0098" title="YamaguchiO , UchidaE , HigoN , MinamiH , KobayashiS , SatoH , et al. Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: a randomized double-blind trial. International Journal of Urology2014;21(6):586-93. [JapicCTI-101309] [sr-incont62099]">Yamaguchi 2014</a>; <a href="./references#CD003781-bbs2-0100" title="JapicCTI-152936. Phase III study of KRP-114V [A phase III, randomized, double-blind, parallel group, placebo controlled, multicenter study to assess the efficacy and safety of the beta-3 agonist KRP-114V in Japanese subjects with symptoms of overactive bladder]. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-152936 (first received 17 June 2015). [JapicCTI-152936] [sr-incont78653]YoshidaM , TakedaM , GotoM , NagaiS , KuroseT . Vibegron, a novel potent and selective beta3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study (Abstract number 1082). European Urology, Supplements2018;17(2):e1531-2. [JapicCTI-152936] [sr-incont78069]YoshidaM , TakedaM , GotohM , NagaiS , KuroseT . Vibegron, a novel potent and selective B3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study. European Urology2018;73(5):783-90. [JapicCTI-152936] [sr-incont77898]YoshidaM , TakedaM , GotohM , YokoyamaO , KakizakiH , TakahashiS , et al. Efficacy of novel beta3-adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: a post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study. International Journal of Urology2019;26(3):369-75. [JapicCTI-152936] [sr-incont78654]YoshidaM , TakedaM , GotohM , YokoyamaO , KakizakiH , TakahashiS , et al. Efficacy of vibegron, a novel selective I²3-adrenoreceptor agonist, on urgency urinary incontinence with overactive bladder: post-hoc analysis of phase iii study (Abstract number 180). Neurourology and Urodynamics2019;38(S3):S114-5. [JapicCTI-152936] [sr-incont78636]">Yoshida 2018</a>; <a href="./references#CD003781-bbs2-0102" title="ZinnerNR , MattiassonA , StantonSL . Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. Journal of the American Geriatrics Society2002;50(5):799-807. [sr-incont14679]">Zinner 2002</a>; <a href="./references#CD003781-bbs2-0103" title="ZinnerN , GittelmanM , HarrisR , SussetJ , KanellosA , AuerbachS . Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial (Abstract number DP51). In: American Urological Association (AUA), 98th Annual Meeting; 2003 Apr 26-May 1; Chicago, Illinois. 2003. [sr-incont31101]ZinnerN , GittelmanM , HarrisR , SussetJ , KanelosA , AuerbachS , Trospium Study Group. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. Journal of Urology2004;171(6 Pt 1):2311-5. [sr-incont17376]">Zinner 2004</a>; <a href="./references#CD003781-bbs2-0104" title="ZinnerN , SussetJ , GittelmanM , ArguinzonizM , RekedaL , HaabF . Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. International Journal of Clinical Practice2006;60(1):119-26. [sr-incont21507]">Zinner 2006</a>). The risk of having constipation for those taking anticholinergics is more than two times higher than for those taking placebo (RR 2.03, 95% CI 1.78 to 2.31; P &lt; 0.000001; <a href="./references#CD003781-fig-0017" title="">Analysis 1.8</a>). </p> <p>The I<sup>2</sup> value for subgroup differences for this outcome is 76.5%. When tolterodine and oxybutynin were deselected, the I<sup>2</sup> value lowered to 0%. When tolterodine and oxybutynin are added to the analyses, the risk of constipation from using anticholinergics is slightly lowered (RR 2.03, 95% CI 1.78 to 2.31), while without them it may be greater (RR 2.39, 95% CI 2.10 to 2.72). Constipation might therefore be better tolerated when taking tolterodine and oxybutynin than other anticholinergics included in the review.   </p> </section> <section id="CD003781-sec-0081"> <h5 class="title">Adverse events: cough</h5> <p>Six studies that reported cough were included in the analysis, with a total of 3853 participants (2091 in the anticholinergic group and 1762 in the placebo group) (<a href="./references#CD003781-bbs2-0024" title="DmochowskiR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. A double-blind, placebo-controlled trial of flexible-dose fesoterodine for overactive bladder (Abstract number 715). In: International Continence Society (ICS); 39th Annual Meeting; 2009 Sep 29-Oct 03; San Francisco, CA. 2009. [sr-incont35627]DmochowskiRR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder [Errata appear in: Urology 2010 Jun;75(6):1519 and in Urology 2011 Jun;77(6):1513]. Urology2010;75(1):62-8. [A0221014] [NCT00536484] [sr-incont39548]DuBeauC , KrausSR , SunF , MorrowJD . Fesoterodine in older vs younger subjects with overactive bladder (Abstract number D87). Journal of the American Geriatrics Society2010;58:S218. [NCT00536484] [sr-incont64309]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. [sr-incont78640]NCT00536484. Fesoterodine flexible dose study [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with overactive bladder]. clinicaltrials.gov/show/NCT00536484 (first received 27 September 2007). [NCT00536484] [sr-incont49160]StaskinD , KhullarV , MichelMC , MorrowJD , SunF , GuanZ , et al. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. Neurourology and Urodynamics2011;30(8):1480-5. [sr-incont42686]">Dmochowski 2010</a>; <a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>; <a href="./references#CD003781-bbs2-0069" title="Drug company. A phase 2, parallel group, stratified, randomized, double blind, placebo-controlled trial to investigate the efficacy and safety of 3 different dosages of sustained release fesoterodine in subjects with overactive bladder showing either involuntary detrusor contractions or normal findings during the baseline urodynamic assessment. Protocol numbers: A0221029 (SP668). ClinicalStudyResults.org (accessed 3 March 2011). [srincont-41111]NittiV , WiatrakM , KreitmanL , LipsitzD . Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB): results of a phase 2 trial (Abstract number 306). In: International Continence Society (ICS); 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21084]">Nitti 2005</a>; <a href="./references#CD003781-bbs2-0070" title="GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NittiVW , DmochowskiR , SandPK , ForstHT , Haag-MolkentellerC , MassowU , et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. Journal of Urology2007;178(6):2488-94. [NCT00138723] [SP584] [srincont-26313]">Nitti 2007</a>; <a href="./references#CD003781-bbs2-0080" title="RudyD , ClineK , GoldbergK , HarrisR . A multicenter, randomized, placebo-controlled trial of trospium chloride in overactive bladder patients (Abstract). Neurourology and Urodynamics2004;23(5/6):600-1. [sr-incont19025]RudyD , ClineK , HarrisR , GoldbergK , DmochowskiR . Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology2006;67(2):275-80. [srincont-21604]RudyD , ClineK , HarrisR , GoldbergK , DmochowskiR . Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. BJU International2006;97(3):540-6. [sr-incont21593]">Rudy 2006</a>; <a href="./references#CD003781-bbs2-0094" title="EUCTR2007-007087-17-SE. A 24-week, multicentre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-007087-17 (first received 13 June 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont64588]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00798434. A study to compare the effectiveness and safety of fesoterodine and placebo in an elderly population of patients who go to the toilet very frequently due to overactive bladder (SOFIA) [A 24-week, multi-centre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00798434 (first received 26 November 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont49847]SchneiderT , BergqvistA , WangJ , WaggA , Ebel-BitounC . Treatment with fesoterodine versus tolterodine for reducing symptom bother in elderly patients with overactive bladder including urgency urinary incontinence. European Urology, Supplements2012;11(1):e687-a. [sr-incont65389]WaggA , CarlssonM , ElsobkyM , FernetM . Effect of flexible dose fesoterodine on cognitive function in &gt;65 year old patients with OAB: data from two RCT (Abstract number 438). Neurourology and Urodynamics2019;38:S297-8. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78651]WaggA , DarekarA , ArumiD , KhullarV , OelkeM . Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people &gt;65 years of age: a post hoc analysis of data from the SOFIA study. Neurourology and Urodynamics2015;34(5):438-43. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont68100]WaggA , ElsobkyM , CarlssonM , FernetM . Response and cognitive safety of fesoterodine in patients &gt;65y old with OAB. Is there a relationship between cognition and treatment response? (Abstract number 183). Neurourology and Urodynamics2019;38:S118-20. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78632]WaggA , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. Journal of the American Geriatrics Society2013;61(2):185-93. [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TrialID.SOFIA.] [sr-incont48008]WaggAS , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Efficacy and tolerability of fesoterodine in older subjects with overactive bladder: results of SOFIA (Abstract number C33). Journal of the American Geriatrics Society2011;59:S124. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont65234]">Wagg 2013a</a>). The estimate implies that participants in the anticholinergic group have a 157% increased risk of cough compared to the placebo group (RR 2.57, 95% CI 1.39 to 4.77; P = 0.03; <a href="./references#CD003781-fig-0018" title="">Analysis 1.9</a>). </p> </section> <section id="CD003781-sec-0082"> <h5 class="title">Adverse events: dizziness</h5> <p>Twenty‐three studies were included in the analysis for dizziness, with a total of 12,444 participants (7709 in the anticholinergic group and 4735 in the placebo group) (<a href="./references#CD003781-bbs2-0004" title="AbramsP , KelleherC , StaskinD , KayR , MartanA , MincikI , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World Journal of Urology2017;35(5):827-38. [NCT01340027] [sr-incont77897]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Cardiovascular safety of combination treatment with mirabegron and solifenacin in patients with overactive bladder in a randomised, double-blind, dose-ranging, Phase II study (Symphony) (Abstract). European Urology, Supplements2014;13(1):e574-e574a. [NCT01340027] [sr-incont67160]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB) - efficacy and safety results from a randomised phase II study (Symphony) (Abstract number 295). Neurourology and Urodynamics2013;32(6):930-1. [NCT01340027] [TrialID.SYMPHONY.] [sr-incont49188]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB): safety results from a phase 2 study (Abstract number MP-16.08). Urology2013;82(3 Suppl 1):S139. [NCT01340027] [sr-incont66675]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: Exploratory responder analyses of efficacy and evaluation of patient reported outcomes from a randomised, double-blind, dose-ranging, phase 2 study (Symphony) (Abstract number MP-24.11). Urology2014;84(4 Suppl 1):S145-6. [NCT01340027] [sr-incont67194]AbramsP , KelleherC , StaskinD , RechbergerT , KayR , MartinaR , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (SYMPHONY). European Urology2015;67(3):577-88. [NCT01340027] [sr-incont66674]NCT01340027, Bristol Urological Institute . A study to evaluate the efficacy, safety and tolerability of mirabegron and solifenacin succinate alone and in combination for the treatment of overactive bladder (symphony) [A randomized, double-blind, factorial, parallel-group, active and placebo-controlled, multicenter dose-ranging study to evaluate the efficacy, safety and tolerability of six dose combinations of solifenacin succinate and mirabegron compared to mirabegron and solifenacin succinate monotherapies in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01340027 (first received 21 April 2011). [178-CL-100] [2010-020601-32] [NCT01340027] [TrialID.SYMPHONY] [sr-incont44510]NittiV , AbramsP , StaskinD , AuerbachS , MartinaR , VanMR . Urinary retention in patients with overactive bladder treated with mirabegron alone and in combination with solifenacin: the results of two randomized, double-blind, phase II studies (Abstract number MP76-13). Journal of Urology2014;191(4 Suppl 1):e886-7. [NCT00410514] [NCT01340027] [TrialID.SYMPHONY] [sr-incont67453]">Abrams 2013</a>; <a href="./references#CD003781-bbs2-0009" title="CardozoL , ChappleCR , Toozs-HobsonP , Grosse-FreeseM , BulittaM , LehmacherW , et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomised, double-blind, multicentre clinical trial. British Journal of Urology International2000;85(6):659-64. [srincont-11732]">Cardozo 2000</a>; <a href="./references#CD003781-bbs2-0016" title="ChappleC , Van KerrebroeckP , TubaroA , Haag-MolkentellerC , ForstHT , MassowU , et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder [Erratum appears in: European Urology 2008,53(6):1319]. European Urology2007;52(4):1204-12. [NCT00220363] [SP583] [srincont-23875]ChappleC , Van KerrebroeckP , TubaroA , MillardR . Fesoterodine in non-neurogenic voiding dysfunction - results on efficacy and safety in a phase 3 trial (Abstract number 379). In: 21st Annual European Association of Urology (EAU) Congress; 2006 Apr 5-8; Paris, France. 2006. [srincont-41109]ChappleC , Van KerrebroeckP , TubaroA , WangJT , HvidstenK , BrodskyM . Efficacy of fesoterodine in patients with overactive bladder (OAB): improvements in OAB symptoms and health-related quality of life (HRQL) (Poster abstract number 1188). Journal of Urology2007;177(4 Suppl S):392. [srincont-31882]ChappleCR , vanKerrebroeckPE , JünemannKP , WangJT , BrodskyM . Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU International2008;102(9):1128-32. [srincont-29255]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. KelleherCJ , TubaroA , WangJT , KoppZ . Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU International2008;102(1):56-61. [srincont-27613]SandPK , MorrowJD , BavendamT , CreangaDL , NittiVW . Efficacy and tolerability of fesoterodine in women with overactive bladder. International Urogynecology Journal2009;20(7):827-35. [srincont-31351]">Chapple 2007a</a>; <a href="./references#CD003781-bbs2-0020" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. [sr-incont75259]ChuF , SmithN , UchidaT . Efficacy and safety of solifenacin succinate 10 mg once daily: a multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder. Current Therapeutic Research - Clinical and Experimental2009;70(6):405-20. [srincont-43324]">Chu 2009</a>; <a href="./references#CD003781-bbs2-0021" title="ChuaME , SeeMC , EsmeňaEB , BalingitJC , MoralesML . Efficacy and safety of gabapentin in comparison to solifenacin succinate in adult overactive bladder treatment. Lower Urinary Tract Symptoms2018;10(2):135-42. [NCT01486706] [sr-incont74529]NCT01486706, ChuaME . Efficacy and safety of gabapentin in treating overactive bladder (OAB). clinicaltrials.gov/show/NCT01486706 (first received 6 December 2011). [NCT01486706] [SLMC10-010] [sr-incont49864]">Chua 2018</a>; <a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>; <a href="./references#CD003781-bbs2-0038" title="HerschornS , HeesakkersJ , Castro-DiazD , WangJT , BrodskyM , GuanZ . Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*. Current Medical Research and Opinion2008;24(12):3513-21. [A6121122] [NCT00143377] [srincont-29250]HerschornS , HeesakkersJ , Castro-DiazD , WangJT , GuanZ , BrodskyM . Tolterodine extended release (TER) improves objective and subjective outcomes after 1 week of treatment in patients with overactive bladder (Abstract number 132). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S78-9. [srincont-26602]">Herschorn 2008</a>; <a href="./references#CD003781-bbs2-0043" title="HommaY , KawabeK . Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World Journal of Urology2004;22(4):251-6. [srincont-19412]HommaY , PaickJS , LeeJG , KawabeK , Japanese and Korean Tolterodine Study Group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU International2003;92(7):741-7. [srincont-16418]">Homma 2003</a>; <a href="./references#CD003781-bbs2-0044" title="HommaY , YamaguchiT , YamaguchiOA . A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2008;15(9):809-15. [srincont-27742]">Homma 2008</a>; <a href="./references#CD003781-bbs2-0050" title="JünemannKP , HessdörferE , Unamba‐OparahI , BerseM , BrünjesR , MadersbacherH . Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. Urologia Internationalis2006;77(4):334-9. [srincont-22199]">Junemann 2006</a>; <a href="./references#CD003781-bbs2-0053" title="CapoJP , TogliaM , Forero-SchwanhaeuserS , HeW . Patients reporting severe overactive bladder symptoms: effects of solifenacin treatment on objective measures and patient-reported outcomes (Abstract number 582). In: International Continence Society (ICS), 38th Annual Meeting; 2008 Oct 20-24; Cairo, Egypt. 2008. [srincont-31844]CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. KarramMM , TogliaMR , SerelsSR , AndohM , FakhouryA , Forero-SchwanhaeuserS . Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology2009;73(1):14-8. [A0221094] [NCT00454896] [TrialID.VENUS.] [srincont-29219]SerelsSR , TogliaMR , Forero-SchwanhaeuserS , HeW . Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms. Current Medical Research and Opinion2010;26(10):2277-85. [srincont-40376]StaskinD , DmochowskiR , SerelsS , AndohM , SmithN . Report from a randomized, placebo-controlled study showing significant improvement in urgency and patient-reported outcomes in overactive bladder patients treated with solifenacin (Abstract number 124). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73-4. [srincont-26600]TogliaM , AndohM , HussainI . Solifenacin improved warning time significantly compared to placebo in patients with overactive bladder (Abstract number 123). Neurourology and Urodynamics2006;25(6):655. [srincont-26629]TogliaM , AndohM , HussainI . Solifenacin improves urgency symtoms as assessed by voiding diaries and patient-reported outcomes (PRO) in patients with overactive bladder (Abstract number 155). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26636]TogliaMR , OstergardDR , AppellRA , AndohM , FakhouryA , HussainIF . Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status. International Urogynecology Journal2010;21(7):847-54. [srincont-40094]TogliaMR , SerelsSR , LarameeC , KarramMM , NandyIM , AndohM , et al. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial. Postgraduate Medicine2009;121(5):151-8. [srincont-34204]ZinnerS , HerschornS , AndohM , HussainI . Responder analyses show statistically significant improvements in incontinence and urgency are associated with reduction in symptom bother and improvement in health-related quality of life: VENUS results (Abstract number 123). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73. [srincont-26599]">Karram 2009</a>; <a href="./references#CD003781-bbs2-0054" title="KhullarV , HillS , LavalKU , SchiotzHA , JonasU , VersiE . Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology2004;64(2):269-74; discussion 274-5. [srincont-19498]KhullarV , HillS , SolankiJ . Assessment of health-related quality of life in patients with overactive bladder taking tolterodine extended release versus placebo (Abstract number 318). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21075]">Khullar 2004</a>; <a href="./references#CD003781-bbs2-0057" title="KosilovK , LoparevS , IvanovskayaM , KosilovaL . A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron. Archives of Gerontology and Geriatrics2015;61(2):212-6. [sr-incont68133]">Kosilov 2015a</a>; <a href="./references#CD003781-bbs2-0060" title="HsiaoSM , ChangTC , ChenCH , WuWY , LinHH . Comparisons of the clinical outcomes and urodynamic effects of mirabegron versus tolterodine treatment for female overactive bladder syndrome: a subgroup analysis of a controlled, randomised, prospective study. Lower Urinary Tract Symptoms2018;10(3):215-20. [NCT01043666] [sr-incont74461]KuoHC , LeeKS , NaY , SoodR , NakajiS , KubotaY , et al. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourology and Urodynamics2015;34(7):685-92. [NCT01043666] [sr-incont68095]Kuo H‐C, Lin H‐H, Yu H‐J, Cheng C‐L, Hung M‐J, LinAT . Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials [Erratum available in: Urological Science 2015;26(2):148]. Urological Science2015;26(1):41-8 . [NCT01043666] [sr-incont68645]NCT01043666. A study of YM178 in subjects with symptoms of overactive bladder  [Phase III study of YM178: a randomized, double-blind, parallel group, placebo and active controlled, multi-center study in subjects with symptoms of overactive bladder]. clinicaltrials.gov/show/NCT01043666 (first received 07 January 2010). [178-CL-090] [NCT01043666] [sr-incont63781]">Kuo 2015</a>; <a href="./references#CD003781-bbs2-0063" title="LeeKS , ChooMS , KimDY , KimJC , KimHJ , MinKS , et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. Journal of Urology2005;174(4 Pt 1):1334-8. [sr-incont21016]LeeKS , ChooMS , PaickJS , LeeJG , SeoJT , LeeJZ , et al. Propiverine hydrochloride reduced frequency and perception of urgency in treatment of overactive bladder: a 12 week prospective, randomized, double blind, placebo controlled study (Abstract number 279). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26640]LeeKS , LeeHW , ChooMS , PaickJS , LeeJG , SeoJT , et al. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'. BJU International2010;105(11):1565-70. [2005-01-08] [NCT00903045] [PROUD] [sr-incont39958]NCT00903045. Urinary urgency outcomes following propiverine treatment for an overactive bladder [Urinary urgency outcomes following propiverine treatment for an overactive bladder: propiverine study on overactive bladder including urgency data (PROUD)]. clinicaltrials.gov/show/NCT009030452005;(first received 15 May 2009). [2005-01-08] [NCT00903045] [TrialID.PROUD] [sr-incont49860]">Lee 2006</a>; <a href="./references#CD003781-bbs2-0066" title="Malone-LeeJG , WalshB , MaugourdMF , Tolterodine in the Elderly Study Group. The safety and clinical efficacy of two doses of tolterodine compared to placebo in elderly patients. In: International Continence Society (ICS), 27th Annual Meeting; 1997 Sep 23-26; Yokohama, Japan. 1997:155-6. [srincont-5855]Malone‐LeeJG , WalshJB , MaugourdMF . Tolterodine: A safe and effective treatment for older patients with overactive bladder. Journal of the American Geriatric Society2001;49(6):700-5. [srincont-12319]WaggA , Malone-LeeJ . Pressure-flow variables in patients treated with tolterodine for detrusor overactivity. BJU International2003;92(9):969-71. [sr-incont16659]">Malone‐Lee 2001</a>; <a href="./references#CD003781-bbs2-0068" title="DmochowskiR , MitchesonD , FrenklT , BennettN , MuddPN . Durable efficacy and safety of long-term once-daily vibegron, a novel oral B-3 adrenergic receptor agonist: A 52-week phase 2 study in patients with overactive bladder syndrome (Abstract number PD50-03). Journal of Urology2018;199(4):e970-1. [sr-incont78091]EUCTR2010-022121-15-IT. A phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2 part clinical study of the efficacy and safety of MK-4618 in patients with overactive bladder - MK4618-008 [A 52-week extension to: a phase iib randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder]. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-022121-15 (first received 12 April 2011). [EUCTR2010-022121-15-IT] [MK4618-008] [NCT01314872] [sr-incont78639]MitchesonD , FrenklT , SamantaS , Anne PintoC , GreenS , BennettN , et al. Vibegron, a novel once daily oral beta-3 agonist, significantly reduces average daily micturitions, urge incontinence episodes and urgency episodes in patients with overactive bladder (Abstract number: podium #34). Neurourology and Urodynamics2018;37(Suppl 1):S565. [EUCTR2010-022121-15-IT] [NCT01314872] [sr-incont78618]MitchesonD , PintoCA , FrenklT , ChenL , PrasadM , MuddPN . Once daily vibegron improves quality of life measures in patients with overactive bladder (Abstract number PUK17). Value in Health2018;21(Suppl 1):S267-8. [EUCTR2010-022121-15-IT] [NCT01314872;] [sr-incont78619]MitchesonHD , SamantaS , MuldowneyK , PintoCA , RochaBA , GreenS , et al. Vibegron (RVT-901/MK-4618/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial. European Urology2019;75(2):274-82. [NCT01314872] [sr-incont78620]NCT01314872. A study of the efficacy and safety of Vibegron (MK-4618) in participants with overactive bladder (OAB) (MK-4618-008) [A phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder a 52-week extension to: a phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder]. clinicaltrials.gov/show/NCT01314872 (first received 15 March 2011). [NCT01314872] [sr-incont63793]UKCRN10391. A phase IIB randomised, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of MK-4618 in patients with overactive bladder . public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=10391 (accessed 28 June 2012). [CCRN525] [UKCRN10391] [sr-incont45046]">Mitcheson 2019</a>; <a href="./references#CD003781-bbs2-0069" title="Drug company. A phase 2, parallel group, stratified, randomized, double blind, placebo-controlled trial to investigate the efficacy and safety of 3 different dosages of sustained release fesoterodine in subjects with overactive bladder showing either involuntary detrusor contractions or normal findings during the baseline urodynamic assessment. Protocol numbers: A0221029 (SP668). ClinicalStudyResults.org (accessed 3 March 2011). [srincont-41111]NittiV , WiatrakM , KreitmanL , LipsitzD . Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB): results of a phase 2 trial (Abstract number 306). In: International Continence Society (ICS); 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21084]">Nitti 2005</a>; <a href="./references#CD003781-bbs2-0079" title="RovnerES , KaplanS , GuanZ , WangJT , RoehrbornCG . Clinical efficacy and safety of tolterodine extended release in male patients with overactive bladder and urgency urinary incontinence (Abstract number 188). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21091]">Rovner 2005</a>; <a href="./references#CD003781-bbs2-0089" title="ThuroffJW , BunkeB , EbnerA , FaberP , deGeeterP , HannappelJ , et al. Randomized, double-blind multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin vs. propantheline vs. placebo. Neurourology and Urodynamics1990;9(4):337-8. [srincont-5108]ThuroffJW , BunkeB , EbnerA , FaberP , deGeeterP , HannappelJ , et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. Journal of Urology1991;145(4):813-7. [srincont-1288]">Thuroff 1991</a>; <a href="./references#CD003781-bbs2-0092" title="ChancellorM , FreedmanS , MitchesonHD , AntociJ , PrimusG , WeinA . Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clinical Drug Investigation2000;19(2):83-91. [srincont-16326]FreemanR , HillS , MillardR , SlackM , SutherstJ , Tolterodine Study Group. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstetrics and Gynecology2003;102(3):605-11. [srincont-16494]GarelyA , Tolterodine Study Group. Once-daily tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder. International Urology Journal2001;12(Suppl 1):S18. [srincont-12012]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of life of patients with overactive bladder receiving tolterodine. Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of patients with overactive bladder receiving tolterodine (Abstract number 82). Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , ReesePR . Health related quality of life of patients with overactive bladder receiving tolterodine once-daily. Neurourology and Urodynamics2000;19(4):519-21. [srincont-9987]KelleherCJ , ReesePR , PleilAM , OkanoGJ . Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. American Journal of Managed Care2002;8(Suppl 19):S608-15. [srincont-17998]KelleherCJ , Tolterodine Study Group. Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2000;11(Suppl 1):S94. [srincont-11915]KrederKJ . Antimuscarinic therapy: relationship between efficacy and side effects in responders and non-responders. Journal of Urology2001;165(Suppl 5):S165. [srincont-16327]KrederKJ . Clinical effectiveness of antimuscarinic therapy: the relationship between efficacy and tolerability. In: Proceedings of the International Continence Society Annual Meeting(ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001:140. [srincont-14376]MallettV . Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2001;12(Suppl 1):4. [srincont-12011]MillardRJ , TamaddonK , Tolterodine Study Group. Randomized controlled trial to compare tolterodine prolonged release capsules and tolterodine immediate release tablets versus placebo in patients with symptoms of detrusor overactivity (Abstract number 57). Australian and New Zealand Journal of Surgery2002;Suppl 72:A140. [sr-incont22190]PleilAM , ReesePR , KelleherCJ , OkanoGJ . Health-related quality of life of patients with overactive bladder receiving immediate-release tolterodine. HEPAC Health Economics in Prevention and Care2001;2(2):69-75. [sr-incont18060]RoehrbornCG , AbramsP , RovnerES , KaplanSA , HerschornS , GuanZ . Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU International2006;97(5):1003-6. [sr-incont21882]SwiftS . Efficacy and tolerability of once-daily tolterodine for women with overactive bladder. In: International Continence Society Annual Meeting (ICS), 31st annual meeting; 2001 Sept 18-21; Seoul, Korea. 2001:No. 329. [srincont-14481]SwiftS . Once-daily tolterodine is effective and well tolerated in women with overactive bladder (Abstract 57). In: 2nd International Consultation on Incontinence; 2001 July 1-3; Paris, France. 2001. [srincont-16319]SwiftSE . Once-daily (OD) tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder (OAB). International Urogynecology Journal2000;11(Suppl 1):S15. [sr-incont11906]SwiftSE . Once-daily administration of extended-release tolterodine is effective and well-tolerated in patients with overactive bladder. In: XVI FIGO World Congress of Obstetrics and Gynecology; 2000 Sept 3-8; Washington DC. Vol. Book 1. 2000:40. [sr-incont12085]SwiftSE . Overactive bladder in females: treatment with once-daily tolterodine. International Urogynecology Journal2001;12(Suppl 3):S71. [sr-incont16328]Van KerrebroeckP , KrederK , JonasU , ZinnerN . Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology2001;57(3):414-21. [sr-incont11953]Van KerrebroeckPEV . Long-term (12 months) efficacy and tolerability of tolterodine once-daily in the treatment of overactive bladder. Neurourology and Urodynamics2001;20(4):401-2. [sr-incont15714]Van KerrebroeckPEVA , Tolterodine Study Group. Long-term tolerability and efficacy of once-daily (OD) tolterodine in the treatment of overactive bladder (OB). International Urogynecology Journal2001;12(Suppl 3):S49. [sr-incont16329]Van KerrebroeckPEVA , Tolterodine Study Group. Significant decreases in perception of urgency and urge incontinence episodes with once-daily tolterodine treatment in patients with overactive bladder (Abstract number 89). Neurourology and Urodynamics2000;19(4):493-4. [sr-incont9980]WeinAJ , KhullarV , WangJT , GuanZ . Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. BJU International2007;99(2):360-3. [sr-incont23180]vanKerrebroeckPE , KelleherCJ , CoyneKS , KoppZ , BrodskyM , WangJT . Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. Health and Quality of Life Outcomes2009;7(13):13. [10.1186/1477-7525-7-13] [sr-incont31438]vanKerrebroeckPE , WangJ , GuanZ . Effects of tolterodine extended release in patients with overactive bladder: perceived treatment benefits improve with efficacy (Abstract number 511). European Urology Supplements2004;3(2):130. [sr-incont31090]">Van Kerrebroeck 2001</a>; <a href="./references#CD003781-bbs2-0094" title="EUCTR2007-007087-17-SE. A 24-week, multicentre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-007087-17 (first received 13 June 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont64588]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00798434. A study to compare the effectiveness and safety of fesoterodine and placebo in an elderly population of patients who go to the toilet very frequently due to overactive bladder (SOFIA) [A 24-week, multi-centre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00798434 (first received 26 November 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont49847]SchneiderT , BergqvistA , WangJ , WaggA , Ebel-BitounC . Treatment with fesoterodine versus tolterodine for reducing symptom bother in elderly patients with overactive bladder including urgency urinary incontinence. European Urology, Supplements2012;11(1):e687-a. [sr-incont65389]WaggA , CarlssonM , ElsobkyM , FernetM . Effect of flexible dose fesoterodine on cognitive function in &gt;65 year old patients with OAB: data from two RCT (Abstract number 438). Neurourology and Urodynamics2019;38:S297-8. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78651]WaggA , DarekarA , ArumiD , KhullarV , OelkeM . Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people &gt;65 years of age: a post hoc analysis of data from the SOFIA study. Neurourology and Urodynamics2015;34(5):438-43. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont68100]WaggA , ElsobkyM , CarlssonM , FernetM . Response and cognitive safety of fesoterodine in patients &gt;65y old with OAB. Is there a relationship between cognition and treatment response? (Abstract number 183). Neurourology and Urodynamics2019;38:S118-20. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78632]WaggA , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. Journal of the American Geriatrics Society2013;61(2):185-93. [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TrialID.SOFIA.] [sr-incont48008]WaggAS , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Efficacy and tolerability of fesoterodine in older subjects with overactive bladder: results of SOFIA (Abstract number C33). Journal of the American Geriatrics Society2011;59:S124. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont65234]">Wagg 2013a</a>; <a href="./references#CD003781-bbs2-0102" title="ZinnerNR , MattiassonA , StantonSL . Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. Journal of the American Geriatrics Society2002;50(5):799-807. [sr-incont14679]">Zinner 2002</a>). The result suggests that the anticholinergic group participants are 37% more at risk of experiencing dizziness compared to the participants in the placebo group (RR 1.37, CI 95% 1.09 to 1.74; P = 0.008; <a href="./references#CD003781-fig-0019" title="">Analysis 1.10</a>). </p> </section> <section id="CD003781-sec-0083"> <h5 class="title">Adverse events: dry eyes</h5> <p>Nine studies were included in the analysis for dry eyes, with a total of 6897 participants (4177 in the anticholinergic group, 2720 in the placebo group) (<a href="./references#CD003781-bbs2-0016" title="ChappleC , Van KerrebroeckP , TubaroA , Haag-MolkentellerC , ForstHT , MassowU , et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder [Erratum appears in: European Urology 2008,53(6):1319]. European Urology2007;52(4):1204-12. [NCT00220363] [SP583] [srincont-23875]ChappleC , Van KerrebroeckP , TubaroA , MillardR . Fesoterodine in non-neurogenic voiding dysfunction - results on efficacy and safety in a phase 3 trial (Abstract number 379). In: 21st Annual European Association of Urology (EAU) Congress; 2006 Apr 5-8; Paris, France. 2006. [srincont-41109]ChappleC , Van KerrebroeckP , TubaroA , WangJT , HvidstenK , BrodskyM . Efficacy of fesoterodine in patients with overactive bladder (OAB): improvements in OAB symptoms and health-related quality of life (HRQL) (Poster abstract number 1188). Journal of Urology2007;177(4 Suppl S):392. [srincont-31882]ChappleCR , vanKerrebroeckPE , JünemannKP , WangJT , BrodskyM . Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU International2008;102(9):1128-32. [srincont-29255]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. KelleherCJ , TubaroA , WangJT , KoppZ . Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU International2008;102(1):56-61. [srincont-27613]SandPK , MorrowJD , BavendamT , CreangaDL , NittiVW . Efficacy and tolerability of fesoterodine in women with overactive bladder. International Urogynecology Journal2009;20(7):827-35. [srincont-31351]">Chapple 2007a</a>; <a href="./references#CD003781-bbs2-0024" title="DmochowskiR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. A double-blind, placebo-controlled trial of flexible-dose fesoterodine for overactive bladder (Abstract number 715). In: International Continence Society (ICS); 39th Annual Meeting; 2009 Sep 29-Oct 03; San Francisco, CA. 2009. [sr-incont35627]DmochowskiRR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder [Errata appear in: Urology 2010 Jun;75(6):1519 and in Urology 2011 Jun;77(6):1513]. Urology2010;75(1):62-8. [A0221014] [NCT00536484] [sr-incont39548]DuBeauC , KrausSR , SunF , MorrowJD . Fesoterodine in older vs younger subjects with overactive bladder (Abstract number D87). Journal of the American Geriatrics Society2010;58:S218. [NCT00536484] [sr-incont64309]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. [sr-incont78640]NCT00536484. Fesoterodine flexible dose study [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with overactive bladder]. clinicaltrials.gov/show/NCT00536484 (first received 27 September 2007). [NCT00536484] [sr-incont49160]StaskinD , KhullarV , MichelMC , MorrowJD , SunF , GuanZ , et al. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. Neurourology and Urodynamics2011;30(8):1480-5. [sr-incont42686]">Dmochowski 2010</a>; <a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>; <a href="./references#CD003781-bbs2-0068" title="DmochowskiR , MitchesonD , FrenklT , BennettN , MuddPN . Durable efficacy and safety of long-term once-daily vibegron, a novel oral B-3 adrenergic receptor agonist: A 52-week phase 2 study in patients with overactive bladder syndrome (Abstract number PD50-03). Journal of Urology2018;199(4):e970-1. [sr-incont78091]EUCTR2010-022121-15-IT. A phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2 part clinical study of the efficacy and safety of MK-4618 in patients with overactive bladder - MK4618-008 [A 52-week extension to: a phase iib randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder]. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-022121-15 (first received 12 April 2011). [EUCTR2010-022121-15-IT] [MK4618-008] [NCT01314872] [sr-incont78639]MitchesonD , FrenklT , SamantaS , Anne PintoC , GreenS , BennettN , et al. Vibegron, a novel once daily oral beta-3 agonist, significantly reduces average daily micturitions, urge incontinence episodes and urgency episodes in patients with overactive bladder (Abstract number: podium #34). Neurourology and Urodynamics2018;37(Suppl 1):S565. [EUCTR2010-022121-15-IT] [NCT01314872] [sr-incont78618]MitchesonD , PintoCA , FrenklT , ChenL , PrasadM , MuddPN . Once daily vibegron improves quality of life measures in patients with overactive bladder (Abstract number PUK17). Value in Health2018;21(Suppl 1):S267-8. [EUCTR2010-022121-15-IT] [NCT01314872;] [sr-incont78619]MitchesonHD , SamantaS , MuldowneyK , PintoCA , RochaBA , GreenS , et al. Vibegron (RVT-901/MK-4618/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial. European Urology2019;75(2):274-82. [NCT01314872] [sr-incont78620]NCT01314872. A study of the efficacy and safety of Vibegron (MK-4618) in participants with overactive bladder (OAB) (MK-4618-008) [A phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder a 52-week extension to: a phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder]. clinicaltrials.gov/show/NCT01314872 (first received 15 March 2011). [NCT01314872] [sr-incont63793]UKCRN10391. A phase IIB randomised, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of MK-4618 in patients with overactive bladder . public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=10391 (accessed 28 June 2012). [CCRN525] [UKCRN10391] [sr-incont45046]">Mitcheson 2019</a>; <a href="./references#CD003781-bbs2-0069" title="Drug company. A phase 2, parallel group, stratified, randomized, double blind, placebo-controlled trial to investigate the efficacy and safety of 3 different dosages of sustained release fesoterodine in subjects with overactive bladder showing either involuntary detrusor contractions or normal findings during the baseline urodynamic assessment. Protocol numbers: A0221029 (SP668). ClinicalStudyResults.org (accessed 3 March 2011). [srincont-41111]NittiV , WiatrakM , KreitmanL , LipsitzD . Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB): results of a phase 2 trial (Abstract number 306). In: International Continence Society (ICS); 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21084]">Nitti 2005</a>; <a href="./references#CD003781-bbs2-0070" title="GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NittiVW , DmochowskiR , SandPK , ForstHT , Haag-MolkentellerC , MassowU , et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. Journal of Urology2007;178(6):2488-94. [NCT00138723] [SP584] [srincont-26313]">Nitti 2007</a>; <a href="./references#CD003781-bbs2-0082" title="ChancellorMB , OefeleinMG , VasavadaS . Obesity is associated with a more severe overactive bladder disease state that is effectively treated with one daily administration of trospium chloride extended release [Erratum available in: Neurourology and Urodynamics 2010;29(5):804]. Neurourology and Urodynamics2010;29(4):551-4. [sr-incont39591]GinsbergDA , OefeleinMG , EllsworthPI . Once-daily administration of trospium chloride extended release provides 24-hour coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials. Neurourology and Urodynamics2011;30(4):563-7. [sr-incont41531]RovnerE , DmochowskiR , WatanabeJ . Once daily (QD) trospium chloride 60mg extended release (XR) is safe and effective in patients (PTS) with the overactive bladder (OAB) syndrome who use multiple concomitant medications (MEDS) (Abstract number: Poster #68). Neurourology and Urodynamics2009;28(2):146-7. [sr-incont31062]SandP , DmochowskiR , ZinnerN , StaskinD . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: results from a multicenter, phase III, placebo-controlled study (Abstract number 269). In: International Continence Society (ICS), 37th Annual Meeting; 2007 Aug 20-24; Rotterdam, the Netherlands. 2007. [sr-incont26676]SandP , StaskinD , ZinnerN , DmochowskiR . Once-daily trospium chloride extended release is effective and well tolerated for the treatment of overactive bladder: results from a multicenter, phase III trial (Abstract number 57). Neurourology and Urodynamics2007;26(5):675. [sr-incont26661]StaskinD , SandP , ZinnerN , DmochowskiR , Trospium Study Group. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. Journal of Urology2007;178(3 Pt 1):978-83; discussion 983-4. [srincont-23909]StaskinDR , RosenbergMT , SandPK , ZinnerNR , DmochowskiRR . Trospium chloride once daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised phase III trials. International Journal of Clinical Practice2009;63(12):1715-23. [sr-incont35458]StaskinDR , SandPK , ZinnerNR . Once-daily trospium chloride extended release is effective and well tolerated for the treatment of overactive bladder: results from a multicenter, phase III trial (Abstract number - poster 22). Neurourology and Urodynamics2007;26(7 Suppl):1106. [srincont-27305]">Staskin 2007</a>; <a href="./references#CD003781-bbs2-0092" title="ChancellorM , FreedmanS , MitchesonHD , AntociJ , PrimusG , WeinA . Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clinical Drug Investigation2000;19(2):83-91. [srincont-16326]FreemanR , HillS , MillardR , SlackM , SutherstJ , Tolterodine Study Group. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstetrics and Gynecology2003;102(3):605-11. [srincont-16494]GarelyA , Tolterodine Study Group. Once-daily tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder. International Urology Journal2001;12(Suppl 1):S18. [srincont-12012]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of life of patients with overactive bladder receiving tolterodine. Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of patients with overactive bladder receiving tolterodine (Abstract number 82). Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , ReesePR . Health related quality of life of patients with overactive bladder receiving tolterodine once-daily. Neurourology and Urodynamics2000;19(4):519-21. [srincont-9987]KelleherCJ , ReesePR , PleilAM , OkanoGJ . Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. American Journal of Managed Care2002;8(Suppl 19):S608-15. [srincont-17998]KelleherCJ , Tolterodine Study Group. Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2000;11(Suppl 1):S94. [srincont-11915]KrederKJ . Antimuscarinic therapy: relationship between efficacy and side effects in responders and non-responders. Journal of Urology2001;165(Suppl 5):S165. [srincont-16327]KrederKJ . Clinical effectiveness of antimuscarinic therapy: the relationship between efficacy and tolerability. In: Proceedings of the International Continence Society Annual Meeting(ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001:140. [srincont-14376]MallettV . Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2001;12(Suppl 1):4. [srincont-12011]MillardRJ , TamaddonK , Tolterodine Study Group. Randomized controlled trial to compare tolterodine prolonged release capsules and tolterodine immediate release tablets versus placebo in patients with symptoms of detrusor overactivity (Abstract number 57). Australian and New Zealand Journal of Surgery2002;Suppl 72:A140. [sr-incont22190]PleilAM , ReesePR , KelleherCJ , OkanoGJ . Health-related quality of life of patients with overactive bladder receiving immediate-release tolterodine. HEPAC Health Economics in Prevention and Care2001;2(2):69-75. [sr-incont18060]RoehrbornCG , AbramsP , RovnerES , KaplanSA , HerschornS , GuanZ . Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU International2006;97(5):1003-6. [sr-incont21882]SwiftS . Efficacy and tolerability of once-daily tolterodine for women with overactive bladder. In: International Continence Society Annual Meeting (ICS), 31st annual meeting; 2001 Sept 18-21; Seoul, Korea. 2001:No. 329. [srincont-14481]SwiftS . Once-daily tolterodine is effective and well tolerated in women with overactive bladder (Abstract 57). In: 2nd International Consultation on Incontinence; 2001 July 1-3; Paris, France. 2001. [srincont-16319]SwiftSE . Once-daily (OD) tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder (OAB). International Urogynecology Journal2000;11(Suppl 1):S15. [sr-incont11906]SwiftSE . Once-daily administration of extended-release tolterodine is effective and well-tolerated in patients with overactive bladder. In: XVI FIGO World Congress of Obstetrics and Gynecology; 2000 Sept 3-8; Washington DC. Vol. Book 1. 2000:40. [sr-incont12085]SwiftSE . Overactive bladder in females: treatment with once-daily tolterodine. International Urogynecology Journal2001;12(Suppl 3):S71. [sr-incont16328]Van KerrebroeckP , KrederK , JonasU , ZinnerN . Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology2001;57(3):414-21. [sr-incont11953]Van KerrebroeckPEV . Long-term (12 months) efficacy and tolerability of tolterodine once-daily in the treatment of overactive bladder. Neurourology and Urodynamics2001;20(4):401-2. [sr-incont15714]Van KerrebroeckPEVA , Tolterodine Study Group. Long-term tolerability and efficacy of once-daily (OD) tolterodine in the treatment of overactive bladder (OB). International Urogynecology Journal2001;12(Suppl 3):S49. [sr-incont16329]Van KerrebroeckPEVA , Tolterodine Study Group. Significant decreases in perception of urgency and urge incontinence episodes with once-daily tolterodine treatment in patients with overactive bladder (Abstract number 89). Neurourology and Urodynamics2000;19(4):493-4. [sr-incont9980]WeinAJ , KhullarV , WangJT , GuanZ . Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. BJU International2007;99(2):360-3. [sr-incont23180]vanKerrebroeckPE , KelleherCJ , CoyneKS , KoppZ , BrodskyM , WangJT . Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. Health and Quality of Life Outcomes2009;7(13):13. [10.1186/1477-7525-7-13] [sr-incont31438]vanKerrebroeckPE , WangJ , GuanZ . Effects of tolterodine extended release in patients with overactive bladder: perceived treatment benefits improve with efficacy (Abstract number 511). European Urology Supplements2004;3(2):130. [sr-incont31090]">Van Kerrebroeck 2001</a>; <a href="./references#CD003781-bbs2-0093" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CrosbyRD , MathiasSD , MarshallTS . Relationships between symptoms, symptom bother, and health-related quality of life in patients with overactive bladder taking solifenacin or placebo in the VIBRANT study. International Journal of Clinical Practice2011;65(2):211-8. [sr-incont41015]GollarKM , YoungDG , BailenJ , HeW , Forero-SchwanhaeuserS . Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: a secondary analysis of the VIBRANT study. Urologic Nursing2012;32(1):38-46. [TrialID.VIBRANT.] [sr-incont44571]Samuels T‐A, MitchesonHD , VardyM , Forero‐SchwanhaeuserS , MarshallT , HeW . Efficacy of solifenacin for symptom bother and other patient-reported outcomes in patients with overactive bladder (OAB): results of a large, double-blind, placebo-controlled trial (Abstract number: poster #74). Neurourology and Urodynamics2009;28(2):149. [sr-incont31063]VardyMD , MitchesonHD , SamuelsTA , Forero-SchwanhaeuserS , HeW . Efficacy of solifenacin on overactive bladder symptoms, symptom bother, and other patient-reported outcomes in subjects with or without incontinence: a post hoc analysis of data from VIBRANT. Female Pelvic Medicine and Reconstructive Surgery2011;17(1):24-9. [TrialID.VIBRANT.] [sr-incont44741]VardyMD , MitchesonHD , SamuelsTA , WegenkeJD , Forero-SchwanhaeuserS , MarshallTS , et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. International Journal of Clinical Practice2009;63(12):1702-14. [905-UC-010] [NCT00573508] [TrialID.VIBRANT.] [sr-incont35459]">Vardy 2009</a>). The estimate implies that there is an 86% greater risk that taking anticholinergics will result in dry eyes compared to placebo (RR 1.86, 95% CI 1.23 to 2.83; P = 0.004; <a href="./references#CD003781-fig-0020" title="">Analysis 1.11</a>). </p> <p>The I<sup>2</sup> value for subgroup differences for this outcome is 43.8%. When tolterodine was deselected, the I<sup>2</sup> value decreased to 0%. With tolterodine, a slight reduction in the risk of dry eyes with anticholinergics was noted (RR 1.86, 95% CI 1.23 to 2.83), whereas there was an increase with tolterodine removed from the analysis (RR 2.90, 95% CI 1.57 to 5.36). This suggests the risk of dry eyes might be reduced when taking tolterodine when compared to other anticholinergics included in this review.   </p> </section> <section id="CD003781-sec-0084"> <h5 class="title">Adverse events: dyspepsia/indigestion</h5> <p>Twenty‐two studies with a total of 12,699 participants (7827 in the anticholinergic group and 4872 in the placebo group) reported dyspepsia/indigestion as an adverse event and were included in the analysis (<a href="./references#CD003781-bbs2-0002" title="AbramsP , FreemanR , AnderströmC , MattiassonA . Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. British Journal of Urology1998;81(6):801-10. [srincont-7871]AbramsP , FreemanRN , AnderstromC , MattiassonA . Efficacy and tolerability of tolterodine vs. oxybutynin and placebo in patients with detrusor instability (Abstract). Journal of Urology1997;157(Suppl 4):103. [srincont-16321]">Abrams 1998</a>; <a href="./references#CD003781-bbs2-0004" title="AbramsP , KelleherC , StaskinD , KayR , MartanA , MincikI , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World Journal of Urology2017;35(5):827-38. [NCT01340027] [sr-incont77897]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Cardiovascular safety of combination treatment with mirabegron and solifenacin in patients with overactive bladder in a randomised, double-blind, dose-ranging, Phase II study (Symphony) (Abstract). European Urology, Supplements2014;13(1):e574-e574a. [NCT01340027] [sr-incont67160]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB) - efficacy and safety results from a randomised phase II study (Symphony) (Abstract number 295). Neurourology and Urodynamics2013;32(6):930-1. [NCT01340027] [TrialID.SYMPHONY.] [sr-incont49188]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB): safety results from a phase 2 study (Abstract number MP-16.08). Urology2013;82(3 Suppl 1):S139. [NCT01340027] [sr-incont66675]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: Exploratory responder analyses of efficacy and evaluation of patient reported outcomes from a randomised, double-blind, dose-ranging, phase 2 study (Symphony) (Abstract number MP-24.11). Urology2014;84(4 Suppl 1):S145-6. [NCT01340027] [sr-incont67194]AbramsP , KelleherC , StaskinD , RechbergerT , KayR , MartinaR , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (SYMPHONY). European Urology2015;67(3):577-88. [NCT01340027] [sr-incont66674]NCT01340027, Bristol Urological Institute . A study to evaluate the efficacy, safety and tolerability of mirabegron and solifenacin succinate alone and in combination for the treatment of overactive bladder (symphony) [A randomized, double-blind, factorial, parallel-group, active and placebo-controlled, multicenter dose-ranging study to evaluate the efficacy, safety and tolerability of six dose combinations of solifenacin succinate and mirabegron compared to mirabegron and solifenacin succinate monotherapies in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01340027 (first received 21 April 2011). [178-CL-100] [2010-020601-32] [NCT01340027] [TrialID.SYMPHONY] [sr-incont44510]NittiV , AbramsP , StaskinD , AuerbachS , MartinaR , VanMR . Urinary retention in patients with overactive bladder treated with mirabegron alone and in combination with solifenacin: the results of two randomized, double-blind, phase II studies (Abstract number MP76-13). Journal of Urology2014;191(4 Suppl 1):e886-7. [NCT00410514] [NCT01340027] [TrialID.SYMPHONY] [sr-incont67453]">Abrams 2013</a>; <a href="./references#CD003781-bbs2-0013" title="ChappleC . Fesoterodine a new effective and well-tolerated antimuscarinic for the treatment of urgency-frequency syndrome: results of a phase 2 controlled study (Abstract 142). Neurourology and Urodynamics2004;23(5/6):598-9. [srincont-19023]Drug company. A Phase 2, parallel group, randomized, double-blind, placebo controlled dose-ranging trial to determine the optimal dose and the tolerability of sustained release SPM 8272 (fesoterodine) in subjects with non-neurogenic bladder overactivity. Protocol numbers: A0221027 (SP582). ClinicalStudyResults.org (accessed 3 March 2011)2002. [Protocol numbers: A0221027 (SP582)] [srincont-41110]">Chapple 2004a</a>; <a href="./references#CD003781-bbs2-0014" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. ChappleCR , AranoP , BoschJH , De RidderD , KramerG , RidderAM . YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo- and tolterodine-controlled, phase-II, dose-finding study (Abstract 75). Neurourology and Urodynamics2002;21(4):381-2. [srincont-14551]ChappleCR , ArañoP , BoschJL , De RidderD , KramerAE , RidderAM . Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU International2004;93(1):71-7. [srincont-17334]KelleherCJ , CardozoL , ChappleCR , HaabF , RidderAM . Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU International2005;95(1):81-5. [srincont-20241]SmithN , GrimesI , RidgeS , TempelD , UchidaT , YamanouchiUS . YM905 is effective and safe as treatment of overactive bladder in women and men: results from phase II study (Abstract). In: International Continence Society (ICS), 32nd Annual Meeting; 2002 Aug 28-30; Heidelberg, Germany. 2002:138-9. [sr-incont14508]">Chapple 2004b</a>; <a href="./references#CD003781-bbs2-0020" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. [sr-incont75259]ChuF , SmithN , UchidaT . Efficacy and safety of solifenacin succinate 10 mg once daily: a multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder. Current Therapeutic Research - Clinical and Experimental2009;70(6):405-20. [srincont-43324]">Chu 2009</a>; <a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>; <a href="./references#CD003781-bbs2-0035" title="HaabF , StewartL , DwyerP . Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. European Urology2004;45(4):420-9. [srincont-17428]">Haab 2004</a>; <a href="./references#CD003781-bbs2-0040" title="EUCTR2012-005735-91-SK. A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-005735-91 (first received 12 November 2013). [178-CL-101] [EUCTR2012-005735-91-SK] [sr-incont78644]HerschornS , ChappleCR , AbramsP , ArlandisS , MitchesonD , LeeKS , et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU International2017;120(4):562-75. [NCT01972841] [sr-incont74470]MuellerER , RobinsonD , KelleherC , StaskinDR , FalconerC , WangJ , et al. Patient reported outcomes from synergy, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with mirabegron and solifenacin monotherapy (Abstract number - Podium #44). Neurourology and Urodynamics2017;36(Suppl S1):S151-2. [NCT01972841] [sr-incont75944]NCT01972841. This was a multinational study comparing the efficacy and safety of two medicines, solifenacin succinate and mirabegron taken together, or separately, or a mock treatment (placebo) in subjects with symptoms of overactive bladder (SYNERGY) [A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01972841 (first received 31 October 2013). [178-CL-101] [EUCTR2012-005735-91] [NCT01972841] [sr-incont63780]RobinsonD , KelleherC , StaskinD , MuellerER , FalconerC , WangJ , et al. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients. Neurourology and Urodynamics2018;37(1):394-406. [NCT01972841] [sr-incont76906]WeberMA , ChappleCR , GratzkeC , HerschornS , RobinsonD , FrankelJM , et al. A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial. Blood Pressure Monitoring2018;23(3):153-63. [NCT01972841] [sr-incont77899]WhiteWB , ChappleC , GratzkeC , HerschornS , RobinsonD , FrankelJ , et al. Cardiovascular safety of the beta3-adrenoceptor agonist mirabegron and the antimuscarinic agent solifenacin in the SYNERGY trial. Journal of Clinical Pharmacology2018;58(8):1084-91. [NCT01972841] [sr-incont78078]">Herschorn 2017a</a>; <a href="./references#CD003781-bbs2-0042" title="HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21072]HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21072]HillS , KhullarV , WyndaeleJJ , LheritierK , . Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. International Urogynecology Journal and Pelvic Floor2006;17(3):239-47. [srincont-22464]">Hill 2005</a>; <a href="./references#CD003781-bbs2-0043" title="HommaY , KawabeK . Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World Journal of Urology2004;22(4):251-6. [srincont-19412]HommaY , PaickJS , LeeJG , KawabeK , Japanese and Korean Tolterodine Study Group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU International2003;92(7):741-7. [srincont-16418]">Homma 2003</a>; <a href="./references#CD003781-bbs2-0044" title="HommaY , YamaguchiT , YamaguchiOA . A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2008;15(9):809-15. [srincont-27742]">Homma 2008</a>; <a href="./references#CD003781-bbs2-0050" title="JünemannKP , HessdörferE , Unamba‐OparahI , BerseM , BrünjesR , MadersbacherH . Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. Urologia Internationalis2006;77(4):334-9. [srincont-22199]">Junemann 2006</a>; <a href="./references#CD003781-bbs2-0054" title="KhullarV , HillS , LavalKU , SchiotzHA , JonasU , VersiE . Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology2004;64(2):269-74; discussion 274-5. [srincont-19498]KhullarV , HillS , SolankiJ . Assessment of health-related quality of life in patients with overactive bladder taking tolterodine extended release versus placebo (Abstract number 318). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21075]">Khullar 2004</a>; <a href="./references#CD003781-bbs2-0066" title="Malone-LeeJG , WalshB , MaugourdMF , Tolterodine in the Elderly Study Group. The safety and clinical efficacy of two doses of tolterodine compared to placebo in elderly patients. In: International Continence Society (ICS), 27th Annual Meeting; 1997 Sep 23-26; Yokohama, Japan. 1997:155-6. [srincont-5855]Malone‐LeeJG , WalshJB , MaugourdMF . Tolterodine: A safe and effective treatment for older patients with overactive bladder. Journal of the American Geriatric Society2001;49(6):700-5. [srincont-12319]WaggA , Malone-LeeJ . Pressure-flow variables in patients treated with tolterodine for detrusor overactivity. BJU International2003;92(9):969-71. [sr-incont16659]">Malone‐Lee 2001</a>; <a href="./references#CD003781-bbs2-0069" title="Drug company. A phase 2, parallel group, stratified, randomized, double blind, placebo-controlled trial to investigate the efficacy and safety of 3 different dosages of sustained release fesoterodine in subjects with overactive bladder showing either involuntary detrusor contractions or normal findings during the baseline urodynamic assessment. Protocol numbers: A0221029 (SP668). ClinicalStudyResults.org (accessed 3 March 2011). [srincont-41111]NittiV , WiatrakM , KreitmanL , LipsitzD . Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB): results of a phase 2 trial (Abstract number 306). In: International Continence Society (ICS); 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21084]">Nitti 2005</a>; <a href="./references#CD003781-bbs2-0079" title="RovnerES , KaplanS , GuanZ , WangJT , RoehrbornCG . Clinical efficacy and safety of tolterodine extended release in male patients with overactive bladder and urgency urinary incontinence (Abstract number 188). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21091]">Rovner 2005</a>; <a href="./references#CD003781-bbs2-0082" title="ChancellorMB , OefeleinMG , VasavadaS . Obesity is associated with a more severe overactive bladder disease state that is effectively treated with one daily administration of trospium chloride extended release [Erratum available in: Neurourology and Urodynamics 2010;29(5):804]. Neurourology and Urodynamics2010;29(4):551-4. [sr-incont39591]GinsbergDA , OefeleinMG , EllsworthPI . Once-daily administration of trospium chloride extended release provides 24-hour coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials. Neurourology and Urodynamics2011;30(4):563-7. [sr-incont41531]RovnerE , DmochowskiR , WatanabeJ . Once daily (QD) trospium chloride 60mg extended release (XR) is safe and effective in patients (PTS) with the overactive bladder (OAB) syndrome who use multiple concomitant medications (MEDS) (Abstract number: Poster #68). Neurourology and Urodynamics2009;28(2):146-7. [sr-incont31062]SandP , DmochowskiR , ZinnerN , StaskinD . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: results from a multicenter, phase III, placebo-controlled study (Abstract number 269). In: International Continence Society (ICS), 37th Annual Meeting; 2007 Aug 20-24; Rotterdam, the Netherlands. 2007. [sr-incont26676]SandP , StaskinD , ZinnerN , DmochowskiR . Once-daily trospium chloride extended release is effective and well tolerated for the treatment of overactive bladder: results from a multicenter, phase III trial (Abstract number 57). Neurourology and Urodynamics2007;26(5):675. [sr-incont26661]StaskinD , SandP , ZinnerN , DmochowskiR , Trospium Study Group. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. Journal of Urology2007;178(3 Pt 1):978-83; discussion 983-4. [srincont-23909]StaskinDR , RosenbergMT , SandPK , ZinnerNR , DmochowskiRR . Trospium chloride once daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised phase III trials. International Journal of Clinical Practice2009;63(12):1715-23. [sr-incont35458]StaskinDR , SandPK , ZinnerNR . Once-daily trospium chloride extended release is effective and well tolerated for the treatment of overactive bladder: results from a multicenter, phase III trial (Abstract number - poster 22). Neurourology and Urodynamics2007;26(7 Suppl):1106. [srincont-27305]">Staskin 2007</a>; <a href="./references#CD003781-bbs2-0092" title="ChancellorM , FreedmanS , MitchesonHD , AntociJ , PrimusG , WeinA . Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clinical Drug Investigation2000;19(2):83-91. [srincont-16326]FreemanR , HillS , MillardR , SlackM , SutherstJ , Tolterodine Study Group. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstetrics and Gynecology2003;102(3):605-11. [srincont-16494]GarelyA , Tolterodine Study Group. Once-daily tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder. International Urology Journal2001;12(Suppl 1):S18. [srincont-12012]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of life of patients with overactive bladder receiving tolterodine. Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of patients with overactive bladder receiving tolterodine (Abstract number 82). Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , ReesePR . Health related quality of life of patients with overactive bladder receiving tolterodine once-daily. Neurourology and Urodynamics2000;19(4):519-21. [srincont-9987]KelleherCJ , ReesePR , PleilAM , OkanoGJ . Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. American Journal of Managed Care2002;8(Suppl 19):S608-15. [srincont-17998]KelleherCJ , Tolterodine Study Group. Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2000;11(Suppl 1):S94. [srincont-11915]KrederKJ . Antimuscarinic therapy: relationship between efficacy and side effects in responders and non-responders. Journal of Urology2001;165(Suppl 5):S165. [srincont-16327]KrederKJ . Clinical effectiveness of antimuscarinic therapy: the relationship between efficacy and tolerability. In: Proceedings of the International Continence Society Annual Meeting(ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001:140. [srincont-14376]MallettV . Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2001;12(Suppl 1):4. [srincont-12011]MillardRJ , TamaddonK , Tolterodine Study Group. Randomized controlled trial to compare tolterodine prolonged release capsules and tolterodine immediate release tablets versus placebo in patients with symptoms of detrusor overactivity (Abstract number 57). Australian and New Zealand Journal of Surgery2002;Suppl 72:A140. [sr-incont22190]PleilAM , ReesePR , KelleherCJ , OkanoGJ . Health-related quality of life of patients with overactive bladder receiving immediate-release tolterodine. HEPAC Health Economics in Prevention and Care2001;2(2):69-75. [sr-incont18060]RoehrbornCG , AbramsP , RovnerES , KaplanSA , HerschornS , GuanZ . Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU International2006;97(5):1003-6. [sr-incont21882]SwiftS . Efficacy and tolerability of once-daily tolterodine for women with overactive bladder. In: International Continence Society Annual Meeting (ICS), 31st annual meeting; 2001 Sept 18-21; Seoul, Korea. 2001:No. 329. [srincont-14481]SwiftS . Once-daily tolterodine is effective and well tolerated in women with overactive bladder (Abstract 57). In: 2nd International Consultation on Incontinence; 2001 July 1-3; Paris, France. 2001. [srincont-16319]SwiftSE . Once-daily (OD) tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder (OAB). International Urogynecology Journal2000;11(Suppl 1):S15. [sr-incont11906]SwiftSE . Once-daily administration of extended-release tolterodine is effective and well-tolerated in patients with overactive bladder. In: XVI FIGO World Congress of Obstetrics and Gynecology; 2000 Sept 3-8; Washington DC. Vol. Book 1. 2000:40. [sr-incont12085]SwiftSE . Overactive bladder in females: treatment with once-daily tolterodine. International Urogynecology Journal2001;12(Suppl 3):S71. [sr-incont16328]Van KerrebroeckP , KrederK , JonasU , ZinnerN . Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology2001;57(3):414-21. [sr-incont11953]Van KerrebroeckPEV . Long-term (12 months) efficacy and tolerability of tolterodine once-daily in the treatment of overactive bladder. Neurourology and Urodynamics2001;20(4):401-2. [sr-incont15714]Van KerrebroeckPEVA , Tolterodine Study Group. Long-term tolerability and efficacy of once-daily (OD) tolterodine in the treatment of overactive bladder (OB). International Urogynecology Journal2001;12(Suppl 3):S49. [sr-incont16329]Van KerrebroeckPEVA , Tolterodine Study Group. Significant decreases in perception of urgency and urge incontinence episodes with once-daily tolterodine treatment in patients with overactive bladder (Abstract number 89). Neurourology and Urodynamics2000;19(4):493-4. [sr-incont9980]WeinAJ , KhullarV , WangJT , GuanZ . Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. BJU International2007;99(2):360-3. [sr-incont23180]vanKerrebroeckPE , KelleherCJ , CoyneKS , KoppZ , BrodskyM , WangJT . Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. Health and Quality of Life Outcomes2009;7(13):13. [10.1186/1477-7525-7-13] [sr-incont31438]vanKerrebroeckPE , WangJ , GuanZ . Effects of tolterodine extended release in patients with overactive bladder: perceived treatment benefits improve with efficacy (Abstract number 511). European Urology Supplements2004;3(2):130. [sr-incont31090]">Van Kerrebroeck 2001</a>; <a href="./references#CD003781-bbs2-0093" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CrosbyRD , MathiasSD , MarshallTS . Relationships between symptoms, symptom bother, and health-related quality of life in patients with overactive bladder taking solifenacin or placebo in the VIBRANT study. International Journal of Clinical Practice2011;65(2):211-8. [sr-incont41015]GollarKM , YoungDG , BailenJ , HeW , Forero-SchwanhaeuserS . Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: a secondary analysis of the VIBRANT study. Urologic Nursing2012;32(1):38-46. [TrialID.VIBRANT.] [sr-incont44571]Samuels T‐A, MitchesonHD , VardyM , Forero‐SchwanhaeuserS , MarshallT , HeW . Efficacy of solifenacin for symptom bother and other patient-reported outcomes in patients with overactive bladder (OAB): results of a large, double-blind, placebo-controlled trial (Abstract number: poster #74). Neurourology and Urodynamics2009;28(2):149. [sr-incont31063]VardyMD , MitchesonHD , SamuelsTA , Forero-SchwanhaeuserS , HeW . Efficacy of solifenacin on overactive bladder symptoms, symptom bother, and other patient-reported outcomes in subjects with or without incontinence: a post hoc analysis of data from VIBRANT. Female Pelvic Medicine and Reconstructive Surgery2011;17(1):24-9. [TrialID.VIBRANT.] [sr-incont44741]VardyMD , MitchesonHD , SamuelsTA , WegenkeJD , Forero-SchwanhaeuserS , MarshallTS , et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. International Journal of Clinical Practice2009;63(12):1702-14. [905-UC-010] [NCT00573508] [TrialID.VIBRANT.] [sr-incont35459]">Vardy 2009</a>; <a href="./references#CD003781-bbs2-0094" title="EUCTR2007-007087-17-SE. A 24-week, multicentre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-007087-17 (first received 13 June 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont64588]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00798434. A study to compare the effectiveness and safety of fesoterodine and placebo in an elderly population of patients who go to the toilet very frequently due to overactive bladder (SOFIA) [A 24-week, multi-centre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00798434 (first received 26 November 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont49847]SchneiderT , BergqvistA , WangJ , WaggA , Ebel-BitounC . Treatment with fesoterodine versus tolterodine for reducing symptom bother in elderly patients with overactive bladder including urgency urinary incontinence. European Urology, Supplements2012;11(1):e687-a. [sr-incont65389]WaggA , CarlssonM , ElsobkyM , FernetM . Effect of flexible dose fesoterodine on cognitive function in &gt;65 year old patients with OAB: data from two RCT (Abstract number 438). Neurourology and Urodynamics2019;38:S297-8. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78651]WaggA , DarekarA , ArumiD , KhullarV , OelkeM . Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people &gt;65 years of age: a post hoc analysis of data from the SOFIA study. Neurourology and Urodynamics2015;34(5):438-43. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont68100]WaggA , ElsobkyM , CarlssonM , FernetM . Response and cognitive safety of fesoterodine in patients &gt;65y old with OAB. Is there a relationship between cognition and treatment response? (Abstract number 183). Neurourology and Urodynamics2019;38:S118-20. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78632]WaggA , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. Journal of the American Geriatrics Society2013;61(2):185-93. [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TrialID.SOFIA.] [sr-incont48008]WaggAS , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Efficacy and tolerability of fesoterodine in older subjects with overactive bladder: results of SOFIA (Abstract number C33). Journal of the American Geriatrics Society2011;59:S124. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont65234]">Wagg 2013a</a>; <a href="./references#CD003781-bbs2-0102" title="ZinnerNR , MattiassonA , StantonSL . Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. Journal of the American Geriatrics Society2002;50(5):799-807. [sr-incont14679]">Zinner 2002</a>; <a href="./references#CD003781-bbs2-0104" title="ZinnerN , SussetJ , GittelmanM , ArguinzonizM , RekedaL , HaabF . Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. International Journal of Clinical Practice2006;60(1):119-26. [sr-incont21507]">Zinner 2006</a>). The result suggests that patients taking anticholinergics are 2.24 times more likely to experience dyspepsia/indigestion than those taking placebo (RR 2.24, 95% CI 1.70 to 2.94; P &lt; 0.00001; <a href="./references#CD003781-fig-0021" title="">Analysis 1.12</a>). </p> <p>The I<sup>2</sup> value for subgroup differences for this outcome is 44.5%. After investigating sensitivity and deselecting tolterodine, the I<sup>2</sup> value reduced to 0%. When tolterodine was added to the analyses, risk of dyspepsia/indigestion with anticholinergics reduced (RR 2.24, 95% CI 1.70 to 2.94), but without tolterodine the risk increased (RR 3.24, 95% CI 2.20 to 4.77). Thus, tolterodine might present less of a risk for dyspepsia/indigestion compared to other anticholinergics included in the review.   </p> </section> <section id="CD003781-sec-0085"> <h5 class="title">Adverse events: flu‐like symptoms/fatigue</h5> <p>Thirteen studies were included in the analysis for flu‐like symptoms/ fatigue, with a total of 8674 participants (5344 in the anticholinergic group and 3330 in the placebo group) (<a href="./references#CD003781-bbs2-0004" title="AbramsP , KelleherC , StaskinD , KayR , MartanA , MincikI , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World Journal of Urology2017;35(5):827-38. [NCT01340027] [sr-incont77897]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Cardiovascular safety of combination treatment with mirabegron and solifenacin in patients with overactive bladder in a randomised, double-blind, dose-ranging, Phase II study (Symphony) (Abstract). European Urology, Supplements2014;13(1):e574-e574a. [NCT01340027] [sr-incont67160]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB) - efficacy and safety results from a randomised phase II study (Symphony) (Abstract number 295). Neurourology and Urodynamics2013;32(6):930-1. [NCT01340027] [TrialID.SYMPHONY.] [sr-incont49188]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB): safety results from a phase 2 study (Abstract number MP-16.08). Urology2013;82(3 Suppl 1):S139. [NCT01340027] [sr-incont66675]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: Exploratory responder analyses of efficacy and evaluation of patient reported outcomes from a randomised, double-blind, dose-ranging, phase 2 study (Symphony) (Abstract number MP-24.11). Urology2014;84(4 Suppl 1):S145-6. [NCT01340027] [sr-incont67194]AbramsP , KelleherC , StaskinD , RechbergerT , KayR , MartinaR , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (SYMPHONY). European Urology2015;67(3):577-88. [NCT01340027] [sr-incont66674]NCT01340027, Bristol Urological Institute . A study to evaluate the efficacy, safety and tolerability of mirabegron and solifenacin succinate alone and in combination for the treatment of overactive bladder (symphony) [A randomized, double-blind, factorial, parallel-group, active and placebo-controlled, multicenter dose-ranging study to evaluate the efficacy, safety and tolerability of six dose combinations of solifenacin succinate and mirabegron compared to mirabegron and solifenacin succinate monotherapies in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01340027 (first received 21 April 2011). [178-CL-100] [2010-020601-32] [NCT01340027] [TrialID.SYMPHONY] [sr-incont44510]NittiV , AbramsP , StaskinD , AuerbachS , MartinaR , VanMR . Urinary retention in patients with overactive bladder treated with mirabegron alone and in combination with solifenacin: the results of two randomized, double-blind, phase II studies (Abstract number MP76-13). Journal of Urology2014;191(4 Suppl 1):e886-7. [NCT00410514] [NCT01340027] [TrialID.SYMPHONY] [sr-incont67453]">Abrams 2013</a>; <a href="./references#CD003781-bbs2-0013" title="ChappleC . Fesoterodine a new effective and well-tolerated antimuscarinic for the treatment of urgency-frequency syndrome: results of a phase 2 controlled study (Abstract 142). Neurourology and Urodynamics2004;23(5/6):598-9. [srincont-19023]Drug company. A Phase 2, parallel group, randomized, double-blind, placebo controlled dose-ranging trial to determine the optimal dose and the tolerability of sustained release SPM 8272 (fesoterodine) in subjects with non-neurogenic bladder overactivity. Protocol numbers: A0221027 (SP582). ClinicalStudyResults.org (accessed 3 March 2011)2002. [Protocol numbers: A0221027 (SP582)] [srincont-41110]">Chapple 2004a</a>; <a href="./references#CD003781-bbs2-0016" title="ChappleC , Van KerrebroeckP , TubaroA , Haag-MolkentellerC , ForstHT , MassowU , et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder [Erratum appears in: European Urology 2008,53(6):1319]. European Urology2007;52(4):1204-12. [NCT00220363] [SP583] [srincont-23875]ChappleC , Van KerrebroeckP , TubaroA , MillardR . Fesoterodine in non-neurogenic voiding dysfunction - results on efficacy and safety in a phase 3 trial (Abstract number 379). In: 21st Annual European Association of Urology (EAU) Congress; 2006 Apr 5-8; Paris, France. 2006. [srincont-41109]ChappleC , Van KerrebroeckP , TubaroA , WangJT , HvidstenK , BrodskyM . Efficacy of fesoterodine in patients with overactive bladder (OAB): improvements in OAB symptoms and health-related quality of life (HRQL) (Poster abstract number 1188). Journal of Urology2007;177(4 Suppl S):392. [srincont-31882]ChappleCR , vanKerrebroeckPE , JünemannKP , WangJT , BrodskyM . Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU International2008;102(9):1128-32. [srincont-29255]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. KelleherCJ , TubaroA , WangJT , KoppZ . Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU International2008;102(1):56-61. [srincont-27613]SandPK , MorrowJD , BavendamT , CreangaDL , NittiVW . Efficacy and tolerability of fesoterodine in women with overactive bladder. International Urogynecology Journal2009;20(7):827-35. [srincont-31351]">Chapple 2007a</a>; <a href="./references#CD003781-bbs2-0024" title="DmochowskiR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. A double-blind, placebo-controlled trial of flexible-dose fesoterodine for overactive bladder (Abstract number 715). In: International Continence Society (ICS); 39th Annual Meeting; 2009 Sep 29-Oct 03; San Francisco, CA. 2009. [sr-incont35627]DmochowskiRR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder [Errata appear in: Urology 2010 Jun;75(6):1519 and in Urology 2011 Jun;77(6):1513]. Urology2010;75(1):62-8. [A0221014] [NCT00536484] [sr-incont39548]DuBeauC , KrausSR , SunF , MorrowJD . Fesoterodine in older vs younger subjects with overactive bladder (Abstract number D87). Journal of the American Geriatrics Society2010;58:S218. [NCT00536484] [sr-incont64309]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. [sr-incont78640]NCT00536484. Fesoterodine flexible dose study [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with overactive bladder]. clinicaltrials.gov/show/NCT00536484 (first received 27 September 2007). [NCT00536484] [sr-incont49160]StaskinD , KhullarV , MichelMC , MorrowJD , SunF , GuanZ , et al. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. Neurourology and Urodynamics2011;30(8):1480-5. [sr-incont42686]">Dmochowski 2010</a>; <a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>; <a href="./references#CD003781-bbs2-0038" title="HerschornS , HeesakkersJ , Castro-DiazD , WangJT , BrodskyM , GuanZ . Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*. Current Medical Research and Opinion2008;24(12):3513-21. [A6121122] [NCT00143377] [srincont-29250]HerschornS , HeesakkersJ , Castro-DiazD , WangJT , GuanZ , BrodskyM . Tolterodine extended release (TER) improves objective and subjective outcomes after 1 week of treatment in patients with overactive bladder (Abstract number 132). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S78-9. [srincont-26602]">Herschorn 2008</a>; <a href="./references#CD003781-bbs2-0042" title="HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21072]HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21072]HillS , KhullarV , WyndaeleJJ , LheritierK , . Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. International Urogynecology Journal and Pelvic Floor2006;17(3):239-47. [srincont-22464]">Hill 2005</a>; <a href="./references#CD003781-bbs2-0053" title="CapoJP , TogliaM , Forero-SchwanhaeuserS , HeW . Patients reporting severe overactive bladder symptoms: effects of solifenacin treatment on objective measures and patient-reported outcomes (Abstract number 582). In: International Continence Society (ICS), 38th Annual Meeting; 2008 Oct 20-24; Cairo, Egypt. 2008. [srincont-31844]CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. KarramMM , TogliaMR , SerelsSR , AndohM , FakhouryA , Forero-SchwanhaeuserS . Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology2009;73(1):14-8. [A0221094] [NCT00454896] [TrialID.VENUS.] [srincont-29219]SerelsSR , TogliaMR , Forero-SchwanhaeuserS , HeW . Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms. Current Medical Research and Opinion2010;26(10):2277-85. [srincont-40376]StaskinD , DmochowskiR , SerelsS , AndohM , SmithN . Report from a randomized, placebo-controlled study showing significant improvement in urgency and patient-reported outcomes in overactive bladder patients treated with solifenacin (Abstract number 124). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73-4. [srincont-26600]TogliaM , AndohM , HussainI . Solifenacin improved warning time significantly compared to placebo in patients with overactive bladder (Abstract number 123). Neurourology and Urodynamics2006;25(6):655. [srincont-26629]TogliaM , AndohM , HussainI . Solifenacin improves urgency symtoms as assessed by voiding diaries and patient-reported outcomes (PRO) in patients with overactive bladder (Abstract number 155). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26636]TogliaMR , OstergardDR , AppellRA , AndohM , FakhouryA , HussainIF . Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status. International Urogynecology Journal2010;21(7):847-54. [srincont-40094]TogliaMR , SerelsSR , LarameeC , KarramMM , NandyIM , AndohM , et al. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial. Postgraduate Medicine2009;121(5):151-8. [srincont-34204]ZinnerS , HerschornS , AndohM , HussainI . Responder analyses show statistically significant improvements in incontinence and urgency are associated with reduction in symptom bother and improvement in health-related quality of life: VENUS results (Abstract number 123). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73. [srincont-26599]">Karram 2009</a>; <a href="./references#CD003781-bbs2-0069" title="Drug company. A phase 2, parallel group, stratified, randomized, double blind, placebo-controlled trial to investigate the efficacy and safety of 3 different dosages of sustained release fesoterodine in subjects with overactive bladder showing either involuntary detrusor contractions or normal findings during the baseline urodynamic assessment. Protocol numbers: A0221029 (SP668). ClinicalStudyResults.org (accessed 3 March 2011). [srincont-41111]NittiV , WiatrakM , KreitmanL , LipsitzD . Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB): results of a phase 2 trial (Abstract number 306). In: International Continence Society (ICS); 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21084]">Nitti 2005</a>; <a href="./references#CD003781-bbs2-0089" title="ThuroffJW , BunkeB , EbnerA , FaberP , deGeeterP , HannappelJ , et al. Randomized, double-blind multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin vs. propantheline vs. placebo. Neurourology and Urodynamics1990;9(4):337-8. [srincont-5108]ThuroffJW , BunkeB , EbnerA , FaberP , deGeeterP , HannappelJ , et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. Journal of Urology1991;145(4):813-7. [srincont-1288]">Thuroff 1991</a>; <a href="./references#CD003781-bbs2-0092" title="ChancellorM , FreedmanS , MitchesonHD , AntociJ , PrimusG , WeinA . Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clinical Drug Investigation2000;19(2):83-91. [srincont-16326]FreemanR , HillS , MillardR , SlackM , SutherstJ , Tolterodine Study Group. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstetrics and Gynecology2003;102(3):605-11. [srincont-16494]GarelyA , Tolterodine Study Group. Once-daily tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder. International Urology Journal2001;12(Suppl 1):S18. [srincont-12012]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of life of patients with overactive bladder receiving tolterodine. Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of patients with overactive bladder receiving tolterodine (Abstract number 82). Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , ReesePR . Health related quality of life of patients with overactive bladder receiving tolterodine once-daily. Neurourology and Urodynamics2000;19(4):519-21. [srincont-9987]KelleherCJ , ReesePR , PleilAM , OkanoGJ . Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. American Journal of Managed Care2002;8(Suppl 19):S608-15. [srincont-17998]KelleherCJ , Tolterodine Study Group. Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2000;11(Suppl 1):S94. [srincont-11915]KrederKJ . Antimuscarinic therapy: relationship between efficacy and side effects in responders and non-responders. Journal of Urology2001;165(Suppl 5):S165. [srincont-16327]KrederKJ . Clinical effectiveness of antimuscarinic therapy: the relationship between efficacy and tolerability. In: Proceedings of the International Continence Society Annual Meeting(ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001:140. [srincont-14376]MallettV . Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2001;12(Suppl 1):4. [srincont-12011]MillardRJ , TamaddonK , Tolterodine Study Group. Randomized controlled trial to compare tolterodine prolonged release capsules and tolterodine immediate release tablets versus placebo in patients with symptoms of detrusor overactivity (Abstract number 57). Australian and New Zealand Journal of Surgery2002;Suppl 72:A140. [sr-incont22190]PleilAM , ReesePR , KelleherCJ , OkanoGJ . Health-related quality of life of patients with overactive bladder receiving immediate-release tolterodine. HEPAC Health Economics in Prevention and Care2001;2(2):69-75. [sr-incont18060]RoehrbornCG , AbramsP , RovnerES , KaplanSA , HerschornS , GuanZ . Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU International2006;97(5):1003-6. [sr-incont21882]SwiftS . Efficacy and tolerability of once-daily tolterodine for women with overactive bladder. In: International Continence Society Annual Meeting (ICS), 31st annual meeting; 2001 Sept 18-21; Seoul, Korea. 2001:No. 329. [srincont-14481]SwiftS . Once-daily tolterodine is effective and well tolerated in women with overactive bladder (Abstract 57). In: 2nd International Consultation on Incontinence; 2001 July 1-3; Paris, France. 2001. [srincont-16319]SwiftSE . Once-daily (OD) tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder (OAB). International Urogynecology Journal2000;11(Suppl 1):S15. [sr-incont11906]SwiftSE . Once-daily administration of extended-release tolterodine is effective and well-tolerated in patients with overactive bladder. In: XVI FIGO World Congress of Obstetrics and Gynecology; 2000 Sept 3-8; Washington DC. Vol. Book 1. 2000:40. [sr-incont12085]SwiftSE . Overactive bladder in females: treatment with once-daily tolterodine. International Urogynecology Journal2001;12(Suppl 3):S71. [sr-incont16328]Van KerrebroeckP , KrederK , JonasU , ZinnerN . Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology2001;57(3):414-21. [sr-incont11953]Van KerrebroeckPEV . Long-term (12 months) efficacy and tolerability of tolterodine once-daily in the treatment of overactive bladder. Neurourology and Urodynamics2001;20(4):401-2. [sr-incont15714]Van KerrebroeckPEVA , Tolterodine Study Group. Long-term tolerability and efficacy of once-daily (OD) tolterodine in the treatment of overactive bladder (OB). International Urogynecology Journal2001;12(Suppl 3):S49. [sr-incont16329]Van KerrebroeckPEVA , Tolterodine Study Group. Significant decreases in perception of urgency and urge incontinence episodes with once-daily tolterodine treatment in patients with overactive bladder (Abstract number 89). Neurourology and Urodynamics2000;19(4):493-4. [sr-incont9980]WeinAJ , KhullarV , WangJT , GuanZ . Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. BJU International2007;99(2):360-3. [sr-incont23180]vanKerrebroeckPE , KelleherCJ , CoyneKS , KoppZ , BrodskyM , WangJT . Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. Health and Quality of Life Outcomes2009;7(13):13. [10.1186/1477-7525-7-13] [sr-incont31438]vanKerrebroeckPE , WangJ , GuanZ . Effects of tolterodine extended release in patients with overactive bladder: perceived treatment benefits improve with efficacy (Abstract number 511). European Urology Supplements2004;3(2):130. [sr-incont31090]">Van Kerrebroeck 2001</a>; <a href="./references#CD003781-bbs2-0093" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CrosbyRD , MathiasSD , MarshallTS . Relationships between symptoms, symptom bother, and health-related quality of life in patients with overactive bladder taking solifenacin or placebo in the VIBRANT study. International Journal of Clinical Practice2011;65(2):211-8. [sr-incont41015]GollarKM , YoungDG , BailenJ , HeW , Forero-SchwanhaeuserS . Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: a secondary analysis of the VIBRANT study. Urologic Nursing2012;32(1):38-46. [TrialID.VIBRANT.] [sr-incont44571]Samuels T‐A, MitchesonHD , VardyM , Forero‐SchwanhaeuserS , MarshallT , HeW . Efficacy of solifenacin for symptom bother and other patient-reported outcomes in patients with overactive bladder (OAB): results of a large, double-blind, placebo-controlled trial (Abstract number: poster #74). Neurourology and Urodynamics2009;28(2):149. [sr-incont31063]VardyMD , MitchesonHD , SamuelsTA , Forero-SchwanhaeuserS , HeW . Efficacy of solifenacin on overactive bladder symptoms, symptom bother, and other patient-reported outcomes in subjects with or without incontinence: a post hoc analysis of data from VIBRANT. Female Pelvic Medicine and Reconstructive Surgery2011;17(1):24-9. [TrialID.VIBRANT.] [sr-incont44741]VardyMD , MitchesonHD , SamuelsTA , WegenkeJD , Forero-SchwanhaeuserS , MarshallTS , et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. International Journal of Clinical Practice2009;63(12):1702-14. [905-UC-010] [NCT00573508] [TrialID.VIBRANT.] [sr-incont35459]">Vardy 2009</a>; <a href="./references#CD003781-bbs2-0094" title="EUCTR2007-007087-17-SE. A 24-week, multicentre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-007087-17 (first received 13 June 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont64588]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00798434. A study to compare the effectiveness and safety of fesoterodine and placebo in an elderly population of patients who go to the toilet very frequently due to overactive bladder (SOFIA) [A 24-week, multi-centre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00798434 (first received 26 November 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont49847]SchneiderT , BergqvistA , WangJ , WaggA , Ebel-BitounC . Treatment with fesoterodine versus tolterodine for reducing symptom bother in elderly patients with overactive bladder including urgency urinary incontinence. European Urology, Supplements2012;11(1):e687-a. [sr-incont65389]WaggA , CarlssonM , ElsobkyM , FernetM . Effect of flexible dose fesoterodine on cognitive function in &gt;65 year old patients with OAB: data from two RCT (Abstract number 438). Neurourology and Urodynamics2019;38:S297-8. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78651]WaggA , DarekarA , ArumiD , KhullarV , OelkeM . Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people &gt;65 years of age: a post hoc analysis of data from the SOFIA study. Neurourology and Urodynamics2015;34(5):438-43. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont68100]WaggA , ElsobkyM , CarlssonM , FernetM . Response and cognitive safety of fesoterodine in patients &gt;65y old with OAB. Is there a relationship between cognition and treatment response? (Abstract number 183). Neurourology and Urodynamics2019;38:S118-20. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78632]WaggA , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. Journal of the American Geriatrics Society2013;61(2):185-93. [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TrialID.SOFIA.] [sr-incont48008]WaggAS , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Efficacy and tolerability of fesoterodine in older subjects with overactive bladder: results of SOFIA (Abstract number C33). Journal of the American Geriatrics Society2011;59:S124. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont65234]">Wagg 2013a</a>). There was no evidence of a difference in the risk of experiencing flu‐like symptoms/fatigue but the confidence interval is wide enough to include differences favouring either anticholinergics or placebo (RR 1.19, 95% CI 0.89 to 1.59; P = 0.23; <a href="./references#CD003781-fig-0022" title="">Analysis 1.13</a>). </p> </section> <section id="CD003781-sec-0086"> <h5 class="title">Adverse events: headache</h5> <p>Forty‐one studies were included in the analysis for headache, with a total of 25,568 participants (16,482 in the anticholinergic group and 9086 in the placebo group) (<a href="./references#CD003781-bbs2-0004" title="AbramsP , KelleherC , StaskinD , KayR , MartanA , MincikI , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World Journal of Urology2017;35(5):827-38. [NCT01340027] [sr-incont77897]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Cardiovascular safety of combination treatment with mirabegron and solifenacin in patients with overactive bladder in a randomised, double-blind, dose-ranging, Phase II study (Symphony) (Abstract). European Urology, Supplements2014;13(1):e574-e574a. [NCT01340027] [sr-incont67160]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB) - efficacy and safety results from a randomised phase II study (Symphony) (Abstract number 295). Neurourology and Urodynamics2013;32(6):930-1. [NCT01340027] [TrialID.SYMPHONY.] [sr-incont49188]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB): safety results from a phase 2 study (Abstract number MP-16.08). Urology2013;82(3 Suppl 1):S139. [NCT01340027] [sr-incont66675]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: Exploratory responder analyses of efficacy and evaluation of patient reported outcomes from a randomised, double-blind, dose-ranging, phase 2 study (Symphony) (Abstract number MP-24.11). Urology2014;84(4 Suppl 1):S145-6. [NCT01340027] [sr-incont67194]AbramsP , KelleherC , StaskinD , RechbergerT , KayR , MartinaR , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (SYMPHONY). European Urology2015;67(3):577-88. [NCT01340027] [sr-incont66674]NCT01340027, Bristol Urological Institute . A study to evaluate the efficacy, safety and tolerability of mirabegron and solifenacin succinate alone and in combination for the treatment of overactive bladder (symphony) [A randomized, double-blind, factorial, parallel-group, active and placebo-controlled, multicenter dose-ranging study to evaluate the efficacy, safety and tolerability of six dose combinations of solifenacin succinate and mirabegron compared to mirabegron and solifenacin succinate monotherapies in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01340027 (first received 21 April 2011). [178-CL-100] [2010-020601-32] [NCT01340027] [TrialID.SYMPHONY] [sr-incont44510]NittiV , AbramsP , StaskinD , AuerbachS , MartinaR , VanMR . Urinary retention in patients with overactive bladder treated with mirabegron alone and in combination with solifenacin: the results of two randomized, double-blind, phase II studies (Abstract number MP76-13). Journal of Urology2014;191(4 Suppl 1):e886-7. [NCT00410514] [NCT01340027] [TrialID.SYMPHONY] [sr-incont67453]">Abrams 2013</a>; <a href="./references#CD003781-bbs2-0009" title="CardozoL , ChappleCR , Toozs-HobsonP , Grosse-FreeseM , BulittaM , LehmacherW , et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomised, double-blind, multicentre clinical trial. British Journal of Urology International2000;85(6):659-64. [srincont-11732]">Cardozo 2000</a>; <a href="./references#CD003781-bbs2-0013" title="ChappleC . Fesoterodine a new effective and well-tolerated antimuscarinic for the treatment of urgency-frequency syndrome: results of a phase 2 controlled study (Abstract 142). Neurourology and Urodynamics2004;23(5/6):598-9. [srincont-19023]Drug company. A Phase 2, parallel group, randomized, double-blind, placebo controlled dose-ranging trial to determine the optimal dose and the tolerability of sustained release SPM 8272 (fesoterodine) in subjects with non-neurogenic bladder overactivity. Protocol numbers: A0221027 (SP582). ClinicalStudyResults.org (accessed 3 March 2011)2002. [Protocol numbers: A0221027 (SP582)] [srincont-41110]">Chapple 2004a</a>; <a href="./references#CD003781-bbs2-0014" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. ChappleCR , AranoP , BoschJH , De RidderD , KramerG , RidderAM . YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo- and tolterodine-controlled, phase-II, dose-finding study (Abstract 75). Neurourology and Urodynamics2002;21(4):381-2. [srincont-14551]ChappleCR , ArañoP , BoschJL , De RidderD , KramerAE , RidderAM . Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU International2004;93(1):71-7. [srincont-17334]KelleherCJ , CardozoL , ChappleCR , HaabF , RidderAM . Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU International2005;95(1):81-5. [srincont-20241]SmithN , GrimesI , RidgeS , TempelD , UchidaT , YamanouchiUS . YM905 is effective and safe as treatment of overactive bladder in women and men: results from phase II study (Abstract). In: International Continence Society (ICS), 32nd Annual Meeting; 2002 Aug 28-30; Heidelberg, Germany. 2002:138-9. [sr-incont14508]">Chapple 2004b</a>; <a href="./references#CD003781-bbs2-0016" title="ChappleC , Van KerrebroeckP , TubaroA , Haag-MolkentellerC , ForstHT , MassowU , et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder [Erratum appears in: European Urology 2008,53(6):1319]. European Urology2007;52(4):1204-12. [NCT00220363] [SP583] [srincont-23875]ChappleC , Van KerrebroeckP , TubaroA , MillardR . Fesoterodine in non-neurogenic voiding dysfunction - results on efficacy and safety in a phase 3 trial (Abstract number 379). In: 21st Annual European Association of Urology (EAU) Congress; 2006 Apr 5-8; Paris, France. 2006. [srincont-41109]ChappleC , Van KerrebroeckP , TubaroA , WangJT , HvidstenK , BrodskyM . Efficacy of fesoterodine in patients with overactive bladder (OAB): improvements in OAB symptoms and health-related quality of life (HRQL) (Poster abstract number 1188). Journal of Urology2007;177(4 Suppl S):392. [srincont-31882]ChappleCR , vanKerrebroeckPE , JünemannKP , WangJT , BrodskyM . Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU International2008;102(9):1128-32. [srincont-29255]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. KelleherCJ , TubaroA , WangJT , KoppZ . Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU International2008;102(1):56-61. [srincont-27613]SandPK , MorrowJD , BavendamT , CreangaDL , NittiVW . Efficacy and tolerability of fesoterodine in women with overactive bladder. International Urogynecology Journal2009;20(7):827-35. [srincont-31351]">Chapple 2007a</a>; <a href="./references#CD003781-bbs2-0020" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. [sr-incont75259]ChuF , SmithN , UchidaT . Efficacy and safety of solifenacin succinate 10 mg once daily: a multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder. Current Therapeutic Research - Clinical and Experimental2009;70(6):405-20. [srincont-43324]">Chu 2009</a>; <a href="./references#CD003781-bbs2-0021" title="ChuaME , SeeMC , EsmeňaEB , BalingitJC , MoralesML . Efficacy and safety of gabapentin in comparison to solifenacin succinate in adult overactive bladder treatment. Lower Urinary Tract Symptoms2018;10(2):135-42. [NCT01486706] [sr-incont74529]NCT01486706, ChuaME . Efficacy and safety of gabapentin in treating overactive bladder (OAB). clinicaltrials.gov/show/NCT01486706 (first received 6 December 2011). [NCT01486706] [SLMC10-010] [sr-incont49864]">Chua 2018</a>; <a href="./references#CD003781-bbs2-0023" title="ChancellorMB , OefeleinMG , VasavadaS . Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release. Neurourology and Urodynamics2010;29(4):551-4. [sr-incont39591]DmochowskiR , StaskinD , SandP , ZinnerN . Trospium chloride 60 mg once daily improves quality of life in subjects with overactive bladder syndrome (Abstract number 277). In: International Continence Society (ICS); 37th Annual Meeting; 2008 Aug 20-24; Rotterdam, the Netherlands. 2007. [srincont-26679]DmochowskiRR , RosenbergMT , ZinnerNR , StaskinDR , SandPK . Extended-release trospium chloride improves quality of life in overactive bladder. Value in Health2010;13(2):251-7. [srincont-40049]DmochowskiRR , SandPK , ZinnerNR , StaskinDR . Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology2008;71(3):449-54. [srincont-27107]DmochowskiRR , ZinnerNR , SandPK . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: Results from a multicenter, phase III, placebo-controlled study (Abstract). Neurourology and Urodynamics2007;26(Suppl 7):1105-6. [srincont-26692]GinsbergDA , OefeleinMG , EllsworthPI . Once-daily administration of trospium chloride extended release provides 24-hr coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials. Neurourology and Urodynamics2011;30(4):563-7. [sr-incont41531]RovnerE , DmochowskiR , WatanabeJ . Once daily (QD) trospium chloride 60 mg extended release (XR) is safe and effective in patients (PTS) with the overactive bladder (OAB) syndrome who use multiple concomitant medications (MEDS) (Abstract number: Poster #68). Neurourology and Urodynamics2009;28(2):146-7. [sr-incont31062]SandP , DmochowskiR , ZinnerN , StaskinD . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: results from a multicenter, phase III, placebo-controlled study (Abstract number 269). In: International Continence Society (ICS), 37th Annual Meeting; 2007 Aug 20-24; Rotterdam, the Netherlands. 2007. [srincont-26676]SandPK , DmochowskiRR , ZinnerNR , StaskinDR , AppellRA . Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome. International Urogynecology Journal and Pelvic Floor Dysfunction2009;20(12):1431-8. [sr-incont39648]SandPK , Johnson IiTM , RovnerES , EllsworthPI , OefeleinMG , StaskinDR . Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged &gt; 75 years) with overactive bladder syndrome. BJU International2011;107(4):612-20. [sr-incont41422]StaskinDR , RosenbergMT , SandPK , ZinnerNR , DmochowskiRR . Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials. International Journal of Clinical Practice2009;63(12):1715-23. [sr-incont35458]">Dmochowski 2008</a>; <a href="./references#CD003781-bbs2-0024" title="DmochowskiR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. A double-blind, placebo-controlled trial of flexible-dose fesoterodine for overactive bladder (Abstract number 715). In: International Continence Society (ICS); 39th Annual Meeting; 2009 Sep 29-Oct 03; San Francisco, CA. 2009. [sr-incont35627]DmochowskiRR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder [Errata appear in: Urology 2010 Jun;75(6):1519 and in Urology 2011 Jun;77(6):1513]. Urology2010;75(1):62-8. [A0221014] [NCT00536484] [sr-incont39548]DuBeauC , KrausSR , SunF , MorrowJD . Fesoterodine in older vs younger subjects with overactive bladder (Abstract number D87). Journal of the American Geriatrics Society2010;58:S218. [NCT00536484] [sr-incont64309]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. [sr-incont78640]NCT00536484. Fesoterodine flexible dose study [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with overactive bladder]. clinicaltrials.gov/show/NCT00536484 (first received 27 September 2007). [NCT00536484] [sr-incont49160]StaskinD , KhullarV , MichelMC , MorrowJD , SunF , GuanZ , et al. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. Neurourology and Urodynamics2011;30(8):1480-5. [sr-incont42686]">Dmochowski 2010</a>; <a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>; <a href="./references#CD003781-bbs2-0035" title="HaabF , StewartL , DwyerP . Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. European Urology2004;45(4):420-9. [srincont-17428]">Haab 2004</a>; <a href="./references#CD003781-bbs2-0038" title="HerschornS , HeesakkersJ , Castro-DiazD , WangJT , BrodskyM , GuanZ . Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*. Current Medical Research and Opinion2008;24(12):3513-21. [A6121122] [NCT00143377] [srincont-29250]HerschornS , HeesakkersJ , Castro-DiazD , WangJT , GuanZ , BrodskyM . Tolterodine extended release (TER) improves objective and subjective outcomes after 1 week of treatment in patients with overactive bladder (Abstract number 132). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S78-9. [srincont-26602]">Herschorn 2008</a>; <a href="./references#CD003781-bbs2-0039" title="CorcosJ , AnguloJC , GarelyAD , CarlssonM , GongJ , GuanZ . Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. Current Medical Research and Opinion2011;27(5):1059-65. [srincont-41596]EUCTR2006-006935-38-SE. 12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006935-38 (first received 16 April 2007). [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont64612]HerschornS , SwiftS , GuanZ , CarlssonM , BrodskyM , GongJ . Efficacy and safety of fesoterodine for overactive bladder in a double-blind, head-to-head comparison trial with tolterodine ER and placebo (Abstract number 710). In: International Continence Society (ICS), 39th Annual Meeting; 2009 Sep 29-Oct 3; San Francisco, CA. 2009. [srincont-35326]HerschornS , SwiftS , GuanZ , CarlssonM , MorrowJD , BrodskyM , et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU International2010;105(1):58-66. [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont39540]NCT00444925. Clinical trial to evaluate the efficacy and safety of Fesoterodine in comparison to Tolterodine for overactive bladder (OAB) [12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder (OAB)]. clinicaltrials.gov/show/NCT00444925 (first received 08 March 2007). [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont49159]">Herschorn 2009a</a>; <a href="./references#CD003781-bbs2-0042" title="HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21072]HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21072]HillS , KhullarV , WyndaeleJJ , LheritierK , . Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. International Urogynecology Journal and Pelvic Floor2006;17(3):239-47. [srincont-22464]">Hill 2005</a>; <a href="./references#CD003781-bbs2-0043" title="HommaY , KawabeK . Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World Journal of Urology2004;22(4):251-6. [srincont-19412]HommaY , PaickJS , LeeJG , KawabeK , Japanese and Korean Tolterodine Study Group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU International2003;92(7):741-7. [srincont-16418]">Homma 2003</a>; <a href="./references#CD003781-bbs2-0044" title="HommaY , YamaguchiT , YamaguchiOA . A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2008;15(9):809-15. [srincont-27742]">Homma 2008</a>; <a href="./references#CD003781-bbs2-0045" title="HommaY , YamaguchiO , Imidafenacin Study Group. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2009;16(5):499-506. [NCT00212732] [ONO-8025-08] [srincont-31368]">Homma 2009</a>; <a href="./references#CD003781-bbs2-0047" title="JacquetinB , WyndaeleJJ . Tolterodine reduces the number of incontinence episodes in patients with an overactive bladder. European Journal of Obstetrics and Gynecology and Reproductive Biology2001;98(1):97-102. [srincont-12200]JacquetinB , WyndaeleJJ . Tolterodine reduces the number of incontinence episodes in patients with detrusor overactivity. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(1):S30. [srincont-5167]">Jacquetin 2001</a>; <a href="./references#CD003781-bbs2-0048" title="JonasU , HofnerK , MadersbacherH , HolmdahlTH . Efficacy and safety of two doses of Tolterodine compared to placebo in patients with detrusor overactivity. Neurourology and Urodynamics1997;16(5):477-8. [srincont-5841]JonasU , HöfnerK , MadersbacherH , HolmdahlTH . Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group. World Journal of Urology1997;15(2):144-51. [srincont-5436]">Jonas 1997</a>; <a href="./references#CD003781-bbs2-0050" title="JünemannKP , HessdörferE , Unamba‐OparahI , BerseM , BrünjesR , MadersbacherH . Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. Urologia Internationalis2006;77(4):334-9. [srincont-22199]">Junemann 2006</a>; <a href="./references#CD003781-bbs2-0051" title="EUCTR2007-006451-39-SE. 12-week, randomized, double-blind, double-dummy, placebo controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-006451-39 (first received 20 February 2008). [A0221046] [EUCTR2007-006451-39-SE] [sr-incont64591]KaplanSA , SchneiderT , FooteJ , GuanZ . Superior efficacy of fesoterodine over tolterodine with rapid onset: a prospective, head-to-head, placebo-controlled trial (Abstract number 67). Neurourology and Urodynamics2010;29(6):905-7. [srincont-40130]KaplanSA , SchneiderT , FooteJE , GuanZ , CarlssonM , GongJ . Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU International2011;107(9):1432-40. [A0221046] [NCT00611026] [srincont-41334]">Kaplan 2011</a>; <a href="./references#CD003781-bbs2-0053" title="CapoJP , TogliaM , Forero-SchwanhaeuserS , HeW . Patients reporting severe overactive bladder symptoms: effects of solifenacin treatment on objective measures and patient-reported outcomes (Abstract number 582). In: International Continence Society (ICS), 38th Annual Meeting; 2008 Oct 20-24; Cairo, Egypt. 2008. [srincont-31844]CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. KarramMM , TogliaMR , SerelsSR , AndohM , FakhouryA , Forero-SchwanhaeuserS . Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology2009;73(1):14-8. [A0221094] [NCT00454896] [TrialID.VENUS.] [srincont-29219]SerelsSR , TogliaMR , Forero-SchwanhaeuserS , HeW . Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms. Current Medical Research and Opinion2010;26(10):2277-85. [srincont-40376]StaskinD , DmochowskiR , SerelsS , AndohM , SmithN . Report from a randomized, placebo-controlled study showing significant improvement in urgency and patient-reported outcomes in overactive bladder patients treated with solifenacin (Abstract number 124). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73-4. [srincont-26600]TogliaM , AndohM , HussainI . Solifenacin improved warning time significantly compared to placebo in patients with overactive bladder (Abstract number 123). Neurourology and Urodynamics2006;25(6):655. [srincont-26629]TogliaM , AndohM , HussainI . Solifenacin improves urgency symtoms as assessed by voiding diaries and patient-reported outcomes (PRO) in patients with overactive bladder (Abstract number 155). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26636]TogliaMR , OstergardDR , AppellRA , AndohM , FakhouryA , HussainIF . Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status. International Urogynecology Journal2010;21(7):847-54. [srincont-40094]TogliaMR , SerelsSR , LarameeC , KarramMM , NandyIM , AndohM , et al. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial. Postgraduate Medicine2009;121(5):151-8. [srincont-34204]ZinnerS , HerschornS , AndohM , HussainI . Responder analyses show statistically significant improvements in incontinence and urgency are associated with reduction in symptom bother and improvement in health-related quality of life: VENUS results (Abstract number 123). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73. [srincont-26599]">Karram 2009</a>; <a href="./references#CD003781-bbs2-0054" title="KhullarV , HillS , LavalKU , SchiotzHA , JonasU , VersiE . Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology2004;64(2):269-74; discussion 274-5. [srincont-19498]KhullarV , HillS , SolankiJ . Assessment of health-related quality of life in patients with overactive bladder taking tolterodine extended release versus placebo (Abstract number 318). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21075]">Khullar 2004</a>; <a href="./references#CD003781-bbs2-0063" title="LeeKS , ChooMS , KimDY , KimJC , KimHJ , MinKS , et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. Journal of Urology2005;174(4 Pt 1):1334-8. [sr-incont21016]LeeKS , ChooMS , PaickJS , LeeJG , SeoJT , LeeJZ , et al. Propiverine hydrochloride reduced frequency and perception of urgency in treatment of overactive bladder: a 12 week prospective, randomized, double blind, placebo controlled study (Abstract number 279). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26640]LeeKS , LeeHW , ChooMS , PaickJS , LeeJG , SeoJT , et al. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'. BJU International2010;105(11):1565-70. [2005-01-08] [NCT00903045] [PROUD] [sr-incont39958]NCT00903045. Urinary urgency outcomes following propiverine treatment for an overactive bladder [Urinary urgency outcomes following propiverine treatment for an overactive bladder: propiverine study on overactive bladder including urgency data (PROUD)]. clinicaltrials.gov/show/NCT009030452005;(first received 15 May 2009). [2005-01-08] [NCT00903045] [TrialID.PROUD] [sr-incont49860]">Lee 2006</a>; <a href="./references#CD003781-bbs2-0066" title="Malone-LeeJG , WalshB , MaugourdMF , Tolterodine in the Elderly Study Group. The safety and clinical efficacy of two doses of tolterodine compared to placebo in elderly patients. In: International Continence Society (ICS), 27th Annual Meeting; 1997 Sep 23-26; Yokohama, Japan. 1997:155-6. [srincont-5855]Malone‐LeeJG , WalshJB , MaugourdMF . Tolterodine: A safe and effective treatment for older patients with overactive bladder. Journal of the American Geriatric Society2001;49(6):700-5. [srincont-12319]WaggA , Malone-LeeJ . Pressure-flow variables in patients treated with tolterodine for detrusor overactivity. BJU International2003;92(9):969-71. [sr-incont16659]">Malone‐Lee 2001</a>; <a href="./references#CD003781-bbs2-0068" title="DmochowskiR , MitchesonD , FrenklT , BennettN , MuddPN . Durable efficacy and safety of long-term once-daily vibegron, a novel oral B-3 adrenergic receptor agonist: A 52-week phase 2 study in patients with overactive bladder syndrome (Abstract number PD50-03). Journal of Urology2018;199(4):e970-1. [sr-incont78091]EUCTR2010-022121-15-IT. A phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2 part clinical study of the efficacy and safety of MK-4618 in patients with overactive bladder - MK4618-008 [A 52-week extension to: a phase iib randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder]. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-022121-15 (first received 12 April 2011). [EUCTR2010-022121-15-IT] [MK4618-008] [NCT01314872] [sr-incont78639]MitchesonD , FrenklT , SamantaS , Anne PintoC , GreenS , BennettN , et al. Vibegron, a novel once daily oral beta-3 agonist, significantly reduces average daily micturitions, urge incontinence episodes and urgency episodes in patients with overactive bladder (Abstract number: podium #34). Neurourology and Urodynamics2018;37(Suppl 1):S565. [EUCTR2010-022121-15-IT] [NCT01314872] [sr-incont78618]MitchesonD , PintoCA , FrenklT , ChenL , PrasadM , MuddPN . Once daily vibegron improves quality of life measures in patients with overactive bladder (Abstract number PUK17). Value in Health2018;21(Suppl 1):S267-8. [EUCTR2010-022121-15-IT] [NCT01314872;] [sr-incont78619]MitchesonHD , SamantaS , MuldowneyK , PintoCA , RochaBA , GreenS , et al. Vibegron (RVT-901/MK-4618/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial. European Urology2019;75(2):274-82. [NCT01314872] [sr-incont78620]NCT01314872. A study of the efficacy and safety of Vibegron (MK-4618) in participants with overactive bladder (OAB) (MK-4618-008) [A phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder a 52-week extension to: a phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder]. clinicaltrials.gov/show/NCT01314872 (first received 15 March 2011). [NCT01314872] [sr-incont63793]UKCRN10391. A phase IIB randomised, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of MK-4618 in patients with overactive bladder . public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=10391 (accessed 28 June 2012). [CCRN525] [UKCRN10391] [sr-incont45046]">Mitcheson 2019</a>; <a href="./references#CD003781-bbs2-0069" title="Drug company. A phase 2, parallel group, stratified, randomized, double blind, placebo-controlled trial to investigate the efficacy and safety of 3 different dosages of sustained release fesoterodine in subjects with overactive bladder showing either involuntary detrusor contractions or normal findings during the baseline urodynamic assessment. Protocol numbers: A0221029 (SP668). ClinicalStudyResults.org (accessed 3 March 2011). [srincont-41111]NittiV , WiatrakM , KreitmanL , LipsitzD . Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB): results of a phase 2 trial (Abstract number 306). In: International Continence Society (ICS); 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21084]">Nitti 2005</a>; <a href="./references#CD003781-bbs2-0070" title="GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NittiVW , DmochowskiR , SandPK , ForstHT , Haag-MolkentellerC , MassowU , et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. Journal of Urology2007;178(6):2488-94. [NCT00138723] [SP584] [srincont-26313]">Nitti 2007</a>; <a href="./references#CD003781-bbs2-0077" title="RogersR , BachmannG , JumadilovaZ , SunF , MorrowJD , GuanZ , et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. International Urogynecology Journal and Pelvic Floor Dysfunction2008;19(11):1551-7. [A6121002] [NCT00143481] [srincont-27729]RogersRG , BachmannG , ScarperoH , JumadilovaZ , SunF , MorrowJD , et al. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. Current Medical Research and Opinion2009;25(9):2159-65. [srincont-32060]">Rogers 2008</a>; <a href="./references#CD003781-bbs2-0079" title="RovnerES , KaplanS , GuanZ , WangJT , RoehrbornCG . Clinical efficacy and safety of tolterodine extended release in male patients with overactive bladder and urgency urinary incontinence (Abstract number 188). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21091]">Rovner 2005</a>; <a href="./references#CD003781-bbs2-0080" title="RudyD , ClineK , GoldbergK , HarrisR . A multicenter, randomized, placebo-controlled trial of trospium chloride in overactive bladder patients (Abstract). Neurourology and Urodynamics2004;23(5/6):600-1. [sr-incont19025]RudyD , ClineK , HarrisR , GoldbergK , DmochowskiR . Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology2006;67(2):275-80. [srincont-21604]RudyD , ClineK , HarrisR , GoldbergK , DmochowskiR . Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. BJU International2006;97(3):540-6. [sr-incont21593]">Rudy 2006</a>; <a href="./references#CD003781-bbs2-0082" title="ChancellorMB , OefeleinMG , VasavadaS . Obesity is associated with a more severe overactive bladder disease state that is effectively treated with one daily administration of trospium chloride extended release [Erratum available in: Neurourology and Urodynamics 2010;29(5):804]. Neurourology and Urodynamics2010;29(4):551-4. [sr-incont39591]GinsbergDA , OefeleinMG , EllsworthPI . Once-daily administration of trospium chloride extended release provides 24-hour coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials. Neurourology and Urodynamics2011;30(4):563-7. [sr-incont41531]RovnerE , DmochowskiR , WatanabeJ . Once daily (QD) trospium chloride 60mg extended release (XR) is safe and effective in patients (PTS) with the overactive bladder (OAB) syndrome who use multiple concomitant medications (MEDS) (Abstract number: Poster #68). Neurourology and Urodynamics2009;28(2):146-7. [sr-incont31062]SandP , DmochowskiR , ZinnerN , StaskinD . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: results from a multicenter, phase III, placebo-controlled study (Abstract number 269). In: International Continence Society (ICS), 37th Annual Meeting; 2007 Aug 20-24; Rotterdam, the Netherlands. 2007. [sr-incont26676]SandP , StaskinD , ZinnerN , DmochowskiR . Once-daily trospium chloride extended release is effective and well tolerated for the treatment of overactive bladder: results from a multicenter, phase III trial (Abstract number 57). Neurourology and Urodynamics2007;26(5):675. [sr-incont26661]StaskinD , SandP , ZinnerN , DmochowskiR , Trospium Study Group. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. Journal of Urology2007;178(3 Pt 1):978-83; discussion 983-4. [srincont-23909]StaskinDR , RosenbergMT , SandPK , ZinnerNR , DmochowskiRR . Trospium chloride once daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised phase III trials. International Journal of Clinical Practice2009;63(12):1715-23. [sr-incont35458]StaskinDR , SandPK , ZinnerNR . Once-daily trospium chloride extended release is effective and well tolerated for the treatment of overactive bladder: results from a multicenter, phase III trial (Abstract number - poster 22). Neurourology and Urodynamics2007;26(7 Suppl):1106. [srincont-27305]">Staskin 2007</a>; <a href="./references#CD003781-bbs2-0084" title="SteersW , CorcosJ . Efficacy, tolerability and safety of darifenacin, an M3 selective receptor antagonist for the treatment of overactive bladder, using a flexible dosing regimen (Abstract number 68). Progres en Urologie2004;14(3 Suppl 3):22. [srincont-22197]">Steers 2004</a>; <a href="./references#CD003781-bbs2-0089" title="ThuroffJW , BunkeB , EbnerA , FaberP , deGeeterP , HannappelJ , et al. Randomized, double-blind multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin vs. propantheline vs. placebo. Neurourology and Urodynamics1990;9(4):337-8. [srincont-5108]ThuroffJW , BunkeB , EbnerA , FaberP , deGeeterP , HannappelJ , et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. Journal of Urology1991;145(4):813-7. [srincont-1288]">Thuroff 1991</a>; <a href="./references#CD003781-bbs2-0092" title="ChancellorM , FreedmanS , MitchesonHD , AntociJ , PrimusG , WeinA . Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clinical Drug Investigation2000;19(2):83-91. [srincont-16326]FreemanR , HillS , MillardR , SlackM , SutherstJ , Tolterodine Study Group. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstetrics and Gynecology2003;102(3):605-11. [srincont-16494]GarelyA , Tolterodine Study Group. Once-daily tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder. International Urology Journal2001;12(Suppl 1):S18. [srincont-12012]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of life of patients with overactive bladder receiving tolterodine. Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of patients with overactive bladder receiving tolterodine (Abstract number 82). Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , ReesePR . Health related quality of life of patients with overactive bladder receiving tolterodine once-daily. Neurourology and Urodynamics2000;19(4):519-21. [srincont-9987]KelleherCJ , ReesePR , PleilAM , OkanoGJ . Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. American Journal of Managed Care2002;8(Suppl 19):S608-15. [srincont-17998]KelleherCJ , Tolterodine Study Group. Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2000;11(Suppl 1):S94. [srincont-11915]KrederKJ . Antimuscarinic therapy: relationship between efficacy and side effects in responders and non-responders. Journal of Urology2001;165(Suppl 5):S165. [srincont-16327]KrederKJ . Clinical effectiveness of antimuscarinic therapy: the relationship between efficacy and tolerability. In: Proceedings of the International Continence Society Annual Meeting(ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001:140. [srincont-14376]MallettV . Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2001;12(Suppl 1):4. [srincont-12011]MillardRJ , TamaddonK , Tolterodine Study Group. Randomized controlled trial to compare tolterodine prolonged release capsules and tolterodine immediate release tablets versus placebo in patients with symptoms of detrusor overactivity (Abstract number 57). Australian and New Zealand Journal of Surgery2002;Suppl 72:A140. [sr-incont22190]PleilAM , ReesePR , KelleherCJ , OkanoGJ . Health-related quality of life of patients with overactive bladder receiving immediate-release tolterodine. HEPAC Health Economics in Prevention and Care2001;2(2):69-75. [sr-incont18060]RoehrbornCG , AbramsP , RovnerES , KaplanSA , HerschornS , GuanZ . Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU International2006;97(5):1003-6. [sr-incont21882]SwiftS . Efficacy and tolerability of once-daily tolterodine for women with overactive bladder. In: International Continence Society Annual Meeting (ICS), 31st annual meeting; 2001 Sept 18-21; Seoul, Korea. 2001:No. 329. [srincont-14481]SwiftS . Once-daily tolterodine is effective and well tolerated in women with overactive bladder (Abstract 57). In: 2nd International Consultation on Incontinence; 2001 July 1-3; Paris, France. 2001. [srincont-16319]SwiftSE . Once-daily (OD) tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder (OAB). International Urogynecology Journal2000;11(Suppl 1):S15. [sr-incont11906]SwiftSE . Once-daily administration of extended-release tolterodine is effective and well-tolerated in patients with overactive bladder. In: XVI FIGO World Congress of Obstetrics and Gynecology; 2000 Sept 3-8; Washington DC. Vol. Book 1. 2000:40. [sr-incont12085]SwiftSE . Overactive bladder in females: treatment with once-daily tolterodine. International Urogynecology Journal2001;12(Suppl 3):S71. [sr-incont16328]Van KerrebroeckP , KrederK , JonasU , ZinnerN . Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology2001;57(3):414-21. [sr-incont11953]Van KerrebroeckPEV . Long-term (12 months) efficacy and tolerability of tolterodine once-daily in the treatment of overactive bladder. Neurourology and Urodynamics2001;20(4):401-2. [sr-incont15714]Van KerrebroeckPEVA , Tolterodine Study Group. Long-term tolerability and efficacy of once-daily (OD) tolterodine in the treatment of overactive bladder (OB). International Urogynecology Journal2001;12(Suppl 3):S49. [sr-incont16329]Van KerrebroeckPEVA , Tolterodine Study Group. Significant decreases in perception of urgency and urge incontinence episodes with once-daily tolterodine treatment in patients with overactive bladder (Abstract number 89). Neurourology and Urodynamics2000;19(4):493-4. [sr-incont9980]WeinAJ , KhullarV , WangJT , GuanZ . Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. BJU International2007;99(2):360-3. [sr-incont23180]vanKerrebroeckPE , KelleherCJ , CoyneKS , KoppZ , BrodskyM , WangJT . Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. Health and Quality of Life Outcomes2009;7(13):13. [10.1186/1477-7525-7-13] [sr-incont31438]vanKerrebroeckPE , WangJ , GuanZ . Effects of tolterodine extended release in patients with overactive bladder: perceived treatment benefits improve with efficacy (Abstract number 511). European Urology Supplements2004;3(2):130. [sr-incont31090]">Van Kerrebroeck 2001</a>; <a href="./references#CD003781-bbs2-0093" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CrosbyRD , MathiasSD , MarshallTS . Relationships between symptoms, symptom bother, and health-related quality of life in patients with overactive bladder taking solifenacin or placebo in the VIBRANT study. International Journal of Clinical Practice2011;65(2):211-8. [sr-incont41015]GollarKM , YoungDG , BailenJ , HeW , Forero-SchwanhaeuserS . Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: a secondary analysis of the VIBRANT study. Urologic Nursing2012;32(1):38-46. [TrialID.VIBRANT.] [sr-incont44571]Samuels T‐A, MitchesonHD , VardyM , Forero‐SchwanhaeuserS , MarshallT , HeW . Efficacy of solifenacin for symptom bother and other patient-reported outcomes in patients with overactive bladder (OAB): results of a large, double-blind, placebo-controlled trial (Abstract number: poster #74). Neurourology and Urodynamics2009;28(2):149. [sr-incont31063]VardyMD , MitchesonHD , SamuelsTA , Forero-SchwanhaeuserS , HeW . Efficacy of solifenacin on overactive bladder symptoms, symptom bother, and other patient-reported outcomes in subjects with or without incontinence: a post hoc analysis of data from VIBRANT. Female Pelvic Medicine and Reconstructive Surgery2011;17(1):24-9. [TrialID.VIBRANT.] [sr-incont44741]VardyMD , MitchesonHD , SamuelsTA , WegenkeJD , Forero-SchwanhaeuserS , MarshallTS , et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. International Journal of Clinical Practice2009;63(12):1702-14. [905-UC-010] [NCT00573508] [TrialID.VIBRANT.] [sr-incont35459]">Vardy 2009</a>; <a href="./references#CD003781-bbs2-0094" title="EUCTR2007-007087-17-SE. A 24-week, multicentre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-007087-17 (first received 13 June 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont64588]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00798434. A study to compare the effectiveness and safety of fesoterodine and placebo in an elderly population of patients who go to the toilet very frequently due to overactive bladder (SOFIA) [A 24-week, multi-centre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00798434 (first received 26 November 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont49847]SchneiderT , BergqvistA , WangJ , WaggA , Ebel-BitounC . Treatment with fesoterodine versus tolterodine for reducing symptom bother in elderly patients with overactive bladder including urgency urinary incontinence. European Urology, Supplements2012;11(1):e687-a. [sr-incont65389]WaggA , CarlssonM , ElsobkyM , FernetM . Effect of flexible dose fesoterodine on cognitive function in &gt;65 year old patients with OAB: data from two RCT (Abstract number 438). Neurourology and Urodynamics2019;38:S297-8. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78651]WaggA , DarekarA , ArumiD , KhullarV , OelkeM . Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people &gt;65 years of age: a post hoc analysis of data from the SOFIA study. Neurourology and Urodynamics2015;34(5):438-43. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont68100]WaggA , ElsobkyM , CarlssonM , FernetM . Response and cognitive safety of fesoterodine in patients &gt;65y old with OAB. Is there a relationship between cognition and treatment response? (Abstract number 183). Neurourology and Urodynamics2019;38:S118-20. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78632]WaggA , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. Journal of the American Geriatrics Society2013;61(2):185-93. [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TrialID.SOFIA.] [sr-incont48008]WaggAS , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Efficacy and tolerability of fesoterodine in older subjects with overactive bladder: results of SOFIA (Abstract number C33). Journal of the American Geriatrics Society2011;59:S124. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont65234]">Wagg 2013a</a>; <a href="./references#CD003781-bbs2-0095" title="GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00911937. A trial to evaluate the efficacy and safety of fesoterodine in patients with symptoms of overactive bladder including nocturnal urinary urgency [A randomized, double blind, placebo controlled, parallel group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with symptoms of overactive bladder including nocturnal urinary urgency]. clinicaltrials.gov/show/NCT00911937 (first received 03 June 2009). [NCT00911937] [sr-incont49848]WeissJ , JumadilovaZ , CarlssonM , FitzGeraldMP , MalhotraA , MartireDL . Effect of antimuscarinic treatment in subjects with overactive bladder, including nocturnal urinary urgency (Abstract number 1963). Journal of Urology2012;187(4 Suppl 1):e792. [NCT00911937] [sr-incont65184]WeissJP , CarlssonMR , ManganEK . Age, gender and nocturnal urgency severity predict response to antimuscarinic treatment (Abstract number 1962). Journal of Urology2013;189(4 Suppl 1):e805. [NCT00911937] [sr-incont65096]WeissJP , JumadilovaZ , JohnsonTM , FitzGeraldMP , CarlssonM , MartireDL , et al. Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency. Journal of Urology2013;189(4):1396-401. [A0221048] [NCT00911937] [sr-incont47568]">Weiss 2013</a>; <a href="./references#CD003781-bbs2-0102" title="ZinnerNR , MattiassonA , StantonSL . Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. Journal of the American Geriatrics Society2002;50(5):799-807. [sr-incont14679]">Zinner 2002</a>; <a href="./references#CD003781-bbs2-0103" title="ZinnerN , GittelmanM , HarrisR , SussetJ , KanellosA , AuerbachS . Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial (Abstract number DP51). In: American Urological Association (AUA), 98th Annual Meeting; 2003 Apr 26-May 1; Chicago, Illinois. 2003. [sr-incont31101]ZinnerN , GittelmanM , HarrisR , SussetJ , KanelosA , AuerbachS , Trospium Study Group. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. Journal of Urology2004;171(6 Pt 1):2311-5. [sr-incont17376]">Zinner 2004</a>; <a href="./references#CD003781-bbs2-0104" title="ZinnerN , SussetJ , GittelmanM , ArguinzonizM , RekedaL , HaabF . Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. International Journal of Clinical Practice2006;60(1):119-26. [sr-incont21507]">Zinner 2006</a>). The result implies that anticholinergics increase the risk of experiencing headache by 20% compared against placebo (RR 1.20, 95% CI 1.05 to 1.36; P = 0.007; <a href="./references#CD003781-fig-0023" title="">Analysis 1.14</a>). </p> </section> <section id="CD003781-sec-0087"> <h5 class="title">Adverse events: insomnia (inability to sleep)</h5> <p>Five studies reported and were included in the analysis for this outcome, with a total of 4391 participants (2440 in the anticholinergic group and 1951 in the placebo group) (<a href="./references#CD003781-bbs2-0024" title="DmochowskiR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. A double-blind, placebo-controlled trial of flexible-dose fesoterodine for overactive bladder (Abstract number 715). In: International Continence Society (ICS); 39th Annual Meeting; 2009 Sep 29-Oct 03; San Francisco, CA. 2009. [sr-incont35627]DmochowskiRR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder [Errata appear in: Urology 2010 Jun;75(6):1519 and in Urology 2011 Jun;77(6):1513]. Urology2010;75(1):62-8. [A0221014] [NCT00536484] [sr-incont39548]DuBeauC , KrausSR , SunF , MorrowJD . Fesoterodine in older vs younger subjects with overactive bladder (Abstract number D87). Journal of the American Geriatrics Society2010;58:S218. [NCT00536484] [sr-incont64309]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. [sr-incont78640]NCT00536484. Fesoterodine flexible dose study [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with overactive bladder]. clinicaltrials.gov/show/NCT00536484 (first received 27 September 2007). [NCT00536484] [sr-incont49160]StaskinD , KhullarV , MichelMC , MorrowJD , SunF , GuanZ , et al. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. Neurourology and Urodynamics2011;30(8):1480-5. [sr-incont42686]">Dmochowski 2010</a>; <a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>; <a href="./references#CD003781-bbs2-0077" title="RogersR , BachmannG , JumadilovaZ , SunF , MorrowJD , GuanZ , et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. International Urogynecology Journal and Pelvic Floor Dysfunction2008;19(11):1551-7. [A6121002] [NCT00143481] [srincont-27729]RogersRG , BachmannG , ScarperoH , JumadilovaZ , SunF , MorrowJD , et al. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. Current Medical Research and Opinion2009;25(9):2159-65. [srincont-32060]">Rogers 2008</a>; <a href="./references#CD003781-bbs2-0092" title="ChancellorM , FreedmanS , MitchesonHD , AntociJ , PrimusG , WeinA . Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clinical Drug Investigation2000;19(2):83-91. [srincont-16326]FreemanR , HillS , MillardR , SlackM , SutherstJ , Tolterodine Study Group. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstetrics and Gynecology2003;102(3):605-11. [srincont-16494]GarelyA , Tolterodine Study Group. Once-daily tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder. International Urology Journal2001;12(Suppl 1):S18. [srincont-12012]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of life of patients with overactive bladder receiving tolterodine. Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of patients with overactive bladder receiving tolterodine (Abstract number 82). Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , ReesePR . Health related quality of life of patients with overactive bladder receiving tolterodine once-daily. Neurourology and Urodynamics2000;19(4):519-21. [srincont-9987]KelleherCJ , ReesePR , PleilAM , OkanoGJ . Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. American Journal of Managed Care2002;8(Suppl 19):S608-15. [srincont-17998]KelleherCJ , Tolterodine Study Group. Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2000;11(Suppl 1):S94. [srincont-11915]KrederKJ . Antimuscarinic therapy: relationship between efficacy and side effects in responders and non-responders. Journal of Urology2001;165(Suppl 5):S165. [srincont-16327]KrederKJ . Clinical effectiveness of antimuscarinic therapy: the relationship between efficacy and tolerability. In: Proceedings of the International Continence Society Annual Meeting(ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001:140. [srincont-14376]MallettV . Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2001;12(Suppl 1):4. [srincont-12011]MillardRJ , TamaddonK , Tolterodine Study Group. Randomized controlled trial to compare tolterodine prolonged release capsules and tolterodine immediate release tablets versus placebo in patients with symptoms of detrusor overactivity (Abstract number 57). Australian and New Zealand Journal of Surgery2002;Suppl 72:A140. [sr-incont22190]PleilAM , ReesePR , KelleherCJ , OkanoGJ . Health-related quality of life of patients with overactive bladder receiving immediate-release tolterodine. HEPAC Health Economics in Prevention and Care2001;2(2):69-75. [sr-incont18060]RoehrbornCG , AbramsP , RovnerES , KaplanSA , HerschornS , GuanZ . Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU International2006;97(5):1003-6. [sr-incont21882]SwiftS . Efficacy and tolerability of once-daily tolterodine for women with overactive bladder. In: International Continence Society Annual Meeting (ICS), 31st annual meeting; 2001 Sept 18-21; Seoul, Korea. 2001:No. 329. [srincont-14481]SwiftS . Once-daily tolterodine is effective and well tolerated in women with overactive bladder (Abstract 57). In: 2nd International Consultation on Incontinence; 2001 July 1-3; Paris, France. 2001. [srincont-16319]SwiftSE . Once-daily (OD) tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder (OAB). International Urogynecology Journal2000;11(Suppl 1):S15. [sr-incont11906]SwiftSE . Once-daily administration of extended-release tolterodine is effective and well-tolerated in patients with overactive bladder. In: XVI FIGO World Congress of Obstetrics and Gynecology; 2000 Sept 3-8; Washington DC. Vol. Book 1. 2000:40. [sr-incont12085]SwiftSE . Overactive bladder in females: treatment with once-daily tolterodine. International Urogynecology Journal2001;12(Suppl 3):S71. [sr-incont16328]Van KerrebroeckP , KrederK , JonasU , ZinnerN . Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology2001;57(3):414-21. [sr-incont11953]Van KerrebroeckPEV . Long-term (12 months) efficacy and tolerability of tolterodine once-daily in the treatment of overactive bladder. Neurourology and Urodynamics2001;20(4):401-2. [sr-incont15714]Van KerrebroeckPEVA , Tolterodine Study Group. Long-term tolerability and efficacy of once-daily (OD) tolterodine in the treatment of overactive bladder (OB). International Urogynecology Journal2001;12(Suppl 3):S49. [sr-incont16329]Van KerrebroeckPEVA , Tolterodine Study Group. Significant decreases in perception of urgency and urge incontinence episodes with once-daily tolterodine treatment in patients with overactive bladder (Abstract number 89). Neurourology and Urodynamics2000;19(4):493-4. [sr-incont9980]WeinAJ , KhullarV , WangJT , GuanZ . Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. BJU International2007;99(2):360-3. [sr-incont23180]vanKerrebroeckPE , KelleherCJ , CoyneKS , KoppZ , BrodskyM , WangJT . Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. Health and Quality of Life Outcomes2009;7(13):13. [10.1186/1477-7525-7-13] [sr-incont31438]vanKerrebroeckPE , WangJ , GuanZ . Effects of tolterodine extended release in patients with overactive bladder: perceived treatment benefits improve with efficacy (Abstract number 511). European Urology Supplements2004;3(2):130. [sr-incont31090]">Van Kerrebroeck 2001</a>; <a href="./references#CD003781-bbs2-0102" title="ZinnerNR , MattiassonA , StantonSL . Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. Journal of the American Geriatrics Society2002;50(5):799-807. [sr-incont14679]">Zinner 2002</a>). There was no evidence of a difference in the risk of experiencing insomnia but the confidence interval is wide enough to include a slight reduction or a large increase in the risk of insomnia with anticholinergics compared with placebo (RR 1.39, 95% CI 0.83 to 2.32; P = 0.21; <a href="./references#CD003781-fig-0024" title="">Analysis 1.15</a>). </p> </section> <section id="CD003781-sec-0088"> <h5 class="title">Adverse events: nasopharyngitis/sore throat</h5> <p>Seventeen studies were included in the analysis for this outcome, with a total of 9833 participants (5744 in the anticholinergic group, 4089 in the placebo group) (<a href="./references#CD003781-bbs2-0004" title="AbramsP , KelleherC , StaskinD , KayR , MartanA , MincikI , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World Journal of Urology2017;35(5):827-38. [NCT01340027] [sr-incont77897]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Cardiovascular safety of combination treatment with mirabegron and solifenacin in patients with overactive bladder in a randomised, double-blind, dose-ranging, Phase II study (Symphony) (Abstract). European Urology, Supplements2014;13(1):e574-e574a. [NCT01340027] [sr-incont67160]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB) - efficacy and safety results from a randomised phase II study (Symphony) (Abstract number 295). Neurourology and Urodynamics2013;32(6):930-1. [NCT01340027] [TrialID.SYMPHONY.] [sr-incont49188]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB): safety results from a phase 2 study (Abstract number MP-16.08). Urology2013;82(3 Suppl 1):S139. [NCT01340027] [sr-incont66675]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: Exploratory responder analyses of efficacy and evaluation of patient reported outcomes from a randomised, double-blind, dose-ranging, phase 2 study (Symphony) (Abstract number MP-24.11). Urology2014;84(4 Suppl 1):S145-6. [NCT01340027] [sr-incont67194]AbramsP , KelleherC , StaskinD , RechbergerT , KayR , MartinaR , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (SYMPHONY). European Urology2015;67(3):577-88. [NCT01340027] [sr-incont66674]NCT01340027, Bristol Urological Institute . A study to evaluate the efficacy, safety and tolerability of mirabegron and solifenacin succinate alone and in combination for the treatment of overactive bladder (symphony) [A randomized, double-blind, factorial, parallel-group, active and placebo-controlled, multicenter dose-ranging study to evaluate the efficacy, safety and tolerability of six dose combinations of solifenacin succinate and mirabegron compared to mirabegron and solifenacin succinate monotherapies in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01340027 (first received 21 April 2011). [178-CL-100] [2010-020601-32] [NCT01340027] [TrialID.SYMPHONY] [sr-incont44510]NittiV , AbramsP , StaskinD , AuerbachS , MartinaR , VanMR . Urinary retention in patients with overactive bladder treated with mirabegron alone and in combination with solifenacin: the results of two randomized, double-blind, phase II studies (Abstract number MP76-13). Journal of Urology2014;191(4 Suppl 1):e886-7. [NCT00410514] [NCT01340027] [TrialID.SYMPHONY] [sr-incont67453]">Abrams 2013</a>; <a href="./references#CD003781-bbs2-0016" title="ChappleC , Van KerrebroeckP , TubaroA , Haag-MolkentellerC , ForstHT , MassowU , et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder [Erratum appears in: European Urology 2008,53(6):1319]. European Urology2007;52(4):1204-12. [NCT00220363] [SP583] [srincont-23875]ChappleC , Van KerrebroeckP , TubaroA , MillardR . Fesoterodine in non-neurogenic voiding dysfunction - results on efficacy and safety in a phase 3 trial (Abstract number 379). In: 21st Annual European Association of Urology (EAU) Congress; 2006 Apr 5-8; Paris, France. 2006. [srincont-41109]ChappleC , Van KerrebroeckP , TubaroA , WangJT , HvidstenK , BrodskyM . Efficacy of fesoterodine in patients with overactive bladder (OAB): improvements in OAB symptoms and health-related quality of life (HRQL) (Poster abstract number 1188). Journal of Urology2007;177(4 Suppl S):392. [srincont-31882]ChappleCR , vanKerrebroeckPE , JünemannKP , WangJT , BrodskyM . Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU International2008;102(9):1128-32. [srincont-29255]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. KelleherCJ , TubaroA , WangJT , KoppZ . Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU International2008;102(1):56-61. [srincont-27613]SandPK , MorrowJD , BavendamT , CreangaDL , NittiVW . Efficacy and tolerability of fesoterodine in women with overactive bladder. International Urogynecology Journal2009;20(7):827-35. [srincont-31351]">Chapple 2007a</a>; <a href="./references#CD003781-bbs2-0020" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. [sr-incont75259]ChuF , SmithN , UchidaT . Efficacy and safety of solifenacin succinate 10 mg once daily: a multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder. Current Therapeutic Research - Clinical and Experimental2009;70(6):405-20. [srincont-43324]">Chu 2009</a>; <a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>; <a href="./references#CD003781-bbs2-0038" title="HerschornS , HeesakkersJ , Castro-DiazD , WangJT , BrodskyM , GuanZ . Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*. Current Medical Research and Opinion2008;24(12):3513-21. [A6121122] [NCT00143377] [srincont-29250]HerschornS , HeesakkersJ , Castro-DiazD , WangJT , GuanZ , BrodskyM . Tolterodine extended release (TER) improves objective and subjective outcomes after 1 week of treatment in patients with overactive bladder (Abstract number 132). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S78-9. [srincont-26602]">Herschorn 2008</a>; <a href="./references#CD003781-bbs2-0042" title="HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21072]HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21072]HillS , KhullarV , WyndaeleJJ , LheritierK , . Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. International Urogynecology Journal and Pelvic Floor2006;17(3):239-47. [srincont-22464]">Hill 2005</a>; <a href="./references#CD003781-bbs2-0044" title="HommaY , YamaguchiT , YamaguchiOA . A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2008;15(9):809-15. [srincont-27742]">Homma 2008</a>; <a href="./references#CD003781-bbs2-0045" title="HommaY , YamaguchiO , Imidafenacin Study Group. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2009;16(5):499-506. [NCT00212732] [ONO-8025-08] [srincont-31368]">Homma 2009</a>; <a href="./references#CD003781-bbs2-0053" title="CapoJP , TogliaM , Forero-SchwanhaeuserS , HeW . Patients reporting severe overactive bladder symptoms: effects of solifenacin treatment on objective measures and patient-reported outcomes (Abstract number 582). In: International Continence Society (ICS), 38th Annual Meeting; 2008 Oct 20-24; Cairo, Egypt. 2008. [srincont-31844]CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. KarramMM , TogliaMR , SerelsSR , AndohM , FakhouryA , Forero-SchwanhaeuserS . Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology2009;73(1):14-8. [A0221094] [NCT00454896] [TrialID.VENUS.] [srincont-29219]SerelsSR , TogliaMR , Forero-SchwanhaeuserS , HeW . Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms. Current Medical Research and Opinion2010;26(10):2277-85. [srincont-40376]StaskinD , DmochowskiR , SerelsS , AndohM , SmithN . Report from a randomized, placebo-controlled study showing significant improvement in urgency and patient-reported outcomes in overactive bladder patients treated with solifenacin (Abstract number 124). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73-4. [srincont-26600]TogliaM , AndohM , HussainI . Solifenacin improved warning time significantly compared to placebo in patients with overactive bladder (Abstract number 123). Neurourology and Urodynamics2006;25(6):655. [srincont-26629]TogliaM , AndohM , HussainI . Solifenacin improves urgency symtoms as assessed by voiding diaries and patient-reported outcomes (PRO) in patients with overactive bladder (Abstract number 155). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26636]TogliaMR , OstergardDR , AppellRA , AndohM , FakhouryA , HussainIF . Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status. International Urogynecology Journal2010;21(7):847-54. [srincont-40094]TogliaMR , SerelsSR , LarameeC , KarramMM , NandyIM , AndohM , et al. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial. Postgraduate Medicine2009;121(5):151-8. [srincont-34204]ZinnerS , HerschornS , AndohM , HussainI . Responder analyses show statistically significant improvements in incontinence and urgency are associated with reduction in symptom bother and improvement in health-related quality of life: VENUS results (Abstract number 123). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73. [srincont-26599]">Karram 2009</a>; <a href="./references#CD003781-bbs2-0060" title="HsiaoSM , ChangTC , ChenCH , WuWY , LinHH . Comparisons of the clinical outcomes and urodynamic effects of mirabegron versus tolterodine treatment for female overactive bladder syndrome: a subgroup analysis of a controlled, randomised, prospective study. Lower Urinary Tract Symptoms2018;10(3):215-20. [NCT01043666] [sr-incont74461]KuoHC , LeeKS , NaY , SoodR , NakajiS , KubotaY , et al. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourology and Urodynamics2015;34(7):685-92. [NCT01043666] [sr-incont68095]Kuo H‐C, Lin H‐H, Yu H‐J, Cheng C‐L, Hung M‐J, LinAT . Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials [Erratum available in: Urological Science 2015;26(2):148]. Urological Science2015;26(1):41-8 . [NCT01043666] [sr-incont68645]NCT01043666. A study of YM178 in subjects with symptoms of overactive bladder  [Phase III study of YM178: a randomized, double-blind, parallel group, placebo and active controlled, multi-center study in subjects with symptoms of overactive bladder]. clinicaltrials.gov/show/NCT01043666 (first received 07 January 2010). [178-CL-090] [NCT01043666] [sr-incont63781]">Kuo 2015</a>; <a href="./references#CD003781-bbs2-0068" title="DmochowskiR , MitchesonD , FrenklT , BennettN , MuddPN . Durable efficacy and safety of long-term once-daily vibegron, a novel oral B-3 adrenergic receptor agonist: A 52-week phase 2 study in patients with overactive bladder syndrome (Abstract number PD50-03). Journal of Urology2018;199(4):e970-1. [sr-incont78091]EUCTR2010-022121-15-IT. A phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2 part clinical study of the efficacy and safety of MK-4618 in patients with overactive bladder - MK4618-008 [A 52-week extension to: a phase iib randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder]. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-022121-15 (first received 12 April 2011). [EUCTR2010-022121-15-IT] [MK4618-008] [NCT01314872] [sr-incont78639]MitchesonD , FrenklT , SamantaS , Anne PintoC , GreenS , BennettN , et al. Vibegron, a novel once daily oral beta-3 agonist, significantly reduces average daily micturitions, urge incontinence episodes and urgency episodes in patients with overactive bladder (Abstract number: podium #34). Neurourology and Urodynamics2018;37(Suppl 1):S565. [EUCTR2010-022121-15-IT] [NCT01314872] [sr-incont78618]MitchesonD , PintoCA , FrenklT , ChenL , PrasadM , MuddPN . Once daily vibegron improves quality of life measures in patients with overactive bladder (Abstract number PUK17). Value in Health2018;21(Suppl 1):S267-8. [EUCTR2010-022121-15-IT] [NCT01314872;] [sr-incont78619]MitchesonHD , SamantaS , MuldowneyK , PintoCA , RochaBA , GreenS , et al. Vibegron (RVT-901/MK-4618/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial. European Urology2019;75(2):274-82. [NCT01314872] [sr-incont78620]NCT01314872. A study of the efficacy and safety of Vibegron (MK-4618) in participants with overactive bladder (OAB) (MK-4618-008) [A phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder a 52-week extension to: a phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder]. clinicaltrials.gov/show/NCT01314872 (first received 15 March 2011). [NCT01314872] [sr-incont63793]UKCRN10391. A phase IIB randomised, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of MK-4618 in patients with overactive bladder . public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=10391 (accessed 28 June 2012). [CCRN525] [UKCRN10391] [sr-incont45046]">Mitcheson 2019</a>; <a href="./references#CD003781-bbs2-0069" title="Drug company. A phase 2, parallel group, stratified, randomized, double blind, placebo-controlled trial to investigate the efficacy and safety of 3 different dosages of sustained release fesoterodine in subjects with overactive bladder showing either involuntary detrusor contractions or normal findings during the baseline urodynamic assessment. Protocol numbers: A0221029 (SP668). ClinicalStudyResults.org (accessed 3 March 2011). [srincont-41111]NittiV , WiatrakM , KreitmanL , LipsitzD . Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB): results of a phase 2 trial (Abstract number 306). In: International Continence Society (ICS); 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21084]">Nitti 2005</a>; <a href="./references#CD003781-bbs2-0070" title="GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NittiVW , DmochowskiR , SandPK , ForstHT , Haag-MolkentellerC , MassowU , et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. Journal of Urology2007;178(6):2488-94. [NCT00138723] [SP584] [srincont-26313]">Nitti 2007</a>; <a href="./references#CD003781-bbs2-0077" title="RogersR , BachmannG , JumadilovaZ , SunF , MorrowJD , GuanZ , et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. International Urogynecology Journal and Pelvic Floor Dysfunction2008;19(11):1551-7. [A6121002] [NCT00143481] [srincont-27729]RogersRG , BachmannG , ScarperoH , JumadilovaZ , SunF , MorrowJD , et al. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. Current Medical Research and Opinion2009;25(9):2159-65. [srincont-32060]">Rogers 2008</a>; <a href="./references#CD003781-bbs2-0080" title="RudyD , ClineK , GoldbergK , HarrisR . A multicenter, randomized, placebo-controlled trial of trospium chloride in overactive bladder patients (Abstract). Neurourology and Urodynamics2004;23(5/6):600-1. [sr-incont19025]RudyD , ClineK , HarrisR , GoldbergK , DmochowskiR . Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology2006;67(2):275-80. [srincont-21604]RudyD , ClineK , HarrisR , GoldbergK , DmochowskiR . Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. BJU International2006;97(3):540-6. [sr-incont21593]">Rudy 2006</a>; <a href="./references#CD003781-bbs2-0094" title="EUCTR2007-007087-17-SE. A 24-week, multicentre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-007087-17 (first received 13 June 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont64588]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00798434. A study to compare the effectiveness and safety of fesoterodine and placebo in an elderly population of patients who go to the toilet very frequently due to overactive bladder (SOFIA) [A 24-week, multi-centre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00798434 (first received 26 November 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont49847]SchneiderT , BergqvistA , WangJ , WaggA , Ebel-BitounC . Treatment with fesoterodine versus tolterodine for reducing symptom bother in elderly patients with overactive bladder including urgency urinary incontinence. European Urology, Supplements2012;11(1):e687-a. [sr-incont65389]WaggA , CarlssonM , ElsobkyM , FernetM . Effect of flexible dose fesoterodine on cognitive function in &gt;65 year old patients with OAB: data from two RCT (Abstract number 438). Neurourology and Urodynamics2019;38:S297-8. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78651]WaggA , DarekarA , ArumiD , KhullarV , OelkeM . Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people &gt;65 years of age: a post hoc analysis of data from the SOFIA study. Neurourology and Urodynamics2015;34(5):438-43. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont68100]WaggA , ElsobkyM , CarlssonM , FernetM . Response and cognitive safety of fesoterodine in patients &gt;65y old with OAB. Is there a relationship between cognition and treatment response? (Abstract number 183). Neurourology and Urodynamics2019;38:S118-20. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78632]WaggA , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. Journal of the American Geriatrics Society2013;61(2):185-93. [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TrialID.SOFIA.] [sr-incont48008]WaggAS , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Efficacy and tolerability of fesoterodine in older subjects with overactive bladder: results of SOFIA (Abstract number C33). Journal of the American Geriatrics Society2011;59:S124. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont65234]">Wagg 2013a</a>; <a href="./references#CD003781-bbs2-0100" title="JapicCTI-152936. Phase III study of KRP-114V [A phase III, randomized, double-blind, parallel group, placebo controlled, multicenter study to assess the efficacy and safety of the beta-3 agonist KRP-114V in Japanese subjects with symptoms of overactive bladder]. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-152936 (first received 17 June 2015). [JapicCTI-152936] [sr-incont78653]YoshidaM , TakedaM , GotoM , NagaiS , KuroseT . Vibegron, a novel potent and selective beta3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study (Abstract number 1082). European Urology, Supplements2018;17(2):e1531-2. [JapicCTI-152936] [sr-incont78069]YoshidaM , TakedaM , GotohM , NagaiS , KuroseT . Vibegron, a novel potent and selective B3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study. European Urology2018;73(5):783-90. [JapicCTI-152936] [sr-incont77898]YoshidaM , TakedaM , GotohM , YokoyamaO , KakizakiH , TakahashiS , et al. Efficacy of novel beta3-adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: a post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study. International Journal of Urology2019;26(3):369-75. [JapicCTI-152936] [sr-incont78654]YoshidaM , TakedaM , GotohM , YokoyamaO , KakizakiH , TakahashiS , et al. Efficacy of vibegron, a novel selective I²3-adrenoreceptor agonist, on urgency urinary incontinence with overactive bladder: post-hoc analysis of phase iii study (Abstract number 180). Neurourology and Urodynamics2019;38(S3):S114-5. [JapicCTI-152936] [sr-incont78636]">Yoshida 2018</a>). The result suggests that the risk of experiencing nasopharyngitis/sore throat is 24% lower in the anticholinergic group than in the placebo group (RR 0.76, 95% CI 0.63 to 0.93; P = 0.006; <a href="./references#CD003781-fig-0025" title="">Analysis 1.16</a>). </p> <p>The I<sup>2</sup> value for subgroup difference for this outcome is 44.2%. However, there are only two subgroups, fesoterodine and tolterodine, and thus subgroup differences cannot be explored between the two. From the analysis, it appears that two studies (<a href="./references#CD003781-bbs2-0102" title="ZinnerNR , MattiassonA , StantonSL . Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. Journal of the American Geriatrics Society2002;50(5):799-807. [sr-incont14679]">Zinner 2002</a>; <a href="./references#CD003781-bbs2-0092" title="ChancellorM , FreedmanS , MitchesonHD , AntociJ , PrimusG , WeinA . Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clinical Drug Investigation2000;19(2):83-91. [srincont-16326]FreemanR , HillS , MillardR , SlackM , SutherstJ , Tolterodine Study Group. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstetrics and Gynecology2003;102(3):605-11. [srincont-16494]GarelyA , Tolterodine Study Group. Once-daily tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder. International Urology Journal2001;12(Suppl 1):S18. [srincont-12012]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of life of patients with overactive bladder receiving tolterodine. Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of patients with overactive bladder receiving tolterodine (Abstract number 82). Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , ReesePR . Health related quality of life of patients with overactive bladder receiving tolterodine once-daily. Neurourology and Urodynamics2000;19(4):519-21. [srincont-9987]KelleherCJ , ReesePR , PleilAM , OkanoGJ . Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. American Journal of Managed Care2002;8(Suppl 19):S608-15. [srincont-17998]KelleherCJ , Tolterodine Study Group. Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2000;11(Suppl 1):S94. [srincont-11915]KrederKJ . Antimuscarinic therapy: relationship between efficacy and side effects in responders and non-responders. Journal of Urology2001;165(Suppl 5):S165. [srincont-16327]KrederKJ . Clinical effectiveness of antimuscarinic therapy: the relationship between efficacy and tolerability. In: Proceedings of the International Continence Society Annual Meeting(ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001:140. [srincont-14376]MallettV . Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2001;12(Suppl 1):4. [srincont-12011]MillardRJ , TamaddonK , Tolterodine Study Group. Randomized controlled trial to compare tolterodine prolonged release capsules and tolterodine immediate release tablets versus placebo in patients with symptoms of detrusor overactivity (Abstract number 57). Australian and New Zealand Journal of Surgery2002;Suppl 72:A140. [sr-incont22190]PleilAM , ReesePR , KelleherCJ , OkanoGJ . Health-related quality of life of patients with overactive bladder receiving immediate-release tolterodine. HEPAC Health Economics in Prevention and Care2001;2(2):69-75. [sr-incont18060]RoehrbornCG , AbramsP , RovnerES , KaplanSA , HerschornS , GuanZ . Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU International2006;97(5):1003-6. [sr-incont21882]SwiftS . Efficacy and tolerability of once-daily tolterodine for women with overactive bladder. In: International Continence Society Annual Meeting (ICS), 31st annual meeting; 2001 Sept 18-21; Seoul, Korea. 2001:No. 329. [srincont-14481]SwiftS . Once-daily tolterodine is effective and well tolerated in women with overactive bladder (Abstract 57). In: 2nd International Consultation on Incontinence; 2001 July 1-3; Paris, France. 2001. [srincont-16319]SwiftSE . Once-daily (OD) tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder (OAB). International Urogynecology Journal2000;11(Suppl 1):S15. [sr-incont11906]SwiftSE . Once-daily administration of extended-release tolterodine is effective and well-tolerated in patients with overactive bladder. In: XVI FIGO World Congress of Obstetrics and Gynecology; 2000 Sept 3-8; Washington DC. Vol. Book 1. 2000:40. [sr-incont12085]SwiftSE . Overactive bladder in females: treatment with once-daily tolterodine. International Urogynecology Journal2001;12(Suppl 3):S71. [sr-incont16328]Van KerrebroeckP , KrederK , JonasU , ZinnerN . Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology2001;57(3):414-21. [sr-incont11953]Van KerrebroeckPEV . Long-term (12 months) efficacy and tolerability of tolterodine once-daily in the treatment of overactive bladder. Neurourology and Urodynamics2001;20(4):401-2. [sr-incont15714]Van KerrebroeckPEVA , Tolterodine Study Group. Long-term tolerability and efficacy of once-daily (OD) tolterodine in the treatment of overactive bladder (OB). International Urogynecology Journal2001;12(Suppl 3):S49. [sr-incont16329]Van KerrebroeckPEVA , Tolterodine Study Group. Significant decreases in perception of urgency and urge incontinence episodes with once-daily tolterodine treatment in patients with overactive bladder (Abstract number 89). Neurourology and Urodynamics2000;19(4):493-4. [sr-incont9980]WeinAJ , KhullarV , WangJT , GuanZ . Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. BJU International2007;99(2):360-3. [sr-incont23180]vanKerrebroeckPE , KelleherCJ , CoyneKS , KoppZ , BrodskyM , WangJT . Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. Health and Quality of Life Outcomes2009;7(13):13. [10.1186/1477-7525-7-13] [sr-incont31438]vanKerrebroeckPE , WangJ , GuanZ . Effects of tolterodine extended release in patients with overactive bladder: perceived treatment benefits improve with efficacy (Abstract number 511). European Urology Supplements2004;3(2):130. [sr-incont31090]">Van Kerrebroeck 2001</a>), out of the five studies included in the analysis (<a href="./references#CD003781-bbs2-0024" title="DmochowskiR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. A double-blind, placebo-controlled trial of flexible-dose fesoterodine for overactive bladder (Abstract number 715). In: International Continence Society (ICS); 39th Annual Meeting; 2009 Sep 29-Oct 03; San Francisco, CA. 2009. [sr-incont35627]DmochowskiRR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder [Errata appear in: Urology 2010 Jun;75(6):1519 and in Urology 2011 Jun;77(6):1513]. Urology2010;75(1):62-8. [A0221014] [NCT00536484] [sr-incont39548]DuBeauC , KrausSR , SunF , MorrowJD . Fesoterodine in older vs younger subjects with overactive bladder (Abstract number D87). Journal of the American Geriatrics Society2010;58:S218. [NCT00536484] [sr-incont64309]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. [sr-incont78640]NCT00536484. Fesoterodine flexible dose study [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with overactive bladder]. clinicaltrials.gov/show/NCT00536484 (first received 27 September 2007). [NCT00536484] [sr-incont49160]StaskinD , KhullarV , MichelMC , MorrowJD , SunF , GuanZ , et al. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. Neurourology and Urodynamics2011;30(8):1480-5. [sr-incont42686]">Dmochowski 2010</a>; <a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>; <a href="./references#CD003781-bbs2-0102" title="ZinnerNR , MattiassonA , StantonSL . Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. Journal of the American Geriatrics Society2002;50(5):799-807. [sr-incont14679]">Zinner 2002</a>; <a href="./references#CD003781-bbs2-0077" title="RogersR , BachmannG , JumadilovaZ , SunF , MorrowJD , GuanZ , et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. International Urogynecology Journal and Pelvic Floor Dysfunction2008;19(11):1551-7. [A6121002] [NCT00143481] [srincont-27729]RogersRG , BachmannG , ScarperoH , JumadilovaZ , SunF , MorrowJD , et al. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. Current Medical Research and Opinion2009;25(9):2159-65. [srincont-32060]">Rogers 2008</a>; <a href="./references#CD003781-bbs2-0092" title="ChancellorM , FreedmanS , MitchesonHD , AntociJ , PrimusG , WeinA . Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clinical Drug Investigation2000;19(2):83-91. [srincont-16326]FreemanR , HillS , MillardR , SlackM , SutherstJ , Tolterodine Study Group. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstetrics and Gynecology2003;102(3):605-11. [srincont-16494]GarelyA , Tolterodine Study Group. Once-daily tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder. International Urology Journal2001;12(Suppl 1):S18. [srincont-12012]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of life of patients with overactive bladder receiving tolterodine. Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of patients with overactive bladder receiving tolterodine (Abstract number 82). Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , ReesePR . Health related quality of life of patients with overactive bladder receiving tolterodine once-daily. Neurourology and Urodynamics2000;19(4):519-21. [srincont-9987]KelleherCJ , ReesePR , PleilAM , OkanoGJ . Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. American Journal of Managed Care2002;8(Suppl 19):S608-15. [srincont-17998]KelleherCJ , Tolterodine Study Group. Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2000;11(Suppl 1):S94. [srincont-11915]KrederKJ . Antimuscarinic therapy: relationship between efficacy and side effects in responders and non-responders. Journal of Urology2001;165(Suppl 5):S165. [srincont-16327]KrederKJ . Clinical effectiveness of antimuscarinic therapy: the relationship between efficacy and tolerability. In: Proceedings of the International Continence Society Annual Meeting(ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001:140. [srincont-14376]MallettV . Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2001;12(Suppl 1):4. [srincont-12011]MillardRJ , TamaddonK , Tolterodine Study Group. Randomized controlled trial to compare tolterodine prolonged release capsules and tolterodine immediate release tablets versus placebo in patients with symptoms of detrusor overactivity (Abstract number 57). Australian and New Zealand Journal of Surgery2002;Suppl 72:A140. [sr-incont22190]PleilAM , ReesePR , KelleherCJ , OkanoGJ . Health-related quality of life of patients with overactive bladder receiving immediate-release tolterodine. HEPAC Health Economics in Prevention and Care2001;2(2):69-75. [sr-incont18060]RoehrbornCG , AbramsP , RovnerES , KaplanSA , HerschornS , GuanZ . Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU International2006;97(5):1003-6. [sr-incont21882]SwiftS . Efficacy and tolerability of once-daily tolterodine for women with overactive bladder. In: International Continence Society Annual Meeting (ICS), 31st annual meeting; 2001 Sept 18-21; Seoul, Korea. 2001:No. 329. [srincont-14481]SwiftS . Once-daily tolterodine is effective and well tolerated in women with overactive bladder (Abstract 57). In: 2nd International Consultation on Incontinence; 2001 July 1-3; Paris, France. 2001. [srincont-16319]SwiftSE . Once-daily (OD) tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder (OAB). International Urogynecology Journal2000;11(Suppl 1):S15. [sr-incont11906]SwiftSE . Once-daily administration of extended-release tolterodine is effective and well-tolerated in patients with overactive bladder. In: XVI FIGO World Congress of Obstetrics and Gynecology; 2000 Sept 3-8; Washington DC. Vol. Book 1. 2000:40. [sr-incont12085]SwiftSE . Overactive bladder in females: treatment with once-daily tolterodine. International Urogynecology Journal2001;12(Suppl 3):S71. [sr-incont16328]Van KerrebroeckP , KrederK , JonasU , ZinnerN . Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology2001;57(3):414-21. [sr-incont11953]Van KerrebroeckPEV . Long-term (12 months) efficacy and tolerability of tolterodine once-daily in the treatment of overactive bladder. Neurourology and Urodynamics2001;20(4):401-2. [sr-incont15714]Van KerrebroeckPEVA , Tolterodine Study Group. Long-term tolerability and efficacy of once-daily (OD) tolterodine in the treatment of overactive bladder (OB). International Urogynecology Journal2001;12(Suppl 3):S49. [sr-incont16329]Van KerrebroeckPEVA , Tolterodine Study Group. Significant decreases in perception of urgency and urge incontinence episodes with once-daily tolterodine treatment in patients with overactive bladder (Abstract number 89). Neurourology and Urodynamics2000;19(4):493-4. [sr-incont9980]WeinAJ , KhullarV , WangJT , GuanZ . Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. BJU International2007;99(2):360-3. [sr-incont23180]vanKerrebroeckPE , KelleherCJ , CoyneKS , KoppZ , BrodskyM , WangJT . Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. Health and Quality of Life Outcomes2009;7(13):13. [10.1186/1477-7525-7-13] [sr-incont31438]vanKerrebroeckPE , WangJ , GuanZ . Effects of tolterodine extended release in patients with overactive bladder: perceived treatment benefits improve with efficacy (Abstract number 511). European Urology Supplements2004;3(2):130. [sr-incont31090]">Van Kerrebroeck 2001</a>), show the opposite direction of effect from the rest of the studies, which could explain the subgroup differences.   </p> </section> <section id="CD003781-sec-0089"> <h5 class="title">Adverse events: nausea</h5> <p>Twenty‐three studies reported on nausea, with a total of 13,605 participants (8432 in the anticholinergic group, 5173 in the placebo group) (<a href="./references#CD003781-bbs2-0002" title="AbramsP , FreemanR , AnderströmC , MattiassonA . Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. British Journal of Urology1998;81(6):801-10. [srincont-7871]AbramsP , FreemanRN , AnderstromC , MattiassonA . Efficacy and tolerability of tolterodine vs. oxybutynin and placebo in patients with detrusor instability (Abstract). Journal of Urology1997;157(Suppl 4):103. [srincont-16321]">Abrams 1998</a>; <a href="./references#CD003781-bbs2-0013" title="ChappleC . Fesoterodine a new effective and well-tolerated antimuscarinic for the treatment of urgency-frequency syndrome: results of a phase 2 controlled study (Abstract 142). Neurourology and Urodynamics2004;23(5/6):598-9. [srincont-19023]Drug company. A Phase 2, parallel group, randomized, double-blind, placebo controlled dose-ranging trial to determine the optimal dose and the tolerability of sustained release SPM 8272 (fesoterodine) in subjects with non-neurogenic bladder overactivity. Protocol numbers: A0221027 (SP582). ClinicalStudyResults.org (accessed 3 March 2011)2002. [Protocol numbers: A0221027 (SP582)] [srincont-41110]">Chapple 2004a</a>; <a href="./references#CD003781-bbs2-0016" title="ChappleC , Van KerrebroeckP , TubaroA , Haag-MolkentellerC , ForstHT , MassowU , et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder [Erratum appears in: European Urology 2008,53(6):1319]. European Urology2007;52(4):1204-12. [NCT00220363] [SP583] [srincont-23875]ChappleC , Van KerrebroeckP , TubaroA , MillardR . Fesoterodine in non-neurogenic voiding dysfunction - results on efficacy and safety in a phase 3 trial (Abstract number 379). In: 21st Annual European Association of Urology (EAU) Congress; 2006 Apr 5-8; Paris, France. 2006. [srincont-41109]ChappleC , Van KerrebroeckP , TubaroA , WangJT , HvidstenK , BrodskyM . Efficacy of fesoterodine in patients with overactive bladder (OAB): improvements in OAB symptoms and health-related quality of life (HRQL) (Poster abstract number 1188). Journal of Urology2007;177(4 Suppl S):392. [srincont-31882]ChappleCR , vanKerrebroeckPE , JünemannKP , WangJT , BrodskyM . Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU International2008;102(9):1128-32. [srincont-29255]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. KelleherCJ , TubaroA , WangJT , KoppZ . Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU International2008;102(1):56-61. [srincont-27613]SandPK , MorrowJD , BavendamT , CreangaDL , NittiVW . Efficacy and tolerability of fesoterodine in women with overactive bladder. International Urogynecology Journal2009;20(7):827-35. [srincont-31351]">Chapple 2007a</a>; <a href="./references#CD003781-bbs2-0020" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. [sr-incont75259]ChuF , SmithN , UchidaT . Efficacy and safety of solifenacin succinate 10 mg once daily: a multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder. Current Therapeutic Research - Clinical and Experimental2009;70(6):405-20. [srincont-43324]">Chu 2009</a>; <a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>; <a href="./references#CD003781-bbs2-0044" title="HommaY , YamaguchiT , YamaguchiOA . A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2008;15(9):809-15. [srincont-27742]">Homma 2008</a>; <a href="./references#CD003781-bbs2-0050" title="JünemannKP , HessdörferE , Unamba‐OparahI , BerseM , BrünjesR , MadersbacherH . Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. Urologia Internationalis2006;77(4):334-9. [srincont-22199]">Junemann 2006</a>; <a href="./references#CD003781-bbs2-0053" title="CapoJP , TogliaM , Forero-SchwanhaeuserS , HeW . Patients reporting severe overactive bladder symptoms: effects of solifenacin treatment on objective measures and patient-reported outcomes (Abstract number 582). In: International Continence Society (ICS), 38th Annual Meeting; 2008 Oct 20-24; Cairo, Egypt. 2008. [srincont-31844]CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. KarramMM , TogliaMR , SerelsSR , AndohM , FakhouryA , Forero-SchwanhaeuserS . Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology2009;73(1):14-8. [A0221094] [NCT00454896] [TrialID.VENUS.] [srincont-29219]SerelsSR , TogliaMR , Forero-SchwanhaeuserS , HeW . Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms. Current Medical Research and Opinion2010;26(10):2277-85. [srincont-40376]StaskinD , DmochowskiR , SerelsS , AndohM , SmithN . Report from a randomized, placebo-controlled study showing significant improvement in urgency and patient-reported outcomes in overactive bladder patients treated with solifenacin (Abstract number 124). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73-4. [srincont-26600]TogliaM , AndohM , HussainI . Solifenacin improved warning time significantly compared to placebo in patients with overactive bladder (Abstract number 123). Neurourology and Urodynamics2006;25(6):655. [srincont-26629]TogliaM , AndohM , HussainI . Solifenacin improves urgency symtoms as assessed by voiding diaries and patient-reported outcomes (PRO) in patients with overactive bladder (Abstract number 155). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26636]TogliaMR , OstergardDR , AppellRA , AndohM , FakhouryA , HussainIF . Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status. International Urogynecology Journal2010;21(7):847-54. [srincont-40094]TogliaMR , SerelsSR , LarameeC , KarramMM , NandyIM , AndohM , et al. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial. Postgraduate Medicine2009;121(5):151-8. [srincont-34204]ZinnerS , HerschornS , AndohM , HussainI . Responder analyses show statistically significant improvements in incontinence and urgency are associated with reduction in symptom bother and improvement in health-related quality of life: VENUS results (Abstract number 123). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73. [srincont-26599]">Karram 2009</a>; <a href="./references#CD003781-bbs2-0054" title="KhullarV , HillS , LavalKU , SchiotzHA , JonasU , VersiE . Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology2004;64(2):269-74; discussion 274-5. [srincont-19498]KhullarV , HillS , SolankiJ . Assessment of health-related quality of life in patients with overactive bladder taking tolterodine extended release versus placebo (Abstract number 318). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21075]">Khullar 2004</a>; <a href="./references#CD003781-bbs2-0057" title="KosilovK , LoparevS , IvanovskayaM , KosilovaL . A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron. Archives of Gerontology and Geriatrics2015;61(2):212-6. [sr-incont68133]">Kosilov 2015a</a>; <a href="./references#CD003781-bbs2-0065" title="ChappleCR , MadersbacherH , DreikornK , DorschnerW , MurtzG . Urodynamics and frequency/volume chart - do they correlate? Treatment analysis of propiverine in comparison to oxybutynin and placebo in urge incontinence (Abstract 224). In: International Continence Society (ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001. [sr-incont14474]HalaskaM , MadersbacherH , VoigtR , HofnerK , MartanA . Propiverine in patients with urgency and urge incontinence - a placebo controlled, multicentre study comparing its tolerability and efficacy with oxybutynin (Abstract number FDP36). International Urogynaecology Journal 2000;11(Suppl 1):S46. [srincont-11912]MadersbacherH , HalaskaM , VoigtR , AlloussiS , HofnerK . A urodynamically controlled multicenter study in patients with urge incontinence: tolerability and efficacy of propiverine hydrochloride in comparison to oxybutynin. In: International Continence Society (ICS), 27th Annual Meeting; 1997 Sep 23-26; Yokohama, Japan. 1997:153-4. [srincont-5854]MadersbacherH , HalaskaM , VoigtR , AlloussiS , HöfnerK . A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU International1999;84(6):646-51. [srincont-9166]">Madersbacher 1999</a>; <a href="./references#CD003781-bbs2-0066" title="Malone-LeeJG , WalshB , MaugourdMF , Tolterodine in the Elderly Study Group. The safety and clinical efficacy of two doses of tolterodine compared to placebo in elderly patients. In: International Continence Society (ICS), 27th Annual Meeting; 1997 Sep 23-26; Yokohama, Japan. 1997:155-6. [srincont-5855]Malone‐LeeJG , WalshJB , MaugourdMF . Tolterodine: A safe and effective treatment for older patients with overactive bladder. Journal of the American Geriatric Society2001;49(6):700-5. [srincont-12319]WaggA , Malone-LeeJ . Pressure-flow variables in patients treated with tolterodine for detrusor overactivity. BJU International2003;92(9):969-71. [sr-incont16659]">Malone‐Lee 2001</a>; <a href="./references#CD003781-bbs2-0068" title="DmochowskiR , MitchesonD , FrenklT , BennettN , MuddPN . Durable efficacy and safety of long-term once-daily vibegron, a novel oral B-3 adrenergic receptor agonist: A 52-week phase 2 study in patients with overactive bladder syndrome (Abstract number PD50-03). Journal of Urology2018;199(4):e970-1. [sr-incont78091]EUCTR2010-022121-15-IT. A phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2 part clinical study of the efficacy and safety of MK-4618 in patients with overactive bladder - MK4618-008 [A 52-week extension to: a phase iib randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder]. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-022121-15 (first received 12 April 2011). [EUCTR2010-022121-15-IT] [MK4618-008] [NCT01314872] [sr-incont78639]MitchesonD , FrenklT , SamantaS , Anne PintoC , GreenS , BennettN , et al. Vibegron, a novel once daily oral beta-3 agonist, significantly reduces average daily micturitions, urge incontinence episodes and urgency episodes in patients with overactive bladder (Abstract number: podium #34). Neurourology and Urodynamics2018;37(Suppl 1):S565. [EUCTR2010-022121-15-IT] [NCT01314872] [sr-incont78618]MitchesonD , PintoCA , FrenklT , ChenL , PrasadM , MuddPN . Once daily vibegron improves quality of life measures in patients with overactive bladder (Abstract number PUK17). Value in Health2018;21(Suppl 1):S267-8. [EUCTR2010-022121-15-IT] [NCT01314872;] [sr-incont78619]MitchesonHD , SamantaS , MuldowneyK , PintoCA , RochaBA , GreenS , et al. Vibegron (RVT-901/MK-4618/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial. European Urology2019;75(2):274-82. [NCT01314872] [sr-incont78620]NCT01314872. A study of the efficacy and safety of Vibegron (MK-4618) in participants with overactive bladder (OAB) (MK-4618-008) [A phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder a 52-week extension to: a phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder]. clinicaltrials.gov/show/NCT01314872 (first received 15 March 2011). [NCT01314872] [sr-incont63793]UKCRN10391. A phase IIB randomised, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of MK-4618 in patients with overactive bladder . public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=10391 (accessed 28 June 2012). [CCRN525] [UKCRN10391] [sr-incont45046]">Mitcheson 2019</a>; <a href="./references#CD003781-bbs2-0069" title="Drug company. A phase 2, parallel group, stratified, randomized, double blind, placebo-controlled trial to investigate the efficacy and safety of 3 different dosages of sustained release fesoterodine in subjects with overactive bladder showing either involuntary detrusor contractions or normal findings during the baseline urodynamic assessment. Protocol numbers: A0221029 (SP668). ClinicalStudyResults.org (accessed 3 March 2011). [srincont-41111]NittiV , WiatrakM , KreitmanL , LipsitzD . Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB): results of a phase 2 trial (Abstract number 306). In: International Continence Society (ICS); 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21084]">Nitti 2005</a>; <a href="./references#CD003781-bbs2-0070" title="GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NittiVW , DmochowskiR , SandPK , ForstHT , Haag-MolkentellerC , MassowU , et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. Journal of Urology2007;178(6):2488-94. [NCT00138723] [SP584] [srincont-26313]">Nitti 2007</a>; <a href="./references#CD003781-bbs2-0082" title="ChancellorMB , OefeleinMG , VasavadaS . Obesity is associated with a more severe overactive bladder disease state that is effectively treated with one daily administration of trospium chloride extended release [Erratum available in: Neurourology and Urodynamics 2010;29(5):804]. Neurourology and Urodynamics2010;29(4):551-4. [sr-incont39591]GinsbergDA , OefeleinMG , EllsworthPI . Once-daily administration of trospium chloride extended release provides 24-hour coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials. Neurourology and Urodynamics2011;30(4):563-7. [sr-incont41531]RovnerE , DmochowskiR , WatanabeJ . Once daily (QD) trospium chloride 60mg extended release (XR) is safe and effective in patients (PTS) with the overactive bladder (OAB) syndrome who use multiple concomitant medications (MEDS) (Abstract number: Poster #68). Neurourology and Urodynamics2009;28(2):146-7. [sr-incont31062]SandP , DmochowskiR , ZinnerN , StaskinD . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: results from a multicenter, phase III, placebo-controlled study (Abstract number 269). In: International Continence Society (ICS), 37th Annual Meeting; 2007 Aug 20-24; Rotterdam, the Netherlands. 2007. [sr-incont26676]SandP , StaskinD , ZinnerN , DmochowskiR . Once-daily trospium chloride extended release is effective and well tolerated for the treatment of overactive bladder: results from a multicenter, phase III trial (Abstract number 57). Neurourology and Urodynamics2007;26(5):675. [sr-incont26661]StaskinD , SandP , ZinnerN , DmochowskiR , Trospium Study Group. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. Journal of Urology2007;178(3 Pt 1):978-83; discussion 983-4. [srincont-23909]StaskinDR , RosenbergMT , SandPK , ZinnerNR , DmochowskiRR . Trospium chloride once daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised phase III trials. International Journal of Clinical Practice2009;63(12):1715-23. [sr-incont35458]StaskinDR , SandPK , ZinnerNR . Once-daily trospium chloride extended release is effective and well tolerated for the treatment of overactive bladder: results from a multicenter, phase III trial (Abstract number - poster 22). Neurourology and Urodynamics2007;26(7 Suppl):1106. [srincont-27305]">Staskin 2007</a>; <a href="./references#CD003781-bbs2-0089" title="ThuroffJW , BunkeB , EbnerA , FaberP , deGeeterP , HannappelJ , et al. Randomized, double-blind multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin vs. propantheline vs. placebo. Neurourology and Urodynamics1990;9(4):337-8. [srincont-5108]ThuroffJW , BunkeB , EbnerA , FaberP , deGeeterP , HannappelJ , et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. Journal of Urology1991;145(4):813-7. [srincont-1288]">Thuroff 1991</a>; <a href="./references#CD003781-bbs2-0091" title="MesselinkEJ , SolerJM , MadersbacherH , ThuroffJW , AmarencoG , Van KerrebroeckEV . Urodynamic aspects of the efficacy of tolterodine, a new anti muscarine drug in the treatment of detrusor hyperreflexia. In: International Continence Society (ICS), 25th Annual Meeting; 1995 Oct 17-20; Sydeney, Australia. 1995:95-6. [srincont-10883]Van KerrebroeckPE , AmarencoG , ThüroffJW , MadersbacherHG , LockMT , MesselinkEJ , et al. Dose-ranging study ot tolterodine in patients with detrusor hyperreflexia. Neurourology and Urodynamics1998;17(5):499-512. [srincont-7852]">Van Kerrebroeck 1998</a>; <a href="./references#CD003781-bbs2-0092" title="ChancellorM , FreedmanS , MitchesonHD , AntociJ , PrimusG , WeinA . Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clinical Drug Investigation2000;19(2):83-91. [srincont-16326]FreemanR , HillS , MillardR , SlackM , SutherstJ , Tolterodine Study Group. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstetrics and Gynecology2003;102(3):605-11. [srincont-16494]GarelyA , Tolterodine Study Group. Once-daily tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder. International Urology Journal2001;12(Suppl 1):S18. [srincont-12012]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of life of patients with overactive bladder receiving tolterodine. Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of patients with overactive bladder receiving tolterodine (Abstract number 82). Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , ReesePR . Health related quality of life of patients with overactive bladder receiving tolterodine once-daily. Neurourology and Urodynamics2000;19(4):519-21. [srincont-9987]KelleherCJ , ReesePR , PleilAM , OkanoGJ . Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. American Journal of Managed Care2002;8(Suppl 19):S608-15. [srincont-17998]KelleherCJ , Tolterodine Study Group. Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2000;11(Suppl 1):S94. [srincont-11915]KrederKJ . Antimuscarinic therapy: relationship between efficacy and side effects in responders and non-responders. Journal of Urology2001;165(Suppl 5):S165. [srincont-16327]KrederKJ . Clinical effectiveness of antimuscarinic therapy: the relationship between efficacy and tolerability. In: Proceedings of the International Continence Society Annual Meeting(ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001:140. [srincont-14376]MallettV . Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2001;12(Suppl 1):4. [srincont-12011]MillardRJ , TamaddonK , Tolterodine Study Group. Randomized controlled trial to compare tolterodine prolonged release capsules and tolterodine immediate release tablets versus placebo in patients with symptoms of detrusor overactivity (Abstract number 57). Australian and New Zealand Journal of Surgery2002;Suppl 72:A140. [sr-incont22190]PleilAM , ReesePR , KelleherCJ , OkanoGJ . Health-related quality of life of patients with overactive bladder receiving immediate-release tolterodine. HEPAC Health Economics in Prevention and Care2001;2(2):69-75. [sr-incont18060]RoehrbornCG , AbramsP , RovnerES , KaplanSA , HerschornS , GuanZ . Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU International2006;97(5):1003-6. [sr-incont21882]SwiftS . Efficacy and tolerability of once-daily tolterodine for women with overactive bladder. In: International Continence Society Annual Meeting (ICS), 31st annual meeting; 2001 Sept 18-21; Seoul, Korea. 2001:No. 329. [srincont-14481]SwiftS . Once-daily tolterodine is effective and well tolerated in women with overactive bladder (Abstract 57). In: 2nd International Consultation on Incontinence; 2001 July 1-3; Paris, France. 2001. [srincont-16319]SwiftSE . Once-daily (OD) tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder (OAB). International Urogynecology Journal2000;11(Suppl 1):S15. [sr-incont11906]SwiftSE . Once-daily administration of extended-release tolterodine is effective and well-tolerated in patients with overactive bladder. In: XVI FIGO World Congress of Obstetrics and Gynecology; 2000 Sept 3-8; Washington DC. Vol. Book 1. 2000:40. [sr-incont12085]SwiftSE . Overactive bladder in females: treatment with once-daily tolterodine. International Urogynecology Journal2001;12(Suppl 3):S71. [sr-incont16328]Van KerrebroeckP , KrederK , JonasU , ZinnerN . Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology2001;57(3):414-21. [sr-incont11953]Van KerrebroeckPEV . Long-term (12 months) efficacy and tolerability of tolterodine once-daily in the treatment of overactive bladder. Neurourology and Urodynamics2001;20(4):401-2. [sr-incont15714]Van KerrebroeckPEVA , Tolterodine Study Group. Long-term tolerability and efficacy of once-daily (OD) tolterodine in the treatment of overactive bladder (OB). International Urogynecology Journal2001;12(Suppl 3):S49. [sr-incont16329]Van KerrebroeckPEVA , Tolterodine Study Group. Significant decreases in perception of urgency and urge incontinence episodes with once-daily tolterodine treatment in patients with overactive bladder (Abstract number 89). Neurourology and Urodynamics2000;19(4):493-4. [sr-incont9980]WeinAJ , KhullarV , WangJT , GuanZ . Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. BJU International2007;99(2):360-3. [sr-incont23180]vanKerrebroeckPE , KelleherCJ , CoyneKS , KoppZ , BrodskyM , WangJT . Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. Health and Quality of Life Outcomes2009;7(13):13. [10.1186/1477-7525-7-13] [sr-incont31438]vanKerrebroeckPE , WangJ , GuanZ . Effects of tolterodine extended release in patients with overactive bladder: perceived treatment benefits improve with efficacy (Abstract number 511). European Urology Supplements2004;3(2):130. [sr-incont31090]">Van Kerrebroeck 2001</a>; <a href="./references#CD003781-bbs2-0093" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CrosbyRD , MathiasSD , MarshallTS . Relationships between symptoms, symptom bother, and health-related quality of life in patients with overactive bladder taking solifenacin or placebo in the VIBRANT study. International Journal of Clinical Practice2011;65(2):211-8. [sr-incont41015]GollarKM , YoungDG , BailenJ , HeW , Forero-SchwanhaeuserS . Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: a secondary analysis of the VIBRANT study. Urologic Nursing2012;32(1):38-46. [TrialID.VIBRANT.] [sr-incont44571]Samuels T‐A, MitchesonHD , VardyM , Forero‐SchwanhaeuserS , MarshallT , HeW . Efficacy of solifenacin for symptom bother and other patient-reported outcomes in patients with overactive bladder (OAB): results of a large, double-blind, placebo-controlled trial (Abstract number: poster #74). Neurourology and Urodynamics2009;28(2):149. [sr-incont31063]VardyMD , MitchesonHD , SamuelsTA , Forero-SchwanhaeuserS , HeW . Efficacy of solifenacin on overactive bladder symptoms, symptom bother, and other patient-reported outcomes in subjects with or without incontinence: a post hoc analysis of data from VIBRANT. Female Pelvic Medicine and Reconstructive Surgery2011;17(1):24-9. [TrialID.VIBRANT.] [sr-incont44741]VardyMD , MitchesonHD , SamuelsTA , WegenkeJD , Forero-SchwanhaeuserS , MarshallTS , et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. International Journal of Clinical Practice2009;63(12):1702-14. [905-UC-010] [NCT00573508] [TrialID.VIBRANT.] [sr-incont35459]">Vardy 2009</a>; <a href="./references#CD003781-bbs2-0094" title="EUCTR2007-007087-17-SE. A 24-week, multicentre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-007087-17 (first received 13 June 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont64588]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00798434. A study to compare the effectiveness and safety of fesoterodine and placebo in an elderly population of patients who go to the toilet very frequently due to overactive bladder (SOFIA) [A 24-week, multi-centre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00798434 (first received 26 November 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont49847]SchneiderT , BergqvistA , WangJ , WaggA , Ebel-BitounC . Treatment with fesoterodine versus tolterodine for reducing symptom bother in elderly patients with overactive bladder including urgency urinary incontinence. European Urology, Supplements2012;11(1):e687-a. [sr-incont65389]WaggA , CarlssonM , ElsobkyM , FernetM . Effect of flexible dose fesoterodine on cognitive function in &gt;65 year old patients with OAB: data from two RCT (Abstract number 438). Neurourology and Urodynamics2019;38:S297-8. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78651]WaggA , DarekarA , ArumiD , KhullarV , OelkeM . Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people &gt;65 years of age: a post hoc analysis of data from the SOFIA study. Neurourology and Urodynamics2015;34(5):438-43. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont68100]WaggA , ElsobkyM , CarlssonM , FernetM . Response and cognitive safety of fesoterodine in patients &gt;65y old with OAB. Is there a relationship between cognition and treatment response? (Abstract number 183). Neurourology and Urodynamics2019;38:S118-20. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78632]WaggA , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. Journal of the American Geriatrics Society2013;61(2):185-93. [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TrialID.SOFIA.] [sr-incont48008]WaggAS , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Efficacy and tolerability of fesoterodine in older subjects with overactive bladder: results of SOFIA (Abstract number C33). Journal of the American Geriatrics Society2011;59:S124. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont65234]">Wagg 2013a</a>; <a href="./references#CD003781-bbs2-0102" title="ZinnerNR , MattiassonA , StantonSL . Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. Journal of the American Geriatrics Society2002;50(5):799-807. [sr-incont14679]">Zinner 2002</a>; <a href="./references#CD003781-bbs2-0104" title="ZinnerN , SussetJ , GittelmanM , ArguinzonizM , RekedaL , HaabF . Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. International Journal of Clinical Practice2006;60(1):119-26. [sr-incont21507]">Zinner 2006</a>). There was no evidence of a difference in the risk of experiencing nausea but the confidence interval is wide enough to include differences favouring either anticholinergics or placebo (RR 0.99, 95% CI 0.79 to 1.23; P = 0.91; <a href="./references#CD003781-fig-0026" title="">Analysis 1.17</a>). </p> </section> <section id="CD003781-sec-0090"> <h5 class="title">Adverse events: pruritus/erythema</h5> <p>Three studies reported on pruritus/erythema, with a total of 981 participants (539 in the anticholinergic group, 442 in the placebo group) (<a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>; <a href="./references#CD003781-bbs2-0057" title="KosilovK , LoparevS , IvanovskayaM , KosilovaL . A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron. Archives of Gerontology and Geriatrics2015;61(2):212-6. [sr-incont68133]">Kosilov 2015a</a>; <a href="./references#CD003781-bbs2-0058" title="KosilovKV , LoparevSA , IvanovskayaMA , KosilovaLV . The efficacy of different doses of solifenacin in elderly patients after treating a urinary tract infection. Arab Journal of Urology Print2015;13(3):203-8. [sr-incont69283]">Kosilov 2015b</a>). There was no evidence of a difference in the risk of experiencing pruritus/erythema but the confidence interval is very wide and include differences favouring either anticholinergics or placebo (RR 2.06, 95% CI 0.44 to 9.55; P = 0.36; <a href="./references#CD003781-fig-0027" title="">Analysis 1.18</a>). </p> </section> <section id="CD003781-sec-0091"> <h5 class="title">Adverse events: urinary tract infection (UTI)</h5> <p>Twenty‐two studies assessed UTI, with a total of 17,541 participants (11,389 in the anticholinergic group and 6152 in the placebo group) (<a href="./references#CD003781-bbs2-0004" title="AbramsP , KelleherC , StaskinD , KayR , MartanA , MincikI , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World Journal of Urology2017;35(5):827-38. [NCT01340027] [sr-incont77897]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Cardiovascular safety of combination treatment with mirabegron and solifenacin in patients with overactive bladder in a randomised, double-blind, dose-ranging, Phase II study (Symphony) (Abstract). European Urology, Supplements2014;13(1):e574-e574a. [NCT01340027] [sr-incont67160]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB) - efficacy and safety results from a randomised phase II study (Symphony) (Abstract number 295). Neurourology and Urodynamics2013;32(6):930-1. [NCT01340027] [TrialID.SYMPHONY.] [sr-incont49188]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB): safety results from a phase 2 study (Abstract number MP-16.08). Urology2013;82(3 Suppl 1):S139. [NCT01340027] [sr-incont66675]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: Exploratory responder analyses of efficacy and evaluation of patient reported outcomes from a randomised, double-blind, dose-ranging, phase 2 study (Symphony) (Abstract number MP-24.11). Urology2014;84(4 Suppl 1):S145-6. [NCT01340027] [sr-incont67194]AbramsP , KelleherC , StaskinD , RechbergerT , KayR , MartinaR , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (SYMPHONY). European Urology2015;67(3):577-88. [NCT01340027] [sr-incont66674]NCT01340027, Bristol Urological Institute . A study to evaluate the efficacy, safety and tolerability of mirabegron and solifenacin succinate alone and in combination for the treatment of overactive bladder (symphony) [A randomized, double-blind, factorial, parallel-group, active and placebo-controlled, multicenter dose-ranging study to evaluate the efficacy, safety and tolerability of six dose combinations of solifenacin succinate and mirabegron compared to mirabegron and solifenacin succinate monotherapies in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01340027 (first received 21 April 2011). [178-CL-100] [2010-020601-32] [NCT01340027] [TrialID.SYMPHONY] [sr-incont44510]NittiV , AbramsP , StaskinD , AuerbachS , MartinaR , VanMR . Urinary retention in patients with overactive bladder treated with mirabegron alone and in combination with solifenacin: the results of two randomized, double-blind, phase II studies (Abstract number MP76-13). Journal of Urology2014;191(4 Suppl 1):e886-7. [NCT00410514] [NCT01340027] [TrialID.SYMPHONY] [sr-incont67453]">Abrams 2013</a>; <a href="./references#CD003781-bbs2-0019" title="ChappleC , HaabF , SchneiderT , CarlssonM , ArumiD . Fesoterodine 8 mg versus fesoterodine 4 mg in patients with overactive bladder and a history of previous antimuscarinic therapy: Results from the EIGHT trial (Abstract number: Poster #M5). Neurourology and Urodynamics2015;34(S1):S20. [NCT01302067] [sr-incont68509]ChappleC , SchneiderT , HaabF , SunF , WhelanL , ScholfieldD , et al. Superiority of fesoterodine 8mg versus fesoterodine 4 mg in reducing urgency urinary incontinence episodes in subjects with overactive bladder: results of the randomized, double-blind, placebo-controlled EIGHT trial (Abstract number: Podium #48). Neurourology and Urodynamics2014;33(2):183-4. [NCT01302067] [sr-incont67484]ChappleC , SchneiderT , HaabF , SunF , WhelanL , ScholfieldD , et al. Superiority of fesoterodine 8mg vs 4mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial. BJU International2014;114(3):418-26. [A0221095] [NCT01302067] [TrialID.EIGHT] [srincont-62537]NCT01302067. A 12 week study to confirm the effectiveness of 8mg of Fesoterodine compared to 4mg of Fesoterodine [A 12-week, randomized, double-blind, placebo controlled, parallel group, multicenter trial in overactive bladder subjects to confirm the efficacy of 8 mg fesoterodine compared to 4 mg fesoterodine]. clinicaltrials.gov/show/NCT01302067 (first received 23 February 2011). [NCT01302067] [sr-incont63792]">Chapple 2014</a>; <a href="./references#CD003781-bbs2-0020" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. [sr-incont75259]ChuF , SmithN , UchidaT . Efficacy and safety of solifenacin succinate 10 mg once daily: a multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder. Current Therapeutic Research - Clinical and Experimental2009;70(6):405-20. [srincont-43324]">Chu 2009</a>; <a href="./references#CD003781-bbs2-0021" title="ChuaME , SeeMC , EsmeňaEB , BalingitJC , MoralesML . Efficacy and safety of gabapentin in comparison to solifenacin succinate in adult overactive bladder treatment. Lower Urinary Tract Symptoms2018;10(2):135-42. [NCT01486706] [sr-incont74529]NCT01486706, ChuaME . Efficacy and safety of gabapentin in treating overactive bladder (OAB). clinicaltrials.gov/show/NCT01486706 (first received 6 December 2011). [NCT01486706] [SLMC10-010] [sr-incont49864]">Chua 2018</a>; <a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>; <a href="./references#CD003781-bbs2-0039" title="CorcosJ , AnguloJC , GarelyAD , CarlssonM , GongJ , GuanZ . Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. Current Medical Research and Opinion2011;27(5):1059-65. [srincont-41596]EUCTR2006-006935-38-SE. 12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006935-38 (first received 16 April 2007). [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont64612]HerschornS , SwiftS , GuanZ , CarlssonM , BrodskyM , GongJ . Efficacy and safety of fesoterodine for overactive bladder in a double-blind, head-to-head comparison trial with tolterodine ER and placebo (Abstract number 710). In: International Continence Society (ICS), 39th Annual Meeting; 2009 Sep 29-Oct 3; San Francisco, CA. 2009. [srincont-35326]HerschornS , SwiftS , GuanZ , CarlssonM , MorrowJD , BrodskyM , et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU International2010;105(1):58-66. [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont39540]NCT00444925. Clinical trial to evaluate the efficacy and safety of Fesoterodine in comparison to Tolterodine for overactive bladder (OAB) [12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder (OAB)]. clinicaltrials.gov/show/NCT00444925 (first received 08 March 2007). [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont49159]">Herschorn 2009a</a>; <a href="./references#CD003781-bbs2-0040" title="EUCTR2012-005735-91-SK. A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-005735-91 (first received 12 November 2013). [178-CL-101] [EUCTR2012-005735-91-SK] [sr-incont78644]HerschornS , ChappleCR , AbramsP , ArlandisS , MitchesonD , LeeKS , et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU International2017;120(4):562-75. [NCT01972841] [sr-incont74470]MuellerER , RobinsonD , KelleherC , StaskinDR , FalconerC , WangJ , et al. Patient reported outcomes from synergy, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with mirabegron and solifenacin monotherapy (Abstract number - Podium #44). Neurourology and Urodynamics2017;36(Suppl S1):S151-2. [NCT01972841] [sr-incont75944]NCT01972841. This was a multinational study comparing the efficacy and safety of two medicines, solifenacin succinate and mirabegron taken together, or separately, or a mock treatment (placebo) in subjects with symptoms of overactive bladder (SYNERGY) [A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01972841 (first received 31 October 2013). [178-CL-101] [EUCTR2012-005735-91] [NCT01972841] [sr-incont63780]RobinsonD , KelleherC , StaskinD , MuellerER , FalconerC , WangJ , et al. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients. Neurourology and Urodynamics2018;37(1):394-406. [NCT01972841] [sr-incont76906]WeberMA , ChappleCR , GratzkeC , HerschornS , RobinsonD , FrankelJM , et al. A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial. Blood Pressure Monitoring2018;23(3):153-63. [NCT01972841] [sr-incont77899]WhiteWB , ChappleC , GratzkeC , HerschornS , RobinsonD , FrankelJ , et al. Cardiovascular safety of the beta3-adrenoceptor agonist mirabegron and the antimuscarinic agent solifenacin in the SYNERGY trial. Journal of Clinical Pharmacology2018;58(8):1084-91. [NCT01972841] [sr-incont78078]">Herschorn 2017a</a>; <a href="./references#CD003781-bbs2-0042" title="HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21072]HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21072]HillS , KhullarV , WyndaeleJJ , LheritierK , . Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. International Urogynecology Journal and Pelvic Floor2006;17(3):239-47. [srincont-22464]">Hill 2005</a>; <a href="./references#CD003781-bbs2-0048" title="JonasU , HofnerK , MadersbacherH , HolmdahlTH . Efficacy and safety of two doses of Tolterodine compared to placebo in patients with detrusor overactivity. Neurourology and Urodynamics1997;16(5):477-8. [srincont-5841]JonasU , HöfnerK , MadersbacherH , HolmdahlTH . Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group. World Journal of Urology1997;15(2):144-51. [srincont-5436]">Jonas 1997</a>; <a href="./references#CD003781-bbs2-0051" title="EUCTR2007-006451-39-SE. 12-week, randomized, double-blind, double-dummy, placebo controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-006451-39 (first received 20 February 2008). [A0221046] [EUCTR2007-006451-39-SE] [sr-incont64591]KaplanSA , SchneiderT , FooteJ , GuanZ . Superior efficacy of fesoterodine over tolterodine with rapid onset: a prospective, head-to-head, placebo-controlled trial (Abstract number 67). Neurourology and Urodynamics2010;29(6):905-7. [srincont-40130]KaplanSA , SchneiderT , FooteJE , GuanZ , CarlssonM , GongJ . Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU International2011;107(9):1432-40. [A0221046] [NCT00611026] [srincont-41334]">Kaplan 2011</a>; <a href="./references#CD003781-bbs2-0053" title="CapoJP , TogliaM , Forero-SchwanhaeuserS , HeW . Patients reporting severe overactive bladder symptoms: effects of solifenacin treatment on objective measures and patient-reported outcomes (Abstract number 582). In: International Continence Society (ICS), 38th Annual Meeting; 2008 Oct 20-24; Cairo, Egypt. 2008. [srincont-31844]CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. KarramMM , TogliaMR , SerelsSR , AndohM , FakhouryA , Forero-SchwanhaeuserS . Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology2009;73(1):14-8. [A0221094] [NCT00454896] [TrialID.VENUS.] [srincont-29219]SerelsSR , TogliaMR , Forero-SchwanhaeuserS , HeW . Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms. Current Medical Research and Opinion2010;26(10):2277-85. [srincont-40376]StaskinD , DmochowskiR , SerelsS , AndohM , SmithN . Report from a randomized, placebo-controlled study showing significant improvement in urgency and patient-reported outcomes in overactive bladder patients treated with solifenacin (Abstract number 124). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73-4. [srincont-26600]TogliaM , AndohM , HussainI . Solifenacin improved warning time significantly compared to placebo in patients with overactive bladder (Abstract number 123). Neurourology and Urodynamics2006;25(6):655. [srincont-26629]TogliaM , AndohM , HussainI . Solifenacin improves urgency symtoms as assessed by voiding diaries and patient-reported outcomes (PRO) in patients with overactive bladder (Abstract number 155). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26636]TogliaMR , OstergardDR , AppellRA , AndohM , FakhouryA , HussainIF . Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status. International Urogynecology Journal2010;21(7):847-54. [srincont-40094]TogliaMR , SerelsSR , LarameeC , KarramMM , NandyIM , AndohM , et al. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial. Postgraduate Medicine2009;121(5):151-8. [srincont-34204]ZinnerS , HerschornS , AndohM , HussainI . Responder analyses show statistically significant improvements in incontinence and urgency are associated with reduction in symptom bother and improvement in health-related quality of life: VENUS results (Abstract number 123). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73. [srincont-26599]">Karram 2009</a>; <a href="./references#CD003781-bbs2-0054" title="KhullarV , HillS , LavalKU , SchiotzHA , JonasU , VersiE . Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology2004;64(2):269-74; discussion 274-5. [srincont-19498]KhullarV , HillS , SolankiJ . Assessment of health-related quality of life in patients with overactive bladder taking tolterodine extended release versus placebo (Abstract number 318). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21075]">Khullar 2004</a>; <a href="./references#CD003781-bbs2-0068" title="DmochowskiR , MitchesonD , FrenklT , BennettN , MuddPN . Durable efficacy and safety of long-term once-daily vibegron, a novel oral B-3 adrenergic receptor agonist: A 52-week phase 2 study in patients with overactive bladder syndrome (Abstract number PD50-03). Journal of Urology2018;199(4):e970-1. [sr-incont78091]EUCTR2010-022121-15-IT. A phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2 part clinical study of the efficacy and safety of MK-4618 in patients with overactive bladder - MK4618-008 [A 52-week extension to: a phase iib randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder]. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-022121-15 (first received 12 April 2011). [EUCTR2010-022121-15-IT] [MK4618-008] [NCT01314872] [sr-incont78639]MitchesonD , FrenklT , SamantaS , Anne PintoC , GreenS , BennettN , et al. Vibegron, a novel once daily oral beta-3 agonist, significantly reduces average daily micturitions, urge incontinence episodes and urgency episodes in patients with overactive bladder (Abstract number: podium #34). Neurourology and Urodynamics2018;37(Suppl 1):S565. [EUCTR2010-022121-15-IT] [NCT01314872] [sr-incont78618]MitchesonD , PintoCA , FrenklT , ChenL , PrasadM , MuddPN . Once daily vibegron improves quality of life measures in patients with overactive bladder (Abstract number PUK17). Value in Health2018;21(Suppl 1):S267-8. [EUCTR2010-022121-15-IT] [NCT01314872;] [sr-incont78619]MitchesonHD , SamantaS , MuldowneyK , PintoCA , RochaBA , GreenS , et al. Vibegron (RVT-901/MK-4618/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial. European Urology2019;75(2):274-82. [NCT01314872] [sr-incont78620]NCT01314872. A study of the efficacy and safety of Vibegron (MK-4618) in participants with overactive bladder (OAB) (MK-4618-008) [A phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder a 52-week extension to: a phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of mk-4618 in patients with overactive bladder]. clinicaltrials.gov/show/NCT01314872 (first received 15 March 2011). [NCT01314872] [sr-incont63793]UKCRN10391. A phase IIB randomised, placebo- and active comparator (tolterodine)-controlled, 2-part clinical study of the efficacy and safety of MK-4618 in patients with overactive bladder . public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=10391 (accessed 28 June 2012). [CCRN525] [UKCRN10391] [sr-incont45046]">Mitcheson 2019</a>; <a href="./references#CD003781-bbs2-0069" title="Drug company. A phase 2, parallel group, stratified, randomized, double blind, placebo-controlled trial to investigate the efficacy and safety of 3 different dosages of sustained release fesoterodine in subjects with overactive bladder showing either involuntary detrusor contractions or normal findings during the baseline urodynamic assessment. Protocol numbers: A0221029 (SP668). ClinicalStudyResults.org (accessed 3 March 2011). [srincont-41111]NittiV , WiatrakM , KreitmanL , LipsitzD . Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB): results of a phase 2 trial (Abstract number 306). In: International Continence Society (ICS); 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21084]">Nitti 2005</a>; <a href="./references#CD003781-bbs2-0070" title="GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NittiVW , DmochowskiR , SandPK , ForstHT , Haag-MolkentellerC , MassowU , et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. Journal of Urology2007;178(6):2488-94. [NCT00138723] [SP584] [srincont-26313]">Nitti 2007</a>; <a href="./references#CD003781-bbs2-0077" title="RogersR , BachmannG , JumadilovaZ , SunF , MorrowJD , GuanZ , et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. International Urogynecology Journal and Pelvic Floor Dysfunction2008;19(11):1551-7. [A6121002] [NCT00143481] [srincont-27729]RogersRG , BachmannG , ScarperoH , JumadilovaZ , SunF , MorrowJD , et al. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. Current Medical Research and Opinion2009;25(9):2159-65. [srincont-32060]">Rogers 2008</a>; <a href="./references#CD003781-bbs2-0080" title="RudyD , ClineK , GoldbergK , HarrisR . A multicenter, randomized, placebo-controlled trial of trospium chloride in overactive bladder patients (Abstract). Neurourology and Urodynamics2004;23(5/6):600-1. [sr-incont19025]RudyD , ClineK , HarrisR , GoldbergK , DmochowskiR . Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology2006;67(2):275-80. [srincont-21604]RudyD , ClineK , HarrisR , GoldbergK , DmochowskiR . Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. BJU International2006;97(3):540-6. [sr-incont21593]">Rudy 2006</a>; <a href="./references#CD003781-bbs2-0082" title="ChancellorMB , OefeleinMG , VasavadaS . Obesity is associated with a more severe overactive bladder disease state that is effectively treated with one daily administration of trospium chloride extended release [Erratum available in: Neurourology and Urodynamics 2010;29(5):804]. Neurourology and Urodynamics2010;29(4):551-4. [sr-incont39591]GinsbergDA , OefeleinMG , EllsworthPI . Once-daily administration of trospium chloride extended release provides 24-hour coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials. Neurourology and Urodynamics2011;30(4):563-7. [sr-incont41531]RovnerE , DmochowskiR , WatanabeJ . Once daily (QD) trospium chloride 60mg extended release (XR) is safe and effective in patients (PTS) with the overactive bladder (OAB) syndrome who use multiple concomitant medications (MEDS) (Abstract number: Poster #68). Neurourology and Urodynamics2009;28(2):146-7. [sr-incont31062]SandP , DmochowskiR , ZinnerN , StaskinD . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: results from a multicenter, phase III, placebo-controlled study (Abstract number 269). In: International Continence Society (ICS), 37th Annual Meeting; 2007 Aug 20-24; Rotterdam, the Netherlands. 2007. [sr-incont26676]SandP , StaskinD , ZinnerN , DmochowskiR . Once-daily trospium chloride extended release is effective and well tolerated for the treatment of overactive bladder: results from a multicenter, phase III trial (Abstract number 57). Neurourology and Urodynamics2007;26(5):675. [sr-incont26661]StaskinD , SandP , ZinnerN , DmochowskiR , Trospium Study Group. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. Journal of Urology2007;178(3 Pt 1):978-83; discussion 983-4. [srincont-23909]StaskinDR , RosenbergMT , SandPK , ZinnerNR , DmochowskiRR . Trospium chloride once daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised phase III trials. International Journal of Clinical Practice2009;63(12):1715-23. [sr-incont35458]StaskinDR , SandPK , ZinnerNR . Once-daily trospium chloride extended release is effective and well tolerated for the treatment of overactive bladder: results from a multicenter, phase III trial (Abstract number - poster 22). Neurourology and Urodynamics2007;26(7 Suppl):1106. [srincont-27305]">Staskin 2007</a>; <a href="./references#CD003781-bbs2-0092" title="ChancellorM , FreedmanS , MitchesonHD , AntociJ , PrimusG , WeinA . Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clinical Drug Investigation2000;19(2):83-91. [srincont-16326]FreemanR , HillS , MillardR , SlackM , SutherstJ , Tolterodine Study Group. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstetrics and Gynecology2003;102(3):605-11. [srincont-16494]GarelyA , Tolterodine Study Group. Once-daily tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder. International Urology Journal2001;12(Suppl 1):S18. [srincont-12012]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of life of patients with overactive bladder receiving tolterodine. Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of patients with overactive bladder receiving tolterodine (Abstract number 82). Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , ReesePR . Health related quality of life of patients with overactive bladder receiving tolterodine once-daily. Neurourology and Urodynamics2000;19(4):519-21. [srincont-9987]KelleherCJ , ReesePR , PleilAM , OkanoGJ . Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. American Journal of Managed Care2002;8(Suppl 19):S608-15. [srincont-17998]KelleherCJ , Tolterodine Study Group. Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2000;11(Suppl 1):S94. [srincont-11915]KrederKJ . Antimuscarinic therapy: relationship between efficacy and side effects in responders and non-responders. Journal of Urology2001;165(Suppl 5):S165. [srincont-16327]KrederKJ . Clinical effectiveness of antimuscarinic therapy: the relationship between efficacy and tolerability. In: Proceedings of the International Continence Society Annual Meeting(ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001:140. [srincont-14376]MallettV . Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2001;12(Suppl 1):4. [srincont-12011]MillardRJ , TamaddonK , Tolterodine Study Group. Randomized controlled trial to compare tolterodine prolonged release capsules and tolterodine immediate release tablets versus placebo in patients with symptoms of detrusor overactivity (Abstract number 57). Australian and New Zealand Journal of Surgery2002;Suppl 72:A140. [sr-incont22190]PleilAM , ReesePR , KelleherCJ , OkanoGJ . Health-related quality of life of patients with overactive bladder receiving immediate-release tolterodine. HEPAC Health Economics in Prevention and Care2001;2(2):69-75. [sr-incont18060]RoehrbornCG , AbramsP , RovnerES , KaplanSA , HerschornS , GuanZ . Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU International2006;97(5):1003-6. [sr-incont21882]SwiftS . Efficacy and tolerability of once-daily tolterodine for women with overactive bladder. In: International Continence Society Annual Meeting (ICS), 31st annual meeting; 2001 Sept 18-21; Seoul, Korea. 2001:No. 329. [srincont-14481]SwiftS . Once-daily tolterodine is effective and well tolerated in women with overactive bladder (Abstract 57). In: 2nd International Consultation on Incontinence; 2001 July 1-3; Paris, France. 2001. [srincont-16319]SwiftSE . Once-daily (OD) tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder (OAB). International Urogynecology Journal2000;11(Suppl 1):S15. [sr-incont11906]SwiftSE . Once-daily administration of extended-release tolterodine is effective and well-tolerated in patients with overactive bladder. In: XVI FIGO World Congress of Obstetrics and Gynecology; 2000 Sept 3-8; Washington DC. Vol. Book 1. 2000:40. [sr-incont12085]SwiftSE . Overactive bladder in females: treatment with once-daily tolterodine. International Urogynecology Journal2001;12(Suppl 3):S71. [sr-incont16328]Van KerrebroeckP , KrederK , JonasU , ZinnerN . Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology2001;57(3):414-21. [sr-incont11953]Van KerrebroeckPEV . Long-term (12 months) efficacy and tolerability of tolterodine once-daily in the treatment of overactive bladder. Neurourology and Urodynamics2001;20(4):401-2. [sr-incont15714]Van KerrebroeckPEVA , Tolterodine Study Group. Long-term tolerability and efficacy of once-daily (OD) tolterodine in the treatment of overactive bladder (OB). International Urogynecology Journal2001;12(Suppl 3):S49. [sr-incont16329]Van KerrebroeckPEVA , Tolterodine Study Group. Significant decreases in perception of urgency and urge incontinence episodes with once-daily tolterodine treatment in patients with overactive bladder (Abstract number 89). Neurourology and Urodynamics2000;19(4):493-4. [sr-incont9980]WeinAJ , KhullarV , WangJT , GuanZ . Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. BJU International2007;99(2):360-3. [sr-incont23180]vanKerrebroeckPE , KelleherCJ , CoyneKS , KoppZ , BrodskyM , WangJT . Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. Health and Quality of Life Outcomes2009;7(13):13. [10.1186/1477-7525-7-13] [sr-incont31438]vanKerrebroeckPE , WangJ , GuanZ . Effects of tolterodine extended release in patients with overactive bladder: perceived treatment benefits improve with efficacy (Abstract number 511). European Urology Supplements2004;3(2):130. [sr-incont31090]">Van Kerrebroeck 2001</a>; <a href="./references#CD003781-bbs2-0094" title="EUCTR2007-007087-17-SE. A 24-week, multicentre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-007087-17 (first received 13 June 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont64588]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00798434. A study to compare the effectiveness and safety of fesoterodine and placebo in an elderly population of patients who go to the toilet very frequently due to overactive bladder (SOFIA) [A 24-week, multi-centre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00798434 (first received 26 November 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont49847]SchneiderT , BergqvistA , WangJ , WaggA , Ebel-BitounC . Treatment with fesoterodine versus tolterodine for reducing symptom bother in elderly patients with overactive bladder including urgency urinary incontinence. European Urology, Supplements2012;11(1):e687-a. [sr-incont65389]WaggA , CarlssonM , ElsobkyM , FernetM . Effect of flexible dose fesoterodine on cognitive function in &gt;65 year old patients with OAB: data from two RCT (Abstract number 438). Neurourology and Urodynamics2019;38:S297-8. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78651]WaggA , DarekarA , ArumiD , KhullarV , OelkeM . Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people &gt;65 years of age: a post hoc analysis of data from the SOFIA study. Neurourology and Urodynamics2015;34(5):438-43. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont68100]WaggA , ElsobkyM , CarlssonM , FernetM . Response and cognitive safety of fesoterodine in patients &gt;65y old with OAB. Is there a relationship between cognition and treatment response? (Abstract number 183). Neurourology and Urodynamics2019;38:S118-20. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78632]WaggA , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. Journal of the American Geriatrics Society2013;61(2):185-93. [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TrialID.SOFIA.] [sr-incont48008]WaggAS , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Efficacy and tolerability of fesoterodine in older subjects with overactive bladder: results of SOFIA (Abstract number C33). Journal of the American Geriatrics Society2011;59:S124. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont65234]">Wagg 2013a</a>; <a href="./references#CD003781-bbs2-0102" title="ZinnerNR , MattiassonA , StantonSL . Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. Journal of the American Geriatrics Society2002;50(5):799-807. [sr-incont14679]">Zinner 2002</a>; <a href="./references#CD003781-bbs2-0104" title="ZinnerN , SussetJ , GittelmanM , ArguinzonizM , RekedaL , HaabF . Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. International Journal of Clinical Practice2006;60(1):119-26. [sr-incont21507]">Zinner 2006</a>). The result suggests that there is a similar or higher risk of UTI with anticholinergics compared with placebo (RR 1.23, 95% CI 1.02 to 1.48; P = 0.03; <a href="./references#CD003781-fig-0028" title="">Analysis 1.19</a>). </p> </section> <section id="CD003781-sec-0092"> <h5 class="title">Number of withdrawals due to adverse events</h5> <p>Sixty‐one RCTs reported the number of withdrawals due to adverse events with a total of 36,943 participants (23,889 in the anticholinergic group and 13,054 in the placebo group) (<a href="./references#CD003781-bbs2-0002" title="AbramsP , FreemanR , AnderströmC , MattiassonA . Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. British Journal of Urology1998;81(6):801-10. [srincont-7871]AbramsP , FreemanRN , AnderstromC , MattiassonA . Efficacy and tolerability of tolterodine vs. oxybutynin and placebo in patients with detrusor instability (Abstract). Journal of Urology1997;157(Suppl 4):103. [srincont-16321]">Abrams 1998</a>; <a href="./references#CD003781-bbs2-0003" title="AbramsP , KaplanS , MillardR . Tolterodine treatment is safe in men with bladder outlet obstruction (BOO) and symptomatic detrusor overactivity (DO) (Abstract). Neurourology and Urodynamics2001;20(4):547-8. [srincont-14372]">Abrams 2001</a>; <a href="./references#CD003781-bbs2-0004" title="AbramsP , KelleherC , StaskinD , KayR , MartanA , MincikI , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World Journal of Urology2017;35(5):827-38. [NCT01340027] [sr-incont77897]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Cardiovascular safety of combination treatment with mirabegron and solifenacin in patients with overactive bladder in a randomised, double-blind, dose-ranging, Phase II study (Symphony) (Abstract). European Urology, Supplements2014;13(1):e574-e574a. [NCT01340027] [sr-incont67160]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB) - efficacy and safety results from a randomised phase II study (Symphony) (Abstract number 295). Neurourology and Urodynamics2013;32(6):930-1. [NCT01340027] [TrialID.SYMPHONY.] [sr-incont49188]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB): safety results from a phase 2 study (Abstract number MP-16.08). Urology2013;82(3 Suppl 1):S139. [NCT01340027] [sr-incont66675]AbramsP , KelleherC , StaskinD , KayR , MartinaR , NewgreenD , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: Exploratory responder analyses of efficacy and evaluation of patient reported outcomes from a randomised, double-blind, dose-ranging, phase 2 study (Symphony) (Abstract number MP-24.11). Urology2014;84(4 Suppl 1):S145-6. [NCT01340027] [sr-incont67194]AbramsP , KelleherC , StaskinD , RechbergerT , KayR , MartinaR , et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (SYMPHONY). European Urology2015;67(3):577-88. [NCT01340027] [sr-incont66674]NCT01340027, Bristol Urological Institute . A study to evaluate the efficacy, safety and tolerability of mirabegron and solifenacin succinate alone and in combination for the treatment of overactive bladder (symphony) [A randomized, double-blind, factorial, parallel-group, active and placebo-controlled, multicenter dose-ranging study to evaluate the efficacy, safety and tolerability of six dose combinations of solifenacin succinate and mirabegron compared to mirabegron and solifenacin succinate monotherapies in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01340027 (first received 21 April 2011). [178-CL-100] [2010-020601-32] [NCT01340027] [TrialID.SYMPHONY] [sr-incont44510]NittiV , AbramsP , StaskinD , AuerbachS , MartinaR , VanMR . Urinary retention in patients with overactive bladder treated with mirabegron alone and in combination with solifenacin: the results of two randomized, double-blind, phase II studies (Abstract number MP76-13). Journal of Urology2014;191(4 Suppl 1):e886-7. [NCT00410514] [NCT01340027] [TrialID.SYMPHONY] [sr-incont67453]">Abrams 2013</a>; <a href="./references#CD003781-bbs2-0005" title="AlloussiS , Laval KU , Ballering-BruhlB , Grobe-FreeseM , BulittaM , SchaferM . Trospium chloride (Spasmo-lyt) in patients with motor urge syndrome (detrusor instability): a double-blind, randomised, multicentre, placebo-controlled study. Journal of Clinical Research1998;1:439-51. [srincont-12005]AlloussiS , Laval K-U, EckertR , Ballering-BruhlB , Grosse-FreeseM , BulittaM , et al. Trospium chloride (Spasmo-lyt(R)) in patients with motor urge syndrome (detrusor instability): a double-blind, randomised, multicentre, placebo-controlled study. Journal of Drug Assessment1999;2(1):27-39. [sr-incont18226]AlloussiS , Laval K-U, MertinsB . Efficacy and tolerability of trospium chloride (spasmo-lyt) versus placebo in patients with motor urge-syndrome. In: International Continence Society (ICS), 28th Annual Meeting; 1998 Sept 14-17; Jerusalem, Israel. 1998:109-10. [sr-incont5684]">Alloussi 1998</a>; <a href="./references#CD003781-bbs2-0010" title="CardozoL , KuzminI , LisecML , MillardR , vanVierssen TripOB , RidderAM , et al. YM905: Results of a randomised, double-blind placebo-controlled trial in patients with symptomatic overactive bladder (Abstract number 104). European Urology Supplements2003;2(1):28. [sr-incont27407]CardozoL , KuzminI , LisecML , MillardRJ , vanVierssen TripOB , RidderAM , et al. A double-blind, randomised, placebo-controlled trial with YM905 in symptomatic overactive bladder (Abstract number P74). Journal of the American Geriatrics Society2003;51 (Suppl 4):S68-9. [sr-incont31100]CardozoL , LisecM , MillardR , vanVierssen TripO , KuzminI , DrogendijkTE , et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. Journal of Urology2004;172(5 (Pt 1 of 2)):1919-24. [srincont-19090]CardozoL . A randomised double-blind, placebo-controlled trial of the once-daily muscarinic receptor antagonist solifenacin succinate for symptoms of overactive bladder (Abstract number 211). International Urogynecology Journal2003;14 (Suppl 1):S64. [sr-incont31104]CardozoL . Solifenacin succinate improves symptoms of an overactive bladder (Abstract number TP77). International Journal of Gynecology and Obstetrics2003;83(Suppl 3):94. [sr-incont31096]KelleherCJ , CardozoL , ChappleCR , HaabF , RidderAM . Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU International2005;95(1):81-5. [srincont-20241]">Cardozo 2004a</a>; <a href="./references#CD003781-bbs2-0011" title="CardozoL , AdamikZ , GuimaraesM , KrhutJ , Labat J-J, PetrovS , et al. Patients with overactive bladder show progressive improvement in urgency and bladder condition during treatment with solifenacin in a randomised, double-blind, placebo-controlled study (SUNRISE) (Abstract number 115). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S67-8. [srincont-26595]CardozoL , AmarencoG , PushkarD , MikulasJ , DrogendijkT , WrightM , et al. Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE). BJU International2013;111(5):804-10. [NCT00801944] [TrialID.SUNRISE.] [sr-incont47554]CardozoL , DewildeT , FeyereislJ , WadieB , AmarencoG , LiapisA , et al. Solifenacin significantly reduces both urgency severity and bother: results from the flexible dose, placebo controlled, multinational SUNRISE study (Abstract number 281). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26641]CardozoL , DrogendijkT , BolodeokuJ . The efficacy of solifenacin 5/10 mg on 'urgency' endpoints in different OAB patient populations: subanalysis of results from the randomised, double-blind SUNRISE study (Abstract number 192). In: International Continence Society (ICS); 38th Annual Meeting; 2008 Oct 20-24; Cairo, Egypt. 2008. [srincont-31885]CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CardozoL , HessdörferE , MilaniR , ArañóP , DewildeL , SlackM , et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU International2008;102(9):1120-7. [NCT00801944] [TrialID.SUNRISE] [srincont-29249]">Cardozo 2008a</a>; <a href="./references#CD003781-bbs2-0013" title="ChappleC . Fesoterodine a new effective and well-tolerated antimuscarinic for the treatment of urgency-frequency syndrome: results of a phase 2 controlled study (Abstract 142). Neurourology and Urodynamics2004;23(5/6):598-9. [srincont-19023]Drug company. A Phase 2, parallel group, randomized, double-blind, placebo controlled dose-ranging trial to determine the optimal dose and the tolerability of sustained release SPM 8272 (fesoterodine) in subjects with non-neurogenic bladder overactivity. Protocol numbers: A0221027 (SP582). ClinicalStudyResults.org (accessed 3 March 2011)2002. [Protocol numbers: A0221027 (SP582)] [srincont-41110]">Chapple 2004a</a>; <a href="./references#CD003781-bbs2-0014" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. ChappleCR , AranoP , BoschJH , De RidderD , KramerG , RidderAM . YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo- and tolterodine-controlled, phase-II, dose-finding study (Abstract 75). Neurourology and Urodynamics2002;21(4):381-2. [srincont-14551]ChappleCR , ArañoP , BoschJL , De RidderD , KramerAE , RidderAM . Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU International2004;93(1):71-7. [srincont-17334]KelleherCJ , CardozoL , ChappleCR , HaabF , RidderAM . Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU International2005;95(1):81-5. [srincont-20241]SmithN , GrimesI , RidgeS , TempelD , UchidaT , YamanouchiUS . YM905 is effective and safe as treatment of overactive bladder in women and men: results from phase II study (Abstract). In: International Continence Society (ICS), 32nd Annual Meeting; 2002 Aug 28-30; Heidelberg, Germany. 2002:138-9. [sr-incont14508]">Chapple 2004b</a>; <a href="./references#CD003781-bbs2-0015" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. ChappleC , RechbergerT , Al-ShukriS , MeffanP , EveraertK , RidderA . Results of a randomized phase 3 study comparing solifenacin succinate with tolterodine and placebo in patients with symptomatic overactive bladder (Abstract). Neurourology and Urodynamics2003;22(5):534-5. [sr-incont16991]ChappleCR , RechbergerT , Al ShukriS , MeffanP , EveraertK , HuangM , et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU International2004;93(3):303-10. [srincont-17270]">Chapple 2004c</a>; <a href="./references#CD003781-bbs2-0016" title="ChappleC , Van KerrebroeckP , TubaroA , Haag-MolkentellerC , ForstHT , MassowU , et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder [Erratum appears in: European Urology 2008,53(6):1319]. European Urology2007;52(4):1204-12. [NCT00220363] [SP583] [srincont-23875]ChappleC , Van KerrebroeckP , TubaroA , MillardR . Fesoterodine in non-neurogenic voiding dysfunction - results on efficacy and safety in a phase 3 trial (Abstract number 379). In: 21st Annual European Association of Urology (EAU) Congress; 2006 Apr 5-8; Paris, France. 2006. [srincont-41109]ChappleC , Van KerrebroeckP , TubaroA , WangJT , HvidstenK , BrodskyM . Efficacy of fesoterodine in patients with overactive bladder (OAB): improvements in OAB symptoms and health-related quality of life (HRQL) (Poster abstract number 1188). Journal of Urology2007;177(4 Suppl S):392. [srincont-31882]ChappleCR , vanKerrebroeckPE , JünemannKP , WangJT , BrodskyM . Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU International2008;102(9):1128-32. [srincont-29255]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. KelleherCJ , TubaroA , WangJT , KoppZ . Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU International2008;102(1):56-61. [srincont-27613]SandPK , MorrowJD , BavendamT , CreangaDL , NittiVW . Efficacy and tolerability of fesoterodine in women with overactive bladder. International Urogynecology Journal2009;20(7):827-35. [srincont-31351]">Chapple 2007a</a>; <a href="./references#CD003781-bbs2-0017" title="ChappleC , DuBeauC , EbingerU , RekedaL , ViegasA . Darifenacin treatment of patients &gt;or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Current Medical Research and Opinion2007;23(10):2347-58. [srincont-23921]">Chapple 2007b</a>; <a href="./references#CD003781-bbs2-0019" title="ChappleC , HaabF , SchneiderT , CarlssonM , ArumiD . Fesoterodine 8 mg versus fesoterodine 4 mg in patients with overactive bladder and a history of previous antimuscarinic therapy: Results from the EIGHT trial (Abstract number: Poster #M5). Neurourology and Urodynamics2015;34(S1):S20. [NCT01302067] [sr-incont68509]ChappleC , SchneiderT , HaabF , SunF , WhelanL , ScholfieldD , et al. Superiority of fesoterodine 8mg versus fesoterodine 4 mg in reducing urgency urinary incontinence episodes in subjects with overactive bladder: results of the randomized, double-blind, placebo-controlled EIGHT trial (Abstract number: Podium #48). Neurourology and Urodynamics2014;33(2):183-4. [NCT01302067] [sr-incont67484]ChappleC , SchneiderT , HaabF , SunF , WhelanL , ScholfieldD , et al. Superiority of fesoterodine 8mg vs 4mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial. BJU International2014;114(3):418-26. [A0221095] [NCT01302067] [TrialID.EIGHT] [srincont-62537]NCT01302067. A 12 week study to confirm the effectiveness of 8mg of Fesoterodine compared to 4mg of Fesoterodine [A 12-week, randomized, double-blind, placebo controlled, parallel group, multicenter trial in overactive bladder subjects to confirm the efficacy of 8 mg fesoterodine compared to 4 mg fesoterodine]. clinicaltrials.gov/show/NCT01302067 (first received 23 February 2011). [NCT01302067] [sr-incont63792]">Chapple 2014</a>; <a href="./references#CD003781-bbs2-0020" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. [sr-incont75259]ChuF , SmithN , UchidaT . Efficacy and safety of solifenacin succinate 10 mg once daily: a multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder. Current Therapeutic Research - Clinical and Experimental2009;70(6):405-20. [srincont-43324]">Chu 2009</a>; <a href="./references#CD003781-bbs2-0021" title="ChuaME , SeeMC , EsmeňaEB , BalingitJC , MoralesML . Efficacy and safety of gabapentin in comparison to solifenacin succinate in adult overactive bladder treatment. Lower Urinary Tract Symptoms2018;10(2):135-42. [NCT01486706] [sr-incont74529]NCT01486706, ChuaME . Efficacy and safety of gabapentin in treating overactive bladder (OAB). clinicaltrials.gov/show/NCT01486706 (first received 6 December 2011). [NCT01486706] [SLMC10-010] [sr-incont49864]">Chua 2018</a>; <a href="./references#CD003781-bbs2-0023" title="ChancellorMB , OefeleinMG , VasavadaS . Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release. Neurourology and Urodynamics2010;29(4):551-4. [sr-incont39591]DmochowskiR , StaskinD , SandP , ZinnerN . Trospium chloride 60 mg once daily improves quality of life in subjects with overactive bladder syndrome (Abstract number 277). In: International Continence Society (ICS); 37th Annual Meeting; 2008 Aug 20-24; Rotterdam, the Netherlands. 2007. [srincont-26679]DmochowskiRR , RosenbergMT , ZinnerNR , StaskinDR , SandPK . Extended-release trospium chloride improves quality of life in overactive bladder. Value in Health2010;13(2):251-7. [srincont-40049]DmochowskiRR , SandPK , ZinnerNR , StaskinDR . Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology2008;71(3):449-54. [srincont-27107]DmochowskiRR , ZinnerNR , SandPK . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: Results from a multicenter, phase III, placebo-controlled study (Abstract). Neurourology and Urodynamics2007;26(Suppl 7):1105-6. [srincont-26692]GinsbergDA , OefeleinMG , EllsworthPI . Once-daily administration of trospium chloride extended release provides 24-hr coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials. Neurourology and Urodynamics2011;30(4):563-7. [sr-incont41531]RovnerE , DmochowskiR , WatanabeJ . Once daily (QD) trospium chloride 60 mg extended release (XR) is safe and effective in patients (PTS) with the overactive bladder (OAB) syndrome who use multiple concomitant medications (MEDS) (Abstract number: Poster #68). Neurourology and Urodynamics2009;28(2):146-7. [sr-incont31062]SandP , DmochowskiR , ZinnerN , StaskinD . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: results from a multicenter, phase III, placebo-controlled study (Abstract number 269). In: International Continence Society (ICS), 37th Annual Meeting; 2007 Aug 20-24; Rotterdam, the Netherlands. 2007. [srincont-26676]SandPK , DmochowskiRR , ZinnerNR , StaskinDR , AppellRA . Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome. International Urogynecology Journal and Pelvic Floor Dysfunction2009;20(12):1431-8. [sr-incont39648]SandPK , Johnson IiTM , RovnerES , EllsworthPI , OefeleinMG , StaskinDR . Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged &gt; 75 years) with overactive bladder syndrome. BJU International2011;107(4):612-20. [sr-incont41422]StaskinDR , RosenbergMT , SandPK , ZinnerNR , DmochowskiRR . Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials. International Journal of Clinical Practice2009;63(12):1715-23. [sr-incont35458]">Dmochowski 2008</a>; <a href="./references#CD003781-bbs2-0024" title="DmochowskiR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. A double-blind, placebo-controlled trial of flexible-dose fesoterodine for overactive bladder (Abstract number 715). In: International Continence Society (ICS); 39th Annual Meeting; 2009 Sep 29-Oct 03; San Francisco, CA. 2009. [sr-incont35627]DmochowskiRR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder [Errata appear in: Urology 2010 Jun;75(6):1519 and in Urology 2011 Jun;77(6):1513]. Urology2010;75(1):62-8. [A0221014] [NCT00536484] [sr-incont39548]DuBeauC , KrausSR , SunF , MorrowJD . Fesoterodine in older vs younger subjects with overactive bladder (Abstract number D87). Journal of the American Geriatrics Society2010;58:S218. [NCT00536484] [sr-incont64309]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. [sr-incont78640]NCT00536484. Fesoterodine flexible dose study [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with overactive bladder]. clinicaltrials.gov/show/NCT00536484 (first received 27 September 2007). [NCT00536484] [sr-incont49160]StaskinD , KhullarV , MichelMC , MorrowJD , SunF , GuanZ , et al. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. Neurourology and Urodynamics2011;30(8):1480-5. [sr-incont42686]">Dmochowski 2010</a>; <a href="./references#CD003781-bbs2-0026" title="DrutzH , AppellRA . Clinical efficacy and safety of Tolterodine vs Oxybutynin and placebo in patients with unstable bladder. Acta Obstetrica et Gynecologica Scandinavica1997;Suppl 167(5):24. [srincont-6671]DrutzHP , AppellRA , GleasonD , KlimbergI , RadomskiS . Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. International Urogynecology Journal and Pelvic Floor Dysfunction1999;10(5):283-9. [srincont-8804]DrutzHP , AppellRA . Enhanced tolerability of tolterodine compared to oxybutynin in a controlled clinical study. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(1):S14. [srincont-5166]">Drutz 1999</a>; <a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>; <a href="./references#CD003781-bbs2-0032" title="GellerE , DumondJ , BowlingJM , KhandelwalC , WuJ , Busby-WhiteheadJ , et al. Effect of an anticholinergic on cognitive function in postmenopausal women: a randomized trial (Abstract number: oral poster 52). Female Pelvic Medicine and Reconstructive Surgery2016;22(5):S61. [sr-incont78607]GellerEJ , DumondJB , BowlingJM , KhandelwalCM , WuJM , Busby-WhiteheadJ , et al. Effect of trospium chloride on cognitive function in women aged 50 and older: a randomized trial. Female Pelvic Medicine &amp; Reconstructive Surgery2017;23(2):118-23. [13-1352] [NCT01922115] [sr-incont74341]NCT01922115. The effect of anticholinergics on cognitive function in the elderly (ACE) [The effect of anticholinergics on cognitive function in the elderly: a randomized controlled trial]. clinicaltrials.gov/show/NCT01922115 (first received 14 August 2013). [13-1352] [NCT01922115] [TrialID.ACE] [sr-incont49282]">Geller 2013</a>; <a href="./references#CD003781-bbs2-0033" title="GotohM , HommaY , YokoyamaO , NishizawaO . Responsiveness and minimal clinically important change in overactive bladder symptom score. Urology2011;78(4):768-73. [srincont-42622]GotohM , YokoyamaO , MatsukawaY , NishizawaO . Responsiveness of overactive bladder symptom score (OABSS): verification based on data in a double-blinded, randomized placebo-controlled study of propiverine hydrochloride in Japanese patients (Abstract number 338). In: Joint Meeting of the International Continence Society (ICS) and the International Urogynecological Association; 2010 Aug 23-27; Toronto, Canada. 2010. [srincont-40173]GotohM , YokoyamaO , NishizawaO . Propiverine hydrochloride in Japanese patients with overactive bladder: A randomized, double-blind, placebo-controlled trial. International Journal of Urology2011;18(5):365-73. [srincont-41510]">Gotoh 2011</a>; <a href="./references#CD003781-bbs2-0035" title="HaabF , StewartL , DwyerP . Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. European Urology2004;45(4):420-9. [srincont-17428]">Haab 2004</a>; <a href="./references#CD003781-bbs2-0038" title="HerschornS , HeesakkersJ , Castro-DiazD , WangJT , BrodskyM , GuanZ . Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*. Current Medical Research and Opinion2008;24(12):3513-21. [A6121122] [NCT00143377] [srincont-29250]HerschornS , HeesakkersJ , Castro-DiazD , WangJT , GuanZ , BrodskyM . Tolterodine extended release (TER) improves objective and subjective outcomes after 1 week of treatment in patients with overactive bladder (Abstract number 132). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S78-9. [srincont-26602]">Herschorn 2008</a>; <a href="./references#CD003781-bbs2-0039" title="CorcosJ , AnguloJC , GarelyAD , CarlssonM , GongJ , GuanZ . Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. Current Medical Research and Opinion2011;27(5):1059-65. [srincont-41596]EUCTR2006-006935-38-SE. 12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006935-38 (first received 16 April 2007). [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont64612]HerschornS , SwiftS , GuanZ , CarlssonM , BrodskyM , GongJ . Efficacy and safety of fesoterodine for overactive bladder in a double-blind, head-to-head comparison trial with tolterodine ER and placebo (Abstract number 710). In: International Continence Society (ICS), 39th Annual Meeting; 2009 Sep 29-Oct 3; San Francisco, CA. 2009. [srincont-35326]HerschornS , SwiftS , GuanZ , CarlssonM , MorrowJD , BrodskyM , et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU International2010;105(1):58-66. [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont39540]NCT00444925. Clinical trial to evaluate the efficacy and safety of Fesoterodine in comparison to Tolterodine for overactive bladder (OAB) [12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder (OAB)]. clinicaltrials.gov/show/NCT00444925 (first received 08 March 2007). [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont49159]">Herschorn 2009a</a>; <a href="./references#CD003781-bbs2-0040" title="EUCTR2012-005735-91-SK. A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-005735-91 (first received 12 November 2013). [178-CL-101] [EUCTR2012-005735-91-SK] [sr-incont78644]HerschornS , ChappleCR , AbramsP , ArlandisS , MitchesonD , LeeKS , et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU International2017;120(4):562-75. [NCT01972841] [sr-incont74470]MuellerER , RobinsonD , KelleherC , StaskinDR , FalconerC , WangJ , et al. Patient reported outcomes from synergy, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with mirabegron and solifenacin monotherapy (Abstract number - Podium #44). Neurourology and Urodynamics2017;36(Suppl S1):S151-2. [NCT01972841] [sr-incont75944]NCT01972841. This was a multinational study comparing the efficacy and safety of two medicines, solifenacin succinate and mirabegron taken together, or separately, or a mock treatment (placebo) in subjects with symptoms of overactive bladder (SYNERGY) [A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01972841 (first received 31 October 2013). [178-CL-101] [EUCTR2012-005735-91] [NCT01972841] [sr-incont63780]RobinsonD , KelleherC , StaskinD , MuellerER , FalconerC , WangJ , et al. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients. Neurourology and Urodynamics2018;37(1):394-406. [NCT01972841] [sr-incont76906]WeberMA , ChappleCR , GratzkeC , HerschornS , RobinsonD , FrankelJM , et al. A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial. Blood Pressure Monitoring2018;23(3):153-63. [NCT01972841] [sr-incont77899]WhiteWB , ChappleC , GratzkeC , HerschornS , RobinsonD , FrankelJ , et al. Cardiovascular safety of the beta3-adrenoceptor agonist mirabegron and the antimuscarinic agent solifenacin in the SYNERGY trial. Journal of Clinical Pharmacology2018;58(8):1084-91. [NCT01972841] [sr-incont78078]">Herschorn 2017a</a>; <a href="./references#CD003781-bbs2-0042" title="HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21072]HillS , KhullarV , Quebe-FehlingE , SteelM . Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in phase III trials (Abstract number 145). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21072]HillS , KhullarV , WyndaeleJJ , LheritierK , . Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. International Urogynecology Journal and Pelvic Floor2006;17(3):239-47. [srincont-22464]">Hill 2005</a>; <a href="./references#CD003781-bbs2-0044" title="HommaY , YamaguchiT , YamaguchiOA . A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2008;15(9):809-15. [srincont-27742]">Homma 2008</a>; <a href="./references#CD003781-bbs2-0045" title="HommaY , YamaguchiO , Imidafenacin Study Group. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2009;16(5):499-506. [NCT00212732] [ONO-8025-08] [srincont-31368]">Homma 2009</a>; <a href="./references#CD003781-bbs2-0046" title="HuangA , HessR , AryaL , RichterH , SubakL , BradleyC , et al. A randomized controlled trial of simple diagnosis and treatment for urgency urinary incontinence in women (Abstract). Journal of General Internal Medicine2011;26:S1. [NCT00862745] [sr-incont64391]HuangAJ , HessR , AryaLA , RichterHE , SubakLL , BradleyCS , et al. Pharmacologic treatment for urgency-predominant urinary incontinence in women diagnosed using a simplified algorithm: a randomized trial. American Journal of Obstetrics and Gynecology2012;206(5):444.e1-11. [GA0221IX] [NCT00862745] [TrialID.BRIDGES.] [srincont-44636]NCT00862745, BrownJ . Bringing simple urge incontinence diagnosis &amp; treatment to providers (BRIDGES)  [A multi-center, randomized, placebo-controlled clinical trial comparing fesoterodine to placebo in women diagnosed with urge urinary incontinence by the 3 Incontinence Questions (3IQ). Followed by a multi-center open label clinical cohort study of long-term effects of treatment with fesoterodine ]. clinicaltrials.gov/show/NCT00862745 (first received 17 March 2009). [NCT00862745] [sr-incont49836]WarsiQ , HuangA , BrownJS , SchembriM , HessR , AryaLA , et al. The effect of pharmacologic treatment of urgency urinary incontinence on sleep quality and daytime sleepiness (Abstract number: paper 37). Female Pelvic Medicine and Reconstructive Surgery2016;22(5 ):S17-8. [NCT00862745] [TrialID.BRIDGES.] [sr-incont78633]WarsiQA , HuangAJ , HessR , AryaLA , RichterHE , BradleyCS , et al. Association of pharmacologic treatment of urgency urinary incontinence with sleep quality and daytime sleepiness. Obstetrics and Gynecology2018;131(2):204-11. [NCT00862745] [sr-incont78239]WinkelmanW , HuangA , SchembriM , RogersRG , RichterHE , MyersDL , et al. Clinical variables moderating response to pharmacologic treatment of urgency-predominant urinary incontinence in a randomized controlled trial (Abstract number: poster 25). In: Female Pelvic Medicine and Reconstructive Surgery. 37th Annual Scientific Meeting of the American Urogynecologic Society; Aug 2016; United States. Vol. 22. Netherlands: Lippincott Williams and Wilkins, 2016:S81. [NCT00862745] [sr-incont78634]WinkelmanWD , HuangAJ , SchembriM , RogersRG , RichterH , MyersDL , et al. Modifiers of response to treatment with fesoterodine for urgency-predominant urinary incontinence in a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2017;23(2):151-6. [sr-incont74308]">Huang 2012</a>; <a href="./references#CD003781-bbs2-0047" title="JacquetinB , WyndaeleJJ . Tolterodine reduces the number of incontinence episodes in patients with an overactive bladder. European Journal of Obstetrics and Gynecology and Reproductive Biology2001;98(1):97-102. [srincont-12200]JacquetinB , WyndaeleJJ . Tolterodine reduces the number of incontinence episodes in patients with detrusor overactivity. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(1):S30. [srincont-5167]">Jacquetin 2001</a>; <a href="./references#CD003781-bbs2-0048" title="JonasU , HofnerK , MadersbacherH , HolmdahlTH . Efficacy and safety of two doses of Tolterodine compared to placebo in patients with detrusor overactivity. Neurourology and Urodynamics1997;16(5):477-8. [srincont-5841]JonasU , HöfnerK , MadersbacherH , HolmdahlTH . Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group. World Journal of Urology1997;15(2):144-51. [srincont-5436]">Jonas 1997</a>; <a href="./references#CD003781-bbs2-0050" title="JünemannKP , HessdörferE , Unamba‐OparahI , BerseM , BrünjesR , MadersbacherH . Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. Urologia Internationalis2006;77(4):334-9. [srincont-22199]">Junemann 2006</a>; <a href="./references#CD003781-bbs2-0051" title="EUCTR2007-006451-39-SE. 12-week, randomized, double-blind, double-dummy, placebo controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-006451-39 (first received 20 February 2008). [A0221046] [EUCTR2007-006451-39-SE] [sr-incont64591]KaplanSA , SchneiderT , FooteJ , GuanZ . Superior efficacy of fesoterodine over tolterodine with rapid onset: a prospective, head-to-head, placebo-controlled trial (Abstract number 67). Neurourology and Urodynamics2010;29(6):905-7. [srincont-40130]KaplanSA , SchneiderT , FooteJE , GuanZ , CarlssonM , GongJ . Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU International2011;107(9):1432-40. [A0221046] [NCT00611026] [srincont-41334]">Kaplan 2011</a>; <a href="./references#CD003781-bbs2-0052" title="CardozoL , KaplanS , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: results from the after study (Abstract number 740) [Erratum appears in: European Urology 2014;65(5):e78]. European Urology Supplements2013;12(1):e740-1. [NCT01302054] [sr-incont63732]CardozoL , KaplanS , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. Erratum: A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: results from the AFTER study [Erratum available in: European Urology Supplement 2013;2012:e740-1]. European Urology2014;65(5):e78 . [A0221094] [NCT01302054] [TrialID.AFTER.] [sr-incont61642]GrenaboL , HerschornS , KaplanSA , CardozoL , ScholfieldD , ArumiD , et al. Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptoms. Current Medical Research and Opinion2017;33(10):1731-6. [NCT01302054] [TrialID.AFTER.] [sr-incont76695]KaplanSA , CardozoL , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER. International Journal of Clinical Practice2014;68(9):1065-73. [A0221094] [NCT01302054] [TrialID.AFTER.] [srincont-63977]KaplanSA , HerschornS , CarlssonM , NtaniosF . Urgency urinary incontinence response rates in subjects with overactive bladder treated with fesoterodine 8 mg after suboptimal response to tolterodine extended release 4 mg: a randomized, double-blind, placebo-controlled trial (Abstract number 546). In: International Continence Society (ICS); 43rd Annual Meeting; 2013 Aug 26-30; Barcelona, Spain. 2013. [NCT01302054] [TrialID.AFTER.] [sr-incont49730]NCT01302054. A clinical study in patients with overactive bladder with leakage of urine, to find out if the medicine, Fesoterodine, works in those patients who did not have enough response to the medicine, tolterodine. [A 14 week randomized parallel group placebo-controlled double-blind multicentre study of fesoterodine 8 mg in overactive bladder patients with sub-optimal response to tolterodine 4 mg extended release (ER)]. clinicaltrials.gov/show/NCT01302054 (first received 23 February 2011). [A0221094] [NCT01302054] [TrialID.AFTER.] [sr-incont49845]">Kaplan 2014</a>; <a href="./references#CD003781-bbs2-0053" title="CapoJP , TogliaM , Forero-SchwanhaeuserS , HeW . Patients reporting severe overactive bladder symptoms: effects of solifenacin treatment on objective measures and patient-reported outcomes (Abstract number 582). In: International Continence Society (ICS), 38th Annual Meeting; 2008 Oct 20-24; Cairo, Egypt. 2008. [srincont-31844]CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. KarramMM , TogliaMR , SerelsSR , AndohM , FakhouryA , Forero-SchwanhaeuserS . Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology2009;73(1):14-8. [A0221094] [NCT00454896] [TrialID.VENUS.] [srincont-29219]SerelsSR , TogliaMR , Forero-SchwanhaeuserS , HeW . Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms. Current Medical Research and Opinion2010;26(10):2277-85. [srincont-40376]StaskinD , DmochowskiR , SerelsS , AndohM , SmithN . Report from a randomized, placebo-controlled study showing significant improvement in urgency and patient-reported outcomes in overactive bladder patients treated with solifenacin (Abstract number 124). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73-4. [srincont-26600]TogliaM , AndohM , HussainI . Solifenacin improved warning time significantly compared to placebo in patients with overactive bladder (Abstract number 123). Neurourology and Urodynamics2006;25(6):655. [srincont-26629]TogliaM , AndohM , HussainI . Solifenacin improves urgency symtoms as assessed by voiding diaries and patient-reported outcomes (PRO) in patients with overactive bladder (Abstract number 155). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26636]TogliaMR , OstergardDR , AppellRA , AndohM , FakhouryA , HussainIF . Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status. International Urogynecology Journal2010;21(7):847-54. [srincont-40094]TogliaMR , SerelsSR , LarameeC , KarramMM , NandyIM , AndohM , et al. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial. Postgraduate Medicine2009;121(5):151-8. [srincont-34204]ZinnerS , HerschornS , AndohM , HussainI . Responder analyses show statistically significant improvements in incontinence and urgency are associated with reduction in symptom bother and improvement in health-related quality of life: VENUS results (Abstract number 123). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73. [srincont-26599]">Karram 2009</a>; <a href="./references#CD003781-bbs2-0054" title="KhullarV , HillS , LavalKU , SchiotzHA , JonasU , VersiE . Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology2004;64(2):269-74; discussion 274-5. [srincont-19498]KhullarV , HillS , SolankiJ . Assessment of health-related quality of life in patients with overactive bladder taking tolterodine extended release versus placebo (Abstract number 318). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21075]">Khullar 2004</a>; <a href="./references#CD003781-bbs2-0057" title="KosilovK , LoparevS , IvanovskayaM , KosilovaL . A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron. Archives of Gerontology and Geriatrics2015;61(2):212-6. [sr-incont68133]">Kosilov 2015a</a>; <a href="./references#CD003781-bbs2-0058" title="KosilovKV , LoparevSA , IvanovskayaMA , KosilovaLV . The efficacy of different doses of solifenacin in elderly patients after treating a urinary tract infection. Arab Journal of Urology Print2015;13(3):203-8. [sr-incont69283]">Kosilov 2015b</a>; <a href="./references#CD003781-bbs2-0060" title="HsiaoSM , ChangTC , ChenCH , WuWY , LinHH . Comparisons of the clinical outcomes and urodynamic effects of mirabegron versus tolterodine treatment for female overactive bladder syndrome: a subgroup analysis of a controlled, randomised, prospective study. Lower Urinary Tract Symptoms2018;10(3):215-20. [NCT01043666] [sr-incont74461]KuoHC , LeeKS , NaY , SoodR , NakajiS , KubotaY , et al. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourology and Urodynamics2015;34(7):685-92. [NCT01043666] [sr-incont68095]Kuo H‐C, Lin H‐H, Yu H‐J, Cheng C‐L, Hung M‐J, LinAT . Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials [Erratum available in: Urological Science 2015;26(2):148]. Urological Science2015;26(1):41-8 . [NCT01043666] [sr-incont68645]NCT01043666. A study of YM178 in subjects with symptoms of overactive bladder  [Phase III study of YM178: a randomized, double-blind, parallel group, placebo and active controlled, multi-center study in subjects with symptoms of overactive bladder]. clinicaltrials.gov/show/NCT01043666 (first received 07 January 2010). [178-CL-090] [NCT01043666] [sr-incont63781]">Kuo 2015</a>; <a href="./references#CD003781-bbs2-0063" title="LeeKS , ChooMS , KimDY , KimJC , KimHJ , MinKS , et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. Journal of Urology2005;174(4 Pt 1):1334-8. [sr-incont21016]LeeKS , ChooMS , PaickJS , LeeJG , SeoJT , LeeJZ , et al. Propiverine hydrochloride reduced frequency and perception of urgency in treatment of overactive bladder: a 12 week prospective, randomized, double blind, placebo controlled study (Abstract number 279). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26640]LeeKS , LeeHW , ChooMS , PaickJS , LeeJG , SeoJT , et al. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'. BJU International2010;105(11):1565-70. [2005-01-08] [NCT00903045] [PROUD] [sr-incont39958]NCT00903045. Urinary urgency outcomes following propiverine treatment for an overactive bladder [Urinary urgency outcomes following propiverine treatment for an overactive bladder: propiverine study on overactive bladder including urgency data (PROUD)]. clinicaltrials.gov/show/NCT009030452005;(first received 15 May 2009). [2005-01-08] [NCT00903045] [TrialID.PROUD] [sr-incont49860]">Lee 2006</a>; <a href="./references#CD003781-bbs2-0065" title="ChappleCR , MadersbacherH , DreikornK , DorschnerW , MurtzG . Urodynamics and frequency/volume chart - do they correlate? Treatment analysis of propiverine in comparison to oxybutynin and placebo in urge incontinence (Abstract 224). In: International Continence Society (ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001. [sr-incont14474]HalaskaM , MadersbacherH , VoigtR , HofnerK , MartanA . Propiverine in patients with urgency and urge incontinence - a placebo controlled, multicentre study comparing its tolerability and efficacy with oxybutynin (Abstract number FDP36). International Urogynaecology Journal 2000;11(Suppl 1):S46. [srincont-11912]MadersbacherH , HalaskaM , VoigtR , AlloussiS , HofnerK . A urodynamically controlled multicenter study in patients with urge incontinence: tolerability and efficacy of propiverine hydrochloride in comparison to oxybutynin. In: International Continence Society (ICS), 27th Annual Meeting; 1997 Sep 23-26; Yokohama, Japan. 1997:153-4. [srincont-5854]MadersbacherH , HalaskaM , VoigtR , AlloussiS , HöfnerK . A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU International1999;84(6):646-51. [srincont-9166]">Madersbacher 1999</a>; <a href="./references#CD003781-bbs2-0066" title="Malone-LeeJG , WalshB , MaugourdMF , Tolterodine in the Elderly Study Group. The safety and clinical efficacy of two doses of tolterodine compared to placebo in elderly patients. In: International Continence Society (ICS), 27th Annual Meeting; 1997 Sep 23-26; Yokohama, Japan. 1997:155-6. [srincont-5855]Malone‐LeeJG , WalshJB , MaugourdMF . Tolterodine: A safe and effective treatment for older patients with overactive bladder. Journal of the American Geriatric Society2001;49(6):700-5. [srincont-12319]WaggA , Malone-LeeJ . Pressure-flow variables in patients treated with tolterodine for detrusor overactivity. BJU International2003;92(9):969-71. [sr-incont16659]">Malone‐Lee 2001</a>; <a href="./references#CD003781-bbs2-0067" title="MillardR , TuttleJ , MooreK , SussetJ , ClarkeB , DwyerP , et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. Journal of Urology1999;161(5):1551-5. [sr-incont8172]MooreK , MillardR , DwyerP , TuttleJ . A randomized controlled multicentre trial of tolterodine in detrusor instability/hyperreflexia. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(Suppl 1):S129. [sr-incont5171]RosamiliaA , DwyerPL , ClarkeB , MooreK , MillardRP , TuttleJ . The clinical efficacy and safety of two doses of Tolterodine in detrusor instability. Acta Obstetrica et Gynecologica Scandinavica1997;6(Suppl 167):24. [sr-incont6670]">Millard 1999</a>; <a href="./references#CD003781-bbs2-0069" title="Drug company. A phase 2, parallel group, stratified, randomized, double blind, placebo-controlled trial to investigate the efficacy and safety of 3 different dosages of sustained release fesoterodine in subjects with overactive bladder showing either involuntary detrusor contractions or normal findings during the baseline urodynamic assessment. Protocol numbers: A0221029 (SP668). ClinicalStudyResults.org (accessed 3 March 2011). [srincont-41111]NittiV , WiatrakM , KreitmanL , LipsitzD . Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB): results of a phase 2 trial (Abstract number 306). In: International Continence Society (ICS); 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [srincont-21084]">Nitti 2005</a>; <a href="./references#CD003781-bbs2-0070" title="GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NittiVW , DmochowskiR , SandPK , ForstHT , Haag-MolkentellerC , MassowU , et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. Journal of Urology2007;178(6):2488-94. [NCT00138723] [SP584] [srincont-26313]">Nitti 2007</a>; <a href="./references#CD003781-bbs2-0072" title="OreskovićS , ButI , BanovićM , GoldstajnMS . The efficacy and safety of solifenacin in patients with overactive bladder syndrome. Collegium Antropologicum2012;36(1):243-8. [srincont-45056]">Oreskovic 2012</a>; <a href="./references#CD003781-bbs2-0074" title="RentzhogSL , StantonL , CardozoL , NelsonE , FallM , AbramsP . Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. British Journal of Urology1998;81(1):42-8. [srincont-5461]">Rentzhog 1998</a>; <a href="./references#CD003781-bbs2-0077" title="RogersR , BachmannG , JumadilovaZ , SunF , MorrowJD , GuanZ , et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. International Urogynecology Journal and Pelvic Floor Dysfunction2008;19(11):1551-7. [A6121002] [NCT00143481] [srincont-27729]RogersRG , BachmannG , ScarperoH , JumadilovaZ , SunF , MorrowJD , et al. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. Current Medical Research and Opinion2009;25(9):2159-65. [srincont-32060]">Rogers 2008</a>; <a href="./references#CD003781-bbs2-0080" title="RudyD , ClineK , GoldbergK , HarrisR . A multicenter, randomized, placebo-controlled trial of trospium chloride in overactive bladder patients (Abstract). Neurourology and Urodynamics2004;23(5/6):600-1. [sr-incont19025]RudyD , ClineK , HarrisR , GoldbergK , DmochowskiR . Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology2006;67(2):275-80. [srincont-21604]RudyD , ClineK , HarrisR , GoldbergK , DmochowskiR . Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. BJU International2006;97(3):540-6. [sr-incont21593]">Rudy 2006</a>; <a href="./references#CD003781-bbs2-0082" title="ChancellorMB , OefeleinMG , VasavadaS . Obesity is associated with a more severe overactive bladder disease state that is effectively treated with one daily administration of trospium chloride extended release [Erratum available in: Neurourology and Urodynamics 2010;29(5):804]. Neurourology and Urodynamics2010;29(4):551-4. [sr-incont39591]GinsbergDA , OefeleinMG , EllsworthPI . Once-daily administration of trospium chloride extended release provides 24-hour coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials. Neurourology and Urodynamics2011;30(4):563-7. [sr-incont41531]RovnerE , DmochowskiR , WatanabeJ . Once daily (QD) trospium chloride 60mg extended release (XR) is safe and effective in patients (PTS) with the overactive bladder (OAB) syndrome who use multiple concomitant medications (MEDS) (Abstract number: Poster #68). Neurourology and Urodynamics2009;28(2):146-7. [sr-incont31062]SandP , DmochowskiR , ZinnerN , StaskinD . Trospium chloride extended-release formulation provides effective relief for the symptoms of overactive bladder, improves patient-reported quality of life, and is well tolerated: results from a multicenter, phase III, placebo-controlled study (Abstract number 269). In: International Continence Society (ICS), 37th Annual Meeting; 2007 Aug 20-24; Rotterdam, the Netherlands. 2007. [sr-incont26676]SandP , StaskinD , ZinnerN , DmochowskiR . Once-daily trospium chloride extended release is effective and well tolerated for the treatment of overactive bladder: results from a multicenter, phase III trial (Abstract number 57). Neurourology and Urodynamics2007;26(5):675. [sr-incont26661]StaskinD , SandP , ZinnerN , DmochowskiR , Trospium Study Group. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. Journal of Urology2007;178(3 Pt 1):978-83; discussion 983-4. [srincont-23909]StaskinDR , RosenbergMT , SandPK , ZinnerNR , DmochowskiRR . Trospium chloride once daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised phase III trials. International Journal of Clinical Practice2009;63(12):1715-23. [sr-incont35458]StaskinDR , SandPK , ZinnerNR . Once-daily trospium chloride extended release is effective and well tolerated for the treatment of overactive bladder: results from a multicenter, phase III trial (Abstract number - poster 22). Neurourology and Urodynamics2007;26(7 Suppl):1106. [srincont-27305]">Staskin 2007</a>; <a href="./references#CD003781-bbs2-0084" title="SteersW , CorcosJ . Efficacy, tolerability and safety of darifenacin, an M3 selective receptor antagonist for the treatment of overactive bladder, using a flexible dosing regimen (Abstract number 68). Progres en Urologie2004;14(3 Suppl 3):22. [srincont-22197]">Steers 2004</a>; <a href="./references#CD003781-bbs2-0086" title="StohrerM , MadersbacherH , RichterR , WehnertJ , DreikornK . Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia - a double-blind, placebo-controlled clinical trial. Spinal Cord1999;37(3):196-200. [sr-incont8146]">Stohrer 1999</a>; <a href="./references#CD003781-bbs2-0089" title="ThuroffJW , BunkeB , EbnerA , FaberP , deGeeterP , HannappelJ , et al. Randomized, double-blind multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin vs. propantheline vs. placebo. Neurourology and Urodynamics1990;9(4):337-8. [srincont-5108]ThuroffJW , BunkeB , EbnerA , FaberP , deGeeterP , HannappelJ , et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. Journal of Urology1991;145(4):813-7. [srincont-1288]">Thuroff 1991</a>; <a href="./references#CD003781-bbs2-0092" title="ChancellorM , FreedmanS , MitchesonHD , AntociJ , PrimusG , WeinA . Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clinical Drug Investigation2000;19(2):83-91. [srincont-16326]FreemanR , HillS , MillardR , SlackM , SutherstJ , Tolterodine Study Group. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstetrics and Gynecology2003;102(3):605-11. [srincont-16494]GarelyA , Tolterodine Study Group. Once-daily tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder. International Urology Journal2001;12(Suppl 1):S18. [srincont-12012]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of life of patients with overactive bladder receiving tolterodine. Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , OkanoGJ , ReesePR . Long-term health-related quality of patients with overactive bladder receiving tolterodine (Abstract number 82). Neurourology and Urodynamics2001;20(4):504-6. [srincont-14492]KelleherCJ , PleilAM , ReesePR . Health related quality of life of patients with overactive bladder receiving tolterodine once-daily. Neurourology and Urodynamics2000;19(4):519-21. [srincont-9987]KelleherCJ , ReesePR , PleilAM , OkanoGJ . Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. American Journal of Managed Care2002;8(Suppl 19):S608-15. [srincont-17998]KelleherCJ , Tolterodine Study Group. Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2000;11(Suppl 1):S94. [srincont-11915]KrederKJ . Antimuscarinic therapy: relationship between efficacy and side effects in responders and non-responders. Journal of Urology2001;165(Suppl 5):S165. [srincont-16327]KrederKJ . Clinical effectiveness of antimuscarinic therapy: the relationship between efficacy and tolerability. In: Proceedings of the International Continence Society Annual Meeting(ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001:140. [srincont-14376]MallettV . Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal2001;12(Suppl 1):4. [srincont-12011]MillardRJ , TamaddonK , Tolterodine Study Group. Randomized controlled trial to compare tolterodine prolonged release capsules and tolterodine immediate release tablets versus placebo in patients with symptoms of detrusor overactivity (Abstract number 57). Australian and New Zealand Journal of Surgery2002;Suppl 72:A140. [sr-incont22190]PleilAM , ReesePR , KelleherCJ , OkanoGJ . Health-related quality of life of patients with overactive bladder receiving immediate-release tolterodine. HEPAC Health Economics in Prevention and Care2001;2(2):69-75. [sr-incont18060]RoehrbornCG , AbramsP , RovnerES , KaplanSA , HerschornS , GuanZ . Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU International2006;97(5):1003-6. [sr-incont21882]SwiftS . Efficacy and tolerability of once-daily tolterodine for women with overactive bladder. In: International Continence Society Annual Meeting (ICS), 31st annual meeting; 2001 Sept 18-21; Seoul, Korea. 2001:No. 329. [srincont-14481]SwiftS . Once-daily tolterodine is effective and well tolerated in women with overactive bladder (Abstract 57). In: 2nd International Consultation on Incontinence; 2001 July 1-3; Paris, France. 2001. [srincont-16319]SwiftSE . Once-daily (OD) tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder (OAB). International Urogynecology Journal2000;11(Suppl 1):S15. [sr-incont11906]SwiftSE . Once-daily administration of extended-release tolterodine is effective and well-tolerated in patients with overactive bladder. In: XVI FIGO World Congress of Obstetrics and Gynecology; 2000 Sept 3-8; Washington DC. Vol. Book 1. 2000:40. [sr-incont12085]SwiftSE . Overactive bladder in females: treatment with once-daily tolterodine. International Urogynecology Journal2001;12(Suppl 3):S71. [sr-incont16328]Van KerrebroeckP , KrederK , JonasU , ZinnerN . Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology2001;57(3):414-21. [sr-incont11953]Van KerrebroeckPEV . Long-term (12 months) efficacy and tolerability of tolterodine once-daily in the treatment of overactive bladder. Neurourology and Urodynamics2001;20(4):401-2. [sr-incont15714]Van KerrebroeckPEVA , Tolterodine Study Group. Long-term tolerability and efficacy of once-daily (OD) tolterodine in the treatment of overactive bladder (OB). International Urogynecology Journal2001;12(Suppl 3):S49. [sr-incont16329]Van KerrebroeckPEVA , Tolterodine Study Group. Significant decreases in perception of urgency and urge incontinence episodes with once-daily tolterodine treatment in patients with overactive bladder (Abstract number 89). Neurourology and Urodynamics2000;19(4):493-4. [sr-incont9980]WeinAJ , KhullarV , WangJT , GuanZ . Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. BJU International2007;99(2):360-3. [sr-incont23180]vanKerrebroeckPE , KelleherCJ , CoyneKS , KoppZ , BrodskyM , WangJT . Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. Health and Quality of Life Outcomes2009;7(13):13. [10.1186/1477-7525-7-13] [sr-incont31438]vanKerrebroeckPE , WangJ , GuanZ . Effects of tolterodine extended release in patients with overactive bladder: perceived treatment benefits improve with efficacy (Abstract number 511). European Urology Supplements2004;3(2):130. [sr-incont31090]">Van Kerrebroeck 2001</a>; <a href="./references#CD003781-bbs2-0093" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CrosbyRD , MathiasSD , MarshallTS . Relationships between symptoms, symptom bother, and health-related quality of life in patients with overactive bladder taking solifenacin or placebo in the VIBRANT study. International Journal of Clinical Practice2011;65(2):211-8. [sr-incont41015]GollarKM , YoungDG , BailenJ , HeW , Forero-SchwanhaeuserS . Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: a secondary analysis of the VIBRANT study. Urologic Nursing2012;32(1):38-46. [TrialID.VIBRANT.] [sr-incont44571]Samuels T‐A, MitchesonHD , VardyM , Forero‐SchwanhaeuserS , MarshallT , HeW . Efficacy of solifenacin for symptom bother and other patient-reported outcomes in patients with overactive bladder (OAB): results of a large, double-blind, placebo-controlled trial (Abstract number: poster #74). Neurourology and Urodynamics2009;28(2):149. [sr-incont31063]VardyMD , MitchesonHD , SamuelsTA , Forero-SchwanhaeuserS , HeW . Efficacy of solifenacin on overactive bladder symptoms, symptom bother, and other patient-reported outcomes in subjects with or without incontinence: a post hoc analysis of data from VIBRANT. Female Pelvic Medicine and Reconstructive Surgery2011;17(1):24-9. [TrialID.VIBRANT.] [sr-incont44741]VardyMD , MitchesonHD , SamuelsTA , WegenkeJD , Forero-SchwanhaeuserS , MarshallTS , et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. International Journal of Clinical Practice2009;63(12):1702-14. [905-UC-010] [NCT00573508] [TrialID.VIBRANT.] [sr-incont35459]">Vardy 2009</a>; <a href="./references#CD003781-bbs2-0094" title="EUCTR2007-007087-17-SE. A 24-week, multicentre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-007087-17 (first received 13 June 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont64588]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00798434. A study to compare the effectiveness and safety of fesoterodine and placebo in an elderly population of patients who go to the toilet very frequently due to overactive bladder (SOFIA) [A 24-week, multi-centre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00798434 (first received 26 November 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont49847]SchneiderT , BergqvistA , WangJ , WaggA , Ebel-BitounC . Treatment with fesoterodine versus tolterodine for reducing symptom bother in elderly patients with overactive bladder including urgency urinary incontinence. European Urology, Supplements2012;11(1):e687-a. [sr-incont65389]WaggA , CarlssonM , ElsobkyM , FernetM . Effect of flexible dose fesoterodine on cognitive function in &gt;65 year old patients with OAB: data from two RCT (Abstract number 438). Neurourology and Urodynamics2019;38:S297-8. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78651]WaggA , DarekarA , ArumiD , KhullarV , OelkeM . Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people &gt;65 years of age: a post hoc analysis of data from the SOFIA study. Neurourology and Urodynamics2015;34(5):438-43. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont68100]WaggA , ElsobkyM , CarlssonM , FernetM . Response and cognitive safety of fesoterodine in patients &gt;65y old with OAB. Is there a relationship between cognition and treatment response? (Abstract number 183). Neurourology and Urodynamics2019;38:S118-20. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78632]WaggA , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. Journal of the American Geriatrics Society2013;61(2):185-93. [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TrialID.SOFIA.] [sr-incont48008]WaggAS , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Efficacy and tolerability of fesoterodine in older subjects with overactive bladder: results of SOFIA (Abstract number C33). Journal of the American Geriatrics Society2011;59:S124. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont65234]">Wagg 2013a</a>; <a href="./references#CD003781-bbs2-0095" title="GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00911937. A trial to evaluate the efficacy and safety of fesoterodine in patients with symptoms of overactive bladder including nocturnal urinary urgency [A randomized, double blind, placebo controlled, parallel group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with symptoms of overactive bladder including nocturnal urinary urgency]. clinicaltrials.gov/show/NCT00911937 (first received 03 June 2009). [NCT00911937] [sr-incont49848]WeissJ , JumadilovaZ , CarlssonM , FitzGeraldMP , MalhotraA , MartireDL . Effect of antimuscarinic treatment in subjects with overactive bladder, including nocturnal urinary urgency (Abstract number 1963). Journal of Urology2012;187(4 Suppl 1):e792. [NCT00911937] [sr-incont65184]WeissJP , CarlssonMR , ManganEK . Age, gender and nocturnal urgency severity predict response to antimuscarinic treatment (Abstract number 1962). Journal of Urology2013;189(4 Suppl 1):e805. [NCT00911937] [sr-incont65096]WeissJP , JumadilovaZ , JohnsonTM , FitzGeraldMP , CarlssonM , MartireDL , et al. Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency. Journal of Urology2013;189(4):1396-401. [A0221048] [NCT00911937] [sr-incont47568]">Weiss 2013</a>; <a href="./references#CD003781-bbs2-0096" title="YamaguchiO , MaruiE , KakizakiH , ItohN , YokotaT , OkadaH , et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU International2007;100(3):579-87. [sr-incont23865]YokoyamaO , YamaguchiO , KakizakiH , ItohN , YokotaT , OkadaH , et al. Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary. Journal of Urology2011;186(1):170-4. [sr-incont41734]">Yamaguchi 2007</a>; <a href="./references#CD003781-bbs2-0098" title="YamaguchiO , UchidaE , HigoN , MinamiH , KobayashiS , SatoH , et al. Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: a randomized double-blind trial. International Journal of Urology2014;21(6):586-93. [JapicCTI-101309] [sr-incont62099]">Yamaguchi 2014</a>; <a href="./references#CD003781-bbs2-0100" title="JapicCTI-152936. Phase III study of KRP-114V [A phase III, randomized, double-blind, parallel group, placebo controlled, multicenter study to assess the efficacy and safety of the beta-3 agonist KRP-114V in Japanese subjects with symptoms of overactive bladder]. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-152936 (first received 17 June 2015). [JapicCTI-152936] [sr-incont78653]YoshidaM , TakedaM , GotoM , NagaiS , KuroseT . Vibegron, a novel potent and selective beta3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study (Abstract number 1082). European Urology, Supplements2018;17(2):e1531-2. [JapicCTI-152936] [sr-incont78069]YoshidaM , TakedaM , GotohM , NagaiS , KuroseT . Vibegron, a novel potent and selective B3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study. European Urology2018;73(5):783-90. [JapicCTI-152936] [sr-incont77898]YoshidaM , TakedaM , GotohM , YokoyamaO , KakizakiH , TakahashiS , et al. Efficacy of novel beta3-adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: a post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study. International Journal of Urology2019;26(3):369-75. [JapicCTI-152936] [sr-incont78654]YoshidaM , TakedaM , GotohM , YokoyamaO , KakizakiH , TakahashiS , et al. Efficacy of vibegron, a novel selective I²3-adrenoreceptor agonist, on urgency urinary incontinence with overactive bladder: post-hoc analysis of phase iii study (Abstract number 180). Neurourology and Urodynamics2019;38(S3):S114-5. [JapicCTI-152936] [sr-incont78636]">Yoshida 2018</a>; <a href="./references#CD003781-bbs2-0103" title="ZinnerN , GittelmanM , HarrisR , SussetJ , KanellosA , AuerbachS . Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial (Abstract number DP51). In: American Urological Association (AUA), 98th Annual Meeting; 2003 Apr 26-May 1; Chicago, Illinois. 2003. [sr-incont31101]ZinnerN , GittelmanM , HarrisR , SussetJ , KanelosA , AuerbachS , Trospium Study Group. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. Journal of Urology2004;171(6 Pt 1):2311-5. [sr-incont17376]">Zinner 2004</a>; <a href="./references#CD003781-bbs2-0104" title="ZinnerN , SussetJ , GittelmanM , ArguinzonizM , RekedaL , HaabF . Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. International Journal of Clinical Practice2006;60(1):119-26. [sr-incont21507]">Zinner 2006</a>). Participants in the anticholinergic group may be more likely to withdraw due to adverse events than those in the placebo group (RR 1.37, 95% CI 1.21 to 1.56; P &lt; 000001; <a href="./references#CD003781-fig-0029" title="">Analysis 1.20</a>; <a href="./full#CD003781-tbl-0001">summary of findings Table 1</a>; low‐certainty evidence). </p> <p>The I<sup>2</sup> value for subgroup differences for this outcome is 42.7%. After investigating sensitivity, and deselecting tolterodine, the I<sup>2</sup> value was reduced to 0%. With tolterodine, the risk of withdrawal due to adverse events due to anticholinergics was lowered (RR 1.37, 95% CI 1.21 to 1.56), while without tolterodine the risk may be increased (RR 1.52, 95% CI 1.33 to 1.72). Thus, tolterodine might be better tolerated overall compared to other drugs included in the review. </p> </section> <section id="CD003781-sec-0093"> <h5 class="title">Number of micturitions per 24 hours at the end of treatment</h5> <p>Thirty studies reported the number of micturitions per 24 hours at the end of treatment with a total of 19,395 participants (12,294 in the anticholinergics group and 7101 in the placebo group) (<a href="./references#CD003781-bbs2-0014" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. ChappleCR , AranoP , BoschJH , De RidderD , KramerG , RidderAM . YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo- and tolterodine-controlled, phase-II, dose-finding study (Abstract 75). Neurourology and Urodynamics2002;21(4):381-2. [srincont-14551]ChappleCR , ArañoP , BoschJL , De RidderD , KramerAE , RidderAM . Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU International2004;93(1):71-7. [srincont-17334]KelleherCJ , CardozoL , ChappleCR , HaabF , RidderAM . Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU International2005;95(1):81-5. [srincont-20241]SmithN , GrimesI , RidgeS , TempelD , UchidaT , YamanouchiUS . YM905 is effective and safe as treatment of overactive bladder in women and men: results from phase II study (Abstract). In: International Continence Society (ICS), 32nd Annual Meeting; 2002 Aug 28-30; Heidelberg, Germany. 2002:138-9. [sr-incont14508]">Chapple 2004b</a>; <a href="./references#CD003781-bbs2-0015" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. ChappleC , RechbergerT , Al-ShukriS , MeffanP , EveraertK , RidderA . Results of a randomized phase 3 study comparing solifenacin succinate with tolterodine and placebo in patients with symptomatic overactive bladder (Abstract). Neurourology and Urodynamics2003;22(5):534-5. [sr-incont16991]ChappleCR , RechbergerT , Al ShukriS , MeffanP , EveraertK , HuangM , et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU International2004;93(3):303-10. [srincont-17270]">Chapple 2004c</a>; <a href="./references#CD003781-bbs2-0016" title="ChappleC , Van KerrebroeckP , TubaroA , Haag-MolkentellerC , ForstHT , MassowU , et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder [Erratum appears in: European Urology 2008,53(6):1319]. European Urology2007;52(4):1204-12. [NCT00220363] [SP583] [srincont-23875]ChappleC , Van KerrebroeckP , TubaroA , MillardR . Fesoterodine in non-neurogenic voiding dysfunction - results on efficacy and safety in a phase 3 trial (Abstract number 379). In: 21st Annual European Association of Urology (EAU) Congress; 2006 Apr 5-8; Paris, France. 2006. [srincont-41109]ChappleC , Van KerrebroeckP , TubaroA , WangJT , HvidstenK , BrodskyM . Efficacy of fesoterodine in patients with overactive bladder (OAB): improvements in OAB symptoms and health-related quality of life (HRQL) (Poster abstract number 1188). Journal of Urology2007;177(4 Suppl S):392. [srincont-31882]ChappleCR , vanKerrebroeckPE , JünemannKP , WangJT , BrodskyM . Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU International2008;102(9):1128-32. [srincont-29255]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. KelleherCJ , TubaroA , WangJT , KoppZ . Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU International2008;102(1):56-61. [srincont-27613]SandPK , MorrowJD , BavendamT , CreangaDL , NittiVW . Efficacy and tolerability of fesoterodine in women with overactive bladder. International Urogynecology Journal2009;20(7):827-35. [srincont-31351]">Chapple 2007a</a>; <a href="./references#CD003781-bbs2-0021" title="ChuaME , SeeMC , EsmeňaEB , BalingitJC , MoralesML . Efficacy and safety of gabapentin in comparison to solifenacin succinate in adult overactive bladder treatment. Lower Urinary Tract Symptoms2018;10(2):135-42. [NCT01486706] [sr-incont74529]NCT01486706, ChuaME . Efficacy and safety of gabapentin in treating overactive bladder (OAB). clinicaltrials.gov/show/NCT01486706 (first received 6 December 2011). [NCT01486706] [SLMC10-010] [sr-incont49864]">Chua 2018</a>; <a href="./references#CD003781-bbs2-0024" title="DmochowskiR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. A double-blind, placebo-controlled trial of flexible-dose fesoterodine for overactive bladder (Abstract number 715). In: International Continence Society (ICS); 39th Annual Meeting; 2009 Sep 29-Oct 03; San Francisco, CA. 2009. [sr-incont35627]DmochowskiRR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder [Errata appear in: Urology 2010 Jun;75(6):1519 and in Urology 2011 Jun;77(6):1513]. Urology2010;75(1):62-8. [A0221014] [NCT00536484] [sr-incont39548]DuBeauC , KrausSR , SunF , MorrowJD . Fesoterodine in older vs younger subjects with overactive bladder (Abstract number D87). Journal of the American Geriatrics Society2010;58:S218. [NCT00536484] [sr-incont64309]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. [sr-incont78640]NCT00536484. Fesoterodine flexible dose study [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with overactive bladder]. clinicaltrials.gov/show/NCT00536484 (first received 27 September 2007). [NCT00536484] [sr-incont49160]StaskinD , KhullarV , MichelMC , MorrowJD , SunF , GuanZ , et al. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. Neurourology and Urodynamics2011;30(8):1480-5. [sr-incont42686]">Dmochowski 2010</a>; <a href="./references#CD003781-bbs2-0026" title="DrutzH , AppellRA . Clinical efficacy and safety of Tolterodine vs Oxybutynin and placebo in patients with unstable bladder. Acta Obstetrica et Gynecologica Scandinavica1997;Suppl 167(5):24. [srincont-6671]DrutzHP , AppellRA , GleasonD , KlimbergI , RadomskiS . Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. International Urogynecology Journal and Pelvic Floor Dysfunction1999;10(5):283-9. [srincont-8804]DrutzHP , AppellRA . Enhanced tolerability of tolterodine compared to oxybutynin in a controlled clinical study. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(1):S14. [srincont-5166]">Drutz 1999</a>; <a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>; <a href="./references#CD003781-bbs2-0033" title="GotohM , HommaY , YokoyamaO , NishizawaO . Responsiveness and minimal clinically important change in overactive bladder symptom score. Urology2011;78(4):768-73. [srincont-42622]GotohM , YokoyamaO , MatsukawaY , NishizawaO . Responsiveness of overactive bladder symptom score (OABSS): verification based on data in a double-blinded, randomized placebo-controlled study of propiverine hydrochloride in Japanese patients (Abstract number 338). In: Joint Meeting of the International Continence Society (ICS) and the International Urogynecological Association; 2010 Aug 23-27; Toronto, Canada. 2010. [srincont-40173]GotohM , YokoyamaO , NishizawaO . Propiverine hydrochloride in Japanese patients with overactive bladder: A randomized, double-blind, placebo-controlled trial. International Journal of Urology2011;18(5):365-73. [srincont-41510]">Gotoh 2011</a>; <a href="./references#CD003781-bbs2-0039" title="CorcosJ , AnguloJC , GarelyAD , CarlssonM , GongJ , GuanZ . Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. Current Medical Research and Opinion2011;27(5):1059-65. [srincont-41596]EUCTR2006-006935-38-SE. 12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006935-38 (first received 16 April 2007). [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont64612]HerschornS , SwiftS , GuanZ , CarlssonM , BrodskyM , GongJ . Efficacy and safety of fesoterodine for overactive bladder in a double-blind, head-to-head comparison trial with tolterodine ER and placebo (Abstract number 710). In: International Continence Society (ICS), 39th Annual Meeting; 2009 Sep 29-Oct 3; San Francisco, CA. 2009. [srincont-35326]HerschornS , SwiftS , GuanZ , CarlssonM , MorrowJD , BrodskyM , et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU International2010;105(1):58-66. [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont39540]NCT00444925. Clinical trial to evaluate the efficacy and safety of Fesoterodine in comparison to Tolterodine for overactive bladder (OAB) [12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder (OAB)]. clinicaltrials.gov/show/NCT00444925 (first received 08 March 2007). [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont49159]">Herschorn 2009a</a>; <a href="./references#CD003781-bbs2-0040" title="EUCTR2012-005735-91-SK. A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-005735-91 (first received 12 November 2013). [178-CL-101] [EUCTR2012-005735-91-SK] [sr-incont78644]HerschornS , ChappleCR , AbramsP , ArlandisS , MitchesonD , LeeKS , et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU International2017;120(4):562-75. [NCT01972841] [sr-incont74470]MuellerER , RobinsonD , KelleherC , StaskinDR , FalconerC , WangJ , et al. Patient reported outcomes from synergy, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with mirabegron and solifenacin monotherapy (Abstract number - Podium #44). Neurourology and Urodynamics2017;36(Suppl S1):S151-2. [NCT01972841] [sr-incont75944]NCT01972841. This was a multinational study comparing the efficacy and safety of two medicines, solifenacin succinate and mirabegron taken together, or separately, or a mock treatment (placebo) in subjects with symptoms of overactive bladder (SYNERGY) [A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01972841 (first received 31 October 2013). [178-CL-101] [EUCTR2012-005735-91] [NCT01972841] [sr-incont63780]RobinsonD , KelleherC , StaskinD , MuellerER , FalconerC , WangJ , et al. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients. Neurourology and Urodynamics2018;37(1):394-406. [NCT01972841] [sr-incont76906]WeberMA , ChappleCR , GratzkeC , HerschornS , RobinsonD , FrankelJM , et al. A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial. Blood Pressure Monitoring2018;23(3):153-63. [NCT01972841] [sr-incont77899]WhiteWB , ChappleC , GratzkeC , HerschornS , RobinsonD , FrankelJ , et al. Cardiovascular safety of the beta3-adrenoceptor agonist mirabegron and the antimuscarinic agent solifenacin in the SYNERGY trial. Journal of Clinical Pharmacology2018;58(8):1084-91. [NCT01972841] [sr-incont78078]">Herschorn 2017a</a>; <a href="./references#CD003781-bbs2-0044" title="HommaY , YamaguchiT , YamaguchiOA . A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2008;15(9):809-15. [srincont-27742]">Homma 2008</a>; <a href="./references#CD003781-bbs2-0045" title="HommaY , YamaguchiO , Imidafenacin Study Group. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2009;16(5):499-506. [NCT00212732] [ONO-8025-08] [srincont-31368]">Homma 2009</a>; <a href="./references#CD003781-bbs2-0047" title="JacquetinB , WyndaeleJJ . Tolterodine reduces the number of incontinence episodes in patients with an overactive bladder. European Journal of Obstetrics and Gynecology and Reproductive Biology2001;98(1):97-102. [srincont-12200]JacquetinB , WyndaeleJJ . Tolterodine reduces the number of incontinence episodes in patients with detrusor overactivity. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(1):S30. [srincont-5167]">Jacquetin 2001</a>; <a href="./references#CD003781-bbs2-0050" title="JünemannKP , HessdörferE , Unamba‐OparahI , BerseM , BrünjesR , MadersbacherH . Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. Urologia Internationalis2006;77(4):334-9. [srincont-22199]">Junemann 2006</a>; <a href="./references#CD003781-bbs2-0051" title="EUCTR2007-006451-39-SE. 12-week, randomized, double-blind, double-dummy, placebo controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-006451-39 (first received 20 February 2008). [A0221046] [EUCTR2007-006451-39-SE] [sr-incont64591]KaplanSA , SchneiderT , FooteJ , GuanZ . Superior efficacy of fesoterodine over tolterodine with rapid onset: a prospective, head-to-head, placebo-controlled trial (Abstract number 67). Neurourology and Urodynamics2010;29(6):905-7. [srincont-40130]KaplanSA , SchneiderT , FooteJE , GuanZ , CarlssonM , GongJ . Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU International2011;107(9):1432-40. [A0221046] [NCT00611026] [srincont-41334]">Kaplan 2011</a>; <a href="./references#CD003781-bbs2-0052" title="CardozoL , KaplanS , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: results from the after study (Abstract number 740) [Erratum appears in: European Urology 2014;65(5):e78]. European Urology Supplements2013;12(1):e740-1. [NCT01302054] [sr-incont63732]CardozoL , KaplanS , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. Erratum: A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: results from the AFTER study [Erratum available in: European Urology Supplement 2013;2012:e740-1]. European Urology2014;65(5):e78 . [A0221094] [NCT01302054] [TrialID.AFTER.] [sr-incont61642]GrenaboL , HerschornS , KaplanSA , CardozoL , ScholfieldD , ArumiD , et al. Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptoms. Current Medical Research and Opinion2017;33(10):1731-6. [NCT01302054] [TrialID.AFTER.] [sr-incont76695]KaplanSA , CardozoL , HerschornS , GrenaboL , CarlssonM , ArumiD , et al. Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER. International Journal of Clinical Practice2014;68(9):1065-73. [A0221094] [NCT01302054] [TrialID.AFTER.] [srincont-63977]KaplanSA , HerschornS , CarlssonM , NtaniosF . Urgency urinary incontinence response rates in subjects with overactive bladder treated with fesoterodine 8 mg after suboptimal response to tolterodine extended release 4 mg: a randomized, double-blind, placebo-controlled trial (Abstract number 546). In: International Continence Society (ICS); 43rd Annual Meeting; 2013 Aug 26-30; Barcelona, Spain. 2013. [NCT01302054] [TrialID.AFTER.] [sr-incont49730]NCT01302054. A clinical study in patients with overactive bladder with leakage of urine, to find out if the medicine, Fesoterodine, works in those patients who did not have enough response to the medicine, tolterodine. [A 14 week randomized parallel group placebo-controlled double-blind multicentre study of fesoterodine 8 mg in overactive bladder patients with sub-optimal response to tolterodine 4 mg extended release (ER)]. clinicaltrials.gov/show/NCT01302054 (first received 23 February 2011). [A0221094] [NCT01302054] [TrialID.AFTER.] [sr-incont49845]">Kaplan 2014</a>; <a href="./references#CD003781-bbs2-0053" title="CapoJP , TogliaM , Forero-SchwanhaeuserS , HeW . Patients reporting severe overactive bladder symptoms: effects of solifenacin treatment on objective measures and patient-reported outcomes (Abstract number 582). In: International Continence Society (ICS), 38th Annual Meeting; 2008 Oct 20-24; Cairo, Egypt. 2008. [srincont-31844]CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. KarramMM , TogliaMR , SerelsSR , AndohM , FakhouryA , Forero-SchwanhaeuserS . Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology2009;73(1):14-8. [A0221094] [NCT00454896] [TrialID.VENUS.] [srincont-29219]SerelsSR , TogliaMR , Forero-SchwanhaeuserS , HeW . Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms. Current Medical Research and Opinion2010;26(10):2277-85. [srincont-40376]StaskinD , DmochowskiR , SerelsS , AndohM , SmithN . Report from a randomized, placebo-controlled study showing significant improvement in urgency and patient-reported outcomes in overactive bladder patients treated with solifenacin (Abstract number 124). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73-4. [srincont-26600]TogliaM , AndohM , HussainI . Solifenacin improved warning time significantly compared to placebo in patients with overactive bladder (Abstract number 123). Neurourology and Urodynamics2006;25(6):655. [srincont-26629]TogliaM , AndohM , HussainI . Solifenacin improves urgency symtoms as assessed by voiding diaries and patient-reported outcomes (PRO) in patients with overactive bladder (Abstract number 155). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26636]TogliaMR , OstergardDR , AppellRA , AndohM , FakhouryA , HussainIF . Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status. International Urogynecology Journal2010;21(7):847-54. [srincont-40094]TogliaMR , SerelsSR , LarameeC , KarramMM , NandyIM , AndohM , et al. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial. Postgraduate Medicine2009;121(5):151-8. [srincont-34204]ZinnerS , HerschornS , AndohM , HussainI . Responder analyses show statistically significant improvements in incontinence and urgency are associated with reduction in symptom bother and improvement in health-related quality of life: VENUS results (Abstract number 123). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73. [srincont-26599]">Karram 2009</a>; <a href="./references#CD003781-bbs2-0054" title="KhullarV , HillS , LavalKU , SchiotzHA , JonasU , VersiE . Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology2004;64(2):269-74; discussion 274-5. [srincont-19498]KhullarV , HillS , SolankiJ . Assessment of health-related quality of life in patients with overactive bladder taking tolterodine extended release versus placebo (Abstract number 318). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21075]">Khullar 2004</a>; <a href="./references#CD003781-bbs2-0060" title="HsiaoSM , ChangTC , ChenCH , WuWY , LinHH . Comparisons of the clinical outcomes and urodynamic effects of mirabegron versus tolterodine treatment for female overactive bladder syndrome: a subgroup analysis of a controlled, randomised, prospective study. Lower Urinary Tract Symptoms2018;10(3):215-20. [NCT01043666] [sr-incont74461]KuoHC , LeeKS , NaY , SoodR , NakajiS , KubotaY , et al. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourology and Urodynamics2015;34(7):685-92. [NCT01043666] [sr-incont68095]Kuo H‐C, Lin H‐H, Yu H‐J, Cheng C‐L, Hung M‐J, LinAT . Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials [Erratum available in: Urological Science 2015;26(2):148]. Urological Science2015;26(1):41-8 . [NCT01043666] [sr-incont68645]NCT01043666. A study of YM178 in subjects with symptoms of overactive bladder  [Phase III study of YM178: a randomized, double-blind, parallel group, placebo and active controlled, multi-center study in subjects with symptoms of overactive bladder]. clinicaltrials.gov/show/NCT01043666 (first received 07 January 2010). [178-CL-090] [NCT01043666] [sr-incont63781]">Kuo 2015</a>; <a href="./references#CD003781-bbs2-0070" title="GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NittiVW , DmochowskiR , SandPK , ForstHT , Haag-MolkentellerC , MassowU , et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. Journal of Urology2007;178(6):2488-94. [NCT00138723] [SP584] [srincont-26313]">Nitti 2007</a>; <a href="./references#CD003781-bbs2-0073" title="NCT01302938. Web-based methodology trial to evaluate the efficacy and safety of tolterodine ER in subjects with overactive bladder (REMOTE) [Exploratory, randomized, double-blind, placebo-controlled, parallel-group, single center, web-based phase IV pilot methodolgy trial to evaluate the efficacy and safety of tolterodine ER in subjects with overactive bladder]. clinicaltrials.gov/ct2/show/NCT01302938 (first received 24 February 2011). [A6121195] [NCT01302938] [TrialID.REMOTE.] [sr-incont43314]OrriM , LipsetCH , JacobsBP , CostelloAJ , CummingsSR . Web-based trial to evaluate the efficacy and safety of tolterodine ER 4 mg in participants with overactive bladder: REMOTE trial. Contemporary Clinical Trials2014;38(2):190-7. [A6121195] [NCT01302938] [TrialID.REMOTE.] [sr-incont62536]">Orri 2014</a>; <a href="./references#CD003781-bbs2-0077" title="RogersR , BachmannG , JumadilovaZ , SunF , MorrowJD , GuanZ , et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. International Urogynecology Journal and Pelvic Floor Dysfunction2008;19(11):1551-7. [A6121002] [NCT00143481] [srincont-27729]RogersRG , BachmannG , ScarperoH , JumadilovaZ , SunF , MorrowJD , et al. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. Current Medical Research and Opinion2009;25(9):2159-65. [srincont-32060]">Rogers 2008</a>; <a href="./references#CD003781-bbs2-0093" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CrosbyRD , MathiasSD , MarshallTS . Relationships between symptoms, symptom bother, and health-related quality of life in patients with overactive bladder taking solifenacin or placebo in the VIBRANT study. International Journal of Clinical Practice2011;65(2):211-8. [sr-incont41015]GollarKM , YoungDG , BailenJ , HeW , Forero-SchwanhaeuserS . Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: a secondary analysis of the VIBRANT study. Urologic Nursing2012;32(1):38-46. [TrialID.VIBRANT.] [sr-incont44571]Samuels T‐A, MitchesonHD , VardyM , Forero‐SchwanhaeuserS , MarshallT , HeW . Efficacy of solifenacin for symptom bother and other patient-reported outcomes in patients with overactive bladder (OAB): results of a large, double-blind, placebo-controlled trial (Abstract number: poster #74). Neurourology and Urodynamics2009;28(2):149. [sr-incont31063]VardyMD , MitchesonHD , SamuelsTA , Forero-SchwanhaeuserS , HeW . Efficacy of solifenacin on overactive bladder symptoms, symptom bother, and other patient-reported outcomes in subjects with or without incontinence: a post hoc analysis of data from VIBRANT. Female Pelvic Medicine and Reconstructive Surgery2011;17(1):24-9. [TrialID.VIBRANT.] [sr-incont44741]VardyMD , MitchesonHD , SamuelsTA , WegenkeJD , Forero-SchwanhaeuserS , MarshallTS , et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. International Journal of Clinical Practice2009;63(12):1702-14. [905-UC-010] [NCT00573508] [TrialID.VIBRANT.] [sr-incont35459]">Vardy 2009</a>; <a href="./references#CD003781-bbs2-0094" title="EUCTR2007-007087-17-SE. A 24-week, multicentre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-007087-17 (first received 13 June 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont64588]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00798434. A study to compare the effectiveness and safety of fesoterodine and placebo in an elderly population of patients who go to the toilet very frequently due to overactive bladder (SOFIA) [A 24-week, multi-centre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00798434 (first received 26 November 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont49847]SchneiderT , BergqvistA , WangJ , WaggA , Ebel-BitounC . Treatment with fesoterodine versus tolterodine for reducing symptom bother in elderly patients with overactive bladder including urgency urinary incontinence. European Urology, Supplements2012;11(1):e687-a. [sr-incont65389]WaggA , CarlssonM , ElsobkyM , FernetM . Effect of flexible dose fesoterodine on cognitive function in &gt;65 year old patients with OAB: data from two RCT (Abstract number 438). Neurourology and Urodynamics2019;38:S297-8. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78651]WaggA , DarekarA , ArumiD , KhullarV , OelkeM . Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people &gt;65 years of age: a post hoc analysis of data from the SOFIA study. Neurourology and Urodynamics2015;34(5):438-43. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont68100]WaggA , ElsobkyM , CarlssonM , FernetM . Response and cognitive safety of fesoterodine in patients &gt;65y old with OAB. Is there a relationship between cognition and treatment response? (Abstract number 183). Neurourology and Urodynamics2019;38:S118-20. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78632]WaggA , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. Journal of the American Geriatrics Society2013;61(2):185-93. [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TrialID.SOFIA.] [sr-incont48008]WaggAS , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Efficacy and tolerability of fesoterodine in older subjects with overactive bladder: results of SOFIA (Abstract number C33). Journal of the American Geriatrics Society2011;59:S124. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont65234]">Wagg 2013a</a>; <a href="./references#CD003781-bbs2-0097" title="NCT00966004. A study to evaluate safety and efficacy of ym178 in patients with overactive bladder [Phase III study of YM178 - a placebo-controlled, double-blind, group comparison study in patients with overactive bladder]. clinicaltrials.gov/show/NCT00966004 (first received 26 August 2009). [178-CL-048] [JapicCTI-R130370] [NCT00966004] [sr-incont63783]YamaguchiO , HidehiroK , YukioH , YasuhikoI , MasayukiT , OsamuN , et al. A phase III, randomized, double-blind, placebo and active controlled study of once-daily mirabegron 50 mg in patients with overactive bladder (Abstract number POD-03.06). Urology2012;80(3 Suppl 1):S10-1. [NCT00966004] [sr-incont65380]YamaguchiO , MaruiE , KakizakiH , HommaY , IgawaY , TakedaM , et al. A phase III, randomized, double-blind, placebo-controlled study of the beta-adrenoceptor agonist, mirabegron 50 mg once-daily, in Japanese patients with overactive bladder. BJU International2014;113(6):951-60. [NCT00966004] [sr-incont50603]">Yamaguchi 2012</a>; <a href="./references#CD003781-bbs2-0098" title="YamaguchiO , UchidaE , HigoN , MinamiH , KobayashiS , SatoH , et al. Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: a randomized double-blind trial. International Journal of Urology2014;21(6):586-93. [JapicCTI-101309] [sr-incont62099]">Yamaguchi 2014</a>; <a href="./references#CD003781-bbs2-0099" title="YongucT , SefikE , InciI , KusbeciOY , CelikS , AydinME , et al. Randomized, controlled trial of fesoterodine fumarate for overactive bladder in Parkinson's disease. World Journal of Urology2019;38(8):2013-9. [sr-incont78635]">Yonguc 2019</a>; <a href="./references#CD003781-bbs2-0100" title="JapicCTI-152936. Phase III study of KRP-114V [A phase III, randomized, double-blind, parallel group, placebo controlled, multicenter study to assess the efficacy and safety of the beta-3 agonist KRP-114V in Japanese subjects with symptoms of overactive bladder]. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-152936 (first received 17 June 2015). [JapicCTI-152936] [sr-incont78653]YoshidaM , TakedaM , GotoM , NagaiS , KuroseT . Vibegron, a novel potent and selective beta3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study (Abstract number 1082). European Urology, Supplements2018;17(2):e1531-2. [JapicCTI-152936] [sr-incont78069]YoshidaM , TakedaM , GotohM , NagaiS , KuroseT . Vibegron, a novel potent and selective B3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study. European Urology2018;73(5):783-90. [JapicCTI-152936] [sr-incont77898]YoshidaM , TakedaM , GotohM , YokoyamaO , KakizakiH , TakahashiS , et al. Efficacy of novel beta3-adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: a post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study. International Journal of Urology2019;26(3):369-75. [JapicCTI-152936] [sr-incont78654]YoshidaM , TakedaM , GotohM , YokoyamaO , KakizakiH , TakahashiS , et al. Efficacy of vibegron, a novel selective I²3-adrenoreceptor agonist, on urgency urinary incontinence with overactive bladder: post-hoc analysis of phase iii study (Abstract number 180). Neurourology and Urodynamics2019;38(S3):S114-5. [JapicCTI-152936] [sr-incont78636]">Yoshida 2018</a>; <a href="./references#CD003781-bbs2-0101" title="NCT01018264, ZesiewiczT . Solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease (URGE-PD) [URGE-PD: a multi-site, double-blind, randomized, placebo controlled trial of solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease]. clinicaltrials.gov/show/NCT01018264 (first received 23 November 2009). [NCT01018264] [sr-incont63790]ZesiewiczTA , EvattM , JahanI , VaughanC , SingerC , OrdoricaR , et al. URGE-PD: a multi-site, double-blind, randomized, placebo controlled trial of solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease (Abstract number 745). Movement Disorders2014;29(Suppl 1):S276-7. [NCT01018264] [sr-incont66602]ZesiewiczTA , EvattM , VaughanCP , JahanI , SingerC , OrdoricaR , et al. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease. Parkinsonism and Related Disorders2015;21(5):514-20. [NCT01018264] [sr-incont66860]">Zesiewicz 2015</a>; <a href="./references#CD003781-bbs2-0102" title="ZinnerNR , MattiassonA , StantonSL . Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. Journal of the American Geriatrics Society2002;50(5):799-807. [sr-incont14679]">Zinner 2002</a>). </p> <p>Anticholinergic drugs probably lead to a slight reduction in the number of micturitions per 24 hours compared to placebo (MD ‐0.85, 95% CI ‐0.98 to ‐0.73; P &lt; 0.00001; <a href="./references#CD003781-fig-0030" title="">Analysis 1.21</a>; <a href="./full#CD003781-tbl-0001">summary of findings Table 1</a>; moderate‐certainty evidence). </p> </section> </section> <section id="CD003781-sec-0094"> <h4 class="title">Publication bias</h4> <p>After inspection of the funnel plots, we suspected publication bias for the 'condition‐specific quality of life' outcome only as the plot does not resemble a symmetrical funnel, i.e. smaller studies without significant results were likely to remain unpublished (see <a href="#CD003781-fig-0004">Figure 4</a>). We did not identify publication bias for any other outcomes (studies appear to be scattered symmetrically around the funnel plots) (<a href="#CD003781-fig-0005">Figure 5</a>; <a href="#CD003781-fig-0006">Figure 6</a>; <a href="#CD003781-fig-0007">Figure 7</a>; <a href="#CD003781-fig-0008">Figure 8</a>; <a href="#CD003781-fig-0009">Figure 9</a>).  </p> <div class="figure" id="CD003781-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="original image" data-id="CD003781-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <div class="figure" id="CD003781-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="original image" data-id="CD003781-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <div class="figure" id="CD003781-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="original image" data-id="CD003781-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <div class="figure" id="CD003781-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="original image" data-id="CD003781-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-FIG-07.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <div class="figure" id="CD003781-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="original image" data-id="CD003781-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-FIG-08.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <div class="figure" id="CD003781-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="original image" data-id="CD003781-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-FIG-09.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003781-sec-0095" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003781-sec-0095"></div> <p>This review is an update of one of a series of Cochrane Reviews of drug therapy for overactive bladder syndrome and should be viewed in that context. Other reviews have considered whether different anticholinergic drugs have different effects (<a href="./references#CD003781-bbs2-0347" title="Madhuvrata P, Cody JD, Ellis G, HerbisonGP , Hay‐SmithEJ . Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database of Systematic Reviews2012, Issue 1. Art. No: CD005429. [DOI: 10.1002/14651858.CD005429.pub2]">Madhuvrata 2012</a>); whether anticholinergic drugs are better than other active (non‐drug) therapies (<a href="./references#CD003781-bbs2-0354" title="RaiBP , CodyJD , AlhassoA , StewartL . Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD003193. [DOI: 10.1002/14651858.CD003193.pub4]">Rai 2012</a>); and whether anticholinergic drugs are better than other drug treatments (<a href="./references#CD003781-bbs2-0359" title="RoxburghC , CookJ , DublinN . Anticholinergic drugs versus other medications for overactive bladder syndrome in adults. Cochrane Database of Systematic Reviews2007, Issue 4. Art. No: CD003190. [DOI: 10.1002/14651858.CD003190.pub4] [CD003190]">Roxburgh 2007</a>). This review shows that while anticholinergic drugs are more effective than placebo, and well tolerated by patients with an improvement in condition‐specific quality of life, the effects on these outcomes are minimal. Thus, the risk of adverse events needs to be considered before administering anticholinergic drugs. </p> <section id="CD003781-sec-0096"> <h3 class="title" id="CD003781-sec-0096">Summary of main results</h3> <p>An overview of the main outcomes can be found in <a href="./full#CD003781-tbl-0001">summary of findings Table 1</a>. </p> <p>There was moderate‐certainty evidence that at the end of the treatment period anticholinergics probably performed more effectively than placebo in terms of patient perception of cure or improvement, the mean number of urgency episodes per 24‐hour period and the mean number of micturitions per 24‐hour period. </p> <p>There was low‐certainty evidence that at the end of the treatment period anticholinergics may slightly increase quality of life. However, low‐certainty evidence also suggested that taking anticholinergic drugs may result in an increase in dry mouth and urinary retention adverse events, and may be slightly more likely to lead participants to withdraw due to adverse events. </p> </section> <section id="CD003781-sec-0097"> <h3 class="title" id="CD003781-sec-0097">Overall completeness and applicability of evidence</h3> <p>There are now a substantial number of studies included in this review, which appear to maintain the conclusions in previous iterations of this review. However, we assessed the majority of the risk of bias domains for these studies as being 'unclear'. In addition, there was some variation in the outcomes reported within studies and in how the same outcomes were measured across studies. </p> <p>We chose not to report urodynamic data as there has been little correlation between such findings and clinical outcome (<a href="./references#CD003781-bbs2-0343" title="Kopp KallnerH , ElmérC ,  AltmanD . Urodynamics as a prognosticator of mirabegron treatment outcomes. Gynecologic and Obstetric Investigation2019;84(5):472-6. [DOI: 10.1159/000496606]">Kopp Kallner 2019</a>). The emphasis on urodynamic measures in the literature should be re‐evaluated with more focus on patient experience and socioeconomic factors. Increasingly, trials are selecting outcomes relating to patient satisfaction and acceptability of treatment, which is to be welcomed as these are important factors in the choice of management. Data from these trials have, however, shown modest effect sizes compared to placebo (e.g. <a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>). No studies identified for inclusion in this review investigated any socioeconomic variables (e.g. income, education status). </p> <p>None of the included studies reported results for those with frequency and/or urgency alone (OAB‐dry) separately to those with urgency urinary incontinence (OAB‐wet). As such, it was not possible to assess differences by type of overactive bladder. Similarly, the only possible subgroup analysis by sex was for withdrawal due to adverse events. It was not possible to investigate potential differences between the sexes for the majority of outcomes. </p> </section> <section id="CD003781-sec-0098"> <h3 class="title" id="CD003781-sec-0098">Quality of the evidence</h3> <p>We assessed the methodological limitations in the design, conduct or reporting of the studies included in this systematic review using the published reports of the studies and we were therefore reliant on the quality of reporting. Overall, the reporting of many studies was inadequate with many not reporting demographic details such as the age, sex or concurrent medications of the participants. This may be important as age and polypharmacy are independent predictors of dry mouth, the main adverse side effect of anticholinergics. Data were not available in some studies for many of the prespecified outcomes of this systematic review. </p> <p>We assessed risk of bias using the Cochrane risk of bias tool. Many studies did not report methods and outcomes sufficiently enough to permit any judgement other than unclear risk. This was most noticeable in the selective outcome reporting domain, where only eight out of the 104 included studies provided enough information to allow judgement to take place. We judged one study to be at high risk of bias for this domain (<a href="./references#CD003781-bbs2-0048" title="JonasU , HofnerK , MadersbacherH , HolmdahlTH . Efficacy and safety of two doses of Tolterodine compared to placebo in patients with detrusor overactivity. Neurourology and Urodynamics1997;16(5):477-8. [srincont-5841]JonasU , HöfnerK , MadersbacherH , HolmdahlTH . Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group. World Journal of Urology1997;15(2):144-51. [srincont-5436]">Jonas 1997</a>), while we judged seven to be at low risk (<a href="./references#CD003781-bbs2-0018" title="ChappleCR , DvorakV , RadziszewskiP , vanKerrebroeckP , WyndaeleJJ , BosmanB , et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder. International Urogynecology Journal2013;24(9):1447-58. [178-CL-044] [NCT00337090] [TrialID.DRAGON.] [sr-incont48549]NCT00337090 . A study of YM178 in patients with symptomatic overactive bladder (DRAGON) [A randomized, double-blind, parallel group, placebo and active controlled, multicenter dose ranging study with the beta-3 agonist YM178 in patients with symptomatic overactive bladder]. clinicaltrials.gov/show/NCT00337090 (first received 15 June 2006). [EudraCT2005-002256-17] [JapicCTI-R130350] [NCT00337090] [sr-incont63803]">Chapple 2013</a>; <a href="./references#CD003781-bbs2-0021" title="ChuaME , SeeMC , EsmeňaEB , BalingitJC , MoralesML . Efficacy and safety of gabapentin in comparison to solifenacin succinate in adult overactive bladder treatment. Lower Urinary Tract Symptoms2018;10(2):135-42. [NCT01486706] [sr-incont74529]NCT01486706, ChuaME . Efficacy and safety of gabapentin in treating overactive bladder (OAB). clinicaltrials.gov/show/NCT01486706 (first received 6 December 2011). [NCT01486706] [SLMC10-010] [sr-incont49864]">Chua 2018</a>; <a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>; <a href="./references#CD003781-bbs2-0028" title="ElbasetM , TahaD , ZahranM , EzzatO , ElhefnawyAS , ElkenawyM , et al. Subjective and objective scales assessment after retreatment with anticholinergics post botox-faded effects in refractory idiopathic overactive bladder: a prospective single blinded randomized trial (Abstract number 132). European Urology, supplements2019;18(1):e172. [sr-incont78652]ElbasetMA , TahaDE , El-HefnawyAS , ZahranMH , ShokeirAA . Assessment of anticholinergic use after fading of BTX-A effects in refractory idiopathic overactive bladder: a prospective blinded randomized trial. International Neurourology Journal2019;23(3):240-8. [sr-incont78605]">Elbaset 2019</a>; <a href="./references#CD003781-bbs2-0032" title="GellerE , DumondJ , BowlingJM , KhandelwalC , WuJ , Busby-WhiteheadJ , et al. Effect of an anticholinergic on cognitive function in postmenopausal women: a randomized trial (Abstract number: oral poster 52). Female Pelvic Medicine and Reconstructive Surgery2016;22(5):S61. [sr-incont78607]GellerEJ , DumondJB , BowlingJM , KhandelwalCM , WuJM , Busby-WhiteheadJ , et al. Effect of trospium chloride on cognitive function in women aged 50 and older: a randomized trial. Female Pelvic Medicine &amp; Reconstructive Surgery2017;23(2):118-23. [13-1352] [NCT01922115] [sr-incont74341]NCT01922115. The effect of anticholinergics on cognitive function in the elderly (ACE) [The effect of anticholinergics on cognitive function in the elderly: a randomized controlled trial]. clinicaltrials.gov/show/NCT01922115 (first received 14 August 2013). [13-1352] [NCT01922115] [TrialID.ACE] [sr-incont49282]">Geller 2013</a>; <a href="./references#CD003781-bbs2-0094" title="EUCTR2007-007087-17-SE. A 24-week, multicentre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-007087-17 (first received 13 June 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont64588]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00798434. A study to compare the effectiveness and safety of fesoterodine and placebo in an elderly population of patients who go to the toilet very frequently due to overactive bladder (SOFIA) [A 24-week, multi-centre trial, comprising a 12-week, randomised, double-blind, placebo-controlled, parallel-group phase followed by a 12-week open-label phase, to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00798434 (first received 26 November 2008). [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TRIALID.SOFIA] [sr-incont49847]SchneiderT , BergqvistA , WangJ , WaggA , Ebel-BitounC . Treatment with fesoterodine versus tolterodine for reducing symptom bother in elderly patients with overactive bladder including urgency urinary incontinence. European Urology, Supplements2012;11(1):e687-a. [sr-incont65389]WaggA , CarlssonM , ElsobkyM , FernetM . Effect of flexible dose fesoterodine on cognitive function in &gt;65 year old patients with OAB: data from two RCT (Abstract number 438). Neurourology and Urodynamics2019;38:S297-8. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78651]WaggA , DarekarA , ArumiD , KhullarV , OelkeM . Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people &gt;65 years of age: a post hoc analysis of data from the SOFIA study. Neurourology and Urodynamics2015;34(5):438-43. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont68100]WaggA , ElsobkyM , CarlssonM , FernetM . Response and cognitive safety of fesoterodine in patients &gt;65y old with OAB. Is there a relationship between cognition and treatment response? (Abstract number 183). Neurourology and Urodynamics2019;38:S118-20. [EUCTR2007-007087-17-SE] [NCT00798434] [NCT00928070] [sr-incont78632]WaggA , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. Journal of the American Geriatrics Society2013;61(2):185-93. [A0221045] [EUCTR2007-007087-17-SE] [NCT00798434] [TrialID.SOFIA.] [sr-incont48008]WaggAS , KhullarV , Marschall-KehrelD , MichelMC , OelkeM , DarekarA , et al. Efficacy and tolerability of fesoterodine in older subjects with overactive bladder: results of SOFIA (Abstract number C33). Journal of the American Geriatrics Society2011;59:S124. [EUCTR2007-007087-17-SE] [NCT00798434] [sr-incont65234]">Wagg 2013a</a>; <a href="./references#CD003781-bbs2-0101" title="NCT01018264, ZesiewiczT . Solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease (URGE-PD) [URGE-PD: a multi-site, double-blind, randomized, placebo controlled trial of solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease]. clinicaltrials.gov/show/NCT01018264 (first received 23 November 2009). [NCT01018264] [sr-incont63790]ZesiewiczTA , EvattM , JahanI , VaughanC , SingerC , OrdoricaR , et al. URGE-PD: a multi-site, double-blind, randomized, placebo controlled trial of solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease (Abstract number 745). Movement Disorders2014;29(Suppl 1):S276-7. [NCT01018264] [sr-incont66602]ZesiewiczTA , EvattM , VaughanCP , JahanI , SingerC , OrdoricaR , et al. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease. Parkinsonism and Related Disorders2015;21(5):514-20. [NCT01018264] [sr-incont66860]">Zesiewicz 2015</a>). In terms of allocation concealment there is a risk of conflict of interest, albeit many industry‐funded trials have to meet strict regulatory standards. Industry‐funded trials can introduce publication bias and lead to a different interpretation of the results (<a href="./references#CD003781-bbs2-0358" title="RosemanM , TurnerEH , LexchinJ , CoyneJC , BeroLA , ThombsBD . Reporting of conflicts of interest from drug trials in Cochrane reviews: cross sectional study. BMJ2012;345:e5155. [DOI: doi.org/10.1136/bmj.e5155]">Roseman 2012</a>). However, it is worth mentioning that conflicts of interest do not necessarily cause biased results, but create a risk (<a href="./references#CD003781-bbs2-0360" title="SavovićJ , AklEA , HróbjartssonA . Financial conflicts of interest in clinical research. Intensive Care Medicine2018;44(10):1767-9. [DOI: doi.org/10.1007/s00134-018-5333-3]">Savović 2018</a>). Our decision to rate ‘allocation concealment’ as high risk of bias in the studies that involved conflict of interest was based on the fact that the randomisation schedule was generated, secured, distributed and stored by Pfizer Global Clinical Data Services, and that no more information was provided regarding this domain. This therefore means that people involved in the allocation concealment process might have known the sequence. However, there were only two studies affected by this rationale and rating (<a href="./references#CD003781-bbs2-0024" title="DmochowskiR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. A double-blind, placebo-controlled trial of flexible-dose fesoterodine for overactive bladder (Abstract number 715). In: International Continence Society (ICS); 39th Annual Meeting; 2009 Sep 29-Oct 03; San Francisco, CA. 2009. [sr-incont35627]DmochowskiRR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder [Errata appear in: Urology 2010 Jun;75(6):1519 and in Urology 2011 Jun;77(6):1513]. Urology2010;75(1):62-8. [A0221014] [NCT00536484] [sr-incont39548]DuBeauC , KrausSR , SunF , MorrowJD . Fesoterodine in older vs younger subjects with overactive bladder (Abstract number D87). Journal of the American Geriatrics Society2010;58:S218. [NCT00536484] [sr-incont64309]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. [sr-incont78640]NCT00536484. Fesoterodine flexible dose study [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with overactive bladder]. clinicaltrials.gov/show/NCT00536484 (first received 27 September 2007). [NCT00536484] [sr-incont49160]StaskinD , KhullarV , MichelMC , MorrowJD , SunF , GuanZ , et al. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. Neurourology and Urodynamics2011;30(8):1480-5. [sr-incont42686]">Dmochowski 2010</a>; <a href="./references#CD003781-bbs2-0027" title="DuBeauC , KrausSR , GrieblingTL , NewmanD , WymanJ , OuslanderJ , et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled study (Abstract number 1352). Journal of Urology2012;187(4 Suppl 1):e548-9. [sr-incont65273]DuBeauCE , KrausSR , GrieblingTL , NewmanDK , WymanJF , JohnsonTM , et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. Journal of Urology2014;191(2):395-404. [A0221049] [NCT00928070] [srincont-50446]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , Carlsson M et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. GrieblingTL , KrausSR , NewmanDK , WymanJF , JohnsonTM , SunF , et al. Patient characteristics are not predictive of fesoterodine efficacy in elderly patients with urgency urinary incontinence (Abstract number 1049). Journal of Urology2013;189(Suppl 4):e430. [sr-incont65350]JohnsonTM , FaisonW , NewmanDK , KrausSR , GrieblingTL , WymanJF , et al. Effect of fesoterodine on urgency incontinence and incontinence absorbent product usage in vulnerable elderly subjects with urgency incontinence (Abstract number A43). Journal of the American Geriatrics Society2013;61:S32. [sr-incont65231]NCT00928070. A study of efficacy and safety of fesoterodine in vulnerable elderly subjects with overactive bladder [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with overactive bladder]. clinicaltrials.gov/show/NCT00928070 (first received 25 June 2009). [A0221049] [NCT00928070] [sr-incont49840]">DuBeau 2014</a>). </p> <p>We assessed the certainty of the evidence using GRADE. We judged the certainty of the evidence to be low for four outcomes (condition‐specific quality of life, dry mouth, urinary retention and withdrawals due to adverse events). We judged the evidence for all the remaining main outcomes to be of moderate certainty. The most common reason for downgrading was study design, though imprecision was also a factor in the downgrading of both the urinary retention and withdrawal due to adverse events outcomes. </p> <p>One of the limitations of the review is that many studies do not contribute to the meta‐analyses. Those that do may or may not be a biased selection of the population of primary trials. We combined data from primary trials recruiting on different criteria or using different drugs in various doses. These factors may influence the estimates of effect in this review. However, the effects appear generally consistent across the included studies that did contribute data. On the few occasions where heterogeneity was observed it proved difficult to explore the reasons. The best way to address these concerns would be to perform an individual patient data meta‐analysis. Many more studies would then contribute to the analysis. In addition, the effect of confounders (such as age, cause of overactive bladder) could be investigated. We also included propantheline, which is not usually used clinically any more. However, it was included in the original review and therefore we did not exclude it in this update. Finally, patient perspective would have been advantageous for this review. However, the original review was conducted a long time ago, before such procedures were common. </p> <p>In general, many of the included studies had the characteristics of explanatory rather than pragmatic trials. Explanatory trials, also known as efficacy trials, address the question 'can this therapy work?' Efficacy studies tend to have strict inclusion and exclusion criteria, a comparison of therapy versus placebo and short‐term outcomes. They measure surrogate rather than patient‐centred outcomes (for example, urodynamics rather than quality of life) and take place in centres of clinical excellence. Their results are commonly used to support applications for drug regulatory approval. In contrast, pragmatic trials, also known as effectiveness trials, address the question 'does this therapy work?'. Effectiveness studies are characterised by large, more heterogeneous samples, comparisons with standard care, less restrictive inclusion/exclusion criteria and long‐term patient‐centred outcomes (<a href="./references#CD003781-bbs2-0357" title="RolandM , TorgersonDJ . Understanding controlled trials: What are pragmatic trials?BMJ1998;316(7127):285.">Roland 1998</a>). Their results inform the choice of management in everyday clinical settings. </p> <p>All the included studies were of short duration and measured outcomes at the end of treatment. Therefore, outcomes were measured when the effects of treatment were likely to be at their maximum. Anticholinergics are unlikely to cure overactive bladder syndrome fully and are only likely to work while the patient is still taking them, so the long‐term effects of continuing treatment are of most clinical interest. Some trials have continued with open‐label follow‐up. The interpretation of these studies is difficult, not only because of the use of active treatment by those originally allocated placebo but also because of the number of overlapping pooled analyses published, based on different numbers of primary studies. In a follow‐up of a single study, it was found that 71% of patients completed 12 months of open‐label follow‐up on extended‐release tolterodine (<a href="./references#CD003781-bbs2-0365" title="Van KerrebroeckPH , Tolterodine study group. Long-term tolerability and efficacy of once-daily (OD) tolterodine in the treatment of overactive bladder (OAB). International Urogynecology Journal2001;12(Suppl 3):549.">Van Kerrebroeck 2001</a>). In contrast, <a href="./references#CD003781-bbs2-0344" title="LawrenceM , GuayDR , BensonSR , AndersonMJ . Immediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis. Pharmacotherapy2000;20(4):470-5.">Lawrence 2000</a> audited a pharmaceutical database in the USA and reported that less than a third of people continued to fill out prescriptions for either immediate‐release tolterodine or immediate‐release oxybutynin six months after the first prescription, although the use of oxybutynin was discontinued faster than tolterodine. This may represent the differences between people prescribed anticholinergics in a trial versus in a more typical care setting. </p> <p>Pharmaceutical companies are continuing to develop anticholinergic drugs. It is worth noting that the majority of the trialists declared pharmaceutical company support (see the <a href="./references#CD003781-sec-0123" title="">Characteristics of included studies</a>). This support ranged from the supply of active and placebo tablets (in blinded packaging) through to full funding, data analysis, writing up and publication of the results. Some of the remaining studies did not make any statement about the absence or presence of company involvement. One study was funded by grants from health research bodies (<a href="./references#CD003781-bbs2-0008" title="BurgioKL , LocherJL , GoodePS , HardinJM , McDowellBJ , CandibD . Behavior vs drug therapy for urge incontinence in older women (Abstract number 26). In: American Urogynecology Society, 15th Annual Scientific Meeting; 1994 Sept 21-24; Toronto, Ontario. 1994:48. [sr-incont14585]BurgioKL , LocherJL , GoodePS , HardinM , McDowellBJ , Dombrowski M et al. Behavioral vs drug treatment for urge urinary incontinence in older women. A randomized controlled trial. JAMA1998;280(23):1995-2000. [srincont-5719]BurgioKL , LocherJL , GoodePS . Combined behavioral and drug therapy for urge incontinence in older women. Journal of the American Geriatrics Society2000;48(4):370-4. [srincont-9006]BurgioKL , LocherJL , RothDL , GoodePS . Psychological improvements associated with behavioral and drug treatment of urge incontinence in older women. Journal of Gerontology. Series B, Psychological Sciences and Social Sciences2001;56(1):P46-51. [srincont-11923]">Burgio 1998</a>). In other settings, meta‐analyses comparing findings from drug company‐funded studies with non‐drug company‐funded trials have found that the outcomes of company‐funded studies are more favourable to the new treatment, although this is not always the case (<a href="./references#CD003781-bbs2-0346" title="LexchinJ , BeroLA , DjulbegovicB , ClarkO . Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ2003;326(7400):1167-70.">Lexchin 2003</a>; <a href="./references#CD003781-bbs2-0351" title="NaciH , DiasS , AdesAE . Industry sponsorship bias in research findings: a network meta-analysis of LDL cholesterol reduction in randomised trials of statins. BMJ2014;349:5741.">Naci 2014</a>). In general in this review, the trials supported by companies were well reported and appeared to be of better methodological quality. However, while they examined issues of efficacy and safety, clinical and cost‐effectiveness outcomes were often overlooked. </p> <p>This review provides evidence of efficacy and of the likelihood of adverse effects, particularly dry mouth. Some studies suggest that the positive effects are translated into improved quality of life while medication continues, at least to a modest level. However, there is very little evidence about the long‐term effects of anticholinergic medication. This applies to fixed‐length courses of treatment and to continued treatment for an indefinite period of time, both during treatment and after it has stopped. Addressing these issues requires a shift in the research agenda to more pragmatic trial designs. </p> </section> <section id="CD003781-sec-0099"> <h3 class="title" id="CD003781-sec-0099">Potential biases in the review process</h3> <p>One potential source of bias may have been introduced while selecting outcomes for the summary of findings table. As data from all the previously included studies from the original review were already entered within RevMan, there is a possibility that the review authors' judgement for selecting the outcomes for the summary of findings table might have been influenced by the data that were already entered. However, in order to reduce the risk of potential bias in the review process, we followed the methods detailed in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003781-bbs2-0338" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). </p> <p>Despite our best efforts, not all relevant literature may have been identified and therefore the included studies may be a biased selection based on what was available. Furthermore, although we attempted to conduct a comprehensive search for studies, the fact that six studies identified in the most recent searches have not yet been incorporated may be a source of potential bias. </p> </section> <section id="CD003781-sec-0100"> <h3 class="title" id="CD003781-sec-0100">Agreements and disagreements with other studies or reviews</h3> <p>We identified several different systematic reviews that investigated the use of anticholinergics in the treatment of overactive bladder syndrome (<a href="./references#CD003781-bbs2-0328" title="ChappleC , KhullarV , GabrielZ , DooleyJA . The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. European Urology2005;48(1):5-26.">Chapple 2005b</a>; <a href="./references#CD003781-bbs2-0329" title="ChappleCR , KhullarV , GabrielZ , MustonD , BitounCE , WeinsteinD . The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. European Urology2008;54(3):543-62.">Chapple 2008a</a>; <a href="./references#CD003781-bbs2-0335" title="HaeuslerG , LeitichH , vanTrotsenburgM , KaiderA , TempferCB . Drug therapy of urinary urge incontinence: a systematic review. Obstetrics and Gynecology2002;100(5 Pt 1):1003-16.">Haeusler 2002</a>; <a href="./references#CD003781-bbs2-0337" title="HarveyMA , BakerK , WellsGA . Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: A meta-analysis. American Journal of Obstetrics and Gynecology2001;185(1):56-61.">Harvey 2001</a>; <a href="./references#CD003781-bbs2-0336" title="HartmannKE , McPheetersML , BillerDH , WardRM , McKoyJN , JeromeRN , et al. Treatment of overactive bladder in women (AHRQ Publication No. 09-E017. Rockville, MD: Agency for Healthcare Research and Quality, Report number 187). Evidence Report/Technology Assessment2009;(187):1-120. [https://www.ahrq.gov/downloads/pub/evidence/pdf/bladder/bladder.pdf]">Hartmann 2009a</a>; <a href="./references#CD003781-bbs2-0342" title="KesslerTM , BachmannLM , MinderC , LohrerD , UmbehrM , SchunemannHJ , et al. Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. PLOS One2011;6(2):e16718.">Kessler 2011a</a>; <a href="./references#CD003781-bbs2-0348" title="McDonaghMS , SeloverD , SantaJ , ThakurtaS . Drug class review: agents for overactive bladder. Portland, Oregon: Oregon Evidence-based Practice Center, Oregon Health and Science University, 2009.">McDonagh 2009</a>; <a href="./references#CD003781-bbs2-0352" title="OefeleinMG . Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder [Review]. Drug Safety2011;34(9):733-54. [sr-incont42947]">Oefelein 2011</a>; <a href="./references#CD003781-bbs2-0356" title="ReynoldsWS , McPheetersM , BlumeJ , SurawiczT , WorleyK , WangL , et al. Comparative effectiveness of anticholinergic therapy for overactive bladder in women: a systematic review and meta-analysis. Obstetrics and Gynecology2015;125(6):1423-32.">Reynolds 2015</a>; <a href="./references#CD003781-bbs2-0362" title="ShamliyanT , WymanJF , RamakrishnanR , SainfortF , KaneRL . Benefits and harms of pharmacologic treatment for urinary incontinence in women: a systematic review. Annals of Internal Medicine2012;156(12):861-74. [sr-incont45314]">Shamliyan 2012</a>). The majority of these reviews were limited to placebo‐controlled studies. While the inclusion criteria of this review allowed for studies that had a no treatment control arm, no studies were identified where that was the case. </p> <p>Most of the other reviews reached similar conclusions to this Cochrane Review, namely that while anticholinergic drugs are more effective than placebo, and well tolerated by patients with an improvement in condition‐specific quality of life, the effects on these outcomes are minimal. They also identify no real differences among the different anticholinergics studied, with the exception of dry mouth. </p> <p>Similar to the another Cochrane Review (<a href="./references#CD003781-bbs2-0347" title="Madhuvrata P, Cody JD, Ellis G, HerbisonGP , Hay‐SmithEJ . Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database of Systematic Reviews2012, Issue 1. Art. No: CD005429. [DOI: 10.1002/14651858.CD005429.pub2]">Madhuvrata 2012</a>), Kessler identifies 10 mg or more of oxybutynin taken orally as presenting the highest risk of dry mouth (<a href="./references#CD003781-bbs2-0342" title="KesslerTM , BachmannLM , MinderC , LohrerD , UmbehrM , SchunemannHJ , et al. Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. PLOS One2011;6(2):e16718.">Kessler 2011a</a>), whereas our review finds the risk to be greater with solifenacin. This could be a consequence of more studies choosing to include solifenacin as an interventional drug in more recent years. </p> <p>Two further meta‐analyses of tolterodine versus placebo have been published (<a href="./references#CD003781-bbs2-0110" title="AppellRA . Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology1997;50(Suppl 6A):90-6 (discussion 97‐9). [sr-incont5482]">Appell 1997</a>; <a href="./references#CD003781-bbs2-0201" title="LarssonG , HallénB , NilvebrantL . Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data. Urology1999;53(5):990-8. [sr-incont8161]">Larsson 1999</a>). However, neither of these publications provides an adequate systematic review of the available trials comparing anticholinergic drugs with placebo. Neither publication reports the objectives of the systematic review, a search strategy, inclusion and exclusion criteria for trials, or the methods of data extraction and analysis. It appears that these meta‐analyses combine the results of pharmaceutical company‐funded phase II (<a href="./references#CD003781-bbs2-0201" title="LarssonG , HallénB , NilvebrantL . Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data. Urology1999;53(5):990-8. [sr-incont8161]">Larsson 1999</a>), or phase III (<a href="./references#CD003781-bbs2-0110" title="AppellRA . Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology1997;50(Suppl 6A):90-6 (discussion 97‐9). [sr-incont5482]">Appell 1997</a>), trials of tolterodine versus placebo. </p> <p>In summary, while most of the reviews align with our conclusions in suggesting that anticholinergics are better than placebo, the effect is modest and may not be of clinical benefit to patients with overactive bladder. Ultimately, the choice must be left to the patient to decide whether their symptoms are sufficiently relieved and whether the side effects are tolerable for the level of improvement achieved. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003781-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/urn:x-wiley:14651858:media:CD003781:CD003781-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA study flow diagram (covering searches from inception to this current version of the review) " data-id="CD003781-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_t/tCD003781-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA study flow diagram (covering searches from inception to this current version of the review)  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/full#CD003781-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003781-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/urn:x-wiley:14651858:media:CD003781:CD003781-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003781-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_t/tCD003781-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/full#CD003781-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003781-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/urn:x-wiley:14651858:media:CD003781:CD003781-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003781-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_t/tCD003781-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/full#CD003781-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003781-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/urn:x-wiley:14651858:media:CD003781:CD003781-FIG-04" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD003781-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_t/tCD003781-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/full#CD003781-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003781-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/urn:x-wiley:14651858:media:CD003781:CD003781-FIG-05" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD003781-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_t/tCD003781-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/full#CD003781-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003781-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/urn:x-wiley:14651858:media:CD003781:CD003781-FIG-06" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD003781-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_t/tCD003781-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/full#CD003781-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003781-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/urn:x-wiley:14651858:media:CD003781:CD003781-FIG-07" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD003781-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-FIG-07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_t/tCD003781-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/full#CD003781-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-FIG-07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003781-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/urn:x-wiley:14651858:media:CD003781:CD003781-FIG-08" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD003781-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-FIG-08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_t/tCD003781-FIG-08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/full#CD003781-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-FIG-08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003781-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/urn:x-wiley:14651858:media:CD003781:CD003781-FIG-09" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD003781-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-FIG-09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_t/tCD003781-FIG-09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/full#CD003781-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-FIG-09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003781-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/urn:x-wiley:14651858:media:CD003781:CD003781-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticholinergics versus placebo, Outcome 1: Mean change from baseline in condition‐specific quality of life" data-id="CD003781-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_t/tCD003781-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Anticholinergics versus placebo, Outcome 1: Mean change from baseline in condition‐specific quality of life </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/references#CD003781-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003781-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/urn:x-wiley:14651858:media:CD003781:CD003781-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticholinergics versus placebo, Outcome 2: Patient perception of cure or improvement" data-id="CD003781-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_t/tCD003781-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Anticholinergics versus placebo, Outcome 2: Patient perception of cure or improvement </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/references#CD003781-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003781-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/urn:x-wiley:14651858:media:CD003781:CD003781-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticholinergics versus placebo, Outcome 3: Mean number of urgency episodes per 24 hours" data-id="CD003781-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_t/tCD003781-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Anticholinergics versus placebo, Outcome 3: Mean number of urgency episodes per 24 hours </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/references#CD003781-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003781-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/urn:x-wiley:14651858:media:CD003781:CD003781-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticholinergics versus placebo, Outcome 4: Adverse events: Dry mouth" data-id="CD003781-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_t/tCD003781-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Anticholinergics versus placebo, Outcome 4: Adverse events: Dry mouth</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/references#CD003781-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003781-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/urn:x-wiley:14651858:media:CD003781:CD003781-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticholinergics versus placebo, Outcome 5: Adverse events: Urinary retention/high residual volume" data-id="CD003781-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_t/tCD003781-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Anticholinergics versus placebo, Outcome 5: Adverse events: Urinary retention/high residual volume </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/references#CD003781-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003781-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/urn:x-wiley:14651858:media:CD003781:CD003781-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticholinergics versus placebo, Outcome 6: Adverse events: Abdominal pain" data-id="CD003781-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_t/tCD003781-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Anticholinergics versus placebo, Outcome 6: Adverse events: Abdominal pain </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/references#CD003781-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003781-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/urn:x-wiley:14651858:media:CD003781:CD003781-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticholinergics versus placebo, Outcome 7: Adverse events: Blurred vision" data-id="CD003781-fig-0016" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_t/tCD003781-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Anticholinergics versus placebo, Outcome 7: Adverse events: Blurred vision </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/references#CD003781-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003781-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/urn:x-wiley:14651858:media:CD003781:CD003781-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticholinergics versus placebo, Outcome 8: Adverse events: Constipation" data-id="CD003781-fig-0017" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_t/tCD003781-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Anticholinergics versus placebo, Outcome 8: Adverse events: Constipation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/references#CD003781-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003781-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/urn:x-wiley:14651858:media:CD003781:CD003781-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticholinergics versus placebo, Outcome 9: Adverse events: Cough" data-id="CD003781-fig-0018" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_t/tCD003781-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Anticholinergics versus placebo, Outcome 9: Adverse events: Cough</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/references#CD003781-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003781-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/urn:x-wiley:14651858:media:CD003781:CD003781-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticholinergics versus placebo, Outcome 10: Adverse events: Dizziness" data-id="CD003781-fig-0019" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_t/tCD003781-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Anticholinergics versus placebo, Outcome 10: Adverse events: Dizziness</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/references#CD003781-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003781-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/urn:x-wiley:14651858:media:CD003781:CD003781-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticholinergics versus placebo, Outcome 11: Adverse events: Dry eyes" data-id="CD003781-fig-0020" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_t/tCD003781-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Anticholinergics versus placebo, Outcome 11: Adverse events: Dry eyes</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/references#CD003781-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003781-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/urn:x-wiley:14651858:media:CD003781:CD003781-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticholinergics versus placebo, Outcome 12: Adverse events: Dyspepsia/indigestion" data-id="CD003781-fig-0021" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_t/tCD003781-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Anticholinergics versus placebo, Outcome 12: Adverse events: Dyspepsia/indigestion</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/references#CD003781-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003781-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/urn:x-wiley:14651858:media:CD003781:CD003781-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticholinergics versus placebo, Outcome 13: Adverse events: Flu‐like symptoms/fatigue" data-id="CD003781-fig-0022" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_t/tCD003781-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Anticholinergics versus placebo, Outcome 13: Adverse events: Flu‐like symptoms/fatigue </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/references#CD003781-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003781-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/urn:x-wiley:14651858:media:CD003781:CD003781-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticholinergics versus placebo, Outcome 14: Adverse events: Headache" data-id="CD003781-fig-0023" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_t/tCD003781-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Anticholinergics versus placebo, Outcome 14: Adverse events: Headache</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/references#CD003781-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003781-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/urn:x-wiley:14651858:media:CD003781:CD003781-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticholinergics versus placebo, Outcome 15: Adverse events: Insomnia (unable to sleep)" data-id="CD003781-fig-0024" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_t/tCD003781-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Anticholinergics versus placebo, Outcome 15: Adverse events: Insomnia (unable to sleep) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/references#CD003781-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003781-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/urn:x-wiley:14651858:media:CD003781:CD003781-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticholinergics versus placebo, Outcome 16: Adverse events: Nasopharyngitis/sore throat" data-id="CD003781-fig-0025" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_t/tCD003781-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Anticholinergics versus placebo, Outcome 16: Adverse events: Nasopharyngitis/sore throat </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/references#CD003781-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003781-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/urn:x-wiley:14651858:media:CD003781:CD003781-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticholinergics versus placebo, Outcome 17: Adverse events: Nausea" data-id="CD003781-fig-0026" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_t/tCD003781-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Anticholinergics versus placebo, Outcome 17: Adverse events: Nausea</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/references#CD003781-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003781-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/urn:x-wiley:14651858:media:CD003781:CD003781-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticholinergics versus placebo, Outcome 18: Adverse events: Pruritus/erythema" data-id="CD003781-fig-0027" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_t/tCD003781-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Anticholinergics versus placebo, Outcome 18: Adverse events: Pruritus/erythema</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/references#CD003781-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003781-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/urn:x-wiley:14651858:media:CD003781:CD003781-CMP-001.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticholinergics versus placebo, Outcome 19: Adverse events: Urinary tract infection (UTI)" data-id="CD003781-fig-0028" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_t/tCD003781-CMP-001.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1: Anticholinergics versus placebo, Outcome 19: Adverse events: Urinary tract infection (UTI) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/references#CD003781-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003781-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/urn:x-wiley:14651858:media:CD003781:CD003781-CMP-001.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticholinergics versus placebo, Outcome 20: Withdrawal due to adverse events" data-id="CD003781-fig-0029" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_t/tCD003781-CMP-001.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1: Anticholinergics versus placebo, Outcome 20: Withdrawal due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/references#CD003781-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003781-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/urn:x-wiley:14651858:media:CD003781:CD003781-CMP-001.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticholinergics versus placebo, Outcome 21: Mean number of micturitions per 24 hours" data-id="CD003781-fig-0030" src="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_t/tCD003781-CMP-001.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1: Anticholinergics versus placebo, Outcome 21: Mean number of micturitions per 24 hours </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/references#CD003781-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/media/CDSR/CD003781/image_n/nCD003781-CMP-001.21.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003781-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Anticholinergics compared to placebo for overactive bladder syndrome in adults</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Anticholinergics compared to placebo for overactive bladder syndrome in adults</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> adults with overactive bladder syndrome<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> anticholinergics<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants (studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Without anticholinergics</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With anticholinergics</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change from baseline in condition‐specific quality of life</b><br/>Scale from: ‐100 to 0<br/>  </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 4.41 lower<br/>(5.28 lower to 3.54 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6804<br/>(12 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patient perception of cure or improvement</b><br/>  </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>424 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>161 more per 1000 (from 64 more to 280 more)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.38</p> <p>(1.15 to 1.66)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8457<br/>(9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean number of urgency episodes per 24 hours</b><br/>  </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of urgency episodes per 24 hours in placebo groups ranged from 1.8 to 10.61 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.85 lower<br/>(1.03 lower to 0.67 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16,875<br/>(23 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: dry mouth</b><br/>  </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>63 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>158 more per 1000 (from 143 more to 174 more)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.50</p> <p>(3.26 to 3.75)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38,368<br/>(66 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events:urinary retention</b><br/>  </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 more per 1000<br/>(from 4 more to 18 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.52</p> <p>(2.04 to 6.08)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7862<br/>(17 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to adverse events</b><br/>  </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 more per 1000<br/>(from 7 more to 19 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.37</p> <p>(1.21 to 1.56)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>3,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36,943<br/>(61 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean number of micturitions per 24 hours</b><br/>  </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of micturitions per 24 hours in placebo groups ranged from 8.6 to 11.69 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.85 lower<br/>(0.98 lower to 0.73 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19,395<br/>(30 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level for serious risk of bias: most of the domains were unclear. </p> <p><sup>2</sup>Downgraded one level for serious publication bias: strongly suspected as the plot does not resemble a symmetrical funnel, i.e. smaller studies without significant results were likely to remain unpublished. </p> <p><sup>3</sup>Downgraded two levels for very serious risk of bias: the majority of the domains were unclear or high risk. </p> <p><sup>4</sup>Downgraded one level for serious imprecision: low number of events reported. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Anticholinergics compared to placebo for overactive bladder syndrome in adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/full#CD003781-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003781-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Quality of life outcome of studies that were not included in meta‐analysis</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>QoL measure</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Direction and measurement of the scale, MCID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Result (mean change from baseline*)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Interpretation</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0014" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. ChappleCR , AranoP , BoschJH , De RidderD , KramerG , RidderAM . YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo- and tolterodine-controlled, phase-II, dose-finding study (Abstract 75). Neurourology and Urodynamics2002;21(4):381-2. [srincont-14551]ChappleCR , ArañoP , BoschJL , De RidderD , KramerAE , RidderAM . Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU International2004;93(1):71-7. [srincont-17334]KelleherCJ , CardozoL , ChappleCR , HaabF , RidderAM . Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU International2005;95(1):81-5. [srincont-20241]SmithN , GrimesI , RidgeS , TempelD , UchidaT , YamanouchiUS . YM905 is effective and safe as treatment of overactive bladder in women and men: results from phase II study (Abstract). In: International Continence Society (ICS), 32nd Annual Meeting; 2002 Aug 28-30; Heidelberg, Germany. 2002:138-9. [sr-incont14508]">Chapple 2004b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Contilife score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Scores range from 0 to 100, lower score indicates higher QoL<br/>MCID: unknown </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tolterodine (n = 37): 9.9</p> <p>Solifenacin (n = 70): 16.4</p> <p>Placebo (n = 36): 4.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticholinergics improve QoL compared to placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0018" title="ChappleCR , DvorakV , RadziszewskiP , vanKerrebroeckP , WyndaeleJJ , BosmanB , et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder. International Urogynecology Journal2013;24(9):1447-58. [178-CL-044] [NCT00337090] [TrialID.DRAGON.] [sr-incont48549]NCT00337090 . A study of YM178 in patients with symptomatic overactive bladder (DRAGON) [A randomized, double-blind, parallel group, placebo and active controlled, multicenter dose ranging study with the beta-3 agonist YM178 in patients with symptomatic overactive bladder]. clinicaltrials.gov/show/NCT00337090 (first received 15 June 2006). [EudraCT2005-002256-17] [JapicCTI-R130350] [NCT00337090] [sr-incont63803]">Chapple 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICIQ‐OABqol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 to 160 overall score with greater values indicating increased impact on QoL<br/>MCID: unknown/unclear </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tolterodine (n = 84): ‐17.42</p> <p>Placebo (n = 162): ‐ 16.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticholinergics improve QoL compared to placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0019" title="ChappleC , HaabF , SchneiderT , CarlssonM , ArumiD . Fesoterodine 8 mg versus fesoterodine 4 mg in patients with overactive bladder and a history of previous antimuscarinic therapy: Results from the EIGHT trial (Abstract number: Poster #M5). Neurourology and Urodynamics2015;34(S1):S20. [NCT01302067] [sr-incont68509]ChappleC , SchneiderT , HaabF , SunF , WhelanL , ScholfieldD , et al. Superiority of fesoterodine 8mg versus fesoterodine 4 mg in reducing urgency urinary incontinence episodes in subjects with overactive bladder: results of the randomized, double-blind, placebo-controlled EIGHT trial (Abstract number: Podium #48). Neurourology and Urodynamics2014;33(2):183-4. [NCT01302067] [sr-incont67484]ChappleC , SchneiderT , HaabF , SunF , WhelanL , ScholfieldD , et al. Superiority of fesoterodine 8mg vs 4mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial. BJU International2014;114(3):418-26. [A0221095] [NCT01302067] [TrialID.EIGHT] [srincont-62537]NCT01302067. A 12 week study to confirm the effectiveness of 8mg of Fesoterodine compared to 4mg of Fesoterodine [A 12-week, randomized, double-blind, placebo controlled, parallel group, multicenter trial in overactive bladder subjects to confirm the efficacy of 8 mg fesoterodine compared to 4 mg fesoterodine]. clinicaltrials.gov/show/NCT01302067 (first received 23 February 2011). [NCT01302067] [sr-incont63792]">Chapple 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OAB‐q (total HRQL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0‐ to 100‐point scale, higher HRQL scores indicate better HRQL<br/>MCID: 10 points </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fesoterodine (n = 1378): 26 </p> <p>Placebo (n = 347): 19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticholinergics improve QoL compared to placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0024" title="DmochowskiR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. A double-blind, placebo-controlled trial of flexible-dose fesoterodine for overactive bladder (Abstract number 715). In: International Continence Society (ICS); 39th Annual Meeting; 2009 Sep 29-Oct 03; San Francisco, CA. 2009. [sr-incont35627]DmochowskiRR , PetersKM , MorrowJD , GuanZ , GongJ , SunF , et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder [Errata appear in: Urology 2010 Jun;75(6):1519 and in Urology 2011 Jun;77(6):1513]. Urology2010;75(1):62-8. [A0221014] [NCT00536484] [sr-incont39548]DuBeauC , KrausSR , SunF , MorrowJD . Fesoterodine in older vs younger subjects with overactive bladder (Abstract number D87). Journal of the American Geriatrics Society2010;58:S218. [NCT00536484] [sr-incont64309]GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. [sr-incont78640]NCT00536484. Fesoterodine flexible dose study [A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with overactive bladder]. clinicaltrials.gov/show/NCT00536484 (first received 27 September 2007). [NCT00536484] [sr-incont49160]StaskinD , KhullarV , MichelMC , MorrowJD , SunF , GuanZ , et al. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. Neurourology and Urodynamics2011;30(8):1480-5. [sr-incont42686]">Dmochowski 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>KHQ incontinence impact score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0‐ to 100‐point scale, lower scores indicates higher QoL<br/>MCID: 5 points </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trospium (n = 530): ‐23</p> <p>Placebo (n = 556): ‐17 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The result shows improvement of QoL in terms of incontinence impact score, but the improvement was also demonstrated in all of the other KHQ domains </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0033" title="GotohM , HommaY , YokoyamaO , NishizawaO . Responsiveness and minimal clinically important change in overactive bladder symptom score. Urology2011;78(4):768-73. [srincont-42622]GotohM , YokoyamaO , MatsukawaY , NishizawaO . Responsiveness of overactive bladder symptom score (OABSS): verification based on data in a double-blinded, randomized placebo-controlled study of propiverine hydrochloride in Japanese patients (Abstract number 338). In: Joint Meeting of the International Continence Society (ICS) and the International Urogynecological Association; 2010 Aug 23-27; Toronto, Canada. 2010. [srincont-40173]GotohM , YokoyamaO , NishizawaO . Propiverine hydrochloride in Japanese patients with overactive bladder: A randomized, double-blind, placebo-controlled trial. International Journal of Urology2011;18(5):365-73. [srincont-41510]">Gotoh 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>KHQ incontinence impact score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0‐ to 100‐point scale, lower scores indicates higher QoL</p> <p>MCID: 5 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Propiverine (n = 284): ‐21</p> <p>Placebo (n = 270): ‐14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The result shows improvement of QoL in terms of incontinence impact score, but the improvement was also demonstrated in all of the other KHQ  domains </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0039" title="CorcosJ , AnguloJC , GarelyAD , CarlssonM , GongJ , GuanZ . Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. Current Medical Research and Opinion2011;27(5):1059-65. [srincont-41596]EUCTR2006-006935-38-SE. 12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006935-38 (first received 16 April 2007). [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont64612]HerschornS , SwiftS , GuanZ , CarlssonM , BrodskyM , GongJ . Efficacy and safety of fesoterodine for overactive bladder in a double-blind, head-to-head comparison trial with tolterodine ER and placebo (Abstract number 710). In: International Continence Society (ICS), 39th Annual Meeting; 2009 Sep 29-Oct 3; San Francisco, CA. 2009. [srincont-35326]HerschornS , SwiftS , GuanZ , CarlssonM , MorrowJD , BrodskyM , et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU International2010;105(1):58-66. [A0221008] [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont39540]NCT00444925. Clinical trial to evaluate the efficacy and safety of Fesoterodine in comparison to Tolterodine for overactive bladder (OAB) [12-week, randomized, double-blind, double-dummy,placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder (OAB)]. clinicaltrials.gov/show/NCT00444925 (first received 08 March 2007). [EUCTR2006-006935-38-SE] [NCT00444925] [sr-incont49159]">Herschorn 2009a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OAB‐q (total HRQL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0– to 100‐point scale, higher HRQL scores indicate better HRQL</p> <p>MCID: 10 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tolterodine (n = 641): 16.3</p> <p>Fesoterodine (n = 636): 19.3</p> <p>Placebo (n = 313): 12.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticholinergics improve QoL compared to placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0043" title="HommaY , KawabeK . Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World Journal of Urology2004;22(4):251-6. [srincont-19412]HommaY , PaickJS , LeeJG , KawabeK , Japanese and Korean Tolterodine Study Group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU International2003;92(7):741-7. [srincont-16418]">Homma 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>KHQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable as data are not shown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Results are not presented in a table. In the text, oxybutynin and tolterodine are described as better than placebo according to P values. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticholinergics improve QoL compared to placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0045" title="HommaY , YamaguchiO , Imidafenacin Study Group. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. International Journal of Urology2009;16(5):499-506. [NCT00212732] [ONO-8025-08] [srincont-31368]">Homma 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>KHQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable as data are not shown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Results are not presented in a table. In the text, imidafenacin and propiverine are described as better than placebo according to P values. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticholinergics improve QoL compared to placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0051" title="EUCTR2007-006451-39-SE. 12-week, randomized, double-blind, double-dummy, placebo controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-006451-39 (first received 20 February 2008). [A0221046] [EUCTR2007-006451-39-SE] [sr-incont64591]KaplanSA , SchneiderT , FooteJ , GuanZ . Superior efficacy of fesoterodine over tolterodine with rapid onset: a prospective, head-to-head, placebo-controlled trial (Abstract number 67). Neurourology and Urodynamics2010;29(6):905-7. [srincont-40130]KaplanSA , SchneiderT , FooteJE , GuanZ , CarlssonM , GongJ . Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU International2011;107(9):1432-40. [A0221046] [NCT00611026] [srincont-41334]">Kaplan 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OAB‐q (total HRQL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0– to 100‐point scale, higher HRQL scores indicate better HRQL</p> <p>MCID: 10 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tolterodine (n = 942): 19.5</p> <p>Fesoterodine (n = 930): 22.9</p> <p>Placebo (n = 462): 17.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticholinergics improve QoL compared to placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0053" title="CapoJP , TogliaM , Forero-SchwanhaeuserS , HeW . Patients reporting severe overactive bladder symptoms: effects of solifenacin treatment on objective measures and patient-reported outcomes (Abstract number 582). In: International Continence Society (ICS), 38th Annual Meeting; 2008 Oct 20-24; Cairo, Egypt. 2008. [srincont-31844]CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. KarramMM , TogliaMR , SerelsSR , AndohM , FakhouryA , Forero-SchwanhaeuserS . Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology2009;73(1):14-8. [A0221094] [NCT00454896] [TrialID.VENUS.] [srincont-29219]SerelsSR , TogliaMR , Forero-SchwanhaeuserS , HeW . Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms. Current Medical Research and Opinion2010;26(10):2277-85. [srincont-40376]StaskinD , DmochowskiR , SerelsS , AndohM , SmithN . Report from a randomized, placebo-controlled study showing significant improvement in urgency and patient-reported outcomes in overactive bladder patients treated with solifenacin (Abstract number 124). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73-4. [srincont-26600]TogliaM , AndohM , HussainI . Solifenacin improved warning time significantly compared to placebo in patients with overactive bladder (Abstract number 123). Neurourology and Urodynamics2006;25(6):655. [srincont-26629]TogliaM , AndohM , HussainI . Solifenacin improves urgency symtoms as assessed by voiding diaries and patient-reported outcomes (PRO) in patients with overactive bladder (Abstract number 155). In: International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand. 2006. [srincont-26636]TogliaMR , OstergardDR , AppellRA , AndohM , FakhouryA , HussainIF . Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status. International Urogynecology Journal2010;21(7):847-54. [srincont-40094]TogliaMR , SerelsSR , LarameeC , KarramMM , NandyIM , AndohM , et al. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial. Postgraduate Medicine2009;121(5):151-8. [srincont-34204]ZinnerS , HerschornS , AndohM , HussainI . Responder analyses show statistically significant improvements in incontinence and urgency are associated with reduction in symptom bother and improvement in health-related quality of life: VENUS results (Abstract number 123). International Urogynecology Journal and Pelvic Floor Dysfunction2007;18(Suppl 1):S73. [srincont-26599]">Karram 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OAB‐q (total HRQL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0– to 100‐point scale, higher HRQL scores indicate better HRQL</p> <p>MCID: 10 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Solifenacin (n = 357): 22.6</p> <p>Placebo (n = 350): 17.2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticholinergics improve QoL compared to placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0054" title="KhullarV , HillS , LavalKU , SchiotzHA , JonasU , VersiE . Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology2004;64(2):269-74; discussion 274-5. [srincont-19498]KhullarV , HillS , SolankiJ . Assessment of health-related quality of life in patients with overactive bladder taking tolterodine extended release versus placebo (Abstract number 318). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21075]">Khullar 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>KHQ incontinence impact score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0‐ to 100‐point scale, lower scores indicates higher QoL</p> <p>MCID: 5 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tolterodine (n = 569): ‐20.4 </p> <p>Placebo (n = 285): ‐15.5 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The result shows improvement of QoL in terms of incontinence impact score, but the improvement was also demonstrated in all of the other KHQ domains </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0072" title="OreskovićS , ButI , BanovićM , GoldstajnMS . The efficacy and safety of solifenacin in patients with overactive bladder syndrome. Collegium Antropologicum2012;36(1):243-8. [srincont-45056]">Oreskovic 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UDI and IIQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UDI: range 0 to 300, lower scores indicate better QoL</p> <p>IIQ: 0 to 400, lower scores indicate better QoL</p> <p>MCID: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UDI score was significantly improved after solifenacin (22.26 ± 5.91 vs 29.61 ± 8.45) compared to placebo. IIQ score was decreased in patients with solifenacin (36.25 ± 10.34 vs 46.86 ± 6.81, P &lt; 0.001) compared to placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticholinergics improve QoL compared to placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0093" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CrosbyRD , MathiasSD , MarshallTS . Relationships between symptoms, symptom bother, and health-related quality of life in patients with overactive bladder taking solifenacin or placebo in the VIBRANT study. International Journal of Clinical Practice2011;65(2):211-8. [sr-incont41015]GollarKM , YoungDG , BailenJ , HeW , Forero-SchwanhaeuserS . Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: a secondary analysis of the VIBRANT study. Urologic Nursing2012;32(1):38-46. [TrialID.VIBRANT.] [sr-incont44571]Samuels T‐A, MitchesonHD , VardyM , Forero‐SchwanhaeuserS , MarshallT , HeW . Efficacy of solifenacin for symptom bother and other patient-reported outcomes in patients with overactive bladder (OAB): results of a large, double-blind, placebo-controlled trial (Abstract number: poster #74). Neurourology and Urodynamics2009;28(2):149. [sr-incont31063]VardyMD , MitchesonHD , SamuelsTA , Forero-SchwanhaeuserS , HeW . Efficacy of solifenacin on overactive bladder symptoms, symptom bother, and other patient-reported outcomes in subjects with or without incontinence: a post hoc analysis of data from VIBRANT. Female Pelvic Medicine and Reconstructive Surgery2011;17(1):24-9. [TrialID.VIBRANT.] [sr-incont44741]VardyMD , MitchesonHD , SamuelsTA , WegenkeJD , Forero-SchwanhaeuserS , MarshallTS , et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. International Journal of Clinical Practice2009;63(12):1702-14. [905-UC-010] [NCT00573508] [TrialID.VIBRANT.] [sr-incont35459]">Vardy 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OAB‐q (total HRQL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0– to 100‐point scale, higher HRQL scores indicate better HRQL</p> <p>MCID: 10 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Solifenacin (n = 374): 25.5</p> <p>Placebo (n = 374): 16.65 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticholinergics improve QoL compared to placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0095" title="GoldmanHB , OelkeM , KaplanSA , KittaT , RussellD , CarlssonM , et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?International Urogynecology Journal2019;30(2):239-44. NCT00911937. A trial to evaluate the efficacy and safety of fesoterodine in patients with symptoms of overactive bladder including nocturnal urinary urgency [A randomized, double blind, placebo controlled, parallel group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with symptoms of overactive bladder including nocturnal urinary urgency]. clinicaltrials.gov/show/NCT00911937 (first received 03 June 2009). [NCT00911937] [sr-incont49848]WeissJ , JumadilovaZ , CarlssonM , FitzGeraldMP , MalhotraA , MartireDL . Effect of antimuscarinic treatment in subjects with overactive bladder, including nocturnal urinary urgency (Abstract number 1963). Journal of Urology2012;187(4 Suppl 1):e792. [NCT00911937] [sr-incont65184]WeissJP , CarlssonMR , ManganEK . Age, gender and nocturnal urgency severity predict response to antimuscarinic treatment (Abstract number 1962). Journal of Urology2013;189(4 Suppl 1):e805. [NCT00911937] [sr-incont65096]WeissJP , JumadilovaZ , JohnsonTM , FitzGeraldMP , CarlssonM , MartireDL , et al. Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency. Journal of Urology2013;189(4):1396-401. [A0221048] [NCT00911937] [sr-incont47568]">Weiss 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OAB‐q (total HRQL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0– to 100‐point scale, higher HRQL scores indicate better HRQL</p> <p>MCID: 10 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fesoterodine (n = 381): 17</p> <p>Placebo (n = 400): 14.9 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticholinergics improve QoL compared to placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0096" title="YamaguchiO , MaruiE , KakizakiH , ItohN , YokotaT , OkadaH , et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU International2007;100(3):579-87. [sr-incont23865]YokoyamaO , YamaguchiO , KakizakiH , ItohN , YokotaT , OkadaH , et al. Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary. Journal of Urology2011;186(1):170-4. [sr-incont41734]">Yamaguchi 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>KHQ incontinence impact score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0‐ to 100‐point scale, lower scores indicates higher QoL</p> <p>MCID: 5 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Solifenacin (n = 754): ‐21.5</p> <p>Propiverine (n = 384): ‐17</p> <p>Placebo (n = 395): ‐7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The result shows improvement of QoL in terms of incontinence impact score, but the improvement was also demonstrated in all of the other KHQ domains </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0098" title="YamaguchiO , UchidaE , HigoN , MinamiH , KobayashiS , SatoH , et al. Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: a randomized double-blind trial. International Journal of Urology2014;21(6):586-93. [JapicCTI-101309] [sr-incont62099]">Yamaguchi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>KHQ incontinence impact score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0‐ to 100‐point scale, lower scores indicates higher QoL</p> <p>MCID: 5 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Propiverine (n = 559): ‐16</p> <p>Placebo (n = 3737): ‐14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The result shows improvement of QoL in terms of incontinence impact score, but the improvement was also demonstrated in all of the other KHQ domains </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0103" title="ZinnerN , GittelmanM , HarrisR , SussetJ , KanellosA , AuerbachS . Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial (Abstract number DP51). In: American Urological Association (AUA), 98th Annual Meeting; 2003 Apr 26-May 1; Chicago, Illinois. 2003. [sr-incont31101]ZinnerN , GittelmanM , HarrisR , SussetJ , KanelosA , AuerbachS , Trospium Study Group. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. Journal of Urology2004;171(6 Pt 1):2311-5. [sr-incont17376]">Zinner 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IIQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 400, lower scores indicate better QoL MCID: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trospium change from baseline score indicated improvement in all IIQ domains (travel, social relationships, emotional health, physical activity) compared to placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticholinergics improve QoL compared to placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0104" title="ZinnerN , SussetJ , GittelmanM , ArguinzonizM , RekedaL , HaabF . Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. International Journal of Clinical Practice2006;60(1):119-26. [sr-incont21507]">Zinner 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OAB‐q, KHQ and ICIQ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable as data are not shown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Darifenacin showed improvement compared to placebo in all domains of all three measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticholinergics improve QoL compared to placebo</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>*unless specified otherwise</p> <p>HRQL: health‐related quality of life<br/>ICIQ: International Consultation of Incontinence Questionnaire<br/>IIQ: Incontinence Impact Questionnaire<br/>KHQ: King's Health Questionnaire<br/>MCID: minimal clinically important difference<br/>OAB‐q: overactive bladder questionnaire<br/>QoL: quality of life<br/>UDI: Urogenital Distress Inventory </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Quality of life outcome of studies that were not included in meta‐analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/full#CD003781-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003781-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Patient perception of cure or improvement outcome in studies that were not included in meta‐analysis (using PPBC measure)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Score/measure</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Interpretation</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0022" title="AmarencoG , SutoryM , FagertunH , WrightM , CompionG , De RidderD . Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Preliminary results from the SONIC urodynamic study (Abstract). European Urology, Supplements2012;11(1):e467-a. [EudraCT2006-005523-42] [NCT00629642] [sr-incont65392]AmarencoG , SutoryM , ZachovalR , AgarwalM , DelPG , TretterR , et al. Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study. Neurourology and Urodynamics2017;36(2):414-21. [EudraCT2006-005523-42] [JapicCTI-R130306] [NCT00629642] [sr-incont72248]De RidderD , AmarencoG , Finazzi-AgroE , AnguloJ , KurenkovA , WrightM , et al. Solifenacin treatment for neurogenic detrusor overactivity: patient-reported outcomes (PROs) from the randomised clinical trial SONIC (Abstract number 333). In: International Continence (ICS); 42nd Annual Meeting; 2012 Oct 15-19; Beijing, China. 2012. [905-EC-005] [EudraCT2006-005523-42] [NCT00629642] [TrialID.SONIC.] [srincont-49739]">De Ridder 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PPBC (change from baseline) </p> <p>Placebo: ‐0.1</p> <p>Solifenacin: ‐0.5 </p> <p>Oxybutynin: ‐0.5</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Solifenacin and oxybutynin may improve patient perception of bladder condition compared to placebo. </p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0040" title="EUCTR2012-005735-91-SK. A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-005735-91 (first received 12 November 2013). [178-CL-101] [EUCTR2012-005735-91-SK] [sr-incont78644]HerschornS , ChappleCR , AbramsP , ArlandisS , MitchesonD , LeeKS , et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU International2017;120(4):562-75. [NCT01972841] [sr-incont74470]MuellerER , RobinsonD , KelleherC , StaskinDR , FalconerC , WangJ , et al. Patient reported outcomes from synergy, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with mirabegron and solifenacin monotherapy (Abstract number - Podium #44). Neurourology and Urodynamics2017;36(Suppl S1):S151-2. [NCT01972841] [sr-incont75944]NCT01972841. This was a multinational study comparing the efficacy and safety of two medicines, solifenacin succinate and mirabegron taken together, or separately, or a mock treatment (placebo) in subjects with symptoms of overactive bladder (SYNERGY) [A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder]. clinicaltrials.gov/show/NCT01972841 (first received 31 October 2013). [178-CL-101] [EUCTR2012-005735-91] [NCT01972841] [sr-incont63780]RobinsonD , KelleherC , StaskinD , MuellerER , FalconerC , WangJ , et al. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients. Neurourology and Urodynamics2018;37(1):394-406. [NCT01972841] [sr-incont76906]WeberMA , ChappleCR , GratzkeC , HerschornS , RobinsonD , FrankelJM , et al. A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial. Blood Pressure Monitoring2018;23(3):153-63. [NCT01972841] [sr-incont77899]WhiteWB , ChappleC , GratzkeC , HerschornS , RobinsonD , FrankelJ , et al. Cardiovascular safety of the beta3-adrenoceptor agonist mirabegron and the antimuscarinic agent solifenacin in the SYNERGY trial. Journal of Clinical Pharmacology2018;58(8):1084-91. [NCT01972841] [sr-incont78078]">Herschorn 2017a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PPBC (change from baseline)</p> <p>Placebo: ‐0.9</p> <p>Solifenacin: ‐1.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Solifenacin may improve patient perception of bladder condition compared to placebo.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>PPBC: patient perception of cure or improvement.</p> <p>A decrease in PPBC score indicates improvement.</p> <p>Minimal clinically important difference is unclear.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Patient perception of cure or improvement outcome in studies that were not included in meta‐analysis (using PPBC measure)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/full#CD003781-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003781-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Patient perception of cure or improvement ‐ direction of effect plot</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b>  </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study design</b>  </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Patient perception of cure or improvement</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0032" title="GellerE , DumondJ , BowlingJM , KhandelwalC , WuJ , Busby-WhiteheadJ , et al. Effect of an anticholinergic on cognitive function in postmenopausal women: a randomized trial (Abstract number: oral poster 52). Female Pelvic Medicine and Reconstructive Surgery2016;22(5):S61. [sr-incont78607]GellerEJ , DumondJB , BowlingJM , KhandelwalCM , WuJM , Busby-WhiteheadJ , et al. Effect of trospium chloride on cognitive function in women aged 50 and older: a randomized trial. Female Pelvic Medicine &amp; Reconstructive Surgery2017;23(2):118-23. [13-1352] [NCT01922115] [sr-incont74341]NCT01922115. The effect of anticholinergics on cognitive function in the elderly (ACE) [The effect of anticholinergics on cognitive function in the elderly: a randomized controlled trial]. clinicaltrials.gov/show/NCT01922115 (first received 14 August 2013). [13-1352] [NCT01922115] [TrialID.ACE] [sr-incont49282]">Geller 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>▲</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0101" title="NCT01018264, ZesiewiczT . Solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease (URGE-PD) [URGE-PD: a multi-site, double-blind, randomized, placebo controlled trial of solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease]. clinicaltrials.gov/show/NCT01018264 (first received 23 November 2009). [NCT01018264] [sr-incont63790]ZesiewiczTA , EvattM , JahanI , VaughanC , SingerC , OrdoricaR , et al. URGE-PD: a multi-site, double-blind, randomized, placebo controlled trial of solifenacin succinate (VESIcare) for the treatment of overactive bladder in Parkinson's disease (Abstract number 745). Movement Disorders2014;29(Suppl 1):S276-7. [NCT01018264] [sr-incont66602]ZesiewiczTA , EvattM , VaughanCP , JahanI , SingerC , OrdoricaR , et al. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease. Parkinsonism and Related Disorders2015;21(5):514-20. [NCT01018264] [sr-incont66860]">Zesiewicz 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>▲</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0008" title="BurgioKL , LocherJL , GoodePS , HardinJM , McDowellBJ , CandibD . Behavior vs drug therapy for urge incontinence in older women (Abstract number 26). In: American Urogynecology Society, 15th Annual Scientific Meeting; 1994 Sept 21-24; Toronto, Ontario. 1994:48. [sr-incont14585]BurgioKL , LocherJL , GoodePS , HardinM , McDowellBJ , Dombrowski M et al. Behavioral vs drug treatment for urge urinary incontinence in older women. A randomized controlled trial. JAMA1998;280(23):1995-2000. [srincont-5719]BurgioKL , LocherJL , GoodePS . Combined behavioral and drug therapy for urge incontinence in older women. Journal of the American Geriatrics Society2000;48(4):370-4. [srincont-9006]BurgioKL , LocherJL , RothDL , GoodePS . Psychological improvements associated with behavioral and drug treatment of urge incontinence in older women. Journal of Gerontology. Series B, Psychological Sciences and Social Sciences2001;56(1):P46-51. [srincont-11923]">Burgio 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>▲</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0054" title="KhullarV , HillS , LavalKU , SchiotzHA , JonasU , VersiE . Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology2004;64(2):269-74; discussion 274-5. [srincont-19498]KhullarV , HillS , SolankiJ . Assessment of health-related quality of life in patients with overactive bladder taking tolterodine extended release versus placebo (Abstract number 318). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21075]">Khullar 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>▲</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0093" title="CardozoL , HerschornS , SnijderR , SiddiquiE , ChappleCR . Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?International Urogynecology Journal2017;28(3):477-88. CrosbyRD , MathiasSD , MarshallTS . Relationships between symptoms, symptom bother, and health-related quality of life in patients with overactive bladder taking solifenacin or placebo in the VIBRANT study. International Journal of Clinical Practice2011;65(2):211-8. [sr-incont41015]GollarKM , YoungDG , BailenJ , HeW , Forero-SchwanhaeuserS . Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: a secondary analysis of the VIBRANT study. Urologic Nursing2012;32(1):38-46. [TrialID.VIBRANT.] [sr-incont44571]Samuels T‐A, MitchesonHD , VardyM , Forero‐SchwanhaeuserS , MarshallT , HeW . Efficacy of solifenacin for symptom bother and other patient-reported outcomes in patients with overactive bladder (OAB): results of a large, double-blind, placebo-controlled trial (Abstract number: poster #74). Neurourology and Urodynamics2009;28(2):149. [sr-incont31063]VardyMD , MitchesonHD , SamuelsTA , Forero-SchwanhaeuserS , HeW . Efficacy of solifenacin on overactive bladder symptoms, symptom bother, and other patient-reported outcomes in subjects with or without incontinence: a post hoc analysis of data from VIBRANT. Female Pelvic Medicine and Reconstructive Surgery2011;17(1):24-9. [TrialID.VIBRANT.] [sr-incont44741]VardyMD , MitchesonHD , SamuelsTA , WegenkeJD , Forero-SchwanhaeuserS , MarshallTS , et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. International Journal of Clinical Practice2009;63(12):1702-14. [905-UC-010] [NCT00573508] [TrialID.VIBRANT.] [sr-incont35459]">Vardy 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>▲</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0067" title="MillardR , TuttleJ , MooreK , SussetJ , ClarkeB , DwyerP , et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. Journal of Urology1999;161(5):1551-5. [sr-incont8172]MooreK , MillardR , DwyerP , TuttleJ . A randomized controlled multicentre trial of tolterodine in detrusor instability/hyperreflexia. International Urogynecology Journal and Pelvic Floor Dysfunction1997;8(Suppl 1):S129. [sr-incont5171]RosamiliaA , DwyerPL , ClarkeB , MooreK , MillardRP , TuttleJ . The clinical efficacy and safety of two doses of Tolterodine in detrusor instability. Acta Obstetrica et Gynecologica Scandinavica1997;6(Suppl 167):24. [sr-incont6670]">Millard 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>▲</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0079" title="RovnerES , KaplanS , GuanZ , WangJT , RoehrbornCG . Clinical efficacy and safety of tolterodine extended release in male patients with overactive bladder and urgency urinary incontinence (Abstract number 188). In: International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2; Montreal, Canada. 2005. [sr-incont21091]">Rovner 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>▲</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003781-bbs2-0088" title="TakayasuH , UenoA , TsutidaS , KoisoK , KuritaK , KawabeK , et al. Clinical effects of propiverine hydrochloride in the treatment of urinary frequency and incontinence associated with detrusor overactivity: a double blind, parallel, placebo controlled multicenter study. Igaku No Ayumi (Progress in Medicine)1990;153(8):459-71. [srincont-12896]TakayasuH , UenoA , TsutidaS , KoisoK , KuritaK , KawabeK , et al. Clinical effects of propiverine hydrochloride in the treatment of urinary frequency and incontinence associated with detrusor overactivity: a double blind, parallel, placebo controlled multicenter study. Igaku No Ayumi (Progress in Medicine)1990;153(8):459-71. [sr-incont12896]">Takayasu 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>▲</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>▲ ‐ represents improvement</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Patient perception of cure or improvement ‐ direction of effect plot</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/full#CD003781-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003781-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Anticholinergics versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Mean change from baseline in condition‐specific quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6804</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.41 [‐5.28, ‐3.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Darifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>399</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.10 [‐10.55, ‐1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Fesoterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.88 [‐6.48, ‐3.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 Solifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1038</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.65 [‐6.20, ‐3.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.4 Tolterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1918</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.87 [‐4.51, ‐1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.5 Propiverine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>974</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.67 [‐10.00, ‐3.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Patient perception of cure or improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [1.15, 1.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Tolterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2792</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.71, 2.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Darifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [1.15, 2.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 Fesoterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [1.12, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Mean number of urgency episodes per 24 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16875</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.85 [‐1.03, ‐0.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Fesoterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.98 [‐1.32, ‐0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Imidafenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1440</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.02 [‐1.46, ‐0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 Propiverine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.49 [‐0.97, ‐0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.4 Solifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.86 [‐1.12, ‐0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.5 Tolterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.52 [‐0.91, ‐0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Adverse events: Dry mouth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.50 [3.26, 3.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Darifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1836</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.15 [3.09, 5.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Fesoterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.92 [3.41, 4.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.3 Imidafenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.80 [1.99, 3.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.4 Oxybutynin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>954</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.02 [2.37, 3.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.5 Propantheline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.73 [0.88, 8.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.6 Propiverine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3741</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.79 [3.00, 4.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.7 Solifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7028</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.19 [3.42, 5.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.8 Tolterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12649</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.02 [2.68, 3.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.9 Trospium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2421</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.33 [2.52, 4.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Adverse events: Urinary retention/high residual volume <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7862</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.52 [2.04, 6.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Fesoterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.66 [1.76, 42.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Oxybutynin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.01 [1.67, 21.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.3 Propiverine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>786</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.91 [0.71, 49.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.4 Solifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.59 [0.86, 7.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.5 Tolterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2482</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.31, 2.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.6 Trospium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>601</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.07 [0.46, 36.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Adverse events: Abdominal pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [1.20, 2.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Darifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.03 [0.23, 17.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Fesoterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1423</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.66, 2.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.3 Imidafenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>772</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.07 [0.55, 149.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.4 Oxybutynin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.34, 6.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.5 Propiverine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.54 [0.58, 157.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.6 Solifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.7 Tolterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.89, 2.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.8 Trospium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.21 [0.77, 6.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Adverse events: Blurred vision <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18639</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [1.26, 1.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Darifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.55 [0.12, 52.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Fesoterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.05, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.3 Imidafenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.49, 4.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.4 Oxybutynin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.92 [0.80, 4.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.5 Propantheline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.45 [0.12, 49.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.6 Propiverine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2527</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.15 [1.29, 3.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.7 Solifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8435</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [1.06, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.8 Tolterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.82 [0.90, 3.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.9 Trospium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>863</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.35, 4.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Adverse events: Constipation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.03 [1.78, 2.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Darifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.59 [1.89, 3.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 Fesoterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8450</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.30 [1.81, 2.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.3 Imidafenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [1.04, 2.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.4 Oxybutynin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.71, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.5 Propantheline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.6 Propiverine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3907</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.93 [1.84, 4.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.7 Solifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.41 [1.70, 3.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.8 Tolterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10804</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [1.06, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.9 Trospium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.13 [1.75, 5.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Adverse events: Cough <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3853</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.57 [1.39, 4.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Fesoterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.17 [1.13, 4.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 Trospium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>658</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.17 [1.02, 65.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Adverse events: Dizziness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [1.09, 1.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Fesoterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2612</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.65, 1.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 Imidafenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.15, 7.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.3 Oxybutynin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.25, 5.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.4 Propantheline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.42 [0.25, 79.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.5 Propiverine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.29, 4.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.6 Solifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1900</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.74, 2.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.7 Tolterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6048</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [1.09, 2.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Adverse events: Dry eyes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6897</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.86 [1.23, 2.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Fesoterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.58 [1.31, 5.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 Solifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>768</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.94 [0.72, 49.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.3 Tolterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.61, 2.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.4 Trospium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>601</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.07 [0.46, 36.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Adverse events: Dyspepsia/indigestion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12699</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.24 [1.70, 2.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 Darifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.99 [1.53, 5.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.2 Fesoterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.86 [1.90, 12.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.3 Imidafenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.4 Oxybutynin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>451</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.85 [1.06, 7.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.5 Propiverine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.06 [0.26, 16.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.6 Solifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2750</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.43 [1.53, 7.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.7 Tolterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.90, 2.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.8 Trospium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>601</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.03 [0.51, 8.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Adverse events: Flu‐like symptoms/fatigue <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.89, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 Darifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.15, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.2 Fesoterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3792</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.64, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.3 Oxybutynin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.05, 30.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.4 Propantheline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.42 [0.25, 79.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.5 Solifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1822</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.19 [0.93, 5.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.6 Tolterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2567</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [0.87, 3.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Adverse events: Headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [1.05, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.1 Darifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1719</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [1.01, 2.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.2 Fesoterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7449</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.99, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.3 Imidafenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.51, 3.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.4 Oxybutynin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.26, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.5 Propantheline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.44 [0.18, 64.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.6 Propiverine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [0.41, 5.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.7 Solifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2700</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.54, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.8 Tolterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8709</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.01, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.9 Trospium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.69, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Adverse events: Insomnia (unable to sleep) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.83, 2.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.1 Fesoterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.89 [0.93, 3.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.2 Tolterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1935</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.43, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Adverse events: Nasopharyngitis/sore throat <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9833</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.63, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.1 Darifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.32, 2.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.2 Fesoterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.59, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.3 Imidafenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.55, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.4 Solifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1726</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.29, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.5 Tolterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2653</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.49, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.6 Trospium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>658</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.50, 2.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Adverse events: Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13605</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.79, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.1 Darifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>439</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [0.56, 5.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.2 Fesoterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3740</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.61, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.3 Imidafenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.03 [0.12, 73.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.4 Oxybutynin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.24, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.5 Propantheline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.25, 5.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.6 Propiverine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.53, 2.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.7 Solifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.71, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.8 Tolterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.54, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.9 Trospium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>601</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.26, 9.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Adverse events: Pruritus/erythema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.06 [0.44, 9.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.1 Fesoterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.00 [0.24, 103.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.2 Solifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>419</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.19, 8.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.19 Adverse events: Urinary tract infection (UTI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [1.02, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.1 Darifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.66, 2.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.2 Fesoterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6312</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.86, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.3 Solifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2641</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.97, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.4 Tolterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.72, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.5 Trospium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.01 [0.98, 4.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.20 Withdrawal due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36943</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [1.21, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.1 Darifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1836</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [0.84, 3.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.2 Fesoterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [1.39, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.3 Imidafenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1668</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.86 [0.29, 11.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.4 Oxybutynin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.06 [0.89, 4.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.5 Propantheline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.44 [0.18, 64.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.6 Propiverine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3858</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.74 [1.01, 3.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.7 Solifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7095</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [1.02, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.8 Tolterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.75, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.9 Trospium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2642</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.88, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.21 Mean number of micturitions per 24 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19395</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.85 [‐0.98, ‐0.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.1 Tolterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.71 [‐0.95, ‐0.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.2 Solifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.02 [‐1.33, ‐0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.3 Fesoterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.90 [‐1.12, ‐0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.4 Oxybutynin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.70 [‐2.47, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.5 Propiverine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2772</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.89 [‐1.20, ‐0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.6 Imidafenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1064</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.76 [‐1.18, ‐0.35]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Anticholinergics versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003781.pub3/references#CD003781-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003781.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD003781-note-0010">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD003781-note-0028">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003781-note-0023">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD003781-note-0025">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD003781-note-0021">Hrvatski</a> </li> <li class="section-language"> <a class="" href="hu#CD003781-note-0026">Magyar</a> </li> <li class="section-language"> <a class="" href="ko#CD003781-note-0016">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD003781-note-0020">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD003781-note-0017">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD003781-note-0014">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD003781-note-0019">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD003781-note-0012">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003781\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003781\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003781\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003781\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003781\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003781\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003781\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003781\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003781\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003781\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003781\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003781\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003781\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003781\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003781\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003781\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003781\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003781\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=k5rEBE5b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003781.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003781.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003781.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003781.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003781.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740711474006"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003781.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740711474009"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003781.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d2641c9e19377',t:'MTc0MDcxMTQ3NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 